



**Acta Haematologica, Vol 43**



Vol. 43, 1970

# Acta Haematologica

International Journal of Haematology  
Journal International d'Hématologie  
Internationale Zeitschrift für Hämatologie

Official Organ of the European Division of the International Society of Haematology

Editors-in Chief

H LUDIN, Basel

G ROSENOW, New York, N Y

Contributing Editors

L HEILMEYER †, Ulm

S MOESCHLIN, Solothurn

A VIDEBAEK, København

J WALDENSTROM, Malmö

Editors

A ALDER, Aarau

H ALESSANDRI, Santiago

G BICKEL, Genève

B. M. VON BONSDORFF, Helsinki

W O CRUZ, Rio de Janeiro

C R. DAS GUPTA, Calcutta

C JIMÉNEZ DIAZ, Madrid

H DUBON-FERRIÈRE, Genève

P FARRERAS, Barcelona

A FIESCHI, Genova

L GROSS, Bronx, N Y

J GUASCH, Barcelona

H HEMMELER, Lausanne

A HITTMAIR, Innsbruck

P INTROZZI, Pavia

F KOLLER, Basel

J H LAWRENCE, Berkeley, Calif.

P LEVINE, Raritan, N J

W LÖFFLER, Zurich

J MALLARMÉ, Paris

L M MEYER, Brooklyn, N Y

W P MURPHY, Boston, Mass

N G NORDENSON, Stockholm

A. Pavlovsky, Buenos Aires

E PONDRE, Bures-sur Yvette

F REIMANN, Istanbul

I SNAFFER, Brooklyn, N Y

E STORTI, Modena

E UNDRITZ, Basel

M VARELA, Buenos Aires

M. C. VERLOOP, Utrecht



S. Karger · Basel (Switzerland) · München · New York

S. Karger AG, Arnold Böcklin-Strasse 25, 4000 Basel 11 (Switzerland)

---

All rights including that of translation into other languages, reserved.  
Photomechanic reproduction (photocopy, microcopy) of this volume or parts thereof  
without special permission of the publishers is prohibited.

© Copyright 1970 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel  
Printed in Switzerland by Buchdruckerei National-Zeitung AG, Basel

# Index

- ADDIS, S vide PANIZON, F  
 AGARWAL, S P vide DUBE, B  
 ARTVINLI, S vide OZAND, P T  
 BAST, G vide SCHULZ, K.  
 BAUER, S vide KIRSCHNER, H  
 BECKER, HJ, KINZCHT, L. H und STRASCHIL, F Die makrozytäre Regeneration der Erythropoese Tierexperimentelle Untersuchungen bei der Phenylhydrazin-hämolyse 144  
 BERNAU, A. vide KLEINHAUER, E.  
 BETKE, K. vide KLEINHAUER, E.  
 BHARGAVA, MANORAMA vide KUMAR, S  
 BRITTINGER, G vide COHNEN, G  
 BUTENANDT, O The Activity of Glutathionperoxydase, Glucose-6-phosphate-dehydrogenase and Glutathionreductase in Sphaerocytes 348  
 CENTA, A. vide SANSONE, G  
 CHAWLA, S C. vide DUBE, B  
 COHNEN, G, SCHOLZ, N, MESSER, B, KÖNIG, E, ZIMMERSCHUTT, E. und BRITTINGER, G Tumorartige intrathorakale extramedulläre Hämatopoese bei hämolytischer Anämie. Bericht über einen Fall und Literaturübersicht 111  
 DANON, D vide DANON, Y  
 DANON Y KLEDMANN, A. and DANON, D The Osmotic Fragility and Density Distribution of Erythrocytes in the Newborn 242  
 DAWSON, Audrey A. vide McANDREW, G M  
 DOBBS J V vide ROSNER, F  
 DREYFUS YOLANDE vide GROSS, LUDWIK  
 DUBE, B, AGARWAL, S P, GUPTA, M M. and CHAWLA, S. C. Congenital Deficiency of Fibrinogen in Two Sisters A Clinical and Haematological Study 120  
 EDWARDS, A E. vide GRIFFITHS, D A.  
 EDWARDS, A E. vide ROSSE, C.  
 EHRENREICH, THEODORE vide GROSS, LUDWIK  
 EKAN, G J F vide LUZZATO, L.  
 FISHER, J W vide KÁLGAOR, L. A  
 FLIEDNER, T M vide HAAS R. J  
 FLIEDNER, T M. vide MEURET, G  
 GACHES C. G C. vide GRIFFITHS, D A.  
 GACHES, C. G C. vide ROSSE, G  
 GALLO, E vide SANSONE, G  
 GELPI, A. P Sickle Cell Disease in Saudi Arabs 89  
 GÖTZ, H. vide SCHEIFFARTH, F  
 GRIFFITHS, D A., ROSSE, C., EDWARDS, A. E., GACHES C. G C., LONG, A. H. L., WRIGHT, J L. W and YOFFEY, J M. Reticulocyte Generation Time and Rate of Discharge from the Marrow 13  
 GRIFFITHS, D A. vide ROSSE, C.  
 GROSS, LUDWIK, DREYFUS, YOLANDE EHRENREICH, THEODORE and MOORE, LORRAINE A Experimental Studies on Leukemia in Guinea Pigs 193

- GUPTA, M. M. vide DUBE, B.
- HAAS R. J., SPARRER, F. und FLEIDNER T. M. Zur Proliferationskinetik der Lebererythropoese heranwachsender Ratten 232
- HITZIO, W. H. vide LO, S. S.
- HONETZ, N. and NEUMANN, E. Behandlungsergebnisse mit Heparin und SP 54 bei autoimmunhämolytischen Anämien 296
- HUDSON, G. vide SMILEY, YVONNE D. L.
- IKKALA, E., SALMI H. J. and SIURALA, M. Gastric Mucosa in Iron Deficiency Anaemia. Results of Follow Up Examinations 228
- KELLER, M. vide KLEINHAUER, E.
- KIENCKE, H. vide SCHULZ, K.
- KIRCHNER, H. und BAUER, S. Wirkung von L-Asparaginase aus *Escherichia coli* auf die Stimulation von Lymphozytenkulturen 210
- KLEINHAUER, E., BERNAU, A., BETKE, K., KELLER, M., KOHNE, E. und RINGEL, K. Heinzkörperbildung in Neugeborenenerythrozyten. I. *In-vitro*-Studien über experimentelle Bedingungen und den Einfluss von Austauschtransfusionen 333
- KLEIMAN, A. vide DANON, Y.
- KNECHT, L. H. vide BECKER, H.
- KOHNE, E. vide KLEINHAUER, E.
- KÖNIG, E. vide COHNEN, G.
- KONOTEV AHUL, F. I. D. vide RINGELHANN, B.
- KONRAD, H. vide SCHULZ, K.
- KOZŁOWSKA, E. vide PAWLAK, A. L.
- KUMAR, S. and BHARGAVA, MANORAMA. Pre-Leukaemic Acute Myelogenous Leukemia 21
- LEE, S. L. vide ROSNER, F.
- LEHMANN, H. vide RINGELHANN, B.
- LEHMANN, H. vide SANSONE, G.
- LEINONEN, I. L. E. A. Cytochemical Studies of Acute Leukemias 219
- LO CURTO, MARGHERITA. Incorporation of <sup>3</sup>H Uridine and <sup>3</sup>H Leucine in Erythroid Cells of Normal and Anemic Rabbits 172
- LONG, A. H. L. vide GRIFFITHS, D. A.
- LONG, A. H. L. vide ROSE, G.
- LO, S. S., HITZIO, W. H. and MARTI, H. R. Hereditary Methemoglobinemia due to Diaphorase Deficiency. Report of a Case of Heterozygote Presenting with Cyanosis after Birth 177
- LORKIN, P. A. vide RINGELHANN, B.
- LUZZATO, L., ESAN, G. J. F. and OGIMUTIA, S. E. The Osmotic Fragility of Red Cells in Newborn and Infants 248
- MALGOR, L. A. and FISHER, J. W. Effects of Erythropoietin and Testosterone on Erythropoiesis in Bone Marrow of Isolated Perfused Hind Limbs of Dogs 321
- MARKKANEN, T. and PILTOLA, O. Binding of Folic Acid Activity by Body Fluids
- MARTI, H. R. vide LO, S. S.
- MAURI, C. vide TOPELLI, U. L.
- MCANDREW, G. M., OGSTON, D. and DAWSON, AUDREY A. An Evaluation of Sternal Tenderness as a sign of leukaemia 309
- MISER, B. vide COHNEN, G.
- MEUREY, G. und FLEIDNER T. M. Zellkinetik der Granulopoese und des Neutrophilensystems bei einem Fall von zyklischer Neutropenie 48
- MOORE, LORRAINE A. vide GROSS, LUDWIG
- NAGY, G. vide SCHÖFF, E.

- NEUMANN, E. *vide* HONETZ, N  
NOWOTHY, P. *vide* SCHULZ, K.  
OGIEMUDIA, S. E. *vide* LUZZATO, L.  
OGSTON, D. *vide* McANDREW, G. M.  
ÖZAND, P. T. and ARTVINLI, S. A Screening Test for Red Blood Cell Catalase 313  
ÖZSOYLU, S. Homozygous Hemoglobin D Punjab 353  
PANIZON, F., ZACCHIELLO, F., SARTORI, E. and ADDIS, S. The Ratio between Normal and Sensitive Erythrocytes in Heterozygous Glucose-6-Phosphate Dehydrogenase Deficient Women 291  
PAWLAK, A. L. and KOZŁOWSKA, F. Swiss Type Hereditary Persistence of Foetal Haemoglobin in a Case of Acquired Haemolytic Anaemia 184  
PELTOLA, O. *vide* MARKKANEN, T.  
PREUSSNER, S. *vide* SCHULZ, K.  
RIEDEL, K. *vide* KLEIHÄLER, E.  
RINGELHANN, B., KONOTEV AHULU, F. I. D., LEHMANN, H. and LORKEN, P. A. A Ghanaian Adult, Homozygous for Hereditary Persistence of Foetal Haemoglobin and Heterozygous for Elliptocytosis 100  
RITZ, N. D. *vide* ROSNER, F.  
ROSNER, F., DOBBS, J. V., RITZ, N. D. and LEE, S. L. Disturbances of Hemostasis in Acute Myeloblastic Leukemia 63  
ROSSE, C., GRIFFITHS, D. A., EDWARDS, A. E., GACHES, C. G. C., LONG, A. H. L., WRIGHT, J. L. W. and YORFEY, J. M. Identity of Erythroblast Precursors in Bone Marrow 80  
ROSSE, C. *vide* GRIFFITHS, D. A.  
SALMI, H. J. *vide* IKKALA, E.  
SANSONE, G., CENTA, A., SCIARRATTA, V., GALLO, E. and LEHMANN, H. Haemoglobin O Indonesia ( $\alpha 116 \text{ Glu} \rightarrow \text{Lys}$ ) in an Italian Family 40  
SARTORI, E. *vide* PANIZON, F.  
SCHIEFFARTH, F., GOTZ, H. and SCHUBERT, R. Immunochemische Untersuchungen an Spaltprodukten menschlicher Gammaglobuline Untersuchungen an Seren mit Hypergammaglobulinämie und Paraproteinämie 257  
SCHOLZ, N. *vide* COHEN, G.  
SCHÖPF, E. and NAGY, G. Fine Structural Features of Lymphocyte Transformation Induced by Mercuric Salts 73  
SCHUBERT, R. *vide* SCHIEFFARTH, F.  
SCHULZ, K., NOWOTHY, P., BAST, G., PREUSSNER, S., KONRAD, H. and KIENCKE, H. Vergleichende Untersuchungen zur Erythrozytenkinetik und zur Knochenmarksmorphologie bei Patienten mit Osteomyelosklerose und Osteomyelofibrose 280  
SCIARRATTA, V. *vide* SANSONE, G.  
SIBLEY, YVONNE D. L. and HUDSON, G. Eosinophil Leucocytes and Recovery from Severe Hypoxia 31  
SIURALA, M. *vide* IKKALA, E.  
SPARKER, E. *vide* HAAS, R. J.  
STRASCHILL, F. *vide* BECKER, H. J.  
TIMSON, J. Effect of Uracl and 2 Thiouracl on Leucocyte Production in the Rat 329  
TORELLI, U. L., VACCARI, G. L. and MAURI, G. Characteristics of the RNA Synthesized *in vitro* by Human Erythroblasts 1  
VACCARI, G. L. *vide* TORELLI, U. L.  
WARDLE, E. N. A Study of the Effects of Possible Toxic Metabolites of Uraemia on Red Cell Metabolism 129  
WRIGHT, J. L. W. *vide* GRIFFITHS, D. A.



WRIGHT J L W vide ROSSE G  
 YOFFEY J M vide GRIFFITHS D A  
 YOFFEY J M vide ROSSE G  
 ZACCINELLO F vide PANIZON F  
 ZIMMERSCHITT E vide COHEN G  
 LIBRI  
 VARIA  
 INDEX RERUM ad Vol 43  
 INDEX AUTORUM ad Vol 43

64 128 360  
 191  
 365  
 374

## Characteristics of the RNA Synthesized *in vitro* by Human Erythroblasts<sup>1</sup>

U. L. TORELLI, G. L. VACCARI and G. MAURI

Institute of Medical Pathology University of Modena, Modena

Several metabolic features of the erythroid differentiation have been recently clarified. It has been shown that the synthetic rates of both RNA and protein decrease during maturation, although at a different rate [3, 15]. Reticulocytes are able to actively synthesize protein, whereas they no longer synthesize RNA [6]. RNA of reticulocytes is synthesized in an early precursor cell and remains functional through the reticulocyte stage [2]. Maturation from erythroblast to reticulocyte is characterized by a decrease in number and size of polyribosomes [9].

An important achievement in recent years has been the demonstration that in animal cells ribosomal RNA is not synthesized directly in its final form, but through a complex molecular sequence. Evidence obtained in different cell lines, such as HeLa cells [8, 11, 18] and cultured lymphocytes [16], suggests that such a sequence in RNA metabolism is a general feature of human cells. However, up to the present this has not been shown in human erythroblasts.

It is at present beyond technical possibilities to obtain from human bone marrow erythroblastic populations at a definite stage of maturation and free from large contamination by other cell types. Therefore, *we have attempted to obtain information concerning RNA synthesis* in human erythroblasts through the study of the nucleated red cells present in the peripheral blood in cases of hemolytic anemia and idiopathic myelofibrosis. Although such cells cannot be considered identical to normal bone marrow erythroblasts, we believe that the basic features

<sup>1</sup> Research supported by a grant from the Consiglio Nazionale delle Ricerche (Contract No. 115 1843 0 1336).

of their RNA metabolism may be considered as essentially similar to those of normal erythroblasts. We have studied in these cells the kinetics of uridine- $^3\text{H}$  incorporation into RNA and the characteristics of sedimentation in sucrose gradients of the RNA labeled after different periods of incubation with uridine- $^3\text{H}$ . Sedimentation experiments were also carried out after incubation with methyl- $^{14}\text{C}$ -methionine, since it has been shown that methylation of RNA offers an extremely sensitive means to follow the processing of the newly synthesized ribosomal RNA [4, 16].

### *Material and Methods*

**Case material.** The cells studied were obtained from 3 patients, chosen because of the unusually high counts of their nucleated circulating red cells. Patient 1 was a 9 year-old boy suffering from severe hemolytic anemia since a few months of age. He had been splenectomized at the age of three, but the only change observed after splenectomy was a relevant increase in the number of nucleated circulating red cells. By accurate hematological screening, thalassemia and abnormal hemoglobin syndromes had been excluded. Several enzyme activities had been evaluated, and a markedly reduced level of G6PD activity had been found. Metabolic studies in this patient have been reported in detail elsewhere [11]. At the time of the present investigation, peripheral cell count was as follows: RBC 2,150,000, nucleated red cells 35,000, WBC 9,600, platelets 185,000. In patient 2, a 56-year-old female, myelofibrosis had been diagnosed 3 years before. Conspicuous splenomegaly was present. The patient had been previously treated with splenic irradiation and busulfan, but at present she was only under androgen treatment, which had started 6 months previously. Peripheral count was as follows: RBC 2,500,000, nucleated red cells 28,000, WBC 11,000, platelets 125,000. In patient 3, a 47-year-old male, anemia and myelofibrosis had been found 4 years before. He had been splenectomized, but the anemia had not improved significantly. When our studies were performed, the peripheral pattern was as follows: RBC 2,250,000, nucleated red cells 31,000, WBC 13,500, platelets 285,000.

**Preparation of erythroblasts.** 30 ml of heparinized blood (20 U/ml) were filtered slowly through a column of commercial nylon fibers (Leukopak, Fenwal Lab., Morton Grove, Ill.),  $10 \times 100$  mm, maintained at  $37^\circ\text{C}$ . The filtered blood was then sedimented by gravity at  $37^\circ\text{C}$ , and the supernatant plasma was discarded. The erythrocyte layer, containing the erythroblasts, was diluted with minimal essential medium (MEM) to a concentration of  $[2 \times 10^6 \text{ erythrocytes per ml}]$ . Erythroblast concentrations ranged from  $2$  to  $4 \times 10^6$  per ml. Five ml fractions were distributed in 25 ml rubber stoppered test tubes rotating at  $37^\circ\text{C}$ , in an atmosphere of 95%  $\text{O}_2$  to 5%  $\text{CO}_2$ . All operations were performed under sterile conditions.

**Time course studies.** To study the kinetics of incorporation of labeled uridine into RNA, the radioactive precursor (uridine- $5\text{-}^3\text{H}$ , 16.0 c/min/mole, Radiochemical Centre, Amersham, England) was added to a 5 ml culture, at the final concentration of  $10 \mu\text{c/ml}$ . 200  $\mu\text{l}$  samples were removed at different intervals, pipetted into 5 ml of 5% TCA at  $4^\circ\text{C}$  and held at this temperature for at least 1 h. Incorporation of labeled precursor into DNA was minimal, as indicated by the low radioactivity of DNA isolated by the MARMON [7] procedure after incubation with uridine- $^3\text{H}$ . RNA radioactivity was assayed on the precipitate by the modification of the SCHREIBER [13] procedure already described [16].

cessed as above mentioned.

*Sucrose gradient analysis* For sedimentation analysis of uridine- $^3\text{H}$  labeled RNA, aliquots of the labeled cultures were harvested at intervals of 30 min, 45 min, 1, 4, 6 and 12 h of exposure to the label. For sedimentation analysis of RNA labeled after incubation of erythroblasts with methyl- $^{14}\text{C}$ -methionine, 10  $\mu\text{c}$  of the radioactive precursor (Radiochemical Centre, 46.0 mc/nmole) were added to 1 ml cultures prepared in methionine-free medium, which were harvested after 30, 60 and 120 min of incubation.

Chicago Corp., Des Plaines, Ill.)

### Results

*Characteristics of the erythroblastic populations* Nucleated cells in our cultures were represented almost exclusively by erythroblasts. Leukocytes were less than 1%. The distribution of the different maturation stages, the percentages of cells labeled with thymidine- $^3\text{H}$  and uridine- $^3\text{H}$  and the average grain counts in the three populations studied are shown in table I. The characteristics of the erythroblastic population in case 1 were definitely different from those of cases 2 and 3, which on the contrary were quite similar. In case 1, virtually all the erythroblasts were at the orthochromatic stage, i.e. the cytoplasm did not show any basophilia and the chromatin of the nucleus was greatly condensed. When studied by autoradiography none of them incorporated thymidine- $^3\text{H}$  and only a few showed some labeling with uridine-

Table 1 Distribution of different maturation stages and average labeling indexes in the 3 erythroblastic populations studied. 1,000 erythroblasts were counted in each case

| Case No. | Maturation stage | Percent of cells | Thymidine- <sup>3</sup> H |                     | Uridine- <sup>3</sup> H  |                     |
|----------|------------------|------------------|---------------------------|---------------------|--------------------------|---------------------|
|          |                  |                  | Percent of labeled cells  | Average grain count | Percent of labeled cells | Average grain count |
| 1        | baso             | 0                | -                         | -                   | -                        | -                   |
|          | poly             | 0.5              | 0                         | -                   | 100                      | 19                  |
|          | ortho            | 99.5             | 0                         | -                   | 9                        | 8                   |
| 2        | baso             | 0                | -                         | -                   | -                        | -                   |
|          | poly             | 18               | 12                        | 21                  | 100                      | 45                  |
|          | ortho            | 82               | 0                         | -                   | 25                       | 18                  |
| 3        | baso             | 0                | -                         | -                   | -                        | -                   |
|          | poly             | 21               | 9                         | 15                  | 100                      | 28                  |
|          | ortho            | 79               | 0                         | -                   | 19                       | 16                  |

<sup>3</sup>H. However, since liquid scintillation counting indicated that a definite amount of radioactive precursor was incorporated into the RNA of these cells in a 30 min period, it seems justified to suppose that a fairly higher percentage of nucleated red cells took up some label, but this amount remained beyond the limits of sensitivity of the autoradiographic method. In cases 2 and 3, on the other hand, a fair portion of the erythroblastic population was at the polychromatic stage, i.e. the cytoplasm showed a varying degree of basophilia and the chromatin was irregularly lumped. Some cells at this stage were labeled after incubation with thymidine-<sup>3</sup>H, and all of them were heavily labeled with uridine-<sup>3</sup>H. Only a small portion of the orthochromatic erythroblasts showed autoradiographically some uptake of uridine-<sup>3</sup>H.

The observation that, after 48 h of incubation, there was a marked reduction in the number of cells of cases 2 and 3 showing cytoplasmic basophilia, as well as in the number of cells labeled with uridine-<sup>3</sup>H, may indicate that some degree of 'maturation' occurred during the incubation period.

*Time course of uridine-<sup>3</sup>H incorporation.* Circulating human erythroblasts maintained *in vitro* in a synthetic medium incorporated uridine-<sup>3</sup>H into RNA for at least 18 h. As shown in figure 1, the amount of acid insoluble radioactive material increased for about 6 h in case 1,




Fig 1 Kinetics of uridine-<sup>3</sup>H incorporation by circulating human erythroblasts. The cpm on the ordinate represent the total acid insoluble radioactive material in 200  $\mu$ l samples




Fig 2 Pattern of labeled RNA estimated by

then reached a plateau decreasing very slowly over the next 10 h. In case 2, on the other hand, this amount continued to increase over the first 12 h, reaching a plateau after this interval.

The amount of radioactivity incorporated in a 30 min interval diminished by increasing the period of preincubation in the absence of the precursor, but remained approximately constant after the 6th hour in case 1 and after the 12th hour in case 2.

When cultures previously incubated with uridine- $^3\text{H}$  for 45 min were added with actinomycin D at the concentration of  $5\mu\text{g/ml}$ , about 85% of the radioactivity became acid soluble in a period of three hours. (At the concentration of  $5\mu\text{g/ml}$ , actinomycin D completely prevented incorporation of uridine- $^3\text{H}$  into RNA.)

These results suggest that the time course of incorporation in our experiments reflected both synthesis and decay. In the first period of erythroblast survival *in vitro*, new production appeared to exceed





Fig. 4. Sedimentation pattern of labeled RNA from erythroblasts of case 2 incubated with uridine- $^3\text{H}$  ( $10\mu\text{c ml}$ ) for 45 min. Centrifugation was at 16,000 rpm for 16 h at  $4^\circ\text{C}$ , in 5–20% sucrose.

Fig. 5. Sedimentation pattern of labeled RNA from erythroblasts of case 2 incubated with uridine- $^3\text{H}$  ( $10\mu\text{c ml}$ ) for 6 h. Centrifugation at 16,000 rpm for 16 h at  $4^\circ\text{C}$ , in 5–20% sucrose.

breakdown, and there was a net increase in the radioactivity incorporated by the cells exposed to the labeled precursor. After an interval of 12 h in cases 2 but of only 6 h in case 1, the rate of RNA synthesis decreased to a level at which it could only equal breakdown. The behavior of cells from case 3 was quite similar to that of cells from case 2.

*Sedimentation patterns of labeled RNA after incubation with uridine  $^3\text{H}$*   
The sedimentation pattern of whole cell RNA extracted from circulating erythroblasts of patient 1, incubated with uridine  $^3\text{H}$  for 45 min, is shown in figure 2. Most of the radioactivity was distributed in the region of the gradient corresponding to sedimentation coefficients of 30–60 S or more. After 6 h of incubation of the same cells, the bulk of radioactive RNA partially overlapped the region of 28 S and 18 S RNA components although the sedimentation profiles clearly indi-




Fig 6 Sedimentation pattern of labeled RNA from erythroblasts of case 2 incubated with uridine- $^3\text{H}$  (10  $\mu\text{C}/\text{ml}$ ) for 6 h. Centrifugation at 16 000 rpm for 16 h at  $4^\circ\text{C}$ , in 5–20% sucrose.

Fig 7 Sedimentation pattern of labeled RNA from erythroblasts of case 1 incubated with methyl  $^{14}\text{C}$ -methionine (10  $\mu\text{C}/\text{ml}$ ) for 2 h. Centrifugation at 18 000 rpm for 16 h at  $4^\circ\text{C}$ , in 5–20% sucrose.



cated that most of the radioactivity sedimented faster than ribosomal RNA (fig. 3). When the same cells were exposed for 6 h to uridine- $^3\text{H}$  after 24 h of preincubation without the labeled precursor, most of the radioactivity sedimented with RNA showing S values higher than 30.

When erythroblasts from case 2, as well as from case 3, were incubated with uridine- $^3\text{H}$  for 45 min, the sedimentation patterns observed were quite similar to that shown in case 1, i.e. most of the radioactivity sedimented in the 30–60 S region of the gradient (fig. 4). On the contrary, when the same cells were incubated with labeled uridine for 6 h, 3 definite radioactive peaks were observed which coincided with the optical density peaks of 28, 18 and 4 S (fig. 5). The pattern was only slightly different when the cells were incubated for 6 h following a 12-hour period of preincubation without the labeled precursor, but when the preincubation lasted for 24 h, only a small portion of radioactivity sedimented with ribosomal RNA (fig. 6), and the pattern resembled that observed with cells from case 1.

*Sedimentation patterns of labeled RNA after incubation of erythroblasts with methyl- $^{14}\text{C}$ -methionine.* The result of the sucrose gradient analysis of




Fig. 8 Sedimentation pattern of labeled RNA from erythroblasts of case 2 incubated with methyl  $^{14}\text{C}$ -methionine (10  $\mu\text{C}/\text{ml}$ ) for 30 min. Centrifugation at 18,000 rpm for 16 h at  $4^\circ\text{C}$ , in 5–20 sucrose.

RNA extracted from the erythroblasts of case 1, incubated with methyl- $^{14}\text{C}$ -methionine for 2 h is shown in figure 7. Besides a fairly large amount of radioactivity in the 4 S region, presumably representing methylated soluble RNA and methioninyl sRNA, two peaks of radioactivity were observed in the region of the gradient between 32 and 45 S (fig. 7). In erythroblasts from cases 2 and 3, after the same period of incubation, the 28 S ribosomal RNA peak was definitely labeled whereas a pattern similar to that obtained with cells from case 1, i.e. with radioactive peaks between 32 and 45 S, was observed after only 30 min of incubation with methyl  $^{14}\text{C}$ -methionine (fig. 8).

### *Discussion*

In all the erythroblastic populations studied the newly synthesized RNA consisted mainly of molecules sedimenting faster than ribosomal RNA, with S values ranging from 30–70 S. After 6 h of incubation with labeled uridine, however, the pattern in case 1 was fairly different from that observed in cases 2 and 3. In the former case only a little radioactivity was associated with ribosomal RNA, whereas in the erythroblastic populations of cases 2 and 3, a relevant proportion of the label sedimented with ribosomal and transfer RNA. Since actinomycin D caused a high rate of RNA breakdown in circulating erythroblasts, possibly by preventing the metabolic stabilization of the newly formed molecules, it was not possible to follow by actinomycin 'chase' the fate of the RNA labeled after short term incubation. However, our experiments show in human erythroblasts, after incubation with methyl- $^{14}\text{C}$ -methionine, the presence of methylated RNA fractions having S values ranging from 32–45 S. This therefore suggests that the rapidly sedimenting RNA labeled with uridine- $^3\text{H}$  in short term incubation of erythroid cells must be considered, at least in part, a ribosomal precursor [4].

In erythroblasts from case 1, on the other hand, uridine  $^3\text{H}$  experiments failed to show any definite labeling of ribosomal RNA after several hours of incubation with the precursor. These cells therefore showed clearly the same seeming discrepancy between the results obtained with uridine- $^3\text{H}$  and those obtained with methyl- $^{14}\text{C}$ -methionine which has been already observed in small lymphocytes [16]. We presume that also in mature erythroblasts the high specificity of methyl

cated that most of the radioactivity sedimented faster than ribosomal RNA (fig. 3). When the same cells were exposed for 6 h to uridine  $^3\text{H}$  after 24 h of preincubation without the labeled precursor, most of the radioactivity sedimented with RNA showing S values higher than 30.

When erythroblasts from case 2, as well as from case 3, were incubated with uridine  $^3\text{H}$  for 15 min, the sedimentation patterns observed were quite similar to that shown in case 1, i.e. most of the radioactivity sedimented in the 30–60 S region of the gradient (fig. 4). On the contrary, when the same cells were incubated with labeled uridine for 6 h, 3 definite radioactive peaks were observed which coincided with the optical density peaks of 28, 18 and 4 S (fig. 5). The pattern was only slightly different when the cells were incubated for 6 h following a 12 hour period of preincubation without the labeled precursor, but when the preincubation lasted for 24 h, only a small portion of radioactivity sedimented with ribosomal RNA (fig. 6), and the pattern resembled that observed with cells from case 1.

*Sedimentation patterns of labeled RNA after incubation of erythroblasts with methyl  $^{14}\text{C}$  methionine.* The result of the sucrose gradient analysis of




Fig. 8. Sedimentation pattern of labeled RNA from erythroblasts of case 2 incubated with methyl  $^{14}\text{C}$ -methionine (10  $\mu\text{C}/\text{ml}$ ) for 30 min. Centrifugation at 18 000 rpm for 16 h at 4  $^{\circ}\text{C}$  in 5–20 sucrose.

RNA extracted from the erythroblasts of case 1, incubated with methyl- $^{14}\text{C}$ -methionine for 2 h is shown in figure 7. Besides a fairly large amount of radioactivity in the 4 S region, presumably representing methylated soluble RNA and methioninyl sRNA, two peaks of radioactivity were observed in the region of the gradient between 32 and 45 S (fig. 7). In erythroblasts from cases 2 and 3, after the same period of incubation, the 28 S ribosomal RNA peak was definitely labeled whereas a pattern similar to that obtained with cells from case 1, i.e. with radioactive peaks between 32 and 45 S, was observed after only 30 min of incubation with methyl- $^{14}\text{C}$ -methionine (fig. 8).

### Discussion

In all the erythroblastic populations studied the newly synthesized RNA consisted mainly of molecules sedimenting faster than ribosomal RNA, with S values ranging from 30–70 S. After 6 h of incubation with labeled uridine, however, the pattern in case 1 was fairly different from that observed in cases 2 and 3. In the former case only a little radioactivity was associated with ribosomal RNA, whereas in the erythroblastic populations of cases 2 and 3, a relevant proportion of the label sedimented with ribosomal and transfer RNA. Since actinomycin D caused a high rate of RNA breakdown in circulating erythroblasts, possibly by preventing the metabolic stabilization of the newly formed molecules, it was not possible to follow by actinomycin 'chase' the fate of the RNA labeled after short term incubation. However, our experiments show in human erythroblasts, after incubation with methyl- $^{14}\text{C}$  methionine, the presence of methylated RNA fractions having S values ranging from 32–45 S. This therefore suggests that the rapidly sedimenting RNA labeled with uridine- $^3\text{H}$  in short term incubation of erythroid cells must be considered, at least in part, a ribosomal precursor [4].

In erythroblasts from case 1, on the other hand, uridine- $^3\text{H}$  experiments failed to show any definite labeling of ribosomal RNA after several hours of incubation with the precursor. These cells therefore showed clearly the same seeming discrepancy between the results obtained with uridine- $^3\text{H}$  and those obtained with methyl- $^{14}\text{C}$ -methionine which has been already observed in small lymphocytes [16]. We presume that also in mature erythroblasts the high specificity of methyl

labeling allows detection of the synthesis of small amounts of ribosomal RNA which in uridine  $^3\text{H}$  experiments are overshadowed by larger amounts of nonribosomal RNA.

Since cell populations from patients with different diseases are considered, one might speculate that the variations observed are related to the different pathological conditions examined. However, it seems likely that the different results are rather due to the different maturation levels of the cell populations studied. In cases 2 and 3, in fact, a fair proportion of the cells was at the polychromatic stage, whereas in case 1 the cell population was formed only by mature orthochromatic erythroblasts.

Under our conditions of cell maintenance *in vitro*, rate of RNA synthesis decreased in all populations studied, reaching a plateau after an interval which in case 1 was much shorter than in cases 2 and 3, and sedimentation experiments indicate that the decrease concerned mainly ribosomal RNA. Since a population containing only mature cells synthesize much less ribosomal RNA than a population containing immature cells, it seems reasonable to suppose that the decrease in ribosomal RNA synthesis which accompanies the *in vitro* survival is not the result of *in vitro* conditions, but rather may be associated with the maturation process.

Our results do not give any information about the functional significance of the rapidly sedimenting non ribosomal RNA synthesized in human mature erythroblasts. The synthesis of an RNA with similar characteristics has been already observed in several types of cells, such as duck nucleated erythrocytes [1, 12], HeLa cells [17] and human small lymphocytes [16].

It seems possible to conclude that erythroblastic populations formed by cells at different level of maturation synthesize a high molecular weight RNA which is, at least in part, a ribosomal precursor. The synthesis of ribosomal precursor RNA decreases during the incubation of erythroblasts *in vitro*. Rather than being the result of *in vitro* conditions, this phenomenon, as previously implied, could be related to the maturation of erythroblasts. In fact, the rate of synthesis of ribosomal precursor was much lower in one of the populations studied formed only by mature orthochromatic erythroblasts.

*Conclusions.* We wish to thank Mr. E. Ruffalo for his generous financial help and Dr. MARIA SOLLA and of Research Laboratories Farmitalia Milan for gifts of HeLa cells.

## Summary

Erythroblastic populations of different maturation levels synthesize a high molecular

stud ed, formed only by mature orthochromatic cells

## References

- 1 ATTARDI, G., PARNAS, H., HWANG, M. I. H. and ATTARDI, B. Giant size rapidly labeled nuclear ribonucleic acid in immature duck erythrocytes *J molec Biol* 20 145 (1966)
- 2 DE BELLIS, R. H., GLUCK, N. and MARKS, P. A. Synthesis of ribonucleic acid in rabbit blood cells *in vivo* *J clin Invest* 43 1329 (1964)
- 3 FANTONI, A., DE LA CHAPELLE, A., RIFKIND, R. A. and MARKS, P. A. Erythroid cell development in fetal mice. Synthetic capacity for different proteins *J molec Biol* 33 79 (1968)
- 4 GREENBERG, H. and PENMAN, S. Methylation and processing of ribosomal RNA in HeLa cells *J molec Biol* 21 527 (1966)
- 5 KIRBY, K. S. Isolation and characterization of ribosomal ribonucleic acid *Biochem J* 96 266 (1963)
- 6 MARKS, P. A., BURKA, E. R. and SCHLESSINGER, D. Protein synthesis in erythroid cells *J molec Biol* 17 117 (1966)
- 7 PENMAN, S. RNA metabolism in the HeLa cell nucleus *J molec Biol* 17 117 (1966)
- 8 PENMAN, S. RNA metabolism in the HeLa cell nucleus *J molec Biol* 17 117 (1966)
- 9 RIFKIND, R. A., DANON, D. and MARKS, P. A. Alterations in polyribosomes during maturation of erythroid cells. Characteristics of rapidly labeled polyribosomes *J molec Biol* 486 (1962)
- 10 SCHERER, R., LATHAM, H. and DARNELL, J. E. Demonstration of an unstable RNA and of a precursor to ribosomal RNA in HeLa cells *Proc nat Acad Sci* 49 240 (1963)
- 11 SCHERER, R., MARCAUD, L., ZAJDELA, F., LONDON, I. M. and GROS, F. Patterns of RNA metabolism in a differentiated cell: a rapidly labeled, unstable 60 S RNA with characteristics of rapidly labeled polyribosomes *J molec Biol* 486 (1962)
- 12 SCHERER, R., MARCAUD, L., ZAJDELA, F., LONDON, I. M. and GROS, F. Patterns of RNA metabolism in a differentiated cell: a rapidly labeled, unstable 60 S RNA with characteristics of rapidly labeled polyribosomes *J molec Biol* 486 (1962)
- 13 SCHERER, R., MARCAUD, L., ZAJDELA, F., LONDON, I. M. and GROS, F. Patterns of RNA metabolism in a differentiated cell: a rapidly labeled, unstable 60 S RNA with characteristics of rapidly labeled polyribosomes *J molec Biol* 486 (1962)
- 14 STORTI, E., LEONCINI, G., TRALDI, A. and FORNANI, G. Metabolic aspects of erythrocytes and leukocytes in a case of congenital non spherocytic haemolytic anemia *Acta haematol, Basel* 35 284 (1966)
- 15 TORELLI, L., ARTUSI, T., GROSSI, G., EMILIA, G. and MAURI, C. An unstable ribonucleic acid in normal human erythrocytes *J molec Biol* 486 (1962)
- 16 TORELLI, L., ARTUSI, T., GROSSI, G., EMILIA, G. and MAURI, C. An unstable ribonucleic acid in normal human erythrocytes *J molec Biol* 486 (1962)

- 17 WARNER, J. R., SOEIRO, R., BIRNBOIM, H. C., GIRARD, M. and DARNELL, J. E. Rapidly labeled HeLa cell nuclear RNA. Identification by zone sedimentation of a heterogeneous fraction separate from ribosomal precursor RNA. *J. molec. Biol.* **19**, 319 (1966)

## Reticulocyte Generation Time and Rate of Discharge from the Marrow<sup>1</sup>

D A GRIFFITHS, C ROSSE, A E EDWARDS, C G C GACHES,  
A H L LONG, J L W WRIGHT and J M YOFFEY

Department of Anatomy, University of Bristol Bristol and Department of Biological  
Structure, University of Washington Seattle, Wash

The number of reticulocytes in the circulating blood is regarded as a valid index of erythropoietic activity. Since practically all red cells are discharged from the marrow while they still possess varying amounts of the substantia granulo filamentosa (SGF) [1], the commencement of the reticulocytosis may also be used as an index of red cell release into the circulation, particularly when erythropoiesis is newly established after a period of depression. Furthermore, the amount of SGF is inversely proportional to the stage of maturity of reticulocytes [2], and therefore, the maturation time of red cell precursors will be represented by the time required for the youngest forms of reticulocytes to appear in the marrow and blood following an erythropoietic stimulus. A quantitative assessment of the reticulocyte response will indicate not only the time required for maturation of red cell precursors, but will also permit a more accurate estimation of the numbers of cells which entered on erythroid differentiation in response to the stimulus.

The polycythemic animal in which erythropoiesis is depressed and in which there are few reticulocytes in either marrow or blood, provides a convenient starting point for the study of red cell maturation following an erythropoietic stimulus.

<sup>1</sup> Supported in part by NIH grant No. AM CA 13145 to C. Rosse and in part by research funds of the Department of Anatomy, University of Bristol, England.



## Materials and Methods

*Animals and Procedure* Polycythemia (around  $6 \times 10^6$  mm<sup>3</sup> blood) was induced in young male guinea pigs of Dunkin-Hartley strain by subjecting them to hypoxia in a chamber at  $\frac{1}{2}$  atmospheric pressure. After 7 days of hypoxia, the guinea pigs were kept in ambient air (period of 'rebound'). On the 9th day of rebound they were divided into two groups: in one group, 10-12 ml of blood was withdrawn by cardiac puncture under light ether anesthesia; in the second group, the animals were not bled and they served as the control. The bled animals were killed in groups of 8 on days, 1, 1 $\frac{1}{2}$ , 2, 2 $\frac{1}{2}$ , 3, 4, 5 and 6 after bleeding. The control animals were also sacrificed in groups of 8 at daily intervals for 6 days (i.e., on the 9th to 15th days of rebound).

Red cell count, hemoglobin, PCV estimations and reticulocyte studies were carried out on mixed venous and arterial blood obtained from the aorta and inferior vena cava at the time of exsanguination. The spleen was weighed and fixed in Zenker formal. Sections were cut at 2  $\mu$  and stained with a modification of Dominici's stain.

*Reticulocyte counts* Marrow and blood reticulocytes were studied on fixed smears [3]. The number of reticulocytes per mm<sup>3</sup> of blood was determined from the red cell count, and their number per mm<sup>3</sup> of marrow from the nucleated cell count obtained by the quantitative technique of Voffa [4].

*Differential counts of reticulocytes* were also made in both blood and marrow, classifying 200 reticulocytes in each into four maturation stages [2] as illustrated in figure 1.

*Statistical analysis* Means and standard deviations were calculated and the data were compared using Student's 't' test. Changes were regarded as significant if 'p' < 0.05 and highly significant if 'p' < 0.001.

## Results

*Red cell count.* In the unbled controls the polycythemia was maintained until the 12th day of rebound, but on the 13th day a significant decrease occurred representing a return toward normal values [5]. In bled animals, the red cell count remained significantly below normal to the end of the observation period ( $2.72 \pm 0.56 \rightarrow 3.90 \pm 0.68 \times 10^6/\text{mm}^3$ ). Hemoglobin and PCV paralleled the changes in the red cell count.

*The spleen* of bled animals showed the first signs of weight increase on the 3rd day ( $612 \pm 105 \rightarrow 917 \pm 254$  mg). This was accompanied by the appearance of young erythroblasts. No change was observed in the controls.

## The Quantitative Reticulocyte Response

a) *Marrow reticulocytes* (fig. 2) In the marrow of the controls the number of reticulocytes remained constant at a level markedly below the normal [6]. In bled animals, however, a significant fall was



Fig 1 Reticulocytes at different maturation grades in the blood, 4 days after Heed ne. Grade I the youngest forms contain a compact mass of SGF, almost completely filling the cell. In grade II the SGF is looser. In grade III it is in the form of loose filaments and granules. Grade IV the most mature forms contain only a few scattered granules. Cells containing a nucleus as well as SGF were not classified as reticulocytes. Marked anisocytosis is present. Stained with new methylene blue supravitaly. MacNeal's tetrachrome counterstain.  $\times 1800$ .




Fig. 2 Number of reticulocytes in the marrow during rebound and after bleeding. Mean  $\pm$  SD.

observed 24 h after bleeding ( $t = 2.5$ ;  $0.05 > p > 0.02$ ), representing the first measurable effect of the stimulus. Although an increase became evident on the 3rd day, only on the 5th day did it reach a significant level ( $t = 10.7$ ;  $p < 0.001$ ).

*b) Blood reticulocytes.* In the blood of the controls, reticulocytes remained at a level significantly below normal until the 14th day of rebound, when a threefold increase ( $t = 2.8$ ;  $p < 0.01$ ) restored their level to normal values [1]. Although in bled animals the values showed a wide variation, the first increase clearly occurred from day 2½ to day 3.

### Reticulocytes of Different Maturation Grades

*a) Marrow* (fig. 3). After bleeding the initial fall in reticulocytes was due to a significant decrease in the more mature forms. The youngest reticulocytes (grade I) showed the first increase from day 2½ to day 3 ( $t = 2.8$ ;  $0.05 > p > 0.02$ ), but this increase was not maintained. The most mature forms (grade IV) did not show any increase throughout the experiment.




Fig 3 Reticulocytes of different maturation grades in the marrow after bleeding. Mean values.




Fig 4 Reticulocytes of different maturation grades in the blood after bleeding. Mean values.

b) *Blood* (fig 4) Up to the 3rd day, reticulocytes were so few in the blood that their accurate grading was not possible. They were predominantly of the more mature type. On the 3rd day, however, reticulocytes of all grades appeared in the blood, and, even grade I continued to be present throughout the experiment. Grade IV showed a continuous increase, reaching a highly significant rise by the 6th day ( $t = 6.5, p < 0.001$ ). In unbled animals the onset of peripheral reticulocytosis was associated with the appearance of grade I reticulocytes in blood and marrow on the 14th day of rebound.

### Discussion

*Reticulocyte discharge from the marrow* In unstimulated animals the abrupt increase in blood reticulocytes was preceded by the return of the red cell count to the range of normal. Although the peripheral reticulocytosis was heralded by the reappearance of erythroblasts [7], restoration of the marrow reticulocyte reserve to the normal level did not take place. In stimulated animals, however, in contrast to the controls, a highly significant accumulation of reticulocytes within the

marrow paralleled the rise in blood reticulocytes. Comparison of these observations with previous studies suggests that the accumulation of reticulocytes in the marrow may be related to the severity of the erythropoietic stimulus. No increase was noted in the marrow at simulated altitudes of 10,000 feet [8], 14,000 feet [5, 9], but a marked increase occurred at 17,000 [10] and 20,000 [8]. During stimulation the increase in marrow reticulocytes was not due to the blocking of the discharge mechanism as it had been suggested [11]. The following observations indicate that reticulocyte discharge was, in fact, accelerated while their numbers were rising within the marrow: (a) marrow and blood reticulocytes increased simultaneously, (b) the peripheral reticulocytosis was unlikely to be due to a splenic contribution, since the splenic response lagged behind that of the marrow, and also because erythropoietin does not produce a reticulocyte release from the spleen, as it does from the marrow [12], (c) grade I reticulocytes showed only a transient peak in the marrow, but they were continuously present in the blood following that peak. They are usually absent from normal blood, (d) in contrast to normal guinea pig blood, grade II and grade III reticulocytes outnumbered the most mature forms, and (e) grade IV reticulocytes never accumulated in the marrow, but showed a continuous increase in the blood.

The uncorrected anemia and the similarity of the reticulocyte curve to the response obtained by repeated daily injections of erythropoietin [13] suggest that in the present experiment the stimulus was operating continuously. Consequently, the accumulation of reticulocytes in the marrow, in spite of their accelerated discharge, can only be explained by a faster rate of red cell production than red cell release.

*The timing of the reticulocyte response.* The latent period before an increase in circulating reticulocytes following erythropoietic stimulation of normal marrow is well documented [5, 9, 14]. In erythropoietically suppressed marrow this period may be expected to be longer.

The non-significant increase in more mature forms of marrow reticulocytes on day 1½-2½ probably reflected the maturation of the few remaining erythroblasts [7]. The significant increase in the youngest forms from day 2½ to day 3 on the other hand, must represent the cells that started their maturation from the erythroid precursor cell. Since erythropoietin has been shown to be present in blood one hour after bleeding [15] and also to produce a measurable response after acting for 6 h on suppressed marrow [16] the present findings indicate

that the time required for the erythropoietin sensitive cell to reach the reticulocyte stage is of the order of  $2\frac{1}{2}$ –3 days

*Acknowledgement* The technical assistance of Mr M FISHER is acknowledged.

### Summary

The reticulocyte response was studied in the blood and bone marrow of guinea pig whose erythropoiesis, following prolonged depression was restimulated by massive acute hemorrhage. The number of reticulocytes fell in blood and marrow 24 h after the stimulus. In the marrow the first increase was noted in the youngest forms of reticulocytes from day  $2\frac{1}{2}$  to day 3, indicating the maturation time of red cell precursors from the erythroid

reticulocytes

### References

- 1 SEIF, M. Reticulocyte studies. *Acta med. scand.* 146 Suppl. 282: 1 (1953)
- 2 TRACHTENBERG, F. Reticulozytenstudien. I. Zahl und Differenzierungsformel der Reticulozyten beim Normalen. *Folia haemat.* 46: 1 (1932)
- 3 BRUYAN, R. K. A method for a permanent preparation of blood and bone marrow reticulocytes. *J. Anat., Lond.* 53: 300 (1964)
- 4 YOFFEY, J. M. *Bone Marrow Reactions* (Edward Arnold, London 1966)
- 5 MOFFATT, D. J., ROSSE, C., SUTHERLAND, I. H. and YOFFEY, J. M. Studies on hypoxia. I. The response of the bone marrow to primary hypoxia. *Acta anat.* 58: 26 (1964)
- 6 BRUYAN, R. K. The effect of intermittent hypoxia upon haemopoiesis in guinea pig. Ph. D. Diss., Bristol (1965)
- 7 ROSSE, C., GRIFFITHS, D. A., EDWARDS, A. E., GACHES, C. G. C., LONG, A. H. L., WRIGHT, J. L. W. and YOFFEY, J. M. Identity of erythroblast precursors in bone marrow. *Acta haemat., Basel* 43: 80 (1970)
- 8 YOFFEY, J. M., SMITH, N. C. W. and WILSON, R. S. E. Studies on hypoxia. V. Changes in the bone marrow during hypoxia at 10 000 and 20 000 feet. *Scand. J. Haemat.* 4: 145 (1967)
- 9 YOFFEY, J. M., ROSSE, C., MOFFATT, D. J. and SUTHERLAND, I. H. Studies on hypoxia. III. The differential response of the bone marrow to primary and secondary hypoxia. *Acta anat.* 62: 476 (1965)
- 10 YOFFEY, J. M. *Journal of the Royal Microscopical Society* 87: 1 (1967)
- 11 SAATHOFF, J. Medullare und extramedullare Erythropoiesis. *Acta haemat.* 43: 80 (1970)

- 13 GURNEY, C. W. WACKMAN, N. and FILMANOWICZ, F. Studies on erythropoiesis. VII. Some quantitative aspects of the erythropoietic response to erythropoietin. *Blood* 17 531 (1961)
- 14 SAATHOFF, J. Über die Latenzzeit des Reticulocyten Anstieges bei Sauerstoffmangel. Versuche an Meerschweinchen und Kaninchen. *Virchows Arch.* 319 107 (1950)
- 15 GORDON, A. S. Hemopoietin. *Physiol. Rev.* 39 1 (1959)
- 16 SCHOOLEY, J. C. Responsiveness of hemopoietic tissue to erythropoietin, in relation to the time of administration and duration of action of the hormone. *Blood* 25 795 (1965)

Authors' address: Dr C. ROSE, Department of Biological Structure, University of Washington, School of Medicine, Seattle, Wash. 98105 (USA). Drs. D. A. GRIFFITHS, A. E. EDWARDS, C. G. C. GACHES, A. H. L. LONG, J. L. W. WRIGHT and J. M. YOFFEY, Department of Anatomy, University of Bristol School of Medicine, Bristol (England). Requests for reprints should be addressed to Dr C. ROSE.

## Pre-Leukaemic Acute Myelogenous Leukaemia<sup>1</sup>

S KUMAR and MANORAMA BHARGAVA

Department of Pathology, Lady Hardinge Medical College, New Delhi

KAPLAN *et al* [8] reported that, in radiation-induced mouse leukaemia treatment of animals with cortisone, in the phase preceding the development of leukaemia, reduced its incidence. This heightened the possibility of recognition of a pre-leukaemic state in human leukaemia with far reaching therapeutic implications. In 1953, BLOCK *et al.* [3] described 12 patients with anaemia, leukopenia and/or purpura in whom, during the period of the blood dyscrasia lasting from 3 to 17 months, none of the recognizable signs and symptoms of leukaemia were present. Later 10 of these patients developed acute myelogenous leukaemia. A number of other observers have also reported the development of acute myeloid leukaemia in patients with an initial blood picture of anaemia, neutropenia or thrombocytopenia or various combinations of these lasting for variable periods [1, 2, 5, 7, 10, 12, 13]. Whether or not these initial blood changes observed before the onset of recognizable acute leukaemia represent a pre-leukaemic stage in its evolution cannot be definitely stated unless more is known about the nature of leukaemia. The purpose of the present communication is to record 7 more instances of acute myelogenous leukaemia in whom a variety of haematologic disorders were encountered before frank leukaemia became evident.

### Material

The 7 cases reported varied in age from 10 to 53 years. Four were females (table 1). They were drawn from a large number of patients referred to our laboratory for blood

<sup>1</sup> Paper presented at the 15th Congress of Asian and Pacific Society of Haematology held in New Delhi in November 1967.



Table I Summary of clinical data on 7 patients

| Case No.       | Age years | Sex | Chief complaints                     | Pre-leukaemic changes |   | Bone marrow                                      | Final diagnosis             |
|----------------|-----------|-----|--------------------------------------|-----------------------|---|--|-----------------------------|
|                |           |     |                                      | Duration months       | Blood   |  |                             |
| 1              | 26        | M   | bony pain, fever                     | 6.5                   | anaemia, neutropenia                                | hypercellular, preponderance of myeloid elements | acute myelogenous leukaemia |
| 2              | 28        | M   | fever, joint pains                   | 9                     | anaemia, neutropenia                                | hypercellular, preponderance of myeloid elements | acute myelogenous leukaemia |
| 3              | 10        | M   | purpura                              | 7                     | thrombocytopenia, neutropenia, anaemia <sup>1</sup> | hypercellular, preponderance of myeloid elements | acute myelogenous leukaemia |
| 4              | 46        | F   | weakness, exertional dyspnoea        | 6                     | pancytopenia  | aplastic   | acute myelogenous leukaemia |
| 5              | 42        | F   | easy fatigability, episodes of fever | 8                     | pancytopenia  | aplastic   | acute myelogenous leukaemia |
| 6              | 58        | F   | loss of stamina, dyspnoea            | 8                     | anaemia, neutropenia                                | hypoplastic                                      | acute myelogenous leukaemia |
| 7 <sup>1</sup> | 32        | F   | exertional dyspnoea, headaches       | 18                    | pancytopenia  | aplastic   | acute myelogenous leukaemia |

<sup>1</sup> History of ingestion of chloramphenicol

examinations during the period 1955 to 1967. Cases 1, 2 and 3 were essentially diagnostic problems and came repeatedly as their blood changes did not conform to any known blood disorder. Many biochemical and bacteriological examinations, omitted from case reports that follow, were performed on these patients to exclude systemic diseases. The other 4 patients were initially diagnosed as suffering from aplastic anaemia and came up for routine

The development of leukaemia, when it occurred, was extremely sudden and the patients rapidly succumbed within 4 to 12 weeks of the onset of the disease

### Case Reports

**Case 1** A 26-year-old medical graduate complained of bouts of pain around the right hip since December 1955. Earlier, in 1941 he was confined to bed for nearly a fortnight




Fig 1 Case 1 blood changes throughout the illness. The arrow marks the first appearance of myeloblasts in peripheral blood. From this period onwards the graph indicates the percentage of neutrophils together with immature myeloid cells.

because of pain all over the body which responded to analgesics, and in 1950 he suffered from two attacks of infectious hepatitis. The bony pain was accompanied by episodes of fever (temperature 100–101°F) off and on.

Physical examination revealed no positive finding except a localized area of tenderness on the right ileum. X-rays of the hip and the chest revealed no abnormality. The hematologic work up of the patient from 1950 to 1955 and all through the period of his illness is set out in figure 1.

For nearly 6½ months the patient suffered from progressive, unexplained anaemia and neutropenia. During this period the platelets ranged between 170,000–300,000 per µl and the blood smears at no time revealed any abnormal cells. The anemia was normocytic and slightly hypochromic. Bone marrow smears were examined twice and showed hypercellularity with an increase in the myeloid elements (table II).

Twenty five days before his death the patient suddenly developed purpuric spots on his limbs, glands became enlarged in the axilla, and the spleen and liver became palpable. Total leukocytes shot up to 78,000/µl, consisting mostly of myeloblasts and promyelocytes.

**Case 2** This 28-years-old male sought medical advice several times during the last 9 months of his life because of fever off and on and pain around the joints. First his left elbow was involved, a week later the right elbow became affected. This was followed 3 months later by swelling around the left ankle. The right ankle was similarly affected 2 months after. There was no effusion in any of the joints and no limitation of movement except that due to pain. The pain was relieved with analgesics.

The patient was well nourished, vital signs were normal and the physical examination did not reveal any abnormality. X-rays of the joints and chest were found normal.

A month prior to his death, the patient came in with marked pallor and puffiness around the face. Tonsils were not enlarged but enlarged lymphnodes were discernable in the sub-mandibular, submental and posterior cervical regions. Gums were swollen and hypertrophic.

Table II Cases 1 and 2 differential count of the bone marrow (%)

| Cells          | Case 1               |                       | Case 2                |                       |                       |
|----------------|----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                | 1 month <sup>1</sup> | 4 months <sup>1</sup> | 2 months <sup>1</sup> | 5 months <sup>1</sup> | 8 months <sup>1</sup> |
| Myeloblast     | 2.0                  | 6.6                   | 3.5                   | 5.8                   | 5.0                   |
| Promyelocyte   | 12.5                 | 22.5                  | 11.0                  | 18.6                  | 21.6                  |
| Myelocyte      | 26.0                 | 26.8                  | 23.0                  | 28.2                  | 30.0                  |
| Metamyelocyte  | 19.0                 | 17.0                  | 17.0                  | 7.0                   | 8.5                   |
| Neutrophil     | 14.0                 | 5.0                   | 15.8                  | 12.0                  | 9.0                   |
| Eosinophil     | 3.0                  | 2.0                   | 2.2                   | —                     | 1.3                   |
| Basophil       | —                    | 0.5                   | —                     | 0.6                   | 0.5                   |
| Lymphocyte     | 12.0                 | 6.0                   | 14.6                  | 10.0                  | 8.6                   |
| Monocyte       | 1.5                  | 1.6                   | 2.4                   | 5.0                   | 3.5                   |
| Plasma cell    | 1.0                  | 1.4                   | —                     | 0.8                   | 1.0                   |
| Normoblasts    | 9.0                  | 10.6                  | 10.5                  | 12.0                  | 8.0                   |
| Megakaryocytes | adequate             | adequate              | adequate              | adequate              | adequate              |
| M:E ratio      | 4.5:1                | 7.5:1                 | 7.0:1                 | 6:1                   | 9.0:1                 |

<sup>1</sup> After the first onset of symptoms

There were a few petechiae and resolving ecchymoses above the left knee. A number of hard, discrete, subcutaneous nodules were palpable all over the body, particularly marked on the thighs. These were histologically found to be leukaemic deposits. The spleen and liver were enlarged 8 cm and 4 cm respectively.

The haematologic work up of this patient during the entire period of his illness is charted in figure 2. The significant features were a progressive fall of haemoglobin from 13.8 to 5.5 g%, over a period of 9 months preceding the onset of leukaemic symptoms. The anaemia was normocytic and hypochromic, associated with neutropenia but the platelets were within normal limits except terminally. Prior to the recognition of leukaemia at no time were immature cells seen in peripheral blood. Only stray nucleated red cells were found.

Bone marrow smears were examined at second, fifth and eighth months after the onset of his symptoms, mainly to exclude a hypoplastic change of the bone marrow. The findings presented in table II showed each time hypercellular marrow with an increase in earlier forms of myeloid cells.




Fig 2 Case 2 blood changes throughout the illness. The arrow marks the first appearance of myeloblasts in peripheral blood. From this period onwards the graph indicates the percentage of neutrophils together with immature myeloid cells.

**Case 3** A 10-year-old boy was followed up from March 1955 to July 1956, at which time he came up for his last admission with classical signs and symptoms of acute leukaemia, consisting of fever, marked pallor, stomatitis, tender and bleeding gums, enlargement of lymphnodes in the axillary, cervical and inguinal regions, hepato-splenomegaly and pronounced sternal tenderness.

He sought medical advice first, in March 1955, for episodes of epistaxis coming on occasionally since October 1954. Hematologic investigations during the episodes showed thrombocytopenia, with platelet counts varying from 68,000-110,000 per  $\mu$ l (table III), accompanied by increased bleeding time, positive capillary fragility (+ +) and poor clot retraction. A diagnosis of idiopathic thrombocytopenic purpura was made, but as the episodes of epistaxis were self limiting no treatment was given. Bone marrow smears examined during this period showed no abnormality.

From November, 1955 his chief complaints were evening rise of temperature varying from 99° to 100°F and rarely going up to 102°F, together with progressive loss of weight. Physical examination was completely normal. Numerous laboratory investigations were obtained, including X-ray of the chest, cultures of blood, urine and sputum, serologic tests for typhoid fever and brucellosis and examination of blood and bone marrow smears for parasites. The haematologic data during the course of his illness is summarized in table III.

Table III Case 3 summary of blood and bone marrow changes

| Date     | Leukocytes<br>$\times 10^3/\mu$ l | Neutrophils<br>% of WBC | Platelets<br>$\times 10^3/\mu$ l | Hb<br>g% | Bone marrow   |
|----------|-----------------------------------|-------------------------|----------------------------------|----------|---|
| March 55 | 12.5                              | 61.0                    | 72.0                             | 11.0     | normocellular<br>M/E ratio 5.8:1<br>megakaryocytes adequate |
| June 55  | 8.6                               | 64.0                    | 85.0                             | 10.8     |   |
| Aug. 55  | 9.2                               | 60.0                    | 106.0                            | 10.5     |   |
| Nov. 55  | 6.8                               | 49.0                    | 110.0                            | 10.5     |   |
| Dec. 55  | 5.0                               | 45.0                    | 90.0                             | 9.8      | hypercellular<br>M/E ratio 6.9:1<br>megakaryocytes adequate |
| Jan. 56  | 5.5                               | 43.0                    | 85.0                             | 9.5      |   |
| Feb. 56  | 6.2                               | 41.0                    | 94.0                             | 9.7      |   |
| March 56 | 5.8                               | 38.0                    | 98.0                             | 9.3      | hypercellular<br>M/E ratio 8:1<br>megakaryocytes normal     |
| April 56 | 11.0                              | 49.0                    | 102.0                            | 9.0      |   |
| May 56   | 22.5                              | 69.0 <sup>1</sup>       | 72.0                             | 9.0      |   |
| June 56  | 70.0                              | 87.0 <sup>1</sup>       | 68.0                             | 8.2      |   |
| July 56  | 112.0                             | 95.0 <sup>1</sup>       | 60.0                             | 7.5      |   |
| Aug. 56  | 94.0                              | 92.0 <sup>1</sup>       | 76.0                             | 7.0      |   |
| Sept. 56 | 105.0                             | 94.0 <sup>1</sup>       | 71.0                             | 6.8      |   |

<sup>1</sup> Stray myeloblasts seen

<sup>2</sup> Large number of myeloblasts and promyelocytes present

The anaemia was hypochromic and macrocytic, characterized by the appearance of fair number of late and intermediate normoblasts in the terminal stages. The bone marrow revealed an increase in cellularity with preponderance of relatively immature myeloid elements and an M/E ratio of 6.9:1.

The patient was treated with broad spectrum antibiotics, anti tubercular drugs and for Kala Azar without any benefit until May 1956, when typical signs and symptoms of acute leukaemia appeared.

**Cases 4, 5, 6, 7** These 4 cases who were females between the ages 34 to 58 years may be considered together as the course of their illness was essentially similar. They all presented with variable symptoms attributable mainly to progressive anaemia. These included pallor, weakness, dyspnoea particularly on exertion, and mild oedema. Significant clinical findings were the absence of any liver, spleen and lymphnode enlargement and lack of bony tenderness. Other systems were entirely normal.

The haemoglobin in these patients varied from 3.5 to 11.2 g % at different periods. There was consistent leukopenia and some degree of thrombocytopenia in at least 3 of the cases (table IV). Examination of the blood smear showed that anaemia was normocytic or macrocytic with MCV ranging between 80 to 102  $\mu\text{m}^3$ . The reticulocyte counts varied from 1.6 to 4.5%.

In all these patients the diagnosis of aplastic or hypoplastic anaemia was reached on the basis of peripheral cytopenia and examination of sternal aspirate. In 3 instances hypocellularity of the bone marrow was confirmed by biopsy. In case 7, the bone marrow aplasia followed the administration of 4 courses of chloramphenicol at intervals of 2-4 weeks, during which she received a total of 20.0 g of the drug for treatment of an eye infection.

As shown in table IV, 6 to 18 months following the onset of aplastic anaemia, these patients developed signs and symptoms that eventually became typical of acute leukaemia. The spleen gradually became enlarged, lymphadenopathy developed and in two the liver also became palpable.

Table IV Cases 4-7 summary of haematologic data before transition into acute leukaemia

| Case No | Hb g%    | Leukocytes $\times 10^3/\mu\text{l}$ | Platelets $\times 10^4/\mu\text{l}$ | Bone marrow smear | Biopsy      | Duration of aplastic phase months |
|---------|----------|--------------------------------------|-------------------------------------|-------------------|-------------|-----------------------------------|
| 4       | 4.5-10.8 | 1.4-5.3                              | 85-178                              | hypo-cellular     | aplastic    | 6.0                               |
| 5       | 6.0-11.2 | 2.0-5.4                              | 156-227                             | hypo-cellular     | hypoplastic | 8.0                               |
| 6       | 3.5-9.0  | 3.0-7.5                              | 77-196                              | hypo-cellular     | not done    | 10.0                              |
| 7       | 5.2-10.0 | 1.1-4.8                              | 94-184                              | hypo-cellular     | aplastic    | 18.0                              |

Each determination shows the range of variation observed during the course of illness.

*Discussion*

The question may be raised whether it is justifiable to differentiate a pre-leukaemic from a leukaemic phase during the illness of a patient who dies of leukaemia. So diverse are the manifestations of leukaemia that the patient could be considered as having leukaemia from the very onset of symptoms. In our cases such differentiation was made possible only on haematological grounds. Thus, the laboratory investigations showed that in none of the patients, in the pre-leukaemic phase, the characteristic enlargement of any of the haemopoietic tissues was demonstrable. On the other hand, 4 of the patients presented with classical features of aplastic anaemia. We have considered these as important criteria to exclude the diagnosis of leukaemia.

The transition to acute myelogenous leukaemia occurred after a variable period of illness during which two types of changes were observed in the blood. In the first 3 cases there was peripheral cytopenia associated with hypercellular marrow, showing an increase in the proportion of immature myeloid cells. The other 4 patients revealed peripheral cytopenia with hypoplasia or aplasia of the bone marrow, without any increase in the primitive cells.

In their studies on behalf of the Atomic Bomb Casualty Commission, MOLONEY and LANGE [15] followed 4 patients for periods of 5 to 37 months before the development of myelogenous leukaemia. During this period, these patients exhibited variable leukocytosis with a tendency to hypercellularity in the bone marrow associated with myeloid immaturity, in 3 of the 4 cases. Anaemia was not a prominent feature.

The occurrence of leukaemia in case 7 is of particular interest in as far as it illustrates that a nonspecific hypersensitivity reaction, like the one caused by chloramphenicol in this instance, may eventually lead to the development of leukaemia. This is further suggested by the case reported by STRAUSS [16] who observed leukaemia to occur following a second vaccination by typhoid and paratyphoid vaccine.

The relationship, if any, between the haematologic changes observed in the pre-leukaemic period to the development of leukaemia, remains obscure. There is, however, evidence to suggest that both aplasia of the haemopoietic tissue as well as the hyperplastic changes in the bone marrow such as described herein, may be regarded as potentially leukaemic disorders. Thus, observations concerning the effect of benzol on the haemopoietic tissue suggest that a range of variation from

complete aplasia of the bone marrow without any evidence of regeneration to a picture closely resembling leukaemia may develop. The myelogenous leukaemia which follows chronic benzol poisoning may be superimposed on aplastic anaemia, or agranulocytosis, the bone marrow being severely hypoplastic or hyperplastic with maturation arrest of granulocytes [4, 6-11]. Further, in experimental animals, the production of agranulocytosis following the administration of anti-leukocytic serum is associated in the bone marrow with maturation arrest of successively more and more primitive stages in the chain of granulocytes [9, 14] lending the marrow a close resemblance to that of leukaemia, although the peripheral blood shows only a picture of agranulocytosis.

It appears that the ultimate reaction of the bone marrow to such agents may be determined by several factors. The dose and length of exposure to the agent, the condition of the affected individual, and the capacity of the marrow tissue to regenerate or, instead, to form 'scar tissue', are some of the factors considered important [17].

It is common experience that blood and bone marrow changes, as described here in the pre-leukaemic stage, rarely terminate in leukaemia. When and why do these changes acquire a leukaemic propensity is not possible to state on the basis of available knowledge. Further studies directed to characterize the pre-leukaemic haemopoietic tissue biochemically or genetically may throw light on the relationship of 'pre-leukaemic' states with true leukaemia.

### Summary

Seven cases are described in whom the development of acute myelogenous leukaemia was preceded by a variety of haematologic disorders. In the pre-leukaemic state which lasted from 6 to 18 months these patients showed anaemia, neutropenia or pancytopenia. There was no evidence of haemolysis. In 3 cases the bone marrow was hypercellular with increase of relatively immature myeloid cells. In the other 4 it was aplastic. In the pre-leukaemic stage none of the patients manifested signs or symptoms characteristic of leukaemia. The development of leukaemia was sudden and resulted in death within 4 to 12 weeks. The problem of pre-leukaemic state in the evolution of acute human leukaemia is discussed.

### References

1. BEYERS M. R., MEYER L. M., LOWENTHAL, M., OEHRIE R. J. and SATTIRY A. A hypocellular marrow in acute leukaemia. Report of 2 cases. Arch. intern. Med. 83: 803 (1951).



- 1. The first of these is the fact that the...
- 2. The second is the fact that the...
- 3. The third is the fact that the...
- 4. The fourth is the fact that the...
- 5. The fifth is the fact that the...
- 6. The sixth is the fact that the...
- 7. The seventh is the fact that the...
- 8. The eighth is the fact that the...
- 9. The ninth is the fact that the...
- 10. The tenth is the fact that the...
- 11. The eleventh is the fact that the...
- 12. The twelfth is the fact that the...
- 13. The thirteenth is the fact that the...
- 14. The fourteenth is the fact that the...
- 15. The fifteenth is the fact that the...
- 16. The sixteenth is the fact that the...
- 17. The seventeenth is the fact that the...
- 18. The eighteenth is the fact that the...
- 19. The nineteenth is the fact that the...
- 20. The twentieth is the fact that the...

## Eosinophil Leucocytes and Recovery from Severe Hypoxia

YVONNE D L SIBLEY and G HUDSON

Department of Anatomy University of Bristol and Department of Haematology University of Sheffield, Sheffield

In a quantitative study already reported [8], striking changes were observed in the numbers of eosinophil granulocytes in the blood and bone marrow of guinea pigs following continuous exposure to a barometric pressure equal to that at an altitude of 20,000 ft (6,096 m) for periods of between 1 and 12 days. From the first day of this exposure to severe hypoxia, the blood eosinophils were increased in number, while the marrow eosinophils showed marked depletion. This confirmed the findings of a preliminary investigation [16] in which similar changes were noted at a simulated altitude of 20,000 ft (6,096 m) although not at one of 10,000 ft (3,048 m). It was apparent that further investigation would be needed to throw light on the import of these changes and it was hoped that further clues might be provided as to the function of the eosinophil leucocytes. In the experiments to be reported here, quantitative methods were used to study the changes in guinea pigs at intervals of between 0 and 7 days following a period of 5 days exposure to severe hypoxia at a simulated altitude of 20,000 ft.

### *Material and Methods*

Healthy male albino guinea pigs of the Dunkin-Hartley strain and aged about 6 or 7 weeks old were placed in a decompression chamber and exposed to a barometric pressure (approx. 330 mm Hg) corresponding to that at an altitude of approximately 20,000 ft (6,096 m) for 5 days. The exposure was continuous except for a short period each day when the chamber was returned to atmospheric pressure to enable the animals to be weighed, the chamber cleaned and the food and drinking water renewed. The processes of compression and decompression each took about 10 min: the rate never being allowed to exceed 4,000 ft (1,220 m) per minute.

TABLE 1.—*Mean granulocyte counts per mm. of sediment in blood plasma and marrow of rats.*

|        | White<br>granulocytes | Neutrophils  | Lymphocytes  | Monocytes   | Eosinophils | Basophils   | Other      |
|--------|-----------------------|--------------|--------------|-------------|-------------|-------------|------------|
| Day 0  | 3000<br>= 700         | —<br>= 50    | 1200<br>= 70 | 800<br>= 80 | 20<br>= 20  | 90<br>= 10  | 20<br>= 10 |
| Day 1  | 3000<br>= 700         | 3000<br>= 80 | 1200<br>= 70 | 20<br>= 20  | 20<br>= 20  | 1<br>= 10   | 11<br>= 0  |
| Day 2  | 3000<br>= 700         | 3000<br>= 80 | 400<br>= 100 | 100<br>= 20 | —<br>= 20   | 40<br>= 10  | 15<br>= 1  |
| Day 3  | 3000<br>= 700         | —<br>= 50    | 40<br>= 100  | —<br>= 20   | 20<br>= 20  | 100<br>= 10 | 20<br>= 0  |
| Day 4  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 5  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 6  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 7  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 8  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 9  | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 10 | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 11 | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |
| Day 12 | 3000<br>= 700         | 40<br>= 50   | 30<br>= 100  | 10<br>= 20  | 20<br>= 20  | 100<br>= 10 | 10<br>= 1  |

— = same as

### DISCUSSION

The findings in the blood and bone marrow at day 0, immediately after a severe exposure to severe hypoxia, were very similar to those reported earlier [3] the main difference being that the blood eosinophil counts were even more strikingly elevated in the present series. In both series, all the marrow granulocytes showed a depression in numbers, the eosinophils being particularly affected and showing evidence of involution at all the three environmental stages studied. The findings at 10-12 intervals after the return to normal atmospheric pressure were characterized in general by a return to values similar to those in the control animals. In the previous experiments [3] when the hypoxia was continued for a further period of 7 days up to a total of 12 days' exposure it was noted that the blood and bone marrow picture continued to be similar to that noted here at day 0. It is concluded from this that the changes observed in the present series between day 0 and

Table III Granulocyte series in bone marrow (thousands per  $\mu$ l)

|         | Total<br>eosino                 | Eosino<br>PMC+MC | Eosino<br>MMC                  | Eosino<br>B+S                  | Eosino<br>other  | Total<br>baso     | Total<br>neutr               |
|---------|---------------------------------|------------------|--------------------------------|--------------------------------|------------------|-------------------|------------------------------|
| Control | 58.7<br>$\pm 16.3$              | 5.4<br>$\pm 3.6$ | 21.2<br>$\pm 6.5$              | 31.2<br>$\pm 13.3$             | 0.9<br>$\pm 0.7$ | 11.1<br>$\pm 5.7$ | 493<br>$\pm 14$              |
| Day 0   | 22.3 <sup>a</sup><br>$\pm 7.7$  | 2.5<br>$\pm 1.1$ | 8.1 <sup>a</sup><br>$\pm 3.1$  | 10.8 <sup>a</sup><br>$\pm 5.5$ | 0.9<br>$\pm 0.5$ | 7.5<br>$\pm 1.8$  | 337 <sup>a</sup><br>$\pm 88$ |
| Day 1   | 25.3 <sup>a</sup><br>$\pm 5.1$  | 2.5<br>$\pm 1.4$ | 5.9 <sup>a</sup><br>$\pm 2.1$  | 15.7 <sup>a</sup><br>$\pm 3.6$ | 1.2<br>$\pm 0.6$ | 7.7<br>$\pm 4.4$  | 320 <sup>a</sup><br>$\pm 60$ |
| Day 2   | 27.9 <sup>a</sup><br>$\pm 12.5$ | 2.6<br>$\pm 1.7$ | 6.9 <sup>a</sup><br>$\pm 1.9$  | 17.5<br>$\pm 10.4$             | 0.9<br>$\pm 0.3$ | 7.6<br>$\pm 1.8$  | 417<br>$\pm 97$              |
| Day 3   | 23.9 <sup>a</sup><br>$\pm 6.3$  | 4.6<br>$\pm 1.3$ | 8.5 <sup>a</sup><br>$\pm 4.1$  | 10.4 <sup>a</sup><br>$\pm 3.0$ | 0.4<br>$\pm 0.3$ | 7.2<br>$\pm 3.1$  | 371<br>$\pm 73$              |
| Day 4   | 28.4 <sup>a</sup><br>$\pm 8.1$  | 3.8<br>$\pm 1.6$ | 13.1 <sup>a</sup><br>$\pm 5.8$ | 10.9 <sup>a</sup><br>$\pm 4.4$ | 0.6<br>$\pm 0.6$ | 7.1<br>$\pm 3.9$  | 419<br>$\pm 11$              |
| Day 5   | 34.3 <sup>a</sup><br>$\pm 13.9$ | 4.5<br>$\pm 2.3$ | 17.1<br>$\pm 8.2$              | 12.3 <sup>a</sup><br>$\pm 5.6$ | 0.4<br>$\pm 0.5$ | 10.2<br>$\pm 2.9$ | 536<br>$\pm 11$              |
| Day 7   | 49.7<br>$\pm 10.3$              | 4.4<br>$\pm 2.3$ | 16.9<br>$\pm 3.7$              | 27.3<br>$\pm 9.1$              | 1.1<br>$\pm 1.0$ | 14.0<br>$\pm 6.5$ | 477<br>$\pm 93$              |

PMC+MC=Promyelocytes and myelocytes. MMC=metamyelocytes. B+S=band and segmented forms

<sup>a</sup>Total neutrophils includes myeloblasts

<sup>1</sup> see table I

day 7 were related to the return to normal barometric pressure and can be interpreted as representing the processes of recovery

The results appear to indicate that marrow eosinophil numbers were restored from the stem-cell end of the series. When compared with the corresponding control value, significant differences could no longer be detected at day 3 in the case of the promyelocytes and myelocytes, at day 5 with the metamyelocytes, and at day 7 in the case of the band and segmented forms. Such a pattern of recovery might be expected if it were the result of increased or restored proliferative activity, a few days being needed for the promyelocytes to develop into mature or almost mature forms. A similar pattern of recovery has been observed in the marrow granulo- and eosinophils after 10 days of corticosteroid administration (8) that the bone marrow had been markedly depressed

From table I, it may be seen that the blood eosinophilia had disappeared by day 2 and that on days 3, 4 and 5 eosinopenia was present. This indicates that in the early stages of recovery, more eosinophils were disappearing from the circulation than were entering it. It was previously noted [8] that during severe hypoxia, the circulatory eosinophilia was associated with a 'shift to the right' in the degree of nuclear segmentation and this was thought consistent with either the eosinophil granulocytes remaining longer in circulation or their re-entering it to a significant degree. The present findings would be consistent with a reversal of this, namely that during recovery there was a more rapid turnover of eosinophils in the blood. Thus, a possible explanation of the eosinopenia on days 3-5 is that it was caused by the time-lag between the commencement of increased eosinophil production in the marrow, and the supply of sufficient numbers of mature forms to maintain the normal blood level. The normal circulation transit time of eosinophil granulocytes is thought to be less than 24 h [3, 5, 14].

Mention may be made here of a preliminary experiment [GRANT, SIBLEY, MOFFATT and HUDSON, unpublished observation] in which a 400 g guinea pig received 5 intraperitoneal injections, each of 1  $\mu$ C/g of body weight at 2 hourly intervals. After the last injection, it was exposed to severe hypoxia under the same conditions as in the present series for a period of 15 days. Blood smears were made at 12 hourly intervals and 100 eosinophils were examined in autoradiographic preparations at each interval. Unlike a normal animal in which

(which was also observed on the 6th day) Although no significance should be attached to this result unless it can be repeated in a larger series, an observation that 100% labelling was not achieved might be explicable in terms of eosinophils remaining longer in circulation or re-entering it after they had left. An early appearance of labelled cells in the blood would not be inconsistent with the changes reported in the early stages of hypoxia [8].

To what extent do the present observations throw light upon factors involved in the eosinophil changes in severe hypoxia? Perhaps one may assume that changes in eosinophil production and distribution merely reflect on underlying disturbances of regulatory mechanisms and in relation to this one may first consider adrenocortical activity. Other quantitative studies [13] have suggested that in certain circumstances at least, cortical hormones may interfere with eosinophilotactic mechanisms, and a similar interpretation can be placed on the observations of other investigators [1, 27]. Furthermore, there is evidence that the adrenal cortex has an important role in adaptation to lowered oxygen tension [28, 29] and it seems likely that the marked increase in adrenal

weight at day 0 (table I) indicated hyperactivity of the adrenal cortex. Others have reported both an increase in adrenal weight and a decrease in the size of the thymus [29, 33] during exposure of experimental animals to lowered barometric pressures. The adrenal weight has been stated to be a good index of adrenocortical activity in experiments of more than a few days duration [25] although some of the weight increase in severe hypoxia might be attributable to the greatly increased vascularity which is known to occur in this condition [10, 28]. In the present experiments, the adrenal glands were still heavier than in the controls for up to 5 days after the period of hypoxia. The reduction in size of the eosinophil population of the bone marrow observed at day 0 was rather similar to that seen after the prolonged administration of glucocorticoids or ACTH [2, 6, 7, 19, 31] but the eosinophilia in the blood was in striking contrast to the eosinopenia characteristically seen after cortical hormone administration or in the stress reaction [4]. It should be borne in mind that the changes induced in other situations by stress and adrenocortical activity are sometimes difficult to interpret e.g. in the 'general adaptation syndrome' [25, 26].

Other factors may have been operative here. In particular, lowered oxygen tension (or one of the associated physicochemical changes) acting at the cellular level might conceivably have played a part by interfering with enzymatic or other mechanisms.

It has already been suggested by other investigations [9, 33] that the general decrease in granulocyte numbers which is observed in the bone marrow of the guinea pig in severe hypoxia (or after haemorrhage) may be partly attributed to the increased commitment of stem cells to red cell production. The possibility that local influences (physical, chemical or both) might be at work within the bone marrow has also been discussed [8] but it is thought unlikely that physical growth pressure of the expanding erythroblastic series was very important in the present circumstances. The possibility that the pattern of eosinophil cell production in extramedullary sites might differ in severe hypoxia from that in the bone marrow was not excluded by the preliminary observations on the histology of the spleen, although the apparent increase in the number of eosinophils in the spleen on day 0 could have been largely the result of infiltration.

The mechanisms underlying normal granulocyte production are known to be complex [23, 24] and perhaps it is not surprising that our understanding of the eosinophil changes in severe hypoxia and subse-



- 13 HUDSON, G The marrow reserve of eosinophils: effect of cortical hormones on the foreign protein response *Brit J Haemat* 10 122-130 (1964)
- 14 HUDSON, G Quantitative study of eosinophil granulocytes *Semin. Hemat.* 5 166-186 (1968)
- 15 HUDSON, G, OSMOND, D G and ROYLANCE, P J Cell populations in the bone marrow of the normal guinea pig *Acta anat.* 57 234-239 (1963)
- 16 HUDSON, G, SMITH, N C W, WILSON, R S and YOFFEY, J M Eosinophil granulocytes and hypoxia *Nature, Lond.* 213 818-819 (1967)
- 17 HUFF, R L, LAWRENCE, J H, SIRI, W E, WASSERMAN, L R. and HENNESSY, T G Effects of changes in altitude on hematopoietic activity *Medicine, Balt.* 30 197-217 (1951)
- 18 KALT, M and HUDSON, G Recovery of haemopoiesis after cyclophosphamide *Acta haemat., Basel* 41 170-179 (1969)
- 19 MEYER, H A and CRAFTS, R C. Further observations on the effect of cortisone and thyroxin on the blood picture of hypophysectomized rats *Blood* 12 11-23 (1957)
- 20 MONCE, C. Chronic mountain sickness *Physiol Rev* 23 166-184 (1943)
- 21 RANDOLPH, T G Blood studies in allergy: the direct counting chamber determinations of eosinophils by propylene glycol aqueous stains *J Allergy* 15 89-96 (1944)
- 22 ROGERS, A. F A high altitude chamber for small animals *J Anat., Lond.* 102 160-161 (1968)
- 23 RYTÖMÄ, T and KIVINIEMI, K Control of granulocyte production I Chalone and anti-chalone, two specific humoral regulators *Cell Tissue Res.* 1 329-340 (1968)
- 24 RYTÖMÄ, T and KIVINIEMI, K Control of granulocyte production II Mode of action of chalone and anti-chalone *Cell Tissue Res.* 1 341-350 (1968)
- 25 SAYERS, G The adrenal cortex and homeostasis. *Physiol. Rev* 30 241-320 (1950)
- 26 SELYE, H The alarm reaction and the diseases of adaptation. *Ann intern Med* 29 403-415 (1948)
- 27 SPERS, R. S and WENCK, U Effect of cortisone on the cellular response during allergic inflammation *Acta haemat. Basel* 17 271-279 (1957)
- 28 STICKNEY, J C. and VAN LIERE, E J Acclimatization to low oxygen tension *Physiol Rev* 33 13-34 (1953)
- 29 THORN, G W, JONES, B F, LEWIS, R. A, MITCHELL, E. R. and KOEFF, G F The role of the adrenal cortex in anoxia: the effect of repeated daily exposures to reduced oxygen pressure *Amer J Physiol* 137 606-619 (1942)
- 30 VERZAR, F Die Zahl der Lymphocyten und eosinophilen Leukocyten in 1800 und 3450 m Höhe Schweiz. med. Wschr. 82 324 (1952)
- 31 WALLOD, D et BROWAERT, J La moëlle osseuse dans les éosinopénies expérimentales

Authors' addresses: Dr G HUDSON, Faculty of Medicine, University of Sheffield, Sheffield S10 2TN; Miss J D L. SIBLEY, 31 Falmouth Grove, Surdon, Ilkley (England)



## Haemoglobin O Indonesia ( $\alpha 116 \text{ Glu} \rightarrow \text{Lys}$ ) in an Italian Family

G. SANSONE, A. CENTA, V. SCIARRATTA, E. GALLO<sup>1</sup>  
and H. LEHMANN

Medical Research Council, Abnormal Haemoglobin Unit, Department of Biochemistry, Cambridge, and University Chair of Human Genetics and Paediatric Department of Galliera Hospitals, Genova

In a preliminary paper some of us [1] presented the results of an investigation on a slow moving haemoglobin which was abnormal in its  $\alpha$ -chains.

### Case Report

The carrier was a 3-year-old girl admitted to the Paediatric Department of Galliera Hospitals (Italy) with an infectious disease. Before that time she had never suffered from anaemia or severe diseases. The abnormal haemoglobin was detected during a screening of all the patients admitted to the Department. It was impossible to study the parents, but the maternal grandmother, of Sicilian extraction, was found to be a carrier of the same abnormality (fig. 1).

Haematological findings were normal and investigations of the abnormal haemoglobin carried out by means of agar gel electrophoresis at acid pH and starch gel electrophoresis (fig. 2-3) showed the presence of a slow moving fraction amounting to about 20% of the total pigment. The variant haemoglobin which migrated a little slower than Hb S was abnormal in its  $\alpha$ -chains as shown by the presence, in concentrated solutions of haemoglobin, of a double  $\Lambda_2$  in starch gel (fig. 4) and a double  $\Gamma$  in agar gel electrophoresis. Further

$\beta$  VIII-IX. No further analyses were possible at that time, but the properties of this haemoglobin variant, compared with others with the same electrophoretic mobility led us to believe it was a new variant which was provisionally called Hb Oliveri from the name of the patient.

The same blood samples were recently re-examined and further analyses were carried out to characterize the amino-acid substitution of this haemoglobin.

<sup>1</sup> On leave from the University Institute of Medical Pathology, Turin, Italy.




Fig. 1 Family tree



Fig. 2 Starch gel electrophoresis (tris buffer, pH 8.9) of the haemoglobin solution of the propositus (bottom) compared with a normal subject (top). At this haemoglobin concentration the abnormal fraction is clearly separated from Hb A<sub>1</sub>, while the double Hb A<sub>2</sub> is hardly visible.



Fig. 3 Starch gel electrophoresis (tris buffer, pH 8.9) of the haemoglobin solution of the propositus (bottom) compared with Hb A-S control (top). The abnormal fraction is slightly slower than Hb S.




Fig 4 Starch gel electrophoresis (tris buffer, pH 8.9) of the haemoglobin solution of the propositus (top) compared with a normal control (bottom). The gel was overloaded to show the double Hb A<sub>2</sub>.




Fig 5 Cellulose acetate electrophoresis (Urea veronal buffer, pH 8.9) of the globin of the propositus (arrow) compared with the globin of a heterozygote for haemoglobins A and S.

### Methods

Haemolysates were prepared from washed red cells and analysed by agar [2] and starch gel electrophoresis [3]. Electrophoresis of the globin in 6 M urea was carried out according to CUNNINGHAM modified [4]. Hybridization was done following the technique described by HARRIS *et al.* [5]. The haemoglobin variant was purified by repeated paper electrophoresis in tris buffer pH 8.9 [6] followed by elution and concentration *in vacuo* until it was free from haemoglobin A. Two dimensional peptide maps (fingerprints) of the whole globin and of the aminoethylated chains prepared according to CUNNINGHAM *et al.* [7] were obtained using the techniques recently summarized by SICK *et al.* [8]. The tryptic peptides were eluted from the paper with 6 M N-ethylmaleimide capillary tubes and hydrolysed at 100°C for 20 h. Amino acids were estimated on an 111 automatic analyzer.

### Results

Electrophoresis of the globin in 6 M urea [4] and hybridization [5] of the variant haemoglobin with canine haemoglobin showed that the  $\beta$ -chains were normal and that the difference responsible for the reduced electrophoretic mobility resided in the  $\alpha$  chains.

Figure 6 shows a fingerprint at pH 6.4 of the variant haemoglobin. A slight increase in the intensity of ninhydrin staining was seen in the region of  $\beta$  Tp VIII-IX which represents residues 66-82 of the 146 residues of the  $\beta$  chains. All the other peptides were in their normal positions and gave normal staining reactions. As the  $\alpha$  chains were responsible for the abnormality and all peptides belonging to those chains were in their expected positions, the increased intensity in the region of  $\beta$  Tp VIII-IX was thought to be due to a peptide arising from the 'core' of the  $\alpha$ -chains which overlapped with  $\beta$  Tp VIII-IX. To confirm this hypothesis, chain separation, aminoethylation of the globin [7] and fingerprinting of the isolated chains was carried out (figs 7 and 8). On aminoethylation (A/E), the 'core' peptides become soluble and are represented on the fingerprint. Even then, in the A/E  $\alpha$  chain a small amount of undissolved material is present and while the residues  $\alpha$  100-104 ( $\alpha$  Tp XIIa) are well defined, the residues  $\alpha$  105-127 ( $\alpha$  Tp XIIb) are found as a poorly defined smear at the




Fig. 6. Peptide chromatogram (fingerprint) of haemoglobin O Indonesia. The arrow indicates the increase in the intensity of ninhydrin staining in the region of  $\beta$  Tp VIII-IX.

origin of the fingerprint. When the tryptic digestion of A/E  $\alpha$ -chain of the variant haemoglobin was carried out, no insoluble material was seen and the fingerprint (fig. 8) differed from that of A/E  $\alpha$ -chain of haemoglobin A by the absence of  $\alpha$  Tp XIIb and the presence of two new peptides: one next to  $\alpha$  Tp VI which corresponded to the spot with increased intensity of ninhydrin staining in the fingerprint of the




Fig 7 Chromatography of globin from haemoglobin O Indonesia (40 mg) on CM-cellulose in 8 M urea 2-mercaptoethanol buffers according to CLEGG *et al* [7]. The gradient was started after the elution volume of 100 ml.

amino-ethylated

$\alpha$  chain




Fig 8 Peptide chromatogram of the amino-ethylated  $\alpha$  chain of haemoglobin O Indonesia.  $\alpha$  Tp XIIa is in its expected position, two new peptides are present:  $\alpha$  Tp XIIb<sub>1</sub> and  $\alpha$  Tp XIIb<sub>2</sub>.

whole globin, and the second between  $\alpha$  Tp V and  $\alpha$  Tp VI. Both peptides gave a positive reaction for histidine.  $\alpha$  Tp XIIa and all the other peptides of the A/E  $\alpha$  chain were in their expected position.

The new peptides were eluted from a preparative fingerprint, hydrolysed with 6 N HCl for 20 h at 108°C and amino acid analysis was carried out. Table I shows the amino acid sequence and the point

Table I Amino acid composition of  $\alpha$  Tp XIIb of haemoglobin A and O Indonesia ( $\alpha$  Tp XIIb comprises residues 105-127 of the 141 residues of the  $\alpha$ -chain [7])

|      |             |     |     |     |     |     |     |     |     |     |            |
|------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------------|
| Hb A | 105<br>Leu  | Leu | Val | Thr | Leu | Ala | Ala | His | Leu | Pro | 115<br>Ala |
| Hb O | 105<br>Leu  | Leu | Val | Thr | Leu | Ala | Ala | His | Leu | Pro | 115<br>Ala |
| Hb A | 116<br>Glu  | Phe | Thr | Pro | Ala | Val | His | Ala | Ser | Leu | 127<br>Asp |
| Hb O | 116<br>Lys† | Phe | Thr | Pro | Ala | Val | His | Ala | Ser | Leu | 127<br>Lys |

The arrow shows the point of tryptic cleavage in haemoglobin O

Table II Amino acid composition of  $\alpha$  Tp XIIb<sub>1</sub> and  $\alpha$  Tp XIIb<sub>2</sub> of Hb O Indonesia

| Amino-acid              | $\alpha$ Tp XIIb <sub>1</sub> |             |                    | $\alpha$ Tp XIIb <sub>2</sub> |             |                    |
|-------------------------|-------------------------------|-------------|--------------------|-------------------------------|-------------|--------------------|
|                         | $\mu$ moles                   | Molar ratio | Corrected residues | $\mu$ moles                   | Molar ratio | Corrected residues |
| Aspartic acid           | 0.004                         | (0.3)       | 0                  | 0.014                         | 1.1         | 1                  |
| Threonine               | 0.018                         | 1.4         | 1                  | 0.014                         | 1.1         | 1                  |
| Serine                  | 0.003                         | (0.6)       | 0                  | 0.014                         | 1.1         | 1                  |
| Glutamic acid           | 0.003                         | (0.2)       | 0                  | —                             | —           | 0                  |
| Proline                 | 0.013                         | 1.0         | 1                  | 0.013                         | 1.0         | 1                  |
| Glycine                 | 0.005                         | (0.4)       | 0                  | —                             | —           | 0                  |
| Alanine                 | 0.036                         | 2.8         | 3                  | 0.024                         | 1.9         | 2                  |
| Valine                  | 0.016                         | 1.2         | 1                  | 0.012                         | 0.9         | 1                  |
| Leucine                 | 0.050                         | 3.9         | 4                  | 0.013                         | 1.0         | 1                  |
| Phenylalanine           | 0.006                         | (0.5)       | 0                  | 0.011                         | 0.9         | 1                  |
| Isoleucine <sup>1</sup> | 0.016                         | 1.0         | 1                  | 0.056                         | 4.5         | 5                  |
| Histidine               | 0.016                         | 1.0         | 1                  | 0.052                         | 4.2         | 4                  |

<sup>1</sup> Basic amino acids were determined on a separate sample and the yields in  $\mu$ moles per residue are different from the yields for the acid and neutral amino acids. The residues in brackets were assumed to be from a contaminant.

Table III Amino acid composition of a Tp XIIb of Hb A<sup>1</sup> and Hb O Indonesia

| Amino acid    | No of residues    |   |
|---------------|-------------------|---|
|               | a Tp XIIb of Hb A | a Tp XIIb <sub>1</sub> -XIIb <sub>2</sub> of Hb O |
| Aspartic acid | 1                 | 1   |
| Threonine     | 2                 | 2   |
| Serine        | 1                 | 1   |
| Glutamic acid | 1                 | -   |
| Proline       | 2                 | 2   |
| Alanine       | 5                 | 5   |
| Valine        | 2                 | 2   |
| Leucine       | 5                 | 5   |
| Phenylalanine | 1                 | 1   |
| Lysine        | 1                 | 2   |
| Histidine     | 2                 | 2   |

<sup>1</sup> HILL and KONIGSBERG, 1962 [9]

of tryptic cleavage of the peptide a Tp XIIb (a 105-127) [7] Table II shows the results of the amino acid analysis of the 2 new peptides present in the fingerprint of the abnormal hemoglobin. Considered together (table III) they differ from a Tp XIIb of hemoglobin A in the presence of two residues of lysine instead of one and in the absence of glutamic acid. In a Tp XIIb of hemoglobin A glutamic acid is the 116th residue, it is absent in this variant and a lysine is present instead. With the exception of this lysine, the amino acid composition of a Tp XIIb<sub>1</sub> is that of the first 12 amino acids of a Tp XIIb of hemoglobin A. As the peptide is a tryptic peptide lysine must be the C terminal amino acid, i.e. is the last residue of the sequence of a Tp XIIb<sub>1</sub> (a 105-116). Moreover a Tp XIIb<sub>2</sub> shows the same composition of the C terminal end of a Tp XIIb in hemoglobin A, i.e. includes the residues 117-127.

### Conclusion

The present hemoglobin shows the following mutation: a 116 Glu → Lys. The same mutation has been described before in hemoglobin O Indonesia. Another case of hemoglobin O Indonesia has been observed by BOTHA, BEALE and LEHMANN [unpublished] in a South African family of 'coloured' non Malay origin. It is likely that the

sporadic findings in Indonesia, South Africa and Italy are due to independent mutations

### Summary

A slow moving  $\alpha$ -chain abnormal haemoglobin found in an Italian family and described previously as 'Hb Olivieri' has now been identified as haemoglobin O Indonesia. The full demonstration of the substitution  $\alpha 116$  (GH 4) glutamic acid  $\rightarrow$  lysine has been possible

### References

- 1 SANSONE, G, CENTA, A e SCIARRATTA, V. L'emoglobina Olivieri: una nuova variante delle alfa catene. *Pathologica* 59: 3-12 (1967)
- 2 ROBINSON, A R, ROBSON, M, HARRISON, A P and ZUELZER, W W. A new technique for differentiation of hemoglobin. *J Lab clin Med* 50: 745-752 (1957)
- 3 SMITHIES, O. An improved procedure for starch-gel electrophoresis. Further variations in the serum proteins of normal individuals. *Biochem J* 71: 583-587 (1959)
- 4 CIERNOFF, A I and PETTIT, N M Jr. The amino acid composition of hemoglobin. III. A qualitative method for identifying abnormalities of the polypeptide chains of hemoglobin. *Blood* 24: 750-756 (1964)
- 5 HUEHN, E R, SHOOTER, E M and BEAVER, G H. On the recombination of canine and human haemoglobins. *J molec Biol* 4: 323-328 (1962)
- 6 CRADOCK-WATSON, J E, FENTON, J B C and LEHMANN, H. Tris buffer for the determination of haemoglobin A<sub>2</sub> by paper electrophoresis. *J clin Path* 12: 372-373 (1959)
- 7 CLEGG, J B, NALCHITOV, M A and WEATHERALL, D J. Abnormal human haemoglobins. Separation and characterization of the  $\alpha$  and  $\beta$  chains by chromatography of two new variants Hb Chesapeake and Hb J (Bangkok). *J molec Biol* 19: 91-103 (1966)
- 8 SICK, N, BEALE, D, IRVINE, D, LEHMANN, H, GOODALL, P T and SHEONA MACDONALD. Haemoglobin G Copenhagen and haemoglobin J Cambridge. Two new  $\beta$ -chain variants of haemoglobin A. *Biochim biophys Acta* 140: 231-242 (1967)
- 9 HILL, R J and KONTAGERO, W. The structure of human hemoglobin IV. The chymotryptic digestion of the  $\alpha$ -chain of human hemoglobin. *J biol Chem* 237: 3151-3162 (1962)

Authors' addresses: Prof Dr G SANSONE, Dr A. CENTA, and Dr V SCIARRATTA, Ospedale Pediatrico S. Filippo, Via Volta 8, Genova (Italy); Dr E. GALLO and Prof Dr H. LEHMANN, Medical Research Council, Abnormal Haemoglobin Unit, Department of Biochemistry, Cambridge (England)



## **Zellkinetik der Granulopoese und des Neutrophilensystems bei einem Fall von zyklischer Neutropenie<sup>1</sup>**

**G. MEURET und T. M. FLIEDNER**

*unter technischer Assistenz von G. BREMER*

Abteilung für klinische Physiologie (Prof. Dr. T. M. FLIEDNER)

Zentrum für klinische Grundlagenforschung  
der Universität Ulm (Ulm (Donau))

Das Krankheitsbild der zyklischen Neutropenie ist gekennzeichnet durch ein autonomes, periodisches Auftreten und Wiederverschwinden von Beschwerden zusammen mit Fieber, Neutropenie und Monozytose. Durch Beobachtungen und Untersuchungen an etwa 50 Fällen konnte Stellung genommen werden zu Fragen wie Geschlechtsverteilung [26, 27], Symptomatik und Krankheitsverlauf [4, 5, 6, 7, 18, 19, 22, 26, 27, 29, 31, 32], Hormonhaushalt [17, 26, 27, 28, 33], Vererbung [11, 16, 20, 23, 27], z. T. auch zu hämatologischen und pathologisch-anatomischen Problemen [15, 21, 24, 25, 26, 27, 28, 30, 34]. Die Frage nach der Ursache der Krankheitssymptome jedoch blieb nahezu ungeklärt.

Es ist Aufgabe dieser Arbeit, das granulozytare Zellerneuerungssystem bei einer Patientin mit zyklischer Neutropenie quantitativ, morphologisch und durch Anwendung verschiedener Zellmarkierungsmethoden mit Radioisotopen zellkinetisch zu beschreiben, um zur Klärung der Pathogenese dieser Erkrankung beizutragen.

### *Material und Methoden*

*Kasuistik:* Untersucht wurde eine 53jährige Patientin (H. & Journal Nr. 13 9267 der Med. Univ. Klinik Freiburg) die seit dem 50. Lebensjahr unter Beschwerden litt, welche einformig und regelmässig in 3wöchigen Abständen rezidierten. Während des Klinik-

<sup>1</sup> Die Untersuchungen wurden durch die Euratom Verträge «Strahlenhämatologie» Nr. 031-64 1 B1AD und 072-68-1 B1OD unterstützt.

ausstriche aus der Mundspüllässigkeit. Die luftgetrockneten und in absolutem Methylalkohol fixierten Ausstriche wurden mit dem Kodak AR10 stripping film autoradiographiert, nach einer Expositionszeit von 69 Tagen entwickelt, fixiert und nach Giemsa gefärbt. Pro Zeitpunkt wurden mindestens 500 myeloische Zellen differenziert und die Silberkornzahlen in der Filmschicht über den Zellkernen bestimmt. Zellkerne, die mehr als 3 Silberkornen aufwiesen, wurden als markiert gewertet. Der prozentuale Anteil markierter Zellen einer Reifungsklasse ergab den «Markierungsindex».

Nach morphologischen Kriterien wurden 8 granulopoetische Zelltypen als Kompartments unterschieden:  $M_1$  = Myeloblast,  $M_2$  = Promyelozyt,  $M_3$  = halbreifer Myelozyt,  $M_4$  = reifer Myelozyt,  $M_5$  = Metamyelozyt,  $M_6$  = Jugendlicher,  $M_7$  = stabkerniger Neutrophiler,  $M_8$  = segmentkerniger Neutrophiler. Die in Abbildung 1 angegebenen Normalwerte für die verschiedenen Kompartments und das Ergebnis zytologischer Differenzierungen von fast 30000 granulopoetischen Zellen in 14 Knochenmarkpräparaten einer Normalperson [12].

*Bestimmung der Neutrophilenspeicher und des Neutrophilenumsatzes im Blut.* Etwa 500 ml Blut

Ende aus dem Infusionsschlauch Blutproben entnommen für Leukozyten-Zählungen und -Differenzierungen und zur Herstellung von Leukozytenkonzentraten. Zur Bestimmung der autotransfundierten Blutmenge wurde das gesamte Transfusionsbesteck vor und nach der Blutentnahme und nach der Reinfusion gewogen.

Unter Berücksichtigung der transfundierten Blutmenge und der Zahl markierter Neutrophiler pro  $\mu$ l Infusionsblut liess sich die Gesamtzahl der reinfundierten markierten Neutrophilen berechnen.

Speichergrössen ermittelt. Die Werte, die sich durch  $M_1$  (Myeloblasten) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_2$  (Promyelozyten) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_3$  (halbreife Myelozyten) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_4$  (reife Myelozyten) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_5$  (Metamyelozyten) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_6$  (Jugendliche) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_7$  (stabkernige Neutrophile) mit deren Neutrophilenspeicher bezogene Neutrophilen, ergaben sich durch  $M_8$  (segmentkernige Neutrophile) mit deren Neutrophilenspeicher bezogene Neutrophilen.

<sup>1</sup> Fa. Radiochemical Centre Amersham, spez. Akt. 5 Ci/mm

<sup>2</sup> Fa. Radiochemical Centre Amersham, spez. Akt. 4820 mCi/mm

*Tabelle 1* Speichergrossen, intravasale Halbwertszeit und Umsatzrate der Neutrophilen in zwei verschiedenen Krankheitsabschnitten bei einer Patientin mit zyklischer Neutropenie. Normalbereiche nach ATHENS *et al.* [2] und ALBARTOV [1]

|             | Neutrophile <sup>1</sup> | GBNS <sup>2</sup> | ZNS <sup>3</sup> | MNS <sup>4</sup> | T <sub>1/2</sub> N <sup>5</sup> | NUR <sup>6</sup> |
|-------------|--------------------------|-------------------|------------------|------------------|---------------------------------|------------------|
| Remission   | 2 400                    | 59                | 16               | 43               | 5                               | 8.2              |
| Neutropenie | 240                      | 10                | 1.6              | 8.4              | 2.3                             | 3                |
| Normal      | 4 500                    | 70                | 31               | 39               | 6.7                             | 6.8              |
|             | (3-7 × 10 <sup>9</sup> ) | (14-160)          | (11-46)          | (0-85)           | (4-10)                          | (2,1-14)         |

<sup>1</sup> Neutrophile pro  $\mu$ l Venenblut

<sup>2</sup> Gesamter Blutneutrophilenspeicher ( $\times 10^9$ /kg Körpergewicht)

<sup>3</sup> Zirkulierender Neutrophilenspeicher ( $\times 10^9$ /kg Körpergewicht)

<sup>4</sup> Marginaler Neutrophilenspeicher ( $\times 10^9$ /kg Körpergewicht)

<sup>5</sup> Intravasale Halbwertszeit der Neutrophilen (h)

<sup>6</sup> Neutrophilenumsatzrate ( $\times 10^9$ /kg Körpergewicht/h)

Die intravasale Halbwertszeit der autotransfundierte Neutrophilen wurde graphisch im halblogarithmischen Koordinatensystem bestimmt (Abb. 3). Bei Kurven mit 2 Abschnitten wurde hierzu der 2. Abschnitt verwendet, d. h. es wurden lediglich die später als 2 h nach der Autotransfusion ermittelten Werte berücksichtigt.

Ein Näherungswert für die stündliche Umsatzrate der Neutrophilen (NUR) ergab sich durch Multiplikation von GBNS mit  $\ln 2$  und Division durch die intravasale Halbwertszeit der markierten Zellen.

Untersuchungen, die mit dieser Methode an der Normalperson durchgeführt wurden, ergaben ähnliche Werte wie sie von ATHENS *et al.* durch Markierung mit DF<sup>31</sup>P und Messung der Radioaktivität der gesamten Leukozyten gefunden wurden. Zur Beurteilung der bei der Patientin gewonnenen Ergebnisse (Tab. 1) wurden deshalb die von diesen Autoren angegebenen Normalbereiche [2] herangezogen.

## Ergebnisse

*Symptomatik und Blutzellstatus* Der klinische Untersuchungsbefund der Patientin war abgesehen von den unten beschriebenen Beschwerden, die intermittierend zusammen mit Neutropenie und Monozytose auftraten, unauffällig.

Während der Beobachtungszeit waren die Werte der Erythrozyten (um 4 Mill. pro  $\mu$ l Blut), der Thrombozyten (um 250 000 pro  $\mu$ l Blut) und der Lymphozyten (um 1500 pro  $\mu$ l Blut) relativ konstant. Die Retikulozytenzahlen waren unverändert leicht erhöht (um 24%<sub>00</sub> entsprechend 96 000 pro  $\mu$ l Blut).

Der Neutrophilenspiegel im Blut schwankte periodisch zwischen leicht neutropenischen Werten und einem nahezu völligen Fehlen der Neutrophilen. Aufgrund der registrierten Neutrophilenkurve (Abb. 1) und der beobachteten Symptomatik wurde der Krankheitszyklus in folgende 4 Abschnitte unterteilt:

1. Einen Abschnitt der «Remission» mit Neutrophilenwerten zwischen 1500-2500 pro  $\mu$ l Blut, während dem sich die Patientin völlig gesund fühlte.

2. Im folgenden «Initialabschnitt der Neutropenie» fiel der Neutrophilenspiegel ab, die Monozytenzahl stieg an, und es traten Beschwerden auf, die mit dem Grad der Neutropenie zunahmen: Müdigkeit, Leistungsschwäche, Appetitlosigkeit, Brechreiz, Erbrechen, nicht lokalisierbare Oberbauchbeschwerden und Fieber.




Abb. 1. Neutrophilenspiegel im Blut, Granulopoese und erythro-granulopoetisches Verhältnis im Knochenmark während einer Phase einer zyklischen Neutropenie (Normalwerte nach FLIEDNER [12])  $M_1$  = Myeloblast,  $M_2$  = Promyelozyt,  $M_3$  = halbreifer Myelozyt,  $M_4$  = reifer Myelozyt,  $M_5$  = Metamyelozyt,  $M_6$  = jugendlicher,  $M_7$  = stabkerniger neutrophiler Granulozyt,  $M_8$  = segmentkerniger neutrophiler Granulozyt. Krankheitsabschnitte 1 Remission, 2 Initialabschnitt der Neutropenie, 3 Zeitpunkt der maximalen Neutropenie, 4 Reparatur.

Ein Anhalt für das Vorliegen eines chronischen oder für das zeitweilige Auftreten eines akuten Infekts war nicht gegeben. Im Status febrilis zweier verschiedener Krankheitszyklen wurde die Serumkonzentration von Änochenanholon und einmal auch von 11 Keto-Pregnanolon bestimmt. Die Werte waren erhöht. In fieberfreien Abschnitten des Krankheitszyklus lagen Normalwerte vor.

3 Im ... ..

100 pro µl  
H hepunkt  
den Bruch

4 Nach diesem etwa 1 bis 2 Tage andauernden Zustand setzte mit dem 4. Krankheitsabschnitt ein Anstieg der Neutrophilen und ein Abfall der Monozyten ein, verbunden mit einem schliesslich vollständigen Verschwinden der Krankheitssymptome («Reparation»).

Die Phasendauer zweier kontinuierlich beobachteter Zyklen lag im Mittel bei 26 Tagen. Etwa 12 Tage entfielen auf die Remission, 9 Tage auf den Initialabschnitt der Neutropenie und 5 Tage auf den Abschnitt der Reparation.

*Zyologische Befunde im Knochenmark* Aufgrund der relativ konstanten Erythrozyten- und Retikulozytenwerte im peripheren Blut wurde eine während des Krankheitsgeschehens gleichbleibende Erythropoese angenommen, zu der die Befunde der Granulopoese in Beziehung gesetzt wurden. Die derart umgerechneten Ergebnisse von Knochenmark-Differentialzählungen (1500–3000 kernhaltige Zellen pro Zeitpunkt) sind in Abbildung 1 dargestellt. Es ergaben sich Kurven, die erkennen lassen, dass synchron mit dem Ansteigen und Absinken des Neutrophilenspiegels im Blut auch bei der Granulopoese im Knochenmark quantitative Veränderungen abliefen. Die übrigen Zellsysteme des Knochenmarks verhielten sich unauffällig.

Zu Beginn der Reparation (2. Tag) erreichte die Gesamtzahl granulopoetischer Zellen das Maximum. Das erythro-granulopoetische Verhältnis betrug in diesem Abschnitt 1:4,5. Die Reifungsstufen  $M_1$ – $M_4$  waren auf das 2–3fache der Norm vermehrt, die reiferen Formen  $M_5$  und  $M_6$  waren im Gegensatz hierzu ähnlich wie im peripheren Blut stark vermindert.

Im weiteren Verlauf der Reparation konnte eine rasche Verschiebung innerhalb der granulopoetischen Zellen zugunsten der reiferen Formen beobachtet werden. Um den 4. Tag dieses Abschnittes lag ein normales Myelogramm vor. Gegen Ende der Reparation (5–6. Tag) und während der Remission (etwa 6–14. Tag) nahm die Zahl sämtlicher Reifungsstufen der Granulopoese zunächst rascher, dann langsamer ab, bis zu einem Minimum am Übergang der Remission in den Initialabschnitt der Neutropenie. Zu diesem Zeitpunkt lag eine hypoplastische Granulopoese vor, deren Gesamtzahl nur noch etwa  $\frac{1}{3}$  der Norm erreichte.

*Zellkinetik der Granulopoese während der Reparation* Etwa 1 Tag nach dem Zeitpunkt der minimalen Neutrophilenzahl im Blut wurde der Patientin  $^3\text{HTDR}$  injiziert. Die Veränderungen der Markierungsindeizes granulopoetischer Vorstufen während der ersten 12 Tage nach der Injektion von  $^3\text{HTDR}$  sind in Abbildung 2 dargestellt. Zum Vergleich wurden in die Diagramme Befunde einer  $^3\text{HTDR}$ -Untersuchung bei einem Patienten mit normaler Hämatopoese eingezeichnet [12].

Die Ergebnisse im Proliferationsspeicher der Granulopoese (Zellformen  $M_1$ – $M_4$ ) wichen nicht signifikant von den Befunden eines hämatologisch gesunden ab. Eindeutige Unterschiede ergaben sich jedoch bei den reiferen, initial nicht markierten Zellkompartments der Granulopoese (Zellformen  $M_5$ – $M_6$ ). Der Einstrom markierter Zellen aus dem Proliferationsspeicher in die Speicher  $M_5$  und nachfolgende erfolgte wesentlich früher als normalerweise. Die ersten markierten jugendlichen Neutrophilen ( $M_5$ ) wurden schon 8,5 h nach der  $^3\text{HTDR}$ -Injektion beobachtet. Markierte stabkernige Neutrophile ( $M_6$ ) finden sich in den Knochenmarkpräparaten 15 h, segmentker-




Abb. 2 Verhalten der Markierungsindizes nach intravenöser Injektion von  $^3\text{H}$ -Thymidin bei granulopoetischen Zellen im Knochenmark bei neutrophilen Granulozyten im peripheren Blut und im Sediment der Mundspülflüssigkeit ( $M_1$ – $M_8$  siehe Legende von Abb. 1)

nige Neutrophile ( $M_4$ ) 38 h nach der Injektion (Normalwerte [ $12$ ]  $M_4 = 12$ ,  $M_7 = 48$ ,  $M_8 = 60$  h). Der höchste Markierungsindex wurde bei  $M_4$  und  $M_7$  38 h, bei  $M_8$  61 h nach der  $^3\text{H}$ -TDR Applikation erreicht. Diese Werte waren mehr als doppelt so hoch wie die zu gleichen Zeitpunkten gemessenen Normalwerte.

Im späteren Verlauf der Untersuchung (etwa nach dem 8. Tag) fanden sich keine eindeutigen Abweichungen der Markierungsindizes von der Norm mehr.

Im venösen Blut konnten 24 h nach der  $^3\text{H}$ -TDR Injektion die ersten markierten stab- und segmentkernigen Granulozyten ( $M_7$  und

M<sub>2</sub>) nachgewiesen werden 43 h nach der Injektion wurden auch in den Autoradiogrammen der Präparate aus dem Sediment der Mundspülflüssigkeit markierte neutrophile Granulozyten gefunden

Die Reifungszeit der Neutrophilen, definiert als Zeitintervall zwischen dem ersten Auftreten markierter Metamyelozyten und dem Erscheinen markierter Neutrophiler im Blut, lag zum Zeitpunkt der Untersuchung bei 13 h. Sie war damit gegenüber der Norm (96–120 h [12]) auf etwa  $1/7$  verkürzt

*Intravasale Halbwertszeit, Speichergrossen und Umsatzrate der Neutrophilen im Blut* Während einer Remission (2400 Neutrophile pro  $\mu$ l Blut) und eines Initialabschnittes der Neutropenie (240 Neutrophile pro  $\mu$ l Blut) wurden zellkinetische Daten der Blutneutrophilen durch Auto-transfusion von  $^3\text{H}$ DFP markierten Neutrophilen ermittelt. Zum Zeitpunkt der ersten Untersuchung während der Remission lag die intravasale Halbwertszeit der Neutrophilen bei 5 h (Abb 3, Trb I), im neutropenischen Krankheitsabschnitt dagegen betrug sie nur 2,3 h.

Während der Remission lagen die Grossen der 3 verschiedenen Neutrophilenspeicher (GBNS, ZNS, MNS) in dem von ATHENS *et al* angegebenen Normalbereich [2]. Zum Zeitpunkt der 2. Untersuchung war im zirkulierenden Blut nur noch  $1/10$  der Neutrophilenmenge der




Abb 3 Markierungsindex neutrophiler Granulozyten im Blut nach Autotransfusion *in vivo* mit  $^3\text{H}$  DFP markierten Granulozyten in zwei Krankheitsabschnitten.

Voruntersuchung vorhanden. Die Abnahme der Grösse von GBNS betrug  $\frac{1}{4}$  des Wertes der Remission, bei MNS machte der Abfall  $\frac{1}{4}$  aus. Die Grösse der Umsatzrate dagegen fiel weniger als  $\frac{1}{3}$  des Ausgangswertes ab.

### Diskussion

#### Analyse der rhythmischen Veränderungen des Neutrophilenspiegels im Blut der untersuchten Patientin

Schwankungen der Neutrophilenzahl im Blut können Veränderungen folgender Komponenten zugrunde liegen: 1. der Zellverteilung zwischen den Neutrophilenspeichern, 2. der Neutrophilenumsatzrate, 3. der Neutrophilenproduktionsrate. Der Erörterung dieser 3 Punkte werden Daten zugrunde gelegt, die durch  $^3\text{HDFP}$  markierte Neutrophile zum Zeitpunkt einer fast maximal ausgeprägten Neutropenie und während einer Remission gewonnen wurden. Da kein Hinweis auf eine sprunghafte Änderung der Neutrophilenkinetik vorlag (es konnten weder Infektzeichen noch Leukozytenantikörper oder Veränderungen der Milzgrösse nachgewiesen werden), kann angenommen werden, dass bei diesen Untersuchungen die während des Zyklus vorkommenden Extremwerte bestimmt wurden, zwischen denen die Umsatzraten und Speichergrossen während der übrigen Abschnitte der Krankheit lagen.

Zu 1. Analysiert man die ermittelten Grossen der Neutrophilenspeicher, so findet man während der Neutropenie einen im Vergleich zur Remission um 90% verminderten Zellgehalt im ZNS, dem ein Abfall von nur 83% im GBNS gegenübersteht (Tab II). Das Ver-

Tabelle II Verhalten der Neutrophilenspeicher während einer Remission und einer fast maximal ausgeprägten Neutropenie

|                | GBNS <sup>1</sup> | ZNS <sup>1</sup> | GBNS/ZNS         | [ZNS] <sup>2</sup> |
|----------------|-------------------|------------------|------------------|--------------------|
| A. Remission   | 59                | 16               | 1.027            | 16                 |
| B. Neutropenie | 10                | 1.6              | 1.016            | 2.24               |
| Abfall (A/B)   | 83%               | 90%              | 40% <sup>3</sup> | 86%                |

<sup>1</sup> GBNS und ZNS = Zellen  $\times 10^3/\text{kg}$  Körpergewicht.

<sup>2</sup> [ZNS] = ZNS wenn GBNS/ZNS = 1.027

<sup>3</sup> Abfall von ZNS als Anteil von GBNS



hältnis von GBNS zu ZNS hatte sich also während der Neutropenie zugunsten von GBNS verschoben. Wird diese Zellverschiebung zwischen den Speichern rechnerisch eliminiert, so wurde sich für ZNS ein Abfall von 86% ergeben, der ausschliesslich Folge des Zellverlusts von GBNS war. Aufgrund dieser Analyse kann gesagt werden, dass die Neutropenie fast ausschliesslich Folge einer Verkleinerung des Gesamtspeichers der Neutrophilen und nur zu 4% durch eine Änderung der Zellverteilung in den Speichern bedingt war.

Zu 2: Die Ursache des zyklisch auftretenden Neutrophilenabfalls war mit Sicherheit nicht ein erhöhter Neutrophilenuntergang, da die Neutrophilenumsatzrate während der neutropenischen Krankheitsabschnitte nicht anstieg, sondern abfiel.

Zu 3: Eine Vorstellung der Neutrophilenproduktionsrate während des Krankheitszyklus soll mit Hilfe des in Abbildung 4 dargestellten Modells der Granulopoese gewonnen werden. Es besteht aus hintereinandergeschalteten Kompartments, in denen sich die verschiedenen Zellformen der Granulopoese während der Proliferation, Reifung und Speicherung jeweils eine bestimmte Zeit aufhalten. Aus der Grosse des Zelleinstroms in das Kompartiment und des Zellabstroms resultiert entweder ein Fließgleichgewicht oder eine Änderung der Zellzahl in diesem. Vorausgesetzt, dass innerhalb des Speichers keine Zellen zugrunde gehen, gilt folgende Beziehung: Änderung der Speichergrosse = Zelleinstrom - Zellabstrom oder: Zelleinstrom = Änderung der Speichergrosse + Zellabstrom (Daten in Zellen pro Zeiteinheit). Durch die Neutrophilenumsatzrate (NUR) und die Änderung des Gesamt-Blutneutrophilenspeichers (GBNS) lässt sich mit dieser Formel zunächst die Rate des Neutrophileneinstroms ins Blut bestimmen. Diese Grosse, eingesetzt als Neutrophilenabstrom aus dem Neutrophilenspeicher des Knochenmarks, ergibt zusammen mit der Änderung der Grosse dieses Kompartments die Produktionsrate von Neutrophilen aus den Präkursoren.

Mit den zur Verfügung stehenden Daten wurde diese Analyse folgendermassen durchgeführt. Die Kurve der Neutrophilenumsatzrate während des Krankheitszyklus in Abbildung 4 ergab sich unter den oben näher ausgeführten Voraussetzungen. Die Daten von GBNS und ZNS (Tab. II) lassen es als wahrscheinlich erscheinen, dass sich die Speicher während der Krankheitsphasen annähernd parallel änderten. Zur Ermittlung der Neutrophileneinstromrate ins Blut konnte also auch die Änderung von ZNS in die Formel eingesetzt werden.

Das Verhalten von ZNS während des Zyklus ergab sich aus einer Kurve, die an den Neutrophilenzahlen im Blut orientiert war. Hierbei wurde, gestützt auf die relativ konstanten

Werte der Erythrozyten, der Retikulozyten und des Hämokrits vorausgesetzt, dass sich das Blutvolumen während des Zyklus nicht wesentlich veränderte. Mit Hilfe dieser Kurve (Abb. 4 «Neutrophile im Blut») konnte für jeden Zeitpunkt ( $t$ ) des Zyklus ein Mass für die Speichergrösse ( $y$ ) bzw. für die tägliche ( $\Delta t = \text{konst.}$ ) Änderung der Speichergrösse ( $\Delta y$ ) abgelesen werden.

Die graphisch durchgeführte Addition von  $\Delta y$  zu den Werten der Neutrophilenumsatzrate in den entsprechenden Zeitpunkten ergab eine Kurve für die Einstromrate der Neutrophilen ins Blut (Abb. 4 «Neutrophilen Einstrom ins Blut»). Die Grösse der Neutrophilenproduktion ergab sich schliesslich durch graphische Addition der Änderungsrate des Neutrophilenspeichers im Knochenmark zu der Kurve des Neutrophileneinstroms ins Blut (Abb. 4 «Neutrophilenbildungsrate im Knochenmark»).

Durch diese zellkinetische Analyse konnte gezeigt werden, dass die Neutrophilenproduktion rhythmisch verlief, mit derselben Phase dauer wie die zyklischen Veränderungen des Neutrophilenspiegels im Blut. Den Schwankungen der Neutrophilenproduktion folgten jeweils gleichgerichtete Veränderungen des Neutrophilenspiegels im Blut. Die bei der untersuchten Patientin beobachteten zyklischen Veränderungen des Neutrophilenspiegels waren somit Folge rhythmischer Schwankungen der Neutrophilenproduktion im Knochenmark.

### Zellkinetik und funktionelles Verhalten der Granulopoese während des Krankheitszyklus

Einen Überblick über die Befunde der verschiedenen Zellkompartments der Granulopoese im Verlauf einer Krankheitsphase vermittelt Abbildung 4 (Die Kurven wurden im letzten Teil des Initialabschnittes der Neutropenie bis zu den Werten eines maximal neutropenischen Zustandes ergänzt). Innerhalb des Krankheitszyklus lassen sich folgende funktionell verschiedene Abschnitte der Granulopoese unterscheiden.

**Reparator (Anfang)** Bei minimalen Neutrophilenwerten im Blut nahen zunächst im Proliferations- und Reifungsspeicher der Zellzahlen rasch zu. Durch eine, wie die Befunde der HTDR-Untersuchung zeigten (Abb. 2), ungestörte Proliferation und stark beschleunigte Reifung setzte dann rasch eine Zunahme der Neutrophilenleistung Neutrophilenspeicher im Knochenmark und im Blut wurden wieder aufgefüllt. Die vorliegende Situation der Granulopoese entspricht etwa einem experimentell herbeigeführten Zustand nach Erspaltung der Neutrophilenpools durch Leukophorese. Dieser Ein-

hältnis von GBNS zu ZNS hatte sich also während der Neutropenie zugunsten von GBNS verschoben. Wird diese Zellverschiebung zwischen den Speichern rechnerisch eliminiert, so würde sich für ZNS ein Abfall von 86% ergeben, der ausschliesslich Folge des Zellverlusts von GBNS war. Aufgrund dieser Analyse kann gesagt werden, dass die Neutropenie fast ausschliesslich Folge einer Verkleinerung des Gesamtspeichers der Neutrophilen und nur zu 4% durch eine Änderung der Zellverteilung in den Speichern bedingt war.

Zu 2: Die Ursache des zyklisch auftretenden Neutrophilenabfalls war mit Sicherheit nicht ein erhöhter Neutrophilenuntergang, da die Neutrophilenumsatzrate während der neutropenischen Krankheitsabschnitte nicht anstieg, sondern abfiel.

Zu 3: Eine Vorstellung der Neutrophilenproduktionsrate während des Krankheitszyklus soll mit Hilfe des in Abbildung 4 dargestellten Modells der Granulopoese gewonnen werden. Es besteht aus hintereinandergeschalteten Kompartments, in denen sich die verschiedenen Zellformen der Granulopoese während der Proliferation, Reifung und Speicherung jeweils eine bestimmte Zeit aufhalten. Aus der Grösse des Zelleinstroms in das Kompartiment und des Zellabstroms resultiert entweder ein Fließgleichgewicht oder eine Änderung der Zellzahl in diesem. Vorausgesetzt, dass innerhalb des Speichers keine Zellen zugrunde gehen, gilt folgende Beziehung: Änderung der Speichergrosse = Zelleinstrom - Zellabstrom oder: Zelleinstrom = Änderung der Speichergrosse + Zellabstrom (Daten in Zellen pro Zeiteinheit). Durch die Neutrophilenumsatzrate (NUR) und die Änderung des Gesamt-Blutneutrophilenspeichers (GBNS) lässt sich mit dieser Formel zunächst die Rate des Neutrophileneinstroms ins Blut bestimmen. Diese Grösse, eingesetzt als Neutrophilenabstrom aus dem Neutrophilenspeicher des Knochenmarks, ergibt zusammen mit der Änderung der Grösse dieses Kompartments die Produktionsrate von Neutrophilen aus den Präkursoren.

Mit den zur Verfügung stehenden Daten wurde diese Analyse folgendermassen durchgeführt. Die Kurve der Neutrophilenumsatzrate während des Krankheitszyklus in Abbildung 4 ergab sich unter den oben näher ausgeführten Voraussetzungen. Die Daten von GBNS und ZNS (Tab. II) lassen es als wahrscheinlich erscheinen, dass sich die Speicher während der Krankheitsphasen annähernd parallel änderten. Zur Ermittlung der Neutrophileneinstromrate ins Blut könnte also auch die Änderung von ZNS in die Formel eingesetzt werden.

Das Verhalten von ZNS während des Zyklus ergab sich aus einer Kurve, die an den Neutrophilenzahlen im Blut orientiert war. Hierbei wurde, gestützt auf die relativ konstanten

Werte der Erythrozyten, der Retikulozyten und des Hämoglobins verbleiben, was das Blutvolumen während des Zykklus meist wesentlich vermindert. Die Werte des Hämoglobins (Abb. 4 «Neutrophile im Blut») konnten für jeden Zeitpunkt des Zykklus mittels der Speichergrasse ( $y$ ) bzw. für die mittlere  $\Delta = \text{Gesamt} - \text{Speichergrasse}$  ( $d y$ ) abgelesen werden.

Die graphisch durchgeführte Addition von  $\Delta$  zu den Werten der Neutrophilenumsatzrate in den entsprechenden Zeitpunkten ergab eine Kurve der Neutrophilen im Blut (Abb. 4 «Neutrophilen-Zunahme im Blut»). Die Grasse der Neutrophilenproduktion ergab sich schließlich durch graphische Addition der Neutrophilenumsatzrate des Neutrophilenspeichers im Knochenmark zu der Kurve der Neutrophilenumsatzrate im Blut (Abb. 4 «Neutrophilenbildungsrate im Knochenmark»).

Durch diese zellkinetische Analyse konnte gezeigt werden, dass die Neutrophilenproduktion rhythmisch verläuft, mit derselben Periodendauer wie die zyklischen Veränderungen des Neutrophilenumsatzes im Blut. Den Schwankungen der Neutrophilenumsatzrate folgten ebenfalls gleichgerichtete Veränderungen des Neutrophilenspiegels im Blut nach. Dies bei der untersuchten Patienten beobachteten zyklischen Veränderungen des Neutrophilenspiegels waren somit Folge rhythmischer Schwankungen der Neutrophilenproduktion im Knochenmark.

### Zellkinetik und funktionelles Verhalten der Granulopoese während des Krankheitszyklus

Einen Überblick über die Befunde der verschiedenen Zellkinetiken der Granulopoese im Verlauf einer Krankheitsphase enthält Abbildung 4. (Die Kurven wurden im letzten Teil des Initialstadiums der Neutropenie bis zu den Werten eines maximal neutrophilen Zustandes ergänzt.) Innerhalb des Krankheitszyklus lassen sich folgende funktionell verschiedene Abschnitte der Granulopoese unterscheiden:

**Reparation (Anfang)** Bei minimalen Neutrophilenwerten im Blut nahmen zunächst im Proliferations- und Reifungsstadium der Zellzahlen rasch zu. Durch eine wie die Befunde der SPTR-Analyse zeigten (Abb. 2) ungestörte Proliferation und stark beschleunigte Reifung setzte dann rasch eine Zunahme der Neutrophilenbildungsrate mit vermehrtem Neutrophilenumsatz ein. In den ersten 4-6 Tagen leerten Neutrophilenspeicher im Knochenmark und im Blut wieder aufgefällt. Die vorliegende Situation der Granulopoese entspricht etwa einem experimentell festgestellten Zustand nach Bestrahlung der Neutrophilenpoese durch Leukopherese. Der Verlauf




Abb. 4 Halbschematische Darstellung des Verhaltens der Zahlen und der Kinetik der verschiedenen Zellformen der Granulopoese während eines Krankheitszyklus

griff wird von einer normalen Granulopoese ebenfalls mit einer Mehrproliferation und Mehrproduktion von Neutrophilen beantwortet [8].

**Reparation (Mitte)** Nachdem die Neutrophilenwerte im Blut der Patientin etwa 500 pro  $\mu$ l erreicht hatten, nahmen die Zellzahlen im Proliferations- und Reifungsspeicher bereits wieder ab.

**Reparation (Ende).** Die zu Beginn der Reparation im Proliferations- und Reifungsspeicher vermehrt neugebildeten Zellen strömten nach der Ausreifung

in den Neutrophilenspeicher des Knochenmarks ein, der am Ende der Reparation seine maximale Zellzahl erreichte

*Remission* Durch den Abfall der Zellzahlen im Proliferations- und Reifungsspeicher ging die Neutrophilenbildungsrate während der Remission stetig zurück. Etwa 3 Tage nach dem Maximum im Knochenmark wurden auch im Blut die höchsten Neutrophilenzahlen gezählt, die jedoch niemals Normalwerte erreichten

Die während der besprochenen Krankheitsabschnitte erhobenen Befunde lassen auf ein funktionell normales Verhalten der Granulopoese zu Beginn der Reparation schliessen. Die Zunahme der Proliferation als Antwort auf die Neutropenie war jedoch «unterdosiert» (Ende der Reparation), so dass keine Normalisierung des Neutrophilenspiegels erreicht wurde (Beginn der Remission). Im Verlauf dieses Krankheitsabschnittes nahm das Missverhältnis zwischen Neutrophilenbildung und Neutrophilenspiegel im Blut weiter zu.

*Initialabschnitt der Neutropenie* Die Neutrophilenbildungsrate und dadurch auch die Zellzahlen in den Neutrophilenspeichern fiel auf Minimalwerte ab. Gleichzeitig aber nahm die Zahl der Neutrophilen-Prakursoren  $M_1$ - $M_4$  wieder zu. Möglicherweise lag diesen Befunden eine Reifungsstörung beim Übergang der jugendlichen zu den stabkernigen Neutrophilen zugrunde. Wurde diese Annahme zutreffen, so könnte ein Neutrophilenanstieg bis auf Werte von 6000 pro  $\mu$ l, der nach einer Prednisonmedikation in dieser Situation beobachtet wurde, als eine durch das Medikament ermöglichte Ausreifung von im Knochenmark «aufgestauten» Prakursoren interpretiert werden. Diese Deutung würde auch den Neutrophilenabfall erklären, der

unter 100 pro  $\mu$ l Blut, sprang plötzlich die Proliferation der Granulopoese für einige Tage wieder voll an, Zeichen einer gestörten Reifung waren dann nicht mehr nachweisbar.

### Ein Modell zur Simulation des funktionellen Verhaltens der Granulopoese

Das granulozytare Zellerneuerungssystem wird in Abbildung 5 als ein Modell dargestellt, in dem die einzelnen Zellkompartments mit




Abb. 5 Ein Modell zur Simulation der Granulopoese bei der Patientin mit zyklischer Neutropenie

Hilfe kaskadenartig hintereinander geschalteter, durch Flüssigkeitsheber verbundener Gefäße nachgeahmt werden.

Der vom Stammzellspeicher ausgehende Zellstrom muss nach Durchfließen des Proliferations- und Reifungsspeichers zwischen den Kompartments  $M_4$  und  $M_5$  ein besonders hohes Niveau überwinden. Ein Regelsystem sondiert den Neutrophilenspiegel im Blut und steuert durch Ventile sowohl den Zelleinstrom in das System aus dem Stammzellspeicher als auch den Zellfluss zum Reifungsspeicher. Eine Spiralfeder erhöht die Reizschwelle der Steuerung derart, dass diese erst bei extrem niedrigen Neutrophilenzahlen anspricht und den Zellfluss für kurze Zeit freigibt. Hierauf erfolgt ein Anstieg des Neutrophilenspiegels im Blut, wodurch das Regelsystem zurück-«kippt» und erneut die Proliferationsaktivität der Granulopoese bremst.

Zellen, die während der auf einige Tage befristeten Freigabe des Zellflusses neu gebildet wurden, durchfließen wellenartig die verschiedenen aufeinanderfolgenden Speicher. Gegen Ende der Remission haben die während der Reparatur vermehrt neu gebildeten Zellen die Kompartments  $M_1$ – $M_4$  der Granulopoese verlassen. In diesen liegt dann ein extrem niedriger Zellspiegel vor, so dass der Zellfluss zwischen den Kompartments  $M_4$  und  $M_5$  abreißt. Während


des Initialabschnittes der Neutropenie stauen sich die von den Präkursorenspeichern nachfliessenden Zellen vor dem Hindernis zwischen  $M_4$  und  $M_7$ , bis schliesslich zu Beginn der Remission der Speicher  $M_4$  wieder ein Niveau erreicht, das den Zelleinstrom in das Kompartiment  $M_7$  ermöglicht.

Obwohl nicht beurteilt werden kann, inwieweit ein solches Modell zur Deutung der Untersuchungsergebnisse bei der Granulopoese herangezogen werden darf, scheint doch der Vorstellung einer gestörten Regulation eine gewisse Wahrscheinlichkeit zuzukommen, da sich in dieses Bild auch andere, rhythmisch auftretende Befunde einordnen lassen. Ähnlich wie bei den in der Literatur dargestellten Fällen, traten auch bei dieser Patientin synchron mit den hamatologischen Veränderungen verschiedene weitere Krankheitssymptome auf, wie z. B. gastrointestinale Beschwerden, Fieber und depressive Verstimmung. Durch eine Analyse der Ursache dieser Symptome an den einzelnen Organen selbst, von denen sie jeweils ausgehen – ähnlich wie sie hier für die Granulopoese unternommen wurde – würde sich wahrscheinlich eine grosse Zahl von Funktionsstörungen aufzeigen lassen, die, obwohl kein direkter pathogenetischer Zusammenhang erkennbar ist, rhythmisch und synchron miteinander auftreten und wieder verschwinden.

Offensichtlich kann also auch zur Deutung der Pathogenese des gesamten Krankheitssyndroms eine gestörte Regulation erwogen werden. Wie bei dem in Abbildung 5 dargestellten Modell der Granulopoese könnte ein vermindert ansprechbares zentrales Steuerungssystem vorliegen, das die Funktion normaler Organe nur noch in weiten Grenzen zu regeln vermag.

### Zusammenfassung

Bei einer Patientin mit zyklischer Neutropenie wurde mit Zellzählungs- und Differenzierungsmethoden zusammen mit verschiedenen Zellmarkierungen durch radioaktive Nuklide ( $^{3}H$ -TDR,  $^{3}H$ -DFP) die Zellkinetik der Granulopoese und des Neutrophilen



„Zellkinetik der Granulopoese und des Neutrophilen“



### Summary

Cellular kinetics of the granulopoiesis and the neutrophilic system were studied by total and differential cell counting methods together with labelling of various elements with radioactive nuclides ( $^3\text{H}$  TDR,  $^3\text{H}$  DFP) in a patient with cyclical neutropenia. The periodic rise and fall of the neutrophil levels in the blood typical of the disease was shown to result from rhythmical fluctuations in the production of neutrophils in the marrow. These in turn were caused by cyclical variations in the proliferative activity of granulopoiesis which can be regarded as the expression of a disturbance of a mechanism controlling proliferation in granulopoiesis by a balance-arm system.

### Literatur

- 1 ALBRITTON, F. C. Standard values of blood p 72 (Philadelphia 1952)
- 2 ATHIENS, J. W., RAAB, S. O., HAAS, O. P., MAURER, A. M., ASHENBRUCKER, H., CARTWRIGHT, G. E. and WINTROBE, M. M. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. *J. clin. Invest.* 40: 159 (1961)
- 3 BAKER, R. J., ROZOLL, D. D. and MEYER, K. The use of surface area as a basis for establishing normal blood volume. *Surg. Gynec. Obstet.* 104: 183 (1957)
- 4 BARLING, B. Chronic cyclic granulopenia. *Proc. roy. Soc. Med.* 61: 653 (1948)
- 5 BARSBY, B. E. and CLOSE, H. G. Recurrent neutrophil agranulocytes. *Lancet*: 99 (1942)
- 6 BECKER, F. T., COVENTRY, W. D. and TULSA, J. L. Recurrent oral and cutaneous infections associated with cyclic neutropenia. *Arch. Derm.* 80: 731 (1959)
- 7 BORNE, S. Cyclic neutropenia in an infant. *Pediatrics* 3: 70 (1949)
- 8 CRADDOCK, C. G., PERRY, S. and LAWRENCE, J. S. The dynamics of leukopoiesis and leukocytosis as studied by leukophoresis and isotopic techniques. *J. clin. Invest.* 35: 286 (1956)
- 9 CROKITE, E. P. and FLIEDNER, T. M. Granulopoiesis. *New Engl. J. Med.* 270: 1347, 1403 (1964)
- 10 CROKITE, E. P., BOND, V. P., FLIEDNER, T. M. and KILLMANN, S. A. The use of tritiated thymidine in the study of hemopoietic cell proliferation. *Ciba Found. Symp. Hemopoiesis*, p. 70 (Churchill, London 1960)
- 11 DÖRKEN, H. Lymphosarkom Leukämie, zyklische Agranulozytose und latente Neutropenie in einer Familie. *Klin. Wochschr.* 32: 173 (1954)
- 12 FLIEDNER, T. M. Der Lebenszyklus neutrophiler Granulozyten, Habilitationsschrift Freiburg (1964)
- 13 FLIEDNER, T. M., CROKITE, E. P. and ROBERTSON, J. S. Granulopoiesis. I. Senescence and random loss of neutrophilic granulocytes in human beings. *Blood* 24: 402 (1964)
- 14 FLIEDNER, T. M., CROKITE, E. P., KILLMANN, S. A. and BOND, V. P. Granulopoiesis. II. Emergence of pattern of labeling of neutrophilic granulocytes in human beings. *Blood* 24: 683 (1964)
- 15 FULLERTON, H. W. and DUGUID, H. L. D. A case of cyclical agranulocytosis with marked improvement following splenectomy. *Blood* 4: 269 (1949)
- 16 HAINEMANN, B. M. and ALT, H. L. Cyclic neutropenia in a father and daughter. *J. amer. med. Ass.* 168: 270 (1958)
- 17 JACKSON, H. and MERRILL, D. Agranulocytic angina associated with the menstrual cycle. *New Engl. J. Med.* 240: 175 (1944)



**L. P. HOLLÄNDER** (editor) *Proceedings of the VIII Congress of the International Society of Blood Transfusion*. Bibliotheca Haematologica No. 29 Part I-IV Karger, Basel/New York 1968 LXIV + 1250 p., 347 fig., 216 tab. Price sFr/Dm 255 -/\$ 61.20/£ 25 10 0

The 11th Congress of the International Society of Blood Transfusion held in 1966 in Sydney, Australia, attracted investigators from the entire scientific world. The disadvantage of a relative long delay in publication of the transactions is balanced by their most careful editing. The vast amount of information gathered at this meeting is comprised within 4 volumes. The general topics treated at this congress again include the major subspecialties of haematology, especially blood preservation, genetics, immunology and protein chemistry. Of particular value is the cumulative subject and authors index from this and previous transactions of the International Society of Blood Transfusion covering the period from 1936 through 1966. The price of the 4 volumes is not too high considering its wealth of information. Clinical haematologists, transfusions specialists and investigators interested in the disorders of the blood will gratefully acknowledge the excellent editorial work of Prof L. P. HOLLÄNDER.

E. A. Beck, Basel

**C. J. C. BRITTON** *Disorders of the Blood. Diagnosis. Pathology. Treatment. Technique*. WHITBY and BRITTON (editors), sections by F. G. J. HAYDON, G. H. TOVEY and J. R. O'BRIEN. 10th edition. Churchill, London 1969 XII + 860 p., 117 fig., 21 pl. Price £ 7/10

Few medical textbooks live up to ten editions. Despite extensive rewriting the 10th edition of WHITBY and BRITTON's book on disorders of the blood contains too much historical information derived from earlier editions. Evaluation of the pathogenesis of a certain haematologic abnormality, its diagnosis and treatment are scattered in a rather arbitrary fashion throughout the various chapters. This lack of coherent organisational concept is also manifested by the many cross references as well as by unnecessary duplications. The figures are of uneven quality and do not always adequately illustrate what they are meant to show. e.g. figure 9 demonstrating a number of grey dots between obviously osseous structures, the whole apparently illustrating 'leukoblastic hyperplasia in bone marrow of femur (chronic myeloid leukaemia)'.

The particular value of the whole textbook does not become more clear when the reader penetrates the text in more detail. There may exist some educational purpose in mentioning a particular paper but not stating what specific information this paper conveys, since the reader really has to go to the library and read the original communication in order to know what he is interested in. As an example I might cite the enumeration of references concerning abnormal haemoglobins on pages 369/370. The reader has no occasion to learn why any given abnormality causes clinical symptoms. This section concludes with the following sentence: 'Haemoglobin Zurich is described by FRICK *et al.* [1962]. The cases showed no enzyme deficiency but had haemolytic crises after sulfonamides'. No mention of the lability of this haemoglobin nor of its tendency towards Heinz body formation! The references are relatively plentiful for a general textbook and sometimes up-to-date, sometimes not. The reviewer should perhaps be pleased that 'fibrinogen Baltimore' (p. 400) is the only abnormal fibrinogen finding its way into this textbook, whereas the abnormal fibrinogen described by von FELTZ in 1966 is for doubtful reasons mentioned in connection with factor XIII deficiency. However, this particular subject has been repeatedly reviewed since 1965 in easily accessible journals and textbooks. Numerous similar examples might be added. In summary this textbook can hardly be recommended to the newcomer in the field of clinical haematology. For more experienced haematologists its technical sections contain some useful information. The book has certainly its merits in mentioning many not so new observations which went to oblivion in other recent textbooks of haematology.

E. A. Beck, Basel

## Disturbances of Hemostasis in Acute Myeloblastic Leukemia<sup>1</sup>

F. ROSNER, J. V. DOBBS, N. D. RITZ and S. L. LEE  
with the technical assistance of THELMA FERNBACH M.T.

Division of Hematology, Department of Medicine, Maimonides Medical Center and State University of New York, Downstate Medical Center, Brooklyn, N.Y.

Patients with acute leukemia frequently have a hemorrhagic tendency. Various mechanisms for this bleeding diathesis have been described including thrombocytopenia, fibrinolysis, and diminution in one or more coagulation factors.

A thrombotic tendency in patients with acute leukemia also occasionally occurs and, when present, is thought to be due to a 'hypercoagulable state' in which thrombocytes [8], antihemophilic globulin [15], fibrinogen [17] and other coagulation factors are increased.

The following results were observed in 49 patients with acute myeloblastic leukemia in whom coagulation studies were performed.

### *Materials and Methods*

*Patient selection.* Between 1967 and 1966, patients were pre-selected for coagulation screening studies. Only patients with hemorrhagic or thrombotic manifestations were studied. Since 1967 hemostatic function has been evaluated in all patients with acute leukemia at the time of admission to the hospital (prior to any antileukemic therapy) and at intervals thereafter. In 23 of the 49 subjects no treatment had been administered at the time of the first coagulation evaluation. With the exception of 4 persons who had acute promyelocytic leukemia all patients had typical findings of acute myeloblastic leukemia. Patients with acute lymphoblastic leukemia and chronic leukemias were excluded from this report.

The technique of LOLES and ROMAN [5] in most patients the clotability of fibrinogen was also measured [12].

<sup>1</sup> Supported by U.S. Public Health Service Grant No. CA-05073, the Furman-Denmark Hemophilia Fund, the Metropolitan Chapter of the National Hemophilia Foundation and the National Leukemia Association, Inc.

**L. F. HOLLÄNDER** (editor) *Proceedings of the XIth Congress of the International Society of Blood Transfusion*. Bibliotheca Haematologica No 29 Part I-IV Karger, Basel/New York 1968 LXIV + 1250 p, 347 fig, 216 tab Price sFr/Dm 255 -/\$ 61.20/£ 25 10 0

The 11th Congress of the International Society of Blood Transfusion held in 1966 in Sydney, Australia, attracted investigators from the entire scientific world. The disadvantage of a relative long delay in publication of the transactions is balanced by their most careful editing. The vast amount of information gathered at this meeting is comprised within 4 volumes. The general topics treated at this congress again include the major subspecialties of haematology, especially blood preservation, genetics, immunology and protein chemistry. Of particular value is the cumulative subject and authors index from this and previous transactions of the International Society of Blood Transfusion covering the period from 1936 through 1966. The price of the 4 volumes is not too high considering its wealth of information. Clinical haematologists, transfusion specialists and investigators interested in the disorders of the blood will gratefully acknowledge the excellent editorial work of Prof L. F. HOLLÄNDER.

E. A. BECK, *Basel*

**C. J. C. BRITTON** *Disorders of the Blood. Diagnosis Pathology Treatment Technique* WHITBY and BRITTON (editors), sections by F. G. J. HAYHOE, G. H. TOVEY and J. R. O'BRIEN. 10th edition. Churchill, London 1969 VII + 860 p, 117 fig, 21 pl Price £ 7/10

Few medical textbooks live up to ten editions. Despite extensive rewriting the 10th edition of WHITBY and BRITTON's book on disorders of the blood contains too much historical information derived from earlier editions. Evaluation of the pathogenesis of a certain haematologic abnormality, its diagnosis and treatment are scattered in a rather arbitrary fashion throughout the various chapters. This lack of coherent organisational concept is also manifested by the many cross references as well as by unnecessary duplications. The figures are of uneven quality and do not always adequately illustrate what they are meant to show, e.g. figure 9 demonstrating a number of grey dots between obviously osseous structures (the whole apparently illustrating 'leukoblastic hyperplasia in bone marrow of femur (chronic myeloid leukaemia)').

The particular value of the whole textbook does not become more clear when the reader penetrates the text in more detail. There may exist some educational purpose in mentioning a particular paper but not stating what specific information this paper conveys, since the reader really has to go to the library and read the original communication in order to know what he is interested in. As an example I might cite the enumeration of references concerning abnormal haemoglobins on pages 369/370. The reader has no occasion to learn why any given abnormality causes clinical symptoms. This section concludes with the following sentence: 'Haemoglobin Zurich is described by FRICK *et al* [1962]. The cases showed no enzyme deficiency but had haemolytic crises after sulfonamides. No mention of the lability of this haemoglobin nor of its tendency towards Heinz body formation! The references are relatively plentiful for a general textbook and sometimes up-to-date, sometimes not. The reviewer should perhaps be pleased that 'fibrinogen Baltimore' (p. 400) is the only abnormal fibrinogen finding its way into this textbook whereas the abnormal fibrinogen described by von FELTEN in 1966 is, for doubtful reasons, mentioned in connection with factor XIII deficiency. However, this particular subject has been repeatedly reviewed since 1965 in easily accessible journals and textbooks. Numerous similar examples might be added. In summary, this textbook can hardly be recommended to the newcomer in the field of clinical haematology. For more experienced haematologists its technical sections contain some useful information. The book has certainly its merits in mentioning many not so new observations which went to oblivion in other recent textbooks of haematology.

E. A. BECK, *Basel*

## Disturbances of Hemostasis in Acute Myeloblastic Leukemia<sup>1</sup>

F ROSNER, J V DOBBS, N D RITZ and S L LEE

with the technical assistance of THELMA FERNBACH M.T.

Division of Hematology Department of Medicine Maimonides Medical Center and State University of New York Downstate Medical Center, Brooklyn, N.Y.

Patients with acute leukemia frequently have a hemorrhagic tendency. Various mechanisms for this bleeding diathesis have been described including thrombocytopenia, fibrinolysis, and diminution in one or more coagulation factors.

A thrombotic tendency in patients with acute leukemia also occasionally occurs and, when present, is thought to be due to a 'hypercoagulable state' in which thrombocytes [8], antihemophilic globulin [15], fibrinogen [17] and other coagulation factors are increased.

The following results were observed in 49 patients with acute myeloblastic leukemia in whom coagulation studies were performed.

### *Materials and Methods*

**Patient selection.** Between 1962 and 1966 patients were pre-selected for coagulation screening studies. Only patients with hemorrhagic or thrombotic manifestations were studied. Since 1967, hemostatic function has been evaluated in all patients with acute leukemia at the time of admission to the hospital (prior to any antileukemic therapy) and at intervals thereafter. In 23 of the 49 subjects no treatment had been administered at the time of the first coagulation evaluation. With the exception of 4 persons who had acute promyelocytic leukemia, all patients had typical findings of acute myeloblastic leukemia. Patients with acute lymphoblastic leukemia and chronic leukemias were excluded from this report.

**Methods.** Partial thromboplastin times were performed according to PROCTOR and RAPAPORT [11]. Prothrombin consumption was estimated as described by AGgeler *et al.* [1]. Thrombin times were determined by the method of LEWIS [9] and fibrinogen levels by the ammonium sulfate technique of COLLS and ROMAN [5]. In most patients the clotability of fibrinogen was also measured [12].

<sup>1</sup> Supported by U.S. Public Health Service Grant No. CA-05923, the Furman-Denmark Hemophilia Fund, the Metropolitan Chapter of the National Hemophilia Foundation and the National Leukemia Association, Inc.

**L. P. HOLLÄNDER (editor) Proceedings of the XIth Congress of the International Society of Blood Transfusion** *Bibliotheca Haematologica* No 29 Part I-IV Karger, Basel/New York 1968 LNV + 1250 p, 317 fig, 216 tab Price sFr /DM 255 -/\$ 61.20/£ 25 10 0

The 11th Congress of the International Society of Blood Transfusion held in 1966 in Sydney, Australia, attracted investigators from the entire scientific world. The disadvantage of a relative long delay in publication of the transactions is balanced by their most careful editing. The vast amount of information gathered at this meeting is comprised within 4 volumes. The general topics treated at this congress again include the major subspecialties of haematology, especially blood preservation, genetics, immunology and protein chemistry. Of particular value is the cumulative subject and authors index from this and previous transactions of the International Society of Blood Transfusion covering the period from 1936 through 1966. The price of the 4 volumes is not too high considering its wealth of information. Clinical haematologists, transfusions specialists and investigators interested in the disorders of the blood will gratefully acknowledge the excellent editorial work of Prof. L. P. HOLLÄNDER.

E. A. BECK, Basel

**C. J. C. BRITTON Disorders of the Blood Diagnosis Pathology Treatment Technique** WHITBY and BRITTON (editors), sections by F. G. J. HAYHOE, G. H. TOVEY and J. R. O'BRIEN 10th edition. Churchill, London 1969 VII + 860 p, 117 fig, 21 pl Price £ 7/10

Few medical textbooks live up to ten editions. Despite extensive rewriting the 10th edition of WHITBY and BRITTON's book on disorders of the blood contains too much historical information derived from earlier editions. Evaluation of the pathogenesis of a certain haematologic abnormality, its diagnosis and treatment are scattered in a rather arbitrary fashion throughout the various chapters. This lack of coherent organisational concept is also manifested by the many cross references as well as by unnecessary duplications. The figures are of uneven quality and do not always adequately illustrate what they are meant to show, e.g. figure 9 demonstrating a number of grey dots between obviously osseous structures, the whole apparently illustrating 'leukoblastic hyperplasia in bone marrow of femur (chronic myeloid leukaemia)'.

The particular value of the whole textbook does not become more clear when the reader penetrates the text in more detail. There may exist some educational purpose in mentioning a particular paper but not stating what specific information this paper conveys, since the reader really has to go to the library and read the original communication in order to know what he is interested in. As an example I might cite the enumeration of references concerning abnormal haemoglobins on pages 369/370. The reader has no occasion to learn why any given abnormality causes clinical symptoms. This section concludes with the following sentence: 'Haemoglobin Zurich is described by FRICK *et al.* [1962]. The cases showed no enzyme deficiency but had haemolytic crises after sulfonamides. No mention of the lability of this haemoglobin nor of its tendency towards Heinz body formation! The references are relatively plentiful for a general textbook and sometimes up-to-date, sometimes not. The reviewer should perhaps be pleased that 'fibrinogen Balumore' (p. 400) is the only abnormal fibrinogen finding its way into this textbook, whereas the abnormal fibrinogen described by VON FELTEN in 1966 is, for doubtful reasons, mentioned in connection with factor XIII deficiency. However, this particular subject has been repeatedly reviewed since 1965 in easily accessible journals and textbooks. Numerous similar examples might be added. In summary, this textbook can hardly be recommended to the newcomer in the field of clinical haematology. For more experienced haematologists its technical sections contain some useful information. The book has certainly its merits in mentioning many not so new observations which went to oblivion in other recent textbooks of haematology.

E. A. BECK, Basel

## Disturbances of Hemostasis in Acute Myeloblastic Leukemia<sup>1</sup>

F. ROSNER, J. V. DOBBS, N. D. RITZ and S. L. LEE  
with the technical assistance of TIZELMA FERNBACH M.T.

Division of Hematology Department of Medicine Maimonides Medical Center and State University of New York, Downstate Medical Center Brooklyn, N.Y.


Patients with acute leukemia frequently have a hemorrhagic tendency. Various mechanisms for this bleeding diathesis have been described including thrombocytopenia, fibrinolysis, and diminution in one or more coagulation factors.

A thrombotic tendency in patients with acute leukemia also occasionally occurs and, when present, is thought to be due to a 'hypercoagulable state' in which thrombocytes [8], antihemophilic globulin [15], fibrinogen [17] and other coagulation factors are increased.

The following results were observed in 49 patients with acute myeloblastic leukemia in whom coagulation studies were performed.

### Materials and Methods

*Patient selection.* Between 1967 and 1966 patients were pre-selected for coagulation screening studies. Only patients with hemorrhagic or thrombotic manifestations were studied. Since 1967 hemostatic function has been evaluated in all patients with acute leukemia at the time of admission to the hospital (prior to any antileukemic therapy) and at intervals



1. Fibrinogen was also measured [12]

<sup>1</sup> Supported by U.S. Public Health Service Grant No. CA-05973, the Furman-Denmark Hemophilia Fund, the Metropolitan Chapter of the National Hemophilia Foundation and the National Leukemia Association, Inc.



Specific assays for factor II (prothrombin) and factor V (proaccelerin) were done by the methods of HJORT *et al.* [7] and BORCHGREVENK *et al.* [4] respectively. Factors VII and X (proconvertin and Stuart factor) were assayed together and factor X alone according to DICKERT [6]. Factor VIII (antihemophilic globulin) was estimated by slight modification of the one stage assay of RAPAPORT *et al.* [13] and factor XIII (fibrin stabilizing factor) was determined as described by LORAND and DICKENMAN [10].

Euglobin lysis time was determined by the method of SIERRA *et al.* [16] and ASTRUP plate lysis was measured according to ASTRUP and MULLERTZ [2]. Casein proteolytic assay was estimated according to RITZ and RUBIN [14].

## Results

### A. Tests of Platelet Function and Vascular Integrity

Of 49 patients platelet counts were below 50,000/mm<sup>3</sup> in 24 patients at the time of first evaluation; 5 patients had counts between 40,000 and 50,000, 5 between 30,000 and 40,000, 7 between 20,000 and 30,000, 4 between 10,000 and 20,000 and 3 below 10,000/mm<sup>3</sup>. Ten subjects had platelet counts between 50,000 and 100,000, and in 15 patients the initial platelet count was greater than 100,000/mm<sup>3</sup> but less than 150,000/mm<sup>3</sup>.

Clot retraction was poor in 19, fair in 9 and good in 21 patients in spite of some degree of thrombocytopenia in 43 of 49 patients.

Qualitative tests of platelet function were performed in 5 individuals. These tests included platelet adhesiveness, platelet aggregation with added adenosine diphosphate, and a modified thromboplastin generation test comparing normal platelets with the patient's platelets. Qualitative platelet abnormalities were detected in only one patient (fig. 1).

The bleeding time was normal in 15 patients in all of whom platelet counts were abnormal (25,000/mm<sup>3</sup> to 140,000/mm<sup>3</sup>). In the 18 patients with prolonged bleeding times, seven values were greater than 10 min. The prolonged bleeding times were associated with varied platelet counts ranging from 12,000/mm<sup>3</sup> to 150,000/mm<sup>3</sup> with four of the counts being 150,000/mm<sup>3</sup>.

### B. Non-Specific Tests of Coagulation (Screening Tests)

*Coagulation time.* None of the 49 patients studied had a shortened coagulation time. In only 6 patients was the coagulation time abnormally prolonged.




Fig 1 Thromboplastin generation test comparing normal platelets with the platelets of one patient. The patient's platelets functioned half as well as the normal platelets. — Normal plasma + normal serum + cephalin 60 × — × patient plasma + patient serum + cephalin 60 --- patient plasma + patient serum + patient platelets — patient plasma + patient serum + normal platelets — normal plasma + normal serum + patient platelets ○—○ normal plasma + normal serum + normal platelets.

**Silicone tube coagulation time** In 3 of 38 patients the values were greater than 30 min. However, in 15 patients the silicone tube coagulation times were less than 15 min. Five of these patients also had elevated fibrinogen levels.

**Prothrombin (Quick) time** This test was performed 68 times in 48 patients. Forty-four determinations showed abnormally long times with 28 values between 13 and 15 s and 16 values greater than 15 s. In 1 patient with a prothrombin time of 16 s, all coagulation factor assays were normal. In all of the 43 remaining patients with high prothrombin times, depression of specific clotting factors were present, usually factors II, V, VIII, and X in various combinations or together with factor I. These abnormalities occurred in half of the patients before therapy was initiated and in half after therapy.




Fig. 2. Specific assays of coagulation factors in 49 patients with acute myeloblastic leukemia.

**Partial thromboplastin time (PTT)** In 3 patients partial thromboplastin time was shortened (less than 30 s) and in 2 of these patients fibrinogen levels were also elevated and silicone clotting times shortened. In 5 other patients partial thromboplastin times were prolonged (greater than 60 s).

**Prothrombin consumption test** (44 patients) In all but 3 patients, platelet counts were less than  $150,000/\text{mm}^3$ . In 24 patients, less than 80% of the prothrombin was consumed. In the other 20 patients normal results were observed. In 7 of these patients platelet counts were below  $150,000/\text{mm}^3$ .

### C. Specific Assays of Coagulation Factors

**Fibrinogen (factor I)** was determined in 45 patients. Abnormally high values were observed on 24 occasions and abnormally low values were detected 13 times. Four patients had fibrinogen levels greater than  $600 \text{ mg}/100 \text{ ml}$  (fig. 2).

*Prothrombin (factor II)* Eleven patients had values below 50% and 3 patients had elevated levels of prothrombin (greater than 150%). In 2 of the latter 3 patients, fibrinogen was also elevated (431 and 605 mg%) In the third patient, the fibrinogen level was at the upper limit of normal (388 mg%) but factor V was also elevated (200%) In all the patients in whom levels of prothrombin were depressed, there was also depression of factor V or one or more of the vitamin K dependent factors (factors VII, IX, X) The prothrombin time was also prolonged in all but one case

*Proaccelerin (factor V)* was assayed in 47 patients, it was normal in 31, decreased (below 65%) in 14, and increased (over 120%) in 2 cases In 1 of the latter 2 cases, fibrinogen, prothrombin, and anti-

39 patients Decreased values (below 50%) were found in 10 patients A single patient had a level of 160%, this subject also had increased fibrinogen and prothrombin levels

*Antihemophilic globulin (factor VIII)* (17 patients) was normal in 13 patients Elevated values were found in 4 patients, in two of whom fibrinogen levels were also increased

*Stuart factor (factor XI)* (32 patients) was normal in 23 patients In the other 9, low values (below 60%) were found Low Stuart factor levels always correlated with decreased values of the other vitamin K dependent factors and prolongation of the prothrombin time

*Thrombin time* (30 patients) The thrombin time was less than 10 s in 11, between 10 and 15 s in 15 and greater than 15 s in 4 patients

*Fibrin stabilizing factor (factor XIII)* Normal values were found in 10 of 15 patients and increased values in the other 5 patients There seemed to be no correlation between levels of factor XIII and other coagulation factors

#### D Tests of Fibrinolytic Activity

Whole clot lysis was observed in only 1 of the 49 patients Euglobulin lysis time was normal in all 12 patients tested The casein assay was abnormal in only 1 of these 12 patients and this patient also had increased fibrinolysis observed on the Astrup plate In 17 other patients, no increased fibrinolytic activity was present on the Astrup plates

### Discussion

In our observations on 19 patients with acute myeloblastic leukemia no uniform coagulation disturbance was found although several patterns of hemostatic abnormality were found.

Thrombocytopenia was a predominant finding (43 of 49 cases) but a bleeding tendency or overt purpura was often absent. The bleeding tendency did not necessarily follow the degree of thrombocytopenia. Three of 6 patients with normal platelet counts had prolonged bleeding times and a hemorrhagic tendency whereas 11 of the 13 patients with thrombocytopenia had normal bleeding times and no bleeding diathesis. None of the other tests performed including clot retraction or prothrombin consumption was more useful than the platelet count in estimating a bleeding tendency. Bleeding due to thrombocytopenia in acute leukemia is diminishing in frequency due to the variability in most large medical centers of platelet transfusions.

Depression of clotting factors was the next most common abnormality encountered and was present in 9 patients with factors II, V, VII, X depressed. In 4 other patients, concentrations of 2 or 3 of these factors were decreased. In all patients, the decrease of these clotting factors was not directly related to therapy since these findings of coagulation disturbances were present in half of the patients before anti-leukemic drugs had been administered.

Qualitative platelet abnormalities causing hemoptysis and purpura in the presence of normal numbers of platelets were found in one of our patients (fig. 1) (However, only in 5 patients were platelet function studies made.)

Hemorrhagic tendency in association with a reduced blood content of fibrinogen may be due to *in vivo* activation of fibrinolysis or to *in vivo* deposition of fibrin (or to a combination of both mechanisms). Earlier studies of patients with acute leukemia by other authors purport to show different mechanisms at play under apparently identical clinical circumstances. Some authors relate the bleeding tendency in acute promyelocytic leukemia to consumption, while others emphasize the role of fibrinolysis. Both consumption coagulopathy and fibrinolysis have also been named as cause for occasional instances of hypofibrinogenemia in association with non promyelocytic leukemias.

In the presented series, 1 of 4 patients with promyelocytic leukemia showed elements of this syndrome and in 1 of these fibrinolysis was

prominent. Ten other patients with other morphologic pictures also had some degree of hypofibrinogenemia. In this series as in most reported instances fibrinolysis appears to be an infrequent primary mechanism for bleeding, its pathogenetic role even when it occurs is not clear.

Intravital fibrin deposition may present itself as hemorrhagic tendency, or with thrombotic phenomena. Elevated levels of platelets or of plasma coagulation factors may be found when a thrombotic tendency is apparent. Increased levels of antihemophilic globulin in acute leukemia occur [15]. Markedly elevated levels of multiple clotting factors and diffuse intravascular coagulation at *post mortem* have occasionally been found [3].

One of the patients in the present study did show clinical manifestations of the 'hypercoagulable state' in the form of thrombophlebitis and possibly cerebral thrombosis. This patient not only had elevated fibrinogen and factor VIII levels but also marked elevations of prothrombin and factor V. Abnormally high fibrinogen levels were found in 21 of the 45 patients where this test was performed. Furthermore, 4 of 17 patients tested had significantly elevated factor VIII levels. These findings help support the concept that hypercoagulability in patients with acute myeloblastic leukemia may be frequently accompany the disease. This concept is predicated on the assumption that an elevation of the plasma clotting factor in the non-activated form is evidence of hypercoagulability. All the measurements reported in the present study are of the non-activated species.

### Summary

Disturbances of hemostatic function in patients with acute leukemia take four forms

1. Hypofibrinogenemia, hypoprothrombinemia, and hypofactor VIII levels. This is the most common disturbance, occurring in 45% of the patients. It is usually associated with bleeding. 2. Thrombocytopenia. This is the second most common disturbance, occurring in 35% of the patients. It is usually associated with bleeding. 3. Thrombocytosis. This is the third most common disturbance, occurring in 15% of the patients. It is usually associated with bleeding. 4. Hypercoagulability. This is the least common disturbance, occurring in 5% of the patients. It is usually associated with thrombosis.

## References

- 1 AGGELER, P M, HOAG, M S, WALLERSTEIN, R O and WHITSELL, D The mild hemophilias. Occult deficiencies of AHE, PTC and PTA frequently responsible for unexpected surgical bleeding *Amer J Med* 30 81-94 (1961)
- 2 ASTRUP, T and MULLERTZ, S The fibrin plate method for estimating fibrinolytic activity *Arch Biochem Biophys* 40 346-351 (1952)
- 3 BAKER, W G, BANG, N U, NACHMAN, R L, RAAPAT, E. and HOROWITZ, H I Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin with autopsy findings of widespread intravascular clotting *Ann intern Med* 61 116-123 (1964)
- 4 BORCHGREVINK, C F, POOL, J G and STORMORSEN, H A new assay for factor V (proaccelerin) using Russell's viper venom *J Lab. clin Med* 55 625-632, (1960)
- 5 COLES, M and ROMAN, W A rapid method for estimating fibrinogen in plasma *J clin Path* 10 282-283 (1957)
- 6 DUCKERT, F Mécanisme de la coagulation *Röntgen Lab Praxis* 13 224-229 (1960)
- 7 HJORT, P, RAPAPORT, S I and OWREN, P A A simple specific one-stage prothrombin assay using Russell's viper venom in cephaline suspension *J Lab. clin Med.* 46 89-97 (1955)
- 8 KOLAKOWSKA POLUBIEC, K., LITWIN, J and TRACZYK, Z A case of myelocytic leukaemia with periodical hyperthrombocytaemia (Polish) *Polski Tyd. Lekar* 20 1166-1167, (1965)
- 9 LEWIS, J H Abnormalities in the fibrinogen-thrombin reaction *Proc. 14th Congr int. Soc. Hemat.*, Mexico City, 1962, vol 2, pp 113-120
- 10 LORAND, L and DICKENMAN, R C Assay method for the 'fibrin stabilizing factor' *Proc. Soc. exp Biol.*, NY 89 45-48 (1955)
- 11 PROCTOR, R R and RAPAPORT, S I The partial thromboplastin time with kaolin A simple screening test for first stage plasma clotting factor deficiencies *Amer J clin Path* 36 212-219 (1961)
- 12 RATNOFF, O and MENZIE, C A new method for the determination of fibrinogen in small samples of plasma *J Lab clin Med* 37 316-320 (1951)
- 13 RAPAPORT, S I, SCHIFFMAN, S, PATCH, M J and WARE, A G A simple, specific one-stage assay for plasma thromboplastin antecedent activity *J Lab clin Med* 57 771-780 (1961)
- 14 ... .. Studies on en
- 15 ... .. 1968 ... 178 ... 5532
- 16 ... ..
- 17 WELSH, J D, ROBINSON, C. and BIRD, R M Serial fibrinogen determinations in patients with leukemia *Amer J med Sci.* 241 207-214 (1961)

## Fine Structural Features of Lymphocyte Transformation Induced by Mercuric Salts

E. SCHOFF and G. NAGY

Department of Dermatology (Director: Prof. J. KMMER) University of Hamburg, Hamburg

Mercuric salts, i.e. mercuric chloride, mercuric cyanide, mercuric acetate, mercuric nitrate and some organic mercurial compounds such as merbromin and oxymercurisalicylic acid induce non specific transformation and mitosis in human peripheral lymphocytes *in vitro* [10, 11, 12]. The transformed cells range from 10-25  $\mu$ m in diameter and have basophilic cytoplasm. The nucleus contains up to 3 nucleoli and the chromatin has a fine reticular pattern (fig. 1 and 2). The mercury stimulated lymphocytes show enhanced RNA and DNA synthesis as demonstrated by autoradiographic technique (fig. 3) [11]. Mercuric chloride has been shown to cause non specific transformation of lymphoid cells from lymph nodes of guinea pig and rat, and from rabbit spleen, too [8]. Previous studies by light microscopy demonstrated that transformation induced by mercurial compounds is morphologically analogous to transformation mediated by phytohemagglutinin (PHA) [10, 11]. The degree of transformation induced by mercurial compounds is lower than in PHA stimulation.

Mercury stimulated lymphocytes have not yet been examined by means of electronmicroscopy. It is the purpose of the present report to describe and compare the ultrastructure of mercury stimulated and PHA stimulated lymphocytes.

### Materials and Methods

Heparinized venous blood (40 units/ml) was obtained from 5 normal adult males and 2 normal adult females. Following spontaneous sedimentation of red cells, the leucocyte-rich plasma was drawn off and passed over a column of fine-mesh perlon wool (Farbwerke



## References

- 1 AGGELER, P M, HOAG, M S, WALLERSTEIN, R O and WINSELL, D The mild hemophilias Occult deficiencies of AHE, PTC and PTA frequently responsible for unexpected surgical bleeding *Amer J Med* 30 84-94 (1961)
- 2 ASTRUP, T and MULLERTZ, S The fibrin plate method for estimating fibrinolytic activity *Arch Biochem Biophys* 40 346-351 (1952)
- 3 BAKER, W G, BANG, N U, NACHMAN, R L, RAAFAT, E. and HOROWITZ, H I Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin with autopsy findings of widespread intravascular clotting *Ann intern Med* 61 116-123 (1964)
- 4 BORCHGREVINK, C F, POOL, J G and STORMORKEN, H A new assay for factor V (proaccelerin accelerator) using Russell's viper venom *J Lab clin Med* 55 625-632, (1960)
- 5 COLES, M and ROMAN, W A rapid method for estimating fibrinogen in plasma. *J clin Path* 10 282-283 (1957)
- 6 DICKERT, F Mécanisme de la coagulation *Röntgen Lab Praxis* 13 224-229 (1960)
- 7 HJORT, P, RAPAPORT, S I and OWREN, P A A simple specific one-stage prothrombin assay using Russell's viper venom in cephaline suspension *J Lab clin Med* 46 89-97 (1955)
- 8 KOLAKOWSKA POLUBIEC, K, LITWIN, J and TRACZYK, Z. A case of myelocytic leukaemia with periodical hyperthrombocytaemia (Polish) *Polski Tyd. Lekar* 20 1166-1167, (1965)
- 9 LEWIS, J H Abnormalities in the fibrinogen thrombin reaction *Proc 15th Congr int Soc. Hemat*, Mexico City, 1962, vol 2, pp 113-120
- 10 LORAND, L. and DICKENMAN, R C Assay method for the 'fibrin stabilizing factor' *Proc. Soc exp Biol NY* 89 45-48 (1955)
- 11 PROCTOR, R. R. and RAPAPORT, S I The partial thromboplastin time with kaolin A simple screening test for first stage plasma clotting factor deficiencies *Amer J clin Path* 36 212-219 (1961)
- 12 RATNOFF, O and MENZIE, C. A new method for the determination of fibrinogen in small samples of plasma *J Lab clin Med* 37 316-320 (1951)
- 13 RAPAPORT, S I, SCHIFFMAN, S, PATCH, M J and WARE, A G A simple, specific one-stage assay for plasma thromboplastin antecedent activity *J Lab clin Med* 57 771-780 (1961)
- 14 RITZ, N D and RUBIN, H Use of chromium 51 tagged casein for the determination of proteolytic activity *J Lab clin Med* 63 344-354 (1964)
- 15 ROSENTHAL, R. L. and SLOAN, F Factor VIII (AHG) activity in acute leukemia *Proc. 15th Congr int. Soc Hemat*, New York 1962, p. 178, Abstract 5532
- 16 SHERRY, S, LINDEMAYER, R I, FLETCHER, A P and ALKJÆRSØ, N Studies on enhanced fibrinolytic activity in man *J clin Invest* 38 810-822 (1959)
- 17 WELSH, J D, ROBINSON, C. and BIRD, R M Serial fibrinogen determinations in patients with leukemia *Amer J med Sci* 241 207-214 (1961)

Authors' address Drs. FRED ROSENER, JOAN V. DOBBS, NORTON D. RITZ and STANLEY L. LEE, Division of Hematology, Maimonides Medical Center, Brooklyn, NY 11219 (USA)

## Fine Structural Features of Lymphocyte Transformation Induced by Mercuric Salts

E. SCHÖPF and G. NAGY


Department of Dermatology (Director: Prof. J. Krumm) University of Hamburg, Hamburg

Mercuric salts, i.e. mercuric chloride, mercuric cyanide, mercuric acetate, mercuric nitrate and some organic mercurial compounds such as merbromin and oxymercurisalicylic acid induce non specific transformation and mitosis in human peripheral lymphocytes *in vitro* [10, 11, 12]. The transformed cells range from 10–25  $\mu$ m in diameter and have basophilic cytoplasm. The nucleus contains up to 3 nucleoli and the chromatin has a fine reticular pattern (fig. 1 and 2). The mercury stimulated lymphocytes show enhanced RNA and DNA-synthesis as demonstrated by autoradiographic technique (fig. 3) [11]. Mercuric chloride has been shown to cause non specific transformation of lymphoid cells from lymph nodes of guinea pig and rat, and from rabbit spleen, too [8]. Previous studies by light microscopy demonstrated that transformation induced by mercurial compounds is morphologically analogous to transformation mediated by phytohemagglutinin (PHA) [10, 11]. The degree of transformation induced by mercurial compounds is lower than in PHA stimulation.

Mercury stimulated lymphocytes have not yet been examined by means of electronmicroscopy. It is the purpose of the present report to describe and compare the ultrastructure of mercury stimulated and PHA stimulated lymphocytes.

### Materials and Methods

Heparinized venous blood (40 units/ml) was obtained from 5 normal adult males and 2 normal adult females. Following spontaneous sedimentation of red cells, the leucocyte-rich plasma was drawn off and passed over a column of fine mesh perlon wool (Farbwerke



Hoechst (Germany) which resulted in a cell suspension containing 80-90% lymphocytes. Aliquots of 4 ml containing 25% autologous plasma and 75% tissue culture medium TC199 (Difco Lab. Detroit, USA) were placed in capped plastic culture tubes (Falcon Plastics, Los Angeles, USA) to give a final cell density of  $1-1.5 \times 10^6$  leucocytes per ml. The cultures were incubated at 37°C with mercuric nitrate or mercuric chloride (final concentration  $3.5 \times 10^{-4}$  M) or 2 µg/ml phytohemagglutinin P (Difco Lab. Detroit, USA) and normal saline solution respectively as control cultures. Cells were harvested 96 h later. Following centrifugation at 4°C (80 g/15 min) the supernatant was discarded, the cell button suspended in Palade's osmium tetroxide fixative for 1 h at 4°C, and the resulting cell suspension

washed with Veronal acetate buffer (pH 7.2) for 20 min, dehydrated and embedded in

### Results

The most prominent fine structural features of transformed lymphocytes include the enlargement of the cells, their nuclei and nucleoli, the proportional shift of heterochromatin to euchromatin, the increase of ribosomal particles, and pseudopodium formation [6, 7, 13]. These changes can be observed regardless of the mode of stimulation (fig. 4 and 6). The main difference between mercury- and PHA stimulated cells was a more prominent aggregation of free ribosomes into polyribosome complexes after incubation with mercuric salts (fig. 4 and 5). Other ultrastructural changes which have been described after PHA stimulation could also be observed after incubation with mercuric salts. Number and distribution of organelles in transformed cells varied greatly. The cytoplasm sometimes contained hardly any organelles besides polyribosomes (fig. 5). Nevertheless, more mitochondria usually could be observed in transformed than in not transformed cells.

Fig. 1. Lymphocytes cultured in mercury free medium (control) ( $\times 1,500$ ).

Fig. 2. Transformation and mitosis of lymphocytes induced by mercuric chloride ( $3.5 \times 10^{-4}$  M) ( $\times 1,500$ ).

Fig. 3. Autoradiographs of mercury-stimulated lymphocytes. Incorporation of  $^3\text{H}$ -uridine showing RNA-synthesis ( $\times 1,500$ ).



*Fig 4* Cell transformed by mercuric nitrate. The abundant cytoplasm contains many polyribosomes and only a few other organelles. Pseudopodium formation is present (P). Nucleoli are prominent (No). The chromatin appears dispersed ( $\times 12,000$ ).

*Fig 5* Parts of two cells transformed by mercuric nitrate. The cell below displays many

Prominent Golgi complexes and a great deal of micropinocytotic vesicles were very often present. The transformed cells sometimes exhibited multivesicular bodies and several bundles of perinuclear microfibrillar structures. Most had a few randomly distributed strands of rough surfaced endoplasmic reticulum as well as variable fat laden vacuoles. A variety of electron-dense, membrane bound cytoplasmic organelles, morphologically fulfilling the criteria for lysosomes were observed in transformed lymphocytes. Definite phagocytic activity could never be found in our material.

All these features of fine structure except the accumulation of polyribosome complexes, were present also in non transformed cells of cultures incubated with mercuric salts as well as in control cultures (fig. 7). However, in transformed cells an increased number and a variable distribution of cell organelles could be observed. There remained cells transformed by PHA or mercuric salts which strikingly resembled monocytes. Besides, there were many intermediate forms, and cells which defied morphological classification.

### Discussion

The evaluation of the morphological changes induced by either mercuric salts or PHA is difficult for culturing alone without any transforming substances can yield a limited proliferation of lymphocytes ('background stimulation'). The morphological differences between transformed and non transformed cells were quantitative rather than qualitative. The vast increase of the polyribosomes was of interest, because it indicated enhanced RNA and protein synthesis confirmed by autoradiographic studies on mercury stimulated lympho-

---

polyribosomes but no increase in the number of other organelles. The cytoplasm of the cell above contains numerous different organelles. *M* mitochondrion, *MB* multivesicular bodies ( $\times 3,000$ ).

*Fig. 6.* Cell transformed by phytohemagglutinin. Aggregation of ribosomes is not as conspicuous as after stimulation by mercuric salts (arrows). Otherwise the morphological features strikingly resemble the ultrastructure of mercury transformed cells. *ER* some strands of rough surfaced endoplasmic reticulum, *N* nucleus, *M* mitochondria ( $\times 12,000$ ).

*Fig. 7.* Lymphocytes from a control culture without any stimulating agent, showing only a few evenly scattered ribosomes. These cells are smaller than stimulated cells. The cell below has ample cytoplasm and a prominent Golgi complex (*C*). *E* erythrocyte, *F* cytoplasmic fibrils, *N* nucleolus ( $\times 12,000$ ).

## Identity of Erythroblast Precursors in Bone Marrow<sup>1</sup>

C. ROSSE, D. A. GRIFFITHS, A. E. EDWARDS, C. G. C. GACHES,  
A. H. L. LONG, J. L. W. WRIGHT and J. M. YOFFEY

Department of Biological Structure, University of Washington, Seattle, Wash., and Department of Anatomy, University of Bristol, Bristol

There is no agreement as yet on the identity of the undifferentiated erythroid precursor cell<sup>2</sup>, although cells morphologically of the lymphocytic series have been attributed this function on the basis of indirect evidence [1-7]. In an attempt to gain further information about the identity of precursors to erythroblasts, the effects of erythropoietic stimulation were studied in bone marrow in which erythropoiesis had previously been depressed.

In the majority of reports the assessment of the response of erythropoietically depressed marrow to restimulation is usually confined to observations on the blood or, in the marrow, to changes in the erythroid population itself. These experiments as well as our earlier studies suggested that on restimulation of erythropoiesis an influx of cells took place into the erythroid compartment. The aim of the present investigation was primarily to identify these cells by correlating quantitative changes in non-erythroid cell populations with the erythroid response.

### *Materials and Methods*

Polycythemia and erythropoietically suppressed bone marrow was produced in guinea pigs using the procedure described previously [8]. Restimulation of erythropoiesis was effected by bleeding on the 9th day of rebound while unbled polycythemic guinea pigs served as controls. Changes in nucleated bone marrow cells were studied in the same series of stimulated and control guinea pigs as for which the blood and marrow reticulocyte data have already been presented [8].

<sup>1</sup> Supported in part by NIH grant No. AM/CA13145 to C. Rosse and in part by research funds from the Department of Anatomy, University of Bristol, England.

<sup>2</sup> The term 'erythroid precursor cell' is used to designate cells which are morphologically not identifiable as erythroblasts but have the potential to differentiate into erythroblasts.

The marrow was examined by a quantitative technique previously described [9] and critically assessed [10, 11]. Differential counts of marrow cells were made by identifying 1 000 nucleated cells in each animal on smears stained with MacNeal's tetrachrome stain. Morphological criteria for cell identification were as previously described and illustrated [12, 13]. In addition, for each bled animal the mitotic index of erythroblasts was determined by recording the incidence of mitosis among 1 000 erythroid cells which were classified into early (proerythroblasts plus basophilic erythroblasts) and late (polychromatic plus orthochromatic) erythroblasts.

The white cell count was determined on mixed venous and arterial blood obtained from the inferior vena cava and aorta at the time of exsanguination. Differential counts were also performed classifying 500 leukocytes in each animal. Red cell parameters and changes in the spleen have been reported separately [8]. The weight of the suprarenal glands was recorded in the stimulated animals.

The results are expressed as mean values  $\pm$  standard deviations. The data were compared using Student's *t* test and changes were regarded significant if  $p < 0.05$  and highly significant if  $p < 0.001$ .

### Results

The total marrow cellularity showed a continuous fall in the unstimulated animals during rebound ( $1.84 \pm 0.02 \times 10^6 \rightarrow 1.40 \pm 0.2 \times 10^6/\text{mm}^3$  marrow), whereas in bled animals the change in cellularity was not significant ( $1.84 \pm 0.02 \times 10^6 \rightarrow 1.67 \pm 0.40 \times 10^6/\text{mm}^3$ ). Marked quantitative changes occurred in both groups, however, within the erythroid and lymphocytic cellular compartments.

**Erythroid cells (fig. 1)** The markedly reduced number of erythro-

blast erythroid increase on day 1½ was not statistically significant but from the 3rd to the 5th days both early and late erythroblasts were elevated to a level highly significant above that in the controls. The number of proerythroblasts rose from  $11,000 \pm 6,000/\text{mm}^3$  on day 2½ to  $42,000 \pm 5,000/\text{mm}^3$  on day 3 after bleeding ( $t = 5.50$ ,  $p < 0.001$ ). The increase in late erythroblasts from the 1st to the 5th day was more than tenfold.

**The erythroid mitotic index (fig. 2)** In the normal guinea pig the mitotic index of early erythroblasts was found to be  $4.25 \pm 0.78\%$  and of the polychromatic erythroblasts  $2.75 \pm 0.93\%$  [14]. On the 9th day of rebound the mitotic index was greatly reduced in both the early ( $1.5 \pm 1.2\%$ ) and late ( $0.5 \pm 0.3\%$ ) erythroblasts. On the 3rd day a value of






Fig 1. Number of early (proerythroblasts + basophilic erythroblasts) and late (polychromatic + orthochromatic) erythroblasts in the bone marrow of polycythemic guinea pigs after bleeding and in the unstimulated control (rebound) Mean values  $\pm$  standard deviation.




Fig 2. Mitotic index of erythroblasts in the bone marrow of polycythemic guinea pigs following restimulation of erythropoiesis. Note increase in late erythroblast mitotic index is delayed in comparison to early erythroblast. Mean values.

$8.4 \pm 2.2\%$  was reached ( $t$  for 9th day rebound to 3rd day = 15.6,  $p < 0.001$ ) and a return toward normal values occurred on the 6th day. The first significant increase in late erythroblast mitotic index was recorded only on the 4th day ( $3.2 \pm 2.3\%$ ,  $t = 3.4$ ,  $p < 0.01$ ).

**Lymphoid cells** (fig. 3). On the 9th day of rebound the numbers of bone marrow small lymphocytes and transitional cells [12] were significantly above the normal. Small (pachychromatic) lymphocytes showed a highly significant decrease ( $t = 4.81$ ,  $p < 0.001$ ) in both the stimulated and unstimulated animals. In contrast transitional cells followed trends significantly different in the bled and unbled groups. Whereas in the unstimulated controls, transitional cells declined steadily during the 6-day period after bleeding, an abrupt decrease occurred approximately to the same level in the span of 24 h, and continued to day 2 $\frac{1}{2}$  ( $t = 3.00$ ,  $0.01 > p > 0.001$ ). The increase on




Fig. 3. Number of pachychromatic small lymphocytes and transitional cells in the bone marrow of polycythemic guinea pigs after bleeding and in the unstimulated control (rebound). Mean values  $\pm$  standard deviation.

the 3rd and 4th days elevated their numbers to a level significantly above the controls ( $t = 2.43$ ,  $p < 0.02$  and  $t = 2.76$ ,  $p < 0.02$  respectively).

*Other cells* Myeloid cells showed a significant increase from the 11th to the 13th day of rebound in unbled animals, while the only significant myeloid change in the stimulated group was a decrease in myeloblasts during the first 24 h after the hemorrhage ( $t = 2.17$ ,  $p < 0.05$ ). Myeloblasts returned to the normal level on the following day. Examination of smears and  $2\ \mu$  thick sections stained with Dominici's stain did not show detectable quantitative changes in monocytes, reticulum cells, macrophages or megakaryocytes. Damaged cells in smears remained around the values found in normal marrow [13].

*White cell count and weight changes in suprarenal glands* In bled animals, in spite of the hemodilution, there was a transient but significant neutrophilia on the first day while in the controls no change was noted. On this day in the bled group there was also a fourfold increase in circulating eosinophils ( $t = 2.24$ ,  $p < 0.02$ ). An elevated lymphocyte count was maintained in both groups throughout the experiment.

The suprarenal glands showed a significant increase in weight on the 1st day after bleeding ( $120 \pm 33\ \text{mg} \rightarrow 175 \pm 20\ \text{mg}$ ). The weight of these glands did not return to the initial level during the observation period.

### Discussion

*Stress effects of experimental procedure* Although the animals were in apparently good health, a significant increase in the weight of the suprarenal glands 24 h after the hemorrhage suggests that they may have been under considerable stress. The peripheral eosinophilia and persistent lymphocytosis do not support this contention nor can the fall of lymphocytes in the stimulated marrow be attributed entirely to stress, since a similar decrease occurred in unbled animals. In spite of the known depressant effect of corticosteroids on marrow lymphocytes [15], the weight increase in the suprarenal glands seems more likely to be due to activity directed toward stabilization of the disturbed fluid balance.

*The quantitative erythroid increase* The total erythroid output by the marrow may be determined from the knowledge of (a) the bone marrow [16] and blood volume [17], (b) the daily physiological loss in red cells [18], (c) the increase in the red cell count [8], (d) the number of marrow reticulocytes [8], and (e) the number of erythro-

blasts During the first 3 days following bleeding,  $7 \times 10^8$  cells were produced by the marrow, splenic red cell output at this time being negligible If these cells were all derived from the  $6 \times 10^7$  mitotable erythroblasts present in the marrow at the time of bleeding, 8 to 9 divisions would have been necessary in the maturation pathway Since no increase was detected in any erythroid parameter in blood or marrow or in mitotic index up to 36 h after the stimulus, these divisions would have had to take place during the following 36 h, giving an over all turnover time of 4 to 5 h Even if the shortest reported erythroblast turnover times are accepted [19] and even if no allowance is made for 'skipped division' shown to occur under conditions similar to the present study [20] the recorded increase in the erythron can only be accounted for by a substantial influx of precursor cells into the erythron within a relatively short period of time This erythroid response is different quantitatively and in its timing from the erythroid recovery obtained in experiments using marrow shielding or transfusion for investigation of hemopoietic stem cells [21, 22]

*Increase in the erythroid mitotic index* While it is generally accepted that erythropoietic stimulation initiates the differentiation of increased numbers of erythroid precursor cells, the effect on the proliferation of erythroblasts is controversial Reports of the failure of anemic serum or erythropoietin to alter the rate of proliferation [23, 24] or DNA synthesis [25] in erythroblasts conflict with those where such an increase was obtained [2, 26-31] To exclude errors due to a 'shift to the left', in the present study, the mitotic index of early and late erythroblasts was recorded separately

Although the stimulus produced a measurable effect on the marrow 24 h after bleeding [8], the proliferation of erythroblasts present in the marrow at that time was apparently not affected The trends shown in figure 2 seem to represent a stream of cells entering the erythroid compartment during the period of stimulation with a significantly increased rate of proliferation A reported increase in  $^3\text{H}$  thymidine incorporation by morphologically unidentified erythroid precursors soon after bleeding [32] supports this thesis It appears, therefore, that the erythropoietic stimulus had a dual effect on the precursor cell (a) it initiated its differentiation, and (b) it increased and determined its rate of proliferation

*The identity of the precursor cells* It is reasonable to assume that 3-4 divisions occurred during the initial 36 hours of the erythroid increase,

in which case it may be calculated that 160,000 to 80,000 cells/mm<sup>3</sup> of marrow were required to commence erythroid differentiation during the preceding period. Changes in cell numbers of this magnitude are readily detected by the quantitative method employed.

Although the transient fall in myeloblasts following the stimulus may be related to the demands placed on the erythroid precursor cell [3], in quantitative terms this demand could have only been met by transitional cells. The total decrease in their numbers amounted to 130,000 cells/mm<sup>3</sup> of marrow during the period preceding the first significant increase in early erythroblasts. Subsequent changes resembled the calculated response of a precursor cell to increased demands on the compartment [33]. In spite of the lack of direct evidence, the possibility of morphological transformation deduced from cytokinetic studies [5, 7], the quantitative and chronological relationship between transitional cells and erythroblasts, as well as the complete morphological spectrum linking the transitional cell to the proerythroblast, point to the transitional cell as the erythroid precursor or erythropoietin-sensitive cell. In normal marrow [34] and during rebound [35], transitional cells represent the major source of marrow small lymphocytes. The steady fall in their number over a period of 3 days during the late stages of rebound and following stimulation may be regarded (at present only speculatively) as a reflection of diminished lymphocyte production, since their average transit time through the marrow has been shown to be 3 days [34]. The relationship of lymphocyte precursors to erythroblast precursors, however, remains to be investigated.

*Acknowledgement* The valuable technical assistance of Mr. M. FISHER is acknowledged

### *Summary*

Suppressed erythropoiesis was restimulated in polycythemic guinea pigs by massive bleeding. Unless unusually short cell cycle times were postulated, a large influx of cells was required into the erythron to account for the increase occurring by the 3rd day. Changes in the erythroid mitotic index indicated that erythroblasts which started maturation from the precursor cell stage had an elevated mitotic index, but the proliferation of erythroblasts present in the marrow at the time of the stimulus was not affected. Small lymphocytes showed a significant decrease in both the bled and control animals. Transitional cells followed different trends in the bled and control groups. The timing and quantitative extent of changes in these cells indicated that the cells entering on erythroid differentiation under the effect of the stimulus were most probably derived from the transitional cell compartment since no other cell could meet the requirements imposed on the erythroid precursor cell in the experiment.

## References

- 1 HARRIS, P F and KUGLER, J H The use of regenerating bone marrow to protect guinea pigs against lethal irradiation. *Acta haemat., Basel* 52 146 (1964)
- 2 YOFFEY, J M, ROSSE, C., MOFFATT, D J and SUTHERLAND, I H Studies on hypoxia III The differential response of the bone marrow to primary and secondary hypoxia *Acta anat.* 62 476 (1965)
- 3 HARRIS, P F, HARRIS R. S and KUGLER, J H Studies of the leucocyte compartment in guinea pig bone marrow after acute haemorrhage and severe hypoxia Evidence for a common stem cell. *Brit. J. Haemat.* 12 419 (1966)
- 4 BENNETT, M. and CUDKOWICZ, G Functional and morphological characterization of stem cells. The unipotential role of 'lymphocytes' of mouse marrow, in YOFFEY The Lymphocyte in Immunology and Haemopoiesis p 183 (Edward Arnold, London 1967)
- 5 MOFFATT, D J, ROSSE, C. and YOFFEY, J M Identity of hemopoietic stem cell *Lancet* ii 547 (1967)
- 6 MORRISON J H and TOFFER, J R. Survival of lethally x irradiated rats after treatment with isogenic marrow lymphocytes. *Amer. J. Physiol.* 213 293 (1967)
- 7 ROSSE, C. and YOFFEY, J M The role of transitional lymphocytes as stem cells in marrow recovering from sublethal irradiation. *Exp. Hemat.* 14 2 (1967)
- 8 GRIFFITHS, D A., ROSSE, C., EDWARDS, A. E., GACHES, C. G C., LOVO, A. H. L., WRIGHT, J L. W. and YOFFEY J M Reticulocyte generation time and rate of discharge from the marrow *Acta haemat., Basel* 43 13 (1970)
- 9 YOFFEY, J M *Quantitative Cellular Haematology* (Thomas, Springfield 1960)
- 10 HARRIS, R. S., HERDAN, G. ANCELL, R. G. and YOFFEY, J M A quantitative comparison of the nucleated cells in the right and left humeral bone marrow of the guinea pig *Blood* 9 374 (1954)
- 11 HUDSON, G., OSMOND D G and ROYLAND, P J Cell populations in the bone marrow of the normal guinea-pig *Acta anat.* 52 234 (1963)
- 12 ROSSE, C. and YOFFEY J M. The morphology of the transitional lymphocyte in guinea-pig bone marrow *J. Anat., Lond.* 102 113 (1967)
- 13 ROSSE, C. The use of the supravital method in a study of cells susceptible to damage in smears of normal and regenerating bone marrow *Blood* 34 72 (1969)
- 14 MOFFATT, D J, ROSSE, C. and YOFFEY, J M. The uptake of tritiated thymidine by guinea-pig bone marrow cells. *J. Anat., Lond.* 102 582 (1967)
- 15 MORRISON J H and TOFFER, J R. Cellular changes in bone marrow following chronic treatment of rats with cortisol *Acta haemat., Basel* 38 250 (1967)
- 16 HUDSON, G. Bone marrow volume in guinea pigs. *J. Anat., Lond.* 92 150 (1958)
- 17 OSMOND, D G and EVERETT, N B. Bone marrow blood volume and total red cell mass of the guinea pig as determined by  $^{59}\text{Fe}$ -erythrocyte dilution and liquid nitrogen freezing *Quart. J. exp. Physiol.* 50 1 (1965)
- 18 EVERETT N B and YOFFEY J M. Life of guinea pig circulating erythrocyte and its relation to erythrocyte population of bone marrow *Proc. Soc. exp. Biol., N.Y.* 101 318 (1959)
- 19 MOVETTE, F C., LOBLIZ, J., GORDON, A. S. ALEXANDER, P., Jr and PO-CHUEN CHAN Erythropoiesis in the rat. Differential rates of DNA synthesis and cell proliferation. *Science* 162 1132 (1968)
- 20 ALPEN E. and CRANWORTH, D. Cellular kinetics and iron utilization in bone marrow as observed by  $^{59}\text{Fe}$  radioautography *Ann. N.Y. Acad. Sci.* 77 753 (1959)
- 21 CUFFEY, R. W. and EVERETT, N B. A radioautographic study of hemopoietic repopulation using irradiated parabiotic rats. *Blood* 28 873 (1966)

- 22 LOUITT, J F Grafts of haemopoietic tissue: the nature of haemopoietic stem cells *J clin Path* 20 535 (1967)
- 23 ERSLEV, A J The effect of anaemic anoxia on the cellular development of nucleated red cells *Blood* 14 386 (1969)
- 24 THOMAS, E. D., LOCITTE, H. L., Jr and STOHLMAN, F., Jr Attempts to develop an *in vitro* system for the assay of erythropoietin *J Lab. clin Med* 55 311 (1960)
- 25 ERSLEV, A J Erythropoietin *in vitro* II Effect on 'stem cells', *Blood* 24 331 (1964)
- 26 BERNARDELLI, L. The proliferation of erythroblasts at normal and low barometric pressure *in vitro* and *in vivo* *Acta haemat*, Basel 22 90 (1959)
- 27 MATOTII, Y. and BEN PORATH, E. Effect of erythropoietin on mitotic rate of erythroblasts in bone marrow cultures *J Lab clin Med* 54 722 (1959)
- 28 LEXMAN, J W and BETHELL, F H Factors in control of haemopoiesis, in WOLSTENHOLM and O CONNOR Ciba Foundation Symposium on Haemopoiesis, p 369 (Churchill, London 1960)
- 29 MOFFATT, D J, ROSSE, C., SUTHERLAND, I H and YOFFEY, J M Studies on hypoxia I The response of the bone marrow to primary hypoxia *Acta anat* 53 26 (1964)
- 30 LORD, B I Erythropoietic cell proliferation during recovery from acute haemorrhage *Brit J Haemat.* 13 160 (1967)
- 31 NECHLES, T F, SHREHAN, R G and MEYER, H J Studies on the control of hemoglobin synthesis Nucleic acid synthesis and normoblast proliferation in the presence of erythropoietin *Ann NY Acad Sci* 149 449 (1968)
- 32 HANNA, I R. A Response of early erythroid precursors to bleeding *Nature, Lond.* 211 355 (1967)
- 33 LAJTHA, L. G., OLIVER, R. and GURNEY, C. W Kinetic model of a bone-marrow stem-cell population *Brit J Haemat.* 8 442 (1962)
- 34 OSWOND, D G and EVERETT, N B Radioautographic studies of bone marrow lymphocytes *in vivo* and in diffusion chamber cultures. *Blood* 23 1 (1964)
- 35 OSWOND, D G Lymphocyte production in the bone marrow: radiographic studies in polycythemic guinea pigs, in YOFFEY The Lymphocyte in Immunology and Haemopoiesis p 120 (Edward Arnold, London 1967)

Authors' address: Dr C. Rosse, Department of Biological Structure, University of Washington, School of Medicine, Seattle, Wash 98105 (USA), Drs D A Griffiths, A E. Edwards, C. G. C. Gaches, A H L. Long, J L. W. Wright and J M Yoffey, Department of Anatomy, University of Bristol, School of Medicine, Bristol (England). Requests for reprints should be addressed to Dr C. Rosse.

## Sickle Cell Disease in Saudi Arabia

A. P. GELPI

Medical Department, Arabian American Oil Company, Dhahran

Previous publications [9, 12] on the distribution of the sickle cell trait in Saudi Arabia have disclosed a unique geographical and ethnic localization of this hemoglobinopathy among the Shiite population of the oasis settlements along the Persian Gulf. The gene frequency approaches 0.20 in some of the remote villages of the Qatif oasis, and the Shiite Saudis are believed to exhibit the highest frequency of the sickle cell trait of any population in the Middle East. It is therefore not surprising that sickle cell disease (SCD) has become a major health problem of increasing importance because of the virtual disappearance of so many infectious, parasitic, and nutritional disorders which previously affected this population. The economic development of the area, and advances in public health, have in greater part been derived from the operations of oil companies along the Western perimeter of the Persian Gulf. These companies maintain and operate hospitals and clinics which provide medical services to large segments of the indigenous population. They promote health education programs, and accommodate the health ministries of host countries with consultative support on matters of mutual interest in the field of public health. It is in this setting that the problem of SCD in Saudi Arabia has evolved. The reported study was carried out under the auspices of the Arabian American Oil Company (ARAMCO), and the patients encountered in clinics and hospitals provided by this company represent experience gained over a 10-year period among a group of adolescent and adult subjects with SCD.

Prior to 1958, not a single case of SCD had been diagnosed in ARAMCO medical facilities, nor for that matter among Saudi Arabs.



In the 10-year period, 1959-1968, the diagnosis had been verified in more than 150 Saudi children and adults. That the diagnosis was frequently overlooked in anemic subjects prior to 1958 is abundantly evident in reviewing earlier medical records. One factor which served to obscure the presence of SCD was holoendemic *falciparum* and *vivax* malaria in the oasis population [5]. The patient with anemia and splenomegaly was generally regarded as a case of malaria, even when parasites could not be demonstrated in blood films. Patients with jaundice and abdominal pain were often diagnosed as cases of viral hepatitis. An associated anemia usually failed to alert the clinician to consider the possibility of a hemolytic disorder. Finally, it was not generally appreciated that the sickle cell trait was known to occur at a significant frequency in certain Caucasian populations.

The purpose of this communication is to summarize the data which have been accumulated over a 10-year period on a group of adolescent and adult Saudi patients with SCD who have been under surveillance in ARAMCO medical facilities, to emphasize certain clinical features which distinguish this group from other reported series with more severe disease, and to consider certain genetic traits within the Saudi oasis population which may modify the expression of SCD.

### Methods

Hemoglobin concentrations were determined by spectroscopic measurement of cyanmethemoglobin preparations. Red cell counts were done in duplicate by a standard counting chamber technique. Hematocrits were measured in capillary tubes by a micro-method. Reticulocyte counts were performed on wet preparations using Brecker's methylene blue stain. The range of normal for each of the above tests among Saudis is comparable with those of Caucasian Americans residing in the same area. *In vitro* sickling was determined by the metabisulphite method of DALAND and CASTLE [6]. The alkali resistant hemoglobin was measured by the method of STYGER *et al* [20]. In normal Saudi adults the alkali resistant hemoglobin fraction was found to be less than 3.0%. Other hemoglobin components were estimated by two methods: 1) Electrophoresis on Whatmann No. 3 MM filter paper strips in a Durrum cell, with a 0.025 M barbital buffer at a pH of 8.6. Hemoglobin bands were stained with bromphenol blue-acetic acid solution. 2) Electrophoresis on Oxoid or Sepharose III cellulose acetate strips in a Gelman horizontal cell, with 0.1 M tris-EDTA borate buffer at a pH of 8.6. Hemoglobin bands were stained with Ponceau S-acetic acid mixture. Hemoglobin components were quantitated either by elution from paper strips and spectroscopic measurement, or by densitometry using the Spinco (model RA) analytrol. With the cellulose acetate membrane separation, it was possible to estimate the percentage of  $A_2$  hemoglobin. Only values above 4.5% were regarded as significantly elevated. Erythrocyte osmotic resistance was determined by visual estimate of the degree of hemolysis in step-wise dilutions of saline between 0.50-0.00%. For normal subjects the range was 0.43-0.31%.

Table 1 Age and sex distribution among 65 Saudi Arabs with sickle cell disease

| Age, Years | Male | Female |
|------------|------|--------|
| 11-20      | 17   | 3      |
| 21-30      | 15   | 12     |
| 31-40      | 15   | —      |
| 41-50      | 2    | —      |
| 50         | 1    | —      |
| Total      | 50   | 15     |

NaCl from beginning to complete hemolysis. In a number of instances, patients were studied with various tests of hepatic function, X-ray examinations of the chest, skeleton, abdomen and kidneys, and electrocardiography, depending upon clinical indications.

Attempts at family investigations were often fruitless with adult patients. Parents and/or siblings were generally not available locally, or resided at such a distance from the laboratory as to make contact difficult. Saudi employees, on occasion, fraudulently claimed dependents in order to procure medical services which were otherwise not available in the area. Polygamous marriages were fairly common, which further obscured family relationships. Finally adult Saudi males were generally reluctant to submit to venipuncture in the absence of significant illness, fearing impotence to be a direct consequence of unrequited blood loss.

The diagnosis of SCD was based on a positive sickling preparation and the demonstration of a slow moving band of hemoglobin comprising greater than 50% of the total hemoglobin components as estimated by elution or densitometry, and corresponding in position to a reference standard of hemoglobin S (Hyland Laboratories).

### Subjects

All patients were representatives of the oasis Shute population from the Eastern province of Saudi Arabia. Most of the adult males were active and gainfully employed. 30 of these subjects were ARAMCO employees. Twenty five subjects were dependents of ARAMCO employees, and 10 had no company affiliations but had been referred by local physicians or government agencies to the ARAMCO medical department. A total of 65 unrelated subjects have been included in this study, and the age and sex distribution is summarized in table 1.

### Clinical Features

Patients presented as cases of unexplained anemia, recurrent bone and/or joint pain, occasionally with abdominal or back pain, and at times with illnesses unrelated to SCD. None of the subjects exhibited the asthenic, eunuchoid habitus thought to be typical of homozygous sickle cell disease among adolescent and adult Negroes. None of the

In the 10-year period, 1959-1968, the diagnosis had been verified in more than 150 Saudi children and adults. That the diagnosis was frequently overlooked in anemic subjects prior to 1958 is abundantly evident in reviewing earlier medical records. One factor which served to obscure the presence of SCD was holoendemic *falciparum* and *vivax* malaria in the oasis population [5]. The patient with anemia and splenomegaly was generally regarded as a case of malaria, even when parasites could not be demonstrated in blood films. Patients with jaundice and abdominal pain were often diagnosed as cases of viral hepatitis. An associated anemia usually failed to alert the clinician to consider the possibility of a hemolytic disorder. Finally, it was not generally appreciated that the sickle cell trait was known to occur at a significant frequency in certain Caucasian populations.

The purpose of this communication is to summarize the data which have been accumulated over a 10-year period on a group of adolescent and adult Saudi patients with SCD who have been under surveillance in ARAMCO medical facilities, to emphasize certain clinical features which distinguish this group from other reported series with more severe disease, and to consider certain genetic traits within the Saudi oasis population which may modify the expression of SCD.

### Methods

Hemoglobin concentrations were determined by spectroscopic measurement of cyanmethemoglobin preparations. Red cell counts were done in duplicate by a standard counting chamber technique. Hematocrits were measured in capillary tubes by a micro-method. Reticulocyte counts were performed on wet preparations using Brecker's methylene blue stain. The range of normal for each of the above tests among Saudis is comparable with those of Caucasian Americans residing in the same area. *In vitro* sickling was determined by the metabisulphite method of DALAND and CASTLE [6]. The alkali resistant hemoglobin was measured by the method of SINGER *et al.* [20]. In normal Saudi adults the alkali resistant hemoglobin fraction was found to be less than 3.0%. Other hemoglobin components were estimated by two methods: 1) Electrophoresis on Whatmann No. 3 MM filter paper strips in a Durrum cell, with a 0.025 M barbital buffer at a pH of 8.6. Hemoglobin bands were stained with bromphenol blue-acetic acid solution. 2) Electrophoresis on Oxoid or Sephadex III cellulose acetate strips in a Gelman horizontal cell, with 0.1 M tris-HDTA borate buffer at a pH of 8.6. Hemoglobin bands were stained with Ponceau S-acetic acid mixture. Hemoglobin components were quantitated either by elution from paper strips and spectroscopic measurement, or by densitometry using the Spinco (model RA) analyzer. With the cellulose acetate membrane separation, it was possible to estimate the percentage of A<sub>2</sub> hemoglobin. Only values above 4.5% were regarded as significantly elevated. Erythrocyte osmotic resistance was determined by visual estimate of the degree of hemolysis in step-wise dilutions of saline between 0.50-0.00%, 1 or normal subjects the range was 0.43-0.31%.

Table 1 Age and sex distribution among 65 Saudi Arabs with sickle cell disease

| Age, Years | Male | Female |
|------------|------|--------|
| 11-20      | 17   | 3      |
| 21-30      | 15   | 12     |
| 31-40      | 15   | ~      |
| 41-50      | 2    | ~      |
| 50         | 1    | ~      |
| Total      | 50   | 15     |

NaCl from beginning to complete hemolysis. In a number of instances, patients were studied with various tests of hepatic function, X ray examinations of the chest, skeleton, abdomen and kidneys, and electrocardiography, depending upon clinical indications.

Attempts at family investigations were often fruitless with adult patients. Parents and or siblings were generally not available locally, or resided at such a distance from the laboratory as to make contact difficult. Saudi employees, on occasion, fraudulently claimed dependents, in order to procure medical services which were otherwise not available in the area. Polygamous marriages were fairly common, which further obscured family relationships. Finally adult Saudi males were generally reluctant to submit to venipuncture in the absence of significant illness, fearing impotence to be a direct consequence of unrequited blood loss.

The diagnosis of SCD was based on a positive sickling preparation and the demonstration of a slow moving band of hemoglobin comprising greater than 50% of the total hemoglobin components as estimated by elution or densitometry, and corresponding in position to a reference standard of hemoglobin S (Hyland Laboratories).

### Subjects

All patients were representatives of the oasis Shu'bi population from the Eastern province of Saudi Arabia. Most of the adult males were active and gainfully employed. 30 of these subjects were ARAMCO employees. Twenty-five subjects were dependents of ARAMCO employees, and 10 had no company affiliations but had been referred by local physicians or government agencies to the ARAMCO medical department. A total of 65 unrelated subjects have been included in this study, and the age and sex distribution is summarized in table 1.

### Clinical Features

Patients presented as cases of unexplained anemia, recurrent bone and or joint pain, occasionally with abdominal or back pain, and at times with illnesses unrelated to SCD. None of the subjects exhibited the asthenic, eunuchoid habitus thought to be typical of homozygous sickle cell disease among adolescent and adult Negroes. None of the

patients had ulcerations of the lower extremities. A past history of bone and joint pain was infrequently obtained, with characteristic involvement of the shoulders and hips. Bouts of abdominal pain were relatively uncommon, and hemolytic or regenerative crises were rare. By far the most consistent, major physical abnormality was the presence of splenomegaly, which was observed in 36 subjects. Hepatomegaly was noted in 20 subjects. Scleral icterus was not infrequent, but cutaneous icterus was seldom observed in the absence of intercurrent, acute liver disease.

Complications directly attributable to SCD were unusual. Two patients experienced thromboembolic episodes, one of whom expired presumably as the result of a massive pulmonary embolism. Intercurrent diseases possibly related to hemoglobinopathy and hemolytic disease included one instance of thrombocytopenia, a case of paroxysmal nocturnal hemoglobinuria reported in detail elsewhere [17], one patient with recurrent, gross hematuria, and 2 patients with cholelithiasis. There have been 3 deaths: one in a 32-year-old male with the nephrotic syndrome and terminal renal insufficiency, another in a 25-year-old female cited previously, who apparently succumbed to a pulmonary embolism, and a third death from unknown causes in a 32-year-old woman.

Abnormal chest X-rays were observed in 15 of 30 subjects having this examination performed. In 6, cardiac enlargement was observed and in 9, a variety of pulmonary lesions were seen which, with one exception could have been associated with underlying SCD. The most frequent abnormalities were nonspecific pulmonary infiltrates and accentuated bronchovascular markings. Skeletal X-rays were obtained in 36 subjects, most often in reference to episodes of bone and joint pain. The vertebrae were frequently shown to be biconcave, and together with the bony pelvis usually showed increased trabeculation and osteoporosis. The proximal long bones often showed cystic changes, with sclerotic zones in and adjacent to the humeral and femoral heads. Finally, the presence of widened cranial diploe in skull films was characteristic of the group.

Abdominal X-rays were obtained in 15 subjects, either as part of a skeletal survey, or in the course of gastrointestinal or pyelographic examination. Eight of these subjects demonstrated splenic opacities either in the form of nodularity or confluent calcific densities (fig. 1). The nature of these changes is not apparent, but presumably could

Table II Miscellaneous hematologic findings among Saudi Arabs with sickle cell disease

|                                | No | Range     | Mean | SD         |
|--------------------------------|----|-----------|------|------------|
| MCV, $\mu\text{m}^3$           | 37 | 61-107    | 87.0 | $\pm 12.9$ |
| MCH, pg                        | 38 | 14-35     | 28.0 | $\pm 4.5$  |
| MCHC, %                        | 52 | 24-36     | 31.0 | $\pm 3.1$  |
| Fetal hemoglobin, %            | 67 | 1.4-24.7  | 10.7 | $\pm 5.7$  |
| RBC osmotic resistance, % NaCl | 26 |           |      |            |
| Beginning hemolysis            |    | 0.46-0.28 | 0.39 | $\pm 0.03$ |
| Complete hemolysis             |    | 0.34-0.0  | 0.26 | $\pm 0.04$ |
| RBC morphology 65 subjects     |    |           |      |            |
| Anisocytosis                   | 13 |           |      |            |
| Poikilocytosis                 | 11 |           |      |            |
| Hypochromia                    | 27 |           |      |            |
| Target cells                   | 14 |           |      |            |
| Elliptocytosis                 | 2  |           |      |            |

represent calcification of splenic infarcts, gross hemosiderin deposits, or both.

There was considerable individual variation in hemoglobin concentrations, and a wide range of hemoglobin concentrations and red cell indices for the group. Abnormal red cell morphology was frequently observed in the blood smears. Red cell osmotic resistance was increased in 24 of 26 subjects tested. Hemoglobin electrophoretic

studies were done in 9 of 15 subjects. Seven of the 9 subjects with elevated A<sub>2</sub> hemoglobin had no detectable hemoglobin A on electrophoresis. A mild to moderate reticulocytosis and a slight elevation of serum bilirubin were consistent findings among all patients tested.

... new and unrelated families, were found to have sickle cell disease. Clinical and hematologic studies are incomplete, but hemoglobin electrophoresis suggests that many of these subjects are examples of sickle cell  $\beta$ -thalassemia.



Fig 1 Abdominal X ray of 39 year-old Saudi ARAMCO employee with sickle cell disease and hepatosplenomegaly. Hemoglobin electrophoresis: S 80.1%, F 14.9%, A<sub>2</sub> 5.0%.

disease 19 showed an S pattern with increased A<sub>2</sub> hemoglobin, 13 showed an S > A pattern, and the remainder showed an S pattern with normal levels of A<sub>2</sub>.

### Discussion

Sickle cell disease has been reported infrequently from the Middle East. In 1956, AKSOY reported a series of 15 cases from Southern

Turkey, among a group of Eti-Turks [1]. Ethnically, this is an Arab group, and likely to have descended from Syrian or Egyptian immigrants. In many ways AASOY's series resembled the group of Saudis discussed in this report. Splenomegaly was observed in 11 of 15 subjects, skeletal X-ray changes were minimal, target cells were conspicuous in the blood films of 10 subjects, and all patients demonstrated increased red cell osmotic resistance. In 1962, SHAIKH and ABU HAYDAR [19] cited isolated case reports from Egypt, and added 3 cases of their own, two from Lebanon and one from Syria. BAKIR and AL-QAYSI reported the first case of SCD from Iraq in 1964 [3].

Traditionally, homozygous SCD has been regarded as an extremely debilitating disease, often fatal in childhood [21]. The diagnosis of SCD with mild manifestations in an adult immediately raises the question of possible heterozygosity for the sickle cell trait and another hemoglobinopathy such as hemoglobin C, D, or E. Of perhaps greater significance within Caucasian populations of the Middle East, is the possibility that sickle cell thalassemia may be present in individuals

SCD apparently does occur, and has been described in 60 Jamaican adults in a recent publication [18].

Among Saudi Arabs, it appears likely that many of the reported cases represent double heterozygosity for the sickle cell trait and another hemoglobinopathy. The occurrence of the S>A hemoglobin electrophoretic pattern in Saudis indicates that the usual type of sickle cell  $\beta$ -thalassemia disease is found in this population. In addition, the presence of increased  $A_2$  hemoglobin in blood samples from many individuals with an S hemoglobin electrophoretic pattern suggests that sickle cell  $\beta$ -thalassemia, with virtually no production of hemoglobin A, may be the most frequent type of sickle cell disease encountered among adults.

Surprisingly, documented cases of thalassemia major are seldom encountered in the Saudi oasis population, from which the cases of

of  
mi



zygous SCD. This would account for an aggregation of cases of sickle cell-thalassemia among adolescents and adults. Unfortunately, a survey for the presence of the  $\beta$ -thalassemia traits has not been attempted in Saudi Arabia.

Recent recognition of hemoglobin H disease and the presence of the  $\alpha$ -thalassemia trait within the Saudi oasis population [16] indicates that double heterozygotes for the sickle cell trait and  $\alpha$ -thalassemia can be expected. Although it has been assumed that no interaction occurs between  $\alpha$ - and  $\beta$ -chain hemoglobinopathies, there is evidence that the presence of the  $\alpha$ -thalassemia trait suppresses hemoglobin S formation in the double heterozygote [22]. This has given rise to speculation that  $\alpha$ -chains combine preferentially with  $\beta^A$ -chains in the presence of  $\beta^S$ -chains. A possible extension of this hypothesis to include preferential combination of  $\alpha$  with  $\gamma$  over  $\alpha$  with  $\beta^S$ -chains in instances of homozygous sickle cell  $\alpha$ -thalassemia disease would lead to the inference that relatively high levels of fetal hemoglobin could be expected in such cases. The pattern of hemoglobin components might thus be indistinguishable from that found in certain instances of sickle cell  $\beta$ -thalassemia disease, with no detectable hemoglobin A, and with elevated hemoglobin F. AKSOY [2] described this phenomenon in a case report of a  $4\frac{1}{2}$ -year-old Turkish boy with clinical evidence of moderately severe SCD, striking abnormal morphology of the red cells, and a fetal hemoglobin of 27%. Studies of the parents revealed the presence of the sickle cell trait in the father, and sickle cell  $\alpha$ -thalassemia in the mother.

There remains the possibility that a few cases of SCD in Saudis represent sickle cell-D-or sickle cell-G-disease. However, discrepancies between the results of sickling preparations and the appearance of S hemoglobin on electrophoresis have not been observed in a large number of routine laboratory investigations on Saudis over the past ten years, nor in the survey for the sickle cell trait cited previously [13], so that a combination of S-D or S-G hemoglobins would appear extremely unlikely.

That the occurrence of sickle cell-hemoglobin C-disease among the group of Saudis discussed in this report is not fortuitous is suggested by the 4 cases from separate families encountered in a group of 65 subjects with SCD. There is no doubt that there has been a continuous infusion of African genes into the East Arabian populations for centuries as a result of the extensive slave-trading operations in the Persian

Gulf [10] Although LEHMANN [12] has suggested that the sickle cell trait originated in Arabia and spread to Africa the reverse is more likely to have been the case

High levels of alkali resistant hemoglobin which have been observed in some cases of SCD among Saudis could be the result of interaction between the sickle cell trait and hereditary persistence of fetal hemoglobin However, the S F heterozygote is characteristically free from the stigmata which accompany homozygous sickle cell disease and sickle cell thalassemia Moreover, the electrophoretic pattern shows absence of hemoglobin A and normal amounts of hemoglobin A<sub>2</sub> Presumably the gene for hereditary persistence of fetal hemoglobin originated in Africa [4] but a similar if not identical trait has been reported in several Greek families [7] Considering the proximity of the

Several isolated instances of unexplained elevation of fetal hemoglobin in otherwise normal adult Saudis have been observed, however, these have not been verified by appropriate follow up and repeated determinations of alkali resistant hemoglobin

LEWIS [14] and LEWIS *et al* [15] have offered the interesting hypothesis that the presence of erythrocyte glucose 6-phosphate dehydrogenase (G 6-PD) deficiency may in some way mitigate full expression of homozygous SCD and have shown that Ghanaian subjects with the sickle cell trait show a significantly higher frequency of G 6 PD deficiency than controls with only hemoglobin A and the frequency is yet higher among subjects with SCD A similar situation prevails in the Saudi orsis population where approximately 60% of male subjects with the sickle cell trait have been observed to have G-6-PD deficiency [9-10] Study of this association among Saudis has not been extended to include a large number of subjects with SCD but the possibility of interaction between hemoglobin S and G 6-PD deficiency might ideally be assessed in a population with a high frequency of both defects and in which the Caucasian G 6-PD mutant is present

One of the interesting biproducts of the reported study has been the demonstration of calcific densities of the spleen in a high proportion of cases in which abdominal X rays were available HENLEY *et al* [11] reported a series of 9 cases of SCD in which distinctive, punctate

densities were seen in the spleen on radiologic examination. In the Saudi cases the splenic densities tended to be conglomerates rather than miliary opacities, and all had palpable spleens on physical examination. It is possible that the disparate radiologic pictures represent two different phenomena, and that in the Saudi group with splenic opacities and splenomegaly, the process is that of massive hemosiderosis. Because of the well-known tendency of adolescents and adults with homozygous SCD to develop splenic atrophy, or actually undergo autosplenectomy, it appears likely that the 'opaque spleen syndrome' indicates a SCD variant rather than homozygous SCD.

The skeletal X-ray findings in Saudi subjects with SCD are not distinctive; they have been described in patients with homozygous disease and SCD variants, and represent varying degrees of bone marrow hyperplasia and the cumulative effects of multiple bone infarcts.

In conclusion, it appears that SCD is frequent among the oasis Saudi Arab population, that a considerable proportion of Saudis with this condition survive into adult life, and that SCD in this group is a heterogeneous assortment of at least 4 entities: homozygous SCD, two types of sickle cell  $\beta$ -thalassemia, and hemoglobin S-C disease.

### *Summary*

A review of clinical and hematologic findings in a group of 65 adult and adolescent Saudi Arabs with sickle cell disease has been presented, with additional data on hemoglobin electrophoretic patterns encountered in another group of 76 incompletely studied subjects with sickle cell disease. This study indicates that sickle cell  $\beta$  thalassemia accounts for a considerable proportion of all cases of sickle cell disease in the Saudi oasis population, and is usually characterized with hemoglobin electrophoresis by absence of hemoglobin A and elevated hemoglobin A<sub>2</sub>. Four cases of hemoglobin S-C disease were encountered in the study. The implications of hypothetical interaction between hemoglobin S- $\alpha$  thalassemia, hereditary persistence of fetal hemoglobin, and G-6-PD deficiency are discussed.

### *References*

- 1 AKSOY M. Sickle-cell anemia in South Turkey. A study of 15 cases in 12 white families. *Blood* 11: 460 (1956).
- 2 AKSOY M. The first observation of homozygous hemoglobin S $\alpha$  thalassemia disease and two types of sickle cell thalassemia disease. A) Sickle cell  $\alpha$  thalassemia disease, B) Sickle cell  $\beta$ -thalassemia disease. *Blood* 22: 757 (1963).

- 3 BAKIR, F and AL-QAYSI, M Sickle cell anaemia in Iraq First case report J Facult Med, Baghdad 6: 26 (1964).
- 4 CONLEY, C. L., WEATHERALL, D. J., RICHARDSON, S. N., SHEPARD, M. A. and CHARACH, S Hereditary persistence of fetal hemoglobin A study of 79 affected persons in 15 negro families in Baltimore Blood 21: 261 (1963)
- 5 DAGGY, R. H. Malaria in oases of eastern Saudi Arabia II Amer J trop Med Hyg 8: 223 (1959)
- 6 DALAND, G. A. and CASTLE, W. R. A simple and rapid method for demonstrating sickling of the red blood cell J Lab clin Med 37: 1082 (1948)
- 7 FIZIAS, P. and STAMATOYANNOPoulos, G Hereditary persistence of fetal hemoglobin in Greece A study and comparison Blood 24: 223 (1964)
- 8 GELPI, A. P. Glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia A survey Blood 25: 486 (1965)
- 9 GELPI, A. P. Glucose-6-phosphate dehydrogenase deficiency, the sickling trait, and malaria in Saudi Arab children J Pediat 71: 133 (1967)
- 10 GELPI, A. P. Glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia. Bull. World Health Org 37: 539 (1967)
- 11 HEMLEY, S. D., MELLINS, H. Z. and FINBY, N. Punctate calcifications of the spleen in sickle cell anemia Amer J Med 34: 483 (1963)
- 12 LEHMANN, H. Distribution of variations in human haemoglobin synthesis, in JONES and DELAFRESNAYE Abnormal hemoglobins, pp. 202-215 (Thomas, Springfield 1959).
- 13 LEHMANN, H., MARANJIAN, G. and MOURANT, A. E. Distribution of sickle-cell haemoglobin in Saudi Arabia Nature Lond 193: 492 (1963)
- 14 LEWIS, R. A. Correlation of S hemoglobin with glucose-6 phosphate dehydrogenase deficiency and its significance Blood 26: 176 (1965)
- 15 LEWIS, R. A. and LEWIS, R. A. Sickle cell disease and glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia Blood 26: 176 (1965)
- 16 LEWIS, R. A. and LEWIS, R. A. Sickle cell disease and glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia Blood 26: 176 (1965)
- 17 PERRINE, R. P. and GELPI, A. P. The sickle cell paroxysmal nocturnal hemoglobinuria syndrome Amer J Med 37: 659 (1964)
- 18 SERJEANT, G. R., RICHARDS, R., BARBOR, P. R. H. and MILNER, P. F. Relatively benign sickle-cell anaemia in 60 patients aged over 30 in the West Indies. Brit. med. J 1963
- 19 SHAHED, M. and ABU HAYDAR, N. Sickle cell disease in Syria and Lebanon Acta haemat., Basel 27 (1962)
- 20 SINGER, K., CHERNOFF, A. I. and SINGER, L. Studies on abnormal hemoglobin I Alkali denaturation. Blood 6: 413 (1951)
- 21 THOMAS, L. S. and THOMAS, L. S. Sickle cell disease and glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia Blood 26: 176 (1965)
- 22 WEATHERALL, D. J. The thalassemia syndromes, pp. 1-272 (Blackwell, London Oxford 1965)
- 23 WENT, L. N. and MACIVER, J. E. Sickle-cell anaemia vs. sickle-cell differentiation from sickle-cell thalassemia Lancet ii: 824 (1958).

## A Ghanaian Adult, Homozygous for Hereditary Persistence of Foetal Haemoglobin and Heterozygous for Elliptocytosis<sup>1</sup>

B RINGELIANN, F I D KONOTFY AHULU,  
H LEHMANN and P A LORAIN

Ghana Medical School Departments of Chemical Pathology and Medicine Accra and  
Medical Research Council Abnormal Haemoglobin Unit University of Cambridge  
Department of Biochemistry Cambridge

The gene which maintains foetal haemoglobin after the neonatal period by a failure to switch from  $\gamma$  chain to  $\beta$  chain production was first described by EDINGTON and LEHMANN in 1955 in Ghana [1], and the description fully reviewed by THOMPSON and LEHMANN in 1962 [2]. This abnormality has been discovered in Uganda by JACOB and RAPER [3], in Jamaica by WENT and MACIVER [4], in the United States by BRADLEY and CONLEY [5], OLIVIA and MYERSON [6], RUCKENAGEL and NEEL [7], KRAUS *et al* [8], in Greece by FESSAS *et al* [9] and in Italy by MANGANELLI *et al* [10]. All the published cases except two records, were heterozygotes. One of the homozygotes first described by WHEELER and KREVENZ [11] and reviewed by CONLEY *et al* [12] in 1963 was an American Negro child. The other report came from Italy, published by POLOSA *et al* [13] on two Caucasian siblings, who were 4 years and 3 years respectively at the time of publication, in 1961.

Homozygosity is very uncommon among the rare haemoglobin carriers because the probability of pairing is low, it is important, therefore, to exclude every possible factor which might disguise hidden heterozygosity, notably thalassaemia and the high F gene. In this paper we present a family where the father is the first described adult homozygous carrier for hereditary persistence of foetal haemoglobin

<sup>1</sup> Supported by a research grant of the World Health Organization and the International Atomic Energy Agency



Table 1

| Name           | Code No | Age years | Position in the family | PCV % | Hb g % | Retic % | WBC/ml | Red cell morphology   |
|----------------|---------|-----------|------------------------|-------|--------|---------|--------|---|
| Boye, B<br>Snr | I 1     | 46        | father<br>(propositus) | 43    | 15.4   | 5.3     | 5 900  | Elliptocytosis,<br>aniso-poikilo-<br>cytosis aniso-<br>chromia, target<br>cells |
| Odatsuro       | I 2     | 42        | mother                 | 42    |        | 0.2     |        | Normocytosis<br>normochromia  |
| Ago, B         | II 1    | 21        | son                    | 15    | 15.0   | 3.2     | 7 800  | Normocytosis<br>normochromia  |
| Boye, B<br>Jr  | II 2    | 14        | son                    | 36    | 12.0   | 2.0     | 6 700  | Normocytosis<br>normochromia  |
| Ashong, B      | II 3    | 10        | son                    | 36    | 11.6   | 3.2     | 6 100  | Elliptocytosis<br>normochromia  |
| Afote, B       | II 4    | 9         | son <sup>1</sup>       | 36    | 12.0   | 0.4     | 5 800  | Normocytosis<br>normochromia  |
| Asiedu, B      | II 5    | 8         | son                    | 35    | 11.6   | 0.8     | 5 900  | Elliptocytosis<br>normochromia  |

<sup>1</sup> Different mother

#### Laboratory Studies

The patient (I 1) had no anaemia, the reticulocyte count was slightly increased more than 80% of his cells were elliptocytes. Many of these cells showed a regular elliptical form, but some of them were elongated with disproportionate longitudinal axis. There was anisocytosis, some elliptical cells had a bend on one end. Small cells and cells with triangular shape could also be seen. Anisochromasia and occasional target cells could also be observed (fig. 1). Serum iron and TIBC were within normal limits. Red cell survival time (T<sub>12</sub>) was 17 days (our normal values 26-39 days). Osmotic fragility of the red cells was slightly decreased (fig. 2).

None of the children of the propositus was anemic, although II 3, 4 and 5 had slightly lower Hb concentration and 3 had a reticulocyte count above 1%. Two of the children had elliptocytosis but without anisopoikilocytosis or anisochromasia. The elliptocytes had a rather regular shape and target cells were absent. The osmotic fragility of the propositus' red cells was slightly decreased, all the other samples showed normal fragility.

The sickling test in all samples was negative. Using the KLEINHAUER and BETKE technique there was no elution of haemoglobin from the red cells of the propositus using acidic buffer (fig. 3). With the same technique some haemoglobin was eluted from the red cells of the children, the cells were 'half empty' but the distribution was uniform: all cells normocytes and elliptocytes contained a certain amount of haemoglobin. The foetal haemoglobin concentration in the blood of the propositus was 87% by the alkali denaturation technique.

Table 1 (continued)

| Hb A | Hb F<br>%       | Hb A <sub>1</sub><br>% | Sickling test | ALLENBACH<br>BETKE test | G-6PD  | Hb type      |
|------|-----------------|------------------------|---------------|-------------------------|--------|--------------|
| 0    | 87 <sup>a</sup> | 0                      | negative      | ++++                    | normal | FF high gene |
| ++++ | 18              | 26                     | negative      | negative                | defect | AA           |
| ++   | 26              | 27                     | negative      | ++                      | defect | AF high gene |
| ++   | 28              | 27                     | negative      | ++                      | defect | AF high gene |
| ++   | 27              | 27                     | negative      | ++                      | defect | AF high gene |
| ++   | 20              | 26                     | negative      | ++                      | defect | AF high gene |
| ++   | 25              | 26                     | negative      | ++                      | defect | AF high gene |

<sup>a</sup> At very high concentration the measurement of Hb F by alkali resistance gives erroneously low results. By other methods Hb F % was 100.

which gives erroneously low results at high concentration of Hb F. In the wife's blood Hb F was below 2% and in the children's between 20 and 28%. Hb A and A<sub>1</sub> were totally absent from the proband's blood as demonstrated particularly on agar electrophoresis for A, and paper electrophoresis for A<sub>1</sub>, however the blood of the children contained both. By electrophoresis on filter paper the blood of the proband showed only one thick band and this was situated between the start line and the usual position of Hb A, near to the latter (fig. 4). On starch gel there was also a single line slightly beyond the Hb A. Neither on starch nor on paper was Hb A visible. On agar pH 6.0 there was a single thick spot ahead of Hb A. The blood of the children had 2 bands, one thinner band on the same level where their father's single line was located, and another thicker band corresponding to their mother's Hb A (fig. 5). G-6PD content of the proband's blood was normal but all the five children had a defect as did the wife (mother of II 1, 2, 3 and 5). Fingerprint of the tryptic digest of the proband's haemolysate showed only the peptides of foetal haemoglobin (fig. 6).

### Discussion

The diagnosis of the homozygous state for hereditary persistence of foetal haemoglobin in our case is based a) on the high concentration






Fig. 1. Red blood cells of the propositus, Leishman staining. Elliptocytes, aniso-poikilocytosis, anisochromia and one target cell.




Fig. 2 Red cell fragility curve, propositus.

of Hb F, b) the absence of Hb A and A<sub>2</sub>, c) the even distribution of acid fast haemoglobin in the red cells, d) on family study: the propositus has only Hb F, his wife Hb A and all the children have both A and F, the latter in high concentration, e) on the result of fingerprinting of the haemoglobin of the propositus.




Fig 3 Blood film, propositus, KLEIHUAE-BETKE technique. The cells are filled with haemoglobin; no elution.




Fig 4 Paper electrophoresis, pH 8.9. The propositus' blood (left) shows one single thick band (Hb F) which is nearer to the starting point than his wife's (Hb A) (right). The former does not contain Hb A<sub>2</sub> which could be seen in the latter's blood as a faint band.

The propositus has also another inherited abnormality: elliptocytosis. The family study has revealed that the father has passed it on to two of his children (fig. 7). The father must therefore be a heterozygote. The genes for elliptocytosis and hereditary persistence of foetal haemoglobin are non-allelic and there does not seem to be




Fig. 5. (I 1, I 2) Normal red blood cells. (II 1-5) Elliptocytes of the children of the propositus.

any linkage between them. However, study of some other characters may further clarify this point. The propositus' elliptocytes were anisocytotic and showed anisochromasia with occasional target cells. The elliptocytes of the two children were rather regular and target cells were absent. This morphological alteration could be due to the high concentration of foetal haemoglobin and the different way of organization of Hb F in the cell [12].

Because of the combination of hereditary persistence of foetal




Fig. 6. Fingerprint of the haemoglobin of the propositus. There is only haemoglobin F present.




Fig. 7. Family tree showing homozygosity for high F and heterozygosity for E-erythrocytosis of the propositus.

haemoglobin and elliptocytosis it is difficult to compare our findings with those of the other 3 individuals described with homozygous high F (table II). The comparison seems to show that there are some common features. The carrier is not retarded in his mental or physical development, clinical signs of haemolysis are very slight or absent, moderate enlargement of the spleen may or may not be present. In the laboratory findings anaemia is rather uncommon, the osmotic

Table II

| Author, year of publication   | Age       | PCV % | Hb g% | Retic % | Hb F %          | Hb A <sub>2</sub> % | Osmotic fragility |
|---|-----------|-------|-------|---------|-----------------|---------------------|-------------------|
| WHITELLER and KRIVANS, 1961 [11]<br>revised by CONLEY <i>et al.</i> , 1963 [12] | 33 months | 41    | 13.3  | 0.6     | 87-92           | 0                   | decreased         |
| POLOSA <i>et al.</i> , 1964 [13]  | 1 years   | -     | 8.8   | 1.8     | 100             | 0                   | decreased         |
| POLOSA <i>et al.</i> , 1964 [13]  | 3 years   | -     | 11    | -       | 100             | 0                   | decreased         |
| Our case  | 45 years  | 43    | 15.4  | 5.3     | 87 <sup>1</sup> | 0                   | decreased         |

<sup>1</sup> See \* table I

fragility is slightly decreased and the red cell survival, determined only in our case, was slightly shortened. There is irregularity in the shape of the red cells with a moderate number of target cells the red cells contain acid fast haemoglobin, and Hb A and A<sub>2</sub> are absent from the blood. The fingerprinting in our case and in one of the others showed only Hb F and this was not different from the Hb F which is in the umbilical blood.

Our case demonstrates that man can reach the fifth decade in a good physical and mental condition with the haemoglobin of a foetus circulating in his body.

### Summary

Laboratory and family studies confirmed the diagnosis of homozygosity for hereditary persistence of foetal haemoglobin and heterozygosity for elliptocytosis in a 45-year-old Ghanaian male. This is the first adult where the homozygous state was found and showed that man can reach the middle age in excellent physical and mental condition with the haemoglobin of a foetus.

Table II (continued)

| Spleen<br>enlarge-<br>ment | Liver<br>enlarge-<br>ment | Red cell<br>morphology   | Signs of haemolysis |            | Red cell<br>survival | Finger<br>prunting     |
|----------------------------|---------------------------|--|---------------------|------------|----------------------|------------------------|
|                            |                           |  | clinical            | laboratory |                      |                        |
| 0                          | 0                         | Aniso-poikilo-<br>cytosis target<br>cells, cells<br>resembling<br>spherocytes  | 0                   | 0          | 0                    | normal<br>foetal<br>Hb |
| ++                         | 0                         | Anisocytosis,<br>hypochromia,<br>anulocytes<br>'pyriform cells'                | +                   | 0          | 0                    | -                      |
| 0                          | ++                        | Aniso-poikilo-<br>cytosis<br>anulocytes  | +                   | 0          | 0                    | -                      |
| ++                         | 0                         | Elliptocytosis,<br>aniso-poikilo-<br>cytosis,<br>anisochromia,<br>target cells | 0                   | +          | 17 days <sup>a</sup> | normal<br>foetal<br>Hb |

\* Our normal 26-39 days.

### References

- 1 LIDINGTON, G M and LEHMANN, H Expression of the sickle gene in Africa. Brit. med. J. 1960, 1, 1000
- 2
- 3
- 4 LEWIS, L A and MACIVER, J L An unusual type of hemophthalmos by sickle-cell thalassemia disease in a
- 5 BRADLEY, T B Jr and CONLEY, C persistence of fetal haemoglobin
- 6 CHEN, J and MYERSON, R M Hereditary persistence of fetal hemoglobin. Amer. J. med. Sci. 247: 215-217 (1961)
- 7 RICKNAGEL, D I and NEILL, J A in STEINBERG Progress in medical genetics, p. 128 Grune & Stratton, New York 1961
- 8 KRAUS, A P, KOCH, B and BURCKLEY, L Two families showing interaction of haemoglobin C or thalassemia with high foetal haemoglobin in adults. Brit. med. J. 1: 1434-1436 (1961)
- 9 FORD, P

- 10 MANCANELLI, G., DALFINO, G. e TANNIOIA, N. Su di un caso di associazione tra talassemia e persistenza ereditaria di emoglobina fetale. *Hematologica* 47: 353 (1962)
  - 11 WHEELER, J. T. and KREVANS, J. R. The homozygous state of persistent fetal hemoglobin and the interaction of persistent fetal hemoglobin with thalassemia. *Bull. Johns Hopk. Hosp.* 190: 217 (1961)
  - 12 CONLEY, C. L., WHEATHERALL, D. J., RICHARDSON, S. N., SHEPARD, M. K. and CHARACHE, S. Hereditary persistence of fetal hemoglobin. A study of 79 affected persons in 15 Negro families in Baltimore. *Blood* 21: 261-281 (1962)
  - 13 POLOSA, P., MOTTA, L., CALCAONO, G. e LUNETTA, M. Prima segnalazione di persistenza ereditaria di Hb a r (P E. Hb a r) allo stato omozigote in due fratelli di razza bianca. *Hemat. lat.* 7: 43-64 (1966)
  - 14 SINGER, K., CHERNOFF, A. J. and SINGER, L. Studies on abnormal hemoglobins. I. Alkali denaturation. *Blood* 5: 413-427 (1951)
  - 15 MARENGO-ROWE, A. J. Rapid electrophoresis and quantitation of haemoglobins on cellulose acetate. *J. clin. Path.* 18: 790-792 (1965)
  - 16 KLEINHAUER, F., BRAUN, G. und BETKE, K. Demonstration von fetalem Hämoglobin in den Erythrocyten eines Blutaustreiches. *Klin. Wschr.* 35: 637 (1957)
  - 17 BREWER, G. L., TARLOW, A. R. and ALVING, A. S. The hemoglobin reduction test for primaquine-type sensitivity of erythrocytes. *J. amer. med. Ass.* 180: 386-388 (1962)
  - 18 PARPART, A. K., LORENZ, P. B., PARPART, F. R., GREGG, J. R. and CHASE, A. M. *Thalassemia and Hemoglobinopathies*. New York: McGraw-Hill, 1964.
  - 19 I. A. H. *Thalassemia and Hemoglobinopathies*. New York: McGraw-Hill, 1964.
  - 20 D. H. *Thalassemia and Hemoglobinopathies*. New York: McGraw-Hill, 1964.
- D Hb a r ( $\beta$  87 threonine-lysine) producing no sickle cell haemoglobin D disease with haemoglobin S. *Nature, Lond.* 205: 1273-1276 (1965)

Authors' addresses: Prof B. RINGELHANN and Dr F. I. D. KONOTEN AHILLU, Ghana Medical School, P. O. Box 4236, Accra (Ghana); Prof HERMANN LEHMANN and P. A. LORRIN, Medical Research Council, Abnormal Haemoglobin Unit, University Department of Biochemistry, Tennis Court Road, Cambridge (England)

## Tumorartige intrathorakale extramedulläre Hämatopoese bei hämolytischer Anämie<sup>1</sup>

Bericht über einen Fall und Literaturübersicht

G. COHNEN, N. SCHOLZ, B. MESSER, E. KÖNIG, E. ZIMMERSCHITT UND  
G. BRITTINGER

Hämatologische Abteilung und Röntgen Abteilung der Medizinischen Klinik und Poliklinik (Geschäftsführender Direktor: Prof. Dr. O. H. ARNOOLD) und Pathologisches Institut (Direktor: Prof. Dr. W. MÜLLER) des Klinikums Essen der Ruhr Universität

Extramedulläre Hämatopoese wird vor allem bei ausgedehnten Knochenmarkveränderungen durch Osteomyelosklerose bzw. Myelofibrose, Marmorknochenkrankheit Albers-Schönberg, Leukämien, Karzinomen oder Lymphogranulomatose [26, 30], in einzelnen Fällen bei Osteodystrophia fibrosa generalisata Recklinghausen [31], Rachitis [15] und Ostitis deformans Paget [9] beobachtet. Ferner tritt sie bei Perniciosa, fetaler Erythroblastose sowie bei akuten Infektionen auf [26–30]. Sie findet im allgemeinen in Milz, Leber und Lymphknoten, gelegentlich in Dura mater, Thymus, Nebennieren, Prostata, Mamma, Parametrien oder organisierten Thromben statt [5, 30] und führt zu einer meist diffusen Infiltration dieser Organe. Das Auftreten tumorformiger extramedullärer Blutbildungsherde im Bereich der Nierenhilf [5, 14], im kleinen Becken [4, 9, 20] und im Thorax gilt dagegen als ungewöhnlich. Die intrathorakale Knochenmarksheterotopie scheint nach der vorliegenden Literatur vorwiegend bei angeborenen hämolytischen Anämien vorzukommen. Es wird im folgenden über eigene Beobachtungen bei einer Patientin mit Kugelzellenanämie berichtet.

### Kasuistik

Pat. G. H., geb. 5. I. 1910: Hausfrau, wurde im April 1966 zum erstenmal in unsere Klinik aufgenommen. Anamnestisch bestand 1972 vorübergehend ein Ikterus ohne sonstige

<sup>1</sup> Herrn Professor Dr. O. H. ARNOOLD zum 60. Geburtstag in Dankbarkeit gewidmet.





Abb. 1 Thoraxaufnahme (a p a b l i n l) Grosse weichteildichte Verschattungen beid paravertebral

Symptome Seit 1937 war eine Anämie bekannt, die nach den Angaben der Patientin als Perniciosa gedeutet und mit Leber- bzw. Vitamin B<sub>12</sub>-Präparaten behandelt wurde.

Zur Familienanamnese war zu erfahren, dass der Vater der Patientin zeitlebens an einer Blutarmut litt und durch eine Gelbfärbung von Gesicht und Skleren auffiel. Er sollte deswegen splenektomiert werden, lehnte die Operation jedoch ab. Er starb mit 71 Jahren an einer Lungenembolie. Bei dem Sohn der Patientin traten bereits in früher Kindheit eine ausgeprägte Anämie und ein Ikterus auf, die angeblich durch einen verstärkten Bluterfall bedingt waren. Die Milzexstirpation im Alter von 7 Jahren führte zu einer prompten Besserung. Seitdem war er völlig beschwerdefrei, ein Ikterus trat nicht mehr auf. Da er seit mehreren Jahren als Monteur im Ausland tätig ist, konnten Blutuntersuchungen nicht durchgeführt werden.

Es bestanden bei der Patientin eine asthmoide Emphysemitracheitis, ein Subarkterus und eine Cholelithiasis. Die Milz war 3 cm unterhalb des Rippenbogens tastbar und von derber Konsistenz. Die Thoraxaufnahme zeigte weichteildichte, homogene Verschattungen beiderseits paravertebral, rechts in Höhe von D 7 bis D 10, links in Höhe von D 9 bis D 11 (Abb. 1). Durch die Bronchoskopie und Mediastinoskopie konnte eine Artdiagnose dieser Tumoren nicht gestellt werden<sup>1</sup>. Auf eine Punktion oder eine Thorakotomie musste wegen der hochgradig eingeschränkten Lungenfunktion verzichtet werden.

Laborbefunde: Hämoglobin 11,3 g/100 ml, Erythrozyten 3,8 Mill./mm<sup>3</sup>, Hb<sub>2</sub> 29%, pc-Hämatokrit 33%, mittlere Hämoglobinkonzentration des Einzelerthrozyten 31,2%, mittlerer Erythrozytendurchmesser 6,4 µm, mittlere Erythrozytendicke 2,5 µm, mittleres Erythrozyteninzellvolumen 86,8 µm<sup>3</sup>, sphärischer Index 0,40. Im Blutausschnitt reichlich kleine, hämoglobunreiche Erythrozyten ohne zentrale Aufhellung (Sphärozyten), Anisozytose. Da der mittlere Erythrozytendurchmesser vermindert und die mittlere Erythro-

<sup>1</sup> Für die Durchführung dieser Untersuchungen danken wir Herrn Priv. Doz. Dr. W. MAASSEN, Chefarzt der Ruhrlandklinik der LVA Rheinprovinz, Essen-Heidhausen.



Abb. 9. Histologisches Bild des Tumorgewebes mit Megakaryozyten-erythropoetischen und granulopoetischen Vorstufen (Hämatoxylin-Eosin  $\times 17$ )

zytend (keine) waren, ergab sich ein erhöhter splärischer Index, der im Zusammenhang mit dem normalen Erythrozyteneinzellösungsvermögen für das Vorliegen von Kugelzellen sprach. Leukozyten  $9400/\text{mm}^3$ , Differentialblutbild: Promyelozyten 2%, Myelozyten 1%, Metamyelozyten 2%, Stäbkerne 22%, Segmentkernige 60%, Lymphozyten 3%, Monozyten 4%, Normoblasten 7%, Retikulozyten 2%, Thrombozyten  $160000/\text{mm}^3$ . Osmotische Resistenz der Erythrozyten 0,45–0,40%, NaCl-Biturbild: direkt Spur und rekt 2,0 mg/100 ml, LDH 96 mU/ml, SCOT 7,2 mU/ml, SGPT 2,7 nU/ml. Direkter und indirekter und Super Coombs-Test negativ. BKS 51/90 mm Hg. Sternalmark: Hyperplasie der Erythropoese mit Vermehrung der kernhaltigen reifen Vorstufen, leicht linksverschobene Cranulopoese.

Aufgrund der Familien- und Eigenanamnese sowie der bei der Patientin erhobenen Blutbefunde wurde die Diagnose einer wahrscheinlich angeborenen Kugelzellenanämie gestellt.

Nach Therapie mit Digoxin, Teracyclin und Expektorantien wurde die Patientin entlassen. Eine Splenektomie lehnte sie ab. Laborbefunde bei der Entlassung: Hämoglobin 11,6 g/100 ml, Erythrozyten  $39 \text{ M}^3/\text{mm}^3$ , Leukozyten  $10400/\text{mm}^3$ , Differentialblutbild: Stäbkerne 3%, Segmentkernige 81%, Basophile 1%, Lymphozyten 13%, Monozyten 2%, Retikulozyten 94%, Bilirubin: direkt negativ und rekt 2,7 mg/100 ml, LDH 167 mU/ml, BKS 70/90 mm Hg.

Im Januar 1969 erfolgte die erneute Einweisung wegen einer Exazerbation der seit Jahren bestehenden schweren hämolytischen Empfindlichkeit und einer Rechtsherz-

insuffizienz. Die Thoraxaufnahme liess eine geringe Grössenzunahme der Tumoren erkennen.

Laborbefunde: Hämoglobin 10,8 g/100 ml, Erythrozyten 3,3 Mill./mm<sup>3</sup>, Hbr 32,5 pg, Hamatokrit 32%; Leukozyten 13 000/mm<sup>3</sup>, Differentialblutbild: Promyelozyten 1%, Stabkernige 21%, Segmentkernige 69%, Basophile 1%, Eosinophile 2%, Lymphozyten 4%, Monozyten 2%, Normoblasten 4; Retikulozyten 130%/<sub>100</sub>. Bilirubin: direkt Spur, indirekt 1,4 mg/100 ml LDH 42 mU/ml BKS 92/125 mm n W.

Trotz Therapie mit Digoxin, Tetracyclin, Expektorantien und intermittierender O<sub>2</sub>-Zufuhr verstarb die Patientin nach vier Tagen unter den Zeichen des akuten Rechtsherzversagens. Als wesentlicher pathogenetischer Faktor der kardialen Insuffizienz dürfte die schwere Lungenfunktionsstörung (obstruktive Ventilationsstörung) bei ausgeprägtem Lungeneinphysem anzusehen sein. Eine Verschlimmerung des Leidens infolge einer zusätzlichen, durch die Tumoren bedingten restriktiven Ventilationsstörung war allerdings nicht sicher auszuschliessen. Eine Lungenembolie lag nicht vor. Die paravertebral, retropleural gelegenen Tumoren wiesen mikroskopisch eine multilobuläre Anordnung auf. Sie bestanden aus einer dunkelroten, weichen Gewebsmasse. Bei der histologischen Untersuchung fielen in dem zellreichen, polymorphen und gefässhaltigen Gewebe immer wieder Megakaryozyten auf (Abb. 2). Ausserdem fanden sich Erythrozyten, Normoblasten, segmentkernige Granulozyten und granulopoetische Vorstufen sowie Plasmazellen und vereinzelt Gewebsbasophile. In dem teilweise septenartig verdichteten Bindegewebe war reichlich eisenpositives Pigment abgelagert.

### *Diskussion*

Intrathorakale Tumoren als seltene Manifestation einer extramedullären Hämatopoese treten vorwiegend bei angeborenen hämolytischen Anämien auf, z. B. bei Kugelzellenanämie, Thalassämie und Sichelzellenanämie (Tab. I). Bei erworbenen hämolytischen Anämien sind sie dagegen bisher nicht beobachtet worden. Auch bei unserer Patientin bestanden tumorartige Veränderungen im hinteren unteren Mediastinum bei einer wahrscheinlich angeborenen hämolytischen Anämie (Kugelzellenanämie). Da histologisch in diesen Tumoren Megakaryozyten, sowie erythropoetische und granulopoetische Vorstufen nachgewiesen wurden, besteht kein Zweifel daran, dass es sich um extramedulläre Blutbildungsherde handelte. Die ausgeprägte Ablagerung von eisenpositivem Pigment kann als Folge rezidivierender Blutungen und/oder einer gesteigerten Hämolyse in diesem Gewebe interpretiert werden. Für eine extramedulläre Hämatopoese sprach auch die im peripheren Blut mehrfach beobachtete pathologische Linksverschiebung [26].

Inzwischen wurde eine zweite Patientin mit einem raumfüllenden tumorartigen Prozess im hinteren Mediastinum beobachtet, bei der ebenfalls eine hämolytische Anämie (Kugelzellenanämie) vorliegt. Obwohl röntgenologisch eine auffallende Ähnlichkeit mit dem bei der ersten Patientin nachgewiesenen Mediastinaltumor besteht, kann die Diagnose eines extramedullären Blutbildungsherdes nicht gestellt werden, da eine histologische Untersuchung bislang nicht möglich war.

Die blutbildenden intrathorakalen Tumoren liegen fast immer beiderseits paravertebral und kommen nur selten oberhalb des 5 Brustwirbelkörpers vor (Tab I). Sie sind rundlich und glatt begrenzt und besitzen eine multilobuläre Anordnung. Eine Verbindung zu den benachbarten Knochen besteht nicht. Im allgemeinen verursachen sie keine klinischen Symptome. Meist treten sie erst nach dem 50 Lebensjahr auf, doch sind sie vereinzelt auch bei jüngeren Patienten beobachtet worden. Ihre Abgrenzung gegenüber anderen raumfordernden Prozessen im hinteren Mediastinum oder in den paravertebralen Lungenabschnitten ist allein durch die Röntgen-Untersuchung nicht sicher möglich. Differentialdiagnostisch kommen vor allem neurogene Tumoren (Neurinome), Malignome (Bronchialkarzinome, Pleuraendotheliome, Metastasen), Lymphome, Mischgeschwülste (Teratome, enterogene und bronchogene Zysten) und Senkungsabszesse in Betracht [1, 16]. Bei unserer zweiten Patientin sprechen die szintigraphischen Untersuchungen gegen das Vorliegen eines Lungentumors oder einer intrathorakalen Nebenmilz. Ein blutbildender intrathorakaler Tumor sollte immer dann in Erwägung gezogen werden, wenn eine angeborene hämolytische Anämie besteht.

Die extramedulläre Hämatopoese wird von den meisten Autoren als Kompensationszeichen angesehen, wenn der Zellbedarf gesteigert oder die Knochenmarkfunktion eingeschränkt ist. Die Pathogenese der intrathorakalen tumorförmigen Blutbildungsherde ist bisher noch nicht geklärt [2, 3, 4, 5, 7, 13, 26, 30]. Sie werden einerseits auf eine metastatische Absiedlung von Knochenmarkzellen, andererseits auf eine Metaplasie von Resten der fetalen Blutbildung zurückgeführt. Ferner wird eine embryonale Keimversprengung diskutiert, die infolge der allgemeinen Aktivitätssteigerung des hämatopoetischen Systems zur Blutbildung angeregt wird. Für die in den Nierenhilf und im präaortalen Gewebe nachgewiesenen extramedullären Blutbildungsherde wurde ebenfalls eine autochthone Entstehung durch Metaplasie von potentiell hämatopoetisch aktiven Zellen angenommen. Im Gegensatz dazu findet unseres Wissens im hinteren Mediastinum auch während der fetalen Blutbildungsperiode keine Hämatopoese statt. Es müssten somit mesenchymale Zellen (Adventitiazellen, Histiozyten) als mögliche hämatopoetische Vorstufen angenommen werden. Dennoch bleibt bisher unverständlich, warum derartige Tumoren vorwiegend bei hämolytischen Anämien und nur selten bei anderen

insuffizienz. Die Thoraxaufnahme liess eine K-

Laborbefunde Hämoglobin 10,8 g/100 ml  
Hämatokrit 32%, Leukozyten 13.000 mm<sup>3</sup>  
Stabkernige 21%, Segmentkernige 69%, 1  
4%, Monozyten 2%, Normoblasten 4%.  
Indirekt 1,4 mg/100 ml LDH 42 mU/ml 1 k.

Trotz Therapie mit Digoxin, Tetracycl  
Zufuhr verstarb die Patientin nach vier T  
versagens. Als wesentlicher pathogenetisch  
schwere Lungenfunktionsstörung (obstruktiv  
genemphysem anzusehen sein. Eine Vers  
durch die Tumoren bedingten restriktive  
auszuschliessen. Eine Lungenembolie l  
genen Tumoren wiesen makroskopisch  
aus einer dunkelroten, weichen Geweb  
dem zellreichen, polymorphen und erf  
auf (Abb. 2). Ausserdem fanden sich E  
zyten und granulopoetische Vorstufen.  
In dem teilweise septenartig verdichte  
abgelagert.

Intrathorakale Tumore  
medullären Hämatopoese  
hischen Anämien auf, z  
Sichelzellenanämie (Tab.  
sind sie dagegen bisher  
Patientin bestanden tun  
Mediastinum bei einer  
Anämie (Kugelzellen  
Megakaryozyten, sowie  
fen nachgewiesen wur  
extramedulläre Blut  
gerung von eisenposit  
Blutungen und/oder  
interpretiert werden  
auch die im perip  
Linksverschiebung

Inzwischen wurde  
Prozess im hinteren  
(Kugelzellenanämie)  
dem bei der ersten  
eines extramedulläre  
suchung bislang nicht

*Tabella 1 (Fortsetzung)*

| Nr. | Aut.                                  | Alter<br>Jahre | Geschlecht<br>m/w | Diagnose                                 | Lokalisation der Tumoren                              |
|-----|---------------------------------------|----------------|-------------------|--|---|
| 14  | HAYFORD, R. B. <i>et al.</i> , 1960   | [12]           | m                 | Kugelfellenanämie                        | bds. paravertebral<br>D 5 D 12                        |
| 15  | HAYWARD, R. B. <i>et al.</i> , 1960   | [12]           | m                 | Verdacht auf Kugelfellenanämie,<br>Gicht | links paravertebral<br>D 8 D 12                       |
| 16  | KNOBLICH, R., 1960                    | [17]           | m                 | Thalassaemia minor                       | links paravertebral<br>D 6-D 11                       |
| 17  | LEWIS, H., 1960                       | [18]           | m                 | Kugelfellenanämie                        | bds. paravertebral<br>D 6-D 12                        |
| 18  | LEWIS, H., 1960                       | [18]           | m                 | Kugelfellenanämie                        | bds. paravertebral<br>unteres Mediastinum<br>D 10     |
| 19  | CONWAY, W. G. <i>et al.</i> , 1960    | [7]            | m                 | Verdacht auf Kugelfellenanämie           | bds. paravertebral                                    |
| 20  | MALAMON, B. <i>et al.</i> , 1962      | [21]           | m                 | Thalassaemia major                       | bds. paravertebral<br>D 2 D 10                        |
| 21  | LOWMAN, R. M. <i>et al.</i> , 1963    | [19]           | m                 | Kugelfellenanämie                        | hinteres Mediastinum                                  |
| 22  | LOWMAN, R. M. <i>et al.</i> , 1963    | [19]           | m                 | Kugelfellenanämie                        | hinteres Mediastinum                                  |
| 23  | PAPAVANILIOU, C. <i>et al.</i> , 1964 | [23]           | m                 | Thalassaemia major                       | bds. paravertebral                                    |
| 24  | PAPAVANILIOU, C. <i>et al.</i> , 1964 | [23]           | m                 | Thalassaemia major                       | rechts paravertebral<br>unteres Mediastinum           |
| 25  | PAPAVANILIOU, C. <i>et al.</i> , 1964 | [23]           | m                 | Thalassaemia major                       | rechts paravertebral                                  |
| 26  | SCHUBAUER, O. S. <i>et al.</i> , 1964 | [29]           | m                 | Thalassaemia intermedia                  | links paravertebral<br>D 9 D 10<br>extradural D 5 D 8 |
| 27  | SCHUBAUER, O. S. <i>et al.</i> , 1964 | [29]           | m                 | Thalassaemia intermedia                  | links paravertebral<br>D 8 D 9                        |
| 28  | STUBBS, R. G. <i>et al.</i> , 1964    | [28]           | m                 | Sichelzellenanämie                       | bds. paravertebral<br>D 8 D 10                        |
| 29  | CONYON, W. B. <i>et al.</i> , 1965    | [6]            | m                 | Kugelfellenanämie                        | bds. paravertebral<br>hinteres Mediastinum            |

mit extramedullärer Blutbildung einhergehenden Erkrankungen beobachtet werden. Vielleicht liegt den Tumoren eine echte Missbildung zugrunde. Gezielte histologische und zytologische Untersuchungen an menschlichen Feten können möglicherweise zu einer Klärung dieser Fragen beitragen

### *Zusammenfassung*

Es wird über eine Patientin mit Kugelzellenanämie berichtet, die tumorartige Veränderungen im hinteren unteren Mediastinum aufwies. In dem Tumorgewebe konnten histologisch Megakaryozyten sowie erythropoetische und granulopoetische Vorstufen nachgewiesen werden. Es handelte sich somit um extramedulläre Blutbildungsherde. In der Literatur sind bisher 29 ähnliche Fälle veröffentlicht worden. Die Pathogenese dieser intrathorakalen extramedullären Hämatopoese wird diskutiert.

### *Literatur*

- 1 ANACKER, H. Erkrankungen des Mediastinum, in HAUBRICH Klinische Röntgen diagnostik innerer Krankheiten vol 1 Thorax, pp 602-624 (Springer, Berlin/Gottin gen/Heidelberg 1963)
- 2 ASA UPMARK, F. Tumour-simulating intrathoracic heterotopia of bone marrow. *Acta radiol* 26: 425-440 (1945)
- 3 BAMATTER, F. Recherches anatomo-cliniques sur lictère hémolytique constitutionnel familial. *Sang* 6: 1-56 (1932)
- 4 BLAISDELL, J. L. Extramedullary hematopoiesis in a retroperitoneal tumor. *Arch Path* 16: 643-648 (1933)
- 5 BRANNAN, D. Extramedullary hematopoiesis in anemias. *Bull John Hopk Hosp* 41: 104-136 (1927)
- 6 CONDON, W. B., SAFARIK, L. R. and FLIZI, F. P. Extramedullary hematopoiesis simulating intrathoracic tumor. *Arch Surg* 90: 643-647 (1965)
- 7 COVENTRY, W. D. and LAMBREE, R. H. Heterotopia of bone marrow simulating mediastinal tumor. A manifestation of chronic hemolytic anemia in adults. *Ann intern Med* 53: 1042-1052 (1960)
- 8 DAWSON OF PENN. The Hume lectures on haemolytic icterus. *Brit med J* 921-928, 963-966 (1931)
- 9 DODGE, O. G. and EVANS, D. M. D. Haemopoiesis in a presacral fatty tumour (myelolipoma). *J Path Bact* 72: 313-317 (1956)
- 10 FOSTER, J. B. T. Primary thoracic myelolipoma. *Arch Path* 65: 293-297 (1958)
- 11 GLEAVE, H. H. Paravertebral heterotopia of bone marrow in a case of acholuric jaundice. *J Path Bact* 42: 530-539 (1936)
- 12 HANFORD, R. B., SCHNEIDER, G. F. and MACCARTHY, J. D. Massive thoracic extramedullary hemopoiesis. *New Engl J Med* 263: 120-123 (1960)
- 13 HARTFALL, S. J. and STEWART, M. J. Massive paravertebral heterotopia of bone marrow in a case of acholuric jaundice. *J Path Bact* 37: 455-459 (1933)
- 14 HOFFMÄTTER, R. und SCHNITZLER, H. Über einen ungewöhnlich grossen retroperitonealen Tumor von eigenartigem histologischem Aufbau. *Arch klin Chir* 140: 567-582 (1926)

- 15 JORDAN, H. E. Extramedullary blood production *Physiol Rev* 22 375-384 (1942)
- 16 KATZ, J. and DZANDIR, R. Localized mediastinal lymph node hyperplasia *Amer J Roentgenol* 81 208-212 (1960)
- 17 ANDRICH, R. Extramedullary hematopoiesis presenting as intrathoracic tumors. *Cancer* 13 462-468 (1960)
- 18 LITWAK, H. Myelolipoma of mediastinum *Radiology* 74 471-473 (1960)
- 19 LOWMAN, R. M., BLOOR, C. M. and NEHCORN, A. W. Roentgen manifestations of thoracic extramedullary hematopoiesis *Dis Chest* 44 154-162 (1963)
- 20 LYALL, A. Massive extramedullary bone-marrow formation in a case of pernicious anemia *J Path Bact* 41 469-472 (1935)
- 21 MALAMOS, B., PAPAVANILIOU, C. and ANTONIOU, A. Tumour-simulating intrathoracic extramedullary hemopoiesis *Acta radiol.* 57 227-231 (1962)
- 22 MARINOZZI, V. Aspetti insoliti dell'iperplasia midollare nelle anemie emolitiche *Haematologica* 43 737-759 (1958)
- 23 PAPAVANILIOU, C. and STIKAKIS, P. Tumour-simulating intrathoracic marrow heterotopia in thalassaemia major *Thorax* 19 121-124 (1964)
- 24 PARAP, A., DYCKHOFF, G. et CAROLL, J. Anémie hémolytique de l'adulte et «tumeurs médiastinales» Hétérotopies médullaires intra thoraciques. *Sem. Hôp., Paris* 33 4231-4240 (1957)
- 25 PLONSKIER, M. Über tumorförmige (extramedulläre, heterotope) subpleurale Knochenmarksherde *Virchows Arch path Anat* 27 804-809 (1930)
- 26 ROHR, K. Das menschliche Knochenmark 3 Aufl (Thieme, Stuttgart 1960)
- 27 SALKERBY, E. R. Heterotopia of the bone marrow without apparent cause *Amer J Path* 1 69-76 (1925)
- 28 SEIDLER, R. C. and BECKER, J. A. Intrathoracic extramedullary hematopoiesis *Radiology* 81 1057-1059 (1964)
- 29 SORWAIHL, O. S., TAYLOR, P. E. and NOYES, W. D. Extramedullary hematopoiesis, mediastinal masses and spinal cord compression *J amer med Ass.* 189 313-317 (1964).
- 30 WINTROBE, M. M. Clinical hematology, 6th ed (Lea & Febiger, Philadelphia 1967)
- 31 YOUNG, J. K. and COOPERMAN, M. B. Von Recklinghausen's disease or osteitis fibrosa. With report of a case presenting multiple cysts and giant-cell tumors *Ann. Surg* 75 171-180 (1922)



## Congenital Deficiency of Fibrinogen in Two Sisters

### A Clinical and Haematological Study

B DUBE, S P AGARWAL, M M GUPTA and S C CHAWLA

Departments of Pathology and Pediatrics College of Medical Sciences BHU, Varanasi

Congenital afibrinogenemia is a rare coagulation anomaly. Since its first description by RABF and SALOMON [31] in 1920, about 60 cases have been added to the literature. From this country, to our knowledge, three instances of this interesting disorder have been recorded [1, 20, 21].

Though death by excessive bleeding has been noted in the siblings of these patients in several reports [5, 17, 20, 22, 23, 32], proven afibrinogenemia in the siblings has been recorded very infrequently [11, 24]. The present communication describes the clinical and haematological features of this entity in two sisters.

### *Material and Methods*

Blood was collected by siliconized syringe in plastic tubes from an antecubital vein and mixed with 3.8% sodium citrate (1 part citrate to 9 parts blood). All the haematologic tests on coagulation unless otherwise stated were performed as described by LICHS and MAC FARLANE [3]. Thrombin employed for determination of thrombin time was prepared according to MELLANBY modified by QUICK [30]. Fibrinogen was estimated as described by QUICK [30]. The platelet count was done by direct counting using Thomas's pipette and improved Neubauer chamber. Sodium citrate was used as diluent.

The studies of platelet adhesion and aggregation were done in citrated platelet rich plasma with the use of phase contrast microscopy. Viscous metamorphosis was studied under the following conditions: in a plastic tube a mixture was made of equal parts of platelet rich plasma (PRP) and a 40 calcium chloride or thrombin (1/1 000 dilution MELLANBY). The tube was shaken for about 10 sec and a drop of mixture was transferred for a cover slip preparation which was studied intermittently for 4 h.

Macroscopic examination of platelet aggregation with adenosinediphosphate (ADP), epinephrine, nor epinephrine and thrombin was carried out at 37°C by adding 0.1 ml of these reagents to 0.2 ml of PRP.

Reaction of platelets to kaolin was studied by the method of HARDISTY *et al* [15].

## Case Reports

**Case 1** R., a Muslim girl, 7 years of age, developed a painful swelling of the gum during the eruption of her first permanent lower right molar tooth. Six days later she started bleeding profusely from this area which was uncontrollable. Next day she was admitted to Sir Sunder Lal Hospital, Banaras Hindu University.

On examination, severe bleeding was noticed from the gum. Bluish discoloration of skin, due to extravasation of blood underneath, was noticed on the right side of the neck, extending up to the clavicle. On interrogation it was revealed that she had displayed bleeding tendency since birth. She had notable umbilical bleeding for about 2 weeks, had easy bruising from mild injuries and her cuts bled for unduly long periods. There was no history of any spontaneous bleeding, nose bleeds or haemarthrosis.

After collection of blood for investigations, one bottle of fresh blood was transfused which effectively controlled the bleeding from the gums within 4 h.

**Case 2** A., one of the elder sisters of R., aged 20 years and married, had similar complaints. She also had umbilical bleeding for about 12 days, had easy bruising and prolonged bleeding from cut injuries and at the time of fall of deciduous teeth. In addition, she has mild menorrhagia. One year back she had conceived but aborted at 3 months and had severe post-abortion uterine bleeding.

The pedigree is depicted in figure 1. The history of consanguinity is quite obvious. Fibrinogen levels less than 200 mg% were observed in both the parents who had one third




Fig. 1. Pedigree of afibrinogenemia.

Table I Coagulation studies

| Test                             | Case 1, 7 years  | Case 2, 20 years                                  |
|----------------------------------|--|---|
| Whole blood clotting time        | infinite<br>(more than 6 h)  | infinite<br>(more than 6 h)                       |
| Kaolin cephalin clotting time    | infinite<br>(more than 6 h)  | infinite<br>(more than 6 h)                       |
| Prothrombin time                 | infinite<br>(more than 6 h)  | infinite<br>(more than 6 h)                       |
| Thrombin time                    | infinite<br>(more than 6 h)  | infinite<br>(more than 6 h)                       |
| Bleeding time<br>(Duke)          | Prolonged oozing from<br>the site of venepuncture<br>Next day after blood transfusion<br>bleeding time was 6 min | Prolonged oozing from<br>the site of venepuncture |
| Platelets                        | 180,000/ $\mu$ l   | 230,000/ $\mu$ l                                  |
| Prothrombin consumption<br>Index | less than 10%<br>(normal)  | less than 10%<br>(normal)                         |
| Thromboplastin generation        | normal   | normal  |
| Thrombin generation              | normal   | normal  |

Table II Fibrinogen studies (cases 1 and 2)

|   |               |
|---|---------------|
| a) Plasma heated to 60°C                            | } No precipit |
| b) Plasma half saturated with NaCl                  |               |
| c) Plasma quarter saturated with Amm sulphate       |               |
| d) Plasma + thrombin No clot                        |               |
| e) Plasma electrophoresis No evidence of fibrinogen |               |

of children with afibrinogenaemia one third with fibrinogen levels less than 200 mg%, and the remaining third with normal fibrinogen values

*Coagulation studies* Tables I and II show the results of coagulation studies done on both the sisters. When to three parts of the patients' plasma, one part of either fresh plasma, old plasma, aluminium hydroxide adsorbed plasma, haemophilic plasma or fibrinogen (Fluka) was added, complete correction of kaolin cephalin clotting time and prothrombin time ensued. The addition of fresh serum had no correcting effect.

#### Studies on Platelets (Case 1)

*Platelet aggregation* Adhesiveness of platelets to glass was studied by direct observation of cover slip preparation under the phase contrast microscope. Though not completely absent, adhesion as well as spreading of platelets were distinctly poor and were followed by weak spontaneous aggregation. However, aggregation was well observed after the addition of either ADP, epinephrine, norepinephrine, thrombin or collagen.

Table III Platelet studies. Macroscopic aggregation of normal and afibrinogenæmic platelets (case 1)

| Product added  | Concentration          | Control<br>sec | Case 1<br>sec |
|----------------|------------------------|----------------|---------------|
| ADP            | $10^{-4}$ M            | 18.4           | 34.5          |
|                | $10^{-4}$ M            | 22.7           | 36.0          |
|                | $10^{-4}$ M            | 24.1           | 39.4          |
|                | $5 \times 10^{-5}$ M   | 26.0           | 37.6          |
| Epinephrine    | $5.4 \times 10^{-4}$ M | 19.0           | 40.7          |
|                | $5.4 \times 10^{-4}$ M | 19.0           | 47.3          |
|                | $2.7 \times 10^{-4}$ M | 19.4           | 51.0          |
|                | $1.3 \times 10^{-4}$ M | 20.0           | 85.4          |
| Norepinephrine | $5.9 \times 10^{-4}$ M | 19.0           | 28.4          |
|                | $5.9 \times 10^{-4}$ M | 19.3           | 28.4          |
|                | $2.9 \times 10^{-4}$ M | 20.0           | 31.4          |
|                | $1.4 \times 10^{-4}$ M | 21.7           | 82.5          |
| Thrombin       | undiluted              | coagulated     | 17.5          |
|                | 1/4                    | 15.4           | 60.0          |
|                | 1/16                   | 17.0           | 75.0          |
|                | 1/64                   | 17.6           | 120           |
|                | 1/256                  | 21.6           | 120           |
|                | 1/1024                 | 23.7           | 120           |
|                | 1/4096                 | 25.4           | 120           |
| Collagen       |                        | 19.0           | 17.2          |

Table II Platelet metamorphosis

|                                | Stages  | Control  | Case 1                 |
|--------------------------------|---|----------|------------------------|
| A Recalcified thrombinized PRP | 1 Early platelet alterations (ring or bubble forms, etc.) | present  | present                |
|                                | 2. Aggregates   | large    | small                  |
|                                | 3 Contraction of aggregates to assume amorphous form      | present  | present                |
|                                | 4 Dissolution   | present  | absent, disaggregation |
| B Collagen + PRP               |   | as above | as in control          |

Table I Reaction of afibrinogenaemic platelets (case I) to kaolin

| Low-spun plasma + high spun plasma |  | Kaolin time<br>sec |
|------------------------------------|--|--------------------|
| Patient                            | Patient  | not clottable      |
| Patient                            | Normal   | 37.5               |
| Patient                            | Patient + fibrinogen<br>(final conc. 300 mg <sup>100</sup> ) | 39.5               |
| Normal                             | Normal   | 31.0               |

Table II Reaction of normal platelets suspended in afibrinogenaemic plasma to kaolin

| Washed normal platelets suspended in | Kaolin time<br>sec |
|--------------------------------------|--------------------|
| Normal high spun plasma              | 33.5               |
| Patients high spun plasma            | 48.0               |

Table III shows that the time of microscopic aggregation of the platelets of our patients is longer than that of control at different concentrations of ADP, epinephrine, nor-epinephrine, thrombin and collagen.

*Platelet metamorphosis* Table IV shows that the platelets in the thrombinized or recalcified plasma did undergo early platelet alterations, i.e. formation of ring or bubble forms, but aggregates were smaller as compared to control observations. Contraction of the aggregates occurred and amorphous appearance was assumed. However, a striking feature was the absence of dissolution in the next stage, on the contrary, a disaggregation ensued. Platelet metamorphosis in the presence of collagen suspension occurred normally.

*Reaction of afibrinogenaemic platelets to kaolin* is shown in table V. Only a mild prolongation of kaolin time was observed when the patients' low spun plasma was mixed with normal high-spun plasma. However a more distinct abnormal behaviour of normal platelets to kaolin was noted when they were suspended in afibrinogenaemic plasma (table VI).

### Discussion

Congenital afibrinogenaemia presents several facets of unusual interest. One remarkable feature is the relative mildness of bleeding tendency in spite of total lack of fibrinogen. Most of the patients have less trouble with bleeding than a haemophilic. Both the sisters reported here bleed only after injuries, they never had epistaxis, haematuria or haemarthrosis. Even the mild menorrhagia seen in the elder sister is not common. The patients of PINNIGER and PRUNTY [28] and LAWSON [22] had fairly normal menstruation. However, the bleeding tendency is notable soon after birth. Both of our patients had umbilical bleeding, a feature which appears to be fairly common as

QUICK [30] has quoted 12 references on its occurrence. The bleeding appears to be more severe during infancy and afterwards the prognosis regarding haemorrhage is quite favourable.

An interesting feature is the occurrence of pregnancy in the elder sister which, unfortunately, terminated at 3 months. The post-abortal bleeding, though prolonged, was controlled without any blood transfusion or hospitalization. Presumably, this is the first recorded instance of conception in a patient with congenital afibrinogenaemia.

Another danger speculated in these patients is that of a compromise with defence mechanism against infection since fibrinogen is supposed to play a role in body defences. The patient of PRENTICE [29] died of fulminating military tuberculosis. CASTEX *et al* [8] were able to control a primary tuberculous infection by plasma transfusions. However, in both of our patients we failed to find any increased susceptibility to infection.

The hereditary nature of the disease was noted even in early studies. Consanguinity of the paternal grandparents was recorded in the first patient described by RABE and SALOMON [31]. Parents were first cousins in cases reported by MACFARLANE [23], HENDERSON [17], PINNIGER and PRUNTY [28] and FRICK and McCLARRIE [12] while in other reports grandparents were first cousins [2, 32].

The presence of consanguinity in our cases is also striking but its significance is reduced by the fact that the patients' paternal grandfather who is a direct descendent from the consanguineous marriage has a fibrinogen level of 276 mg%, and it is only in his wife that a level below 200 mg% is present. The mode of inheritance appears to be autosomal recessive. In heterozygous states only slight lowering of fibrinogen is observed but homozygous pattern may result in extreme deficiency.

The role of plasma fibrinogen in the normal platelet aggregation has been pointed out by several workers [4, 7, 9, 10, 14, 18, 25, 26]. INERMAN *et al* [18] demonstrated that the anomaly of aggregation is more evident spontaneously, in the presence of epinephrine, nor epinephrine, or a small amount of ADP than with the larger amounts of ADP in the presence of collagen or during coagulation.

In this investigation afibrinogenaemic platelets showed poor adhesion to glass and weak spontaneous aggregation in their own citrated plasma. After the addition of ADP, adrenaline, noradrenaline and thrombin aggregation ensued but after a delayed interval.

INCEMAN *et al.* [18] reported agreeable findings regarding ADP and thrombin but they noticed no aggregation at all with epinephrine and norepinephrine in comparable concentrations.

Early morphologic metamorphosis of platelets occurred normally in our patient. This finding supports the earlier view that intrinsic thrombin can act on platelets and induce the release of nucleotides [6] and 5-hydroxytryptamine [16], and may act on platelets through another protein than fibrinogen [13, 18, 27].

Normal platelets when suspended in afibrinogenæmic plasma showed delayed reaction to kaolin. INCEMAN *et al.* [18] also quoted a personal communication from HARDISTY to the similar effect and posed the question of whether it was related to platelet phagocytosis.

A new intriguing aspect of fibrinopenia has been brought out by the seemingly paradoxical occurrence of venous thrombosis followed by pulmonary embolism [19]. According to those authors, only platelets and no fibrin could be found in any clot. It is possible that in each patient, the platelets may have carried some absorbed fibrinogen which may have been initially helpful in the mechanical formation of platelet thrombi.

### Summary

Congenital deficiency of fibrinogen is described in two sisters aged 7 and 20 years respectively. Both had markedly prolonged umbilical bleeding and easy bruising afterwards. The elder sister has mild menorrhagia and had prolonged post-abortion uterine bleeding after 3 months of gestation. The haematological studies including the platelet behaviour are reported and discussed. The family study indicates the mode of inheritance to be probably autosomal recessive.

### References

1. BASU, A. K. Fibrinogen deficiency. *Bull. Calcutta Sch. trop. Med.* 11: 146 (1966)
2. BIDDAL, I. e. AMMANTINI, L. Contributo allo studio della afibrinogenemia. *Arch. ital. Pediat. Puer. c.* 11: 374 (1946)
3. BIGGS, R. and MACFARLANE, R. G. Treatment of haemophilia and other coagulation disorders (Blackwell, Oxford 1966)
4. BRINKHOUT, K. M., READ, M. S. and MASON, R. G. Plasma thrombocyte agglutinating activity and fibrinogen. *Lab. Invest.* 14: 335 (1965)
5. BLCEK, V. Ein Fall der angeborenen familiären Afibrinogenämie. *Ann. paediat.* 177: 111 (1951).
6. CAEN, J. Is fibrinogen the plasma co-factor in ADP-induced human platelet aggregation. *Nature, Lond.* 205: 1120 (1965)
7. CAEN, J. et INCEMAN, S. Considérations sur l'allongement du temps de saignement dans l'afibrinogénémie congénitale. *Nouv. Rev. franç. Hémat.* 3: 575 (1963)





---

## Libri

---

L. P. HOLLÄNDER und M. MATTHIJS: *Ergebnisse der Bluttransfusionsforschung*. Vol 10 Bibliotheca Haematologica, No 32 Bericht der Deutschen Gesellschaft für Bluttransfusion Graz, Mai 1968 Karger, Basel New York 1969 318 p., 92 fig., 72 tab Preis DM/£fr 79 -/US \$ 18 95/158s

Die Hauptthemen dieses Kongressberichtes umfassen aktuelle Gebiete der Hämatologie genetisch bedingte Serumgruppen, neuere Aspekte der Therapie und Prophylaxe des Morbus haemolyticus neonatorum, Automation und Dokumentation im Bluttransfusionsdienst, erworbene Störungen der Hämostase (Verbrauchskoagulopathien). Entsprechend der Themenwahl ist der Nutzerfolg unterschiedlich. In klar begrenzten Gebieten erhält der Nicht-Spezialist in wenigen Seiten eine ausgezeichnete Orientierung während bei komplexeren und wissenschaftlich noch stark kontroversen Fragen, wie den Verbrauchskoagulopathien, auf Grund von Einzeldarstellungen kein einheitliches Bild zustande kommen kann. Dem hämatologisch interessierten Arzt kann diese Zusammenstellung mehrerer hämatologisch interessanter Themen empfohlen werden. W. H. Hertzog, Zürich

G. DUBAIL: *Histopathologie du ganglion lymphatique Mazon*, Paris 1969, 183 p., 100 fig. 68 F

Das Buch verfolgt vorwiegend praktische Zwecke: jede besprochene Krankheit, bei welcher Lymphknotenveränderungen auftreten können, wird zunächst vom klinischen Standpunkt kurz geschildert, es folgt jeweils eine Anzahl Mikrophotographien mit einer ausführlichen histologischen Beschreibung der Befunde, einem Kommentar zur Differentialdiagnose und einer Erläuterung der möglichen Fehldiagnosen. Die eingehende klinische und histopathologische Besprechung von 12 ausgesuchten Beobachtungen, mit den entsprechenden Diskussionen zur Differentialdiagnose, bildet eine sehr interessante und vor allem instruktive Vervollständigung des Werkes. Als Schlusskapitel wird eine Zusammenstellung der speziellen technischen Angaben gebracht, die bei Fixierung, Einbettung und Färbung von Lymphknoten Biopsien berücksichtigt werden sollten.

Im grossen und ganzen ist die vorliegende Zusammenstellung sehr nützlich, sie wird sowohl dem Kliniker wie dem Histopathologen willkommene Hinweise vermitteln, auch wenn leider die Bilder in Schwarzweiss-Reproduktion nicht immer sehr gelungen sind, wie es eigentlich in einem Atlas sein sollte (vor allem nicht die Übersichtsaufnahmen!). Die Literatur berücksichtigt eingehend das französische und anglo-amerikanische Schrifttum, nicht aber die Literatur deutscher Sprache. F. C. ROULET, Basel

## A Study of the Effects of Possible Toxic Metabolites of Uraemia on Red Cell Metabolism

E. N. WARDLE

Department of Medicine Wellcome Research Laboratories, Royal Victoria Infirmary,  
Newcastle upon Tyne

Poor haemopoiesis as a result of low production of erythropoietin is one factor in the anaemia of uraemia [5] but there is in some patients a short red cell survival [19]. Normal red cells also have impaired survival when transfused into uraemic subjects [30] and this suggests that serum factors contribute to the anaemia. Moreover erythrocytes from normal subjects show increased autohaemolysis and potassium loss when incubated in serum from uraemic patients [14].

In this report a study has been made of their effects on erythrocytes of those metabolites that may contribute to the toxemia of uraemia. Such metabolites include phenols [10, 20, 29, 32] and phenolic acids [16, 21] derived from bacterial degradation in the gut or by endogenous metabolism of phenylalanine, tyrosine and tryptophan, aliphatic amines [33], oxalic acid [11], and guanidines including the recently discovered metabolite guanidino-succinic acid [7].

Such metabolites may induce premature red cell ageing. The present study reports the effects of suspected toxic substances on red cell shape, on osmotic fragility and autohaemolysis, on the formation of methaemoglobin and on the uptake of radio-active phosphorus and potassium. Measurements have also been made of their action on the enzymes pyruvate kinase and glutathione reductase, these being two key points in the metabolism of the cell, and on the reduced glutathione content of cells during incubation in buffered media and of red cells taken from uraemic patients before and after *in vivo* dialysis.

### Methods

The substances given in table I were selected for study and made up in 0.9% saline. Table I gives the final concentration used in the incubation studies, they are well above the values obtained in uraemia.

Incubation was carried out in GEY's solution [13] which was buffered with an equal volume of 0.01 M phosphate buffer to the appropriate pH (pH 6.8, 7.4, 7.8). Red cells were drawn from a normal donor into heparin, centrifuged and the buffy layer removed, then washed twice in 0.9% NaCl before use. 1 000 units of sodium heparin (Weddell Pharmaceuticals, London) which contains 0.15% chlorocresol was used for 50 ml of venous blood. The packed cell volumes of these suspensions were measured at the commencement of the incubation time, by spinning at 2 000 g for 30 minutes. Two volumes of washed packed red cells were added to one volume of the buffered GEY's solution plus one volume of the reagent in 0.9% NaCl and incubation was carried out at 37°C for the stated time period with continuous shaking of the tubes.

*Reduced glutathione* (GSH) estimations were made, in triplicate, according to the method of BAUTLER *et al* [2] in which the yellow colour produced by DTNB (5,5-dithio-bis 2-nitrobenzoic acid) was measured at 412 nm. The glutathione content of the red cells is obtained from the whole blood GSH by correction for the packed cell volume.

*Pyruvate kinase* was estimated by the method of TANAKA *et al* [36]. The unit is that activity resulting in the conversion of one micromole NADH to NAD per minute by  $10^{12}$  erythrocytes. The change during the 4th to 14th minute is used for calculation purposes as this is linear.

For the estimation, haemolysates were prepared after two hours' incubation of red cell suspensions at 37°C in the various reagents in GEY's solution buffered at pH 7.4. The haemolysates were diluted in reagent to give a haemoglobin of 0.15 g%, for the estimation. This gives a value for red cell pyruvate kinase that has been exposed within the red cell for two hours at 37°C to the appropriate reagent and which is then suspended as a haemolysate in that reagent for the test.

*Glutathione reductase*. Red cells were incubated in the presence of the various reagents for two hours at 37°C in GEY's solution buffered at 7.4, and the red cell haemolysate was then prepared. Glutathione reductase was measured according to the method of WASSER *et al* [42] in which 0.2 ml haemolysate containing glutathione reductase, 1.5 ml of 0.01 M phosphate buffer (pH 7.4), 0.5 ml reagent in GEY's solution buffered at pH 7.4 and 0.1 ml of 0.002 M NADPH solution were incubated together at 37°C for 20 min. Oxidised glutathione (0.1 ml of 0.033 M) was added to the mixture and the change of optical density at 340 nm measured at 30 second intervals for 6 min. A blank was used for each reagent without NADPH. A unit is a change of optical density of 0.001 per ml of enzyme per minute and is equivalent to  $0.48 \times 10^3$   $\mu$ m of NADPH oxidised per ml of enzyme per minute. Control values were 50 units per minute per ml packed red cells.

*<sup>32</sup>P uptake*. Radioactive phosphorus (1  $\mu$ C <sup>32</sup>P as orthophosphate) was added to the incubation mixture in GEY's solution buffered at pH 7.4 and incubation was carried out at 37°C with frequent shaking, after which time the cells were washed three times with 0.9% NaCl. After the final wash the cells were lysed and made up to 10 ml with water for counting in a scintillation counter.

*Methaemoglobin* was estimated by the method of EVELYN and MALLOY [12]. The incubation period was 2 hours at 37°C.

*Autohaemolysis* was estimated by the method of DACE and LEWIS [9] after incubation for 48 hours at 37°C.

*Heinz body formation*. Cells were stained by adding one volume of blood to 4 volumes 0.5% methyl violet in saline. After 10 min one drop of mixture was smeared on a slide and examined immediately.

<sup>42</sup>K uptake was performed by the method of SOLOMON [34] by measuring the disappearance of <sup>42</sup>K from 0.1 ml supernatant samples, taken after 2 and 4 hours incubation of red cells in reagent in Gey's solution buffered at pH 7.4. From the initial and final serum and whole blood potassium concentration, measured by flame photometer the uptake of total potassium was also calculated. The results are expressed as the average potassium influx in mEq/l of cells per hour and as the total uptake of radio-potassium at 2 and 4 hours.

### Results

**GSH** The effects on the red cell GSH of incubation of normal cells for 2 hours and overnight at pH 6.8, for 2 hours and overnight at pH 7.4, and for 2 hours at pH 7.8, was ascertained. The results are given in table I and are expressed as standard deviations. It will be seen that the most significant deviations are given on incubation of normal cells for 2 hours at pH 7.4 and that guanidine, oxalate, mandelic acid, ammonia and phenol depress the GSH values, whereas these are raised by the amines dimethylamine and ethanolamine and by indoleacetic acid. The metabolites of tryptophan lower the GSH values as do creatine, creatinine and uric acid. Cysteine gave high values because its own free-SH groups give a yellow colour with DTNB. Experiments were also carried out in which red cells were incubated for 4 and 6-hour periods at pH values of 6.8, 7.0, 7.2, 7.4, 7.6 and 7.8, to determine the effect upon red cell GSH. Only at pH 6.8 was there any significant effect (lower than 3 SD) on the reduced glutathione.

To make some comparison with the situation in chronic uraemia, the glutathione instability of uraemic red cells incubated in their own plasma for 2 hours, with and without phenylhydrazine, was made. The results (as GSH in mg per 100 ml packed cells) of 12 uraemic values and 12 controls are shown in table II. It can be seen that there is no significant difference between the two groups but uraemic cells show a slight lowering of GSH with phenylhydrazine.

In addition, some GSH levels were measured on chronic uraemic patients before and immediately after *in vivo* dialysis (table III). There was a small overall reduction of GSH shown by a mean value of 0.8 mg GSH per g of haemoglobin (standard deviation  $\pm 2.1$ ). Wide fluctuations in the absolute glutathione content of the red cells and in the mean corpuscular haemoglobin concentration (MCHC) are evident with dialysis. Values in mg/100 ml red cells are given to enable comparison with other authors. The variations in MCHC as a result of

Table 1 Results of reduced glutathione estimations on red cell incubates

| Reagent                                 | Incubation reagent strength mg/100 ml | pH 6.8<br>2 h | Over-<br>night | pH 7.4<br>2 h | Over-<br>night | pH 7.8<br>2 h |
|---|---------------------------------------|---------------|----------------|---------------|----------------|---------------|
| Urea                                    | 250                                   | -             | -              | -             | -              | +1            |
| Creatine                                | 15                                    | -1            | -              | -2            | -              | +1            |
| Creatinine                              | 15                                    | -1            | -              | -1            | -              | +1            |
| Uric acid                               | 8                                     | -             | -              | -2            | -              | +1            |
| Guanidine                               | 50                                    | -             | -1             | -3            | -              | -             |
| Oxalate                                 | 50                                    | -1            | -1             | -3            | -1             | -             |
| Ammonia                                 | 4                                     | -             | -              | -1            | +1             | -             |
| Mandelic acid <sup>1</sup>              | 50                                    | -             | -2             | -3            | -1             | +1            |
| Phenol                                  | 25                                    | -1            | -1             | -3            | -              | +1            |
| Indole-3-acetic acid                    | 250                                   | -             | +1             | +1            | +1             | +1            |
| Dimethylamine                           | 1,600                                 | +1            | -              | +1            | -              | +3            |
| Ethanolamine                            | 500                                   | +1            | -              | +3            | -              | +1            |
| Cysteine                                | 5                                     | +5            | +5             | +5            | +5             | +3            |
| Glycine                                 | 5                                     | +1            | +3             | +3            | -              | -             |
| Hippuric acid                           | 5                                     | -             | -              | -             | -              | -             |
| Glycollic acid                          | 5                                     | +1            | +3             | +3            | -              | -             |
| Sodium benzoate                         | 1                                     | -             | +2             | -             | -              | -             |
| Magnesium sulphate                      | 25                                    | +1            | -              | +3            | -              | -             |
| Kynurenine                              | 0.200                                 | -             | -              | -1            | -              | -             |
| Anthranilic acid                        | 0.250                                 | +1            | -              | -1            | -              | -             |
| Cinnamic acid                           | 0.500                                 | -             | -              | -3            | -              | +1            |
| 3-Hydroxy-anthranilic acid              | 0.250                                 | -             | -              | -2            | -              | -             |
| Nicotinamide                            | 0.400                                 | -             | -              | -3            | -              | -             |
| Control values<br>(mg/100 ml red cells) |                                       | 55.0<br>±8.4  | 55.0<br>±6.7   | 66.0<br>±3.1  | 55.0<br>±8.0   | 60<br>±10.5   |

The reduced glutathione values at zero time were  $66.0 \pm 3.1$  mg/100 ml red cells. Values in table are expressed as standard deviations.

<sup>1</sup> Hydroxy phenyl-acetic acid

dialysis reflect changes in cellular hydration. When correction is made by expressing the glutathione content of the cells per g of haemoglobin there is no consistent change and for the series as a whole no significant change. A single dialysis of a chronic uraemic patient does not render that patient non-uraemic but there may be a threefold reduction of blood urea (and probably of other metabolites).

Table II

| Sample  | Before incubation | After incubation no additive | With phenylhydrazine |
|---------|-------------------|------------------------------|----------------------|
| Normal  | 65.6 $\pm$ 9.2    | 58.2 $\pm$ 6.5               | 50.9 $\pm$ 9.25      |
| Uraemic | 65.6 $\pm$ 10.4   | 55.9 $\pm$ 4.45              | 46.4 $\pm$ 9.03      |

Table III Changes in red cell GSH after dialysis of 15 uraemic patients

| mg/100 ml red cells |                | mg g Hb         |                  | MCBC            |                |
|---------------------|----------------|-----------------|------------------|-----------------|----------------|
| Before dialysis     | After dialysis | Before dialysis | After dialysis   | Before dialysis | After dialysis |
| 90.0                | 44.0           | 9.4             | 3.3 <sub>3</sub> | 36.0            | 33.0           |
| 104.0               | 123.0          | 13.7            | 16.2             | 36.0            | 40.0           |
| 191.0               | 74.0           | 15.2            | 8.4              | 35.0            | 32.6           |
| 50.5                | 57.0           | 5.0             | 6.9 <sub>3</sub> | 42.0            | 34.2           |
| 57.0                | 63.0           | 6.7             | 7.9              | 28.4            | 34.2           |
| 54.0                | 55.0           | 6.1             | 6.7              | 30.7            | 33.0           |
| 65.5                | 70.5           | 8.85            | 8.0              | 33.6            | 31.0           |
| 70.0                | 64.0           | 7.5             | 6.5              | 32.0            | 32.6           |
| 45.0                | 44.0           | 6.25            | 5.7              | 32.8            | 33.0           |
| 40.0                | 40.0           | 6.7             | 7.5              | 33.0            | 32.0           |
| 82.0                | 84.5           | 12.6            | 12.1             | 29.0            | 29.0           |
| 70.0                | 56.0           | 10.1            | 7.2              | 27.0            | 27.0           |
| 42.0                | 31.0           | 4.18            | 3.46             | 33.0            | 30.0           |
| 60.5                | 53.5           | 9.0             | 6.2              | 20.0            | 23.0           |
| 64.5                | 72.0           | 8.5             | 9.2              | 27.0            | 27.0           |

It is concluded that there is no significant reduction of GSH of the red cell in chronic uraemia, that dialysis of patients does not alter significantly the GSH of the red cells, that a pH sufficient to cause marked instability is unusual in life, but that since some of the agents that are retained in uraemia lower the glutathione to a certain extent and others raise the value, a state of balance may actually exist. Clearly this might vary from patient to patient. An accurate assessment will only be forthcoming when there are sensitive techniques for estimating blood levels of the possible toxic substances.

<sup>32</sup>P uptake. Triplicate uptake measurements of <sup>32</sup>P into normal red cells from Gey's solution buffered to pH 7.4 and to which the appro-

Table II. Uptake of  $^{32}\text{P}$  orthophosphate into red cells incubated with various substances

| Reagent                    | 2 h       | SD <sup>1</sup> | 4 h       | SD <sup>1</sup> |
|----------------------------|-----------|-----------------|-----------|-----------------|
| Control                    | 4,478     |                 | 6,563     |                 |
| Mean of 6 values           | $\pm 280$ |                 | $\pm 180$ |                 |
| Urea                       | 4,677     | -               | 7,053     | +2              |
| Creatine                   | 5,492     | +3              | 7,448     | +4              |
| Creatinine                 | 4,977     | +1              | 6,863     | +1              |
| Uric acid                  | 5,190     | +2              | 7,200     | +3              |
| Guanidine                  | 4,736     | -               | 6,573     | -               |
| Oxalate                    | 5,634     | +3              | 8,454     | > +4            |
| Ammonia                    | 4,730     | +2              | 7,628     | > +4            |
| Mandelic acid              | 5,193     | -1              | 7,643     | > +4            |
| Phenol                     | 3,994     | +2              | 6,293     | -1              |
| Indole-3-acetic acid       | 5,166     | +1              | 7,118     | +3              |
| Dimethylamine              | 4,871     | -1              | 7,299     | +4              |
| Ethanolamine               | 4,144     | +3              | 6,707     | -               |
| Cysteine                   | 5,563     | +2              | 6,453     | > +4            |
| Glycine                    | 5,281     | +3              | 7,952     | -1              |
| Hippuric acid              | 4,746     | -               | 6,381     | > +4            |
| Glycolic acid              | 4,426     | -               | 7,485     | +3              |
| Sodium benzoate            | 4,403     | +1              | 7,123     | +1              |
| Magnesium sulphate         | 4,063     | +3              | 6,702     | +3              |
| Kynurenine                 | 5,346     | -               | 7,124     | +2              |
| Anthranilic acid           | 4,662     | -               | 6,961     | +2              |
| Cinnamic acid              | 4,508     | -               | 6,952     | +2              |
| 3-Hydroxy-anthranilic acid | 4,623     | -               | 7,356     | +4              |
| Nicotinamide               | 4,726     | -               | 6,802     | +1              |
| Hydroxylamine              | 5,673     | +4              | 7,783     | > +4            |
| Thiocyanate                | 5,018     | +1              | 7,167     | +3              |

| Reagent       | mg%  | 2 h   | SD   | 4 h   | SD   |
|---------------|------|-------|------|-------|------|
| Oxalate       | 50.0 | 5,602 |      | 9,173 |      |
|               | 25.0 | 5,431 | > +4 | 9,683 | > +4 |
|               | 10.0 | 5,365 | +3   | 8,704 | > +4 |
|               | 2.5  | 4,875 | +3   | 7,332 | > +4 |
| Ammonia       | 4.0  | 4,932 | +1   | 8,224 | +4   |
|               | 2.0  | 4,948 | +1   | 8,183 | > +4 |
|               | 1.0  | 4,875 | +1   | 7,624 | > +4 |
|               | 0.5  | 4,802 | +1   | 7,381 | > +4 |
| Mandelic acid | 50.0 | 5,054 | +2   | 7,963 | +4   |
|               | 25.0 | 4,609 | -    | 6,873 | > +4 |
|               | 6.5  | 4,513 | -    | 6,894 | +1   |
|               | 2.5  | 4,571 | -    | 6,000 | +1   |

Table II (continued)

| Reagent | mg%  | 2 h   | SD | 4 h   | SD |
|---------|------|-------|----|-------|----|
| Phenol  | 25.0 | 4,643 | -  | 6,754 | +1 |
|         | 12.5 | 4,581 | -  | 6,537 | -  |
|         | 5.0  | 4,624 | -  | 6,504 | -  |
|         | 1.25 | 4,578 | -  | 6,089 | -2 |

Counts in 300 sec are recorded

<sup>1</sup> The standard deviation is taken from the mean of 6 control values.

appropriate reagent had been added, were made after 2 and 4 hours' incubation. The values as counts in 300 sec, are recorded in table IV where it may be seen that most of the reagents used, with the notable exception of phenol, caused an increased uptake of radioactivity compared with the control values.

Depression of uptake of radioactivity was observed with the following reagents: 1. 25% alcohol, 2. 25% glycerol, 3. 25% sucrose, 4. 25% glucose, 5. 25% fructose, 6. 25% mannitol, 7. 25% inulin, 8. 25% dextran, 9. 25% polyvinylpyrrolidone, 10. 25% polyvinylalcohol, 11. 25% polyvinylcarbazole, 12. 25% polyvinylpyrrolidone, 13. 25% polyvinylcarbazole, 14. 25% polyvinylpyrrolidone, 15. 25% polyvinylcarbazole, 16. 25% polyvinylpyrrolidone, 17. 25% polyvinylcarbazole, 18. 25% polyvinylpyrrolidone, 19. 25% polyvinylcarbazole, 20. 25% polyvinylpyrrolidone, 21. 25% polyvinylcarbazole, 22. 25% polyvinylpyrrolidone, 23. 25% polyvinylcarbazole, 24. 25% polyvinylpyrrolidone, 25. 25% polyvinylcarbazole, 26. 25% polyvinylpyrrolidone, 27. 25% polyvinylcarbazole, 28. 25% polyvinylpyrrolidone, 29. 25% polyvinylcarbazole, 30. 25% polyvinylpyrrolidone, 31. 25% polyvinylcarbazole, 32. 25% polyvinylpyrrolidone, 33. 25% polyvinylcarbazole, 34. 25% polyvinylpyrrolidone, 35. 25% polyvinylcarbazole, 36. 25% polyvinylpyrrolidone, 37. 25% polyvinylcarbazole, 38. 25% polyvinylpyrrolidone, 39. 25% polyvinylcarbazole, 40. 25% polyvinylpyrrolidone, 41. 25% polyvinylcarbazole, 42. 25% polyvinylpyrrolidone, 43. 25% polyvinylcarbazole, 44. 25% polyvinylpyrrolidone, 45. 25% polyvinylcarbazole, 46. 25% polyvinylpyrrolidone, 47. 25% polyvinylcarbazole, 48. 25% polyvinylpyrrolidone, 49. 25% polyvinylcarbazole, 50. 25% polyvinylpyrrolidone, 51. 25% polyvinylcarbazole, 52. 25% polyvinylpyrrolidone, 53. 25% polyvinylcarbazole, 54. 25% polyvinylpyrrolidone, 55. 25% polyvinylcarbazole, 56. 25% polyvinylpyrrolidone, 57. 25% polyvinylcarbazole, 58. 25% polyvinylpyrrolidone, 59. 25% polyvinylcarbazole, 60. 25% polyvinylpyrrolidone, 61. 25% polyvinylcarbazole, 62. 25% polyvinylpyrrolidone, 63. 25% polyvinylcarbazole, 64. 25% polyvinylpyrrolidone, 65. 25% polyvinylcarbazole, 66. 25% polyvinylpyrrolidone, 67. 25% polyvinylcarbazole, 68. 25% polyvinylpyrrolidone, 69. 25% polyvinylcarbazole, 70. 25% polyvinylpyrrolidone, 71. 25% polyvinylcarbazole, 72. 25% polyvinylpyrrolidone, 73. 25% polyvinylcarbazole, 74. 25% polyvinylpyrrolidone, 75. 25% polyvinylcarbazole, 76. 25% polyvinylpyrrolidone, 77. 25% polyvinylcarbazole, 78. 25% polyvinylpyrrolidone, 79. 25% polyvinylcarbazole, 80. 25% polyvinylpyrrolidone, 81. 25% polyvinylcarbazole, 82. 25% polyvinylpyrrolidone, 83. 25% polyvinylcarbazole, 84. 25% polyvinylpyrrolidone, 85. 25% polyvinylcarbazole, 86. 25% polyvinylpyrrolidone, 87. 25% polyvinylcarbazole, 88. 25% polyvinylpyrrolidone, 89. 25% polyvinylcarbazole, 90. 25% polyvinylpyrrolidone, 91. 25% polyvinylcarbazole, 92. 25% polyvinylpyrrolidone, 93. 25% polyvinylcarbazole, 94. 25% polyvinylpyrrolidone, 95. 25% polyvinylcarbazole, 96. 25% polyvinylpyrrolidone, 97. 25% polyvinylcarbazole, 98. 25% polyvinylpyrrolidone, 99. 25% polyvinylcarbazole, 100. 25% polyvinylpyrrolidone.

100 ml are sufficient to increase phosphorus uptake. Phenol, gives values for <sup>32</sup>P uptake similar to control values but low concentrations depress <sup>32</sup>P uptake. The results are given as standard deviations from the mean of 6 control values, that is  $\pm 280$  (counts in 300 sec) for the 2 hour values and  $\pm 180$  for the 4-hour uptakes. Similar measurements were made with red cells suspended in Gey's solution buffered at different pH values, and it was found that progressive reduction of pH below 7.4 was associated with progressive impairment of <sup>32</sup>P uptake.

In further experiments, measurements of <sup>32</sup>P uptake were made on red cells taken from uraemic and normal persons and suspended for up to 6 hours in Gey's solution at pH 7.4. The mean of 6 values (counts per 300 sec) for each group, with a correction for PCV are given in table V. The initial depression of uptake in the uraemic red cells is quite striking. The results suggest that by the sixth hour a toxic metabolic has been washed out of the uraemic cells or that a possible intracellular acidosis has been corrected. In view of the fact that no nitrogenous product depressed <sup>32</sup>P uptake but that an acid pH did, the depression of uptake by the uraemic cells may be due to a lowering



Table 1

| Sample  | Uptake of $^{32}\text{P}$ in counts |                  |                  |
|---------|-------------------------------------|------------------|------------------|
|         | 2 h                                 | 4 h              | 6 h              |
| Uraemic | $1\,972 \pm 453$                    | $3\,949 \pm 687$ | $5\,146 \pm 790$ |
| Normal  | $3\,223 \pm 180$                    | $4\,910 \pm 139$ | $5\,862 \pm 121$ |

of their intracellular pH. When the cells were first removed from chronic uraemic patients the intracellular pH may have been low but later restored to normal in the buffer at pH 7.4.

*Pyruvate kinase and glutathione reductase* (table VI). The results of estimation of pyruvate kinase show that all the reagents tested impair the enzyme activity. Guanidine is particularly potent, but even the usually recognised metabolites of uraemia (urea, creatinine and uric acid) have quite a marked effect on this enzyme. In the case of glutathione reductase, it is of interest that some metabolites such as glycine and hippuric acid, indole acetic acid and urea, impair the action whereas others, such as oxalate, ammonia and mandelic acid and phenol, enhance the activity.

*Methaemoglobin formation*. As seen in table VI some of the various reagents were able to produce methaemoglobin in amounts that are known to exist in uraemia.

*Autohaemolysis*. None of the reagents used produced decisively abnormal values.

*Osmotic fragility*. The red cells of the peripheral blood in uraemia show no change in osmotic fragility. Fragility studies were performed after 2 hours incubation of normal red cells in the appropriate reagents (mandelic acid, oxalate, phenol, guanidine urea, ammonia and indole acetic acid) and none of these substances showed any direct *in vitro* effect upon the fragility of the red cells.

However, a shift of pH below 7.2, begins to increase red cell fragility which probably parallels impaired red cell glycolysis (or phosphorus uptake). Detailed studies of the effect of pH on red cell fragility were reported by PARPART *et al* [28].

*Red cell shape*. Red cells were incubated in Gex's solution buffered at pH 7.4 and with the various reagents for up to 24 hours. In the case of cells in buffered Gex's solution it was found that abnormal shapes began to appear after about 15 hours incubation. Many of the reagents

Table 11 The effect of various substances on methaemoglobin formation. Pyruvate kinase and glutathione reductase activities

| Reagent                    | Methaemoglobin<br>% Hb | Pyruvate kinase<br>units $10^{10}$ RBC | Glutathione<br>reductase<br>units/min/ml<br>RBC |
|----------------------------|------------------------|--|---|
| Controls                   | 0.6                    | 3.3-4.0                                | 50  |
| Urea                       | 0.6                    | 1.9                                    | 37  |
| Creatine                   | 0                      | 2.11                                   | 35  |
| Creatinine                 | 0.6                    | 1.33                                   | 52  |
| Uric acid                  | 0.3                    | 1.22                                   | 46  |
| Guanidine                  | 1.2                    | 0.55                                   | 52  |
| Oxalate                    | 1.5                    | 1.43                                   | 90  |
| Ammonia                    | 0.6                    | 2.32                                   | 93  |
| Mandelic acid              | 1.8                    | 1.44                                   | 62  |
| Phenol                     | 2.4                    | 1.68                                   | 70  |
| Indole-3-acetic acid       | 1.5                    | 1.75                                   | 24  |
| D-methylamine              | 0.3                    | 2.26                                   | 56  |
| Ethanolamine               | 0.6                    | 3.0                                    | 40  |
| Cysteine                   | 0                      | -                                      | 135   |
| Glycine                    | 0                      | -                                      | 53  |
| Iso-pyruvic acid           | 0                      | -                                      | 6   |
| Glycolic acid              | 1.2                    | -                                      | 5   |
| Sodium benzoate            | 3.0                    | -                                      | 68  |
| Magnesium sulphate         | 3.0                    | -                                      | 68  |
| Kynurenine                 | 3.3                    | 1.47                                   | 56  |
| Anthranilic acid           | 0.9                    | 2.24                                   | 62  |
| Cinnamic acid              | 0                      | 1.06                                   | 43  |
| 3-Hydroxy-anthranilic acid | 3.6                    | 3.0                                    | 21  |
| Nicotinamide               | 0                      | 1.36                                   | 28  |
| Hydroxylamine              | 3.0                    | -                                      | 0   |
| Thiocyanate                | 1.2                    | -                                      | 72  |

used induced the formation of 'formes en anneau' (1) (urea, guanidine, phenol, ammonia, mandelamine, indole and oxalate) together with abnormally crenated and distorted cells after only two hours' incubation. Further, a shift of pff below 7.2 would effect a similar change in a very short time.

*Heinz body formation* No Heinz bodies were found in the blood of uraemic patients or in incubated red cells.

*<sup>42</sup>K uptake and potassium reflux studies* The results are given in table VII. The control values for the influx of potassium in mEq/l of cells

Table 1 II Uptake by red cells of  $^{42}\text{K}$  at 2 and 4 h incubation time

|                            | $^{42}\text{K}$ uptake   |       |         | Average K uptake from medium mEq/l cells per hour |
|----------------------------|--------------------------|-------|---------|---|
|                            | counts in 300 sec<br>2 h | 4 h   | 2-4th h |   |
| Controls                   | 2,000                    | 5,580 | 3,580   | 1.47  |
|                            | 2,200                    | 6,100 | 3,900   | 1.47  |
|                            | 2,350                    | 6,850 | 4,300   | 1.47  |
| Urea                       | 4,100                    | 7,750 | 3,650   | 1.50  |
| Creatine                   | 2,600                    | 6,650 | 4,050   | 2.18  |
| Creatinine                 | 3,300                    | 9,000 | 6,300   | 2.18  |
| Uric acid                  | 3,100                    | 6,650 | 3,550   | 1.91  |
| Guanidine                  | 2,000                    | 8,000 | 6,000   | 2.09  |
| Oxalate                    | 4,200                    | 6,930 | 2,780   | 1.40  |
| Ammonia                    | 3,250                    | 7,750 | 4,500   | 1.73  |
| Mandelic acid              | 1,350                    | 8,050 | 6,700   | 2.36  |
| Phenol                     | 2,550                    | 8,800 | 6,250   | 2.27  |
| Indole-3-acetic acid       | 1,550                    | 8,870 | 7,370   | 2.45  |
| Dimethylamine              | 1,170                    | 6,820 | 5,750   | 2.45  |
| Ethanolamine               | 1,750                    | 8,070 | 6,320   | 2.27  |
| Cysteine                   | 2,000                    | 8,350 | 6,350   | 2.18  |
| Anthranilic acid           | 2,000                    | 9,000 | 7,000   | 2.27  |
| 3-Hydroxy anthranilic acid | 2,000                    | 9,400 | 7,400   | 2.27  |

The uptake of  $^{42}\text{K}$  between the second and fourth hour correlates with the average potassium uptake per hour. Reagents are separable into two groups according to whether the uptake is greater than 5,000 counts (in 300 sec) between the second and fourth hour. Urea and oxalate are anomalous as the uptake was greatest in the first two hours and thereafter  $\text{K}$  influx declined.

per hour approximate to the values obtained by SOLOMOV [34]. It will be seen that all the reagents studied produce an increase of potassium influx and of radio potassium uptake especially between the second and fourth hour and that this value correlates with the total potassium uptake per hour. However, urea and oxalate are anomalous as the uptake was greatest in the first 2 hours and then fell off and the average potassium uptake (mEq/l cells/hour) was not then different from the control values. The reagents are in fact separable into two groups according to whether the uptake is greater than 5,000 counts between two and four hours. The substances which caused an uptake of over 8,000 counts in 4 hours and which also produced a potassium

influx greater than 2.0 mEq/l of cells per hour were phenol and mandelic acid, creatinine and guanidine, anthranilic and three hydroxy-anthranilic acids, indole acetic acid, ethanolamine and cysteine. There was no direct correlation with those substances that produced the greatest effect on  $^{32}\text{P}$  uptake.

### Discussion

The known facts concerning altered red cell metabolism in uraemia are conflicting probably because in some patients there is a higher percentage of young cells with higher enzyme values. Some authors have reported that glucose uptake by the cells is increased [23] or decreased [24, 25] there is increased methaemoglobinisation [3] and reduced glutathione can be increased [43] or normal [41] in chronic uraemia but low in acute anuria [37]. Also it is known that the enzyme hexokinase is very sensitive to acidosis [3] there is reduced activity of erythrocyte pyruvate kinase [3] and unimpaired activity of glucose-6-phosphate dehydrogenase but increased activity of glutathione reductase [6]. In addition there may be failure of the sodium pump [8, 24, 39] but a high ATP [22, 23] and increased efflux of potassium and uptake of  $^{32}\text{P}$  is low [22, 23].

Table VIII gives a synopsis of some of the data and it will be seen that phenol and the phenolic acid, mandelic acid, together with acidosis could effect most of these changes. Guanidine is also a very toxic metabolite and lowers the glutathione content of the cell and the pyruvate kinase activity and actually increases the potassium influx. Urea, creatinine and uric acid produce minor changes but clearly have no great toxicity. Oxalate and ammonia produce some changes akin to phenol and indole acetic acid. The amines and the tryptophan metabolites show variable toxic effects but no consistent pattern.

It is clear that a single toxic metabolite will not account for the demonstrable abnormalities but certain classes of metabolite can be defined. The overall action is complex, thus several of the reagents have an effect on red cell metabolism, thus several of the reagents on glutathione synthesis.

caused an increased uptake of  $^{32}\text{P}$ , an action opposite to that occurring in uraemia but nevertheless indicating a threat to the integrity of the

Table 1 III Synopsis of conclusions Normal red cells treated with various substances

| Uraemia                |               | Urea | Mandelic acid | Phenol | Indole/ amines | Acidosis | Guanine |
|------------------------|---------------|------|---------------|--------|----------------|----------|---------|
| Glutathione            | low (?)       | +    | ++            | ++     | 0              | ++       | ++      |
| G reductase            | raised        | 0    | +             | +      | 0              |          | 0       |
| Methaemoglobin         | raised        | 0    | ++            | +++    | + / 0          |          | ++      |
| Pyruvate kinase        | low           | +    | +             | +      | + / 0          | +        | +++     |
| <sup>32</sup> P uptake | low           | 0    | 0             | +      | 0              | ++       | 0       |
| <sup>42</sup> K uptake | increased (?) | 0    | ++            | ++     | ++             |          | ++      |
| Cell crenation         |               | +    | ++            | ++     | ++             | fragile  | ++      |

0 = no effect of added reagent + = positive effect of the reagent.

cell. In hereditary spherocytosis [17] increased uptake of phosphorus and increased glycolysis occur as part of an attempt to increase sodium pumping and similarly when normal cells are exposed to sulphhydryl inhibitors [18], or to sodium fluoride [15]. The increased uptake of <sup>42</sup>K induced by many of the reagents is difficult to explain but may be due to the breakdown of larger to smaller molecules within the cell, especially associated with the intracellular production of phosphates and so there might be an indirect link with reduced phosphorus uptake. ATP is always present within the erythrocyte when the intracellular potassium is rising [44] and when ATP falls potassium leaks into the medium. An early uptake of potassium with a dramatic fall off has been shown with urea at 250 mg%, and with ovalite. In fact the rate of glycolysis is partly controlled by the magnitude of ion transport, the link being that ADP produced by ATPase stimulates 3 phosphoglycerate kinase [15].

It has been the hope of many investigators to explain the 'burr cell'. If by this we mean the fragmented cell, then this occurs in association with intravascular coagulation [4], a process involved in the pathogenesis of some types of renal disease [38] and is indeed an indication of short red cell survival [31]. On the other hand crenated cells can be produced by washing to remove cholesterol [26] and spicule formation is a feature of pyruvate kinase deficiency [27]. Table VIII shows that guanidine is the most potent inhibitor of pyruvate kinase but phenol and urea are depressors.

The results here indicate that a combination of phenolic compounds together with acidosis is capable of producing crippling metabolic derangement of the red cell but that guanidine and its derivatives may have similar effects.

### Summary

A study has been made of possible toxic metabolites of uraemia on red cell shape, autohaemolysis and fragility, on reduced glutathione and methaemoglobin content of red cells, on glutathione reductase and pyruvate kinase activity and on  $^{32}\text{P}$  and  $^{42}\text{K}$  uptake by red cells. Analysis of the effect of individual compounds gives some insight into the complex metabolic situation that must exist in uraemia. Most retained compounds are detoxicated but the combined effects of phenolic acids and guanidine compounds with the acidosis of uraemia would appear to be sufficient to account for shortening of the red cell life span.

### References

1. Brown, M. Metabolism of urea in the red blood cell. *Br. J. Haematol.* 11: 1-11 (1966)
2. Brown, M. The effect of urea on the red blood cell. *Br. J. Haematol.* 11: 12-13 (1966)
3. Brown, M. The effect of urea on the red blood cell. *Br. J. Haematol.* 11: 14-15 (1966)
4. Brown, M. The effect of urea on the red blood cell. *Br. J. Haematol.* 11: 16-17 (1966)
5. Brown, R. Plasma erythropoietin in chronic uraemia. *Brit. med. J.* ii 1036 (1965)
6. Balvetty, O., Nenci, G. G. and Parma, A. Inhibition by urea of uraemic patients. *Lancet* ii 906 (1965)
7. Cohen, B. D., Stern, I. M. and Barras, J. E. Guanidylsuccinic aciduria in uraemia. *Amer. J. Med.* 45: 63 (1968)
8. Cole, C., Balazs, J. W. and Welt, L. G. Induction of a ouabain sensitive ATPase defect by uraemic plasma. *Abstract. Clin. Res.* 10: 90 (1968)
9. Dacie, J. V. and Lewis, S. M. *Practical haematology*, 3rd ed., pp. 141-144 (Churchill, London)
10. Brown, M. The effect of urea on the red blood cell. *Br. J. Haematol.* 11: 18-19 (1966)
11. Brown, M. The effect of urea on the red blood cell. *Br. J. Haematol.* 11: 20-21 (1966)
12. Evelyn, K. A. and Malloy, H. T. Microdetermination of oxyhaemoglobin, met-haemoglobin and sulf-haemoglobin in a single sample of blood. *J. biol. Chem.* 125: 655 (1938)
13. Gay, G. O. and Gay, M. K. Maintenance of human normal cells and tumour cells in continuous culture. *Amer. J. Cancer Res.* 27: 45-76 (1936)
14. Giovanetti, S., Balazs, P. L. and Ovet, L. Spontaneous *in vitro* autohaemolysis of blood from chronic uraemic patients. *Clin. Sci.* 29: 407-416 (1965)
15. Gornley, D. R. H. Inhibition of uptake of radio-active phosphate by human erythrocytes *in vitro*. *Amer. J. Physiol.* 174: 213 (1951)
16. Hicks, J. M., Yotco, D. W. and Wootton, I. D. P. Abnormal blood constituents in acute renal failure. *Clin. chim. Acta* 7: 623 (1962)

- 17 JACOB, H S and JANDL, J H Cell membrane permeability in the pathogenesis of hereditary spherocytosis *J clin Invest* 43 1704 (1964)
- 18 JACOB, H S and JANDL, J H Effects of sulphydryl inhibition on red blood cells I *J clin Invest* 41 779 (1962)
- 19 JOSEF, R A, McALISTER, J M and FRANKFORD, T A J Isotope investigations of red cell metabolism in patients with chronic renal failure *Proc Europ Dialy Transplant Ass* 5 213 (1968)
- 20 KRAMER, B, SELIGSON, H, BALTRUSH, H and SELIGSON, D The isolation of several aromatic acids from the haemodialysis fluids of uraemic patients *Clin chim, Acta* 11 363-371 (1965)
- 21 KUROYANAGI, T, KURIBU, A, SUGIYAMA, H and SAITO, M The ADP and ATP levels and the phosphorylative activity of erythrocytes in patients with uraemia associated with chronic renal failure *Tohoku J exp Med* 81 105 (1964)
- 22 erythrocyte glycolysis *Metabolism* 13 629-635 (1964)
- 23 MURTHAD, I F and JONES, F Lowered glucose utilisation, phosphate uptake and reduced glutathione following uretero-caval anastomosis *Proc Soc exp Biol, NY* 102 351 (1959)
- 24 MURPHY, J R Erythrocyte Metabolism III Relationship of energy metabolism and serum factors to the osmotic fragility following incubation *J Lab clin Med* 60 86 (1962)
- 25 NATHAN, D G, OSKI, F A, SIDEL, V W, GARDNER, F H and DIAMOND, L K Studies of erythrocyte spicule formation in haemolytic anaemia *Brit J Haemat* 12 385 (1966)
- 26 PARPART, A K, LORENZ, P B, PARPART, F R, GRECO, J R and CHASE, A M Osmotic resistance (fragility) of human red cells *J clin Invest* 26 636 (1947)
- 27 RAHN, P R The chemical basis of uraemia blood phenol *J Urol, Baltimore* 51 110-116 (1944)
- 28 REFS, S B, SCHIEFELIN, W G, POND, J C, McMANUS, T and GUILD, W R Effect of dialysis and purine ribosides upon the anaemia of uraemia *J clin Invest* 36 923 (1957)
- 29 REGOECZI, F, RUBENBERG, M L and BRAIN, M G Intravascular haemolysis and disseminated intravascular coagulation *Lancet* i 601 (1967)
- 30 SCHMIDT, I G, McILVAIN, N F and BOWEN, J J Plasma amino and ether soluble phenols in uraemia *Amer J clin Path* 20 253 (1950)
- 31 SIEMENHOFF, M L, ASATOOR, A M, MILNE, M D and ZILVA, J F Retention of aliphatic amines in uraemia *Clin Sci* 23 65-77 (1963)
- 32 SOLOMON, A K Permeability of the human erythrocyte to sodium and potassium *J Gen Physiol* 30 57 (1952)
- 33 TANAKA, K R Studies on red cell ATP in uraemia and other diseases *Abstract Clin Res* 15 134 (1967)
- 34 TANAKA, K R, VALANTINE, W N and MIWA, S Pyruvate kinase deficiency hereditary non-spherocytic haemolytic anaemia *Brit J Haemat* 8 160 (1962)
- 35 THEIL, C B, BRODINE, C L and DOOLAN, P D Red cell glutathione content and stability in renal insufficiency *J Lab clin Med* 58 736-742 (1961)
- 36 VASALLI, P and McCLELLAN, R T The coagulation process and glomerular disease *Amer J Med* 30 179 (1965)
- 37 WELT, L G A further evaluation of erythrocyte sodium transport in control subjects and patients with uraemia *Nephron* 6 406-417 (1969)

- 40 WELT, L. G., SACIS, J. R. and McMANUS, J. T. Anion transport defect in erythrocytes from uraemic patients. *Trans. Am. Amer. Physns* 77 169-181 (1964)
- 41 WERNZE, H. und KOCH, W. Über der Glutathion-Gehalt der Erythrocyten bei Chronisch renaler Insuffizienz. *Klin. Wochr* 43 451-454 (1965)
- 42 WEST, M., BERGER, C., ROVY, H. and ZINKERMAN, H. J. Estimation of glutathione reductase. *J. Lab. clin. Med* 57 946 (1961)
- 43 WASTERVELT, F. B. and SCHREINER, G. E. The carbohydrate intolerance of uraemic patients. *Ann intern Med* 57 266 (1962)
- 44 WHITTAM, R. Potassium movements and ATP in human red cells. *J. Physiol., Lond* 140 479-497 (1958)
- 45 WHITTAM, R. and CIGAR, M. E. Correlation between active cation transport and metabolism in erythrocytes. *Biochem. J* 97 214 (1965)





Acetylphenylhydrazin (APH) 0,5%. Lösung frisch hergestellt, Einzeldosis (soweit nicht anders angegeben) 15 mg/kg, meist wurde an 3 aufeinanderfolgenden Tagen je eine Dosis s.c. injiziert, die Tage nach APH wurden vom 1. Injektionstag an gezählt.


Bei 18 Tieren wurden auf dem Höhepunkt der Retikulozytose 100 µg/kg Actinomycin D (Dactinomycin)<sup>2</sup> i.v. injiziert. Da viele Tiere frühzeitig während des Versuchs starben, konnten die Ergebnisse dieser Versuchsreihe nur von 6 Tieren ausgewertet werden. Fünf Tieren wurde nach 3 Tagen die gleiche Dosis Actinomycin D nochmals gegeben.



12000 g, Doppelbestimmung

Aus diesen Messwerten wurden Hämoglobingehalt ( $Hb_g = MCH$ ), Hämoglobinkonzentration ( $MCHC$ ) und mittleres Erythrozytenvolumen ( $MCV$ ) berechnet.

Retikulozyten-Färbung mit Brillantkresylblau 1% in 0,9% NaCl (3 Tropfen Blut + 3 Tropfen Farbstoff) 30 min in versch. kaltem Röhrchen, Ausstriche. Die Farbstofflösung ist hypertensisch. Vergleichende Größenmessungen (Price-Jones-Kurven) mit einer isotonischen Brillantkresylblaulösung (in 0,7% NaCl, 309 mOsm) ergaben jedoch keine Unterschiede. Die Abnahme des Zelldurchmessers bei Vitalfärbung (im Unterschied zur panoptischen Färbung) ist durch den Farbstoff bedingt [105]. Auszählung von je 1000 Erythrozyten, Angabe in % Retikulozyten bzw. Umrechnung auf Retik./mm<sup>3</sup>. Die Retikulozytenzahlen liegen bei dieser Methode etwas höher als bei Giemsa-gegrüßfärbten oder Feuchtpreparaten. Normalwerte (Mittelwert von 50 unbehandelten Kaninchen)  $37,5 \pm 17,5\%$ .



und Genauigkeit ergibt

Innenkörper-Färbung und Auszählung wie bei den Retikulozyten. Dabei erscheinen die Innenkörper hellblau, die Substantia granulo-filamentosa blauviolett.

Untersuchung einzelner Schichten des Erythrozytensedimentes. Heparinblut wurde in eigens hierfür hergestellten schmalen Glasröhrchen 20 min zentrifugiert (1000 g). Nach Abheben des Plasmaoberflusses und der Leukozytenschicht wurde das Erythrozytensediment in genau 3 Teile geteilt, das obere und untere Drittel mit etwas Plasma verdünnt und die mittlere Schicht verworfen.

Messung der Volumenverteilungskurve der Erythrozyten-Suspensionsmedium 340 ml n 15 Na<sub>2</sub>HPO<sub>4</sub>, 50 ml n 15 KH<sub>2</sub>PO<sub>4</sub>, 69 g NaCl, 44 ml Formalin 40%, demineralisiertes Wasser ad 1000, pH 7,4-7,55, 293-295 mOsm. Der Puffer wurde vor Gebrauch gefiltert. Zählwertzahl bei der verwendeten elektrischen Einstellung 100-200 Partikel/ml Blutverdünnung 1:5000, Messung mit Coulter Counter Modell B mit automatischer Registrierung (Plotter f). Kapillardurchgang 100 µ. Messung mit maximaler Verstärkung 1: AMP = 1,9, um den Meßbereich zwischen 20 bis 200 (V<sub>1</sub>/V<sub>2</sub> = 1). Unterer Schwellenwert zur Erythrozytenzählung D 12. Volumeneinstellung aus dem MCV-Wert einer Blutprobe (Mittelwert aus 10fach-Bestimmung von Hämatokrit, Erythrozytenzahl und Volumenverteilungskurve).

<sup>2</sup> Wir danken der Firma Sharp & Dohme, München, für die Überlassung der Versuchsmengen Dactinomycin.

*Ergebnisse***Hämolyse durch Acetylphenylhydrazin (APH), Stimulierung der Erythropoese, Hemmung durch Actinomycin D**

Nach APH kommt es innerhalb weniger Tage zu einer schweren Anämie, die eine starke Mehrproduktion von Erythrozyten auslöst. Die Retikulozyten steigen am 5. bis 6. Tag nach der 1. Injektion auf 500 bis 700‰. Die neugebildeten Zellen sind ausserordentlich gross und enthalten mehr Hämoglobin als normale Erythrozyten; die Volumenzunahme ist aber grosser als die Hämoglobinzunahme, so dass eine Abnahme des MCHC-Wertes resultiert [s. auch 2, 28, 76, 80, 100, 101]. Nach weniger als 2 Wochen sind die Ausgangswerte wieder erreicht.

Alle Erythrozyten, die sich während der Einwirkung des APH in der Zirkulation befinden und Innenkörper bilden, werden innerhalb weniger Tage hämolysiert. Dies wurde durch gleichzeitige <sup>51</sup>Cr-Markierung und Auszählung der Innenkörper nachgewiesen: Bei 5 Tieren wurde am Tag der 1. APH-Injektion eine autologe <sup>51</sup>Cr-Markierung vorgenommen und in den folgenden Tagen die Aktivität gemessen und der Anteil der Innenkörper (‰) gezählt. Die etwa parallel verlaufende Abnahme von Radioaktivität und Zahl der Innenkörper spricht dafür, dass nach 9–11 Tagen alle vergifteten Erythrozyten aus dem Kreislauf eliminiert sind. Die Zerstörung der gesamten Zellpopulation bildet die Voraussetzung dafür, dass während der anschliessenden Regenerationsphase die neugebildeten Erythrozyten ohne Beimischung älterer Zellen untersucht werden können.

In einer zweiten Versuchsserie (6 Kaninchen) wurde auf dem Höhepunkt des Retikulozytenanstiegs die Erythropoese vollständig gehemmt. Dies geschah durch intravenöse Injektion von Actinomycin D, dessen Wirkung auf die Erythropoese *in vitro* [26, 35] und *in vivo* [49, 103] eingehend untersucht worden ist.

Actinomycin D kann in seiner Wirkungsweise auf die Erythropoese gewissermassen als Erythropoetin-Antagonist angesehen werden, d.h. es wirkt nur in den ganz frühen Stadien der Erythropoese auf die Zellbildung und beeinflusst nicht die späteren Ausreifungsstadien [33, 49, 53, 78, 79], ist also kein allgemeines Mitosegift.

Die Grossenmessungen der Erythrozyten konnten dadurch an einer recht einheitlichen «Kohorte» vorgenommen werden, unbeeinflusst vom Zustrom weiterer Zellen aus späteren Phasen der Regeneration.

*Tabelle 1 Differenzierung des Rot-Kultursystem nach Aktivierung der Erythropoese durch Phenylhydrazinanalyse (25.-27. B.) und Hemmung durch Actinomycin D (30. B.)* *Wurddüngung von je 200 Reisk (N 105)*

[illegible]

Der Eintritt der vollständigen Erythropoesehemmung wurde a) durch Retikulozytenzählung und -differenzierung und b) durch Bestimmung der  $^{59}\text{Fe}$ -Inkorporationsrate nachgewiesen.

a) Die Retikulozyten fallen 4–5 Tage nach Actinomycin D auf 0 ab. Schon vorher kann der Eintritt der Hemmung durch Differenzierung der Reifestadien [44] nachgewiesen werden (Tab. I): Wird der Retikulozytennachschub plötzlich unterbunden, dann reifen die vorhandenen Retikulozyten aus, d.h. sie verschwinden in der Reihenfolge I–IV, bis schliesslich nur noch ausgereifte Erythrozyten zu finden sind. Dieser Prozess der Ausreifung *in vivo* gleicht somit dem, wie er durch *in-vitro*-Studien [4, 11, 44, 81] bekannt ist. Die aufwendige Retikulozytendifferenzierung wurde bei 2 Tieren durchgeführt. Bei den übrigen wurde der Nachweis der vollständigen Erythropoesehemmung durch

b) die Messung der  $^{59}\text{Fe}$ -Inkorporation erbracht. Bei 4 Tieren wurden am 3. Tag nach der 1. Actinomycin-D-Injektion 10  $\mu\text{Ci}$   $^{59}\text{Fe}$




Abb 1 Wirkung von Actinomycin D auf Retikulozytenzahl und  $^{59}\text{Fe}$ -Inkorporation  
Oben Vollblut Unten gewaschene Erythrozyten

14 injiziert. In Abständen von 1-3 Tagen wurde Blut entnommen, die Aktivität nach Ende des Versuchs von allen Proben (je 0,5 ml Vollblut) gemessen und in Imp/min/ml Ery-Sediment umgerechnet. Die Radioaktivität nimmt nur ganz allmählich ab (Abb 1, obere Hälfte) und ist während des gesamten Stadiums der Erythropoesehemmung im Plasma nachzuweisen, die  $^{59}\text{Fe}$  Clearance ist also enorm verlängert (normal bei Kaninchen  $t_{1/2} \approx 60-80$  min [20]). Mit Wegfall der Actinomycin D Wirkung steigen Retikulozytenzahl und  $^{59}\text{Fe}$  Inkorporation parallel an. Werden die Blutproben  $1 \times$  in  $0,9\%$  NaCl gewaschen und die Aktivitätsmessungen im plasmafreien Erythrozytensediment vorgenommen, dann ist für die Dauer der Actinomycin D Wirkung keine Radioaktivität im Blut nachweisbar (Abb 1, untere Hälfte).

Vom Zeitpunkt des Abfalls der Retikulozytenzahlen bis zu ihrem Wiederanstieg besteht also eine vollständige Hemmung der Erythropoese.

### Die Erythrozytengröße in der Regenerationsphase der APH Anämie

a) *Messung des Retikulozytendurchmessers*. Bereits bei Durchmusterung des Brillantkresyllblutpräparates erkennt man, dass die Retikulozyten auffällig gross sind, grösser als die Retikulozyten im steady state.

Darunter befinden sich besonders in den ersten 10 Tagen nach APH zahlreiche



Bei 7 Kaninchen während des

durchmesser stimmt zeitlich mit der Zunahme der relativen ( $\%_{\text{rel}}$ ) Retikulozytenzahlen überein [8]. Wegen der raschen Abnahme der Erythrozytenzahl in dieser Versuchsphase stellen aber nur die absoluten Retikulozytenzahlen (Retik./mm<sup>3</sup>) ein Mass für die Zellneubildung

dar. Ihr höchster Wert wird regelmässig später als der maximale Retikulozytendurchmesser erreicht.

Nach 12–14 Tagen ist die Anämie wieder ausgeglichen; in den folgenden Tagen treten Retikulozyten auf, deren Durchmesser kleiner ist als im steady state. Ganz allmählich nimmt die Retikulozytengrösse dann wieder zu, hat aber in manchen Fällen bei Versuchsende (28 Tage nach APH) den Ausgangswert noch nicht erreicht. Die Produktion kleiner Erythrozyten in der Spätphase der Regeneration ist nicht Folge eines inzwischen eingetretenen Eisenmangels. Denn die Tiere erhielten jeden 4. Tag 30 mg FeIII i.m.

b) Messung des mittleren Zellvolumens (MGV). Während wir mit den Retikulozyten immer die neu in das Blut eingeschwemmten Erythro-




Abb. 2. Mittlerer Retikulozytendurchmesser und Retikulozytenzahl bei APH-Anämie.

Tabelle II Zahl und mittlere Durchmesser der Retikulocyten nach Phenylhydrazinämolyse

| Tag | K 97  |                                       |            |       | K 99                                  |            |       |                                       | K 100 |                                       |            |       | K 101                                 |       |                                       |            |
|-----|-------|---------------------------------------|------------|-------|---------------------------------------|------------|-------|---------------------------------------|-------|---------------------------------------|------------|-------|---------------------------------------|-------|---------------------------------------|------------|
|     | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | Durchm. µm | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | Durchm. µm | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | Durchm. µm | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | • 100 | pro mm <sup>2</sup> × 10 <sup>3</sup> | Durchm. µm |
| 0   | 52    | 370                                   | 5.6        | 73    | 125                                   | 6.7        | 55    | 189                                   | 53    | 507                                   | 6.2        | 44    | 286                                   | 44    | 286                                   | 5.6        |
| 5   | 71    | 427                                   | 6.1        | 7.6   | 740                                   | 6.6        | 241   |                                       | 632   | 675                                   | 7.1        | 507   | 533                                   | 507   | 533                                   | 6.1        |
| 7   | 415   | 812                                   | 8.0        | 83    | 933                                   | 6.9        | 610   | 1108                                  | 408   | 640                                   | 6.9        | 522   | 505                                   | 522   | 505                                   | 7.4        |
| 8   | 517   | 1255                                  | 6.8        | 430   | 1159                                  | 6.8        | 595   | 1327                                  | 402   | 677                                   | 6.7        | 411   | 779                                   | 411   | 779                                   | 6.5        |
| 9   | 445   | 1210                                  | 7.1        | 368   | 1015                                  | 6.7        | 532   | 920                                   | 296   | 603                                   | 6.6        | 290   | 571                                   | 290   | 571                                   | 5.9        |
| 10  | 587   | 1374                                  | 6.8        | 259   | 740                                   | 6.2        | 285   | 802                                   | 333   | 558                                   | 6.5        | 262   | 558                                   | 262   | 558                                   | 5.9        |
| 15  | 114   | 4.4                                   | 5.7        | 153   | 675                                   | 5.4        | 145   | 578                                   | 151   | 613                                   | 5.8        | 139   | 538                                   | 139   | 538                                   | 5.8        |
| 17  | 608   | 433                                   | 4.8        | 91    | 370                                   | 6.0        | 51    | 217                                   | 89    | 365                                   | 5.7        | 107   | 460                                   | 107   | 460                                   | 5.6        |
| 19  | 67    | 291                                   | 5.8        | 55    | 258                                   | 6.3        | 57    | 29                                    | 72    | 512                                   | 5.6        | 41    | 189                                   | 41    | 189                                   | 6.2        |



zyten oder zumindest solche messen, deren Entstehungszeit zeitlich eng umschrieben ist, repräsentiert der MCV-Wert immer alle bis zu diesem Zeitpunkt produzierten und noch im Blut kreisenden Zellen.

Wie schon von früheren Autoren [17, 25] beschrieben, tritt nach grossen APH-Dosen (45–60 mg/kg) eine schwere Anämie (1,0–1,2 Mill. Ery./mm<sup>3</sup>), nach geringeren Dosen (20–30 mg/kg) eine mittelschwere Anämie (2,8–3,0 Mill. Ery./mm<sup>3</sup>) auf. Vom Schweregrad der Anämie wiederum ist die Grosse der in der Regenerationsphase neugebildeten Erythrozyten abhängig. Dies geht aus Abbildung 3 hervor, in der bei 26 Versuchen der höchste gemessene MCV-Wert gegen die niedrigste Erythrozytenzahl aufgetragen ist.

Aus den fortlaufenden MCV-Bestimmungen ergibt sich (Abb. 4): von einem Ausgangswert von etwa 70  $\mu\text{m}^3$  steigt der MCV-Wert bei den schweren Anämien auf das Doppelte (136–141  $\mu\text{m}^3$ ), bei den mittelschweren Anämien auf das 1  $\frac{1}{2}$ -fache (102–105  $\mu\text{m}^3$ ) an. Bei den schweren Anämien finden sich die maximalen MCV-Werte zwischen dem 6. und 9. Tag nach APH; aber bereits am 10.–12. Tag liegen die





Abb. 3 Abhängigkeit des MCV in der Regeneration vom Grad der Anämie



114 4 Erythrozytenzahl und MCV in der Regenerationsphase der APH Hämolyse

MCV-Werte wieder um  $100 \mu m^3$ . Dies beweist noch nicht, dass die Makrozyten mit dem doppelten Zellvolumen innerhalb dieser kurzen Zeit zugrunde gegangen sind. Denn zu diesem Zeitpunkt sind die neugebildeten Erythrozyten normal gross oder bereits mikrozytär (Abb. 2, Tab. II). Der rasche Rückgang des MCV ist deshalb sicher zu einem erheblichen Teil durch die Mischung einer normal grossen mit einer makrozytären Population bedingt. Im weiteren Verlauf nehmen die

MCV-Werte allmählich ab, da die Ausschwemmung relativ kleiner Erythrozyten anhält. Erst nach etwa 40 Tagen ist der Ausgangswert des MCV wieder erreicht [25].

Die Erythrozyten- und MCV-Kurven von K 58, 60, 67 weichen von dem geschilderten Verlauf ab. Bei diesen Tieren hatten wir an die APH-Hämolyse vom 11.-18. Tag eine «Verdünnungsanämie» [9] durch Infusionen grosser Mengen eines Plasmaexpanders angeschlossen. Deshalb steigt die Erythrozytenzahl während dieser Zeit nicht an, das mittlere Zellvolumen nimmt nochmals gering zu.

c) *Messung der Volumenverteilungskurve (VK)*. Im Gegensatz zum MCV bietet die Messung der VK die Möglichkeit, Änderungen in der Grössenverteilung und das Auftreten und Verschwinden von Zellen eines umschriebenen Volumenbereiches zu erfassen. Da sich während des Versuchs die Erythrozyten-Gesamtzahl stark ändert, muss die Auswertung der VK über die bisher ausschliesslich übliche Beurteilung der prozentualen VK hinaus auch die absoluten Werte (Ery/mm<sup>3</sup>) innerhalb jeder Grössenklasse berücksichtigen.

Von «absolut» sollte streng genommen nur in bezug auf die Gesamtzahl aller zirkulierenden Erythrozyten gesprochen werden. Wegen der weitgehenden Konstanz des Blutvolumens bei akut verlaufenden Anämien [29, 34, 38, 48] kann aber ohne grössere Fehler die Erythrozytenkonzentration (Ery/mm<sup>3</sup>) als Mass für die Gesamtheit der Erythrozyten angesehen werden.

Abbildung 5 gibt eine Verlaufsuntersuchung derartiger absoluter VK wieder, aus der Serie, bei der Actinomycin D 5 Tage nach der 1. APH-Injektion gegeben wurde. Sämtliche VK sind im gleichen Massstab aufgetragen, wodurch das Verschwinden und Wiederauftreten der Erythrozyten in den einzelnen Volumenklassen klar zur Darstellung kommt.

In den ersten Tagen nehmen die Zellen aller Grössen stark ab, am 7. II. ist der Normozytengipfel (bei 57  $\mu\text{m}^3$ ) verschwunden. Die erste makrozytäre Regeneration ist am 4. II. deutlicher am 5. II. zu erkennen (Doppelgipfel). In der Phase der Actinomycin-D-Hemmung (7.-11. II.) nimmt die Kurvenhöhe ab, der breite Kurvengipfel im Makrozytenbereich (102  $\mu\text{m}^3$ ) wandert allmählich nach links (11. II. 83  $\mu\text{m}^3$ ). Mit Wegfall der Actinomycinwirkung (ab 15. II.) nimmt die Höhe der Kurven wieder zu, der Gipfel verschiebt sich weiter nach links, ab 28. II. liegt der Kurvengipfel erstmals links vom Ausgangswert, erst am 2. I. findet sich wieder die normale VK.

Eine selektive Messung der VK der jeweils neugebildeten Erythrozyten, analog zur Durchmesserbestimmung der Retikulozyten, ist

mit dem verwendeten Anreicherungsverfahren nicht möglich. Im oberen Drittel des Erythrozytensedimentes sind aber die Retikulozyten und jüngsten Erythrozyten stark angereichert; ihre prozentuale VK ist in Abbildung 6 dargestellt.




Abb. 5. Absolute Volumenverteilungskurven bei Phenylhydrazinämie APH 31 10, 1 11, 2 11 je 15 mg/kg Actinovercin D 5.11., 9 11 je 100  $\mu$ g/kg




Abb. 6 Prozentuale Volumenverteilungskurve und mittleres Zellvolumen (MCV) des oberen Drittels des Erythrozytensedimentes.

3 Tag Zunahme der Makrozyten 4 Tag Doppelgipfel 5 Tag Normozyten stark vermindert, Makrozyten-gipfel ( $102 \mu\text{m}^3$ ) Mit Nachlassen der Actinomycinwirkung setzt die Regeneration erneut makrozytär ein. Im weiteren Verlauf verschwinden die Makrozyten aus der oberen Schicht, der Kurvengipfel wandert nach links, über die G-pfeillage der Ausgangskurve hinaus. Die Parallele zu den Retikulozytenmessungen (Abb 2) ist evident.

Die Regeneration nach APH-Hämolyse ist somit makrozytär, solange eine schwere Anämie besteht. Über ein normozytäres Zwischenstadium wird sie dann fast mikrozytär. Dieser Umschlag wird besonders deutlich bei Gegenüberstellung der VK von Vollblut, oberem und unterem Drittel des Erythrozytensedimentes aus der Früh- und der Spätphase des Versuchsablaufs (Abb 7).

Am 5. Tag aus der 7. (Abb. 7b) Regenerat fast identisch mit dem arithmetischen Mittel aus oberem und unterem Drittel des Erythrozytensedimentes.

Um die Größenänderungen der Erythrozyten besser erkennen und Zellstörungen von Zellschrumpfung nach Möglichkeit voneinander abgrenzen zu können, haben wir die absoluten VK zu verschiedenen Zeitpunkten aufgezeichnet und für jeden Messpunkt der VK die Differenz der Erythrozyten berechnet. In den Abbildungen 8 und 9 sind die so ermittelten Differenzkurven für einen Versuchsablauf dargestellt. Die Ergebnisse der übrigen Versuche sind in Tabelle IV zusammengefasst. In den Abbildungen sind links die absoluten VK ( $\text{Ery mm}^3$ ), rechts die Differenzkurven dargestellt. Die zeitlich erste VK ist jeweils mit Punkten ( $\bullet$ ), die zweite mit offenen Kreisen ( $\circ$ ) gekennzeichnet.

Abbildung 8 zeigt die Größenänderungen von Beginn der APH-Vergiftung bis zum Eintritt der vollständigen Erythropoesehemmung. Abbildung 8a umfasst das Stadium der reinen Hämolyse, die negative Differenzkurve stellt das genaue Spiegelbild einer normalen VK dar.

Die makrozytäre Regeneration, die überdeckt die auch in dem Volumenbereich von mehr als  $83 \mu\text{m}^3$  fortbestehende Hämolyse. Die Änderung der Gesamt Erythrozytenzahl ist die Resultante von Produktion und Destruktion; die Abnahme der Gesamtzahl beträgt

$690 \times 10^3$ , die Differenzkurve zeigt dagegen eine Zellzerstörung von  $1423 \times 10^3$  allein im Volumenbereich bis  $88 \mu\text{m}^3$  an. Die Zellzerstörung ist also mehr als doppelt so gross wie die Abnahme der Erythrozytenzahl.




Abb. 7. Prozentuale Volumenverteilungskurven von Vollblut, oberem und unterem Drittel des Erythrozytensedimentes, a) in der Frühphase, b) in der Spätphase der APH-Anämie.




Abb. 8. Volumenverteilungskurven und Differenzkurven in der ersten Phase der APT Hämolyse. Am 25., 26. und 27. 8. wurden je 15 mg/kg APT injiziert.

Die Änderungen der VK während der anschließenden achttägigen Erythropoieschemmung sind in Abbildung 9 dargestellt, unterteilt in 3 kurze Zeitintervalle, während derer sich die VK immer mehr nach links verschiebt. Die Abnahme der Erythrozytenzahl beträgt während des gesamten Zeitraums  $320 \times 10^9$ , aus den negativen Anteilen der 3 Differenzkurven ergibt sich dagegen eine Abnahme von  $305 + 200 + 130 = 635 \times 10^9$ . Im positiven Bereich der Differenzkurven ist eine Zellzunahme von  $191 + 84 + 38 = 313 \times 10^9$  nachweisbar, obwohl während dieser Zeit keine Erythrozyten aus dem Knochenmark in die Blutbahn eintreten. Das heisst, dass eine entsprechende Zahl von Makrozyten zu kleineren Zellen geschrumpft sein muss. Der positive Bereich der Differenzkurven gibt somit den Anteil wieder, den die Zellschrumpfung am Rückgang der Makrozyten hat. Der Anteil der Hämolyse ergibt sich aus der Differenz zwischen dem negativen und



dem positiven Bereich der Differenzkurven. Zunächst überwiegt die Schrumpfung (Abb. 9a), später die Hämolyse (Abb. 9c).

Die Abgrenzung dieser Intervalle wurde nach Berechnung der absoluten VK so vorgenommen, dass charakteristische Häufigkeitsänderungen in der Grössenverteilung zusammengefasst wurden. Sie sind deshalb nicht gleich lang, zum besseren Vergleich wurden deshalb in Tabelle III Schrumpfung und Hämolyse für jedes Intervall auf den Durchschnittswert pro 24 Std. umgerechnet. Die Hämolyse zeigt in den 3 Intervallen keine Tendenz in Richtung einer Zu- oder Abnahme, die Schrumpfrate ist im 1. Intervall (a) am grössten und sinkt dann kontinuierlich ab. Dementsprechend nimmt der MCHC-Wert im 1. Intervall zu. Die MCV-Abnahme in Intervall a) ist mehr durch Schrumpfung als durch Hämolyse

wiegend werden die besonders grossen Erythrozyten hämolysiert (MCV-Abnahme)




Abb. 9 Absolute Volumenverteilungskurven und Differenzkurven während einer 24stündigen Hemmung der Erythropoese durch Actinomycin D

Wie aus Abbildung 9 hervorgeht, erfasst die Hämolysen in den Intervallen b) und c) auch Zellen einer Grössenklasse, deren Häufigkeit zuvor (infolge Schrumpfung grösserer Zellen) zugenommen hatte. Ein Teil der Makrozyten schrumpft also zunächst, um dann doch noch hämolysiert zu werden.

Tabelle IV zeigt Schrumpfung und Hämolysen während der ersten 48 Std. nach vollständiger Erythropoesehemmung bei den übrigen Versuchstieren. In allen Versuchen ist die Abnahme der Makrozyten nicht nur durch Hämolysen, sondern auch durch eine Zellschrumpfung verursacht.

Tabelle III

| Intervall | Std. | Schrumpfung<br>pro 24 Std.<br>Ery $\times 10^3$ | Hämolysen<br>pro 24 Std.<br>Ery $\times 10^3$ | MCV<br>$\mu\text{m}^3$ | MCHC<br>% | HbE<br>% |
|-----------|------|---|---|------------------------|-----------|----------|
| a) 31.8   |      |   |   | 150                    | 25.0      | 36.9     |
| 3.9       | 63   | 7.3   | 43  | 124                    | 30.5      | 36.9     |
| b) 3.9    |      |   |   | 124                    | 30.5      | 36.9     |
| 6.9       | 81   | 25  | 34  | 115                    | 30.5      | 34.9     |
| c) 6.9    |      |   |   | 115                    | 30.5      | 34.9     |
| 8.9       | 48   | 19  | 46  | 97                     | 32.2      | 31.2     |

Schrumpfungen und Hämolysen pro 24 Std. in 3 Intervallen (a, b, c)

Tabelle II Schrumpfung und Hämolysen in den ersten 48 Stunden der vollständigen Erythropoesehemmung

| Kan.<br>Nr. | Makrozyten-<br>Abnahme<br>$\times 10^3$ | Schrumpfung          |                                      | Hämolysen            |                                      | HbE<br>%    | MCV<br>$\mu\text{m}^3$ | MCHC<br>%   |
|-------------|---|----------------------|--------------------------------------|----------------------|--------------------------------------|-------------|------------------------|-------------|
|             |   | Ery<br>$\times 10^3$ | % der<br>Makro-<br>zyten-<br>Abnahme | Ery<br>$\times 10^3$ | % der<br>Makro-<br>zyten-<br>Abnahme |             |                        |             |
| K. 54 137   |   | 47                   | 32                                   | 90                   | 68                                   | 32.6 ± 31.0 | 134 ± 124              | 24.3 ± 25.0 |
| K. 105 310  |   | 54                   | 17.4                                 | 2.6                  | 82.6                                 | 32.0 ± 32.0 | 119 ± 109              | 26.9 ± 30.0 |
| K. 111 170  |   | 160                  | 62.5                                 | 53                   | 17.7                                 | 34.0 ± 33.5 | 125 ± 119              | 28.2 ± 29.7 |
| K. 118 118  |   | 61                   | 51.6                                 | 57                   | 45.4                                 | 40.0 ± 37.0 | 147 ± 131              | 27.5 ± 27.1 |

## Diskussion

Die Regeneration der Erythropoese nach APH-Hämolyse ist gekennzeichnet durch das Auftreten makrozytärer Retikulozyten mit dem  $1\frac{1}{2}$ - bis 2fachen Volumen normaler Erythrozyten. Je schwerer die Anämie, umso ausgeprägter ist die Makrozytose. In zahlreichen Arbeiten haben sich besonders STOILMAN *et al* [18, 81, 89, 92] sowie BOROOK *et al* [13, 14, 15] um die Klärung dieses Phänomens bemüht. Es darf danach als gesichert gelten, dass die Makrozytose dadurch zustande kommt, dass bei starker Stimulierung eine (oder zwei) Reifeteilungen übersprungen werden («skipped division»), die Retikulozyten also durch Entkernung der polychromatischen (oder basophilen) Normoblasten entstehen. Die vorzeitig ausgeschwemmten Zellen haben eine verkürzte Lebenszeit [5, 18, 69, 84, 103], die Makrozytose ist nach wenigen Tagen nicht mehr nachweisbar. Dieser «Panikmechanismus» der Erythropoese [84] vermag immerhin, den bedrohlichen Grad der Anämie zu überwinden. Er ist grundsätzlich von der normalen Zellbildung mit Kernausstossung der ausgereiften orthochromatischen Normoblasten und der Ausschwemmung von Erythrozyten mit normaler Lebenszeit zu unterscheiden. Wir haben deshalb diesen Modus der Zellbildung, der in seiner Auswirkung auf die periphere Erythrozytenzahl zwischen normaler (effektiver) und der ineffektiven Erythropoese [30, 41] steht, als semi-effektive Erythropoese bezeichnet [7, 10]. Er kommt auch, allerdings in quantitativ unbedeutendem Ausmass, bei ausgeglichener Zellbildung vor [57, 63, 86].

Die vorliegenden Untersuchungen haben gezeigt, dass das rasche Verschwinden der Makrozyten nicht nur auf einer Hämolyse, sondern auch auf einer Zellschrumpfung beruht. Ein indirekter Beweis hierfür ergibt sich aus dem Vergleich der mittleren Retikulozytendurchmesser mit der absoluten Retikulozytenzahl während des gesamten Versuchsablaufs. Der Retikulozytenanstieg am 5–8 Tag nach APH kommt nicht allein durch die zunehmende Zellausschwemmung zustande, sondern auch dadurch, dass die Reifungszeit im Blut verlängert ist [31, 77], was in einer erheblichen Linksverschiebung der Reifestadien der Retikulozyten zu erkennen ist. Dadurch kommt es zu einer Kumulation, die maximalen Retikulozytenzahlen werden regelmässig nach dem Maximum der Retikulozytendurchmesser gefunden. In Anbetracht der Kumulation ist dies so zu erklären, dass die ausreifenden Retikulozyten an Grösse abnehmen [72].

Der direkte Beweis für die Schrumpfung makrozytärer Erythrozyten wurde durch Messung der Volumensverteilungskurven (VH) und Berechnung der Differenzkurven erbracht. Die Interpretation dieser Ergebnisse erfordert eine kritische Bewertung der Messmethode.

Seit der grundlegenden Arbeit von BRECHER *et al.* [14] wurde bis in jüngste Zeit [24-96] angenommen, dass die rechtsschiefe VH, die wir bei Messung mit dem Coulter Counter oder ähnlichen Geräten erhalten, der realen Grössenverteilung der Erythrozyten entspricht. Zahlreiche Autoren haben sich mit dieser Rechtsschiefe auseinandergesetzt [24-36, 46-65, 67-70, 96-98, 104], die im Gegensatz zur Normalverteilung der Erythrozytendurchmesser sei. DILL [19] fand bei methodischen Modifikationen der üblichen Grössenmessung eine Gausssche Normalverteilung. THOM [94-95] konnte in ausgedehnten Versuchen nachweisen, dass die Stromdichte am Rand der Kapillarroffnung grösser ist als in der Achse der Messöffnung, so dass Erythrozyten, die über den Rand der Öffnung in die Messkapillare einströmen, zu gross registriert werden. Bei Verwendung einer modifizierten Kapillarroffnung, die es erlaubt, die Zellen ausschliesslich im Zentralstrahl zu messen, fand auch er eine Gausssche Normalverteilung der Erythrozytenvolumina.

Bei den in den Abbildungen 5-9 dargestellten VH ist, ebenso wie bei allen früheren Messungen der VH bei APII-Hämolyse [17-18, '00], dieser methodisch bedingte Messfehler



In allen Versuchen ist nach vollständiger Erythropoesehemmung eine erhebliche Zunahme normozytärer Erythrozyten nachweisbar, die nur durch Schrumpfung von Makrozyten entstanden sein können. Der Anteil der Schrumpfung am Rückgang der Makrozyten ist in den ersten Tagen am grössten, ein Teil der Makrozyten, die zunächst geschrumpft waren, wird in den folgenden Tagen dann doch noch hämolytisiert.

Ausser Schrumpfung und Hämolyse ist als 3. Möglichkeit des Schicksals der Makrozyten die von WEICHER [99] dokumentierte Retikulozytenbildung in Betracht zu ziehen. Sie ist aufgrund der Differenzkurve in Abbildung 9a und der Befunde bei den übrigen Versuchsreihen auszuschliessen. Zu Beginn der Knochenmarkshemmung wurden 6-3% Retikulozyten gezählt, am Ende des 1. Intervalls (3-9) 0. Wäre die Abnahme der Makrozyten durch eine Teilung verursacht, dann wäre eine Verdoppelung der Erythrozyten mit halbem Volumen und dadurch ein erheblicher Anstieg der Gesamtzellzahl zu erwarten. Die Hypothese der Retikulozytenbildung ist bereits von LOWESSER [64] widerlegt worden.

Die Ergebnisse zeigen, dass den Zellgrössenänderungen bei der Regeneration wesentlich kompliziertere Vorgänge zugrunde liegen, als ursprünglich [17, '88] angenommen worden war. Geradezu dramatische Vorgänge von Zellproduktion, Hämolyse und Schrumpfung

*Diskussion*

Die Regeneration der Erythropoese nach APH-Hämolyse ist gekennzeichnet durch das Auftreten makrozytärer Retikulozyten mit dem  $1\frac{1}{2}$ - bis 2fachen Volumen normaler Erythrozyten. Je schwerer die Anämie, umso ausgeprägter ist die Makrozytose. In zahlreichen Arbeiten haben sich besonders *STOILMAN et al.* [18, 84, 89, 92] sowie *BOR-SOOK et al.* [13, 14, 15] um die Klärung dieses Phänomens bemüht. Es darf danach als gesichert gelten, dass die Makrozytose dadurch zustande kommt, dass bei starker Stimulierung eine (oder zwei) Reifeteilungen übersprungen werden («skipped division»), die Retikulozyten also durch Entkernung der polychromatischen (oder basophilen) Normoblasten entstehen. Die vorzeitig ausgeschwemmten Zellen haben eine verkürzte Lebenszeit [5, 18, 69, 84, 103]; die Makrozytose ist nach wenigen Tagen nicht mehr nachweisbar. Dieser «Panikmechanismus» der Erythropoese [84] vermag immerhin, den bedrohlichen Grad der Anämie zu überwinden. Er ist grundsätzlich von der normalen Zellbildung mit Kernausschüttung der ausgereiften orthochromatischen Normoblasten und der Ausschwemmung von Erythrozyten mit normaler Lebenszeit zu unterscheiden. Wir haben deshalb diesen Modus der Zellbildung, der in seiner Auswirkung auf die periphere Erythrozytenzahl zwischen normaler (effektiver) und der ineffektiven Erythropoese [30, 41] steht, als semi-effektive Erythropoese bezeichnet [7, 10]. Er kommt auch, allerdings in quantitativ unbedeutendem Ausmass, bei ausgeglichener Zellbildung vor [57, 63, 86].

Die vorliegenden Untersuchungen haben gezeigt, dass das rasche Verschwinden der Makrozyten nicht nur auf einer Hämolyse, sondern auch auf einer Zellschrumpfung beruht. Ein indirekter Beweis hierfür ergibt sich aus dem Vergleich der mittleren Retikulozytendurchmesser mit der absoluten Retikulozytenzahl während des gesamten Versuchsablaufs. Der Retikulozytenanstieg am 5.-8. Tag nach APH kommt nicht allein durch die zunehmende Zellausschwemmung zustande, sondern auch dadurch, dass die Reifungszeit im Blut verlängert ist [31, 77], was an einer erheblichen Linksverschiebung der Reifestadien der Retikulozyten zu erkennen ist. Dadurch kommt es zu einer Kumulation; die maximalen Retikulozytenzahlen werden regelmässig nach dem Maximum der Retikulozytendurchmesser gefunden. In Anbetracht der Kumulation ist dies so zu erklären, dass die ausreifenden Retikulozyten an Grösse abnehmen [72].

## Summary

After experimental haemolytic anaemia caused by acetylphenylhydrazine there is a restoration of erythropoiesis showing a markedly macrocytic character. The more severe the anaemia the larger are the erythrocytes formed. The macrocytic cell population is replaced within a few days by a normocytic one. When the number of erythrocytes has regained the initial value cells are produced for a time which are smaller than normal. After a few days nothing more remains to be seen of the macrocytosis of the first regeneration phase. By inhibiting erythropoiesis with actinomycin D at the peak of reticulocytosis it was shown by means of the volume distribution curve that some of the macrocytes undergo haemolysis whereas others shrink to the size of normal erythrocytes. The continuous rise in the number of erythrocytes in the regenerative phase after anaemia thus conceals complex processes of overproduction, haemolysis and cell shrinkage. These results are discussed in the light of STOUTMAN's model of erythropoiesis.

## Literatur

- 1 ALLEN, E. L. and CRANFORD, D. Observations on the regulation of erythropoiesis and on cellular dynamics by  $^{59}\text{Fe}$  autoradiography in STOUTMAN: The kinetics of cellular proliferation, p. 290 (New York 1959).
- 2 AMER, E. Durchmesser und Hämoglobingehalt der Erythrozyten. *Acta haemat., Basel* 15: 305 (1954).
- 3 AMER, E. Morphologische Charakteristika der Erythrozyten und ihre Deutung für funktionelle Vorgänge des roten Systems. *Wien. klin. Wochschr.* 72: 569-573 (1960).
- 4 BALDINI, M. and PANNACCIULLI, I. The maturation rate of reticulocytes. *Blood* 15: 614 (1960).
- 5 BECKER, HJ. Reiz und Reaktion bei Aktivierung der Erythropoese. Tierexperimentelle und klinische Untersuchungen zur Erythrozytenregulation. Habilitationsschrift, Frankfurt/Main (1967).
- 6 BECKER, HJ. und HARTJE, L. Untersuchungen über die Reticulocytose bei experimenteller Verdünnungsanämie. *Pflüger* 167: 17 (1966).
- 7 BECKER, HJ. und HOLLENDER, J. Die Volumenverteilungskurve der Erythrozyten in der klinischen Diagnostik. *Verh. d. sch. Ges. inn. Med.* 73: 419 (1967).
- 8 BECKER, HJ. und KRECHT, L. H. Über die Reticulocytenregulation bei Aktivierung der Erythropoese. *Verh. d. sch. Ges. inn. Med.* 72: 25 (1966).
- 9 BECKER, HJ. und SPENGLER, D. Die Verdünnungsanämie. *Acta haemat., Basel* 35: 1 (1966).
- 10 BECKER, HJ. und STRAUSS, F. Makrozytose und sekundäre Erythropoese bei experimenteller hämolytischer Anämie. *Hämatologie und Bluttransfusion* 8: 33 (1967).
- 11 BRASSMAN, S. E. Reticulocytosis and counting of reticulocytes. *Med. Clin. N. A.* 67: 170 (1963).
- 12 V. BRUNN, J. Über das Wesen der Hypochromie. *Z. ges. inn. Med.* 3: 331 (1948).
- 13 BROWN, H. DNA, RNA and protein synthesis after acute severe haemolysis: a picture of erythropoiesis at the combined morphological and molecular levels. *Ann. N. Y. Acad. Sci.* 119: 523 (1964).
- 14 BROWN, H., LUCHE, J. R., SCARF, J. L. and MIZZERT, R. L. Synthesis of hemoglobin in relation to maturation of erythroid cells. *Nature Lond.* 197: 517 (1962).
- 15 BROWN, H. and WELLS, A. Hemoglobin synthesis in relation to erythroid cell maturation. *Proc. 9th Congr. europ. Soc. Haemat., London 1963*, p. 83. Karger, Basel/München/New York 1963.

Diese Hypothese, die die Hämoglobinkonzentration in den Erythrozyten in den Mittelpunkt der Erythrokinetik stellt, ist u. E. von besonderem Interesse in einem grosseren biologischen Zusammenhang vergleicht man das mittlere Zellvolumen (MCV), den Hämoglobingehalt ( $Hb_E$ ) und die Hämoglobinkonzentration (MCHC) bei grosseren Zahl von Säugetier-Erythrozyten, dann findet man verschiedene MCV- und  $Hb_E$ -Werte, während die MCHC-Werte gering schwanken. PONDER [74] hat diese Indices von 21 verschiedenen Säugetieren zusammengestellt: die Werte des MCV lagen zwischen 14 und  $84 \mu m^3$ , die des  $Hb_E$  zwischen 7 und 26 pg, die MCHC-Werte schwankten dagegen nur zwischen 30 und 35%. JUNG [47] hat auf Hinweis auf die Studien von PERUTZ [73] darauf hingewiesen, dass ein Hämoglobinmolekül zur optimalen Funktion des Gasaustausches einen Rotationsraum braucht; die Grenzkonzentration, bei der ein Hämoglobinmolekül gerade noch dieser Rotationsraum zugefügt steht, beträgt 34%. Bei dieser Konzentration besitzt ein Erythrozyt die höchste Sauerstoffkapazität. Eine Steigerung der Hämoglobinkonzentration würde die hohe Reaktionsgeschwindigkeit des Farbstoffs im Zellinnern, aber auch das Diffusionsvermögen für Gase einschränken. Der gleiche Parameter, der sowohl in der Säugetierreihe als auch beim Menschen unter physiologischen und pathologischen Bedingungen weitgehend konstant ist [3, 12, 23, 39, 71] steht damit im Mittelpunkt der Vorstellungen über die Regulation der Erythropoese, nach der die Erythropoetin-gesteuerte Hämoglobinsynthese bei Erreichen einer kritischen Konzentration der Hämoglobinsynthese hemmt, eine weitere Zellteilung verhindert und die Ausschwemmung der Retikulozyten einleitet.

### Zusammenfassung

Nach experimenteller hämolytischer Anämie durch Acetylphenylhydrazin kommt es zu einer ausgeprägt makrozytären Regeneration der Erythropoese. Die makrozytären Erythrozyten sind um so grösser, je schwerer die Anämie ist. Die makrozytäre Phase wird nach wenigen Tagen von einer normozytären abgelöst. Wenn die Erythrozytenzahl den Ausgangswert wieder erreicht hat, werden vorübergehend Zellen gebildet, die kleiner als normal sind. Die Makrozytose der ersten Regenerationsphase ist bereits nach 3 bis 5 Tagen nicht mehr nachweisbar. Bei Hemmung der Erythropoese durch Actinomycin D auf dem Höhepunkt der Retikulozytose konnte mit Hilfe der Volumenveränderung nachgewiesen werden, dass die Makrozyten teilweise hämolytisch werden, teilweise aber auch zu normal grossen Erythrozyten schrumpfen. Hinter dem steilen Anstieg der Erythrozytenzahl in der Regenerationsphase der Anämie verbergen sich somit komplexe Vorgänge von Mehrproduktion, Hämolyse und Zellschrumpfung. Die Ergebnisse werden im Zusammenhang mit dem Modell der Erythropoese von STOKESMAN diskutiert.

- 39 HALLBERG, L. Blood volume, hemolysis and regeneration of blood in pernicious anemia. *Scand. J. clin. Lab. Invest.* 7, Suppl. 1<sup>o</sup> 1 (1955)
- 40 HANNA, I. R. A., TARRANT, R. G., and LAMERTON, L. F. Shortening of the cell-cycle time of erythroid precursors in response to anemia. *Brit. J. Haemat.* 15: 381 (1969)
- 41 HAURANT, F. I. and TOCANTINS, L. M. Ineffective erythropoiesis. *Amer. J. Med.* 31: 519 (1961)
- 42 HEILMEYER, L. Diskussionsbemerkung zu HARVEY. Beobachtungen über Achromocyten. *Schweiz. med. Wochr.* 79: 844 (1949)
- 43 HEILMEYER, L. und EILERS, T. Der kryptogene Erythrozytenmangel. *Schweiz. med. Wochr.* 78: 975 (1948)
- 44 HEILMEYER, L. und WESTERLINGS, R. Reifungsstudien an überlebenden Reticulocyten *in vivo* und ihre Bedeutung für die Schätzung der täglichen Hämoglobinproduktion *in vivo*. *Z. klin. Med.* 121: 361 (1932)
- 45 HEINZA, M. E. and GOLDWASSER, E. Facilitated iron entry into marrow cells. An induced permease-like activity. *Fed. Proc.* 25: 234 (1966)
- 46 INGRAM, M. Frequency distribution histograms and MCV changes of various fractions of erythrocyte populations. *Bibl. haemat.* 24: 37 (1966)
- 47 JUNO, F. Strukturprobleme am roten Bluthörperchen. *Naturwissenschaften* 57: 229-234 (1970)
- 48 KAUFMANN, W. und MÜLLER, A. A. Expansion des Plasmavolumens nach rascher Verminderung der zirkulierenden Pflutmenge. *Z. Anat. Forsch.* 6: 719 (1953)
- 49 KEIGHTLEY, G. and LOWY, P. H. Actinomycin and erythropoiesis and the production of erythropoietin in mice. *Blood* 27: 637 (1966)
- 50 KETTEL, H. G., BERMAN, H., JONES, H., and MACLACHLAN, E. The chemical composition of normal red blood cells, including variability among centrifuged cells. *Blood* 19: 370 (1955)
- 51 KILMANN, S. A. On the size of normal human reticulocytes. *Acta med. scand.* 177: 579 (1964)
- 52 KLEMA, R. und ROSENGER, H. Untersuchungen über Färbbarkeit, Resistenz und Formeigenschaften der menschlichen Reticulocyten. *Folia haemat.* Lpz. 51: 414 (1934)
- 53 KRAVITZ, S. R. and GOLDWASSER, E. On the mechanism of erythropoietin-induced differentiation. II. The effect on RNA-Synthesis. *Biochim. biophys. Acta* 133: 325 (1965)
- 54 KRAVITZ, L. M., ICHIM, I., and KRAVITZ, T. Effect of erythropoietin upon hemoglobin biosynthesis. *Ann. N.Y. Acad. Sci.* 149: 475 (1968)
- 55 KUNZER, W. und ARND, E. Zur Frage der Hämoglobinarmen Zellen im Knochentumor (Achromocyten, Substantiaochromocyten). *Z. Kinderheilk.* 63: 601 (1950)
- 56 LAJTHA, L. G. Recent studies in erythroid differentiation and proliferation. *Medicine* 41: 675 (1964)
- 57 LAJTHA, L. G. and OLIVER, R. Studies on the kinetics of erythropoiesis. A model of the erythron. In: WOLSTENHOLME and O. CONWAY. *Hemopoiesis*, Ciba Found. Symp. p. 299 (London 1960)
- 58 LARSEN, G. I. The distribution of red cell diameters in liver disease. An investigation of the maturation of the erythrocyte. *Acta med. scand. Suppl.* 27: 1 (1948)
- 59 LEVITZELL, R. and STOWMAN, F. Regulation of erythropoiesis. VII. The determinants of red cell size in iron-deficiency states. *Pediatrics* 57: 62 (1966)
- 60 LEWIS, J. B. and ROSSIGNOL, H. A comparison of amino acid incorporation into the hemoglobin and ribosomes of marrow erythroid cells and circulating reticulocytes of severely anemic rabbits. *Biochem.* 2: 379 (1973)
- 61 LÖNN, G. W. Die Reifung des Reticulocyten. *Acta haemat., Basel* 9: 273 (1966)



- 16 BRECHER, G., JAKOBK, E. F., SCHNEIDERMAN, M. A.; WILLIAMS, G. Z., and SCHMIDT, P. J. Size distribution of erythrocytes. *Ann. N.Y. Acad. Sci.* 99: 242 (1962)
- 17 BRECHER, G. and STOHLMAN, F. Reticulocyte size and erythropoietic stimulation. *Proc. Soc. exp. Biol.* N.Y. 107: 887 (1961)
- 18 BRECHER, G. and STOHLMAN, F. The macrocyte response to erythropoietin stimulation in JACOBSON and DOYLE Erythropoiesis p. 216 (New York 1962)
- 19 BULL, B. S. On the distribution of red cell volumes. *Blood* 31: 503 (1968)
- 20 BURWELL, E. L., BRICKLEY, B. A., and FINCH, C. A. Erythrocyte life span in small animals. *Amer. J. Physiol.* 172: 718 (1953)
- 21 CANHAM, P. B. and BURTON, A. C. Distribution of size and shape in populations of normal human red cells. *Circulat. Res.* 22: 405 (1968)
- 22 CHALFIV, D. Differences between young and mature rabbit erythrocytes. *J. cell comp. Physiol.* 47: 215 (1956)
- 23 CONRAD, M. E. and CROSBY, W. H. The natural history of iron deficiency induced by phlebotomy. *Blood* 20: 173 (1962)
- 24 COOPERSMITH, A. and INGRAM, M. Red cell volume and erythropoiesis I. Age density volume relationship of normocytes. *Amer. J. Physiol.* 215: 1276 (1968)
- 25 CRUZ, W. O. Acetylphenylhydrazine anemia I. The mechanism of erythrocyte destruction and regeneration. *Amer. J. med. Sci.* 202: 781 (1941)
- 26 DLKES, P. P. and GOLDWASSER, E. On the mechanism of erythropoietin induced differentiation III. The nature of erythropoietin action on  $^{14}\text{C}$ -Glucosamine incorporation by marrow cells in culture. *Biochim. biophys. Acta* 103: 447 (1965)
- 27 ERSLEV, A. J. The effect of anemic anoxia on the cellular development of nucleated red cells. *Blood* 14: 386 (1959)
- 28 FICHEL, H., GELLESSEN, K., WALTHER, H.-W. und WEICKER, H. Der Hämoglobingehalt des Reticulozyten. *Folia haemat.* N.F. 4: 77 (1960)
- 29 FICHEL, H., v. MALLINCKRODT, A., PRANZ, M. und WEICKER, H. Die Beeinflussung der Erythrozyten- und der Reticulozytenzahl durch die Veränderungen des Plasmavolumens während der Reticulozytenkrise. *Schweiz. med. Wschr.* 89: 1069 (1959)
- 30 FINCH, C. A., COLEMAN, D. H., MOTULSKY, A. G., DONOHUE, D. M., and REIFF, R. H. Erythrokinetics in pernicious anemia. *Blood* 11: 807 (1956)
- 31 FINCH, C. A., HANSON, M. L., and DONOHUE, D. M. Kinetics of erythropoiesis. A comparison of response to anemia induced by phenylhydrazine and by blood loss. *Amer. J. Physiol.* 197: 761 (1959)
- 32 FISHER, J. W., LAJTHA, L. G., BUTTOO, A. S., and PORTEOUS, D. D. Direct effects of erythropoietin on the bone marrow of the isolated perfused hind limbs of rabbits. *Brit. J. Haemat.* 11: 342 (1963)
- 33 GALLIEN LARTIGUE, O. and GOLDWASSER, E. On the mechanism of erythropoietin induced differentiation I. The effect of specific inhibitors on hemoglobin synthesis. *Biochim. biophys. Acta* 103: 319 (1965)
- 34 GIBSON, J. G., HARRIS, A. W., and SWIGERT, V. W. Clinical studies of the blood volume VIII. Macrocytic and hypochromic anemias due to chronic blood loss, hemolysis and miscellaneous causes, and polycythemia vera. *J. clin. Invest.* 18: 621 (1939)
- 35 GLOWACKI, E. R. and MILLETTE, R. L. Polyribosomes and the loss of hemoglobin synthesis in the maturing reticulocyte. *J. molec. Biol.* 11: 116 (1965)
- 36 GUTMANN, J., HOFMANN, G., and RUTHENSTROTH BAUER, G. Exact methods for measuring the volume distribution of erythrocytes on the basis of the Coulter principle. *Bibl. haemat.* 24: 42 (1966)
- 37 HÄNZEL, U. Zur Achromozytenfrage. *Acta haemat.* Basel 3: 30 (1950)
- 38 HAHN, L., BALFOUR, W. M., ROSS, J. F., BALF, W. F., and WHIFFLE, G. H. Red cell volume circulating and total as determined by radio iron. *Science* 93: 87 (1941)

- 39 HALLBERG L. Blood volume, hemolysis and regeneration of blood in pernicious anemia. *Scand. J. clin. Lab. Invest.* 7 Suppl. 16 1 (1955)
- 40 HANNA, I. R. A., TARRATT R. G., and LAMERTON L. F. Shortening of the cell-cycle time of erythroid precursors in response to anaemia. *Brit. J. Haemat.* 16 381 (1969)
- 41 HAUBRANT, F. I. and TOCANTINS, L. M. Ineffective erythropoiesis. *Amer. J. Med.* 31 519 (1961)
- 42 HEILMEYER L. Diskussionsbemerkung zu HÄHNEL. Beobachtungen über Achromocyten. *Schweiz. med. Wochschr.* 79 844 (1949)
- 43 HEILMEYER L. und EILERS T. Der kryptogene Erythrozytenumsatz. *Schweiz. med. Wochschr.* 78 975 (1948)
- 44 HEILMEYER L. und WESTLINDER R. Reifungsstudien an überlebenden Reticulocyten *in vitro* und ihre Bedeutung für die Schätzung der täglichen Hämoglobinproduktion *in vivo*. *Z. klin. Med.* 171 361 (1957)
- 45 HENDA M. F. and GOLDWATER L. Facilitated iron entry into marrow cells. An induced permeability-like activity. *Fed. Proc.* 25 284 (1966)
- 46 INGRAM M. Frequency distribution histograms and MICN changes of various fractions of erythrocyte populations. *Bibl. haemat.* 24 37 (1966)
- 47 JUNG J. Strukturprobleme am roten Blutkörperchen. *Naturwissenschaften* 37 229 234 (1950)
- 48 KAUFMANN W. und MEYER A. A. Expansion des Plasmavolumens nach rascher Verminderung der zirkulierenden Blutmenge. *Z. Kreislaufforsch.* 47 719 (1958)
- 49 KEMPLEY C. and LOWY P. H. Actinomycin and erythropoiesis and the production of erythropoietin *in vivo*. *Blood* 27 637 (1966)
- 50 KESTEL H. C., BERMAN H., JONES, H., and MACLACHLAN F. The chemical composition of normal red blood cells including variability among centrifuged cells. *Blood* 10 370 (1955)
- 51 KILMANN S. A. On the size of normal human reticulocytes. *Acta med. scand.* 170 579 (1961)
- 52 KISMA, R. und ROSENBERG H. Untersuchungen über Färbbarkeit, Reiztendenz und Formvermögen der menschlichen Reticulocyten. *Folia haemat. Lpz.* 51 414 (1934)
- 53 KRAVITZ S. R. and GOLDWATER F. On the mechanism of erythropoietin-induced differentiation II. The effect on RNA-Synthesis. *Biochim. biophys. Acta* 103 3 5 (1965)
- 54 KRAVITZ, L. M., IUCHI, L., and KRAVITZ, T. Effect of erythropoietin upon hemoglobin biosynthesis. *Ann. N.Y. Acad. Sci.* 119 423 (1968)
- 55 KUNZER W. und ARND E. Zur Frage der hämoglobinnarmen Zellen im Kindesalter (Achromocytocyten, Achromocyten, Substanzschatten). *Z. Kinderheilk.* 68 601 (1950)
- 56 LASTHA, I. C. Recent studies in erythroid differentiation and proliferation. *Medicine* 41 6, 5 (1964)
- 57 LASTHA, I. C. and OLIVER R. Studies on the kinetics of erythropoiesis. A model of the erythron in Wistar-Kyoto and O'Connor Haemopoiesis. *Ciba Found. Symp.* p. 787 London 1960
- 58 LARSEN C. The distribution of red cell diameters in liver disease. An investigation of the maturation of the erythrocyte. *Acta med. scand. Suppl.* 221 1 (1948)
- 59 LEVITZKAL R. and STROMMAN F. Regulation of erythropoiesis. VII. The determinants of red cell size in iron deficiency anemia. *Pediatrics* 35 62 (1965)
- 60 LEWIS J. B. and BOWMAN, H. A comparison of amino acid incorporation into the hemoglobin and ribosomes of marrow erythroid cells and circulating reticulocytes of severely anemic rabbits. *Biochem.* 9 329 (1963)
- 61 LÖWEN C. W. Die Reifung des Reticulocyten. *Acta haemat. Basel* 36 273 (1966)

- 62 LONDON, I M, SHEMIN, D and RITTENBERG, D Synthesis of heme *in vivo* by the immature nonnucleated mammalian erythrocyte *J biol Chem* 183 749 (1950)
- 63 LONDON, I M, WEST, R., SHEMIN, D, and RITTENBERG, D On the origin of heme pigment in normal man *J biol Chem* 181 351 (1950)
- 64 LOWENSTEIN, L M Studies on reticulocyte division *Exp. Cell Res* 17 336 (1959)
- 65 LUSHBAUGH, C. C., BASMANN, N J, and GLASCOCK, G Electronic measurement of cellular volumes. II Frequency distribution of erythrocyte volumes *Blood* 20 241 (1962)
- 66 MATTERN, C. F T, BRACKETT, F S, and OLSON, B J Determination of number and size of particles by electrical gating *Blood cells J appl Physiol* 10 56 (1957)
- 67 MORSE, B S and STROHLMAN, F Regulation of erythropoiesis XVIII The effect of vincristine and erythropoietin on bone marrow *J clin Invest* 45 1241 (1966)
- 68 MURPHY, W P Production of reticulocytes erythrocytes and hemoglobin in anemia *Arch intern Med* 57 829 (1933)
- 69 NEUBERGER, A and NIVEN J S F Haemoglobin formation in rabbits *J Physiol* 112 292 (1951)
- 70 ORTIEV, G F and INGRAM, M Changes in kinetics of erythropoiesis as related in frequency distribution of erythrocyte volumes of acutely bled dogs *Univ. of Rochester, Atomic Energy Project UC-48*
- 71 OSGOOD, E F, HASKINS, H D, and TROTMAN, F. E. The value of accurately determined color, volume and saturation indexes in anemias *J Lab clin Med* 17 859 (1932)
- 72 PADLINO, W Variations of the mean diameter in the ripening of the erythrocyte *Acta med scand* 136 141 (1949)
- 73 PERUTZ, M F Submicroscopic structure of red cell *Nature, Lond* 161 204 (1948)
- 74 PONDER, E. Hemolysis and related phenomena (New York 1948)
- 75 POWNER, E R and BERMAN, L Effect of erythropoietin on DNA Synthesis by erythroblasts *in vivo* *Blood* 30 189 (1967)
- 76 RAPOPORT, S, GUEST, G M, and WINO, M Size, hemoglobin content, and acid-soluble phosphorus of erythrocytes of rabbits with phenylhydrazine-induced reticulocytosis *Proc. Soc exp Biol, N Y* 57 344 (1944)
- 77 REIF, R H, NUTTER, J Y, DONOHUE D M, and FRICH, C. A The relative number of marrow reticulocytes *Amer J clin Path* 30 199 (1958)
- 78 REISSMANN, K R and ITO, K Selective eradication of erythropoiesis by actinomycin D as a result of interference with hormonally controlled effector pathway of cell differentiation *Blood* 28 201 (1966)
- 79 REISSMANN, K R and ITO, K Selective inhibition of erythroid cell differentiation in the mouse by low dose of actinomycin D *Ann N Y Acad Sci* 149 193 (1968)
- 80 REIZENSTEIN, P G and OGATA, K Haemoglobin content of rat reticulocytes formed during rapid blood regeneration *Acta med scand* 159 439 (1957)
- 81 SEIF, M Reticulocyte studies The liberation of red blood corpuscles from the bone marrow into the peripheral blood and the production of erythrocytes elucidated by reticulocyte investigations *Acta med scand Suppl* 282 1 (1953)
- 82 SENO, S, MIYAHARA, M, ASAKURA, H, OCHI, O, MATSUOKA, K, and TOYAMA, T Macrocytosis resulting from early denucleation of erythroid precursors. *Blood* 24 582 (1964)
- 83 STROHLMAN, F Humoral regulation of erythropoiesis VI Mechanism of action of erythropoietin in the irradiated animal *Proc Soc exp Biol, N Y* 107 751 (1961)
- 84 STROHLMAN, F Humoral regulation of erythropoiesis VII Shortened survival of erythrocytes produced by erythropoietin or severe anemia *Proc Soc exp Biol, N Y* 107 884 (1961)
- 85 STROHLMAN, F Regulation of erythropoiesis *Trans N Y Acad Sci* 24 312 (1962)

86. STOHLMAN, F. Humoral regulation of erythropoiesis. XIV. A model for abnormal erythropoiesis in Thalassemia. *Ann. N.Y. Acad. Sci.* 119: 578 (1964)
87. STOHLMAN, F., BELAND, A., and HOWARD, D. Mechanism of macrocytic response to erythropoietin. *J. clin. Invest.* 42: 934 (1963).
88. STOHLMAN, F. and BRECHER, G. Regenerative macrocytosis in experimental phenylhydrazine anemia. *J. clin. Invest.* 40: 1081 (1961).
89. STOHLMAN, F., BRECHER, G., and MORRIS, R. R. Humoral regulation of erythropoiesis. VIII. The kinetics of red cell production and the effect of erythropoietin, in JACOBSON and DOYLE Erythropoiesis, p. 162 (New York 1962)
90. STOHLMAN, F., FARR, S., MORSE, B., HOWARD, D., and DOROVAN, J. Regulation of erythropoiesis. XX. Kinetics of red cell production. *Ann. N.Y. Acad. Sci.* 119: 156 (1964)
91. STOHLMAN, F., HOWARD, D., and BELAND, A. Humoral regulation of erythropoiesis. XII. Effect of erythropoietin and iron on cell size in iron deficiency anemia. *Proc. Soc. exp. Biol.*, NY 113: 996 (1963)
92. STOHLMAN, F., LUCARELLI, G., HOWARD, D., MORSE, B., and LEVETZEL, R. Regulation of erythropoiesis. XVI. Cytokinetic patterns in disorders of erythropoiesis. *Medicine* 43: 651 (1964)
93. TARRUTT, R. G. Cell population kinetics of the erythroid system in the rat. The response to protracted anaemia and to continuous gamma irradiation. *Brit. J. Haemat.* 15: 9 (1969)
94. THOM, R. Erythrozytenvolumenverteilungskurve in der hämatologischen Diagnostik. *Dtsch. med. Wochschr.* 94: 617 (1969)
95. THOM, R. Persönliche Mitteilung
96. UFF, A. and LAUBACH, C. C. Some effects of electrical fields on red blood cells with remarks on electronic red cell sizing. *Brit. J. Haemat.* 15: 527 (1968)
97. WALSH, R. J., THOMAS, E. D., CHOW, S. K., FLUJARTY, R. G., and IRVING, C. A. Iron metabolism. Heme synthesis in vivo by immature erythrocytes. *Science* 110: 396 (1949)
98. WEIN, R. I. and BOWLER, A. J. The influence of hemoglobin concentration on the distribution pattern of the volumes of human erythrocytes. *Blood* 29: 297 (1967)
99. WIECKER, H. Masse-, Mengen- und Zeitrelation zwischen Reticulocyten und Erythrocyten. *Folia haemat.*, Lpz. 20: 329 (1959)
100. WIECKER, H., FRISCH, H. und WILD, M. Hämoglobingehalt und Hämoglobinkonzentration des Reticulocyten. *Klin. Wochschr.* 33: 962 (1955)
101. WIECKER, H. und FRISCH, H. Das Reticulocytenvolumen. *Klin. Wochschr.* 33: 1074 (1955)
102. WIECKER, H., KIJATH, I. und FRISCH, H. Achromocyten und Achromoreticulocyten. *Acta haemat.*, Basel 21: 329 (1959)
103. WILNER-ZEHAVI, T., LEAK, G., and MACER, J. Studies on the biochemical alterations of protein synthesizing apparatus in maturing rabbit reticulocytes. *Blood* 27: 319 (1966)
104. WINTER, H. and STEAD, R. P. The skewness of volume distribution curves of erythrocytes. *Aust. J. exp. Biol. med. Sci.* 43: 637 (1965)
105. WITTEKAMP, D. und REITSCH, G. Zur Frage der Beziehung zwischen Substantia granuloclammentosa und Karyom. I. Untersuchungen über den Einfluss verschiedener karyotomischer Substanzen auf die Darstellung basophiler Strukturen in jugendlichen Erythrocyten. *Z. Zellwuch.* 67: 217 (1965).

## Incorporation of $^3\text{H}$ -Uridine and $^3\text{H}$ -Leucine in Erythroid Cells of Normal and Anemic Rabbits<sup>1</sup>

MARGHERITA LO CURTO

Paediatric Clinic, University of Palermo, Palermo

It is well known that in the anoxic tissue of anemic animals a humoral factor or erythropoietin is generated, which stimulates the stem cells [4]. It has been observed in anemic rabbits [5] and in hypertransfused mice [7] that this factor operates by accelerating the differentiation of stem cells to proerythroblasts.

Already in 1959 MATOTH *et al* [11] reported some results on the effect of erythropoietin on mitosis. They incubated in normal serum bone marrow cells of rabbits made anemic by bleeding and observed that the mitotic rate of anemic bone marrow cells was higher than that of normal ones in the same conditions. The authors concluded that anemic bone marrow becomes hyperactive because of the erythropoietin stimulation *in vivo*. In order to see whether this increased mitotic activity is connected with changes in the metabolic pathway, we have undertaken a study of  $^3\text{H}$ -uridine and  $^3\text{H}$ -leucine incorporation in erythroid cells of normal and anemic rabbits.

### Methods

Two normal and two anemic rabbits weighing approximately 3 kg have been used. The animals were made anemic by phenylhydrazine, following the method of Borsook *et al* [2]. In the anemic animals the reticulocyte count was 70-80%, and the bone marrow smears stained with May Grünwald-Giemsa showed erythroid hyperplasia.

Bone marrow was obtained from the femur. In each experiment 1 ml of bone marrow was suspended in 1 ml of Eagle's medium and then incubated at 37° C in silicon covered conical tubes.

<sup>1</sup> The experimental part of this work has been carried out at the Institute of Animal Morphology, Free University of Brussels.

Fig. 1. Range of experiments. Figure 1 shows typical results for each experiment. (1) The rate of  $^3\text{H}$ -uridine

$^3\text{H}$ -uridine, since it acts on the DNA-dependent RNA [9] (3) The rate of protein synthesis was studied by adding  $^3\text{H}$  leucine, at 5  $\mu\text{C}/\text{ml}$  concentration (spec. act. 500  $\text{mc}/\text{mm}$ ), to the culture medium [3] (4) Since puromycin releases the labelled protein from ribosomes [1, 12] we studied the ribosomal activity by adding puromycin at 1  $\mu\text{g}/\text{ml}$  concentration to a replica tube with  $^3\text{H}$  leucine in the medium. Following 3 hours of incubation some smears were made on gelatin coated slides and fixed in methanol. The slides were coated with nuclear emulsion Ilford K 5, and, after the required exposure time at 4° C, autoradiographs were developed and stained with May-Grünwald-Giemsa, for differential counts.

For each stage of erythroid line, a minimum of 100 elements were examined. The number of grains was counted visually and the labelling index was calculated in the proerythroblasts, basophil, polychromatic and orthochromatic erythroblasts in the slide of each experiment.

### Results

The results are shown in figures 1-3. As can be seen, the incorporation of  $^3\text{H}$ -uridine and  $^3\text{H}$ -leucine in erythroid cells decreases as maturation proceeds [8-6], the decrease being however smaller for  $^3\text{H}$ -leucine incorporation. From the results of figure 3, one can see that the uptake of  $^3\text{H}$ -uridine and  $^3\text{H}$ -leucine is considerably higher in




Fig. 1a. Normal rabbit; b anemic rabbit. —  $^3\text{H}$ -uridine uptake, - -  $^3\text{H}$ -uridine uptake in presence of actinomycin D. P proerythroblasts, B basophil erythroblasts, P<sub>2</sub> polychromatic erythroblasts, O orthochromatic erythroblasts.

\* Actinomycin D was a gift from Merck-Schering-Deben.

proerythroblasts of anemic than in those of normal animals. In more mature erythroblasts the above effect is less conspicuous.

Actinomycin D reduces the incorporation of the  $^3\text{H}$ -uridine precursor by about 50% (fig 1), especially in immature stages. Puromycin acts on  $^3\text{H}$ -leucine incorporation of all stages of erythroid line, but its effect is mainly exerted on the proerythroblasts of anemic animals (fig 2).




Fig 2a Normal rabbits, b anemic rabbits —  $^3\text{H}$  leucine uptake, ---  $^3\text{H}$  leucine uptake in presence of puromycin. Abbreviations: see figure 1.




Fig 3a  $^3\text{H}$  uridine uptake, b  $^3\text{H}$  leucine uptake — Normal rabbits, --- anemic rabbits. Abbreviations: see figure 1.

### Discussion

The results show that the rate of nucleic acid and protein synthesis of erythroid cells is higher in anemic animals. Actinomycin D reduces the increase of nucleic acid synthesis. It is known that actinomycin D acts on the DNA dependent RNA [9]. TORELLI *et al.* [15] reported that the rapidly degraded RNA observed in immature erythroid cells is an unstable messenger RNA synthesized in the more immature stages, that does not act as 'a template' for protein synthesis [16].

Early experimental observations [13] indicate that erythropoietin containing cultures of bone marrow cells show an increase in the rate of  $^{14}\text{C}$ -uridine uptake during 4 hours of incubation, while in the control cultures a decrease of this rate is observed. Actinomycin D added to the culture prevented the above mentioned increase. It thus appears that erythropoietin acts on the actinomycin sensitive RNA fraction, i.e. m RNA [9]. One may thus assume that the same m RNA fraction is increased in the erythroid cells of anemic animals, for the erythropoietin stimulation *in vivo*.

Since protein synthesis is mediated through m RNA [10] and it provides differentiation, it seems reasonable to conclude that in anemic animals the effect of differentiation may be similar to the effect on mitosis reported by MATHOT *et al.* [11]. According to the experimental results mentioned in the introduction [5] one can believe that erythropoietin is the factor mainly involved in stimulative action on the erythroid cells of anemic animals.

The mechanism of action of erythropoietin has been recently studied by STOHLMAN *et al.* [14], who concluded that it acts not only by differentiating the precursor cells, but also by accelerating the hemoglobin synthesis in the differentiated erythroid precursor still capable of synthesizing RNA. In agreement with this model, the increased metabolism found in the present experiments can be related to the stimulative action of erythropoietin on the proerythroblasts of anemic animals.

**Acknowledgments.** The author expresses her gratitude to Drs. A. FIORE, and F. GAVOTTO for their help and criticism.

### Summary

The incorporation of  $^3\text{H}$ -uridine and  $^3\text{H}$ -leucine in erythroid cells of normal and anemic rabbit has been studied by autoradiography. The rate of m RNA and protein synthesis is higher in proerythroblasts of anemic animals. The increased metabolism can be related to the stimulative action of erythropoietin on the cells of anemic animals.



## References

- 1 ALLEN, D and ZAMECHNIK, P C. The effect of puromycin on rabbit reticulocyte ribosomes. *Biochim. biophys Acta* 55 865 (1962)
- 2 BORSOOK, C L., DEASY, A J., HAEGEN SMIT, KEIGHLEY, G and LOWY, P H. Incorporation *in vitro* of labelled amino acids into proteins of rabbit reticulocytes. *J. biol. Chem.* 196 669 (1952)
- 3 DROZ, B and WARSZAWSKY, H. Reliability of the radioautographic technique for the detection of newly synthesized protein. *J. Histochem. Cytochem.* 11 427 (1963)
- 4 ERSLEV, A J. Physiologic control of red cell production. *Blood* 10 954 (1955)
- 5 ERSLEV, A J. The effect of anemic anoxia on the cellular development of nucleated red cells. *Blood* 14 386 (1959)
- 6 FICQ, A., GAYOSTO, V et ERRERA, M. Incorporation *in vitro* de glycine- $^{14}\text{C}$  dans les cellules individuelles de la moelle osseuse. *Exp. Cell Res.* 6 69 (1954)
- 7 FILMANOWITZ, E. and GUNNEY, C. W. Studies on erythropoiesis. XVI. Response to a single dose of erythropoietin in polycythemic mouse. *J. Lab. clin. Med.* 57 65 (1961)
- 8 GAYOSTO, F., FICQ, A. et ERRERA, M. Incorporation *in vitro* de glycine- $^{14}\text{C}$  dans les cellules individuelles de la moelle osseuse. *Exp. Cell Res.* 6 238 (1954)
- 9 GOLDBERG, I H and RADINOWITZ, M. Actinomycin D inhibition of DNA-dependent synthesis of RNA. *Science* 136 315 (1962)
- 10 JACOB, F and MONOD, J. Genetics regulatory mechanism in the synthesis of proteins. *J. molec. Biol.* 3 318 (1961)
- 11 MATOTIH, Y and BEN PORATH, E. Effect of erythropoietin on the mitotic rate of erythroblasts in bone marrow cultures. *J. Lab. clin. Med.* 54 722 (1959)
- 12 MORRIS, A J., ALINOWITZ, R., FAVELUKES, S and SCHWEET, R. Inhibition of protein synthesis by puromycin. *Biochemistry* 2 1034 (1963)
- 13 SANFORD, B., KRAUTZ, S B and GOLDWASSER, E. On the mechanism of erythropoietin induced differentiation. II. The effect on RNA synthesis. *Biochim. biophys. Acta* 103 325 (1965)
- 14 STOHLMAN, F Jr., EBBE, S., MORSE, B., HOWARD, D and DONOVAN, J. Regulation of erythropoiesis. XX. Kinetics of red cell production. *Ann. N.Y. Acad. Sci.* 149 156 (1968)
- 15 TORELLI, V., GROSSI, G., ARTUSI, T., EMILIA, G., ATTIVA, I R. and MAURI, C. RNA and protein metabolism in normal human erythroblasts and granuloblasts. *Acta haemat., Basel* 32 271 (1964)
- 16 TORELLI, V., ARTUSI, T., GROSSI, G., EMILIA, G. and MAURI, C. An unstable RNA in normal human erythroblasts. *Nature, Lond.* 207 755 (1965)

## Hereditary Methemoglobinemia due to Diaphorase Deficiency

Report of a Case of Heterozygote Presenting with Cyanosis After Birth

S S LO, W H HIRTZIG and H R MARTI

Department of Pediatrics (Director Prof A PRADER) University of Zurich, Zurich and  
Department of Medicine (Director Prof H R MARTI) Kantonsspital Aarau, Aarau

Methemoglobinemia is characterized by a diffuse slate gray cyanosis and caused by excessive amounts of methemoglobin in the erythrocytes. This disorder may result from a) exposure to oxidizing agents and drugs such as nitrates, aniline derivatives, resorcin, and sulfonamides, b) genetically determined deficiency of one of the enzymes required for reduction of methemoglobin to hemoglobin, and c) genetically determined abnormalities in the structure of hemoglobin molecule (HbM) which increase the susceptibility to oxidation and decrease the susceptibility to reduction.

About 250 cases of hereditary methemoglobinemia, presumed or proved to be due to DPNH methemoglobin reductase (diaphorase)

have been reported since 1844 [1]. The condition is trans-

mitted as an autosomal recessive trait. Homozygotes are not cyanotic and have normal levels of methemoglobin [2] with moderate degrees of enzyme deficiency. Heterozygotes with high concentrations of methemoglobin are uncommon. However during the last years a small number of cases have been described [3, 9, 15, 17]. We have recently had an opportunity in observing a heterozygote presenting with cyanotic attacks and a high level of methemoglobin after birth who at the same time had a typical anemia.

### Methods

Routine hematological and biochemical investigations were performed by standard methods.


Methemoglobin was determined by the standard method of FELLYN and MALLOY [6]. For the determination of DPNH methemoglobin reductase the method of SCOTT [18] was used. The conventional methods for the evaluation of the reduction of methemoglobin in intact erythrocytes [14] and for the determinations of glycolytic enzymes in hemolysates [4] have been described elsewhere. The capacity of methemoglobin reduction during red cell incubation with lactate is expressed in mg reduced hemoglobin per 100 mg methemoglobin per hour. For the determination of reduced glutathione the method of STRANSON [19] was used. The presence of HbM was excluded by starch block electrophoresis pH 6.5, pH 7.0 and pH 8.6 and by spectral analyses of methemoglobin and methemoglobin-cyanide.

### Case History

B.D. (J No. 8595/66), a male infant of Italian origin, born in 1966 was admitted to us at 12 days old for further investigations of his cyanotic attacks. He is only child and was born at full term, weighing 4.5 kg, after a normal pregnancy. There was no history of drug-taking, exposure to toxic agents which may enhance the oxidation of hemoglobin, diarrhoea or hemolysis during pregnancy. The infant appeared to be well after birth until 4 days old when he was noticed to have cyanosis of the lips which gradually became more prominent. Two days later he developed dyspnoea. However, the cyanosis and breathlessness seemed to be transiently improved by oxygen. On admission he had cyanosis of the lips, hands and feet which was more marked when the child was crying. Apart from the irritability and jitteriness there was no positive evidence, clinically nor radiologically, of heart or lung diseases. Preliminary investigations showed: Hb 19 g%, of which 12.5% methemoglobin, hematocrit 60%, serum Ca 6.8 mg%, blood sugar 97 mg%. Further investigations on several occasions showed the following results:

*Methemoglobinemia* The results are summarized in table 1 and figure 2.

*Hypocalcemia* Serum Ca 6.8 mg%, Phosphate 6.9 mg%, Alk. phosphatase 137 IU. Serum protein 5.7 g%. Blood urea 17.5 mg%. Urinary Ca excretion 3 mg/kg body weight/24 h. Urin phosphate excretion 31.7 mg/kg body weight/24 h. Creatinin clearance 62 ml/min.



- Father, heterozygote
- Propositus, heterozygote with transient methemoglobinemia
- ○ Said to have cyanosis but not investigated

Fig. 1. Genealogical tree of family.




Fig. 2. Levels of hemoglobin, methemoglobin, diaphorase, and serum Ca in patient B. D.

Plasma clearance 8.3 ml/min. Results of parathyroidectomy indicated the presence of hypoparathyroidism. X-rays of the skull normal. EEGs negative.

**Course:** Fig. 2. Without specific treatment the methemoglobin levels gradually fell from 12.5% Hb 14 g% at 12 days old to 6.5% Hb 14 g% at 4 weeks old, and to nil Hb 12 g% at 6 months old during which the cyanosis also disappeared. On admission the patient was given calcium  $\text{gluconate}$  on three occasions and the serum Ca rose to a maximum of 7.5 mg%. At 1 month old he was given vitamin D 20,000 units daily for a fortnight and following this the serum Ca became normalised.

**Family history:** The patient's mother stated that her husband has cyanosis of the lips, cheeks, and both hands when he is annoyed and when the weather is cold. Other members of the family on the paternal side are said to have similar phenomena. Unfortunately we are not in the position to investigate the rest of the family as the parents are not willing to disclose our findings to them. If these vague but true can be accepted as evidence of methemoglobinemia we may construct a family tree as shown in figure 1.

### Discussion

Normally small amounts of methemoglobin are being constantly produced [16]. In normal adults methemoglobin levels average 0.62% of the total hemoglobin, with a range of 0 to 1.9% [6]. Slightly higher

Table 1 Results of investigations from the patient and his parents on different occasions.

|  | Patient   |          |             |           | Father    |          |             |           | Mother    |            |               |  |
|--|-----------|----------|-------------|-----------|-----------|----------|-------------|-----------|-----------|------------|---------------|--|
|  | July 1966 | Dec 1966 | August 1968 | Sept 1969 | July 1966 | Dec 1966 | August 1968 | Sept 1969 | July 1966 | Sept. 1969 | Normal values |  |
| Hemoglobin, g <sup>100</sup>   | 14        | 12       | 13          | 13.5      | 15        | -        | 15.5        | 15.2      | 13        | 12.5       |               |  |
| Reticulocytes, %   | 2         | 2        | 3           | 2.4       | -         | -        | 2.3         | 2.9       | -         | 4.5        |               |  |
| Hematocrit, %  | 40        | -        | 40          | 41.0      | -         | -        | 49.0        | 48.0      | -         | 39.0       |               |  |
| Methemoglobin %  | 6.5       | 0        | 0.69        | 0.81      | 0         | 0        | 0           | 0.61      | 0         | 0.47       |               |  |
| Diphosphatase, IU  | 86        | 88       | 68          | 90.0      | 102       | 85       | 85.0        | 97.0      | 150       | 141        | 120-200       |  |
| Hemoglobin M, %  | 0         | 0        | 0           | 0         | 0         | 0        | 0           | 0         | 0         | 0          |               |  |
| Capacity of methemoglobin reduction<br>mg <sup>100</sup> /hour during incubation with<br>lactate to hemoglobin | -         | -        | 16          | -         | -         | -        | 4.7         | -         | -         | -          | 8-12          |  |
| Glucose-6-phosphate dehydrogenase,<br>IU   | 16        | 21       | 20          | 18.0      | -         | 17       | 20.0        | 15.0      | -         | 14.0       | 12-22         |  |
| 6-phosphogluconic dehydrogenase, IU  | -         | 16       | 19          | 16.0      | -         | 22       | -           | 17.0      | -         | 18.0       | 10-16         |  |
| Glutathione reductase, IU  | -         | 16       | 12          | 11.0      | -         | 12       | -           | 11.0      | -         | 11.0       | 7-14          |  |
| Hexokinase, IU   | -         | -        | 16          | 21        | -         | -        | -           | 1.5       | -         | 1.9        | 0.8-2         |  |
| Phosphoglyceromutase, IU   | -         | -        | 34          | 64.0      | -         | -        | -           | 54.0      | -         | 73.0       | 20-38         |  |
| Pyruvate kinase IU   | -         | -        | 40          | 34.0      | -         | -        | -           | 39.0      | -         | 42.0       | 24-56         |  |
| Reduced glutathione,<br>mg <sup>100</sup> /100 ml Lys  | -         | 59       | 66          | 63.0      | -         | 59       | -           | 69.0      | -         | 67.0       | 50-90         |  |

levels up to 4.1% of methemoglobin in newborn infants, particularly in prematures, have been found by KRAVITZ *et al* [12]. In hereditary methemoglobinemia, homozygotes have levels of methemoglobin generally exceeding 10% and they may even be as high as 60 to 70% of the total hemoglobin in severely affected children. Our patient, a heterozygote, started to have cyanotic attacks at 4 days old. At 12 days old 12.5% of the total hemoglobin was methemoglobin. Heterozygotes presenting with cyanosis and high levels of methemoglobin are extremely rare and provide further evidence, that the deficiency in DPNH-methemoglobin reductase is a heterogenous disorder. Our observation may be the third heterozygote known in the literature to show a high level of methemoglobin with cyanosis and reduced DPNH-methemoglobin reductase in the newborn period, the other two cases were published by RICHARD and MOINET [17] and HARPER *et al* [9] respectively.

Antimalarial drugs have recently been observed in adults to produce methemoglobinemia in heterozygotes who otherwise have normal levels of methemoglobin but abnormal DPNH-methemoglobin reductase [3]. In our case, the patient was said to have cyanosis at age 4 days. There was no relevant history during pregnancy and careful examination of the infant's environment (hospital nursery) for possible toxic agents and drugs which may give rise to methemoglobinemia was negative. Our investigations showed that in addition to methemoglobinemia the infant had hypocalcemia. At one month old his serum Ca was subnormal and 6.5% of the total hemoglobin was methemoglobin. After a fortnight course of vitamin D the serum Ca was normalized. The concentration of methemoglobin was then not determined but at 6 months old there was no methemoglobin detected and the serum Ca remained normal. Without specific treatment for his methemoglobinemia the levels of methemoglobin became normal. Could this be a coincidence or could hypocalcemia which causes no clinically detectable methemoglobinemia stress heterozygotes to produce significant methemoglobinemia in the newborn period? The answer to these questions requires further observations since this is the only case so far described.

Hereditary methemoglobinemia associated with various degrees of mental retardation has been reported in several cases [5, 7, 8, 10, 13, 21] and there has been controversy as to the cause of this association. In the case most similar to ours described by HARPER *et al* [9] with

transient methemoglobinemia in a heterozygote for diaphorase deficiency a marked mental retardation with disturbed speech development and left hand preference was observed. As possible causes the authors discuss an analogous enzyme deficiency in blood and brain; nervous system damage by hypoxia or by hyperbilirubinemia; or activation of other genes. However, none has mentioned hypocalcemia as a possible contributing factor to the neurological disability. Should we fail to recognize and alleviate the hypocalcemia in our patient, the child might have developed epileptic attacks which might or might not ultimately affect his mental state. The role of hypocalcemia in the association of methemoglobinemia and mental retardation is uncertain but certainly needs to be examined, as the latter arising from hypocalcemia is preventable.

### Summary

hemoglobinemia in heterozygotes and as a contributing factor in the association of methemoglobinemia and neurological disorders is discussed

### References

- 1 BETAI, K., STEIN, H., und TÖNZ, O. Untersuchung einer Familie mit kongenitaler Methämoglobinämie durch Reduktaseinsuffizienz. *Dtsch. med. Wochschr.* 87: 65-68 (1962)
- 2 CAWTIN, M., BRILEY, C. H. II., LAPPAY, L. J., and COHEN, J. E. Hereditary diaphorase deficiency and methemoglobinemia. *Arch. intern. Med.* 113: 578-585 (1964)
- 3 COHEN, R. J., SACIN, J. R., WICKER, D. J., and CONRAD, M. E. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. *New Engl. J. Med.* 279: 1127-1131 (1968)
- 4 DEUBELBEIN, K. A. und MARTI, H. R. Erythrocytenenzym Bestimmungen bei hämolytischen Anämien. *Praxis* 54: 402 (1965)
- 5 DINE, M. S. Congenital methemoglobinemia in the newborn period. *Amer. J. Dis. Child.* 92: 15-19 (1965)
- 6 EVELYN, K. A. and MALLOY, H. T. Microdetermination of oxyhemoglobin, methemoglobin and sulhemoglobin in a single sample of blood. *J. biol. Chem.* 127: 655 (1933)
- 7 GIBSON, R. Familial idiopathic methemoglobinemia associated with oligophrenia. *Amer. J. ment. Defic.* 61: 207 (1965)
- 8 GRAYBILL, A., LILIENTHAL, J. L., Jr., RILEY, R. L. The report of a case of idiopathic congenital methemoglobinemia. *Bull. Johns Hopk. Hosp.* 76: 155-162 (1945)
- 9 HARPER, M. A., ROBIN, H., and HARLEY, J. D. Transient infantile cyanosis in a diaphorase-deficient male. *Aust. paediat. J.* 4: 144-150 (1968)

- 10 JAFFE I R, NEWMANN C, ROTHBERG H, WILSON F T, and WEBSTER R M. Hereditary methemoglobinemia associated with severe mental retardation. *Clin. Res.* 17: 217 (1964).
- 11 JAFFE I R. Hereditary methemoglobinemia associated with abnormalities in the metabolism of erythrocytes. *Amer. J. Med.* 41: 78-93 (1966).
- 12 KRAVITZ H, ELEGANT L D, KAHN E, and KACAN B M. Methemoglobin values in premature and mature infants and children. *Amer. J. Dis. Child.* 91: 1 (1958).
- 13 LEE M H and JOLLY H. Severe congenital methemoglobinemia in an infant. *Lancet* i: 1147-1148 (1957).
- 14 MARTI H R. Normale und abnormale menschliche Hämoglobine. *Pathologie und Klinik in Einzeldarstellungen*, Vol. 13 (Springer, Berlin Göttingen Heidelberg 1963).
- 15 OZGENEL S. Hereditary methemoglobinemic cyanosis due to diaphorase deficiency in three successive generations. *Acta haemat., Basel* 37: 26-283 (1967).
- 16 PAUL, W D and KAHN E R. Methemoglobin: A normal constituent of blood. *Proc. Soc. exp. Biol. NY* 5: 55 (1944).
- 17 RICHARD J et MORNET J. A propos d'un cas des méthémoglobinémie de type récurrent. Cyanose des premiers mois chez un héterozygote. *Pédiatrie* 19: 379 (1964).
- 18 SCOTT F M. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia. *J. clin. Invest.* 39: 1176-1179 (1960).
- 19 STEVENSON T D, McDONALD B L, and ROWEN S. Colorimetric method for determination of erythrocyte glutathione. *J. Lab. clin. Med.* 5: 157 (1960).
- 20 WEBSTER DREW ET C., WEBSTER J F, and SARGENT F. Familial idiopathic methemoglobinemia associated with mental deficiency and neurological abnormalities. *Brit. med. J.* i: 114-118 (1953).



## Swiss Type Hereditary Persistence of Foetal Haemoglobin in a Case of Acquired Haemolytic Anaemia

A. L. PAWLAK and F. KOZŁOWSKA

Department of Human Genetics (Head: Prof. A. HORST) and 1st Department of Internal  
Medicine (Head: Prof. K. JASŃSKI), Medical School, Poznań

High concentrations of foetal haemoglobin (Hb F) in red blood cells has been found in several types of anaemias in adults. This may result from the diminution of  $\beta$ -chain synthesis (in  $\beta$ -thalassaemia) or from accelerated breakdown of labile  $\beta$ -chain variants of haemoglobin. The mechanisms responsible for the increase of Hb F concentration in other types of anaemias remain, however, uncertain.

On the other hand various types of hereditary persistence of Hb F synthesis were reported in which no evidence of accelerated haemolysis or anaemia has been found. Hb F contributes 14, 21 and 25% of total haemoglobin in heterozygotes for the Greek, Mongolian and African types respectively [1, 2]. In a case of homozygote of an African type *hereditary persistence of Hb F*, the latter constituted 100% of haemoglobin, yet anaemia did not occur. In all those types of the trait Hb F is present in all erythrocytes in similar concentrations. The Swiss type of hereditary persistence of Hb F differs from the former traits by lower concentrations of foetal haemoglobin in heterozygotes (1-2.5%) and its unequal concentration in individual erythrocytes. The morphology of red blood cells in Swiss type of hereditary persistence of Hb F is normal, in contradistinction to thalassaemia minor in which similar levels of Hb F occur [3, 4].

In the case to be reported in this communication Swiss type hereditary persistence of Hb F has been diagnosed on the basis of family study. In the course of an acquired haemolytic anaemia in this case high Hb F concentrations (up to 23%) were found.

### Case Report

The patient A. K., 32, housewife, was admitted to the Department of Internal Medicine in March 1968 because of anaemia and jaundice. The first symptoms of general weakness, pains of joints and jaundice occurred in November 1967. Viral hepatitis was diagnosed at that time, but was not confirmed following 3 weeks hospitalization. At the time of admission no enlargement of the spleen or liver was found. She did not report to have any haematological disorder before.

The results of determinations of total haemoglobin, Hb 1, total serum bilirubin and reticulocytes are given in figure 1. The red blood cell mean corpuscular volume was  $100 \mu\text{m}^3$ . No direct reacting bilirubin was found in the serum in the course of the study. The results of the direct and the indirect Coombs' tests were positive (6.3 G, direct Coombs test titre 1:32). The osmotic fragility of erythrocytes was increased (6.3 G, 0.7–0.46% NaCl). The orthochromatic erythroblasts composed 6% of nucleated cells in the peripheral blood (6.3 G), and numerous spherocytes, macrocytes and megaloblasts were also present. Serum iron was  $170 \mu\text{g}\%$ . The  $T_{1/2}$  of  $^{51}\text{Cr}$  labelled erythrocytes was 6.5 days and the index of activities above the spleen and above the liver was 3.6 (normal values 1.5–2.4, July 28–30, 1968).<sup>1</sup> The activities of glucose-6-phosphate dehydrogenase and of the phosphoenolpyruvate kinase in erythrocytes were slightly elevated.

An immune acquired haemolytic anaemia has been diagnosed on the basis of the results reported. Patients condition has been improving during the treatment with prednisone (encorton, Polfa) and after the transfusion of red blood cells suspended in saline (direct Coombs test titre 4–7 G, 1:32). A haemolytic crisis has occurred on August 23, 1968 (direct Coombs test titre 1:64). Since the previous  $^{51}\text{Cr}$  study has indicated that the spleen




Fig. 1. Course in the haemoglobin concentration, Hb 1 content, total serum bilirubin and percentage of reticulocytes in the patient A. K. blood during the study.

<sup>1</sup> Results of this study were provided by Dr. M. GAWLIK from the 2nd Department of Internal Medicine, Medical School, Poznań.

## Swiss Type Hereditary Persistence of Foetal Haemoglobin in a Case of Acquired Haemolytic Anaemia

A. L. PAWLAK and G. KOZŁOWSKA

Department of Human Genetics (Head Prof A HORST) and 1st Department of Internal  
Medicine (Head Prof K JASIŃSKI), Medical School, Poznań

High concentrations of foetal haemoglobin (Hb F) in red blood cells has been found in several types of anaemias in adults. This may result from the diminution of  $\beta$ -chain synthesis (in  $\beta$ -thalassaemia) or from accelerated breakdown of labile  $\beta$ -chain variants of haemoglobin. The mechanisms responsible for the increase of Hb F concentration in other types of anaemias remain, however, uncertain.

On the other hand various types of hereditary persistence of Hb F synthesis were reported in which no evidence of accelerated haemolysis or anaemia has been found. Hb F contributes 14, 21 and 25% of total haemoglobin in heterozygotes for the Greek, Mongolian and African types respectively [1, 2]. In a case of homozygote of an African type hereditary persistence of Hb F, the latter constituted 100% of haemoglobin, yet anaemia did not occur. In all those types of the trait Hb F is present in all erythrocytes in similar concentrations. The Swiss type of hereditary persistence of Hb F differs from the former traits by lower concentrations of foetal haemoglobin in heterozygotes (1-2.5%) and its unequal concentration in individual erythrocytes. The morphology of red blood cells in Swiss type of hereditary persistence of Hb F is normal, in contradistinction to thalassaemia minor in which similar levels of Hb F occur [3, 4].

In the case to be reported in this communication Swiss type hereditary persistence of Hb F has been diagnosed on the basis of family study. In the course of an acquired haemolytic anaemia in this case high Hb F concentrations (up to 23%) were found.

In the haemolysates a fraction of haemoglobin with the electrophoretic mobility of Hb F has been found. The quantity of this fraction (21%) corresponded well to the concentration of the alkali-resistant haemoglobin in this haemolysate (21.3, 1968).

The changes in the Hb F level during the study are presented on figure 1. Lowering of the Hb F content coincided with the increase in total Hb content. As no transfusions were given April-June 1968, this coincidence suggests that lowering of Hb F level may be related to the reduced intensity of haemolysis.

The heterogeneous distribution of Hb F in the erythrocytes has been demonstrated (fig. 3b). Furthermore differences in Hb F content were found in erythrocytes of the patient different in relation to age and sedimentation properties (4.3, 1969). Red blood cells suspensions in 0.9% NaCl (hematocrit 20%) were centrifuged in 10 cm long test tubes for 10 min at 600 g. The Hb F concentration was found to be 8% in the



Fig. 3. The heterogeneity of Hb F in erythrocytes. The Hb F concentration is stained with 0.9% NaCl. DARK SPOTS: Hb F.

was the main site of accelerated haemolysis, splenectomy was performed. A lung infarct occurred following this operation. As the thromboelastogram showed increase in the coagulability, anticoagulants (heparin and later phenhydren, Polfa) have been administered. After splenectomy lowering of bilirubin concentration and an increase in the total haemoglobin were noted (fig. 1). Direct Coombs test titre has been as follows: 20 9 68 1 64, 24 10 68 1 32, 4 3 69 1 32.

The concentration of Hb F in haemolyates was determined with 2 methods: (1) alkali denaturation of cyanhaemoglobin [5]. Normal values in our conditions are up to 1% in adults, (2) electrophoresis on starch gel in the vertical system of SMITHIES [6] with continuous buffer *tris*-EDTA-boric acid, pH 8.6 [7]. After separation of Hb A and Hb F gel was stained with bromophenol blue. Then the Hb-bound stain was eluted separately and its amounts were determined spectrophotometrically [8].

Histochemical staining of blood smears for Hb F in erythrocytes was made according to BETKE and KLEINHAEUER [9].

Determinations of Hb A<sub>2</sub> were performed by starch block electrophoresis in barbital buffer 0.06 M, pH 8.6 [10]. The electrophoresis was carried out at 4°C with current 3 mA per cm<sup>2</sup> of the cross section of the block.

The test for autohaemolysis was done as described by YOUNG [11].

Activity of glucose-6-phosphate dehydrogenase was determined with the method of ZERNIKIAN [12] and that of phosphoenolpyruvate kinase with the BUCKLER's method according to WISSEMAN's modification [13].

The remaining laboratory investigations were carried out using standard methods.

## Results

Increased autohaemolysis of the patients blood was noted at the admission (48 hours' incubation *in vitro*): defibrinated blood 20% (normal up to 2%), defibrinated blood with glucose 23% (normal up to 1%), defibrinated blood with ATP 15% (normal up to 1%).




Fig. 2. Family tree. The concentrations of haemoglobin F and haemoglobin A<sub>2</sub> (in %) and the age of members of patient's family. The patient is indicated with arrow. Subjects suspected to have a Swiss type hereditary persistence of Hb F are designated as half-shaded circles.

In the haemolysates a fraction of haemoglobin with the electrophoretic mobility of Hb F has been found. The quantity of this fraction (21%) corresponded well to the concentration of the alkali-resistant haemoglobin in this haemolysate (21.3, 1968).

The changes in the Hb F level during the study are presented on figure 1. Lowering of the Hb F content coincided with the increase in total Hb content. As no transfusions were given April-June 1968, this coincidence suggests that lowering of Hb F level may be related to the reduced intensity of haemolysis.

The heterogeneous distribution of Hb F in the erythrocytes has been demonstrated (fig. 3b). Furthermore, differences in Hb F content were found in erythrocytes of the patient different in relation to age and sedimentation properties (4.3, 1969). Red blood cells suspensions in 0.9% NaCl (hematocrit 20%) were centrifuged in 10 cm long test tubes for 10 min at 600 g. The Hb F concentration was found to be 8% in the




Fig. 1. The change of Hb F content during the Hb F concentration study. The Hb F content is given as a percentage of total Hb F. Hb F concentration is given as a percentage of total Hb.

the fraction of erythrocyte haemoglobin about  $LE_1 + LE_2$ , in the mother fraction and  $LE_1$ , in the patient fraction. The unagglutinated red blood cells contained  $LE_1$  and the E erythrocytes about  $LE_1$ .

The E<sub>1</sub> E concentration in red blood cells resistant to haemolysis in  $LE_1$  NaCl about  $50\%$  of cells fixed has been  $LE_1$  with  $LE_2$  in small amounts. This observation can be interpreted as the result of diminished normal resistance of red blood cells containing I-I weak antigen.

It is evident the possibility of the familial character of the inheritance of E<sub>1</sub> E concentration in the patient, her parents, brother and children have been studied. The P<sub>1</sub> and her father married were in good health. His  $A_2$  level and the red cell mean corpuscular volume were in normal range. The level of E<sub>1</sub> E was however normal in the mother (A<sub>1</sub>) and daughter A<sub>1</sub>B<sub>1</sub> of the subject. Extensive investigation of E<sub>1</sub> E in erythrocytes of demonstrated heterozygosity in other cases (see I. 1.).

### Discussion

The elevated level of E<sub>1</sub> E in the serum of the described autoimmune hemolytic anemia in the subject under study is interesting because of the possibility of a hypothetical persistence of fetal haemoglobin. Similar studies in Swiss type hemolytic persistence of E<sub>1</sub> E (1-2) have established the dominant character of this trait. High levels of E<sub>1</sub> E in the serum of the mother and daughter of the patient support the diagnosis of Swiss type hemolytic persistence of E<sub>1</sub> E in the patient (see I.).

The absence of I-I-haemoglobin in the in question family can be explained as an autosomal and recessive trait (see I. 1.). The normal level of E<sub>1</sub> E<sub>2</sub> however an additional evidence against the absence of I-haemoglobin. Somewhat has been found in the patient, not in the other members of the family. The disease is consistent with persistence but not with the genetically determined dominant heterozygosity. The exact location of autoantibodies by isolation of E<sub>1</sub> E<sub>2</sub> should be explained in the future, the  $LE_1$  erythrocyte antigen deficiency in the activity of the enzyme has been found to be normal.

Levels of E<sub>1</sub> E ranging from 1 to 15%, as is well described in cases of acquired hemolytic anemia (1-3). Nevertheless, in families in

patients with elevated Hb F levels in the course of aplastic anaemia no cases of the Swiss type hereditary persistence of Hb F have been found [16, 17]

While the homogenous distribution of Hb F in erythrocytes in cases with the increased Hb F level is a pathognomonic symptom of some types of the hereditary persistence of Hb F, the heterogeneous distribution of this haemoglobin can be found in all remaining cases [18]

In the case investigated the greater concentration of Hb F in the bottom layer of red blood cells suggests that the life span of cells containing Hb F is longer than that of Hb A containing cells. A greater concentration of Hb F in the bottom layer of red blood cells has been already described in the heterozygotes of  $\beta$ -thalassaemia [19]. In this condition the longer life span of Hb F containing cells has been verified by the finding that the glycine 2  $^{14}\text{C}$ -labelled Hb F remains longer in the circulation than the labelled Hb A [20]. This difference is believed to increase the compensatory effect of increased  $\gamma$ -chain synthesis in  $\beta$ -thalassaemia. In the patient studied the longer life span of the Hb F containing cells is interesting because of the different autoimmune mechanism of accelerated haemolysis. It might be speculated that longer life span of these cells in the patient can be related to presumptive differences in the antigenicity of Hb F containing erythrocytes as compared to Hb A containing cells.

If we consider the patient to have the Swiss type hereditary persistence of Hb F, the supposed differences in the red blood cells life span would explain the Hb F concentrations found in peripheral blood. If 2% of erythrocytes produced contained Hb F and had the normal life span, the shortening of the life span of the remaining erythrocytes to one fifth of the normal would cause the increase in the percentage of circulating Hb F containing cells to 10%. With normal compensatory capacity of the bone marrow, this would not cause anaemia [21]. Anaemia found in the patient at the beginning of the study corresponds to the shortening of the mean red blood cells life span to less than one tenth of the normal. Assuming a normal life span of Hb F containing cells, differences in the rates of haemolysis would explain the concentrations of 20% of Hb F in peripheral blood. The diminution of Hb F level coinciding with the reduced intensity of haemolysis (e.g. 1 April-June, 1968) seems to confirm this interpretation.

A different mechanism of the increase in Hb F level in cases with accelerated erythropoiesis has been proposed by BUCHSNER [22]. He



top fraction of erythrocytes (reticulocyte count 2.5%), 8.7% in the middle fraction and 14% in the bottom fraction. The unseparated red blood cells contained 11% of Hb F (reticulocyte count 1.0%).

The Hb F concentration in red blood cells resistant to haemolysis in 0.5% NaCl (about 50% of cells lysed) has been 18% (with 12% in whole blood, 21.5, 1968). This however can be interpreted as the result of diminished osmotic resistance of red blood cells transfused 8-9 weeks earlier.

To investigate the possibilities of the familial character of the increase in Hb F concentration in the patient, her parents, brothers and children have been studied (fig. 2). All her relatives studied were in good health. Hb A<sub>2</sub> levels and the red cell mean corpuscular volume were in normal range. The level of Hb F was however elevated in the mother (G A) and daughter (A K) of the subject. Heterogeneous distribution of Hb F in erythrocytes was demonstrated histochemically in these cases (fig. 3).

### Discussion

The elevated level of Hb F in the course of the acquired autoimmune haemolytic anaemia in the subject under study is interesting because of the coexisting Swiss type hereditary persistence of foetal haemoglobin. Family studies in Swiss type hereditary persistence of Hb F [3, 4] have established the dominant character of this trait. High levels of Hb F in the blood of the mother and daughter of the patient supports the diagnosis of Swiss type hereditary persistence of Hb F in the patient (fig. 2).

The diagnosis of  $\beta\delta$  thalassaemia in the investigated family can be excluded as no microcytosis and hypochromia have been found. The normal level of Hb A<sub>2</sub> provides an additional evidence against the diagnosis of  $\beta$  thalassaemia. Spherocytosis has been found in the patient, but not in the other members of the family. This finding is consistent with symptomatic, but not with the genetically determined dominant spherocytosis. The partial correction of autohaemolysis by addition of ATP cannot be explained by the TANKA type [14] pyruvate kinase deficiency as the activity of this enzyme has been found to be elevated.

Levels of Hb F ranging from 5 to 25% have been described in cases of acquired anaemias in adults [15-17]. Nevertheless, in families of

patients with elevated Hb F levels in the course of aplastic anaemia no cases of the Swiss type hereditary persistence of Hb F have been found [16, 17].

While the homogenous distribution of Hb F in erythrocytes in cases with the increased Hb F level is a pathognomonic symptom of some types of the hereditary persistence of Hb F, the heterogeneous distribution of this haemoglobin can be found in all remaining cases [18].

In the case investigated the greater concentration of Hb F in the bottom layer of red blood cells suggests that the life span of cells containing Hb F is longer than that of Hb A containing cells. A greater concentration of Hb F in the bottom layer of red blood cells has been already described in the heterozygotes of  $\beta$ -thalassaemia [19]. In this condition the longer life span of Hb F containing cells has been verified by the finding that the glycine 2-<sup>14</sup>C-labelled Hb F remains longer in the circulation than the labelled Hb A [20]. This difference is believed to increase the compensatory effect of increased  $\gamma$ -chain synthesis in  $\beta$ -thalassaemia. In the patient studied the longer life span of the Hb F containing cells is interesting because of the different autoimmune mechanism of accelerated haemolysis. It might be speculated that longer life span of these cells in the patient can be related to presumptive differences in the antigenicity of Hb F containing erythrocytes as compared to Hb A containing cells.

If we consider the patient to have the Swiss type hereditary persistence of Hb F, the supposed differences in the red blood cells life span would explain the Hb F concentrations found in peripheral blood. If 2% of erythrocytes produced contained Hb F and had the normal life span, the shortening of the life span of the remaining erythrocytes to one fifth of the normal would cause the increase in the percentage of circulating Hb F containing cells to 10%. With normal compensatory capacity of the bone marrow, this would not cause anaemia [21]. Anaemia found in the patient at the beginning of the study corresponds to the shortening of the mean red blood cells life span to less than one tenth of the normal. Assuming a normal life span of Hb F containing cells, differences in the rates of haemolysis would explain the concentrations of 20% of Hb F in peripheral blood. The diminution of Hb F level coinciding with the reduced intensity of haemolysis (e.g. 1 April June, 1963) seems to confirm this interpretation.

A different mechanism of the increase in Hb F level in cases with accelerated erythropoiesis has been proposed by BACCHONI [22]. He

supposed the greater concentration of Hb F in erythrocytes released from the bone marrow after fewer than normal number of divisions of progenitor cells

Further studies are necessary to see how often the increases of Hb F level in the course of accelerated haemolysis appear in patients with the Swiss type hereditary persistence of Hb F, and to estimate the difference in the life span of Hb A and of Hb F containing erythrocytes in these cases.

*Acknowledgements* We should like to thank Prof. A. HORST for suggestions concerning immune differences between the Hb F and the Hb A containing cells as well as to Prof. A. JASINSKI for initiation of the study

### Summary

In a woman 32 years old an increase in foetal haemoglobin (Hb F) level (23-10%) has been found in the course of autoimmune haemolytic anaemia. No hypochromia and no increase in Hb A<sub>2</sub> level have been found in the patient and in the members of her family. The family investigation corroborate the diagnosis of the Swiss type hereditary persistence of Hb F in patient's mother, daughter and in the patient. The higher concentration of Hb F in the bottom layer of erythrocytes is considered as evidence of accelerated haemolysis of Hb A containing cells as compared with Hb F containing cells. This difference in red blood cells life span is discussed in relation to the observed Hb F levels and to the presumptive differences in the antigenicity between the Hb F and the Hb A containing cells.

### References

1. WEATHERALL, D. J. The thalassaemia syndrome (Blackwell, Oxford 1965)
2. WASI, P., POOTRAKUL, S. and NA NAKORN. Hereditary persistence of foetal haemoglobin in a Thai family. The first instance in the Mongol race and in association with haemoglobin E. *Brit. J. Haemat.* **14**: 501-506 (1968)
3. MARTI, H. R. Die Vermehrung des alkaliresistenten Hämoglobins bei hämatologisch gesunden Erwachsenen, in LEHMANN and BETKE. Hämoglobin-colloquium pp. 93-100 (Thieme, Stuttgart 1962)
4. MARTI, H. R. Normale und anomale menschliche Hämoglobine (Springer, Berlin/Göttingen/Heidelberg 1963)
5. BETKE, K., MARTI, H. R. and SCHLICHT, I. Estimation of small percentages of foetal haemoglobin. *Nature, Lond.* **184**: 1877 (1959)
6. SMITHIES, O. An improved procedure for starch gel electrophoresis. *Biochem. J.* **71**: 585-589 (1959)
7. WINTERHALTER, K. H. and HUEHNS, E. R. Preparation, properties and specific recombination of a  $\beta$ -globin subunits. *J. Biol. Chem.* **239**: 3699-3705 (1964)
8. RICCO, G., GALLO, E., FIORINA, L. and PRATO, V. A simple method for the quantitation of haemoglobin fractions obtained by starch gel electrophoresis. *Acta haemat. Basel* **33**: 306-316 (1967)

- 9 BETKE K and KLEINHAUER, F. Fetal and bleibender Eukaryotoff in Erythrocyten und Erythroblasten von menschlichen Feten und Neugeborenen. Blut 6: 211-219 (1958)
- 10 KENZEL, H. G., CAPPELLINI, R., MÜLLER EBERHARD, U. and WOLF, J. Observations on the major haemic hemoglobin component in the blood of normal individuals and patients with thalassemia. J. clin. Invest. 39: 1615-1625 (1957)
- 11 YOUNG, L. H., IZZO, M. J., ALTMAN, K. I. and SWITZER, S. H. Studies on spontaneous *in vivo* autohemolysis in hemolytic disorders. Paediatrics 11: 977-997 (1956)
- 12 ZIMMERMAN, W. H. An *in vivo* abnormality of glutathione metabolism in erythrocytes from normal newborns. Pediatrics 21: 18-32 (1959)
- 13 WEISMAN, L., TÖNIG, O., RUCHSBERG, R. and VERGER, P. Die Enzyme-Pyruvat-Kinase bei Gesunden und bei nichtsphärocytärer, hämolytischer Pyruvat-Kinase-Mangel. Andenw. Klin. Woch. 43: 1311-1318 (1955)
- 14 TANAKA, K., R. VALENTINE, W. N. and MIWA, S. Pyruvate kinase deficiency hereditary nonspherocytic hemolytic anemia. Blood 19: 257-269 (1962)
- 15 M. KAWAKI, K. and SZYMANSKOWSKA, Z. Hemoglobina płodowa w chorobach krwi. Pol. Tyg. Lek. 21: 912-913 (1966)
- 16 JONKE, J. H. P. Über Hämoglobinopathien mit besonderer Berücksichtigung der Cooley-Anderson-Schwere. med. Woch. 91: 1037-1042 (1961)
- 17 DIAMOND, L. K. Alkali resistant hemoglobin in aplastic anemia: acquired and congenital types. Blood 18: 807-809 (1961)
- 18 FOWLER, P. after ref. 1
- 19 GARZIDA, T. G., NATHAN, D. G. and CARDNER, F. H. Thalassemia trait. Genetic consequences of increased fetal and A<sub>2</sub> hemoglobins. New Engl. J. Med. 270: 1212-1215 (1964)
- 20 GARZIDA, T. G., NATHAN, D. G. and CARDNER, F. H. The turnover of hemoglobins A<sub>1</sub> and A<sub>2</sub> in the peripheral blood of three patients with thalassemia. J. clin. Invest. 42: 1678-1679 (1963)
- 21 LAWKOWICZ, W. and KRZEMIŃSKA-LAWKOWICZOWA, I. Kliniczna diagnostyka różnicowa w hematologii. Państw. Zakł. Wydz. Lek., Warszawa (1966)
- 22 BACERINS, C. Correlation between genetics and chemistry of human hemoglobins. in TAYLOR, Molecular genetics, part I, p. 462 (Academic Press, New York-London 1963)

# International Society of Blood Transfusion

Sy . . . . .

(West Germany)

Morning session (9-11 a.m.) 10-12-min presentations Chairmen A J ZUCKERMAN

Britain), A J ZUCKERMAN (Great Britain)

Afternoon session (3-6 p.m.) 6-8-min short presentations Chairmen B S BLUMBERG (USA), J P. SOULIER (France) Speakers I L. BARNER (USA), H BERTHOLD (West Germany), F. DEINHARDT (USA), D J. GOCKE (USA), G A ICGRIFFO (USA), F O MACCALLUM (Great Britain), R H PERCELL (USA), G RITTNER (West Germany), M SEYFRIED (Poland), P TAYLOR (Great Britain)

General discussion between all the speakers

All applications for this symposium should be sent to Prof J P SOULIER, General Secretary of the International Society of Blood Transfusion, 6, rue Alexandre Cabanel,

to attend this symposium) or pay a one day fee only for this special day (Tageskarte)

## VI. Kongress der Weltföderation für Hämophilie

Baden bei Wien, 25-27 Juli 1970

Veranstalter Österreichische Hämophilie-Gesellschaft unter Mitwirkung der Wiener Medizinischen Akademie für ärztliche Fortbildung

Tagungsort Kongresshaus, Baden bei Wien

Wissenschaftliche Themen 1 Neue Forschungsergebnisse auf dem Gebiet der Hämophilie 2 Standardisierung der Methoden für die Bestimmung des Hämophiliefaktors 3 Therapie der Hämophilie, a) Neue Faktor VIII- und Faktor IX-Konzentrate, b) Zahnpflege, c) Orthopädie und Unfälle, d) Diskussion über Nebenerscheinungen

In der prämedizinischen Sektion werden Diskussionen über drei Themen abgehalten 1 Die Schule und berufliche Probleme 2 Krankenversicherung 3 Rationalisierung der Therapie und Herabsetzung ihrer Kosten

Kongress Sprachen Deutsch, Englisch, Französisch, Spanisch

Teilnehmerbeiträge ÖS 750 für aktive Teilnehmer, ÖS 250 - für Begleitpersonen

Anfragen und Anmeldung Sekretariat c/o Wiener Medizinische Akademie, Stadiongasse 6-B, A 1010 Wien (Austria)

## Experimental Studies on Leukemia in Guinea Pigs<sup>1</sup>

LUDWIK GROSS, YOLANDE DREYFUSS, THEODOR EHRFELD  
and LORRAINE A. MOORE

Cancer Research Unit, Veterans Administration Hospital, Bronx, N.Y.

Leukemia and lymphosarcoma have long been observed to develop occasionally in middle-aged guinea pigs. The lymphoid tumors could be transmitted by cell graft, inducing disseminated lymphosarcomas and generalized leukemia in guinea pigs [6, 10, 11].

In 1951, CONDON and LORENZ [1] observed several cases of leukemia developing spontaneously in guinea pigs bred at the National Cancer Institute in Bethesda, Md. Among a total of 303 guinea pigs observed, 10 animals developed leukemia, an incidence of 3.3%. Transplantation was accomplished in young guinea pigs of the same strain [1].

In subsequent studies dealing with experimental transmission of 12B and 12C leukemia which originated in 'strain 2' guinea pigs, JUSTER and KOTZ [4, 5] employed either young adult 'strain 2' guinea pigs or first generation hybrids. Both were consistently susceptible to inoculation of either 12B or 12C leukemia. Inoculation of cell suspensions prepared from leukemic spleens induced stem-cell leukemia after 2 to 3 weeks. Transmission by centrifuged, presumably cell-free extracts prepared from leukemic spleens was also reported [4], the extracts were centrifuged 1 to 3 consecutive times at 5,500 to 11,000 g/m. The final supernate was inoculated, and induced leukemia after 15 to 21 days. Inoculation of plasma harvested from leukemic animals induced leukemia after 15 to 30 days. Attempts to transmit leukemia by filtered extracts were reported to have been successful in a few instances [4], the disease developed in the inoculated animals

<sup>1</sup>Address reprint requests to Dr. L. Gross, Division of Hematology, Memorial Fund for American Cancer Society, and the Virginia and D. K. Ludwig Foundation.

after a short latency, not different from that observed following inoculation of blood plasma or of leukemic cell suspensions

However, in a similar study, carried out in another laboratory leukemia could not be transmitted in guinea pigs by leukemic extracts passed through either Seitz or Millipore filters [E. M. NADEL, personal communication to the author, 1967]. In the same study transmission by centrifuged extracts was successful, blood plasma that had been centrifuged several times at low speed followed by high speed centrifugation at 35 000 rpm was also leukemogenic on inoculation tests

### *Experiments on Transmission of L2C Guinea Pig Leukemia Carried out in our Laboratory*

We are very grateful to Dr C. W. JUNGBLUT, Lenox Hill Hospital, New York City, from whom we obtained on August 8, 1968, a (Hartley  $\times$  strain 2)  $F_1$  hybrid guinea pig with fully developed (L2C strain) transplanted leukemia. A cell suspension prepared aseptically from spleen, lymph nodes and from a leukemic tumor removed from this animal was inoculated subcutaneously into 2 young adult  $F_1$  hybrid guinea pigs. About 2 weeks

*Animals used* 'Strain 2' guinea pigs were purchased from Horton's Laboratory Animals

experiments. The Hartley guinea pigs were purchased from Camm Research Institute, Wayne, N. J. Both 'strain 2' guinea pigs and  $F_1$  hybrids were found to be consistently susceptible to induction, by cell-graft, of L2C leukemia. Hartley guinea pigs are resistant

*Induction of leukemia by cell-graft* Within 2 to 3 weeks after subcutaneous inoculations of leukemic cell suspensions of 10 or 20% concentration into either 'strain 2' guinea pigs or  $F_1$  hybrids, small, firm, subcutaneous tumors developed at the site of inoculation, increased in size gradually and were followed within a week to 10 days by the development of generalized leukemia. One of the most prominent features of the induced leukemia was a consistent increase in the number of white cells in peripheral blood, with appearance of primitive stem cells and development of anemia; this striking change in peripheral blood morphology was first noticed several days after the development of subcutaneous tumors at the site of inoculation. The number of white cells then increased gradually, reaching, usually within 5 to 10 days, in terminal phase of the disease, 300,000 to 500,000 WBC/mm<sup>3</sup>, with predominance of primitive stem cells.

*Preparation of leukemic suspension.* A guinea pig with induced leukemia was sacrificed by ether inhalation. After the skin was shaved the abdominal cavity was exposed. Fragments of spleen and of the subcutaneous tumor which developed at the site of inoculation of the neoplastic tumor and in some instances also of a peripheral lymph node and of the liver were removed aseptically, weighed, cut with scissors and ground by hand in a mortar with physiological saline solution being added to obtain a cell suspension of either 10 or 70% concentration. The cell suspension was then passed through a sterile scale cloth and used immediately for inoculation. In some instances when susceptible animals were not available for inoculation the cell suspension was frozen in carbon dioxide dry ice at  $-70^{\circ}\text{C}$ . and used for inoculation one or several weeks later, occasionally after longer intervals.

### Serial Passage by Subcutaneous Inoculations of Leukemic Cell Suspensions

Continuous serial cell-graft passages were accomplished by subcutaneous inoculations of leukemic cell suspensions of 10 or 70% concentration into young adult guinea pigs. In each passage 2 or 3 guinea pigs were inoculated, as soon as one of the inoculated animals developed general leukemia and the peripheral white blood count reached a high level.

*Total Results of subcutaneous inoculation of leukemic cell suspensions into young adult  $F_1$  and  $F_2$  hybrid guinea pigs*

| Strain                    | Leukemic cell conc. % | Days prior to death | No. guinea pigs inoculated | No. developed leuk. | Leukemic % |
|---------------------------|-----------------------|---------------------|----------------------------|---------------------|------------|
| Strain 2                  | 70                    | 9                   | 24                         | 24                  |            |
|                           | 70                    | 1                   | 13                         | 13                  |            |
|                           | 10                    | 1                   | 13                         | 13                  |            |
| Total                     |                       |                     | 51                         | 51                  | 100        |
| $F_2$ hybrid <sup>a</sup> | 70                    | 9                   | 9                          | 8 <sup>b</sup>      |            |
|                           | 70                    | 1                   | 3                          | 2 <sup>c</sup>      |            |
|                           | 10                    | 1                   | 4                          | 4                   |            |
| Total                     |                       |                     | 16                         | 14                  | 87         |

*Summary of 172 serial subcutaneous passages.* In all of the 172 animals which were inoculated 115 leukemic cell suspensions were used, most of which after propagation of seven had been kept at  $-70^{\circ}\text{C}$ . for 9 to 15 days prior to use. A average latency from inoculation to appearance of leukemia was 11 days. A average time of survival with terminal phase of disease 1 day.

<sup>a</sup> Approximately 10% of the animals died at time of inoculation.

<sup>b</sup> 11 days prior to death of 13 animals.

<sup>c</sup> One animal kept at  $-70^{\circ}\text{C}$ . 31 days and died after 15 days.



Table II Titration experiments Induction of leukemia with serial dilutions of leukemic cell suspensions

| Strain                              | Leuk cell conc   | No guinea pigs inoc <sup>1</sup> | No dev leuk    | Leuk inc % | Avg initial latency days <sup>2</sup> | Avg terminal latency days <sup>2</sup> |
|-------------------------------------|------------------|----------------------------------|----------------|------------|---------------------------------------|--|
| 'Strain 2'                          | 10 <sup>-3</sup> | 5                                | 5              | 100        | 15                                    | 21                                     |
|                                     | 10 <sup>-3</sup> | 9                                | 9              | 100        | 16                                    | 24                                     |
|                                     | 10 <sup>-4</sup> | 5                                | 5              | 100        | 25                                    | 48                                     |
| F <sub>1</sub> hybrids <sup>3</sup> | 10 <sup>-3</sup> | 4                                | 3 <sup>4</sup> | 75         | 16                                    | 21                                     |
|                                     | 10 <sup>-4</sup> | 2                                | 2              | 100        | 22                                    | 42                                     |

<sup>1</sup> All inoculations subcutaneous, 1 ml each, into young adult guinea pigs, approximately 1 to 2 months old

<sup>2</sup> (Hartley ♀ × strain 2 ♂) F<sub>1</sub> hybrids

<sup>3</sup> Initial latency, from inoculation to appearance of tumors at site of inoculation  
Terminal latency, from inoculation to terminal phase of disease

<sup>4</sup> One still alive and well at 2½ months of age

the animal was sacrificed, and its spleen and leukemic tumors were used for the preparation of a cell suspension serving for the next passage (table I). Fifty-one 'strain 2' guinea pigs and 16 F<sub>1</sub> hybrids were inoculated. All 51 'strain 2' guinea pigs and 14 out of 16 F<sub>1</sub> hybrids developed subcutaneous leukemic tumors at the site of inoculation after a latency varying in most instances from 10 to 15 days, followed a few days later by the development of generalized leukemia (table I).

The terminal phase of the disease was usually reached about 3 weeks after inoculation. The disease was progressive in all instances. There was no spontaneous recovery. All leukemic animals died, or were sacrificed when moribund, in terminal phases of the disease.

When higher dilutions of the leukemic cell suspensions were inoculated, the development of disease was delayed by one or two, or occasionally by three weeks (table II).

*Dosage. Induction of leukemia with serial dilutions of leukemic cell suspensions.* An attempt was made to determine the dose and concentration of leukemic cell suspensions necessary to induce leukemia, following subcutaneous inoculation into young adult 'strain 2' guinea pigs. Cell suspensions of 10 or 20% concentration were uniformly leukemogenic, and induced a rapidly progressing disease after a short latency of about 2 weeks. When 10<sup>-3</sup> or 10<sup>-4</sup> dilutions were inoculated subcutaneously, leukemia was also induced in all 'strain 2', and in 5 out of 6 F<sub>1</sub> hybrid



Fig. 1. Dissected female guinea pig born to a Hartley female and a "strain 2" male was mated subcutaneously when 25 days old with a 19-day-old male of a "leukemic cell" suspension and developed a subcutaneous tumor at the site of mating on 18 months by a grossly red mass. Leukemia (45/60 WBC/mm<sup>3</sup>). Sacrificed 19 days after inoculation. Note the very large spleen, S, and liver, and also enlarged lymph nodes, LN, in the axillary area and in the cervical region.

guinea pigs (table II), but the latency was prolonged. The induced disease did not differ from that resulting from inoculation of larger doses, except for the initial delay in the development of tumors and subsequent symptoms of generalized leukemia.

*Inoculation of leukemic cell suspensions into young adult Hartley guinea pigs* Two young adult Hartley guinea pigs were inoculated subcutaneously with large doses (2.5 ml) of a leukemic cell suspension of 20% concentration. One was sacrificed after 80 days and another 190 days after inoculation. Neither developed leukemia.

*Transmission by plasma.* It is of interest that leukemia could readily be induced in young adult 'strain 2' or  $\Gamma_1$  hybrid guinea pigs by subcutaneous inoculation of centrifuged, but not filtered, plasma.

Blood mixed with a few drops of heparin was collected directly from the heart of anesthetized leukemic guinea pigs. In most instances the blood was mixed with an equal volume of physiological saline solution. The blood was centrifuged at 2,000 rpm for 10 min, plasma was then collected carefully, transferred to other tubes, and again centrifuged at 2,000 or 4,000 rpm for 5 or 10 min. In two experiments, the second supernate was again centrifuged at either 2,000 or 4,000 rpm for 5 or 10 min. In one experiment a fourth centrifugation was made at 9,500 rpm. The final supernate was then inoculated subcutaneously.

Out of 6 inoculated animals, 4 developed subcutaneous tumors at the site of inoculation, after a latency varying from 23 to 38 days, followed within a few days by generalized stem-cell leukemia. However, when plasma was filtered, after a preliminary centrifugation, through Sela 02 filter candle, and then inoculated into 2 guinea pigs, no leukemia resulted.

*Attempt to transmit leukemia by centrifuged extracts.* An attempt was made to transmit leukemia in guinea pigs by centrifuged, presumably cell-free extracts. In the first experiment, the leukemic cell suspension of 10% concentration was centrifuged at 3,000 rpm for 15 min. The supernate was centrifuged again at 9,500 rpm for 5 min; the second supernate was injected into a young adult 'strain 2' guinea pig. A local tumor developed at the site of inoculation after 31 days, followed shortly by generalized leukemia.

In 5 other experiments, the leukemic cell suspensions of 10 or 20% concentration were first centrifuged two or three consecutive times at 3,000 rpm for 15 min each. The second, or third supernate, respectively, was submitted to a final centrifugation at 9,500 rpm for 15 to 20 min. The final supernate was then inoculated subcutaneously (1 to 2 ml each), into 2 newborn, 3 less than 4-day-old, and 4 young adult guinea pigs. None of these animals has yet developed subcutaneous tumors or generalized leukemia. They have been observed thus far for 2 to 3 months.

*Attempt to Transmit Leukemia in Guinea Pigs by Filtered Extracts*

An attempt was made to transmit leukemia in guinea pigs by filtered extracts. A total of 100 guinea pigs was inoculated. None of the inoculated animals has yet developed leukemia, they all are in good health and have been observed thus far for 3 to 16 months.

Leukemic cell suspensions of 10 or 20% concentration prepared from leukemic tumors and spleens in the usual manner, were centrifuged at 3,000 rpm for 15 min; the supernate was centrifuged again at 9,400 rpm for 5 min. The second supernate was then passed through Selasfiltrer candles. Small groups of animals, one or two, in a few experiments up to 5 at a time, were inoculated in 39 experiments. Twenty-four filtered extracts were prepared, each from a different leukemic donor. Eleven filtrates were used immediately or prepared and all remaining filtrates were stored at  $-70^{\circ}\text{C}$  for 1 to 1 $\frac{1}{2}$  days prior to their use for inoculation.

Seventy-nine weanling guinea pigs were inoculated subcutaneously with the filtered extract (1 to 2 ml each) as follows: 15 strain 2, 36  $\frac{1}{2}$  hybrid, and 28 Hartley guinea pigs.

In a 51 and 21 weanling 1 to 2 month-old guinea pigs (19 strain 2, and 2  $\frac{1}{2}$  hybrids) were also inoculated subcutaneously (2 to 3 ml each; a few received 3 to 5 ml of the filtrate).


All inoculated animals are in good health at the time of this writing. They have been observed thus far for 3 to 16 months.

*Pathologic Manifestations*

Since the inoculations of leukemic cell suspensions were subcutaneous, the first manifestation was the induction of leukemic tumors at the site of inoculation. The subcutaneous tumors were at first circumscribed, moderately firm, with uneven edges, they soon infiltrated and adhered to the surrounding tissues, growing rapidly, within a few days they measured 1 or 2 cm in diameter, and became larger in terminal phases of the disease. Metastatic tumors developed in most instances, particularly in axillary and cervical lymph nodes, followed by a generalized leukemia.

The peripheral blood count had to be followed closely, since the animals usually reached the terminal phase of the disease only 5 to 10 days after they had developed subcutaneous tumors at the site of inoculation.

The tumors at the site of inoculation were made up of undifferentiated tumor cells arranged in masses and had no encapsulation. On incision, the tumor masses were found to be made up of almost packed cells, many of which were large and stained pinkish. They consisted of large areas of small pink stained tumor cells among the leukocytes, but among the tumor cells were approximately 10 to 30% of large pale pink cells which were pointed. Some of these were apparently "macrophage" type.





*Fig 2 a* Peripheral blood from a leukemic guinea pig in advanced phase of the disease (177,000 WBC/mm<sup>3</sup> with 63% of blast cells). Large numbers of undifferentiated stem cells are present (Wright stain,  $\times 1,000$ ) *b* Bone marrow from a guinea pig in advanced phase of disease (peripheral blood count 160 400 WBC/mm<sup>3</sup> with 90% of blast cells). Stem cells with large nuclei and nucleoli and occasional indented nuclei replaced the normal bone marrow element (Wright and Giemsa stain,  $\times 1,000$ )

In the visceral leukemic infiltrations, the cells were found to grow in masses apparently without forming supporting stroma or capillaries (fig. 3a). However, at the site of inoculation, the tumors invading soft tissues and muscles had a fine stroma and many small capillaries apparently growing with the tumors. Silver stains for reticulin (Gomori's silver methenamine) were done on representative sections of the various sites of leukemic tumor infiltrations. Reticulin fibers were present only in the tumors found at the site of inoculation but not in the visceral leukemic masses. The reticulin fibers in the tumors which developed at the site of inoculation were abundant and in places branched off into fine fibers which resembled individual cells. It is possible but not likely that the reticulin fibers are components of the infiltrating cells and not of the tumor. The pattern of growth of the inoculation site tumors would suggest that in soft tissues leukemia forms a histocytic or reticular cell stroma.

When the abdominal cavity of such animals was exposed, a prominent and striking feature was a considerable enlargement of spleen and liver, the spleen was frail, brittle and usually broke into fragments on attempt at removal. In advanced cases, the liver was very large, filling up a large part of the abdominal cavity. In practically all instances there was also a moderately large white, oblong mesenteric tumor. The peripheral lymph nodes were frequently enlarged and replaced by leukemic tumors, particularly in the axillary area, and often also in the cervical region (fig. 1). Of particular interest was the fact that in no case did we observe thymic tumors.

On microscopic examination, there was infiltration of cells in all organs but particularly in liver (fig. 3b) and spleen and to some extent also of peripheral lymph nodes, which showed nodular and extensive infiltration with leukemic cells. Other organs, such as kidneys, lungs, heart, and stomach showed a lower degree of involvement. The infiltrating cells were similar to the cells of the peripheral blood. In the bone marrow and in tumor masses, the infiltrating cells resembled the masses of cells in tumors. The cells were fairly uniform and showed distinct evidence of the nucleus as seen in the peripheral blood. The nuclei of peripheral blood cells appeared as well developed, larger, globular, prominent nuclei. This was not due to the frequent presence of tumor cells in the glomerular capillaries (fig. 3c). The plasma could not be seen.

*Peripheral blood and bone marrow.* As leukemic animals approached the terminal phase of the disease, the peripheral blood count was usually very high (over 200,000 WBC/mm<sup>3</sup>) and consisted principally of large, primitive blast cells with large nuclei, 2 to 3 prominent nucleoli, scanty cytoplasm and an occasional indentation or infolding of the nucleus. The cytoplasm was light blue and often contained many vacuoles (fig. 2a). Numerous mitoses could be observed, particularly in some cases. Smaller cells were usually present. In addition to stem cells, there were small numbers of mature lymphocytes, polymorphonuclears, and less frequently, metamyelocytes, eosinophils and monocytes. Occasional basophilic leukocytes were present.



*Fig 3 a* Leukemic tumor infiltrating the liver of a leukemic guinea pig in an advanced phase of the disease. The cells are fairly uniform with large, occasionally indented nuclei, prominent nucleoli and many mitoses (hematoxylin and eosin,  $\times 570$ ) *b* Same animal. Low power photomicrograph of liver infiltrated with leukemic cells (hematoxylin and eosin,  $\times 140$ ) *c* Kidney glomeruli with leukemic cells filling the capillaries and afferent arteriole (Periodic-acid Schiff,  $\times 220$ )

The so-called Jukloff bodies [9] peculiar to guinea pig blood, are found occasionally in the blood cells of both normal and leukemic guinea pigs. These are cytoplasmic inclusion bodies found in cells of the lymphocyte series. On blood smears stained routinely with Wright stain, they appear red and smooth or as vacuoles with dark red granules.

In some cases, the peripheral white cell count was in the 40,000 to 50,000 WBC/mm<sup>3</sup> range and in these instances there were, in addition to the large number of blasts, also significant numbers of polymorphonuclears, as well as lymphocytes and occasionally also metamyelocytes. There was also a gradual development of anemia.

In all advanced cases of leukemia an extensive replacement of normal bone marrow population by cells resembling stem cells seen in the peripheral blood could be observed (fig. 2b).

The following is a random sample of hematologic studies performed on 15 leukemic guinea pigs in terminal phases of the disease. All showed a marked elevation in peripheral white blood cell counts, which ranged from 166,000 to 518,000/mm<sup>3</sup> with an average of 242,000/mm<sup>3</sup>. Blood smears showed a large percentage of peripheral cells or blasts, ranging from 54 to 96%, with an average of 83%. (The stem cells were negative for peroxidase reaction.) The percentage of mature granulocytes was decreased to an average of 9%, and that of mature normal lymphocytes to an average of only 6%. The number of platelets also appeared to be decreased.


The leukemic animals presented a marked anemia with hemoglobin values ranging from 4.4 to 10.2 g per 100 ml of whole blood. There was a moderate anisocytosis of red blood cells, with presence of poikilocytes and cremated red blood cells, some diffuse and punctate basophilic, and an occasional nucleated red blood cell.

### *Electron Microscopic Studies<sup>2</sup>*

Examination of ultrathin sections prepared from organs of 14 leukemic guinea pigs revealed in the cisternae of the endoplasmic reticulum in the leukemic cells the presence of doughnut-like virus particles; these particles had two concentric membranes, relatively electron lucent centers, and measured about 90 to 100 m $\mu$  in diameter; they appeared to be formed by budding from the membranes of the endoplasmic reticulum into the cisternae (fig. 4). In addition, mature spherical particles about 103 m $\mu$  in overall diameter, with thick rough outer envelopes and centrally located electron-dense nucleoids, were found in intercellular spaces; the average diameter of the nucleoids was about 50 m $\mu$  (fig. 5).

<sup>2</sup> In cooperation with Dr. Otto G. Hirsch. A more detailed description of the electron microscopic electron microscopy in guinea pig leukemia will be published in a separate paper.





*Fig 4* Ultrathin section of a fragment of a leukemic cell infiltrating the lungs in a leukemic 'strain 2' guinea pig. This animal was inoculated with leukemic plasma, developed a generalized stem-cell leukemia ( $183,500 \text{ WBC/mm}^3$ ) and was sacrificed, when moribund, 46 days after inoculation. Within the cisternae of the endoplasmic reticulum are budding (b) and immature (i) leukemic virus particles ( $\times 68,000$ )

Virus particles observed in our studies of guinea pig leukemia were essentially similar to those previously described by OBLER [8] and also by NADIL *et al.* [7].

The doughnut like particles and particles with nucleoids were found in organs of all 14 animals examined; they were observed in a variety of tissues, such as subcutaneous and visceral leukemic tumors, spleen, lymph nodes, and bone marrow, as well as in leukemic cells infiltrating the liver, ovaries, uterus and lungs.

In a control study, no virus particles were found either in the endoplasmic reticulum or in the intercellular spaces of tissue fragments of spleen, liver, lymph nodes, or bone marrow from 9 normal, healthy 'strain 2' guinea pigs examined [3].

The virus particles found in organs of leukemic guinea pigs were different from those observed in mouse, rat, or cat leukemia [2, 3]. They were less numerous and were located mostly in the endoplasmic reticulum; we have never observed these particles budding from the outer cell membranes; they had frequently a slightly smaller overall diameter, and smaller, more dense and more homogeneous nucleoids than virus particles observed in leukemic mice, rats, and cats. There was much less variation in the overall size of the virus particles in guinea pig leukemia as compared with particles observed in mouse leukemia. Furthermore, virus particles observed in guinea pig leukemia had a thick, granular, rather fuzzy outer coat.

The nucleoids of the mature mouse, rat, and cat leukemia virus particles vary in size, shape and density, whereas the nucleoids of the mature guinea pig virus particles are more regular in size, spherical shape and density, and vary much less in diameter.

In the mouse, rat and cat, immature leukemic virus particles form by budding from the outer cell membranes and from vacuolar membranes of megakaryocytes. In the guinea pig, on the other hand, immature particles form by budding from membranes of endoplasmic reticulum. Consequently, immature and also mature mouse, rat and cat leukemia virus particles are usually located in the intercellular spaces, whereas most of the guinea pig virus particles appear within membranes of the endoplasmic reticulum, and only a few can be found in intercellular spaces.

In general, mouse, rat and cat leukemia virus particles were present in larger but less in the organs of leukemic animals as compared than guinea pig leukemia virus particles.



*Fig 5* Mature virus particles (m) in intercellular spaces from areas infiltrated with leukemic cells *a* Fragment of an ovary, and *b* fragment of lungs, from a 'strain 2' guinea pig with generalized stem-cell leukemia. Same animal as in figure 4 (*a*  $\times 122,000$ , *b*  $\times 116,000$ )

*Discussion*

The I 2C strain of guinea pig leukemia could be transmitted consistently, by cell graft, in 'strain 2' or in F<sub>1</sub> hybrid guinea pigs, inducing a rapidly progressing stem-cell leukemia in the inoculated animals. No spontaneous regression of the induced disease was observed in any case among the 65 guinea pigs which developed leukemia as a result of subcutaneous inoculation of leukemic cell suspensions of 10 or 20% concentration.

Transmission by plasma was also accomplished, however, when the plasma was filtered and then used for inoculation, no leukemia developed in the inoculated animals.

Transmission by a centrifuged extract succeeded in one experiment in which only two consecutive centrifugations were made. In this animal a local tumor developed at the site of subcutaneous inoculation, followed later by generalized leukemia. No leukemia has been induced thus far with extracts that had been submitted to 3 or 4 consecutive centrifugations. However, guinea pigs inoculated with such extracts are relatively young, and are still being observed. Should these preliminary results be corroborated by further observations and should the remaining animals survive, free from leukemia, it would then appear that one or two consecutive centrifugations may not be sufficient to sediment all cells or cell fragments. The fact that a leukemic tumor developed in the only positive animal at the site of inoculation would be consistent with such an assumption.

Different experimental conditions may be valid for transmission of leukemia with plasma, because of the viscosity of such extracts. Even several successive centrifugations did not prevent plasma extracts from inducing leukemia on inoculation tests. It is possible that a few cells or cell fragments may remain in plasma extracts even after several centrifugations, inducing again local tumors at the site of inoculation, followed later by the development of generalized leukemia. No leukemia, however, could be transmitted thus far with a filtered plasma extract.

Transmission by filtered tumor and spleen extracts has not yet succeeded in our laboratory. However, our experiments are still in progress.

The apparent difficulty in transmitting leukemia in guinea pigs by filtered extracts has been stressed in previous studies. Although Jung-

BLUT and KODZA [4] reported transmission of guinea pig leukemia by filtered extracts, certain reservations must be raised in reference to these experiments; the latency was very short, about 3 weeks. The narrow and specific strain susceptibility to inoculation with either leukemic cell suspensions, centrifuged extracts, or plasma, is also significant; only 'strain 2' or F<sub>1</sub> hybrid guinea pigs were susceptible in our experiments as well as in those previously reported [1, 4, 5]. Short latency and a narrow strain susceptibility usually refer to transmission by cell-graft of tumors or leukemia, and would be rather unusual in experiments dealing with the induction of leukemia, or tumors, by a cell-free agent.

The presence of spherical virus-like particles with characteristic granular outer coats in organs of leukemic animals was striking and could be readily revealed on electron microscopic examination. These particles could be differentiated from virus particles observed in leukemic mice, rats, cats and chickens.

### *Summary*

The L2C leukemia strain is consistently transmissible by cell graft in 'strain 2' or F<sub>1</sub> hybrid guinea pigs. The inoculated animals developed tumors at the site of inoculation, followed by a generalized leukemia, the thymus was not affected. Practically all animals developed in terminal phases of the disease very high white blood cell counts with predominance of stem cells.

Transmission by centrifuged extracts was successful only in one experiment in which 2 successive centrifugations were employed, but not when the extracts were submitted to 3 or 4 successive centrifugations. Transmission by plasma was accomplished, but not with plasma filtrate. Seventy nine newborn and 21 young adult guinea pigs were inoculated with filtered spleen and tumor extracts, but none has thus far developed leukemia.

Electron microscopic studies revealed consistent presence in the leukemic cells of spherical particles approximately 100 m $\mu$  in diameter, having a fuzzy, granular outer coat, some of them had electron-dense, centrally located nucleoids.

### *References*

- 1 CONGDON, C. C. and LORENZ, E. Leukemia in guinea pigs. *Amer J Path* 30 337-359 (1954)
- 2 GROSS, L. and FELDMAN, D. G. Virus particles in guinea pig leukemia and in rat mammary carcinoma. *Abstract Proc amer Ass Cancer Res* 10 33 (1969)
- 3 GROSS, L. and FELDMAN, D. G. Comparative study of the morphology and distribution of virus particles causing leukemia and lymphosarcoma in mice, rats, cats and guinea pigs. *Arch Geschwulstforsch* (in press, 1970)

- 4 JEWELLER, C. W. and KOTZ, H. Attempts to adapt leukemia L2C from inbred to non inbred guinea pigs. *Amer. J. Path.* 37: 191-201 (1960)
- 5 JEWELLER, C. W. and KOTZ, H. Studies of leukemia L2C in guinea pigs. *Arch. Viroforsch.* 12: 537-551 (1962)
- 6 MEYER, C. *Sarcoma espontaneo trasplantable en el cobayo*. *Rev. Inst. Bact., Buenos Aires* 7: 147-151 (1918)
- 7 NATH, L., RANFIELD, W., BOWYER, S., and TOWNES, A. J. Virus particles associated with strain 2 guinea pig leukemia (L2C-NB). *J. nat. Cancer Inst.* 37: 979-991 (1967)
- 8 OSTER, S. R. Observations on a new virus associated with guinea pig leukemia: preliminary note. *J. nat. Cancer Inst.* 37: 797-800 (1967)
- 9 SCHALL, O. W. *Veterinary Hematology*, p. 392 ( Lea & Febiger, Philadelphia 1965)
- 10 SNIJDERS, E. P. Over een overerfbare leukemie bij cavia's. *Ned. T. Geneesk.* 70: 1259-1262 (1926)
- 11 SNIJDERS, E. P. Lange resultaten van proefinoculeringen met een overerfbare cavia leukemie. in: *HANDELS VAN HET NEDERLAND Natuurwet. Genoot.* Congr. 21, pp. 160-164 Amsterdam 1927

## Wirkung von L-Asparaginase aus *Escherichia coli* auf die Stimulation von Lymphozytenkulturen<sup>1</sup>

H. KIRCHNER und S. BAUER

Hämatologische Abteilung (Prof. Dr. H. BÄCHTER) Klinikum Steglitz  
der Freien Universität Berlin

Stimulation von Lymphozyten *in vitro* wurde erstmals 1959 von HUNGERFORD *et al* und 1960 von NOWELL als Folge der Einwirkung eines Phytohemagglutinins aus *Phaseolus vulgaris* (PHA) beschrieben [22, 30]. Dabei entstehen aus den Lymphozyten nach anfänglicher Steigerung der Protein- und RNS-Synthese die sogenannten Blasten, die eine hohe DNS-Syntheserate und Zellteilungsfrequenz aufweisen [8, 12, 27, 51]. Ausser dem PHA ist seither eine Anzahl von Stimulationsmechanismen gefunden und mehrfach zusammenfassend dargestellt worden [1, 25, 29, 35, 36, 16].

Kürzlich wurde gezeigt, dass das zytostatisch wirksame Enzym L-Asparaginase aus *E. coli* [neuere deutschsprachige Übersichten bei 6, 18, 31, 17] die PHA bedingte Stimulation der Lymphozyten des Blutes Gesunder zu hemmen vermag [2, 21]. Da die Wirkungsweise des Enzymes im System der Lymphozytenkultur noch ungeklärt ist, erscheint es von Interesse, zu untersuchen, ob auch andere Stimulationsmechanismen durch L-Asparaginase in gleicher Weise beeinflusst werden können. In der vorliegenden Arbeit wurden Lymphozytenkulturen mit verschiedenen Antigenen [15, 10], Staphylokokken-Kultur-Extrakt [26], Streptolysin O [21], Pokeweed Mitogen [11, 16] und Quecksilber-II-chlorid [18] stimuliert und in jedem Fall der Einfluss von L-Asparaginase aus *Escherichia coli* untersucht.

<sup>1</sup> Wir bedanken uns bei Dr. J. SOVEN den Behringwerken Marburg für die Überlassung der L-Asparaginase und bei Dr. KERNER Bakteriell. Untersuchungsabteilung des Instituts für Hygiene und Mikrobiologie der FU (Direktor: Prof. Dr. B. SCHMIDT) im Klinikum Steglitz für den zur Herstellung des Staphylokokkenextraktes verwendeten Stamm.

## Gesetzkulturmethoden

Lymphocytenkulturen wurden in folgender Weise unter Beachtung steriler Hautelen gewonnen. Heparinwasser (20 IE/ml) Venenblut gesunder Freiwilliger wurde mit Macrodon 6% (Knoll) im Verhältnis 1:10 vermischt und nach 45 min mit gerösterter Mentation (Temperatur bei einem Neigungswinkel von 45°) der leukocytenreiche Plasmaüberstand mit Pasteurpipetten vorsichtig entnommen. Die zur Kultivierung verwendeten Zentrifugengewinne mit 5% Kanntopfen dicht verschlossen) enthielten jeweils 5 ml Kulturansatz, der aus Zellsuspensionen 4-6 Millionen Zellen pro ml Fibrinogen und Medium TC 192 (Difco) im Verhältnis 1:1-4 hergestellt worden war. Die Endkonzentration der Antikörperkonzentration und Streptozin betrug 100 IE/ml. Angereicherte Lymphocytenfraktionen verwendeten wir bei diesen Versuchen nicht, da in letzter Zeit mehrfach gezeigt worden war, dass gerade die Anwesenheit von monoklonogenen Makrophagen in der Kultur in vielen Fällen für eine optimale Stimulation zuwendig ist [17-20].

Die zu verwendenden Antigenen und gegebenenfalls Adjuvantien wurden den Kulturen zu Versuchsbeginn zugesetzt und diese dann über den jeweils notwendigen Zeitraum bei 37°C in einem ungastischen Ernschrank inkubiert. Zu Versuchende wurden nach Zentrifugation (ca. 400 g) 10 min von den Sedimenten Ausstriche angefertigt und in üblicher Weise nach Papanicolaou gefärbt. Von jedem Ausstrich wurden zur Bestimmung des Prozentsatzes Plattenartige Zellen 100 intakte Lymphocyten Zellen ausgezählt, wobei die Unterscheidung von Platten und Makrophagen bei nahezu jeder Zelle auf Grund morphologischer Kriterien [9] so genau möglich war und die sogenannten Zwischentypen nicht als Platten gewertet wurden. So entstande Transformation zu Platten war bei unbehandelten Kontrollen in unserem System sehr selten, unter 0,0%. Hierin stimmen unsere Versuche mit den Ergebnissen von Carson [11] weitgehend überein.

Die Transformationsversuche wurden nach der von Turk et al. [12] angegebenen Methode durchgeföhrt.

## Materialien

Die folgenden Substanzen wurden den Kulturen in Aliquots von 0,1 ml Ansatz zugelegt: adjuvante Verlebungserstärker mit 0,1% wässriger Kaliumbichromat-angereichert und die jeweiligen Endkonzentrationen: Phosphoryliertes P. D. in 2 µl; 1 µl Adjuvant M. (Grand Island Biological Company) 70 µl; 1 µl Quecksilber-Hydroxydiphenyl-Merck 1 µl; 1 µl Alkoholisches Tetrad 2 µl; 1 µl Vaccine Antigen 2 µl; 1 µl Streptozin 0,2 µl; 1 µl Adjuvante Substanzen von den Befragungswerken. Die Adjuvantien wurden jeweils über eine von den Befragungswerken Maßnahme zur Verfestigung gesetzt und für die Versuche in 10% wässriger NaCl-Lösung verdünnt, damit die Endkonzentrationen zwischen 0,5 und 1 µl betrugen. Nachfolgend wird angegeben, wie nach der von Turk et al. beschriebenen Methode hergestellt [12] und in Konzentrationen von 0,1 µl bis 10 µl pro Kulturenatz verwendet. Zusätzlich kam Salicylsäure-Befragungswerkzeug in einer Konzentration von 0,01 µl zur Anwendung.

## Ergebnisse

Stimulierung der Kulturen. In einer früheren Versuchsreihe untersuchten wir die Effektivität Platten mit bei 20 gesunden Blutproben, deren Reaktionen der Reaktionstypen in Kultur auf verschiedene Antigene untersucht wurden. Es



handelte sich dabei um Alt-Tuberkulin, Tetanus Toxoid, Vaccinia-Antigen und Streptolysin O. Bei einer durchschnittlichen spontanen Transformationsrate von unter 0,05% wurden diejenigen Kulturen als positiv betrachtet, die mindestens 1% Blisten bei Auswertung von 1000 intakten Lymphozytären Zellen nach einem 6tägigen Kulturintervall aufwiesen.

Zur Prüfung des Einflusses der L-Asparaginase auf die Antigen-induzierte Stimulation wurde bei den jetzigen Experimenten die Versuchsanordnung so gewählt, dass im Falle jedes einzelnen Antigens mindestens 5 verschiedene Versuche mit 5 verschiedenen Blutspendern durchgeführt wurden. Der Prozentsatz Blisten in den lediglich mit Antigen behandelten Kontrollen aus diesen Versuchen ist in Tabelle 1 dargestellt. Bei jedem Versuch wurde gleichzeitig eine Kontrolle mitgeführt, die nur L-Asparaginase erhielt. Die daraus gewonnenen Präparate erschienen sowohl nach morphologischen Kriterien wie auch betreff der Trypanblauversuche durch das Enzym völlig unbeeinflusst zu sein.

Wurde in diesen Versuchen L-Asparaginase aus *E. coli* zusammen mit dem Antigen zu Versuchsbeginn den Kulturen zugesetzt, so konnte damit in jedem Fall die Blistenentstehung vollständig verhindert werden, d. h. bei Untersuchung der gefärbten Ausstriche nach Beendigung der Kulturen waren keinerlei Blisten nachzuweisen, obwohl die typischen kleinen Lymphozyten auf den Ausstrichen in grosser Zahl morphologisch intakt erschienen und auch bei Untersuchungen mit Trypanblau der Prozentsatz gefärbter Zellen sich nicht wesentlich von den Kontrollen unterschied.

*Andere Stimulationsmechanismen.* Ausser den Antigenen verwendeten wir noch folgende weitere Substanzen zur Stimulation von Lympho-

*Tabelle 1* Prozentsatz sogenannter Blisten in antigenstimulierten Lymphozytenkulturen nach 6 Tagen mit und ohne Zusatz von L-Asparaginase aus *E. coli* (0.5 bis 10 IE/ml). Werte aus jeweils mindestens 5 Versuchen mit 5 verschiedenen Blutspendern.

|                  | L-Asparaginase |     |
|------------------|----------------|-----|
|                  | ohne           | mit |
| Alt-Tuberkulin   | 2.30           | 0   |
| Tetanus Toxoid   | 2.26           | 0   |
| Streptolysin O   | 4.25           | 0   |
| Vaccinia-Antigen | 1.9            | 0   |

Tabelle II: Prozentzahl beimpfter Blasten in stimulierten Leukämie-Kulturen mit und ohne Zusatz von L-Asparaginase aus *E. coli* 05-10 IF ml. Werte aus jeweils mindestens 10 Versuchen mit 10 verschiedenen Blutspendern

|                   | PHA <sup>1</sup> | PWM <sup>2</sup> | HgCl <sub>2</sub> | SF <sup>3</sup> |
|-------------------|------------------|------------------|-------------------|-----------------|
| Ohne Asparaginase | 60-65%           | 30-50%           | 5-33%             | 2-35%           |
| Mit Asparaginase  | 0                | 0                | 0                 | 0               |

<sup>1</sup> Phytohämagglutinin aus *Phaseolus vulgaris*

<sup>2</sup> Pokeweed Mitogen

<sup>3</sup> Staphylokokken Filtrat

zytenkulturen. Phytohämagglutinin P aus *Phaseolus vulgaris* (PHA), Pokeweed Mitogen (PWM) (Kulturdauer jeweils 3 Tage) sowie Staphylokokken Filtrat (SF), Staphylolysin und Quecksilber-II-chlorid (Sublimat) bei 4-tägigem Kulturintervall. Untersucht wurden jeweils mindestens 10 verschiedene Kulturansätze von 10 verschiedenen Blutspendern.

Die spontane Transformationsrate lag auch in den Kontrollen dieser Versuche unter 0,05 %, lediglich mit L-Asparaginase behandelte Kulturen erschienen entsprechend den obigen Versuchen völlig unbeeinflusst. Der Prozentatz stimulierter Zellen in den entsprechenden Versuchen ist in Tabelle II dargestellt. Wir finden dabei im Falle des PHA ziemlich konstant eine grosse Zahl Blastenzellen (60-65%), bei PWM waren es deutlich weniger (30-50%), die Stimulation war jedoch in den einzelnen Versuchen ebenfalls recht einheitlich. Im Gegensatz dazu standen die anderen Simulationsmechanismen, bei denen erhebliche Unterschiede zwischen den einzelnen Blutspendern bestanden. Wir finden bei Quecksilber-II-chlorid 5-33% Blasten und bei Staphylokokken Filtrat 2-35%. Ein wesentlicher Unterschied zwischen Staphylokokken Kultur Filtrat und Staphylolysin, das vorwiegend Staphylokokken Hämolyse enthält, bestand nicht.

Die Beeinflussung der Blastenzellteilung durch L-Asparaginase aus *E. coli* war bei allen diesen Simulationsmechanismen gleich und entsprach den obigen Versuchen mit Antigenen. Die Stimulation liess sich durch gleichzeitige Gabe von Streptomycin und L-Asparaginase bei Versuchsdauern ab 12 Stunden verhindern, so dass die bei Beeinträchtigung des Versuches angefertigten Ausstriche in allen Fällen lediglich unstimulierte Blastenzellen neben Makroplasmen gelassen blieben und degenerierenden Plasmazellen fehlten. Dabei schlossen die

Lymphozyten nach morphologischen Kriterien und bei Anwendung der Trypanblaumethode als ungeschädigte lebende Zellen

### Diskussion

Von vielen Untersuchern wird zwischen «spezifischer» und «unspezifischer» Stimulation von Lymphozyten *in vitro* unterschieden. Zur Begründung dient die Tatsache, dass Antigene nur bei vorheriger Sensibilisierung einen relativ kleinen Prozentsatz der Lymphozyten nach etwa 6tagigem Kulturintervall stimulieren, während andere Substanzen (am besten untersucht ist das PHA) einen weitaus grosseren Anteil der Zellen aller Gesunden nach kürzerer Kulturdauer zu sogenannten Blasten transformieren. In beiden Fällen werden in den in unbehandelten Kulturen inaktiven kleinen Lymphozyten ganz entscheidende morphologische und biochemische Veränderungen induziert (u.a. DNS-Synthese und Mitosen), deren Ursache jedoch weder bei den «spezifischen» noch bei den «unspezifischen» Mechanismen bekannt ist. Vor allem ist es nicht entschieden, ob der Stimulationsvorgang in beiden Fällen der gleiche ist, oder ob dabei wesentliche Unterschiede bestehen. Es erschien deshalb von Interesse zu untersuchen, ob die beschriebene Hemmung der PHA-Wirkung auf Lymphozytenkulturen durch L-Asparaginase [2, 24] auch bei verschiedenen anderen Stimulationsmechanismen nachweisbar ist.

Unsere Experimente ergaben, dass die Stimulationswirkung sämtlicher untersuchten Antigene durch gleichzeitige Gabe des Enzymes zu Versuchsbeginn verhindert werden konnte, d.h. Blasten waren in den nach 6 Tagen angefertigten Ausstrichen nicht nachweisbar. Das gleiche galt bei unterschiedlichem Kulturintervall für die Versuche mit Pokeweed-Mitogen, Staphylokokkenfiltrat und Quecksilber-II-chlorid. In allen Fällen erwies sich die L-Asparaginase als ausserordentlich wirksam in der Unterdrückung des Transformationsvorganges und wir haben in allen beschriebenen Experimenten tatsächlich keine einzige Blastenzelle nach Gabe von L-Asparaginase aus *E. coli* gefunden. Es bestand also hierin kein Unterschied zwischen «spezifischen» und «unspezifischen» Stimulationsmechanismen.

L-Asparaginase ist in der verwendeten Konzentration weitgehend atoxisch für normale unbehandelte Lymphozyten in Kultur [49, eigene Beobachtungen] und wir halten es auf Grund der Trypanblauver-

nische für unwahrscheinlich, dass im Falle der stimulierten Kulturen lediglich die Blasten oder deren Vorläufer als Folge der Enzymbehandlung selektiv vernichtet werden. Wir nehmen dagegen an, dass die Stoffwechselvorgänge, die zur Blastenbildung und Mitose führen, an irgendeiner Stelle so beeinflusst werden, dass die Transformation unterbleibt. Es ist möglich, dass es sich dabei nicht nur um eine Folge der Spaltung von exogenem Asparagin handelt, sondern dass für L-Asparaginase auch ein spezifischer intrazellulärer Angriffspunkt gegeben ist. Welcher Art die Stoffwechselvorgänge sind, die den Angriffspunkt des Enzymes darstellen, ist auf Grund der bisherigen rein morphologischen Untersuchungen nicht näher zu definieren. In diesem Zusammenhang könnte es jedoch von Interesse sein, dass bei Gabe der L-Asparaginase 12 und 24 Stunden nach Phytohemagglutinin noch eine Hemmung der Blastenbildung nachweisbar ist [24] und dass die Asparaginasewirkung auf PHA-Kulturen zu Versuchsende nicht nachweisbar ist, wenn die Zellen 12 Stunden nach Gabe von PHA und Enzym gewaschen werden und neues Medium erhalten (unveröffentlichte Beobachtungen).

Die anderen in der Literatur beschriebenen Agentien mit der Fähigkeit, die Transformation der Lymphozyten *in vitro* zu hemmen, sind recht vielfältiger Art. Es handelt sich dabei u. a. um Hormone [31, 32], Stoffwechsellinhibitoren [23, 33, 41, 42, 44], Zytostatika [3, 20], Makromoleküle [5, 13, 37], Viren [21, 50, 53], Extrakte aus Mykoplasmen [14], Ouabain, Adamantinhydrochlorid und Natriumsalzylat [39, 43, 45]. Sämtliche dieser Möglichkeiten sind von großem Interesse, da sie u. U. indirekten Aufschluss über den Stimulationsmechanismus der Lymphozyten erbringen können. Ein Enzym wie L-Asparaginase mit einer chemisch relativ einfach zu definierenden Wirkungsweise erscheint aus dem gleichen Grund besonders geeignet, weitere Untersuchungen an stimulierten Lymphozytenkulturen durchzuführen. Die Wirksamkeit der L-Asparaginase in diesem System ist neben den Befunden an regenerierender Rattenleber, an Kaninchenei-Embryonen und Knochenmarkskulturen [1, 7, 10], ein zusätzlicher Hinweis dafür, dass dieses Enzym nicht nur spezifisch Tumorzellen beeinflusst, sondern auch andere schnell proliferierende Gewebe.

Zusammenfassung

Die Wirkung von L-Asparaginase auf die Transformation von Lymphozyten wurde untersucht. Die Enzymbehandlung führt zu einer Hemmung der Blastenbildung in Kulturen, die mit Phytohemagglutinin stimuliert wurden. Die Hemmung ist dosisabhängig und tritt bereits bei einer Konzentration von 10<sup>-6</sup> M ein. Die Hemmung ist reversibel und tritt bei einer Konzentration von 10<sup>-6</sup> M ein.

hamagglutinin P, Pokeweed Mitogen, Quecksilber II-chlorid und Staphylokokken Kultur-Filtrat stimuliert. In allen Fällen konnte die Entstehung von Blasten und Mitosen vollständig verhindert werden, wenn L-Asparaginase aus *Escherichia coli* zusammen mit dem stimulierenden Agens zu Versuchsbeginn gegeben wurde. Hierbei bestand kein Unterschied zwischen «spezifischen» und «unspezifischen» Stimulationsmechanismen.

### Summary

Normal peripheral lymphocyte cultures were stimulated with antigens (old tuberculin, tetanus toxoid, vaccinia antigen and streptolysin O), as well as with Phytohaemagglutinin of *Phaseolus vulgaris*, Pokeweed mitogen, staphylococcal filtrate and mercuric chloride. In any case the development of blasts and mitosis in culture could be prevented completely when L-asparaginase from *Escherichia coli* was added together with the stimulant at the beginning of the culture. There was no difference between the so called specific and non-specific stimuli.

### Literatur

- 1 ADAMSON, R. H. and FABRO, S. Embryotoxic effect of L-Asparaginase. *Nature* 218: 1164-1165 (1968).
- 2 ASTALDI, G., BURGIO, G. R., IRE, J., GENOVA, R., and ASTALDI, A. A., Jr. L-Asparaginase and blastogenesis. *Lancet* 1: 423 (1969).
- 3 ASTALDI, G., ERIDANI, S., PONTI, G. B., VALENTINI, R., and GIANGRADE, A. Influence of antiblastic agents applied either *in vivo* or *in vitro* on human lymphocyte transformation in cell culture. *Blut* 29: 8-16 (1969).
- 4 BACH, F. H. and HIRSCHORN, K. The *in vitro* immune response of peripheral blood lymphocytes. *Sem. Haemat.* 2: 68-89 (1965).
- 5 BACHI, G., BUSSI, A. M., SARTORIS, S., VERGNANO, F., and FAZIO, M. Delay of human lymphocyte 'blast' transformation by homologous RNA. *Acta haemat., Basel* 39: 270-275 (1968).
- 6 BAUER, K. Zur Biochemie der Asparaginase. *Med. Klin.* 64: 9-12 (1969).
- 7 BECKER, F. F. and BROOME, J. D. L-Asparaginase. Inhibition of early mitosis in regenerating rat liver. *Science* 156: 1602-1603 (1967).
- 8 BENDER, M. A. and PRESCOTT, D. M. DNA synthesis and mitosis in cultures of human peripheral leukocytes. *Exp. Cell Res.* 27: 221-229 (1962).
- 9 BRÜCHER, H., DILL, A., and GRABER, M. Untersuchungen über Blut- und Gewebemakrophagen. *Acta haemat., Basel* 41: 76-93 (1969).
- 10 CARON, G. A. Further observations on spontaneous blastoid transformation of human small lymphocytes *in vitro*. *Brit. J. Haemat.* 16: 313-322 (1969).
- 11 CHESIN, L. N., BORJESON, J., WELSH, P. D., DOUGLAS, S. D., and COOPER, H. L. Studies on human peripheral blood lymphocytes *in vitro*. II. Morphological and biochemical studies on the transformation of lymphocytes by pokeweed mitogen. *J. exp. Med.* 124: 873-884 (1966).
- 12 COOPER, H. L. and RUBIN, A. D. RNA metabolism in lymphocytes stimulated by phytohemagglutinin: initial responses to phytohemagglutinin. *Blood* 25: 1014-1027 (1965).
- 13 COOPERBAND, S. R., BONDEVIA, H., SCHMID, K., and MANNICK, J. A. Transformation of human lymphocytes: inhibition by homologous alpha globulin. *Science* 159: 1243-1244 (1968).

- 14 CARTERMAN R. and MURTON H. F. Reversible inhibition of mitosis in lymphocyte cultures by non-viable mycoplasma. *Proc. Soc. exp. Biol.*, NY 121: 793-795 (1968).
- 15 LARRY M. W., ROOTH S., and LUCILLA M. C. G. The response of lymphocytes to antigen challenge in vitro. *Lancet* I: 109-111 (1973).
- 16 JARVIS P., BARBER B. F., BERNHARD L. L., and JANCER H. Mitogenic activity in *Physalis americana* (goosefoot). *Lancet* I: 1100-1101 (1974).
- 17 GONZALEZ J. Role of monocytes in the mixed leukocyte culture reaction. *Proc. Soc. exp. Biol.*, NY 177: 30-33 (1977).
- 18 CRISTOMANN L. L. Asparaginase and Leukemia. *Klin. Wochschr.* 47: 11-14 (1979).
- 19 HARRIS J. E. Effect of L-Asparaginase on the activity of normal mouse bone marrow. *U.S. Armed Forces Forces*. *Nature* 273: 740-743 (1979).
- 20 HERBER E. M. and OPPENSTEIN J. J. Inhibition of in vitro lymphocyte transformation during chemotherapy in man. *Cancer Res.* 27: 40-46 (1977).
- 21 HUNTERSON K., NEUBERMAN R. R., VERHO S., and GRIMMAN R. H. The action of streptolysin S on peripheral lymphocytes of normal subjects and patients with acute rheumatic fever. *Proc. nat. Acad. Sci. Wash.* 52: 1151-1157 (1974).
- 22 HUNTERSON D. A., DOWDLEY A. J., NEWELL P. C., and BURCH S. The chromosome constitution of a human phenotypic leukaemia. *Am. J. Hum. Genet.* 11: 215-231 (1979).
- 23 HUNTER D. and HUNTERSON K. Suppression of in vitro lymphocyte responses by chloroquine. *New Engl. J. Med.* 273: 2377 (1979).
- 24 KIRCHNER H. and BURCH S. Wirkung von L-Asparaginase auf *Escherichia coli* und *Physalis americana* in planktonkulturen. *Klin. Wochschr.* 49: 50-51 (1970).
- 25 LEE S. R. Lymphocyte isolation (North Holland Publishing Co., Amsterdam 1968).
- 26 LEE S. R. and HUNTER T. M. Surface and non-surface stimulation of peripheral lymphocytes. *Lancet* i: 93-95 (1974).
- 27 MACLENNAN O. R. and FAN CHU F. C. Jr. The effect of phytohemagglutinin on leukocyte cultures as measured by  $^{32}$ P incorporation in the DNA, RNA and acid-soluble fractions. *Biol. J.* 403: 43-51 (1975).
- 28 MONTGOMERY J. R., NORTH M. A., ROOTH W. I., MILLER J. L., OLSON C. B. and GORE R. A. Anal inhibition of lymphocyte response to phytohemagglutinin. *Science* 170: 1493-1495 (1970).
- 29 NEWELL P. C. and RICHIERI M. The action of phytohemagglutinin in vivo and in vitro in man. *Proc. Assoc. L.* 1: 185 (1975).
- 30 NEWELL P. C. Phytohemagglutinin in vitro and in vivo in man. *Proc. Assoc. L.* 1: 185 (1975).
- 31 NEWELL P. C. Inhibition of human leukocyte response by phytohemagglutinin. *Cancer Res.* 37: 1518-1521 (1977).
- 32 NEWELL P. C. Mitogenic stimulation of human lymphocytes. *Int. Proc.* 2: 73-78 (1978).
- 33 NEWELL P. C. Mitogenic stimulation and chromosome damage by mitogens in human lymphocytes. *Am. J. Cell. Res.* 5: 411-419 (1974).
- 34 OBERLIN H. E. and SCHMIDT H. K. Hemmung der Agglutination des Menschen durch L-Asparaginase. *Klin. Wochschr.* 47: 4-7 (1979).
- 35 OPPENSTEIN J. J. Reversible in vitro lymphocyte transformation induced by streptolysin S. *Proc. Soc. exp. Biol. Med.* 77: 71-75 (1977).
- 36 OPPENSTEIN J. J. In vitro lymphocyte transformation and in vivo effects of streptolysin S on lymphocytes. *Am. J. Physiol.* 235: 315-318.
- 37 OPPENSTEIN J. J., HUNTERSON K. D., KAY J. E., and OBERLIN H. E. Effects of streptolysin S and treatment of lymphocytes with streptolysin S on the phytohemagglutinin response. *Am. J. Cell. Res.* 5: 419-424 (1974).
- 38 OPPENSTEIN J. J., RICHIERI M. C., and HUNTER T. M. The transformation of cul-

- lumpurified lymphocytes with nonspecific and specific antigenic stimuli *J Immunol* 101 262-270 (1968)
- 39 PACHMAN, L. M., ESTERLY, N. B., and PETERSON, R. D. A. The effect of therapeutic concentrations of sodium salicylate on isolated human peripheral blood lymphocytes *in vitro* *Fed Proc* 28 294 (1969)
  - 40 PEARMAIN, G., LACETTE, R. R., and FITZGERALD, P. H. Tuberculin induced mitosis in peripheral blood leucocytes. *Lancet* 1 637-638 (1963)
  - 41 PISCIOTTA, A. V. and DEPREY, G. Inhibition of mitosis by chloramphenicol in phytohemagglutinin stimulated lymphocytes *Blood* 30 457-464 (1967)
  - 42 PISCIOTTA, A. V., WESTRING, D. W., and DEPREY, G. Studies on agranulocytosis VIII Inhibition of mitosis in phytohemagglutinin stimulated lymphocytes by chlorpromazine *J Lab clin Med* 70 229-235 (1967)
  - 43 QUASTEL, M. R. and KAPLAN, J. G. Inhibition by ouabain of human lymphocyte transformation induced by phytohemagglutinin *in vitro* *Nature* 219 198-200 (1968)
  - 44 RABINOWITZ, Y., SCHINO, I., and WILHITE, B. A. Metabolic responses of separated leucocytes to phytohemagglutinin. Effects of anerobiasis, actinomycin D, and puromycin *Brit J Haemat* 15 455-464 (1968)
  - 45 RAWLS, W. E., MELNICK, J. L., OLSON, G. B., DENT, P. B., and GOOD, R. A. Effect of adamantane hydrochloride on the response of human lymphocytes to phytohemagglutinin *Science* 159 506-507 (1967)
  - 46 ROBBINS, J. H. Tissue culture studies of the human lymphocyte *Science* 146 1648-1654 (1964)
  - 47 SCHMIDT, C. G. und GALLMEIER, W. M. Zur Enzymtherapie der Leukämien *Dtsch med Wschr* 93 2299-2309 (1968)
  - 48 SCHÖPF, F., SCHULZ, K. H., und GROMM, M. Transformationen und Mitosen von Lymphozyten *in vitro* durch Quecksilber II chlorid *Naturwissenschaften* 54 568-569 (1967)
  - 49 SCHREFA, R., DOLOWY, W. C., and AMMERLAAL, R. N. L-Asparaginase toxicity to normal and leukemic human lymphocytes *Science* 155 329-330 (1967)
  - 50 SMITHWICK, E. M. and BERCOVITZ, S. *In vitro* suppression of the lymphocyte response to tuberculin by live measles virus *Proc Soc exp Biol, NY* 123 276-278 (1966)
  - 51 TANAKA, Y., EPSTEIN, L. B., BRECHER, G., and STOHLMAN, F., Jr. Transformation of lymphocytes in cultures of human peripheral blood *Blood* 22 614-629 (1963)
  - 52 TURK, A., GLADE, P. R., and CHIESSIN, L. N. Blast like transformation induced in peripheral blood lymphocytes by cellular injury: a comparison of sonication and phytohemagglutinin *Blood* 33 329-340 (1969)
  - 53 WILLIAMS, F. TH. C., MELNICK, J. L., and RAWLS, W. E. Viral inhibition of the phytohemagglutinin response of human lymphocytes and application to viral hepatitis *Proc Soc exp Biol* 130 652-661 (1969)

Adresse der Autoren: Dr. H. KIRCHNER und S. BAUER, Hämatologische Abteilung, Klinikum Steglitz der Freien Universität Berlin, Hindenburgdamm 30, D 1 Berlin 45 (Deutschland)

## Cytochemical Studies of Acute Leukemias

E. A. IINONEN

Sigepson Memorial Institute, University of Michigan, Ann Arbor, Mich.

In combining cytochemical and morphological analysis, an attempt was made to correlate alterations in cellular structure with differences in chemical composition. As recent evidence has indicated that the major defect in the acute leukemias is the impairment of cellular differentiation and maturation [5, 7] studies to obtain cytochemical profiles of the primitive cells were undertaken.

### *Materials and Methods*

Blood and bone marrow films were obtained from 71 patients with acute leukemias: 29 with acute lymphocytic leukemia (ALL), 23 with acute myelomonocytic and acute monocyte leukemia (AML), 19 with acute granulocytic leukemia (AGL) including 5 patients in the acute phase of chronic granulocytic leukemia.

Coated slides consisted of blood and bone marrow films of 16 hours by adults and 5 patients with newborn congenital diseases.

Six cytochemical reactions were used: periodic acid-Schiff (PAS), Sudan black B, acid phosphatase, alkaline phosphatase, nonspecific esterase, and phosphatidylase. The methods employed for the reactions were: SHERMAN and STRONG [11] for Sudan black B and PAS; [13] for alkaline phosphatase; ABRAMSON [1] for acid phosphatase; WARMUTH and WOLF [14] for nonspecific esterase; LILJAND and PAKKILA [6] for phosphatidylase; and periodic acid-Schiff reaction for glycogen and glycogenolysis. Wright's stain was employed for morphological evaluation.

A semiquantitative scoring method was used for estimating the intensity of the cytochemical reactions in the cells. The range of color values for each cell was scored 0-4+ (0 = no reaction; 4+ = most intense). All cells of each type were examined for each reaction with 4X as the highest possible mean score.

### *Results*

PAS reaction in lymphoblasts of ALL exhibits a moderate to intense reactivity (— + + + +). Morphoblasts of ALL weak to



- lumpurified lymphocytes with nonspecific and specific antigenic stimuli. *J Immunol* **101**: 262-270 (1968)
39. FACHMAN I. M., ESTERLY, N. B., and PETERSON, R. D. A. The effect of therapeutic concentrations of sodium silylate on isolated human peripheral blood lymphocytes *in vitro*. *Fed Proc* **29**: 291 (1969)
  40. PEARMAIN G., LACETTE R. R., and FITZGERALD, P. H. Tuberculin induced mitosis in peripheral blood leucocytes. *Lancet* **1**: 637-638 (1963)
  41. Pisciotta A. V. and DePREY, G. Inhibition of mitosis by chloramphenicol in phytohemagglutinin stimulated lymphocytes. *Blood* **30**: 457-461 (1967)
  42. Pisciotta, A. V., WISTRING, D. W., and DePREY, G. Studies on agranulocytosis. VIII. Inhibition of mitosis in phytohemagglutinin stimulated lymphocytes by chlorpromazine. *J Lab clin Med* **70**: 229-235 (1967)
  43. QUASTEL, M. R. and KAPLAN J. G. Inhibition by ouabain of human lymphocyte transformation induced by phytohemagglutinin *in vitro*. *Nature* **219**: 198-200 (1968)
  44. RABINOWITZ, Y., SCHIMO, I., and WILHITE B. A. Metabolic responses of separated leucocytes to phytohemagglutinin. Effects of anaerobiosis, actinomycin D and puromycin. *Brit J Haemat* **15**: 455-461 (1968)
  45. RAWLS, W. I., MELNICK J. I., OLSON, G. B., DENT, P. B., and GOOD R. A. Effect of adamantane hydrochloride on the response of human lymphocytes to phytohemagglutinin. *Science* **158**: 506-507 (1967)
  46. ROBBINS J. H. Tissue culture studies of the human lymphocyte. *Science* **146**: 1618-1654 (1964)
  47. SCHINDT C. G. und GALLMEIER, W. M. Zur Enzymtherapie der Leukämien. *Dtsch med Wschr* **93**: 2299-2309 (1968)
  48. SCHÖPF, F., SCHILLZ K. H., und GROMM M. Transformationen und Mitosen von Lymphozyten *in vitro* durch Quecksilber II chlorid. *Naturwissenschaften* **54**: 568-569 (1967)
  49. SCHREK R., DOLOWY, W. C., and AMMERLAAL, R. N. L-Asparaginase toxicity to normal and leukemic human lymphocytes. *Science* **155**: 329-330 (1967)
  50. SMITHWICK F. M. and BERCOVICH, S. *In vitro* suppression of the lymphocyte response to tuberculin by live measles virus. *Proc Soc exp Biol NY* **123**: 276-278 (1966)
  51. TANAKA, Y., ISTEIN I. B., BRECHER G. and STOHLMAN I., Jr. Transformation of lymphocytes in cultures of human peripheral blood. *Blood* **22**: 614-629 (1963)
  52. TURK A., GLADF, P. R. and CHIESIN, I. N. Blast like transformation induced in peripheral blood lymphocytes by cellular injury: a comparison of sonication and phytohemagglutinin. *Blood* **33**: 329-340 (1969)
  53. WILFELS I. TH. C. MELNICK J. I. and RAWLS, W. F. Viral inhibition of the phytohemagglutinin response of human lymphocytes and application to viral hepatitis. *Proc Soc exp Biol* **130**: 652-661 (1969)

Adresse der Autoren: Dr. H. KIRCHNER und S. BAUTR, Hämatologische Abteilung, Klinikum Steglitz der Freien Universität Berlin, Hindenburgdamm 30, D-1 Berlin 45 (Deutschland)

## Cytochemical Studies of Acute Leukemias

E. A. LEINONEN

Simpson Memorial Institute, University of Michigan Ann Arbor, Mich

In combining cytochemical and morphological analysis, an attempt was made to correlate alterations in cellular structure with differences in chemical composition. As recent evidence has indicated that the major defect in the acute leukemias is the impairment of cellular differentiation and maturation [5, 7] studies to obtain cytochemical profiles of the primitive cells were undertaken.

### *Materials and Methods*

Blood and bone marrow films were obtained from 71 patients with acute leukemias: 29 with acute lymphocytic leukemia (ALL), 23 with acute myelomonocytic and acute monocytic leukemia (AML), 19 with acute granulocytic leukemia (AGL) including 5 patients in the acute phase of chronic granulocytic leukemia.


Controls consisted of blood and bone marrow films of 16 healthy adults and 5 patients with non-hematological diseases.

Six cytochemical reactions were used: periodic acid-Schiff, Sudan black B, acid phosphatase, alkaline phosphatase, nonspecific esterase and phosphorylase. The methods employed for the reactions were: SHEEHAN and STOREY [16] for lipids; GOLDBERG and BARKA [9] for acid phosphatase; ACKERMAN [1] for alkaline phosphatase; WACHSTEIN and WOLF [20] for nonspecific esterase; ERÄNKÖ and PALKAMA [6] for phosphorylase, and periodic acid-Schiff reaction for glycogen and glycoprotein. Wright's stain was employed for morphological evaluation.

A semiquantitative scoring method was used for estimating the intensity of the cytochemical enzyme activity. The rating of individual cells was from colorless to intense (0-4+). To obtain a total score, 100 cells of each type were counted for each reaction with 400 as the highest possible mean score.

### *Results*

PAS reaction in lymphoblasts of ALL exhibits a moderate to intense reactivity (++-++++), monoblasts of AML weak to



*Fig 1* Wright's stain and PAS reaction in the primitive cells of the acute leukemia. Wright's stain *a* Lymphoblasts from ALL, *b* monoblasts from AML, *c* myeloblasts from AGL. PAS reaction *d* PAS reaction in lymphoblasts from ALL exhibiting fine and coarse granules and clumps of reactive material, *e* PAS reaction in monoblasts from AML demonstrating fine and coarse granules, *f* PAS reaction in myeloblasts from AGL showing diffuse staining ( $\times 1,500$ )

strong coloration (+-++), and myeloblasts of AGL weak to moderate activity (+-++) (table I). PAS reaction patterns in lymphoblasts of ALL show fine to coarse particulate granules with coarse clumps of positive material frequently seen, monoblasts of AML exhibit diffuse staining, fine and coarse granules, but no clumps of reactive material, myeloblasts of AGL are often nonreactive or show diffuse coloration with an occasional cell possessing particulate

glycogen granules. Most often, the reactive granules have a peripherol extracytoplasmic distribution (fig. 1d-f).

Generally, the degree of phosphorylase activity and its intracellular localization in the primitive cells of the acute leukemias corresponds closely with the extracytoplasmic distribution and the relative amount of preformed glycogen demonstrated by the PAS reaction (table I). On occasion, individual blast cells from the acute leukemias show a more intense phosphorylase reaction than would be expected from their PAS reactivity.

Sudan Black B reaction in lymphoblasts of ALL exhibits weak to moderate staining (- - - +), monoblasts of AML, moderate to intense reaction (+ + + - - -), and myeloblasts of AGL moderate to strong coloration (- - - + - +) (table I). Reaction patterns in lymphoblasts of ALL appear as small sudanophilic granules localizing near the nucleus (-) with many cells nonreactive, in monoblasts of AML as small and large sudanophilic granules depositing randomly in the cytoplasm with some cells exhibiting areas of intense activity, and in myeloblasts of AGL as small and moderately large sudanophilic granules localizing near the periphery of the cytoplasm (fig. 2a-c).

Acid phosphatase activity in lymphoblasts of ALL shows weak to moderate activity (- - - +) and monoblasts of AML and myeloblasts of AGL demonstrate moderate to strong reactivity (- - - + +) (table I). The reaction granules range in size from small to large granules with a cytoplasmic localization more intense near the nucleus (-) (fig. 2d-f).

Primitive cells in leukemia, like the normal precursor cells, are negative for alkaline phosphatase activity. As alkaline phosphatase reaction is demonstrable in the mature neutrophils of the patients with acute leukemia, the neutrophils may be used in assessing levels of leukocyte alkaline phosphatase reactivity. The reactivity is variable as fine granules with the majority of neutrophils in ALL exhibiting strong to intense activity (- - - - - +), in AML showing weak to strong reactions (- - - +), and in AGL demonstrating weak activity (+) with numerous cells nonreactive. Many of the neutrophils in AGL appear to have alterations in size and number of specific granules, but an occasional neutrophil will exhibit moderate activity (table I).

Nonspecific esterase reaction in lymphoblasts of ALL has weak to moderate reactivity (- - - -) with fine to coarse granules localizing




Fig 1. Monoblasts from AML showing diffuse staining, *a* monoblasts from AML showing fine granules, *b* monoblasts from AML showing coarse granules, *c* PAS reaction in monoblasts from AML demonstrating fine and coarse granules, *d* PAS reaction in myeloblasts from AGL showing diffuse staining, *e* PAS reaction in myeloblasts from AGL showing fine granules, *f* PAS reaction in myeloblasts from AGL showing coarse granules ( $\times 1,500$ ).

strong coloration (+-+++), and myeloblasts of AGL weak to moderate activity (+-++) (table I). PAS reaction patterns in lymphoblasts of ALL show fine to coarse particulate granules with coarse clumps of positive material frequently seen, monoblasts of AML exhibit diffuse staining, fine and coarse granules, but no clumps of reactive material; myeloblasts of AGL are often nonreactive or show diffuse coloration with an occasional cell possessing particulate

glycogen granules. Most often, the reactive granules have a peripheral cytoplasmic distribution (Fig. 1d-f).

Generally, the degree of phosphorylase activity and its intracellular localization in the primitive cells of the acute leukemia corresponds closely with the cytoplasmic distribution and the relative amount of preformed glycogen demonstrated by the PAS reaction (table I). On occasion individual blast cells from the acute leukemia may show a more intense phosphorylase reaction than would be expected from their PAS reactivity.

Sudan Black B reaction in lymphoblasts of ALL exhibit weak to moderate staining (— + +), monoblasts of AMI moderate to intense reaction (— + + + +), and myeloblasts of AGL moderate to strong coloration (— + + + +) (table I). Reaction patterns in lymphoblasts of ALL appear as small sudanophilic granules localizing near the nuclear leaf with many cells nonreactive, in monoblasts of AMI as small and large sudanophilic granules depositing randomly in the cytoplasm with some cells exhibiting areas of intense activity, and in myeloblasts of AGL as small and moderately large sudanophilic granules localizing near the periphery of the cytoplasm (Fig. 2a-c).

Acid phosphatase activity in lymphoblasts of ALL shows weak to moderate activity (— +) and monoblasts of AMI and myeloblasts of AGL demonstrate moderate to strong reactivity (— + + + +) (table I). The reaction granules range in size from small to large granules with a cytoplasmic localization more intense near the nuclear leaf (Fig. 2d-f).

Primitive cells in leukemia, like the normal precursor cells, are negative for alkaline phosphatase activity. As alkaline phosphatase reaction is demonstrable in the mature neutrophils of the patients with acute leukemia, the neutrophils may be used in assessing levels of leukocyte alkaline phosphatase reactivity. The reactivity is variable as fine granules with the majority of neutrophils in ALL exhibiting strong to intense activity (— + + + +), in AMI showing weak to strong reactions (— + +), and in AGL demonstrating weak activity (— +) with numerous cells nonreactive. Many of the neutrophils in AGL appear to have alterations in size and number of specific granules but an occasional neutrophil will exhibit moderate activity (table I).

Nonspecific esterase reaction in lymphoblasts of ALL has weak to moderate reactivity (— + +) with fine to coarse granules localizing

*Table 1* Summary of cytochemical reactivity and mean scores of primitive cells of patients with acute leukemias and blood and bone marrow cells of normal controls. Reactivity rated as weak, moderate, strong, and intense

| Cytochemical reaction | Cell type          | Reactivity |     |     |      | Mean score |
|-----------------------|--------------------|------------|-----|-----|------|------------|
|                       |                    | wk         | mod | str | int  |            |
| PAS                   | L-lymphoblast      |            | ++  | +++ | ++++ | 134        |
|                       | N lymphocyte       | +          | ++  |     |      | 39         |
|                       | L-monoblast        | +          | ++  | +++ |      | 88         |
|                       | N-monocyte         | +          | ++  | +++ |      | 74         |
|                       | L-myeloblast       | +          | ++  |     |      | 53         |
|                       | N-myeloblast       | +          |     |     |      | 35         |
| Phosphorylase         | L-lymphoblast      |            | ++  | +++ | ++++ | 120        |
|                       | N lymphocyte       | +          | ++  |     |      | 38         |
|                       | L-monoblast        | +          | ++  | +++ |      | 84         |
|                       | N-monocyte         | +          | ++  | +++ |      | 71         |
|                       | L-myeloblast       | +          | ++  |     |      | 46         |
|                       | N myeloblast       | +          |     |     |      | 33         |
| Sudan black B         | L-lymphoblast      | +          | ++  |     |      | 56         |
|                       | N-lymphocyte       | +          | ++  |     |      | 54         |
|                       | L-monoblast        |            | ++  | +++ | ++++ | 142        |
|                       | N-monocyte         |            | ++  | +++ |      | 131        |
|                       | L-myeloblast       |            | ++  | +++ |      | 127        |
|                       | N-myeloblast       | +          | ++  |     |      | 96         |
| Nonspecific esterase  | L-lymphoblast      | +          | ++  |     |      | 71         |
|                       | N-lymphocyte       | +          | ++  |     |      | 68         |
|                       | L-monoblast        |            | ++  | +++ | ++++ | 144        |
|                       | N-monocyte         |            | ++  | +++ |      | 140        |
|                       | L-myeloblast       | +          | ++  |     |      | 75         |
|                       | N-myeloblast       | +          | ++  |     |      | 73         |
| Acid phosphatase      | L-lymphoblast      | +          | ++  |     |      | 90         |
|                       | N-lymphocyte       | +          | ++  |     |      | 94         |
|                       | L-monoblast        |            | ++  | +++ |      | 128        |
|                       | N-monocyte         |            | ++  | +++ |      | 132        |
|                       | L-myeloblast       |            | ++  | +++ |      | 120        |
|                       | N-myeloblast       | +          | ++  |     |      | 86         |
| Alkaline phosphatase  | L-neutrophil (ALL) | +          | ++  | +++ | ++++ | 180        |
|                       | L-neutrophil (AML) | +          | ++  | +++ |      | 91         |
|                       | L-neutrophil (AGL) | +          | ++  |     |      | 25         |
|                       | N neutrophil       | +          | ++  | +++ |      | 82         |

L Leukemic, N normal




Fig. 2 Sudan black reaction and acid phosphatase activity in the primary cells of the acute leukemias. Sudan black reaction: a Lymphoblasts from ALL showing a few reaction granules localizing primarily near the nuclear bed; b monoblasts from AMI demonstrating fine and coarse granules scattered throughout the cytoplasm; c a myeloblast from AGI showing fine to moderately coarse granules localizing near the periphery of the cytoplasm. Acid phosphatase: d Lymphoblasts from ALL demonstrating localizations in small and large granules with most intense activity near the nuclear bed; e monoblasts from AMI exhibiting reactivity in small and large granules depositing more intensely near the nuclear bed; f myeloblasts from AGI showing more intense activity in a perinuclear position  $\times 1,500$ .

primarily in the perinuclear cytoplasm. Monoblasts of AMI show moderate to intense reaction (+ + + + +) with heavier and coarser granules depositing randomly in the cytoplasm. Myeloblasts of AGI exhibit weak to moderate activity (+ + +) with fine to moderately coarse granules scattered throughout the cytoplasm (table 1, (fig 3a-c)).





Fig 3 Nonspecific esterase activity in the primitive cells of the acute leukemias: *a*, A lymphoblast from ALL showing fine and coarse granules localizing primarily near the nuclear hof, *b*, monoblasts from AML exhibiting fine and coarse granules depositing randomly throughout the cytoplasm, *c*, myeloblasts from AGL demonstrating fine and moderately coarse granules scattered throughout the cytoplasm ( $\times 1,500$ )

In general, the cytochemical reactivity and reaction patterns in normal blood and bone marrow cells are similar to those observed in the primitive cells of the acute leukemias except that the reactivity often appears less intense. However, the alkaline phosphatase reaction in normal mature neutrophils shows strong activity in a majority of the cells (table I). In normal lymphocytes, no clumps of PAS reactive material can be observed and no particulate PAS reactive granules appear in normal myeloblasts. Sudan black B reaction in myeloblasts of AGL shows greater reactivity than that observed in normal myeloblasts.

### Discussion

Cytological and electron microscopic cytochemical studies reveal that acid phosphatase and nonspecific esterase activities localize in azurophilic and specific granules of leukocytes [3, 12], alkaline phosphatase activity in the specific granules of mature neutrophils [2, 3], and lipids in the mitochondria and cytoplasmic granules of leukocytes [2, 12]. Comparison of the mean amounts of acid phosphatase, nonspecific esterase, and Sudan black B reactions of the primitive cells of ALL and AML to mature normal cells and myeloblasts of AGL to

# A.H.G. Factor VIII

## Maws

Concentrated Anti-Haemophilic Globulin Bovine and Porcine  
for **safe surgery in haemophilia.**

Invaluable for treatment of refractory cases.  
Emergency supplies available for immediate air despatch.

OTHER MAWS PRODUCTS INCLUDE -

**MAWS BOVINE THROMBIN** - 750 200 and 500 HEM Unit Ampoules  
**THROMBORAL (Oral Thrombin)** - for control of gastric, pleural haemorrhage

**MAWS**

Telephone (day or night) 01 442 5555

Further information on request to Maws Pharmacy Supplies Limited, Buxton, England



# The Hemophiliac and his World *et son monde* L'univers de l'hémophile

Proceedings of the 5th Congress  
of the World Federation of Hemophilia  
*Comptes rendus du 5<sup>e</sup> Congrès de la Fédération Mondiale de l'Hémophilie*  
Montreal, August 26–28, 1968

Edited by *R. Gourdeau* (Montreal)  
VIII + 214 p., 38 fig., 46 tab., 1969  
SFr 56 – / US\$ 13.45 / DM 56 – / 112 s

## Chapter Headings

Specific Therapy of Hemophilia – Non-Specific Therapy of Hemophilia –  
Prophylaxis and Complications in Hemophilia – Orthopaedic and Other  
Surgical Aspects of Hemophilia – Para Medical Session

Introduction  
by  
*F. Schnabel*

The 1968 Montreal Congress is an assembly that brings together doctors and laymen around a single subject: hemophilia. This provides us with the opportunity to acknowledge and indeed to acclaim the doctors and scientists for their contributions to the revolutionary advances in the treatment of hemophilia.

Over the years hemophiliacs have endured on hope. No longer do hemophiliacs resign themselves to fate. Now is the time of expectancy with expectation: kindled high by recent success. The challenge before us is to translate our exploding medical knowledge into a pattern that will make this knowledge available to hemophiliacs throughout the world.



**S. Karger · Basel (Switzerland) · München · New York**

Switzerland: S. Karger AG, Arnold Böcklin-Strasse 25, CH-4000 Basel 11  
USA: Albert J. Phibbig, Inc., P.O. Box 352, White Plains, NY 10602  
Great Britain: Academic Press, Berkeley Square House, Berkeley Square, London, W1X 8BA  
Bundesrepublik Deutschland: S. Karger GmbH, Am Hofstrasse 9, D-8034 Germering/München  
West-Berlin: Walter Schulze, Schöneberger Ufer 59, D-1000 Berlin 35

# MOLTER SEREN



überzeugen  
durch Qualität

Das Ergebnis 20-jähriger Erfahrung  
in der Herstellung von Bluttestseren

Dr. Molter GmbH Serum-Institut 6900 Heidelberg 1 Postfach 1210

# Pathology of Erythroblastic Mitosis in Occupational Benzenic Erythropathy and Erythremia

E G Rondanelli P Gorini G Gerna E Magliulo

X+ 188 p 44 fig 1970 SFr 63 - / US\$ 15 10 / DM 63 - / 126 s

The origin of erythroblast anomalies in erythremia is a problem in hematological cytology which has to be considered on the basis of the existing relationship between disorders of erythroblastic mitosis and morphological atypias of interkinetic erythroblasts.

This concept has been acquired alone on the basis of morphological data gathered during studies of human myeloid tissues in cases of erythremia. The existence of causal relationship was inferred from the concomitance of anomalies of interkinetic cells and of atypical mitotic figures.

Our research program deals with such methodological indications and although limited to the study of the

action of benzene in erythroblasts it exceeds the question of benzene cytotoxicology because it also deals with the vaster problem of cellular pathology in the erythremic disease. Our studies are planned according to the following schedule:

- 1 morphological and dynamic *in vitro* studies of erythroblastic mitosis in normal animals
- 2 morphological and dynamic *in vitro* studies of erythroblastic mitosis of animals exposed to the action of benzene
- 3 comparative morphological study of mitotic pathology in experimental animals and in the bone marrow of patients with benzenic erythremia



S Karger Basel (Switzerland) Munchen New York

Switzerland S Karger AG, Arnold Böcklin-Strasse 25 CH-4000 Basel 11

normal myeloblasts suggests that a more advanced cytoplasmic differentiation of the primitive cells has occurred with numerous cytoplasmic granules and mitochondria appearing at an earlier time in maturation. The altered levels of alkaline phosphatase activity seen in the mature neutrophils of AGL may result from the qualitative and quantitative difference observed in the specific granules, while the higher levels appearing in the mature neutrophils of ALL and AML may denote their response to infectious and stress situations [19].

In the present study, the significantly greater mean amounts of PAS reaction observed in the primitive cells of the acute leukemias as compared to normal controls is not in agreement with an earlier investigation [8] which reveals no significant differences in the glycogen content of these cells. Moreover, the results support other evidence [11] which shows that the PAS reactive material in myeloblasts of AGL is as intense as normally seen in promyelocytes and myelocytes. It has been suggested that the glycogen increase in leukemia may be compatible with an increase in the proliferative and metabolic activity of the lymphocytic system as seen in other nonleukemic diseases [15]. It is conceivable that in leukemia the presence or absence of specific enzymes and/or organelles concerned with the enzymatic control of glycolysis may be responsible for the increased amounts of glycogen seen in the primitive cells. The present study and other investigations [11, 21] suggest that the increased levels of phosphorylase activity parallel closely the increased amounts of preformed glycogen. These observations tend to show that the increased levels of glycogen may result from an increase in the levels of phosphorylase activity.

The primitive cells of the patients in the acute phase of chronic granulocytic leukemia do not show significantly different enzyme reaction patterns of the acid phosphatase, nonspecific esterase, or Sudan black B reactions as compared to the primitive cells of untreated patients with AGL.

Biochemical analysis of the leukocytes of the acute leukemias shows lower levels of alkaline and acid phosphatase activities as compared to higher levels found in normal controls [4-18]. It has been stated that the lower levels of alkaline and acid phosphatase reactions observed is attributable to the low phosphatase activity of the primitive cells with increased activity appearing with maturation [4]. Cytochemically, the present study shows that small and significant differences in alkaline and acid phosphatase activities may be observed in the neutro-

phils and primitive cells, respectively, of the acute leukemias. The cytochemical results agree with biochemical observations which indicate that nonspecific esterase activity is similar in the primitive cells of the acute leukemias and normal blood and bone marrow cells [10, 17]. Sudan black B reaction for lipids tends to support the biochemical results of increased lipase activity in AGL and decreased lipase activity in ALL [13, 14].

PAS and Sudan black reactions and nonspecific esterase, acid phosphatase, and alkaline phosphatase activities may be valuable in the differentiation and classification of the primitive cells of the acute leukemias. Comparisons of the mean amounts of these reactions suggest their usefulness in the diagnoses of the acute leukemias. Moreover, our cytochemical evidence indicates that the primitive cells of the acute leukemias, which exhibit morphological and cytochemical variations, can be distinguished as specific types and are not modifications of a single precursor cell. The cytochemical reactions show sufficient variations in their mean scores and reaction patterns to suggest the existence of several varieties of stem cells.

*Acknowledgements* Dr CHRIS J. D. ZARAFONETIS of Simpson Memorial Institute, University of Michigan, and Dr G. ADOLPH ACKERMAN of the Department of Anatomy, Ohio State University, gave helpful suggestions and advice, Dr INTA J. ERTTEL and Miss AGNES I. FRITZELL provided the blood and bone marrow specimens used in the study.

### *Summary*

Blood and bone marrow films of 71 patients with acute leukemias and 21 controls were evaluated morphologically and cytochemically. A semiquantitative scoring method was used for estimating the intensity of the cytochemical enzyme reactions. Variations in the level of scores and reaction patterns of the acid phosphatase, nonspecific esterase, and alkaline phosphatase activities and the Sudan black and PAS reactions may provide additional criteria for the separation and classification of the acute leukemias. Altered enzyme patterns exhibited by the primitive cells of the acute leukemias correlate closely with the degree of cytoplasmic and granular development and/or maturation. Morphological and cytochemical variations indicate that the primitive cells of the acute leukemias represent specific varieties of stem cells.

### *References*

1. ACKERMAN, G. A. Substituted naphthol AS phosphate derivatives for the localization of leukocyte alkaline phosphatase activity. *Lab Invest* 11: 563 (1962).
2. ACKERMAN, G. A. Histochemical differentiation during neutrophil development and maturation. *Ann NY Acad. Sci.* 113: 537 (1964).

3. BARTON D F and FARGHAM, M G. Enzyme composition of polymorphonuclear leukocyte granules. *J Cell Biol* 31: 8 (1967)
4. BECK, W S. and VALENTINE, W N. Biochemical studies on leukocytes. II. Phosphatase activity in chronic myelocytic leukemia, acute leukemia, and myelodysplastic syndromes. *J Lab. clin. Med.* 57: 245 (1951)
5. BIRMAN H R. The leukemias - proliferative or accumulative? *Trans N* 235 (1967)
6. EKLUND O and FARGHAM, A. Improved localization of phosphatase by the use of polyvinyl pyrrrolone and high substrate concentration. *J Histochem. Cytochem.* 9: 525 (1961)
7. GARDNER, F, PILLER, A, PACE, C., and FARGHAM, L. Proliferation and maturation defect in acute leukemia cells. *Nature Lond.* 201: 97 (1964)
8. GIBB R P and STOWELL, R E. Changes in human blood cells. *Blood* 6: 569 (1957)
9. GOLDBERG, A J. and BARRA, T. Acid phosphatase activity in human blood cells. *Nature Lond.* 211: 297 (1966)
10. HAYES E R, VALENTINE W N, TOLLETT J H, and LAWRENCE J S. Esterase and lysine activity of leukocytes and erythrocytes in leukaemia and disease. *Amer J Med Sci.* 227: 377 (1954)
11. HAYES E G J, QUAGLINO D, and JONES P. The cytology and cytochemistry of acute leukemia. pp. 84-90 (Munksgaard & Sons, London 1964)
12. HIRSHI J G. and GIBB, A Z. Degenerative and autolytic functions of lysosomes in phagocytic cells. *J. Cell. Phys.* 21: 1073 (1963)
13. KILGUS C. Lipid synthesis in human leukocytes in acute leukemia. *Ann. Ann. Med.* 87: 292 (1964)
14. MALAMON R, MIRAL C, LEVIN G., and MAYER J. The in vivo incorporation of acetate-<sup>14</sup>C into normal and leukemic leukocyte lipids. *J. Lipid Res.* 3: 722 (1962)
15. MITES W J, BERGHA, L J, MIRMIRAN J B., and DARTMOUTH W. Cytochemical studies of phagocytic content of leukocytes in lymphocytic prolymphocytosis. *Trans N* 245 (1968)
16. SHEPHERD H L. and STONEY, G W. An improved method of staining leukocyte granules with Sudan black B. *J. Pa. A. Soc.* 57: 356 (1964)
17. VALENTINE W N. The metabolism of the leukemic leukocytes. *Amer J Med.* 20: 679 (1960)
18. VALENTINE W N. and BECK, W S. Biochemical studies on leukocytes. I. Phosphatase activity in leukaemia, lymphocytosis, and myelocytic leukemia. *J. Lab. clin. Med.* 57: 33 (1951)
19. VALENTINE W N, TOLLETT J H, SCHWARTZ D H., and REYNOLDS J. The relationship of leukocyte alkaline phosphatase to stress, to ACTH, and to adrenal 17-OH corticosteroids. *J. Lab. clin. Med.* 49: 721 (1957)
20. WACHSTEIN M. and WOLF, G. The histochemical demonstration of esterase activity in human blood and bone marrow smears. *J. Histochem. Cytochem.* 6: 47 (1958)
21. WELCH W R. and SCHWARTZ M. A new technique for the histochemical demonstration of phosphatase in blood films. *Acta haemat. Trans N* 304 (1966)



## Gastric Mucosa in Iron Deficiency Anaemia

### Results of Follow-Up Examinations

E. IKKALA, H. J. SALMI and M. SIURALA

Second Department of Medicine, University of Helsinki, Helsinki

We have previously [1] described the findings in gastric biopsies of 100 patients with iron deficiency anaemia. In 47 of the patients a second gastric biopsy was performed after approximately 6 months' iron treatment. Slight changes (improvement or worsening) were seen in some patients, but in general the state of the gastric mucosa had remained unchanged. It seemed possible, that a more prolonged follow-up would throw some light upon the complex relations between iron deficiency anaemia and gastritis.

The present study concerns the gastric biopsy findings in 48 of our original 100 patients 7 years after the first examination.

### *Series and Methods*

The series consists of 48 patients, 45 females and 3 males, who attended the follow-up examination to which all the 100 patients of our original series were invited. The mean age of the series at the first examination (94 females and 6 males) was 35.3 years and that of the patients of the present series 36.5 years. Nine out of 25 patients with a normal gastric mucosa at the first examination, 25 out of 39 patients with superficial gastritis and 14 out of 36 with atrophic gastritis were re-examined.

There were no significant differences between the original and the present series in the number of patients with diseases of obvious significance for the development of iron deficiency. In 18 patients of the present series the case histories revealed factors clearly influencing the iron balance: intestinal malabsorption in 2, ulcerative colitis in 2, and profuse menstrual, haemorrhoidal or nasal bleedings in 14 patients.

The haematological examination consisted of a complete peripheral blood picture, bone marrow examination including sideroblast staining, serum iron and total iron binding capacity determinations, and serum vitamin B<sub>12</sub> determination.

The acidity of the gastric contents was determined by maximal Histalog® test (2 hours' continuous suction after 2 mg/kg betazole).

Gastric biopsies were performed with the blind suction biopsy tube and in all 148 specimens were obtained. The specimens seemed to be representative of the state of the whole

gastric body mucosa is that there was a close correlation between the state of body glands and the maximal acid output. Mean maximal acid output in patients with normal gastric mucosa was 7.6 mEq % in patients with superficial gastritis 9.6 mEq %, in patients with partial loss of normal glands 0.2 mEq %, and in patients with total loss of normal body glands 0 mEq %.

### Results

In the course of the follow-up 30 of the 43 patients had had one or more anaemic episodes and had received iron medication more or less regularly. Normal haemoglobin values had been concurrently found in only 13 patients, and of the remaining 5 patients no examinations had been performed. The occurrence of anaemia did not correlate with the biopsical findings at the first examination. Thus anaemic episodes had been present in 6 of 14 patients with atrophic gastritis and in 7 of 9 patients with normal gastric mucosa at the first examination.

At the present examination only 19 patients were non-iron deficient, while 12 had distinct iron deficiency anaemia and 17 sideropenia with haemoglobin levels over 12 g/100 ml. One of the non-iron deficient patients fulfilled the criteria of Addisonian pernicious anaemia. There was no definite correlation between various haematological parameters and the biopsical state of the gastric mucosa at the present examination.

The changes occurring in the state of the gastric mucosa during the follow-up period are shown in table I. It appears that the state remained unchanged in 33, got worse in 12 and improved in 3 patients. In table II the changes in the state of the mucosa during the follow-up period are correlated with the haematological findings during the follow-up and at the present examination. Some correlations are seen. 2 of the 3 patients histologically improved had not been anaemic during the follow-up and none of them was anaemic at the present examination although two were sideropenic, while 9 of the 12 patients with progression of mucosal changes had had anaemia during the follow-up (the remaining 3 had not been examined) and 5 of them had iron deficiency anaemia at the present examination. Moreover it should be noted that gastritis was found in 81 % of the patients re-examined, while the prevalence of gastritis in randomly selected subjects of a Finnish rural population of almost corresponding mean age was 52 % [2]. On the other hand, the occurrence of atrophic gastritis showed a rather clear correlation with the age of the patients at the present examination: the median age of patients with normal gastric mucosa was 39 years (22-59 years), that of patients with superficial gastritis 39 years



Serum vitamin B<sub>12</sub> levels were normal in all but 2 patients: the one with pernicious anaemia and another with intestinal malabsorption.

### Discussion

The most striking observation was the relapsing tendency of sideropenia, although measures to prevent the recurrence of iron deficiency anaemia were stressed to each patient at the first examination. Obviously the original, known and unknown, causes of iron deficiency had persisted and the treatment given had not been sufficient to overcome these. There was no evidence to suggest that atrophic gastritis had predisposed to relapses of iron deficiency. On the other hand, normalization of the histological features occurred mainly in those who had not been anaemic during the follow-up, whereas most of the patients with worsened mucosal findings had been anaemic and showed signs of iron deficiency. In one patient the normalization of gastric mucosa was accompanied by the return of acid secretion. Hence, the evidence available does not favour the primary significance of gastritis in the development of iron deficiency. In contrast they suggest that iron deficiency predisposes to alterations of the gastric mucosa. The present follow-up series is, however, too small and the biopsical method not reliable enough to permit any definite conclusions. The judging of the results is, in addition, complicated by the age-dependent progression of gastritis [2].

### Summary

The fate of the gastric body mucosa was followed-up for about 7 years in 43 out of 100 biopsically examined patients with iron deficiency anaemia. During the follow-up period 30 of the 43 patients had one or more anaemic episodes, and at re-examinations 12 were found to have iron deficiency anaemia and an additional 17 sideropenia without anaemia. The occurrence of anaemia did not correlate with biopsical findings at the first examination. At the re-examination the state of the gastric mucosa was found to have improved in 3, got worse in 12 and remained unchanged in 33. Anaemic episodes were more frequent in those who showed a progression of gastritis than in those improved.

### References

- 1 TERALA, F. and SIBALA, M. Gastric lesion in iron deficiency anaemia. *Acta haemat. Basel* 31: 313-324 (1964).
- 2 SIBALA, M., HONKONEN, M., VAADE, J., and TERALA, M. Prevalence of gastritis in a rural population. *Scand. J. Gastroint. J.* 211-223 (1968).

Authors' address: Dr E. TERALA, Dr H. J. SALON and Dr M. SIBALA, Second Department of Medicine, Meilahus Hospital, Helsinki 29 (Finland).

## Zur Proliferationskinetik der Lebererythropoese heranwachsender Ratten<sup>1</sup>

R. J. HAAS, E. SPARRER<sup>2</sup> und T. M. FLIEDNER

Abteilung für Klinische Physiologie der Universität Ulm

Die neonatale Hämpoese der Ratte wird zur Zeit der Geburt beinahe ausnahmslos von extramedullären Ursprungsorten gespeist. Dabei ist eine der Hauptproduktionsstätten die Leber. Die Untersuchung der Entwicklungskinetik der Lebererythropoese erschien lohnend, da entsprechende Untersuchungen zur Proliferationskinetik der neonatalen Knochenmarkerythropoese in unserer Gruppe erarbeitet wurden [11, 12]. Ein Vergleich der Lebererythropoese in den ersten Wochen nach Geburt mit der des Knochenmarkes liess Hinweise über unterschiedliche Proliferationsmodi erwarten. Ein derart unterschiedlicher Zellumsatz kann vermutet werden, da es sich im einen Fall um ein untergehendes, im anderen Fall um ein im Aufbau befindliches Zellsystem handelt.

Zur Untersuchung dieser Fragen wurde eine zytokinetische Methode angewandt, die es ermöglicht, mittels radioaktiven Thymidins (<sup>3</sup>H-TdR) *alle* Zellkerne zu markieren, auch diejenigen, die eine nur sehr langsame Proliferationsaktivität aufweisen und daher zytokinetisch als «Ruhezellen» bezeichnet werden können [8, 9].

### *Material und Methoden*

**Versuchstiere** Als Versuchstiere dienten 4 Monate alte Wistaratten mit einem durchschnittlichen Körpergewicht von 180 g. Der Ovulationszyklus wurde durch Vaginalab-

<sup>1</sup> Die Untersuchungen wurden durch die Euratom-Verträge «Strahlenhämatologie» Nr. 031-64-1-BIAD und 072-68-1-BIOD unterstützt.

<sup>2</sup> Wesentliche Teile dieser Arbeit entstammen der Dissertation von E. SPARRER, Universität Ulm.

stunde bestimmt [12]. Die Regulation wurde über Nacht herbeigeführt. Als Beginn der Gravität galt 000 Uhr dieses Tages, wenn im Vaginalaustriß Spermen nachweisbar waren.

**<sup>3</sup>H-TdR Applikation:** Den schwangeren Ratten wurde von 9 Tag der Gravität an (entsprechend dem Beginn der Organogenese [13] bis zum Geburtstermin 15 µCi/g Tag <sup>3</sup>H-Thymidin in physiologischer Kochsalzlösung verabreicht. Die spezifische Aktivität des <sup>3</sup>H-TdR betrug 20 Ci/mMol. Die Applikation des <sup>3</sup>H-TdR erfolgte bei der Hälfte der Tiere alle 6 Stunden i.p. Die andere Hälfte erhielt <sup>3</sup>H-TdR kontinuierlich über die Schwanzvene mittels eines Polyäthylenkatheters (nach fixierter Methode nach Latta et al., [14]). Die hinsichtlich des Markierungsverfahrens bei beiden Methoden kein Unterschied festzustellen wurde [9] wurden die Tiere im folgenden jeweils zusammengefaßt.

**Tötung der Tiere:** Ausgewertet wurden insgesamt 51 junge Ratten. Die Tötung der Tiere erfolgte 1, 2, 6, 1\*, 24, 30, 30 Stunden, 3, 4, 6, 10 Tage und 2, 4, 6, 8, 10, 21 Wochen nach der Geburt.

**Aufarbeitung des Materials:** Von der Leber wurden jeweils hat äquivalente und zytologische Präparate angefertigt. Die Aufarbeitungsfolge der Tupspräparate erfolgte mit der entsprechenden Lente (Kodak AR 10 Methode). Die histologischen Präparate wurden erst einer flüssigen Fixierung (Büdel-Lösung) unterworfen. Die Fixationskonzentration für die zytologischen Präparate betrug 9 für die hat äquivalenten 45 Tage. Nach üblicher Entwicklung und Färbung wurden die Tupspräparate mit Gemma bei einem pH von 3,75 der histologischen Präparate mit Hamatoxylin-Eosin gefärbt.

In den Tupspräparaten kamen von jedem Tier zu jedem Zeitpunkt für die zytologische oder Färbung und für die Untersuchung des Markierungsverhaltens mindestens 200 erythrocytische Zellen zur Auswertung. Die zytologische Klassifizierung der Erythrocyten erfolgte in Anlehnung an das Schema von Wenzel [11]. In den hat äquivalenten Präparaten wurde zu verschiedenen Zeitpunkten der Entwicklung der Tiere nach Gehört das Verhalten der einzelnen Erythrocyten verschiedenen Reifungsstadien zugeordnet. Dafür kamen pro Zeitpunkt und Tier mindestens 700 Zellen zur Auswertung, die in 5 Mikrophotographien (145-fache Vergrößerung) ausgeätzt wurden.

### *Ergebnisse*

In den zytologischen und histologischen Präparaten der Leber waren *alle* Zellkerne markiert, wenn die Tiere kurz nach der letzten <sup>3</sup>H-TdR-Applikation getötet wurden. Bei allen Neugeborenen war diese 100%ige Markierung der Zellen vorhanden, unabhängig von der angewandten Methode der <sup>3</sup>H-TdR-Applikation. Die Markierungsintensität in den zytologischen Tupspräparaten schwankte zwischen 20–70 Körnchen über den verschiedenen Zellen der Erythropoese. Es fand sich keine Zelle mit weniger als 5 Körnchen.

**Entwicklung der Leberhämatopoese nach Geburt:** Die Entwicklung der neonatalen Rattenleber ist durch allmähliches, auch makroskopisch sichtbares Zurückgehen der hämatopoetischen Funktion dieses Organs zugunsten der Ausbildung des eigentlichen Leberparenchyms gekennzeichnet. Interessanterweise sind die Lebergewichte neugeborener

\* <sup>3</sup>H-TdR vom Radiochemical Center, Amersham, England.

Ratten in den ersten 6 Tagen nach Geburt relativ konstant zwischen 0,2 und 0,3 g, d.h., dass in den ersten Tagen keine Gewichtszunahme der Leber gegenüber dem Geburtsgewicht feststellbar ist. Erst ab dem 6. Lebenstag kommt es dann zu einem linearen Anstieg des Lebergewichtes, der bis 6 Wochen nach Geburt verfolgt wurde. Dabei ist in den ersten Lebenstagen eine deutliche mitotische Aktivität des Leberparenchyms erkennbar. Die neonatale Lebergewichtsentwicklung resultiert somit aus dem Verschwinden der Hämopoese und der Zunahme der Leberzellen.

Die histologischen Präparate lassen folgende Entwicklung erkennen: Zur Zeit der Geburt ist die typische Leberstruktur mit Läppchenaufbau noch nicht ausgebildet, vielmehr dominieren herdförmig oder dissiminiert im Leberparenchym gelegene erythropoetische Zellen. Daneben finden sich myelopoetische Zellen, meist um Lebergefäße gelagert. Vereinzelt werden auch Megakaryozyten inmitten des Leberparenchyms gesehen. Innerhalb der ersten Lebenswoche kommt es zu einem allmählichen Rückgang der Leberhämopoese. Dabei liegen jetzt die erythropoetischen Zellen nur noch in kleinen Inseln vor. In dieser Zeit verschwindet die Myelopoese und Megakaryozytopoese vollständig. Zwei Wochen nach Geburt ist die typische Leberläppchenstruktur ausgebildet. Kleine erythropoetische Herde sind ohne besondere topographische Beziehung im Parenchym verstreut. Drei Wochen nach Geburt ist auch in der Leber keine Erythropoese mehr sichtbar.

In Abbildung 1 sind die zahlenmässigen Veränderungen der Erythropoese im Verhältnis zu den Leberparenchemzellen in Abhängigkeit von der Zeit nach Geburt dargestellt. Daraus ergibt sich, dass unmittelbar nach Geburt etwa 50% aller Zellen der Leber zur Erythropoese gehören und dass dieser Anteil innerhalb von 10 Tagen auf weniger als 10% abfällt.

Es war nun von besonderem Interesse zu untersuchen, ob sich das Verhältnis der erythropoetischen Zellen zueinander in den ersten Tagen nach Geburt ändert. Ein plotzliches Aufhören der Proliferation und Differenzierung von Stammzellen in erythropoetische Vorstufen müsste ein deutliches Verschwinden der unreifen Erythroblasten lange vor dem Zurückgehen der reiferen Zellformen zur Folge haben. In Abbildung 2 sind die Prozentzahlen der einzelnen Reifungsstufen der Erythropoese im Verhältnis zur Gesamterythropoese zu den verschiedenen Zeiten nach Geburt eingetragen, die in Lebertupspräpara-




Abb. 1 Änderung der relativen Erythroblastenzahl in der Leber als Funktion der Zeit. Jeder Punkt der Kurve repräsentiert mindestens 5 Tiere. Die Standardfehler sind angegeben.




Abb. 2 Prozentualer Anteil der einzelnen erythropoetischen Reifungsstufen in der Leber zu verschiedenen Zeitpunkten nach Geburt.






Abb 3 Markierungsverhalten der Lebererythropoese als Funktion der Zeit

ten ermittelt wurden. Dabei zeigt sich, dass sich bis zum 6 Tag nach Geburt das Verhältnis der einzelnen Zellklassen zueinander nicht verändert. Fasst man nun sämtliche Zellen (insgesamt wurden 31500 Zellen ausdifferenziert) der verschiedenen Reifungsstufen zu allen ausgewerteten Zeitpunkten nach Geburt zusammen und setzt sie miteinander in Beziehung, so ergibt sich, dass von 500 pro Präparat ausgezählten Zellen im Mittel 5 E<sub>1</sub>-Zellen, 15 E<sub>2</sub>-Zellen, 60 E<sub>3</sub>-Zellen, 132 E<sub>4</sub>-Zellen und 288 E<sub>5</sub>-Zellen ausgezählt wurden entsprechend 1% E<sub>1</sub>-, 3% E<sub>2</sub>-, 12% E<sub>3</sub>-, 26% E<sub>4</sub>- und 58% E<sub>5</sub>-Zellen. Aus dieser Verteilung der einzelnen erythropoetischen Vorstufen in der neonatalen Leber ergibt sich fast eine Verdoppelung der Zellen von einer Reifungsstufe zur nächsten.

*Proliferationsverhalten erythropoetischer Zellen der Leber bei vollständig markierten neugeborenen Ratten* Das Markierungsverhalten der Lebererythropoese wurde in Tupspräparaten, die autoradiographisch behandelt waren, untersucht. Neben den 5 Klassen kernhaltiger erythro-




Abb. 4 Markierungsintensität der Lebererythropoese als Funktion der Zeit

poetischer Vorstufen wurde eine Zellgruppe «undifferenzierter Blasten» unterschieden. Diese werden von einigen Autoren als mögliche Vorläufer der Erythropoese angesehen [16, 17]

Der Abfall des Markierungsindex über diesen Zellpopulationen in Abhängigkeit von der Zeit ist in Abbildung 3 aufgetragen: Die Blasten bleiben bis 24 h p. p. 100% markiert. Anschliessend kommt es zu einem stetigen Abfall des Markierungsindex, bis nach 6 Tagen praktisch keine Blasten mehr markiert sind. Ein ähnlicher Verlauf findet sich auch bei den Markierungsindices der übrigen erythropoetischen Vor-

stufen. Die Markierungsintensität der Erythropoese ist in Abbildung 4 dargestellt.

Zellpopulationen praktisch nicht mehr als markiert zu erkennen. In Abbildung 4 sind die Veränderungen der Markierungsintensität der hämopoetischen Blasten und verschiedenen Vorstufen der Erythropoese dargestellt. Daraus geht hervor, dass die mittlere Silberkornzahl der noch undifferenzierten Blasten in den ersten 12 Stunden p. p. von etwa 50 auf etwa 15 Körnchen pro Zelle abfällt. Danach fallen die Werte langsamer ab bis auf im Mittel 2 Silberkörner pro Blastkern 6 Tage p. p. Die erythropoetischen Zellvorstufen E<sub>1</sub>-E<sub>4</sub> zeigen einen

ähnlichen Verlauf: Auch bei allen diesen Zellkategorien kommt es innerhalb der ersten 12 Stunden p.p. zu einem rapiden Abfall der Markierungsintensität gefolgt von einem langsameren Abfall, bis 6 Tage p.p. nur noch wenige Körnchen über den Zellen erkennbar sind. Eine zeichnerische Subtraktion der beiden Komponenten der Kurven ergab folgende Halbwertszeiten für den Abfall der Markierung im ersten Teil: Blasten ca. 3 h,  $E_1$  ca. 3,5 h,  $E_2$  ca. 6 h,  $E_3$  ca. 5 h,  $E_4$  ca. 4 h und  $E_5$  ca. 7 h.

### *Diskussion*

Die vorgelegten Befunde demonstrieren die Möglichkeit, durch eine 100%ige Markierung der Zellkerne neugeborener Ratten, die Umsatzkinetik schnell proliferierender Zellen wie etwa die der Lebererythropoese zu untersuchen. Da zu Beginn der Untersuchung alle Zellen markiert waren, kann der Abfall der Thymidinmarkierung über den Zellen als Mass für den Zellumsatz gelten, ohne dass zunächst der Einstrom eines vorgeschalteten nichtmarkierten Zellsystems berücksichtigt werden müsste.

Voraussetzung zur Anwendung der 100%igen Markierung ist der Nachweis, dass die angewandten  $^3\text{H}$ -TdR-Dosierungen keine offensichtliche oder latente Schädigung der zu untersuchenden Zellpopulation herbeiführten. Die bisher gesammelten Befunde zu dieser Frage sind an anderer Stelle ausführlich dargestellt worden [8-10]. Für die hier angewandten Dosen kann davon ausgegangen werden, dass keine Einflüsse durch die Radiotoxizität des Tritium-Thymidins berücksichtigt werden müssen.

Weiterhin musste geprüft werden, inwieweit eine Reutilisation von  $^3\text{H}$ -TdR markierten DNS-Bausteinen zustande kommt [2, 7, 14, 19]. Ein solcher Einfluss ist gerade durch den allmählichen Untergang rasch proliferierender hämopoetischer Zellsysteme in der Leber gut denkbar. Die Untersuchung dieser Frage [ausführliche Darstellung s. 20] ergab eine deutliche Beeinflussung des Abfalls der Markierungsintensität aller erythropoetischen Zellen und der undifferenzierten Blasten. Eine weitgehende Ausschaltung der Reutilisation durch wiederholte Applikation von inaktivem Thymidin änderte jedoch nichts am prinzipiellen Kurvenverlauf für den Markierungsindex und die Markierungsintensität. Diese Beobachtung steht in guter Übereinstimmung mit den Befunden, die wir für schnell proliferieren-

de Zellsysteme des Knochenmarkes erheben konnten [9]. Bei beiden Zellsystemen spielen Reutilisationsprozesse von  $^3\text{H}$  markierter DNS oder deren Bausteine eine etwa gleich starke Rolle.

Der rasche Umsatz der Erythropoese des Knochenmarkes ist wohl bekannt [3-6]. Die vorliegenden Untersuchungen sollten nun zum Verständnis der Proliferationskinetik eines schnell proliferierenden Systems dienen zu einem Zeitpunkt, zu dem dieses abgebaut wird. Es konnte im Vorhergehenden nachgewiesen werden, dass während der neonatalen Entwicklung der Rattenleber die verschiedenen Reifestufen der Erythropoese im gleichen Verhältnis zueinander verschwinden. Dieser Befund spricht dafür, dass die Umsatzgeschwindigkeit der Erythropoese der Leber in allen kernhaltigen Reifungsklassen *allotaktisch* abnimmt. Wenn nämlich ein plotzliches Auflösen der Differenzierung und Proliferation einer Vorstufe, z. B. der Blasten, eintrete, müsste ein Verschwinden der Zellformen im Sinne einer auslaufenden «Pipeline» erwartet werden, d. h., es müsste zunächst die  $\text{L}_1$ -Population, dann die  $\text{L}_2$ -Population usw. verschwinden, ein Vorgang, der nicht beobachtet werden konnte. Da jedoch andererseits kein vermehrtes Absterben erythropoetischer Zellen in der Leber auftritt, muss man annehmen, dass bei verlangsamter Produktion reife Normoblasten mit etwa gleicher Geschwindigkeit ins Blut abströmen wie zu früheren Entwicklungsstadien, so dass sich das Kompartiment der Erythropoese langsam entleert. Dass tatsächlich Normoblasten im peripheren Blut existieren, solange bei der Ratte extramedulläre Blutbildung vorhanden ist, konnte in anderen Untersuchungen nachgewiesen werden [1]. Die Beobachtung des Markierungsverhaltens während der Neonatalperiode erbringt ebenfalls die Bestätigung, dass es zu einer verlangsamten Proliferationsaktivität der ganzen Population kommt, bis diese endlich aus der Leber verschwindet. So konnte gezeigt werden, dass erythropoetischen Populationen einen Abfall der Markierungsintensität in den ersten 24 Stunden nach Geburt von mindestens 50% aufweisen, anschliessend aber ein wesentlich geringerer Abfall der Markierungsintensität bis zum 6. Lebenstag über diesen Zellen auftritt. Dieser prinzipielle Kurvenverlauf ist auch unter Berücksichtigung der  $^3\text{H}$  TdR-Reutilisation nachweisbar. Ein Vergleich der Markierungswerte der Lebererythropoese mit denen des Knochenmarkes der gleichen Tiere [11, 12] zeigt, dass 24 h nach Geburt im Knochenmark im Gegensatz zur Lebererythropoese noch alle erythropoetischen Zellen 100% markiert sind. Der Abfall der

Markierungsintensität über  $E_1$ -Zellen des Knochenmarkes tritt mit einer Halbwertszeit von etwa 12 h erst viel später als in der Leber auf, nämlich 24 h nach Geburt. Die Lebererythropoese verhält sich also zytokinetisch anders als die sich entwickelnde Knochenmarkerythropoese wie zu erwarten war [Einzelheiten s. 12]. Für die Zeit kurz nach Geburt kann aus der Betrachtung der Halbwertszeiten für den Markierungsabfall auf einen sehr schnellen Zellumsatz geschlossen werden, während 12 h p.p. eine starke Verlangsamung beobachtet wurde. Dieser Befund steht in guter Übereinstimmung mit den Ergebnissen von LUGARELLI *et al.* [18], der kurze Generationszeiten der pranatalen Lebererythropoese in der Grossenordnung von 4–6 h gefunden hat.

### *Zusammenfassung*

Durch kontinuierliche  $^3\text{H}$  Thymidin Gabe während der Schwangerschaft wurde eine Markierung aller Zellkerne der Leber neugeborener Ratten ermöglicht. Die Tötung der neugeborenen Ratten zu verschiedenen Zeiten nach Geburt erlaubte die zytokinetische Untersuchung der Lebererythropoese während der Neonatalperiode. Es konnte gezeigt werden, dass die Lebererythropoese einer anderen Kinetik folgt als die Erythropoese des sich entwickelnden Knochenmarkes der gleichen Tiere. In den ersten 12 Stunden p.p. weist die Lebererythropoese einen sehr raschen Zellumsatz auf, der sich anschliessend parallel zum Verschwinden der Zellpopulation, immer mehr verlangsamt.

### *Summary*

By repeated or continuous application of  $^3\text{H}$  thymidine to rats during pregnancy, labelling of all cells of newborn liver was achieved. The newborn rats were sacrificed at different times after birth and a study made of the subsequent development of erythropoietic cells. The kinetics of erythropoiesis in the liver were found to differ from the kinetics of erythropoiesis in the developing bone marrow of the same animals. The very rapid cell turnover of erythropoietic liver cells during the first 12 h after birth is followed by a continuous decrease of proliferative activity subsequent to the disappearance of erythropoiesis in the liver.

### *Literatur*

1. BLATTMANN, H. Zytokinetische Untersuchungen zur Entstehung und Regeneration des Blutlymphozytenspeichers bei Ratten unter Verwendung der vollständigen Markierungsmethode mit  $^3\text{H}$ -Thymidin. Inaug. Diss. Ulm (1969).
2. BRYANT, R. J. Reutilization of lymphocyte DNA by cells of intestinal crypts and regenerating liver. *J. Cell Biol.* 18: 515 (1963).
3. CRONKITE, E. P., FLIEDNER, T. M., BOND, V. P., RUBINI, J. R. and HUGHES, W. L. Dynamics of the proliferating cell systems of man studied with tritiated thymidine. *J. clin. Invest.* 37: 837 (1958).
4. CRONKITE, E. P., FLIEDNER, T. M., BOND, V. P., RUBINI, J. R., BRECHER, G. and QUASTLER, H. Dynamics of hemopoietic proliferation in man and mice studied by  $^3\text{H}$  thymidine incorporation into DNA. *Ann. NY Acad. Sci.* 77: 803 (1959).

5. CROVATTE, E. P., BROWN, V. P., FLEISHER, T. M. and RUSSEL, J. R. The use of tritiated thymidine in the study of DNA synthesis and cell turnover in hematopoietic tissue. *Lab. Invest.* 8: 283 (1977).
6. CROVATTE, E. P., FLEISHER, T. M., KILBAMANN, S. A. and RUSSEL, J. R. Tris- and labelled thymidine. Its hematologic toxicity and use in the study of growth rates and the potentials in normal and malignant tumors of man and animals, in: *Trium in the physical and biological sciences*, vol. 2. Int. Atomic Energy Agency, 1977 (1972).
7. FLEISCHER, L. E., BROWN, V. P. and HUGHES, W. L. Problems of thymidine mutation and toxicity of tritium radiation in the bone marrow of rats. Vortrag auf dem Colloquium on Utilization of Pyrimidine Nucleosides, M.J. (Belgen) März 1973.
8. FLEISHER, T. M., HAAS, R. J., STEINER, H. and ANAND, A. C. Complete labeling of all cell nuclei in newborn rats with  $^3\text{H}$ -thymidine. A tool for the evaluation of rapidly and slowly proliferating cell systems. *Lab. Invest.* 37: 249 (1977).
9. FLEISHER, T. M., HAAS, R. J. and STEINER, H. Die  $^3\text{H}$ -Thymidin Markierung aller Zellkerne neugeborener Ratten. *Acta haematol. Suppl.* 8: 231 (1977).
10. FLEISHER, T. M., HAAS, R. J., BROWN, I. and HARRIS, E. B. Radiation effects produced in pregnant rats and their offspring by continuous infusion of tritiated thymidine. Proc. 9th Annual Half and Energy Symp., Richland (U.S. Atomic Energy Commission) 1979.
11. HAAS, R. J., STEINER, H. and FLEISHER, T. M. Autoradiographic studies on rapidly and slowly proliferating cell systems in neonatal bone marrow. *Helv. med. Acta* 36: 54 (1977).
12. HAAS, R. J., FLEISHER, T. M. und SPARRER, E. Autoradiographische Untersuchungen zur zyklometrischen Analyse der neonatalen Erythropoese bei Ratten. *Hämatologie und Bluttransfusion*, Bd. 8, p. 21 (Lehmann, München) 1979.
13. HENNINGER, B. Vorkursfächer zur Entwicklungsgeschichte der Wirbeltiere. *Fak. F. Naturw. 15. Ergänzungsheft (Fischer, Jena) 1977*.
14. HILL, M. The uptake of deoxythymine and released from damaged cells in tissue culture. *Exp. Cell Res.* 45: 533 (1977).
15. LITTLE, J. R., BRISCHER, G., FRANKLY, T. R. and ROSE, S. Determination of lymphocyte turnover by continuous infusion of  $^3\text{H}$ -thymidine. *Blood* 37: 239 (1972).
16. LICABELLI, G., PORCELLINI, A., CARNEVALLI, C., FERRARI, L., RIZZOLI, V., HOWARD, D., STOHLMAN, F. e BUTTER, U. L'eritropoesi nel periodo fetale e neonatale del ratto. I. *Atti del Farmaco. Acta haematol.* 37: 293 (1974).
17. LICABELLI, G., PORCELLINI, A., CARNEVALLI, C. and RIZZOLI, U. Zur Proliferationskinetik der fetaalen Erythropoese der Ratte. Jahresbericht 1975-66. T. M. FLEISHER, Association Europ. Atom-Gemeinschaft-Gesellschaft Strahlenforschung EUR 97331 47 (1976).
18. FREYMEYER, E. *Pathologie der Laboratoriumstiere*, p. 419 (Springer, Berlin Göttingen/Heidelberg) 1978.
19. ROSENBERG, S. H., BALCHER, G., LAURIE, J. S. and HALEY, J. E. Leucocyte labeling in rats during and after continuous infusion of tritiated thymidine. Implications for lymphocyte longevity and DNA mutation. *Blood* 27: 291 (1975).
20. SPARRER, E. Über die Proliferationskinetik der Parenchymzellen und der hämatopoetischen Zellen der Rattenleber in der neonatalen Phase nach kompletter  $^3\text{H}$ -Thymidin-Markierung. *Inaug. Diss. Ulm* (1979).
21. WEICKER, H. Exakte Kriterien des Knochenmarks. Die Mass und Mengenrelationen der Erythroblasten als Ausdruck der Reifungs- und Teilungsgewichte der Erythropoese. *Schweiz. med. Wochs.* 81: 245-251 (1974).

Adresse der Autoren: Drs. R. J. HAAS, E. SPARRER und T. M. FLEISHER, Abteilung für Klinische Physiologie, Universität Ulm, Parkstrasse 11, D-77 U7m (Deutschland).

## The Osmotic Fragility and Density Distribution of Erythrocytes in the Newborn<sup>1</sup>

Y. DANON, A. KLEIMANN and D. DANON

Department of Medicine B, Meir Hospital, Kfar Saba, and Section of Biological Ultra-structure, The Weizmann Institute of Science, Rehovot

Various opinions have been expressed regarding the differences in osmotic fragility between normal newborn red blood cells as compared to the cells of normal adults. GOLDBLOOM and GOTLIEB [8] reported increased osmotic fragility of newborn red blood cells. WHITBY and HYNES [13], cited by WINTROBE [14], claimed that the red blood corpuscles of newborn children are somewhat more fragile than those of adults, but did not regard the difference as significant. WAUGH *et al.* [12] reviewed 15 papers on the subject and concluded that fetal cells are slightly more resistant. Their own experiments indicated that the main feature of fetal cells with regard to their osmotic fragility is an increased range and a slight tendency to increased resistance. FINDLAY [6], testing the salt concentration at which 50% hemolysis occurred, found that blood taken from the umbilical cord was more resistant. However, the difference was not apparent when the blood of the newborn was compared with that of the adult. SJÖLIN [10] reported similar results, emphasizing the presence of a population of more resistant cells in cord blood. This population of resistant cells gradually decreases until complete disappearance at the onset of puberty. In cattle, the differences in methods employed and especially to the limited number of points which were used to construct the osmotic fragility curve.

<sup>1</sup> This work was submitted as a partial fulfillment of MD thesis in the Hebrew University Hadassah Medical School, Jerusalem.

In the present work, the osmotic fragility of blood from the umbilical cord is compared to that of blood from adults, using a method whereby the osmotic fragility curve is recorded, in great detail, on the basis of continuously decreasing salt concentrations [4]. Additional information was obtained by establishing the density distribution of the red blood cells (DDC) by differential flotation, using mixtures of phthalate esters of predetermined specific gravity as described by DANON and MARIKOVSKY [5].

### *Materials and Methods*

Blood was withdrawn from the umbilical cord of 100 newborn babies by opening the surgical clamp. After discarding the first few drops, the blood samples were collected into a test tube previously wetted with heparin. Specimens that subsequently developed hemolytic disorders are not included in these 100 samples.

Normal adult blood obtained from 50 laboratory and hospital staff members by venipuncture was transferred into heparinized test tubes after removal of the needle. The fragility curves were obtained by using a fragilograph Model D-2 (Elmeda Ltd., Haifa, Israel). A battery of 20 phthalate esters was used for DDC determinations (Crank & Milschke Ltd., POB 1122 Rehovot, Israel).

All blood samples were tested within two hours after withdrawal. Cord blood was generally tested immediately.

### *Results and Discussion*

It can be seen from figure 1 that fetal blood is generally more resistant to osmotic pressure than the blood of adults. The narrow overlapping region indicates that up to 90% hemolysis may occur in the different types of cells at the same salt concentration.

From the DDC (fig. 2) it is apparent that the umbilical cord blood has a considerable proportion of cells of lower specific gravity, indicating mainly higher hydration. The overlap is more marked than that observed in the fragilograms. It should be noted that cells of a high specific gravity, similar to the densest cells of adult blood, may be found in cord blood, reaching sometimes up to about 10% of the cells. These may be cells of adult type as found to exist in cattle even before the actual birth of the calf [7]. They may also be senescent fetal type cells.

Blood from umbilical cord containing two distinct populations of cells as depicted in figures 3 and 4 may sometimes occur.

The increase in osmotic resistance generally observed in red cells from cord blood in this study is in contradiction with the increased






Fig 1 Range of normal adult (---) and newborn (—) fragiligrams Abscissa = time in minutes Ordinate = percent lamellar bodies using fetal red between

100

---

0

gravity  
tively  
fetal red  
adult red




Fig. 3. A fragility gram obtained from umbilical cord blood showing bimodality which is indicative of two cell populations, apparent in the derivative curve (---) as a shoulder on the right. It is not recognizable in the cumulative curve (—)




Fig. 4. DDC obtained from umbilical cord blood of the same blood from which the fragility grams of figure 3 were obtained. Note the high proportion of cells with low specific gravity and the apparent bimodality

fragility reported by several authors [8, 13]. The data obtained by the 50% hemolysis test are of limited value as can be seen from the considerable amount of overlap in the osmotic resistance values for cord and adult blood at this level of hemolysis (fig. 1). SjöLIN [10]




Fig 1. Range of normal adult (---) and newborn (—) fragiligrans. Abscissa = time in minutes. Ordinate = percent hemolysis. The baseline was adjusted to hematocrite 50%, using the nomograms supplied with the fragiligraph. Note the narrow overlapping area between the two ranges and the relatively wide range of osmotic fragility of newborn blood.




Fig 2. Range of normal adult (---) and newborn (—) DDC. Abscissa = specific gravity of separating fluid. Ordinate = percent cells below separating fluid. Note the relatively wide range of normal DDC of fetal blood and the existence of a small proportion of fetal red cells having a specific gravity similar or higher than that of the oldest or densest adult red blood cells.




Fig. 3. A fragility graph obtained from umbilical cord blood showing bimodality which is indicative of two cell populations, apparent in the derivative curve (---) as a shoulder on the right. It is not recognizable in the cumulative curve (—)




Fig. 4. DDC obtained from umbilical cord blood of the same blood from which the fragility graph of Figure 3 were obtained. Note the high proportion of cells with low specific gravity and the apparent bimodality

fragility reported by several authors [8, 13]. The data obtained by the 50% hemolysis test are of limited value as can be seen from the considerable amount of overlap in the osmotic resistance values for cord and adult blood at this level of hemolysis (fig. 1). Sjölin [10]

and CRAWFORD *et al* [3] have pointed out the presence of a small proportion of osmotically resistant cells in cord blood. They attributed this increased resistance to the relatively high proportion of reticulocytes in cord blood. SMITH [11] noted that the proportion of cells with increased resistance is higher than 10%. However, our data indicate that the fetal cells hemolyse later, i.e. at lower salt concentrations, than any reticulocytes of normal adults. Also in the DDC, some cells show a specific gravity lower than any normal reticulocytes of adults. These characteristics of cord blood cells seem to indicate a structural difference in addition to the higher concentration of fetal hemoglobin, as pointed out by ZIPURSKY *et al* [15]. Those differences are even more sharply delineated in cattle blood [3, 9].

It has been shown that, in the adult life of some mammals, a population of cells larger and more hydrated than the normal reticulocytes may sometimes occur [1]. The characteristics of these cells correspond to the skip of one cell division, such cells would reach the circulation having larger diameters, and a higher surface to volume ratio and a higher proportion of water [1, 2]. These features may contribute, at least partially, to the higher osmotic resistance and the lower specific gravity of these cells. Similar properties may cause the higher resistance of cells from cord blood. In view of these results, it seems not unreasonable to assume that during life in utero, when the rate of blood formation is confronted with the needs of the body of the foetus and its high rate of growth, a high rate erythropoiesis and frequently 'skipped generation' may predominate [1].

### Summary

The osmotic fragility of red cells from the newborn was compared with that of adult erythrocytes using a fragiligraph Model D-2. Density distribution of cells (DDC) of the two groups was determined by the method of Kleimann and Danon [1964]. The DDC of fetal cells showed a higher density than the densest cells of adults. The osmotic fragility of fetal cells was higher than that of adult cells. The DDC of fetal cells was shifted to the right of the DDC of adult cells. The DDC of fetal cells was shifted to the right of the DDC of adult cells.

is of higher density than the densest cells of adults

### References

1. BORSOOK, H. A picture of erythropoiesis at the combined morphologic and molecular levels. *Blood* 24: 202 (1964).

2. RESCHER, G. and STROELMAN, F. Reticulocyte size and erythropoietic stimulation. *Proc. Soc. exp. Biol., N.Y.* 177: 257 (1971).
3. CRAWFORD, H., CUTRUBBI, M. and MOLLISON, P. L. Hemolytic disease of the newborn due to anti-A. *Blood* 8: 620 (1953).
4. DAWON, D. A rapid micro-method for recording red cell osmotic fragility by continuous decrease of salt concentration. *J. clin. Path.* 15: 337 (1963).
5. DAWON, D. and MARSHOVAT, Y. Determination of density distribution of red cell population. *J. Lab. clin. Med.* 64: 663 (1964).
6. FINDLAY, L. The fragility of the red cell to hypotonic saline in infancy and childhood. *Arch. Dis. Child.* 30: 64 (1945).
7. FREY, V. F., PERR, K. and DAWON, D. Correlation between osmotic resistance and fetal hemoglobin in bovine erythrocytes. *Exp. Cell Res.* 30: 361 (1973).
8. GOLDBLOOM, A. and GOTTLIEB, R. Icterus neonatorum. *Amer. J. Dis. Child.* 37: 57 (1929).
9. PERR, K. and DAWON, D. Comparative structure analysis of fetal and adult type red cells in newborn and adult cattle. *Res. Vet. Sci.* 6: 442 (1963).
10. SPOLIN, S. The resistance of red cells in man. *Acta paediatr., Suppl.* 98, #7: 370 (1954).
11. SMITH, C. A. The physiology of the newborn infant, 2nd ed., p. 124 (Thomas, Springfield 1953).
12. WATON, T. R., MERCHANT, F. T. and MARCHAN, G. B. Blood studies on new born. *Amer. J. med. Sci.* 156: 646 (1937).
13. WHITBY, L. E. H. and HYMAN, M. The quantitative estimation of the fragility of the red cell corpuscle. *J. Path. Bact.* 47: 219 (1935).
14. WINTROBE, M. M. Clinical hematology, 4th ed., p. 175 (Lea & Febiger, Philadelphia 1967).
15. ZIMSKY, A., NISLANTZ, P. J., POLLOCK, J., GROWN, B. and ISRAEL, L. G. The distribution of fetal hemoglobin in the blood of normal children and adults. *Pediatrics* 30: 637 (1957).

Authors' addresses: Dr Y. DAWON, Israel Defence Forces and Prof. Dr D. DAWON, Section of Biological Ultrastructure, The Weizmann Institute of Science, Rehovot, Dr A. KATZMAN, Dept. of Medicine 'B', Meir Hospital, Kfar Saba (Israel) - Requests for reprints to Prof. D. DAWON.

## The Osmotic Fragility of Red Cells in Newborns and Infants

L. LUZZATTO, G. J. F. ESAN and S. E. OGIENUDIA

Sub-Department of Haematology, University College Hospital, Ibadan

Erythropoiesis undergoes a series of striking changes during development in mammals [9, 11], and human fetal cells differ from adult cells in numerous respects [reviewed by C. A. SMITH, 17]. Analysis of osmotic fragility yields important information as to the homogeneity, the shape and the surface to volume ratio of a population of red cells. Earlier work has indicated that on the average newborn erythrocytes tend to be osmotically more resistant than in the adult but that abnormally fragile cells are also present [19]. DANON *et al.* [3] have recently confirmed these data by use of an automatic (fragiligram) technique [2]. In this paper, we show how the wider range of osmotic fragility is a unique characteristic of normal newborn cells which can be precisely quantitated, which is not due to the presence of fetal haemoglobin *per se*, and which disappears physiologically during the first few weeks of life.

### *Materials and Methods*

*Adult subjects* were healthy blood donors with no clinical disease and a haemoglobin level of at least 13.8 g/100 ml. The *newborns* were babies born in this Hospital without any selection, except for the omission of those who subsequently developed jaundice. Blood samples from *infants* between 1 and 10 weeks of age, and free of any clinical abnormality, were obtained from the welfare and immunization clinic.

*Collection of blood specimens* Venous blood from adults and cord blood from newborns was collected with one-fifth volume of ACD solution (disodium citrate, monohydrate, 2 g, glucose, 3 g, in a final volume of 120 ml) and stored for a maximum of 12 h at 4°C. Blood from infants was obtained by heelprick and collected directly in 15 volumes of barbitone buffered saline (2.5 mM barbitone-HCl, pH 7.4, in 0.147 M NaCl).

*Osmotic fragility curves* or 'fragiligrams' were obtained as described by DANON [2] by use of a fragiligraph, model D2 (Elmedix, Haifa, Israel). When ready for the test, each sample

was centrifuged, the packed cells were diluted 1:50 with bathosmectaline and equilibrated for 30 min. Exactly 40  $\mu$ l were then delivered in the dialysis frame by using a 50  $\mu$ l precision syringe (model 703 Hamilton Co., WI, U.S.A.). The test was then carried out as recommended in the manufacturer's hand book.

In order to ensure comparability of results to each other and to those obtained by other methods we always referred to the salt concentration curve with the following additional precautions: 1) The water chamber of the instrument was always kept at a temperature of 30°C by circulation of distilled water through the jacket; the water required to fill the chamber was pre-equilibrated at the same temperature. 2) The salt calibration was carried out daily. 3) In every frag-gram the cumulative and the salt curve were recorded simultaneously. In a perfect test the salt curve should tend asymptotically to 90% of the full-scale deflection. All frag-grams in which the end value of the salt curve was outside the range 85-95 were repeated (in order to achieve this, it was sometimes necessary to repeat a frag-gram up to three times). 4) A derivative curve was always recorded simultaneously to a cumulative curve on a sample in which the cumulative and the salt curve had already been recorded (the relationship between derivative and salt curve could then be obtained by reference to the cumulative curve present in both tests). When all these precautions are taken it is found that results on the same sample are always directly comparable. By the direct comparison of cumulative curves recorded without simultaneous salt curves was unsatisfactory. We have very often found that under the conditions described above venous blood and capillary blood yield the same result, and that short term storage in ACD has no effect.

### Results

*Osmotic fragility of red blood cells in newborns compared to adults.* We found in many cases that cord blood erythrocytes appear somewhat more resistant than in the adult, in agreement with DAWSON *et al.* [3]. However, when the difference is expressed quantitatively in terms of mean corpuscular fragility (MCF—the concentration of NaCl at which 50% of red cells are haemolyzed), it is seen not to be statistically significant (table I). Indeed, although the mean value of MCF is slightly lower in newborns, the range of values is so wide (fig. 1), as to overlap almost totally with the values observed in adults (table I, and compare with fig. 1 of FAN, 4). Thus, the MCF of cord blood is not characteristically different from that of adult blood.

*Quantitation of the osmotic fragility range in the erythrocyte population of newborns and adults.* One of the advantages of the 'fragiligram' method over the standard technique of testing osmotic fragility is that the former covers continuously the full range of tonicity from that of physiological saline to that of distilled water. Moreover, the instrument can record automatically, in addition to the cumulative osmotic fragility curve, also its first derivative, which gives a direct visual representation of the distribution of red cells having different resistance to lysis within the blood sample. The striking feature of a newborn's



Table I Comparison of three indices of osmotic fragility in erythrocytes from adults and newborns

|  | MCF <sup>1</sup> |           | $\Delta_{20-80}$ <sup>2</sup> |           | $\sigma$ <sup>3</sup> |          |
|--|------------------|-----------|-------------------------------|-----------|-----------------------|----------|
|  | Adults           | Newborns  | Adults                        | Newborns  | Adults                | Newborns |
| Number tested  | 130              | 70        | 35                            | 35        | 15                    | 15       |
| Range  | 0.31-0.52        | 0.25-0.55 | 0.07-0.16                     | 0.12-0.20 | 0.9-1.2               | 1.3-2.0  |
| Median   | 0.41             | 0.40      | 0.10                          | 0.16      | 1.1                   | 1.7      |
| Mode   | 0.42             | 0.40      | 0.10                          | 0.18      | 1.1                   | 1.7      |
| Mean   | 0.43             | 0.41      | 0.10                          | 0.16      | 1.1                   | 1.67     |
| Standard deviation                                     | 0.05             | 0.04      | 0.025                         | 0.02      | 0.096                 | 0.226    |
| Significance of difference between adults and newborns | <i>t</i> 1.62    |           | 9.61                          |           | 8.26                  |          |
|  | <i>P</i> > 0.1   |           | < 0.001                       |           | < 0.001               |          |

<sup>1</sup> Mean Corpuscular Fragility, expressed as the percent NaCl concentration which causes 50% haemolysis

<sup>2</sup> The difference between percent NaCl concentration which causes 20% haemolysis and the concentration which causes 80% haemolysis

<sup>3</sup> The width of the osmotic fragility range within the red cell population, measured as the distance along the abscissa between the peak and the inflection point of the derivative fragility curve

fragiligram, compared to the adult, is the wider range of osmotic fragility (fig 2). This is reflected in a more 'sluggish' sigmoid shape of the cumulative curve, and in a wider base of the bell-shaped derivative curve. In order to express quantitatively the amplitude characteristic of a fragiligram, two indices are introduced: (1) The difference between the salt concentration which causes 20% haemolysis and the salt concentration which causes 80% haemolysis, which we designate  $\Delta_{20-80}$ ; (2) The distance between the peak of the derivative curve and the inflection point of its descending branch, which we designate  $\sigma$  (fig 2), and which is measured along the abscissa in arbitrary units (we have used centimeters for convenience).

The values of  $\Delta_{20-80}$  in newborns as a group are considerably higher than in adults. The difference is highly significant statistically (table I), although there is still ample overlap between the two groups; thus, about 30% of the adult samples fall in the cord blood range, and about 50% of the cord bloods fall in the adult range. The difference in the values of  $\sigma$  in the two groups is also highly significant statistically; moreover, there is no overlap between the two. This index effectively




Fig. 1 Distribution of the values of mean corpuscular fragility (MCF) in 70 cord blunts. The cases are grouped according to the NaCl concentration shown on the abscissa,  $\pm 0.01\%$ . Thus, for instance, the cases of the bar marked 0.41 had MCF between 0.40 and 0.42. The NaCl concentrations were read directly from the salt curve on the fraglogram.




Fig. 2 Typical example of fraglograms from a normal adult and from a normal newborn. The cumulative curve *c*) and the derivative curve *d*) are both shown. The time scale on the abscissa is logarithmically related to decreasing salt concentration. The horizontal broken line joining the peak ordinate of the derivative curve to the inflection point of the latter (*σ*) is used as a measure of the range of osmotic fragility within the erythrocyte population. The osmotic fragility parameters (see table I) in these two examples were as follows: adult MCF = 0.40,  $d_{50-90}$  = 0.10,  $\sigma$  = 1.05; newborn MCF = 0.45,  $d_{50-90}$  = 0.17,  $\sigma$  = 2.0.




Fig 3 Age-dependence of the osmotic fragility range (scattergram). The values of  $\sigma$  are given on the ordinate. The inset shows the time course of change of  $\sigma$  in an individual infant from birth to 6 weeks of age.

resolves the two groups, in that  $\sigma$  is always 1.2 or less in adults, but 1.3 or more in newborns (table I).

*Age related changes in the osmotic fragility range.* When does the transition take place from a cord blood type to an adult type of osmotic fragility curve? In order to answer this question we have obtained fragiligrams at serial times from 15 infants between the age of 1 and 12 weeks. The transition from one to the other type of fragiligram was found to occur very early in life, usually within 4 weeks (fig 3). This can be shown most clearly by following the changes which take place in an individual baby. In the example shown in the inset of figure 3 the value of  $\sigma$  falls exponentially from 1.85 at birth to 1.2 (i.e. within the adult range) by the age of 6 weeks.

### Discussion

Erythropoiesis before and after birth is different in several respects and most strikingly in the 'switch' from fetal to adult haemoglobin production. Morphologically, erythrocytes in the newborn have a larger size, and a higher haemoglobin content than in the adult, while the haemoglobin concentration is similar to that in the adult [7]. Metabolically, differences have been reported in many of the red cell

enzymes [15, 21]. Functionally, it has been proven that at least some of the newborn's erythrocytes have a shorter life span than in the adult [8, 13], but the mechanism for this is unknown.

The osmotic fragility of red cells is a composite index of their shape, hydration and, with certain limitations, of their proneness to *in vivo* destruction. Indeed, whereas high osmotic resistance does not always correlate with high viability (the typical contradictory example being thalassaemia major), low osmotic resistance invariably indicates that the cells tend to a spherical shape, and therefore are liable to premature removal from the circulation. On the average, the osmotic fragility of erythrocytes is similar in newborns and adults. But this current statement [17, 18] must be qualified by reference to previous work which had already demonstrated the simultaneous presence of unusually resistant and unusually fragile red cells in cord blood (e.g. 20). WAGH *et al.* [19] previous papers are quoted in their comprehensive article] even coined the term 'anisohaemolysis' for this phenomenon.

We have confirmed these earlier observations, as well as more recent ones [3, 16]. The MCF values are not significantly different in newborns and adults (table 1) and are in good agreement with those reported by CRAWFORD *et al.* [1] and by HENDRICKS and WATSON-WILLIAMS [7a] in Nigeria. On the other hand, comparison of full fragility curves (fig. 2) clearly demonstrates that the span of haemolysis from higher to lower salt concentrations is wider in newborns than in adults. In addition, exploiting the greater accuracy afforded by the automatic over the manual technique, we were able to obtain a quantitative expression of the degree of anisohaemolysis, by the two parameters which we have called  $\Delta_{20-80}$  and  $\sigma^1$  respectively.

It has been found in cattle<sup>2</sup> that the osmotic fragility curves of newborn animals are similar to those of adult animals, but that the newborn animals have a higher percentage of reticulocytes. This indicates that also in man haemoglobin F is not directly responsible for the characteristic features of the newborn's fragiligram (high values of  $\Delta_{20-80}$  and of  $\sigma$ ). a) The time course of 'conversion' from neonatal to adult type of fragiligram is quite different from the time course of

<sup>1</sup> It may be noted that in order to determine  $\sigma$  it is necessary to obtain a derivative curve and to locate its inflection point. This was done by eye in our study and estimates by independent observers agreed within less than 10%. By contrast the determination of  $\Delta_{20-80}$  does not require any subjective evaluation and can be done even on data obtained from standard (non-automatic) osmotic fragility curves.

Table II Osmotic fragility in subjects with hereditary persistence of fetal haemoglobin

| Case | Age<br>years | Haemoglobin<br>electrophoresis | Percentage<br>of Hb F | Fragil gram data |                  |          |
|------|--------------|--------------------------------|-----------------------|------------------|------------------|----------|
|      |              |                                |                       | MCF              | $\Delta_{10-90}$ | $\sigma$ |
| 1    | 5            | A+F                            | 30                    | 0.44             | 0.09             | 1.0      |
| 2    | 4            | S+F                            | 48                    | 0.38             | 0.12             | 1.2      |
| 3    | 7            | A+F                            | 35                    | 0.42             | 0.11             | 1.1      |

The diagnosis of hereditary persistence of haemoglobin F was based on the following findings (in addition to those shown in the table) a) There was uniform distribution of haemoglobin F within the red cell population [as judged by the elution technique 10] b) There was no clinical or haematological evidence of thalassaemia (nor of sickle cell disease in case 2) c) In cases 1 and 2 the genetic abnormality could be traced to one of the parents

disappearance of haemoglobin F. Thus,  $\sigma$  changes abruptly after birth and falls to adult values by 4-6 weeks (fig 3), at a time when haemoglobin F is still the major haemoglobin component in the infant's blood (fetal haemoglobin decreases to adult range only at the age of 4-8 months [22]) b) In three children heterozygotes for hereditary persistence of haemoglobin F [9] we found that the fragiligram was unquestionably of the adult type (table II). Thus, haemoglobin F is not the basis for anisohemolysis, i.e. for the simultaneous presence of unusually resistant and unusually fragile cells.

We rather suggest that these two fractions of the erythrocyte population may arise by distinct mechanisms. The origin of the more resistant cells has been discussed by DANON *et al* [3], and lies perhaps in 'accelerated erythropoiesis'. The origin of the more fragile cells is probably related to one or more of the several metabolic deficiencies of the newborn's erythrocytes [6, 12], which may impinge on membrane function and thus be conducive to spherocytosis. The early disappearance of the fragile cells suggests that they are prone to haemolysis *in vivo* as well as *in vitro*. We propose to investigate whether this can account for the accelerated erythrocyte destruction that is characteristic of the perinatal period, and whether an exaggerated rate of this process underlies some cases of otherwise unexplained neonatal jaundice.

*Acknowledgements* We thank Miss C. JAGUN and Mr O. O. AKUTE for valuable technical assistance. We are greatly indebted to Prof. DAVID DANON for initiating us to the fragil graph.

and to Elmedici for help in obtaining the instrument. We thank the staff of the Department of Obstetrics for providing us with samples of cord bloods. Prof. R. G. HENNINGSEN and Dr. FAMILLET and his colleagues in the Department of Pediatrics for samples from infants. The Medical Illustration Unit, University of Illinois, has produced the figures. Financial support was given by the World Health Organization.

### Summary

The osmotic fragility of red cells was analysed by an automatic technique in 70 newborn babies and in 13 infants who were tested at serial intervals between the age of one and 12 weeks. The most characteristic feature of the newborn's blood is a wide range of osmotic fragility (anacharmolysis) which can be precisely quantitated by measuring the width of the first derivative of the osmotic fragility curve. The value of this parameter designated  $\sigma$  is high in the newborn and usually falls to within the adult range during the first 4-6 weeks of life. These data indicate that fetal haemoglobin (which persists for several months) is not responsible as such for the peculiar osmotic fragility pattern observed in cord blood and that an osmotically fragile fraction of the newborn's red cell population undergoes selective destruction very soon after birth.

### References

1. CRAWFORD H., CUTLER M. and MOLLISON P. L. Haemolytic disease of the newborn due to anti-A. *Brnd* 8: 620 (1955).
2. DAWON D. A rapid micro-method for recording red cell osmotic fragility by continuous decrease of salt concentration. *J. clin. Path.* 16: 35 (1963).
3. DAWON D., KLEIMAN A. and DAWON D. The osmotic fragility and density distribution of erythrocytes in the newborn. *Acta haemat., Basel* 43: 247-247 (1970).
4. EARN G. J. F. The thalassaemia syndromes in N. Africa. *Brit. J. Haemat.* (in press 1970).
5. FRET J. F., PERE, K. and DAWON D. Correlation between osmotic resistance and fetal haemoglobin in bovine erythrocytes. *Exp. Cell Res.* 30: 561 (1973).
6. CHOM, R. T., BRACCI, R., REDDAUER, N., SCHROEDER, E. and KOCHEK, J. A. Hydrogen peroxide toxicity and detoxification in the erythrocytes of newborn infants. *Blood* 29: 481 (1967).
7. GUTY G. M. and BROWN E. W. Erythrocytes and haemoglobin of the blood in infancy and childhood. *Amer. J. Dis. Child.* 93: 469 (1957).
- 7a. HENNINGSEN R. C. and WATSON WILLIAMS F. J. Erythrocyte osmotic fragility in Nigerian infants and adults. *Brit. Med. J.* ii: 169 (1961).
8. HOLLINGSWORTH J. W. Lifespan of fetal erythrocytes. *J. Lab. clin. Med.* 45: 469 (1955).
9. INGRAM V. M. Haemoglobins in genetics and evolution (Columbia Univ. Press, New York 1963).
10. KLEIMANER E. und BETER, K. Demonstration von fetalem Haemoglobin in den Erythrocyten eines Blutausstrichs. *Klin. Wochs.* 35: 637 (1957).
11. MAREL, P. A. and KOVACS J. S. In MONTAGNY and MONTAGNY Current topics in developmental biology vol 1 p. 213 (Academic Press, New York 1966).
12. McDONALD C. D. and HYDMAN T. H. J. A comparative study of enzymic activities in normal adult and cord blood erythrocytes as related to the reduction of methemoglobin. *Clin. chim. Acta* 7: 555 (1962).
13. MOLLISON P. L. Blood transfusion in clinical medicine (Blackwell Oxford 1961).

- 14 PERK, K. and DANOV, D. Comparative structure analysis of foetal and adult type red cells in newborn and adult cattle. *Res Vet Sci* 6: 442 (1965)
- 15 SCHROTER, W. Frühkindliche Manifestationen erythrocytärer Enzymdefekte. *Dtsch med Wschr* 93: 1202 (1968)
- 16 SJÖLIN, S. The resistance of red cells *in vitro*. *Acta paediat*, Uppsala #3 (Suppl. 93) 5 (1954)
- 17 SMITH, C. A. The physiology of the newborn infant (Thomas, Springfield 1959)
- 18 SMITH, C. H. Blood diseases of infancy and childhood (Mosby, St. Louis 1966)
- 19 WAUGH, T. R., MERCHANT, F. T. and MAUGHAN, G. B. Blood studies on the newborn. I. *Amer J med Sci* 193: 646 (1939)
- 20 WHITBY, L. E. H. and HYNES, M. The quantitative estimation of the fragility of the red corpuscles. *J Path Bact* 40: 219 (1935)
- 21 ZIFURSKY, A. The erythrocytes of the newborn infant. *Sem Haemat* 2: 167
- 22 ZIFURSKY, A. Fetal haemoglobin levels in the fetus and newborn and the postnatal decline of fetal haemoglobin, in FOMOV Fetal haemoglobin, 52nd Ross Conf. pediat. Res. (Ross Laboratories, Columbus 1966)

## Immunochemische Untersuchungen an Spaltprodukten menschlicher Gammaglobuline

Untersuchungen an Seren mit Hypergammaglobulinämie und Paraproteinämie

J. SCHNEIFARTIG, H. GÖTZ und R. SCHUBERT

Abteilung für klinische Immunologie des Universitätskrankenhauses Erlangen-Nürnberg  
Vorstand: Prof. Dr. J. SCHNEIFARTIG

Die in den letzten Jahren gewonnenen Erkenntnisse über die Polypeptidstruktur der Immunglobuline (Ig) von Mensch und Tier, haben mit Bezug auf die Immunglobuline des menschlichen Serums zu folgender Einteilung geführt. Das Immunglobulinsystem besteht insgesamt aus fünf Einzelfraktionen, die nach der Entschlüsselung der World Health Organization des Jahres 1964 [33a] als IgA, IgG und IgM bezeichnet werden, inzwischen sind zwei neue Ig-Klassen nachgewiesen und charakterisiert worden, das IgD und das IgE [26, 27, 33b, 41]. Darüber hinaus wurden in Seren von Gesunden Mikrogammaglobuline  $\mu$ -Globuline aufgedeckt [2], deren Bedeutung als Immunglobuline bisher allerdings nicht geklärt werden konnte. Schließlich wird diskutiert, ob das C-reaktive Protein ebenfalls zu den physiologischen  $\gamma$ -Globulinen gerechnet werden darf [19 a, b, 35, 46, 48].

Jedes der fünf erstgenannten Immunglobuline ist durch bestimmte physikalische, biochemische und immunologische Eigenschaften ausgezeichnet. Sie unterscheiden sich also hinsichtlich ihres Molekulargewichtes bzw. ihrer Sedimentationskonstanten, hinsichtlich ihrer elektrophoretischen Beweglichkeit und ihrer Diffusionsfähigkeit sowie ihrer antigenbindenden Eigenschaften. Auf Grund einer Beobachtung von PORTER aus dem Jahre 1959 [37] lassen sich die vorgenannten Immunglobuline durch Papain-Einwirkung fermentativ spalten, dabei entstehen klassenspezifische sowie kreuzreagierende Polypeptidketten. Entsprechend ihrer Aminosäuresequenz wurden sie als sogenannte H- (heavy-) und L- (light-) Ketten bezeichnet. Jüngste Forschungsarbeiten haben die Struktur dieser Bruchstücke aufgezeigt.



Es ist heute bekannt, dass an die verschiedenen  $\gamma$ -Globulin-Bruchstücke auch klinisch interessante Eigenschaften, etwa genetische Faktoren, antigenbindende oder Paraprotein-Eigenschaften gebunden sind [1, 6, 8, 9, 10, 11, 12, 13, 16, 18, 28, 38, 39, 40, 52]

In vorliegender Arbeit sollten  $\gamma$ -Globulin-Analysen mit Differenzierung von Papain- und Zysteamin-Spaltprodukten vorgenommen werden, mit der besonderen Fragestellung der Nutzbarkeit solcher Untersuchungen für die klinische Routinediagnostik.

### *Material und Methodik*

Untersucht wurden die Seren von einem Patienten mit chronischer Hepatitis, ferner das Serum eines Kranken mit primär chronischer Polyarthritis weiterhin das Serum eines Patienten mit chronisch rezidivierender Asthma Bronchitis und schliesslich das Serum eines Patienten mit  $\lambda$ -G Myelom. Alle Patientenserum waren durch eine Hypergamma globulinämie ausgezeichnet.

Die Seren wurden zunächst papierelektrophoretisch und mit der Elektrophorese auf Celluloseacetatfolien (CAF) sowie immunoelektrophoretisch differenziert. Von jedem Serum wurde ferner die Gammaglobulinfraktion durch Ryanolfällung sowie durch Trennung an der DEAE-Säule von den übrigen Serumproteinfraktionen isoliert. Der Globulinkomplex wurde nunmehr jeweils mit Papain mit Zysteamin als auch mit Papain und Zysteamin behandelt. Die Spaltprodukte wurden immunoelektrophoretisch unter Verwendung eines polyvalenten Antihumanserums sowie monoklonaler Antiseren gegen die verschiedenen Ig Subfraktionen IgA, IgG, IgM, IgD und schliesslich unter Verwendung monoklonaler Antiseren gegen H- und L-Ketten analysiert.

#### *Papierelektrophorese*

Die Papierelektrophorese wurde nach dem bekannten Verfahren von GRASSMANN und HANNIG [22, 44] durchgeführt.

#### *Elektrophorese auf Celluloseacetatfolien*

Die CAF Elektrophorese wurde im Prinzip nach den Angaben von KOUK [29 a-c] vorgenommen. Zur Auswertung der Farbintensitäten der elektrophoretisch getrennten und mit Amidoschwarz gefärbten Proteinfraktionen wurde der Zeiss-Integralschreiber<sup>1</sup> gewählt.

#### *Immunoelektrophorese*

Die Immunoelektrophorese wurde nach den Angaben von GRABAR und WILLIAMS [20, 21] in der Modifikation nach SCHNEIDEGGER [42] durchgeführt. Für einzelne Analysen sätze wurden darüber hinaus Agarplatten mit den Abmessungen 19 x 12 cm mit 8 Austragestellen und 7 Antiserumkanälen verwendet.

Als Antiseren wurden ein handelsübliches polyvalentes Antihumanserum sowie monoklonale Antiseren gegen IgA, IgG, IgM, IgD<sup>2</sup>, aber auch gegen Fab-Fragment (=L-Ketten) und Fc Fragment (=H Ketten)<sup>3</sup> gewählt.

<sup>1</sup> Fa Zeiss Oberkochen

<sup>2</sup> Polyvalentes Antihumanserum sowie Fab- und Fc Fragment Antiseren Fa Hyland Lab., Los Angeles Calif. USA

<sup>3</sup> Monoklonale Antiseren der Behringwerke Marburg/Lahn

*Material und Methode*

a) *Prüfung des Vorvorganges* wurde nach folgenden eigenen Erfahrungen [45] bzw. nach den Angaben von HOSZJI und SURANA [25] Handel übliches Rivanol® wurde als 0,2% ige wässrige Lösung verwendet. 1 ml des zu untersuchenden Serums wurde mit 2,5 ml der Rivanol-Lösung versetzt. Die entstandene Fällung wurde 30 min bei 4000 U/min in der Küllertrennfuge abtrennungsfähig. Der Überstand konnte ohne Dialyse weiter verarbeitet werden.

b) *Trennung über die DEAE-Säule* wurde wie [14] angewandt wurde im Prinzip das von a) ständiger Verfahren nach PETERSEN und SMITH [34, 35]. Nach Auflösen der DEAE-Säule und Packen der Säule (2,5 x 40,0 cm bis H<sub>2</sub>O 17,0 cm) wurde die Säule drei mal mit einem Puffer (pH 7,0) gewaschen. Danach wurde die Säule mit 50 ml der Serumprobe überpackt. Nach zweifacher Aufnahme des Serums von der Säule wurde mit einem anderen Puffer (pH 5,0) die Säule aufgefällt. Dies wurde auch wiederholt, bis die erste Infrafraktion eluiert war. Eine auf gleiche Weise gewonnene zweite Fraktion enthält  $\alpha_2$  und  $\beta$ -Globuline. Folgende Puffer:  
 Puffer I: 0,01 M pH 7,0 100,0 ml NaH<sub>2</sub>PO<sub>4</sub>, 8,5 ml NaHPO<sub>4</sub>  
 Puffer II: 0,01 M pH 5,0 100,0 ml NaH<sub>2</sub>PO<sub>4</sub>, 2,6 ml NaHPO<sub>4</sub>

*Papain-Vergleich*

Die beiden  $\gamma$ -Globulinfraktionen, die nach Rivanol-Fällung sowie die nach Trennung an der DEAE-Säule erhaltenen Serums wurden den nachfolgenden Papain-Vergleich unterzogen. Jede Probe wurde zunächst mit Papain versetzt, wobei im Prinzip nach den Angaben von PETERSEN [34, 35] vorgegangen wurde. Nach einer Gesamtmeßzeit von 10 min wurde die Analyse beendet. Die Proben mit Papain und einem Puffer versetzt. Das Mengenverhältnis betrug 1 mg Papain auf umgerechnet 100 mg Eiweiß. Der Puffer bestand aus 0,1 M Na-Phosphatpuffer pH 7,0 0,01 M Calcium und 0,01 M Äthylendiamintetraacetat. Dieses Gemisch wurde bei 37°C für die Dauer von 1 h inkubiert. Anschließend wurden die einzelnen Proben 4 h lang gegen 100 ml eines 0,01 M Phosphatpuffers pH 7,0 und danach gegen 1000 ml desselben Puffers 24 h dialysiert.

*Behandlung der Proben mit Zymozym*

Im Hinblick auf das bei DETTMER und MONTAG [7 & 53] beschriebene Verfahren wurde folgendermaßen vorgegangen. Eine 1 M Zymozym-Lösung in 0,1 M Puffer pH 7,2 und 0,01 M wurde jeweils 1:10 mit der  $\gamma$ -Globulin-Probe verdünnt. Das Gemisch wurde bei Raumtemperatur inkubiert und wurde 2 h dialysiert gegen 0,01 M Manganacetat.

*Resultate**Befunde bei Aufbereitung bzw.  $\gamma$ -Globulinreinigung der Patientenserum*

Bei Vergleich der  $\gamma$ -Globulin-Präparate nach Rivanol-Fällung sowie nach Trennung in der DEAE-Säule, ist zunächst festzustellen, dass beide Methoden eine relativ gute Ausbeute hinsichtlich der  $\gamma$ -Globulinfraktion ergaben. Bei beiden Methoden waren allerdings auch Verunreinigungen durch ein bis zwei Komponenten des  $\beta$ -Bereiches und in Einzelfällen sogar durch  $\alpha_2$ -Globulinfraktionen nicht zu vermeiden. In Fällen mit relativ hoher  $\gamma$ -Globulin-Konzentration, z. B. beim  $\gamma$ -G Myelom, aber auch bei der chronischen Hepatitis, war der Reinheits

\* Rivanol Hoechst DAB 6




Abb 1 Diagramme der elektrophoretischen Analysen auf Zelluloseacetatfolien der untersuchten Seren und deren  $\gamma$  Globulinkomplexe

grad der  $\gamma$ -Globulin-Fraktion wesentlich höher als im Falle etwa der primär chronischen Polyarthrit is. Diese Feststellungen waren sowohl mit der Immunelektrophorese als auch mit den relativ groben Methoden der Papier- und CAF-Elektrophorese zu treffen (Abb 1).

*Befunde nach Spaltung der  $\gamma$ -Globulinfraction durch Papainwirkung* Bei allen untersuchten Seren gelang die Darstellung von zwei Komponenten, die sich sowohl in ihrer elektrophoretischen Beweglichkeit als




Abb. 2 Immunoelektrophoretische Analysen des G<sub>2</sub>-Frac. des Serums einer chronischen Hepatitis nach Behandlung mit Tapan

auch in ihren immunologischen Eigenschaften (Kreuzungsphänomen) voneinander unterschieden. Sie entsprachen, wie mit monoklonalen Antisera bewiesen werden konnte, den Fc- (H-chains) bzw. den Fab- (L-chains) Fragmenten (Abb. 2). Im Falle des hier analysierten  $\gamma$ -G




Abb 3 Immunelektrophoretische Befunde der  $\gamma$ -G Myelom Fraktion. Oben nach Behandlung mit Papain, unten nach Einwirkung von Papain und Zysteamin

Myeloms konnte zwischen dem typischen Fc-Fragment und dem ebenfalls charakteristischen Fab-Fragment eine zusätzliche Komponente wahrgenommen werden, die sowohl das Fc- als auch das Fab-Präzipitat total kreuzte (Abb 3). Mit der GAF-Elektrophorese war das  $\gamma$ -Globulin nach Papaineinwirkung als ein relativ breiter Komplex darstellbar, der seinerseits zwei bis drei Subfraktionen erkennen liess. Eine Differenzierung in  $\gamma$ -Globulin Komponenten mit exakt definierbaren elektrophoretischen Beweglichkeiten gelang nicht (Abb 1).

Im übrigen ist bemerkenswert, dass die vergleichsweise mit angesetzten, nicht gespaltenen Vollseren bei Verwendung monoklonaler Antiseren ebenfalls eine Differenzierung in H- und L-Ketten zulassen, wobei lediglich die elektrophoretischen Beweglichkeitsunterschiede der Fc- und Fab-Fragmente nicht so deutlich in Erscheinung treten. Sie sind aber prinzipiell nachweisbar (Abb 4).

*Befunde nach Spaltung der  $\gamma$  Globulinfraktion durch Zysteamineinwirkung*  
Hier konnte in den Fällen mit chronischer Hepatitis sowie der primär chronischen Polyarthritiden ebenfalls ein Spaltungsphänomen mit der Darstellung von zwei Komponenten mit unterschiedlicher Wanderungsgeschwindigkeit festgestellt werden, wobei die beiden Komponenten keine sichere Kreuzung, sondern nur eine Teilidentität aufwiesen. Sie entsprachen aber wiederum den H- und L-Ketten der  $\gamma$ -G Fraktion, wie dies unter Verwendung monoklonaler Antiseren gezeigt werden konnte (Abb 5).

Bei dem Serum mit  $\gamma$ -G-Myelom konnte eine sichere Aufspaltung nicht erzielt werden. Stattdessen zeigte sich eine Doppelung der Präzipitationslinien des  $\gamma$ -G Globulins, die im gleichen Masse mit dem polyvalenten Antiserum, dem anti- $\gamma$ -G-Serum sowie mit monoklonalen Antiseren gegen H-, nicht aber gegen L-Ketten auspräzipitierte.




Abb. 4. In immunoelektrophoretischer Analysensatz des unbehandelten Voll-Serums des Patienten mit chronischer Hepatitis unter Verwendung eines polyvalenten Anti-human-serums. MHS sowie verschiedener monovalenter Antigen gegen die bekannten Immunglobulin Klassen und gegen H- und L-Ketten (on IgG).

*Befunde nach Spaltung des  $\gamma$ -Globulinfraktion durch Papain und Zysteamin einwirkung.* Die Ergebnisse dieser Versuchsreihe entsprechen im wesentlichen den Befunden allein nach Papaineinwirkung, d. h. es zeigte sich in allen Fällen eine Aufspaltung des  $\gamma$ -Globulin Komplexes in




Abb 5 Immunelektrophoretischer Analysensatz des  $\gamma$  G Globulins des Serums einer chronischen Hepatitis nach Behandlung mit Zysteamin

zwei Komponenten. Die Fraktion näher der Auftragestelle entsprach den H-Ketten, die näher der Kathode gelegene den L-Ketten. Es ergab sich jedoch mit Regelmässigkeit ein auffälliges Phänomen, nämlich die Feststellung, dass bei Reaktion des gespaltenen Komplexes gegen das monovalente  $\gamma$ -G-Globulin jeweils nur die Komponente der H-Ketten zur Darstellung gelangte, nicht aber die der L-Ketten (Abb 6)




Abb. 6. In 8 unvielektrolysierten Analysenröhrchen des  $\gamma$ -Globulins des Serum einer chronischen Hepatitis nach Behandlung mit Tapan und Zysan.

### Diskussion

Die Befunde der vorliegenden Serumanalysen nach Papan-Einwirkung, mit der Darstellung von zwei Komponenten mit unterschiedlichen elektrophoretischen und immunologischen Eigenschaften, wie sie regelmässig in den vorgegebenen Globulin-Komplexen nachzu-



weisen waren, bestätigen die seit PORTER [37] erzielten gleichartigen Ergebnisse [1, 3, 5, 9, 10, 13, 14, 18, 52, 54]. Bekanntlich entspricht die eine der beiden Komponenten, und zwar die der Kathode näher gelegene, dem sogenannten Fab-Fragment, das seinerseits zur Hauptsache aus L-Ketten und zu einem kleinen Teil aus H-Ketten besteht [14, 15, 54]. Die andere Komponente, die der Auftragestelle näher gelegen ist, entspricht dem sogenannten Fc-Fragment, das ausschließlich aus H-Ketten besteht.

Die ersten Untersuchungen über derartige, durch fermentative Aufschliessung von  $\gamma$ -Globulinen gewonnenen Spaltprodukten, sind erstmals von PORTER [37] an Seren immunisierter Tiere vorgenommen worden, ohne dass damals die Bedeutung dieser Bruchstücke mit Bezug auf eine Spezifizierung der  $\gamma$ -Globulinfractionen in verschiedene Immunglobulin-Klassen schon klar erkannt worden wäre. Dank der in den letzten Jahren erfolgten chemischen und immunchemischen Aufklärungsarbeit an diesen Spaltprodukten [5, 6, 10, 14, 15, 16, 32, 38, 39, 40], wissen wir heute, dass jedes Immunglobulin-Molekül aus zwei klassenspezifischen H-Ketten und zwei L-Ketten bestimmter Prägung ( $K=I$  oder  $L=II$ ) besteht [9, 10, 13, 14, 15, 16, 28, 33, 39, 47, 54]. Dabei sind die L-Ketten allen Immunglobulinen gemeinsam, zu mindest untereinander immunologisch verwandt, während die H-Ketten durch die klassenspezifischen Merkmale  $\alpha$  (IgA),  $\gamma$  (IgG),  $\mu$  (IgM),  $\delta$  (IgD) und  $\epsilon$  (IgE) ausgezeichnet sind. Die L-Ketten kommen in zwei verschiedenen Typen (I oder II, s. o.) vor, wobei jedes Immunglobulin-Molekül entweder zwei L-Typ I-Ketten oder zwei L-Typ II-Ketten besitzt. In einem Individuum lassen sich aber sowohl Moleküle mit L-Ketten vom Typ I als auch Moleküle mit L-Ketten vom Typ II nachweisen, wobei das Verhältnis von Typ I zu Typ II von Immunglobulinklasse zu Immunglobulinklasse unterschiedlich angegeben wird [in 47, in 54].

Diese Kenntnisse über Struktur und Funktion der Immunglobuline haben zu völlig neuen Aspekten auch in der klinischen Medizin geführt. Sie erlangen insbesondere Bedeutung bei der Aufklärung von Anomalien im Bereich der  $\gamma$ -Globuline bzw. für die Erruierung von Strukturänderungen innerhalb eines  $\gamma$ -Globulin-Moleküls bei Paraproteinosen [11, 18, 23]. Unter der Voraussetzung, dass in Zukunft spezifische monovalente Antiseren gegen H- und L-Ketten zur Verfügung stehen werden, und dass unter Umständen der methodische Aufwand des fermentativen Spaltungsprozesses auf klinische Routine-

Ansprüche abgestimmt oder sogar entbehrlich werden kann, stellt diese  $\gamma$ -Globulin-Analyse eine wesentliche Bereicherung für die Paraprotein- und wahrscheinlich auch für die allgen eine  $\gamma$ -Globulin-Diagnostik pathologischer Seren dar.

Inzwischen gesammelte Erfahrungen und weitere Erkenntnisse an pathologischen menschlichen Seren, wie sie das Schrifttum aufweisen, haben gezeigt, dass sowohl bei den Paraproteinen als auch bei den stark vermehrten  $\gamma$ -Globulinen im Rahmen anderer Erkrankungen

Hepatitis, primär chronische Polyarthritis, Retikulosen und andere mehrere Systemerkrankungen die meisten Strukturveränderungen an den H-Ketten gebunden sind [1, 3, 43–52]. Bei Paraproteinen finden sich Anomalien aber an H- und L-Ketten [43]. Darüber hinaus wurden in den letzten Jahren Krankheitsfälle beschrieben, welche durch ein Syndrom mit Paraproteinämie, Paraproteinurie und Hepatosplenomegalie gekennzeichnet sind und [17, 34]. Auf Grund von Strukturanalysen dieser Paraproteine durch FRANKLIN [17] konnte gezeigt werden, dass bei dieser Paraproteinämie die atypische I-Fraktion nur aus strukturveränderten H-chains aufgebaut ist. Nach seinem Entdecker wird dieses Syndrom seither Franklin-Syndrom, die Krankheit H-Ketten-Krankheit genannt. Gewissermaßen das Pendant zur «H-chain-disease» stellt die Bence-Jones-Paraproteinämie mit Paraproteinurie als Mischsyndrom dar. Hier bestehen die Paraproteine-Moleküle nur aus L-Ketten.

Nach heutiger Kenntnis ist die  $\gamma$ -Globulin-Synthese der verschiedenen Immunglobulin-Klassen an ganz bestimmte Zellklone gebunden [4]. Möglicherweise erfolgt sogar die Polypeptidketten-Bildung klonal und somit isoliert, so dass H- und L-Ketten erst sekundär zu klassenspezifischen Ig-Systemen komplettiert werden müssen.

In vorliegender Arbeit standen die vorgenannten monovalenten Antisera gegen die verschiedenen Ig-Klassen sowie gegen H-Ketten von IgG und gegen L- Typ I und Typ II -Ketten von Bence-Jones-Proteinen zur Verfügung. Die darstellbaren Bruchstücke nach Papain- und Zymocain-Einwirkung konnten damit exakt identifiziert werden. Erwähnenswert erscheint ein Befund bei Analyse des  $\gamma$ -G-Myelomproteins, wobei eine zusätzliche Präzipitationslinie mit – wenn auch geringer, aber dennoch definierbarer – unterschiedlicher elektrophoretischer Beweglichkeit zwischen Fab- und Fc-Fragment wahrgenommen werden konnte. Ähnliche Beobachtungen wurden an den Immunglobulinen von Versuchstieren gemacht. Eine genaue Zuordnung

des in der vorliegenden Analysenreihe beobachteten Präzipitationsphanomens zu einer immunochemisch definierbaren  $\gamma$ -Molekül-Komponente gelang nicht. Möglicherweise handelt es sich um eine Variante des Fd-Fragments. Nachdem in den übrigen untersuchten pathologischen Seren eine derartige Fraktion nicht nachgewiesen werden konnte, darf angenommen werden, dass es sich um eine Besonderheit des Paraproteins handelt.

Die mit Zysteamin behandelten gleichen Seren, deren Spaltprodukte prinzipiell anderer Art sein sollten, als diejenigen nach Papain-spaltung, ergaben überraschenderweise «phanomenologisch» ähnliche Präzipitate, d.h. eine schneller wandernde und eine näher der Kathode zugewandte Linie, wie das auch bei Papainspaltung wahrgenommen werden konnte. Mit einem polyvalenten Antiserum stellten sich allerdings die beiden Präzipitate nicht mit einem Kreuzungsphanomen dar, sondern zeigten Teilidentität. Diese Befunde bestätigen Beobachtungen, wie sie auch von anderer Seite [28, 30, in 17] mitgeteilt wurden.

Die Feststellung schliesslich, dass auch an nicht gespaltenen  $\gamma$ -Globulinen bzw. an unbehandelten Vollseren unter Verwendung monoklonaler Antisera, eine Differenzierung des Ig-Systems und darüber hinaus sogar der isolierte Nachweis von H- und L-Ketten möglich ist, dürfte für die zukünftigen Routine-Untersuchungen an  $\gamma$ -Globulinen nicht nur im Forschungslaboratorium sondern auch für das klinische Labor eine wertvolle Bereicherung darstellen. Für die monoklonalen Ig-Fraktionen ist dies bereits eine gelaufene Methode zur Differenzierung der  $\gamma$ -Globuline geworden. [43] Mit immunochemischer Technik gelingt es darüber hinaus, die einzelnen Globulinfraktionen *quantitativ* zu bestimmen [12, 31, 19, 51]. Es wird in naher Zukunft möglich sein, auch H- und L-Ketten-Relationen quantitativ zu erfassen.

Über die diagnostisch verwertbare Anwendung monoklonaler Antisera gegen H- und L-Ketten liegen bislang allerdings nicht genügend praktische Erfahrungen vor. Eigene Untersuchungen an insgesamt 160 pathologischen Seren mit  $\gamma$ -Globulin-Varianten lassen eine sichere Differenzierung in H-, L- und Bence-Jones-Typen auch am nicht gespaltenen  $\gamma$ -Globulin zu [43].

Prinzipiell konnten die vorliegenden Analysen und deren Befunde zeigen, dass  $\gamma$ -Globuline durch Einwirkung von Papain bzw. Zysteamin, ungeachtet ihrer krankheitsspezifisch verursachten Anreicherung, grundsätzlich gleichartige Spaltprodukte aufweisen, was auf einen

gleichartigen Bauplan der pathologischen wie der physiologischen  $\gamma$ -Globuline schliessen lässt. Paraproteine zeigen dabei gewisse Strukturänderungen, die offenbar an den H-Ketten fassbar werden.

### Zusammenfassung

Die Sedimente der Seren von 4 Patienten mit verschiedenen Leukämien (chronische Hepatit primäre chronische Polyarthrit, chronische rezidivierende Myeloma Leukämie) wurden durch elementare Spaltung mit Papain sowie Behandlung mit  $\text{FeCl}_3$  anion und nachfolgende immunologische Differenzierung analysiert. Verwendet wurden monoklonale Antikörper gegen Seren zur vergleichenden Beurteilung der Spaltprodukte der verschiedenen  $\gamma$ -Globuline. In jedem Fall war eine Spaltung in H- und L-Ketten möglich. Bei einem Myelom war das spezifische Paraprotein Präzipitat an die H-Ketten gebunden. Es war ausserdem ein zusätzliches, H-Ketten spezifisches Präzipitat nachweisbar. Die Differenzierung in H- und L-Ketten ist sowohl am gereinigten Sediment als auch an nicht behandelten Sclereren möglich.

### Summary

The sediments of sera of 4 patients with different diseases (chronic hepatitis, chronic rheumatoid arthritis, chronic recurrent myeloma, but also chronic lymphogranulomatosis) have been analysed by enzymatic cleavage by papain as well as by treatment and immunological differentiation using monoclone antibodies against polypeptide chains for comparing the globulin split products. A cleavage into H- and L-chains was possible in every case. In one myeloma the paraprotein precipitate was precipitated by the H-chains. Moreover in the case of paraproteinemia another H-chain specific precipitate could be demonstrated. H- and L-chains could be demonstrated in the cleaved gamma globulin paraprotein as well as in the not treated patients sera using monoclone antibodies against H- and L-chains.

### Literatur

- 1 BALLHAUS R. F., BEANER G. M., TOMINAKA K. T., and PUTNAM F. W. New human antigenic types defined by heavy chain determinants. *Science* **117**, 118 (1954).
- 2 BERZARD L. Studies on the plasma proteins in normal human urine. *Clin. Chim. Acta* **6**, 413 (1961).
- 3 BEANER G. M., BALLHAUS R. F., TOMINAKA K. T., and PUTNAM F. W. Heavy chain subclasses of human  $\gamma$ -globulin. *J. exp. Med.* **122**, 303 (1965).
- 4 PAVLEY E. M. The chemical selection theory of acquired immunity. (Cambridge Univ. Press, London 1950).
- 5 GELN, R. and SYKESWORTH C. T. The disulfide bonds of human and rabbit  $\gamma$ -globulin. *Biochem. J.* **59**, 29 (1962).
- 6 COHEN S. Properties of the peptide chains of normal and pathological human  $\gamma$ -globulins. *Biochem. J.* **89**, 331 (1963).
- 7 DUBACH H. F. Molecular transport of a  $\gamma_2$  type human serum globulin. *Fed. Proc.* **21**, 77 (1962).
- 8 DUBACH H. F. and MORTON J. F. Dissociation of human serum macroglobulins. *Science* **125**, 600 (1957).
- 9 FORTMANN G. M. and TOMLIN M. D. Studies on structural units of the  $\gamma$ -globulins. *J. exp. Med.* **113**, 861 (1961).

- 10 EDELMAN, G M, HEREMANS, J F, KUNAEI, H G, and HEREMANS, M TH Immunological studies of human  $\gamma$ -globulin J exp Med 112 203 (1960)
- 11 FAHEY, J I Heterogeneity of myeloma proteins J clin Invest 42 111 (1963)
- 12 FAHEY, J I and MCKELVEY, L M Quantitative determination of serum immunoglobulins in antibody agar plates J Immunol 94 81 (1965)
- 13 FLEISCHMAN, J B, PAIR, R H, and PORTER, R R Reduction of gamma globulins. Arch Biochem Biophys, suppl 1 174 (1962)
- 14 FLEISCHMAN, J B, PORTER, R R, and PRESS, T M The arrangement of the peptide chains in  $\gamma$ -globulin Biochem J 88 220 (1963)
- 15 FOUGEREAL, M, EDELMAN, D V M, and EDELMAN, G M Corroboration of recent models of the  $\gamma$ -G immunoglobulin molecule J exp Med 121 373 (1964)
- 16 FRANKLIN, E C Structural units of human 7S  $\gamma$ -globulin J clin Invest 39 1933 (1960)
- 17 FRANKLIN, E C, LOWENSTEIN, J, BIGELOW, B, and MELTZER, M Heavy chain disease - a new disorder of serum  $\gamma$ -globulins Amer J Med 37 332 (1964)
- 18 FRANKLIN, E C and STANWORTH, D R Antigenic relationships between immune globulins and certain paraproteins in man J exp Med 114 521 (1961)
- 19 GÖTZ, H, PEREZ-MIRANDA und SCHEIFFARTII, I a) Antigeneigenschaften des C-reaktiven Proteins Z klin Chem klin Biochem 7/3 270 (1969), b) Newer findings about C-reactive protein 17th Coll Protides of the Biol Fluids (Brugge, 1969)
- 20 GRABAR, P und BURTON, P Immunelektrophoretische Analyse (Elsevier Amsterdam 1964)
- 21 GRABAR, P et WILLIAMS, C A Methode permettant l'étude conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines Biochim biophys Acta 10 193 (1953)
- 22 GRASSMANN W, HANNIG, K und KNEDEL, M Über ein Verfahren zur elektrophoretischen Bestimmung der Serumproteine auf Filterpapier Dtsch med Wschr 76 333 (1951)
- 23 GREY, H M and KUNAEI, H G H-chain subgroups of myeloma proteins and normal 7S  $\gamma$ -globulin J exp Med 120 253 (1964)
- 24 HEIMBLERGER, N und SCHMIDTBERGER, R Moderne Verfahren der Chromatographie und Elektrophorese zur Präparation von Plasmaproteinen Behringwerkzeit, Heft 47 83 (1964)
- 25 HOREJŠI J and SNETANA R Isolation of  $\gamma$ -globulin from blood serum by Rivanol Acta med scand 155 65 (1956)
- 26 ISHIZAKA, K und ISHIZAKA, T (a) Physicochemical properties of reaginic antibody I Association of reaginic activity with an immunoglobulin other than  $\gamma$ -A or  $\gamma$ -G globulin J Allergy 37 169 (1966) (b) Effect of reduction and alkylation on allergen combining properties of reaginic antibody J Allergy 37 135 (1966)
- 27 ISHIZAKA, K, ISHIZAKA, T und HORNBOON, M M Physico-chemical properties of human reaginic antibody IV Presence of a unique immunoglobulin as a carrier of reaginic activity J Immunol 97 75 (1966)
- 28 KAMINSKI M The analysis of the antigenic structure of protein molecules Progr Allergy 9 79 (1965)
- 29 KOHN J (a) New supporting medium for zone electrophoresis Biochem J 65 9 (1957) (b) A cellulose acetate supporting medium for zone electrophoresis Clin chim Acta 2 297 (1957) (c) Zur Technik der GAF Elektrophorese Arzt Laborat 10 233 (1964)
- 30 MACPHERSON C. F. and SAFFRAN, M An albumin and  $\gamma$ -globulin characteristic of bovine cerebrospinal fluid J Immunol 95 629 (1965)
- 31 MANCINI G, CARONARA, A O and HEREMANS J F Immunochemical quantitation of antigens by single radial immunodiffusion Immunochem 2 230 (1965)

- 32 MARLER E., NELSON C. A. and TAYLOR, C. The polypeptide chains of rabbit  $\gamma$ -globulin and its papain cleaved fragments. *Biochem. J.* 2: 279 (1964)
33. Nomenclature for human immunoglobulins. (a) *Bull. World Health. Ass.* 30: 447 (1964) (b) Immunoglobulin E. A new class of human immunoglobulin. *Immunochem.* 5: 377 (1962)
34. OBERMANN E. F. and TAKAHARA, K. Clinical and immunochemical studies of four cases of heavy (H2) chain disease. *Amer. J. Med. Sc.* 251 (1964)
35. PEREZ MIRANDA, M. and GUTTE, H. Corrective protein a normal immunoglobulin? *Lancet* ii: 1315 (1965)
36. PETERSON E. A. and SOBER, H. A. Chromatography of proteins. I. Cellulose ion-exchange adsorbents. *J. Amer. chem. Soc.* 79: 551 (1957)
37. PORTER, R. R. The hydrolysis of rabbit  $\gamma$ -globulin and antibodies with crystalline papain. *Biochem. J.* 73: 119 (1959)
38. PORTER, R. R. and PERRY, L. M. Immunochemistry. *Ann. Rev. Biochem.* 31: 625 (1962)
39. PUTNAM F. W., FAHEY C. W. and JANN L. T. Site of cleavage of  $\gamma$ -globulins by papain. *Biochim. biophys. Acta* 51: 279 (1962)
40. ROWE, D. S. The separation and antigenic characterization of some fractions of papain digests of human serum  $\gamma$ -globulins. In *Immunology* 5: 531 (1962)
41. ROWE, D. S. and FAHEY, J. L. A new class of human immunoglobulins. I. A unique myeloma protein. *J. exp. Med.* 121: 185 (1965)
42. SCHIFFARTH, J. J. Une micro-méthode de l'immunoélectrophorèse. *Int. Arch. Allergy* 7: 103 (1955)
43. SCHIFFARTH, F. und GÖTTE, H.  $\gamma$ -Globulin-Differenzierung mit monoklonalen Antisera. *Klin. Wochschr.* 4: 1165 (1968)
44. SCHIFFARTH, F., BERG, G. und GÖTTE, H. *Paperelektrophorese in Klinik und Praxis*. Urban u. Schwarzenberg München Berlin Wien 1962
45. SCHIFFARTH, F., GÖTTE, H. und ZIEGLA, L. Reindarstellung von  $\gamma$ -Globulin mit Rivanol. *Z. Immun. Forsch.* 115: 92 (1968)
46. SCHIFFARTH, F., PEREZ MIRANDA, M. und GÖTTE, H. Nachweis des Korrektiven Proteins in normalen Serum im Druck
47. SCHULTZ, H. L. and HERMANN, J. I. *Molecular biology of human proteins* (Elsevier, Amsterdam London New York 1966)
48. SCHULTZ, H. L., SCHWACK, G., SONNET, J., HERMANN, J. I. und MÖSTLICH, J. I.  $\gamma$ -N-Globulin, eine in immunoelektrophoretisch nachweisbare  $\gamma$ -Globulinkomponente mit Beziehungen zum Korrektiven Protein. *Klin. Wochschr.* 38: 62 (1960)
49. SCHWACK, G. und STÖRIKO, K. Qualitative und quantitative Plasmaprotein Bestimmung durch Immunprecipitation. *Laborat. H. Reagentswerke* 5 (1964)
50. SOBER, H. A., GUTTER, F. J., WYKHOFF, M. M., and PETERSON, E. A. Chromatography of proteins. II. Fractionation of serum protein on anion-exchange cellulose. *J. Amer. chem. Soc.* 78: 756 (1956)
51. STÖRIKO, K. Immunologische Methoden zur Bestimmung von Plasmaeiproteinen. *Ärzt. Laborat. H.* 181 (1961)
52. TERRY, W. D. and FAHEY, J. L. Subclasses of human  $\gamma$ -globulin based on differences in the heavy polypeptide chains. *Science* 140: 400 (1961)
53. TRICHENSTORF, F. W., SCHULZEIN, P. G. und KALLER, E. Darstellung des  $\gamma_1$  Makroglobulins durch Zysteamin. *Verl. dtsch. Ges. inn. Med.* 70: 223 (1964)
54. WEIR, D. M. *Handbook of experimental immunology* (Blackwell, Oxford Edn) 1967

Adresse der Autoren: Prof. Dr. F. SCHIFFARTH, Priv. Doz. Dr. H. GÖTTE und Dr. R. SONNET, Abteilung für klinische Immunologie des Universitätskrankenhauses Erlangen-Nürnberg, Krankenhausstrasse 12, D-857 Erlangen (Deutschland)

## Binding of Folic Acid Activity by Body Fluids

T. MARKKANEN and O. PELTOLA

Department of Medicine (Chief: P. BRUMMER), and Department of Medical Microbiology (Chief: E. MUSTAKALLIO), University of Turku, Turku

Total folic acid activity (FAA) in most body fluids has been studied in detail, and the influence of various pathological conditions on it is fairly well known. The question of whether, and to what extent, FAA is bound to proteins or naturally present in a free state has been basely studied. As early as 1956, TOENNIS *et al.* [15] noticed this activity in Cohn's fractions IV+V and certain sub-fractions. CONDIT and GROB [1] noted in electrophoresis a kind of overlapping between the albumin spot and FAA but interpreted it as methodical. JOHNS *et al.* [7] assumed that there was little if any free FAA in fasting plasma. NEAL and WILLIAMS [11] experimented with the behaviour of labelled FAA in electrophoresis and found that it moved faster towards the anode than did albumin. Only slight activities were observed in the protein region. The majority of these coincided with albumin. In addition, HAMBERS *et al.* [4], SEVITT and HOFFBRAND [13], and RETIEF and HUSKISSON [12] have discussed the question of the binding of FAA in their papers on renal and hepatic diseases. METZ and HERBERT [10] mentioned unsuccessful attempts to demonstrate binders for folic acid in normal human serum, analogous to those present for vitamin B<sub>12</sub>. METZ *et al.* [9] found with labelled FAA, however, that binding, though weak, does occur, and that FAA can be eliminated from the serum by coated charcoal.

The FAA of milk has been found to be bound by proteins. The binding seems to be highly specific, as it is not broken by autoclaving [2, 3]. Similar results for milk were reported by METZ and HERBERT [10], and METZ *et al.* [9].

In the present study the behaviour of FAA vis-à-vis protein fractions




Fig. 1. The serum of a young healthy male test subject (FAA 5.2 ng/ml) fractionated with Sephadex® G-200. The dots indicate protein distribution, the vertical lines the FAA distribution.

in Sephadex® filtrations was observed. Sera, cerebrospinal fluids, mother's milk and synovial fluids were filtered.

### Material and Methods

Venous blood was taken into a 100 ml centrifuge tube from male and female patients

study were carried out without any preserving agents. The sera were filtered while they were fresh, and the technique described in connection with the preliminary studies [8] was followed in every detail.

The cerebrospinal fluids were drawn from healthy volunteers by lumbar puncture. The specimens were immediately centrifuged and placed in gel filtration. The technique described above was used.

The mother's milk specimens also were centrifuged while they were fresh, and the skimmed milk was then filtered. The technique used was as described above.

The synovial fluid was also centrifuged in order to eliminate whatever cell contamination may have been present. No preservatives were added either here or in the cerebrospinal fluid and milk specimens. The technique of filtration was as described above.

The filtration gels were Sephadex® G-200 and G-25 (Fig. 2). The FAA activity of the fractions obtained was measured by the L-cases method as described earlier [8]. The protein determinations were carried out with the biuret reaction [8].






Fig 2a The same serum as in figure 1. Filtration with Sephadex® G-25. b The protein zone FAA obtained on the previous filtration re-filtered with Sephadex® G-200. For explanations see figure 1.

### Results

Figure 1 shows the typical form of FAA distribution in the Sephadex® G 200 filtration of the serum of a healthy subject. FAA is noted in 3 maxima: first maximum (5%) in the zone of high-molecular globulins, second maximum (30%) in the albumin zone, and the remainder, third maximum (65%) in the post-protein zone. When the serum of the same person was filtered with Sephadex® G-25 (fig 2a) and subsequently the FAA of the protein zone was re-separated with Sephadex® G-200 (fig 2b), it was found that no L casei activity was separated from the FAA of the protein zone on re-filtration. The G-25 filtration had separated the free (or liberated) FAA. In the re-filtration of the FAA of the protein zone the recovery had been complete. This activity was clearly divided into two maxima, which coincided completely with the maxima of figure 1.

Figure 3a shows the distribution of FAA in filtered cerebrospinal fluid: only 5% is in the protein zone and the remaining 95% in the




Fig. 3a. Cerebrospinal fluid of a healthy subject (FAA 14.5 ng/ml in Sephadex® G-200 filtration). b Skimmed mother's milk (FAA 6.6 ng/ml in Sephadex® G-200 filtration). c Synovial fluid (FAA 3.3 ng/ml in Sephadex® G-200 filtration). For explanations see figure 1.

post protein zone. A small activity peak is visible in the pre albumin area and a slightly more pronounced activity in the posterior margin of the albumin.

Figure 3b shows the distribution of FAA in filtered fresh mother's milk (skimmed). It may be pointed out, however, that in skimmed milk the FAA was 6.6 ng/ml and in the creamy component 185.5 ng/ml. This latter part has so far not been fractionated and its FAA reviewed. The measured protein zone covered 60% of all the FAA obtained, the balance being in the post protein zone. The two maxima of the protein zone were almost equal in size, about 30% of the FAA obtained. Consequently, the percentage of FAA in the protein area is higher in skimmed milk than in serum.




Fig 4 Sera of patients with various diseases in Sephadex® G-200 filtration: a Pernicious anaemia (FAA 4.0 ng/ml), b megaloblastic tapeworm anaemia (FAA 5.6 ng/ml), c myeloma (FAA 5.6 ng/ml), d folate deficiency (FAA 2.5 ng/ml). For explanations see figure 1.

Figure 3c reveals that the FAA of the synovial fluid, studied by this method, remained entirely outside the protein zone.

Figure 4 presents the results from pathological sera: (a) in pernicious anaemia (untreated) 14% (4+10%) of the FAA was in the protein zone, (b) in megaloblastic tapeworm anaemia (untreated) 16% (3+13%), (c) in myeloma 11% (4+7%), and (d) in folic acid deficiency originating in the small intestine 10% (7+3%).

### Discussion

The results of this study permit the conclusion that serum, examined by this method, contains natural FAA even in the protein zone (approximately one-third), although the majority (approximately

two-thirds) emerge beyond the protein fractions. The present experiments, however, failed to show whether the 'free' FAA emerging in the post protein zone had during filtration totally or partially separated from the FAA in the protein zone. Furthermore, the chemical structure and molecular size of the FAA in the various fractions are not yet clear. In preliminary experiments it was found [8] that about one third of the FAA of the post protein zone was dialysable through a membrane which passes particles of a molecular weight of 5000. It is possible that polyglutamates of chains of varying lengths are involved.

The Sephadex® gel filtration distinctly separates the FAA that remains in the protein zone. When first filtered with Sephadex® G-25 the above 'free' FAA fraction is distinctly separated from the 'bound' FAA fraction. No further activity appears to be separated from the latter during the period of re-fractionation with Sephadex® G-200. This may mean that the binding of FAA by various proteins in this zone is relatively firm. From this two activity maxima are clearly distinguishable on the basis of the preliminary immunoelectrophoretic studies the first maximum contained very high molecular globulins, the second proteins equal to the size classes of albumin and transferrin. Three main lines require further study: the exact definitions of the proteins which carry the FAA in the protein zone, the additional capacity, if any, of these proteins to bind FAA, and the role of these proteins and their affinity to FAA in folate metabolism in physiological and pathophysiological conditions. Although the FAA of the protein zone in the present patients with megaloblastic anaemia was considerably smaller than in healthy subjects, no conclusions can be drawn on the basis of these few cases. The 'bound' volume of FAA of a patient with folate deficiency is also exceedingly small. In myeloma the relative shares of FAA do not seem to differ distinctly from normal. On the basis of experience obtained in our laboratory to date it would seem that in older age groups, especially women, the first FAA maximum is often weak or perhaps absent.

The maxima recorded for mother's milk were largely similar to those obtained for sera, though they are considerably more pronounced than in the sera, and distinctly more FAA is verified in the protein zone (a higher degree of binding?) than for serum. The present results are parallel with those recorded by Gurrus *et al.* [3], according to whom milk evidently had at least two fractions which may bind FAA firmly.

Closer study, in particular, is required to determine the fraction to which the high FAA's in the creamy component of the milk are bound.

According to earlier studies, the FAA of the cerebrospinal fluid is of the same or even greater magnitude than the corresponding serum activity [5, 6, 14, 16]. According to the present findings, practically all the FAA of the cerebrospinal fluid is in the 'free' form. Only trace spots are noted in the protein zone. From the neurological point of view, it would apparently be interesting to study the possible effects of various pathological conditions of the central nervous system on the binding of cerebrospinal fluid FAA. To this end, both the total FAA and its distribution into the various fractions of cerebrospinal fluids should be determined.

### Summary

The presence of natural FAA sera, cerebrospinal fluid, mother's milk and synovial fluid was studied. In the serum of healthy subjects the FAA was divided into 3 maxima: (1) in the high molecular (globulin) zone, (2) in the albumin zone, (3) in the post-protein zone. Sera of patients with pernicious anaemia, megaloblastic tapeworm anaemia, folate deficiency and myeloma showed the same FAA maxima. The FAA of cerebrospinal fluid was almost entirely located in the post-protein zone. In skimmed mother's milk, the FAA maxima were located on the same sites inside and outside the protein fractions. The FAA of the synovial fluid fell completely outside the protein zone.

### References

1. CONNOR, P. T. and GROS, D. Observations on the metabolism of folic acid in man and on the effect of aminopterin. *Cancer* 11: 525 (1958).
2. GUTTE, J. The folate binding in milk. *Amer. J. clin. Nutr.* 20: 1 (1967).
3. GUTTE, J., MANDELBAUM-SHAYIT, FR., and GROSSOWITZ, N. Binding of folic acid and derivatives by milk. *Amer. J. clin. Nutr.* 22: 156 (1969).
4. HAMPER, C. L., STREIFF, R., NATHAN, D. G., SNYDER, D., and MERRILL, J. P. Megaloblastic hematopoiesis in utero and in patients on long-term hemodialysis. *New Engl. J. Med.* 276: 551 (1967).
5. HERBERT, V. Symposium on folic acid deficiency. *Proc. roy. Soc. Med.* 57: 331 (1964).
6. HERBERT, V. and ZALUSKY, R. Selective concentration of folic acid activity in cerebrospinal fluid. *Fed. Proc.* 20: 433 (1961).
7. JOHN, D. G., SPERTZ, S., and BURCH, A. S. V. The metabolism of injected folic acid in man. *J. clin. Invest.* 40: 1634 (1961).
8. MARKKANEN, T. Pteroylglyamic acid (PGA) activity of serum in gel filtration. *Life Sciences* 7: 687 (1968).
9. METZ, J., ZALUSKY, R., and HERBERT, V. Folic acid binding by serum and milk. *Amer. J. clin. Nutr.* 21: 209 (1968).

10. MITZ, J. and HERRERT, A. Folate binders in milk and human serum, their use in coated charcoal assay of folic acid: their possible physiological role. *J. clin. Invest.* 40: 1096 (1967).
11. NEAL, G. E. and WILLIAMS, D. C. The fate of intravenously injected folate in rats. *Biochem. Pharmac.* 11: 903 (1965).
12. RETTER, F. P. and HILANOW, A. J. Serum and urinary folate in liver disease. *Brit. med. J.* ii: 150 (1967).
13. SEVITT, L. H. and HOFFBRAND, A. V. Serum folate and vitamin B<sub>12</sub> levels in acute and chronic renal disease. Effect of peritoneal dialysis. *Brit. med. J.* ii: 18 (1967).
14. SOMMER, H., OLSHTOFF, N., and RABER, H. Elevated vitamin levels in cerebrospinal fluid in multiple sclerosis. *Proc. Soc. exp. Biol., N.Y.* 59: 334 (1966).
15. TORVON, G., LIND, E., and PERLINA, P. M. Precursors of the folic acid-active factors of blood. *J. biol. Chem.* 237: 255 (1966).
16. WELLS, D. G. and CARY, H. J. Lactobacillus cases. C.S.F. folate activity. *Brit. med. J.* 3: 234 (1967).

## Vergleichende Untersuchungen zur Erythrozytenkinetik und zur Knochenmarksmorphologie bei Patienten mit Osteomyelosklerose und Osteomyelofibrose

K. SCHULZ, P. NOWOTNY, G. BAST, S. PREUSSNER, H. KONRAD und  
H. KIENCKE

Medizinische Universitätsklinik Rostock  
(Direktor Prof. Dr. M. GULZOW), Rostock

Die Osteomyelosklerose bzw. die Myelofibrose sind heute durch die breite Anwendung der intravitalen Knochenbiopsie häufig diagnostizierte Krankheitsbilder [1, 4, 5, 11, 21, 27, 33]. Die bei derartigen Patienten frühzeitig auftretende therapieresistente Anämie stellt den behandelnden Arzt vor viele diagnostische und therapeutische Probleme [9, 12, 28, 33]. Durch die Ergebnisse moderner nuklearmedizinischer Untersuchungsverfahren unter Verwendung der Nuklide  $^{51}\text{Fe}$  und  $^{51}\text{Cr}$  wird heute die Ursache dieser Anämie vorwiegend in der Kombination einer Erythrozytenminderproduktion und eines gesteigerten peripheren Abbaus der roten Blutkörperchen gesehen [2, 3, 8, 17, 20, 24, 30, 34]. Der Leber, vor allem aber der Milz kommt in der Anämiepathogenese häufig eine Doppelrolle zu, da sie als extramedulläre Blutbildungsstätten einmal wesentlich zur Produktion der roten Blutkörperchen beitragen, andererseits aber in diesen Organen oft eine gesteigerte Erythrozytoklasie auftritt [2, 16, 17, 30]. Auch die Ausbildung eines vergrößerten Erythrozytendepots in der oft stark vergrößerten Milz im Sinne eines Hyperspleniesyndroms ist häufig von entscheidender Bedeutung für die Entwicklung des Erythrozytendefizits [13, 31]. Wie HIRTMAIR [12] erst 1969 betonte, sind vergleichende Darstellungen zwischen den Untersuchungsergebnissen zur Erythrozytenkinetik und morphologischen Knochenmarksbefunden sowie klinischen Parametern bis jetzt überhaupt nicht oder nur in sehr geringem Umfang durchgeführt worden, die bei der meist nur sehr




Abb. 1. Ort des maximalen Erythrozytenabbaus bei Patienten mit Myelofibrose und Osteomyeloklastose

Kleiner Zahl von untersuchten Kranken keine bindenden Aussagen gestatten

### Material und Methoden

Bei 34 Patienten mit Osteomyeloklastose bzw. Myelofibrose erfolgte die Bestimmung der »schreibbaren halben Erythrozytenlebensdauer« nach den Angaben von MONTAGNA und VALL [19-33] bei gleichzeitiger Messung von Oberflächenaktivitäten und Berechnung von »Überschussimpulsen« bzw. »zusätzlicher Aktivitätswerte« nach dem Verfahren von HUGHES-JONES und SEAR [15]. Bei 16 Kranken wurden Untersuchungen zur Erythrozyten nach den Angaben von HERR *et al.* [14] bzw. POLLOCK und MONTAGNA [29] bei gleichzeitigen Oberflächenaktivitätsmessungen über Leber, Milz, Herz und Kreislauf durchgeführt.

Die Diagnose einer Osteomyeloklastose bzw. Myelofibrose wurde stets durch die histologische Untersuchung eines mittels intravitaler Knochenbiopsie [1] gewonnenen Knochenzyllinders gesichert. Die Krankheitsstadien der Osteomyeloklastose wurden nach den Angaben von OCELSKY [23] in 3 Phasen differenziert: 1. Die fibrosteoklastische Phase oder Stadium I, 2. die osteoplastische Zwischenphase oder Stadium II und 3. die osteoplastische Stützungsphase oder Stadium III.

Die Krankheitsstadien wurden nach den Angaben von OCELSKY [23] in 3 Phasen differenziert: 1. Die fibrosteoklastische Phase oder Stadium I, 2. die osteoplastische Zwischenphase oder Stadium II und 3. die osteoplastische Stützungsphase oder Stadium III.

Wir sind uns bewusst, dass gelegentliche Phasen zwischen den einzelnen Krankheitsstadien eintreten werden, die nur bedingt eine Zuordnung in die angegebene Stadieneinteilung gestatten. Wegen der für die Vergleichsdiagnostik notwendigen Übersicht wurde nach mehreren Kontrollbiopsien das Krankheitsstadium der Krankheitsphase zugerechnet, der der Knochenmarksprozess am nächsten steht. Die Bewertung des erythropoetischen Zellgehalts im histologischen Knochenmarkpräparat bzw. im Sternalmarkausstrich erfolgte grundsätzlich immer vom gleichen Untersucher nach semiquantitativen Gesichtspunkten. Eine ge-



## Vergleichende Untersuchungen zur Erythrozytenkinetik und zur Knochenmarksmorphologie bei Patienten mit Osteomyelosklerose und Osteomyelofibrose

K. SCHULZ, P. NOWOTNY, G. BAST, S. PREUSSNER, H. KONRAD und  
H. KIENCKE

Medizinische Universitätsklinik Rostock  
(Direktor Prof. Dr. M. GÜLZOW), Rostock

Die Osteomyelosklerose bzw. die Myelofibrose sind heute durch die breite Anwendung der intravitralen Knochenbiopsie häufig diagnostizierte Krankheitsbilder [1, 4, 5, 11, 21, 27, 33]. Die bei derartigen Patienten frühzeitig auftretende therapieresistente Anämie stellt den behandelnden Arzt vor viele diagnostische und therapeutische Probleme [9, 12, 28, 33]. Durch die Ergebnisse moderner nuklearmedizinischer Untersuchungsverfahren unter Verwendung der Nuklide  $^{59}\text{Fe}$  und  $^{51}\text{Cr}$  wird heute die Ursache dieser Anämie vorwiegend in der Kombination einer Erythrozytenminderproduktion und eines gesteigerten peripheren Abbaus der roten Blutkörperchen gesehen [2, 3, 8, 17, 20, 24, 30, 34]. Der Leber, vor allem aber der Milz kommt in der Anämiepathogenese häufig eine Doppelrolle zu, da sie als extramedulläre Blutbildungsstätten einmal wesentlich zur Produktion der roten Blutkörperchen beitragen, andererseits aber in diesen Organen oft eine gesteigerte Erythrozytoklasie auftritt [2, 16, 17, 30]. Auch die Ausbildung eines vergrößerten Erythrozytendepots in der oft stark vergrößerten Milz im Sinne eines Hyperspleniesyndroms ist häufig von entscheidender Bedeutung für die Entwicklung des Erythrozytendefizits [13, 31]. Wie HIRTMAIR [12] erst 1969 betonte, sind vergleichende Darstellungen zwischen den Untersuchungsergebnissen zur Erythrozytenkinetik und morphologischen Knochenmarksbefunden sowie klinischen Parametern bis jetzt überhaupt nicht oder nur in sehr geringem Umfang durchgeführt worden, die bei der meist nur sehr




Abb. 1. Ort des maximalen Erststadiums aus dem Rast mit Myelofibrose und Osteomyeloklasen

Meinen Zahl von untersuchten Kranken keine bindenden Aussagen gestatten

### Material und Methoden

Bei 34 Patienten mit Osteomyeloklasen bzw. Myelofibrose erfolgte die Bestimmung der »alkalischen halben Erythrozyten-Glykolyse« nach den Angaben von MOLLATH und VALL [19, 21] bei gleichzeitiger Messung von Oxyfärbung  $\times 2$  m und Berechnung »Osteomyeloklasen« bzw. »alkalischer Aktivität« nach dem Verfahren von HIGGINS-JONES und SETA [15]. Bei 16 Kranken wurden Untersuchungen zur Erythrozyten nach den Angaben von HIGGS et al. [16] bzw. POULSEN und MONTGOMERY [20] bei gleichzeitiger Oxyfärbung  $\times 2$  m und Berechnung »Osteomyeloklasen« nach dem Verfahren von HIGGS et al. [16] durchgeführt.

Die Diagnose einer Osteomyeloklasen bzw. Myelofibrose wurde stets durch die histologische Untersuchung eines mittels intravitaler Knochenbiopsie [1] gewonnenen Knochenzylinders gestellt. Die Krankheitsstadien der Osteomyeloklasen wurden nach den Angaben von OSTROM [23] in 3 Phasen differenziert: I Die fibrozytäre Phase oder Stadium I, II die osteozytäre Phase oder Stadium II und III die osteozytäre Phase oder Stadium III.

In Übereinstimmung mit anderen Autoren [1, 11, 20, 22] wurde auf Grund langjähriger Verlaufskontrollen die Myelofibrose ohne Mithinwirkung des Knochens vom Krankheitsbild der Osteomyeloklasen abgegrenzt. Auf die Problematik eines derartigen aus formal-pathogenetischer Sicht bedingten Vorgehens kann in diesem Zusammenhang nicht eingegangen werden.

Wir sind uns bewusst, dass gelegentliche Phasen zwischen den einzelnen Krankheitsstadien erfasst werden, die nur bedingt eine Zuordnung in die angegebene Stadieneinteilung gestatten. Wegen der für die Vergleichsarstellungen besseren Übersicht wurde nach mehreren Kontrollbiopsien das Krankheitsbild der Krankheitsphase zugeordnet, der der Knochenmarkserreger am nächsten liegt. Die Stadieneinteilung ist im histologischen Bild immer

Tabelle I Erythrozytenkinetik bei Patienten mit Osteomyelose und Myelofibrose

| Parameter der Erythrozytenkinetik | ↓  | = | ↑  | insgesamt |
|-----------------------------------|----|---|----|-----------|
| Plasmaessenceclearance            | 3  | 1 | 12 | 16        |
| Plasmaessenturnover               | 1  | 4 | 11 | 16        |
| Eiseninkorporationsrate           | 11 | 5 | —  | 16        |
| «Scheinbare» halbe Überlebenszeit | 28 | 6 | —  | 34        |

↓ = herabgesetzt, = = normal, ↑ = gesteigert

Tabelle II Lokalisation und Umfang der Erythropoese bei 16 Kranken mit Osteomyelose und Myelofibrose

| Erythropoese in | «effektiv» | «ineffektiv» |
|-----------------|------------|--------------|
| Knochenmark     | 7          | 2            |
| Milz            | 5          | 5            |
| Leber           | 3          | 8            |

naue Auszählung der erythropoetischen Vorstufen täuscht nur eine Pseudoexaktheit vor [33], die den semiquantitativen Aussagen nicht überlegen ist. Die Untersuchungsergebnisse zur Erythrozytenkinetik wurden mit klinischen Parametern und den Knochenmarksbefunden verglichen und die zu treffenden Aussagen durch statistische Analysen geprüft (Korrelationsanalyse,  $\chi^2$  Test, m x k Tafel).

### Resultate

Die Untersuchungsergebnisse der Erythrozytenkinetik entsprachen den Angaben anderer Autoren [2, 17, 24, 30] (Tab. I). Die Mehrzahl der mit  $^{59}\text{Fe}$  untersuchten Kranken wies eine beschleunigte Eisen-Clearance, einen erhöhten Eisenumsatz und eine verminderte Eiseninkorporationsrate auf. Bei  $\frac{3}{4}$  der untersuchten Kranken war die «scheinbare halbe Erythrozytenüberlebensdauer» der roten Blutkörperchen verkürzt.





Abb. 7. Eisenkörperchen und Oberflächenaktivitätsmessungen bei der Pat. 13 J.

Die Oberflächenaktivitätsmessungen bei den mit Radioeisen untersuchten Patienten wiesen immer auf das Vorliegen einer extramedullären Erythropoese hin (Tab. II). Der Kurvenverlauf und die Berechnung bestimmter Indizes nach den Angaben von BRUNNER [2] ließen bei einzelnen Patienten mit überwiegend medullärer Blutbildung bei der Hälfte der Kranken mit einer extramedullären hepatoerythropoese sowie bei der Mehrzahl der Patienten mit hepatischen Blutbildungsstätten auf eine ineffektive Erythropoese schließen. Drei Kranke zeigten eine verstärkte hepatische, 6 eine gesteigerte




Abb. 3. Eiseninkorporation und Oberflächenaktivitätsmessungen bei dem Pat. h. 7

liente Erythrozytendestruktion, bei 13 Patienten fand sich sowohl in der Leber als auch in der Milz eine erhebliche Erythrozytoklasie, bei weiteren 6 Kranken muss ein gesteigerter Erythrozytenabbau generalisiert im RHS angenommen werden (Abb. 1).

Die vergleichenden Darstellungen zwischen den Untersuchungsergebnissen der Erythrozytenkinetik und den morphologischen Knochenmarksbefunden sowie einzelnen klinischen Daten gestatten folgende Aussagen (Tab. III).

1. Bei Patienten mit Osteomyelosklerose und Myelofibrose besteht zwischen der Eiseninkorporationsrate und dem Hämoglobingehalt

Tabelle III Verhalten der Parameter der Erythrokinetik im Vergleich zum Knochenmarksbefund und zu den Werten des roten Blutes

| Verglichene Parameter      |                            | r      | r <sup>2</sup> | f  | p   |
|----------------------------|----------------------------|--------|----------------|----|-----|
| Krankheitsstadium          | - Clearance                |        | 3,99           | 4  | >5% |
|                            | - Plasmaeisenturnover      |        | 3,50           | 4  | >5% |
|                            | - Eiseneinbaurrate         |        | 6,77           | 6  | >5% |
| Eisenkinetik insgesamt     | Hb                         | +0,573 |                | 14 | <5% |
|                            | Erythrozytenzahl           | +0,511 |                | 14 | <5% |
|                            | Erythropoese (Hst.)        | +0,573 |                | 14 | <5% |
|                            | Erythropoese (Sternalmark) | +0,433 |                | 14 | >5% |
|                            | Hämoapoese (Hst.)          | +0,573 |                | 14 | <5% |
| Erythrozyten-eisenturnover | Erythropoese (Hst.)        | +0,211 |                | 13 | >5% |
|                            | - Hämoapoese (Hst.)        | +0,573 |                | 13 | <5% |

sowie der Erythrozytenzahl zwar ein statistisch gesicherter, aber nicht sehr ausgeprägter Zusammenhang. Diese Aussage steht mit den Angaben von SZUR und SMITH [31] in Einklang, aber im Gegensatz zur Mitteilung von KESSE FLAAS *et al.* [17].

2. Es lassen sich keine statistisch gesicherten Beziehungen zwischen den Krankheitsphasen und dem Verhalten der Eisenclearance, des Plasmaeisenturnover sowie der Eiseneinbaurrate erkennen. Die Effektivität und das Ausmass der medullären, aber auch der extramedullären Erythropoese erscheint so vom Krankheitsstadium weitgehend unabhängig. Dieses Ergebnis einer funktionellen Betrachtung des erythropoetischen Systems stimmt mit den pathologisch anatomischen Vergleichsbefunden der Arbeitsgruppe um FITCHCOCK [28] überein.

3. Es läßt sich eine positive Verbundenheit zwischen dem Verhalten der Erythropoese und der Eiseneinbaurrate sowie der Eiseneinbaurrate und der Eiseneinbaurrate feststellen.

#### Relation E

Vorstufen im Sternalmarkausstrich nicht getroffen werden. Eine noch engere Beziehung ergibt sich zwischen der in toto beurteilten Hämoapoese des Knochenmarks und der Grösse der Eiseneinkorporation. Diese Aussage wird durch die bei Markhyperplasien im histologischen Präparat nur unzureichende Differenzierung der einzelnen Markzellen verständlich, so dass auch dem erfahrenen Untersucher ein

Tabelle IV. Ort der Erythropoese im Vergleich zu klinischen Parametern

|  | $\chi^2$ | f | p   |
|--|----------|---|-----|
| Knochenmarkserythropoese (Hist.) – erythropoetische Knochenmarksaktivität erfasst mit $^{59}\text{Fe}$ | 10,76    | 4 | <5% |
| Hepatische Erythropoese – Krankheitsstadium  | 1,96     | 2 | >5% |
| Hepatische, effektive Erythropoese – Krankheitsstadium   | 1,18     | 2 | >5% |
| Laenale Erythropoese – Krankheitsstadium   | 4,16     | 2 | >5% |
| Knochenmarkserythropoese – Krankheitsstadium   | 2,30     | 2 | >5% |
| Effektive Erythropoese im Knochenmark – Krankheitsstadium  | 2,25     | 2 | >5% |
| Laenale Erythropoese – Milzgrösse  | 6,69     | 2 | <5% |
| Hepatische Erythropoese – Milzgrösse   | 6,09     | 2 | <5% |

gewisser Anteil der erythropoetischen Stammzellen der Beobachtung entgehen [33].

4. Die Ergebnisse der Oberflächenaktivitätsmessungen über dem Knochenmark bestätigen den Zusammenhang zwischen dem morphologischen und funktionellen Verhalten der medullären Erythropoese. Der Kurvenverlauf der Oberflächenaktivitäten über dem Knochenmark weist dann auf eine medulläre Blutbildung hin, wenn diese auch im histologischen Schnitt erfasst wird (Tab. IV).

Zwei Beispiele lassen ein derartiges funktionelles und morphologisch übereinstimmendes Verhalten der Erythropoese erkennen. Bei der 1. Patientin mit dem Stadium I einer Osteomyelosklerose liessen sich eine regelrechte Eiseneinbaurrate (Abb. 2) und die Zeichen der Blutbildung im Knochenmark und Milz erfassen. Bei dem anderen Patienten mit einer Osteomyelosklerose im Stadium III fanden sich nur eine sehr stark herabgesetzte Eiseneinbaurrate (Abb. 3) und die Merkmale einer ineffektiven hepatischen Erythropoese.

5. Auch die Ergebnisse der Oberflächenaktivitätsmessungen (Tab. IV) lassen ebenso wie die Befunde des Eisenstoffwechsels enge Beziehungen zwischen dem Ausmass der medullären Erythropoese bzw. dem Vorliegen von extramedullären Blutbildungsstätten in Leber und Milz und der Krankheitsphase vermissen, ein *in vivo*-Befund, der den pathologisch-anatomischen Untersuchungsergebnissen früherer Autoren [11, 28] entspricht. Diese Aussage bezieht sich sowohl auf das Vorliegen einer effektiven als auch einer ineffektiven Erythropoese. Sie kann die von PRIMILLA [30] aufgestellte These zur Abhängigkeit der

Tabelle 1 Vergleich der Erythrozytenüberlebensdauerbestimmung mit klinischen Parametern bei Patienten mit Myelofibrose und Osteomyelitis

|   | r      | $\chi^2$ | f  | p    |
|---|--------|----------|----|------|
| Erythrozytenüberlebensdauer - Knochenmark-erythropoese (Hst.) | -0.621 |          | 3* | 0.1% |
| Retikuloerythrozytenzahl - Knochenmark-erythropoese (Hst.)    | +0.095 |          | 3* | > 5% |
| Erythrozytenüberlebensdauer - Retikuloerythrozytenzahl        | -0.503 |          | 3* | 1%   |
| Erythrozytenüberlebensdauer - Krankheitsstadium               |        | 1.44     | 4  | > 5% |
| Leinale Erythrozytendestruktion - Krankheitsstadium           |        | 3.27     | 3  | > 5% |
| Hepatische Erythrozytendestruktion - Krankheitsstadium        |        | 6.10     | 3  | > 5% |
| Leinale Erythrozytendestruktion - Milzgrösse                  |        | 1.33     | 3  | > 5% |

extramedullären Blutbildung vom Krankheitsstadium nicht bestätigen.

6. Es besteht ein eindeutiger negativer Zusammenhang zwischen der Milzgrösse und dem Nachweis einer extramedullären leinalem Hämopoese. Bei Patienten mit Riesenmilzen wiesen die Ergebnisse der Oberflächenaktivitätsmessungen nur selten auf das Vorliegen extramedullärer Blutbildungsstätten in diesen Organen hin. Zur Interpretation dieser Aussage müssen die in derartigen Milztumoren häufig starke Fibrosierung sowie die immer wieder eintretenden Milzinfarkte mit Beeinträchtigung der Milzfunktion in Erwägung gezogen werden [9, 28, 32, 33]. Ausserdem konnte bei Kranken mit sehr grossen Milztumoren häufiger eine hepatische Hämopoese erfasst werden, als es bei Kranken mit einer nur gering vergrösserten Milz der Fall war. Ob bei derartigen Patienten eine stärkere Einbeziehung der Leber in die Krankheitsgeschehen stattfindet [11] oder ein Übergang der extramedullären Blutbildung von der Milz auf die Leber erfolgt, kann zur Zeit nur zur Diskussion gestellt werden.

7. Zwischen dem Ausmass der morphologisch erfassbaren medullären Erythropoese und der Erythrozytenüberlebensdauer besteht eine



enge negative Korrelation (Tab. V). Es könnte angenommen werden, dass durch die Steigerung der Erythropoese die verstärkte periphere Destruktion kompensiert wird. Da sich aber zwischen der histologisch nachgewiesenen medullären Erythropoese und der Retikulozytenzahl kein Zusammenhang ermitteln liess, andererseits aber eine enge Beziehung zwischen dem Ausmass der Retikulozytose und der Erythrozytenüberlebensdauer besteht, muss angenommen werden, dass die medulläre Erythropoese dann weitgehend ineffektiv ist und eine gewisse Kompensation des gesteigerten Erythrozytenabbaus nur durch die extramedullären Blutbildungsstätten erfolgt.

8. Zwischen der Erythrozytenüberlebensdauer bzw. dem Vorliegen einer gesteigerten Erythrozytendestruktion in Leber bzw. Milz und dem Krankheitsstadium konnte keine statistisch zu sichernde Beziehung ermittelt werden.

Trotz der nur mit einer gewissen Zurückhaltung zu interpretieren den Aussagen statistischer Vergleichsuntersuchungen an biologischen Kollektiven lassen die vorliegenden Untersuchungsergebnisse erkennen, dass die histologischen und zytologischen Befunde des Knochenmarks sowie bestimmte klinische Parameter nur bedingt einen Rückschluss auf das funktionelle Verhalten der Erythropoese und der Erythrozyten gestatten. Diese Folgerung wird durch die Komplexität der Anämiegenese bei Patienten mit Myelofibrose und Osteomyelosklerose verständlich, da sie aus der Kombination einer Erythrozytenminderproduktion oft verbunden mit einer ineffektiven Erythropoese [2, 10, 30] und einer gesteigerten klonalen oder hepatischen Erythrozytoklasie bzw. eines beschleunigten Abbaus einer minderwertigen, kurzlebigen Erythrozytenpopulation [2, 12, 17, 24, 30] und einer verstärkten Blutzellspeicherung in der vergrösserten Milz [13, 31] resultiert. Nur die kombinierte Anwendung morphologischer Untersuchungsverfahren und moderner Untersuchungen zur Erythrozytenkinetik können zum Verständnis der Anämie bei Osteomyelosklerose und Myelofibrose beitragen. Es erscheint daher erforderlich, diese Diagnose grundsätzlich durch die histologische Untersuchung eines Knochenmarkschnittes zu stellen und gegebenenfalls den Krankheitsverlauf durch Kontrollbiopsien zu verfolgen, zusätzlich aber immer die nuklearmedizinischen Verfahren einzusetzen, um exakte Einblicke in das Wesen der schon frühzeitig auftretenden Anämie zu gewinnen und so prognostische Aussagen zum Wert der einzuschlagenden therapeutischen Massnahmen zu treffen.

## Zusammenfassung

Bei 37 Patienten mit Myelofibrose bzw. Osteomyeloklierose wurde die Erythrozytenkinetik mit den histologischen und zytologischen Knochenmarkbefunden und einzelnen klinischen Daten verglichen. Eine direkte Abhängigkeit konnte zwischen den Parametern des Eisenstoffwechsels sowie der Erythrozytenzerkleinerungsverteilung und den Krankheitsstadien nicht ermittelt werden. Dagegen besteht zwischen dem Vorliegen einer leichten und hepatischen extramedullären Hämoopoese und der Größe der Milz ein statistisch gesicherter Zusammenhang. Die Aussagekraft derartiger Vergleichsuntersuchungen für das Verständnis der Anämiegenese bei Patienten mit Myelofibrose und Osteomyeloklierose wird betont.

## Summary

The kinetics of erythrocyte movements were compared with bone marrow cytology and histology and certain other clinical data in 37 patients with myelofibrosis or osteomyeloclerosis. No direct correlation was found between iron metabolism and erythrocyte survival on the one hand and the different stages of the illness on the other. There is, however, a statistically significant relationship between the presence of splenic and hepatic extramedullary haemopoiesis and the size of the spleen. The importance of such comparisons for understanding the origin of anaemia in patients suffering from myelofibrosis and osteomyeloclerosis is emphasized.

## Literatur

1. BARTHELEMYER, H. und PAPAGEORGIOU, A. Die Knochenmarkbioptie als Methode in der Hämatologie. *Dtsch. med. Wochschr.* 89 358 (1963).
2. BRENNER, H. E. Die Osteomyeloklierose. *Acta haemat., Basel* 31 257 (1965).
3. BRENNER, H. E. Die Differentialdiagnose hämatologischer Erkrankungen. *Schweiz. med. Wochschr.* 95 285 (1965).
4. BURKHARDT, R. Technische Verbesserungen und Anwendungsbereich der Histobioptie. *Klin. Wochschr.* 44 326 (1966).
5. CITRONER, H. und JEMERER, H. Histologischer Bild-Atlas der Knochen- und Knochenmarkbioptie (Boehringer, Mannheim 1965).
6. FROCHT, H., HOFETZ, N. und KEMT, E. Weitere Untersuchungen zur Frage der Erythrokinetik bei Bluthrarkthosen. *Wien. klin. Wochschr.* 78 777 (1966).
7. GERVITZ, N. R. and BERLIN, N. I. Erythrokinetic studies in severe bone marrow failure of diverse etiology. *Blood* 18 637 (1962).
8. GIBLERT, E. R., COLEMAN, D. H., FIRENZA-BIGOLI, G., DOMONTE, D. M., MORTUARI, A. G. and FENCIE, C. A. Erythrokinetics. Quantitative measurement of red cell production and destruction in normal subjects and patients with anemia. *Blood* 17 291 (1966).
9. HARTMANN, G., ALIMA, R., CITRONER, H. und RIEDER, H. Zur Klinik und Pathologie der Osteomyeloklierose. *Wien. Z. inn. Med.* 49 137 (1979).
10. HAURANT, F. and TOCANTINS, L. M. Ineffective erythropoiesis. *Amer. J. Med.* 31 519 (1961).
11. HOFFMANN, A. Myelofibrosen, Osteoklierosen und verwandte Zustände, in HEILMEYER und HOFFMANN Handbuch der gesamten Hämatologie, Bd. IV/2 (Urban & Schwarzenberg, München/Berlin 1963).

- 12 HITTMAIR, A. Ungeklärte therapieresistente Anämien, in HEILMAYER und HITTMAIR Handbuch der gesamten Hämatologie Bd V/3 (Urban & Schwarzenberg München/Berlin 1969)
- 13 HUBER, H., LEWIS, S. M. und SZUR, L. Zur Anämie bei Osteomyelose Blut 18 257 (1969)
- 14 HUFF, R. L., HENESSY, L. G., AUSTIN, R. E., GARCIA, J. F., ROBERTS, B. M., and LAWRENCE, J. H. Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J clin Invest 29 1011 (1950)
- 15 HUGHES JONES N. C. and SZUR, L. Determination of the sites of red cell destruction using  $^{51}\text{Cr}$  labelled cells Brit J Haemat 3 320 (1957)
- 16 KEIDERLING, W. und WETZEL, H. P. Radioeisen in der hämatologischen Diagnostik Dtsch. med. Wschr. 90 1337 (1965)
- 17 KESSE ELIAS, M., GYFTAKI, E., ALEIZOL TERZAKI V., and MALAMOS, B.  $^{51}\text{Fe}$  and  $^{51}\text{Cr}$  studies in aplastic anaemia and myelofibrosis. Acta haemat., Basel 29 139 (1968)
- 18 KUBA J., WIEDERMANN, B. und WIEDERMANN, M. Zur diagnostischen Auswertung von Oberflächenaktivitätsmessungen bei Untersuchungen der Erythrokinetik mit Radioeisen und Radiochrom. Z. ges. inn. Med. 19 465 (1964)
- 19 MOLLISON, P. L. and VALL, N. The use of the isotope  $^{51}\text{Cr}$  as a label for red cells Brit. J. Haemat. 1 62 (1955)
- 20 NATHAN, D. G. and BERLIN, N. J. Studies of the production on life-span of erythrocytes in myeloid metaplasia Blood 18 668 (1959)
- 21 NOWOTNY, P. und SCHULZ, K. Die Bedeutung der Knochenbiopsie für die Diagnostik hämatologischer Erkrankungen Folia haemat., Lpz. 81 185 (1963)
- 22 NOWOTNY, P. Biopsische Befunde bei der Osteomyelose Z. ges. inn. Med. 19 197 (1964)
- 23 OECHELIN, J. R. Osteomyelose und Skelett. Acta haemat. 16 214 (1956)
- 24 OETTING, H. F., KUHN, W. und PRIBILLA, W. Isotopenuntersuchungen der Erythrokinetik bei Splenomegalie Med. Welt 1198 (1963)
- 25 OETTING, H. F. und PRIBILLA, W. Die Erythrokinetik bei Osteomyelofibrose Klin. Wschr. 42 483 (1964)
- 26 PAPAGEORGIOU, A. Die Knochenveränderungen der Myelofibrosen und Osteomyelofibrosen Acta haemat. 28 201 (1962)
- 27 PAPAGEORGIOU, A. Diagnostik der Myelofibrosen und Osteomyelosen Dtsch. med. Wschr. 90 436 (1965)
- 28 PITCOCK, J. A., REINHARD, E. H., JUSTUS B. W., and MENDELSON, R. S. A clinical and pathological study of seventy cases of myelofibrosis Amer. J. intern. Med. 57 73 (1962)
- 29 POLLACOVZ, M. and MORTIMER, R. The quantitative determination of individual iron kinetics and hemoglobin formation in human subjects Clin. Res. Proc. 4 51 (1956)
- 30 PRIBILLA, W. Erythrokinetik (Westdeutscher Verlag Köln/Opladen 1964)
- 31 PRIBILLA, W. Über einige Funktionen der Milz Internist 8 345 (1967)
- 32 ROHR, K. Myelofibrose und Osteomyelose Acta haemat. 15 209 (1956)
- 33 ROHR, K. Das menschliche Knochenmark (Thieme, Stuttgart 1960)
- 34 SZUR, L. and SMITH, M. D. Red-cell production and destruction in myelofibrosis Brit J Haemat. 7 147 (1961)
- 35 VETTER, H. und VALL, N. Radiosotopen Technik in der klinischen Forschung und Diagnostik (Urban & Schwarzenberg München/Berlin 1960)

Adresse der Autoren: Dr. med. habil. K. SCHULZ, Dr. med. P. NOWOTNY, Prof. Dr. med. habil. G. BAST, Dr. med. S. PREUSSNER, Dr. med. H. KONRAD und Dipl.-Phys. H. KIENCKE, Medizinische Universitäts-Klinik, Ernst Heydemann Strasse, 25 Rostock (DDR)

## The Ratio between Normal and Sensitive Erythrocytes in Heterozygous Glucose-6-Phosphate Dehydrogenase Deficient Women<sup>1</sup>

F. PANIZON, F. ZACCHIELLO, E. SARTORI and S. ADDA

Pediatric Clinics of the Universities of Trieste and Padua, and Clinical Research Laboratory General Hospital Samsù

The existence of two different populations of red blood cells in heterozygous glucose-6-phosphate dehydrogenase (G-6-PD) deficient women has been demonstrated [2, 6, 10]. Consistent with Lyon's hypothesis it is generally assumed that about half of the erythrocytes are normal and half are deficient. Nevertheless, accurate estimates of the ratio between normal and sensitive cells, drawn from a consistent number of appropriately chosen subjects, are not available and the possibility of a selective mechanism, modifying the theoretical ratio of one, cannot be ruled out.

A reliable method to discriminate between the two kinds of erythrocytes consists in treating blood *in vitro* with an oxidizing drug, such as menadione or primaquine at a concentration at which sensitive erythrocytes alone are damaged [10]. The injured cells are no longer viable and are rapidly sequestered and destroyed if transfused into human beings. If the blood is previously labelled with <sup>51</sup>Cr the percent of residual radioactivity found after 24 hours equals the percent of non-enzyme-deficient cells [10]. We used this method over a long period of time, and we collected rather extensive material on this problem. These findings will be described in this paper.

### Material and Method

*Selection of subjects.* Heterozygous subjects cannot be selected merely on the basis of enzymatic assays, because G-6-PD levels in women are highly variable and a considerable

<sup>1</sup> This work was supported by grant from C.N.R.




Fig 1 Percent of sensitive cells in the blood of 18 heterozygous G-6-PD deficient women

amount of heterozygous individuals may remain undetected. Thus, we made our choice on a genetic basis and included in our sample (a) women who had both a normal and a G-6-PD deficient son, and (b) women who had a G-6-PD deficient father and a normal son or vice versa.

Eighteen heterozygote women were studied for the detection of the percentage of sensitive cells. This test was repeated in several different periods in 3 of the women, and was determined during the fava bean season in 8 of the women without clinical symptoms of haemolysis.

*Determination of sensitive erythrocytes in G-6-PD deficient heterozygotes.* The blood was collected in sterile bottles with heparin and 2 mg of glucose/ml were added. It was used fresh or stored for no longer than 12 hours at about 4°C. In all cases the blood was incubated for 3 hours at 37°C with menadione sodium bisulphite  $1 \times 10^{-4}M$  or with primaquine  $8 \times 10^{-4}M$ , labelled with  $^{51}Cr$  ( $1 \mu C/kg$  of the recipient's body weight) and transfused into compatible volunteers. Blood samples were taken 5 min and 24 hours later. The percent of radioactivity of the second sample corresponds to the percent of non-deficient erythrocytes in the transfused blood. The accuracy, precision and reliability of the method have already been demonstrated [10].

### Results and Discussion

On the basis of the collected material we tried to give an answer to the following three questions: (1) Is the ratio between normal and G-6-PD deficient erythrocytes in heterozygous women determined at random? (2) Is the ratio constant in each subject, in basic conditions?




Fig 2 Percent of sensitive cells in the blood of 3 heterozygous women studied in different periods at intervals of several months

(3) Does the ingestion of fava beans regularly enhance a lysis of G-6-PD deficient erythrocytes?

We are not in a position to provide a definitive answer to the first question. Figure 1 shows the distribution of the percent of sensitive cells in a group of 18 heterozygous women where any potential factor of haemolysis, such as fever, drug consumption, fava bean flowering and so on, are absent at that time. The data are highly scattered. The curve is skewed to the left: the mean percent of sensitive cells is  $40\% \pm 17$ , instead of the expected  $50\%$ . This may suggest a selective disadvantage for sensitive cells. However, the difference between the actual and expected ratio is statistically unreliable.

As to the second problem, we may assume that, in basic conditions, the ratio between sensitive and non-sensitive erythrocytes does not

The third problem deserves a few preliminary comments. It is currently assumed that severe fava induced haemolysis only occasionally occurs, even in G-6-PD deficient subjects who eat fava beans. Someone still holds that fava induced haemolysis requires an allergic sensitisation, in addition to the enzymatic defect [3, 4, 5]. PANIZOV and VULLO [7] have already demonstrated that extracorporeal factors, possibly related to the metabolism of fava-poison, are of




Fig 3 Percent of sensitive cells in the blood of 8 heterozygous subjects outside (□) and during (■) fava season

paramount importance in producing a severe hemolytic crisis. Nevertheless, the effect of fava beans on G-6-PD deficient erythrocytes is not mediated [8]. Therefore, it is possible that subclinical hemolysis is always present after ingestion of fava beans in G-6-PD deficient subjects [1, 9]. The study of the ratio between normal and sensitive erythrocytes in heterozygous subjects during the fava season is another possible approach to this problem. If this ratio decreases during this period, it can be assumed that a subclinical hemolysis, due to the ingestion or inhalation of fava beans – which are found everywhere in Sardinia – has occurred. Actually, a definite drop in sensitive erythrocytes occurred in 6 out of 8 cases studied both during and outside the fava season (fig 3). Therefore, the hypothesis that fava-induced subclinical haemolysis is the rule in sensitive subjects is confirmed.

### Conclusions

The ratio between sensitive and normal erythrocytes is compatible with the hypothesis of a random inactivation of the X chromosome. This ratio is fixed in basic conditions. Environmental factors can temporarily modify this ratio without any clinical evidence, in particular, it seems that fava beans represent an important factor of subclinical haemolysis in almost all sensitive subjects.

## Summary

In two survival curves of red cells damaged *in vitro* by methylene and urea benzaldiazide or primaquine are a reliable method for discriminating between normal and G-6-PD deficient erythrocytes. The ratio between the two kinds of erythrocytes was determined in 18 heterozygous G-6-PD deficient women. The study was repeated in 3 women in different periods and in 8 women during the fava season. The results indicate that the ratio between normal and sensitive erythrocytes is (a) constant like with the hypothesis of a random inactivation of the X chromosome, (b) found in basic conditions, (c) most found in subjects who have come into contact with fava beans even when clinical haemolysis is absent.

## References

1. ARNOLDI M., BERNINI I., CARCARI L., LATTE R., MONTIERY, A. G. e SINGALONI M.: Indagine genetica sulla predisposizione al favismo. I. Il problema e i metodi. Fluttuazioni stagionali dei livelli di glucosio-6-fosfato deidrogenasi in Sardegna. Interazione con la talassemia al livello fenotipico. *Accademia Lincei, Rend. Sc. Fis. Mat. Nat.* 76 (1970).
2. REUTLER E. and BALLINI M. G.: The separation of glucosyl-phosphate dehydrogenase deficient erythrocytes from band of heterozygotes for glucosyl-phosphate dehydrogenase deficiency. *Lancet* i 187 (1964).
3. CARCARI L.: Eritrosi ereditaria e anemia emolitica (Ottol e Medica. Pisa 1968).
4. KANTON, S. Z. and HOCH, D.: Studies on the pathogenesis of favism. *Bull. Res. Coun. Israel Sect. A Chem.* 17: 142 (1971).
5. KANTON, S. Z., PINKHAS, J. and DOLATTI M.: Immunologic studies in a case of favism. *J. Allergy* 31: 390 (1972).
6. KAPLAN, J. C., DREYFUS, J. C. et PERIN, M.: La structure en quelque d'un chromosome X chez la femme. *Nouv. Rev. franç. Hémat.* 5: 835 (1973).
7. PANIZON, F. and VELLO, C.: The mechanism of haemolysis in favism. Research on the role of non-corpuscular factors. *Acta haemat., Basel* 29: 337 (1971).
8. PANIZON, F. and ZACCHELLLO F.: The mechanism of haemolysis in favism: some analogy in the activity of primaquine and fava juice. *Acta haemat., Basel* 31: 129 (1973).
9. PERONA, G. P.: L'eritrosi ereditaria da fava nei soggetti con difetto di G-6-PD. *Acta paediat. Lit.* 19: 533 (1974).
10. SARTORI E., PANIZON F. and ZACCHELLLO F.: Binomial distribution of erythrocytes in heterozygotes for strong Mediterranean glucosyl-phosphate dehydrogenase deficiency. *J. med. Genet.* 3: 42 (1966).

Authors' addresses: Dr. FRANCO PANIZON, Clinica Pediatrica, Università di Torino, Torino.  
 Dr. FRANCO ZACCHELLLO and Dr. ERNESTO SARTORI, Clinica Pediatrica, Università di Padova, via Giustiniani 6 35100 Padova.  
 Dr. SALVATORE ADDO, Clinical Research Laboratory General Hospital, Sassari (Italy).



## Behandlungsergebnisse mit Heparin und SP 54 bei autoimmunhämolytischen Anämien

N. HONETZ und E. NEUMANN

I. Medizinische Universitätsklinik (Vorstand Prof. E. DEUTSCH), Wien

Bisher liegen zahlreiche Berichte über günstige Behandlungsergebnisse der hämolytischen Anämien mit Heparin vor. Erstmals behandelte im Jahre 1949 OWREN [4] auf diese Weise einen Fall mit autoimmunhämolytischer Anämie, wobei die tägliche Verabreichung von 350 mg Heparin keine, eine wesentlich höhere Dosis jedoch eine günstige Beeinflussung der Hämolyse erkennen liess. Allerdings musste die Therapie infolge auftretender Blutungen vorzeitig abgebrochen werden. In der Folge wurde mehrmals von anderen Autoren über Erfolge mit der Heparintherapie berichtet, die erforderlichen Dosen waren jedoch ausserordentlich unterschiedlich und bewegten sich zwischen 50 und 800 mg pro Tag [1, 3, 5, 6, 7, 8, 10].

Keine Ergebnisse existieren bei der genannten Erkrankung mit dem Heparinoid SP 54 (Polyanion\*, Bene Chemie), obwohl sich *in vitro* eine günstige Beeinflussung der Immunhämolyse feststellen lässt. So konnte die durch monophasische Kältehämolysine hervorgerufene Hämolyse bei Fall H. L. durch verschiedene Konzentrationen Heparin wie auch SP 54 dosisabhängig gehemmt werden, wobei die von beiden Substanzen hierzu erforderlichen Mengen annähernd gleich waren (Abb. 1). Gleichsinnige Resultate konnten wir auch mit dem Serum einer Patientin mit Wärmehämolysinen (Pat. H. E.) erzielen. Da die Beeinflussung des Blutgerinnungssystems mit SP 54 wesentlich geringer als mit Heparin ist, haben wir bei unseren Untersuchungen an Patienten hauptsächlich SP 54 angewendet.

### *Krankengut und Methodik*

Die Untersuchungen wurden an 10 Fällen mit autoimmunhämolytischer Anämie vorgenommen, wobei 6mal Wärmekörper und 3mal Kältekörper nachgewiesen




Abb. 1. Inkubation einer 30%igen Suspension gewaschener Erythrozyten der Blutgruppe O mit dem Serum der Patten in 11 L. 30 min bei 4°C und anschließend 30 min bei Zimmertemperatur. Das Serum wurde vorher mit Salzsäure auf ein pH von 6,8 gebracht und mit verschiedenen Konzentrationen von Heparin und SP 54 vorbehandelt. ● Heparin ○ SP 54

werden konnten. Ein Fall nahm insoweit eine Sonderstellung ein, als die zum Nachweis einer Immunhämolyse üblichen Tests negativ waren, die im Autohämolyseversuch feststellbare Hämolyse jedoch durch Dekompensierung und Zugabe von Heparin gehemmt werden konnte. Von den übrigen Fällen lag 3 mal die idiopathische und 6 mal die symptomatische Form der Erkrankung vor. Das SP 54 wurde bei 6 Patienten im Kurzversuch in einer Dosis von 400/600 bzw. 700 mg im Laufe von 24 Stunden mittels einer Motorspritze infundiert. Sechs Patienten erhielten das SP 54 subkutan oder intramuskulär in einer Menge von 100 bis 400 mg durch 4 bis 15 Tage täglich und 3 Patienten erhielten SP 54 peroral. Heparin (Heparin Novo®) wurde einmal mit einer Gesamtdosis von 180 mg über 24 Stunden infundiert, bei 3 Patienten in einer Dosis von 150–370 mg über einen Zeitraum von 4 bis 28 Tagen subkutan in Depotform verabreicht (Tabelle I).

**Patient E C.**, männlich, 23 Jahre, 3 Monate vor Aufnahme erstmals Ikterus, seither zunehmende Anämie und mehrfach Transfusionen.

**Befunde bei der Aufnahme:** Ery 2,44 Mill. Hb 9,0 g%. Retikulozyten 470‰. Serum-bilirubin 8,6 mg%, davon indirekt 7,1 mg%. Osmotische Erythrozytenresistenz: komplette Lyse bei 0,5%, unkomplette Lyse bei 0,85%. NaCl-Direkter Coombs-Test 1/64 positiv. Kälteagglutinititer 1/4. Leukozyten 6250. Diff. BB unauffällig. Siernalmark bis auf gesteigerte Erythropoese o.B. Scheinbare halbe Erythrozytenlebensdauer 4 Tage.

**Diagnose:** Idiopathische autoimmune hämolytische Anämie. Therapie: Depot-Heparin subkutan und nachher SP 54 peroral.

**Patient H F.** weiblich, 34 Jahre, 4 Monate nach Entbindung eines normalen Kindes erstmals Müdigkeit, Ohrensausen, Schwindel. Bei der Aufnahme Subikterus, Blässe, unterer Milzpol 2 QF unter Rippenbogen.

**Befunde:** Ery 1,96 Mill. Hb 6,0 g%. Retikulozyten 214‰. Leukozyten 11000. Im Diff. BB vereinzelt Normoblasten. Im Siernalmark neben deutlicher Vermehrung der Erythropoese Zeichen einer megaklastischen Reifungstörung. Serum-bilirubin 4,3 mg%, davon indirekt 3,1 mg%. Direkter Coombs-Test 1/64 positiv. Kälteagglutinititer 1/32 positiv. Wärmehämolyse nachweisbar. Scheinbare halbe Erythrozytenlebensdauer




Abb. 2

3 Tage. Auf Prednisolonthherapie nur unzureichender Anstieg der Erythrozyten, daher 10 Monate nach Diagnosestellung Milzexstirpation, damit Teilerfolg erzielbar.

Diagnose: Idiopathische autoimmune hämolytische Anämie. Therapie: SP 54 zu verschiedenen Zeitpunkten als Infusion, intramuskulär und peroral.

**Patient B F**, männlich, 55 Jahre: seit 1 Jahr Bestehen einer chronischen Lymphadenose bekannt. Wegen Subikterus und starker Anämisierung Spitalaufnahme.

Befunde: Erythrozyten 2,12 Mill., Hb 8,1 g%, Leukozyten 270 000, im Diff. BB 93%, kleine Lymphozyten. Serumbilirubin 3,3 mg%, davon indirekt 2,7 mg%. Direkter Coombs-Test 1:256 positiv, Kälteagglutinititer 1:4. Hepatosplenomegalie, zahlreiche harte, vergrößerte Lymphknoten.

Diagnose: Symptomatische autoimmune hämolytische Anämie bei chronischer Lymphadenose. Therapie: SP 54 intramuskulär.

**Patient F H**, weiblich, 37 Jahre: 2 Monate vor Aufnahme grippaler Infekt, danach zunehmende Blässe, Subikterus und Fieber. Milzpalp. 5 QF unter dem Rippenbogen, Leber geringfügig vergrößert.

Befunde: Erythrozyten 1,98 Mill., Hb 4,8 g%, Retikulozyten 106%/100, Leukozyten 2400, im Diff. BB zahlreiche Normoblasten, geringe Linksverschiebung der Granulopoese. Im Sternalmark starke Vermehrung des erythropoetischen Anteiles. Osmotische Erythrozytenresistenz: komplette Hämolyse bis 0,45%, Teilhämolyse bis 0,85% NaCl. Haptoglobine im Serum nicht nachweisbar. Serumbilirubin 2,9 mg%, davon indirekt 2,0 mg%. Indirekter Coombs-Test negativ, direkter Coombs-Test mit Antigammaglobulin, Antinongammaglobulin und mit Antigamma + Antinongammaglobulin negativ. Hämolyse im Autohämolysetest durch Dekomplementierung und Hepatinzusatz hemmbar. Leberbiopsie: Blutbildungsherde, kein Anhalt für Systemerkrankung.






Abb 3 Patientin H E.

Diagnose Immunhämolyse unklarer Genese Therapie Depot Heparin subkutan und später SP 54 peroral

Patient H L., weiblich, 69 Jahre erste Anämiesymptome 9 Monate vor der Klinikaufnahme, zahlreiche Transfusionen und Prednisolon. Bei Aufnahme Subikterus, Blässe, mäßige Lebervergrößerung und Konsistenzvermehrung, unterer Milzpol 2 QF unter dem Rippenbogen

Befunde Erythrozyten 1,7 Mill, Hb 6,1 g%, Reticulozyten 55%, Leukozyten 3850, im Diff BB 66%, nicht ganz typische Lymphozyten Serumbilirubin 4,0 mg%, davon 3,0 mg% indirekt Im Sternalmark Vermehrung lymphoide Retikulumzellen In der Leberbiopsie Infiltration der Periportalfelder mit lymphoiden Retikulumzellen, kleine herd- und streifenförmige Rundzellenansammlungen auch in den Sinusoiden Direkter Coombs-Test mit Antugammaglobulin negativ, mit Antunongammaglobulin 1/16 schwach positiv, Kälteagglutininiter gegen Zellen der Blutgruppe O über 1/1024 positiv Nachweis monophasischer Kältehämolysine Scheinbare halbe Erythrozytenlebensdauer 13 Tage, die sedimentationsanalytische Untersuchung des Serums ergibt einen Anteil von 11% Globulinen mit einer Sedimentationskonstanten von 19 S

Diagnose Symptomatische autoimmune hämolytische Anämie durch Kälteantikörper bei Lymphoretikulose Therapie Heparin intravenös, später SP 54 subkutan

Patient H R., männlich, 70 Jahre Als Ursache einer seit 3 Jahren bestehenden hämolytischen Anämie wurde eine chronische Lymphadenose gefunden. Zahlreiche derbe Lymphknoten, mäßige Leber- und Milzvergrößerung Sternalmark, Leberbiopsie und peripherer Blutausschnitt ergaben für eine chronische Lymphadenose typische Befunde




Abb. 1 Patient 5 J

Serumlaktat 1,23 mg%, davon 1,0 mg% indirekt. Erythrozyten 2,7 Mill. Hb 10,0 g%, Reticulocyten 70% Leukozyten (BAO) Direkt er Coombs-Test 1 (64 positiv bei 1:16) in 1:16, Osmotische Erythrozytenresistenz normal. Schwere hämolytische Krise, Erythrozytenlebensdauer 7 Tage.

Diagnose: Symptomatische autoimmune hämolytische Anämie bei chronischer Lymphadenose. Therapie: SP 54 als Infusion.

Patient 5 J männlich, 67 Jahre, 4 Jahre vor Aufnahme Diagnosestellung einer chronischen Lymphadenose. In letzter Zeit zunehmende Anämie und Subikterus. Bei der Aufnahme zahlreiche derbe bis knochenartige Lymphknoten unterer Leberrand 3 QF unterer Milzspitze handbreit unter dem Rippenbogen.

Befunde: Erythrozyten 2,3 Mill. Hb 6,5 g%, Reticulocyten 110% Leukozyten 6,500 mit 92% kleinen Lymphocyten im Diff. Bl. Osmotische Erythrozytenresistenz Teilhämolys bis 0,7%, komplette Hämolys bis 0,4% NaCl. Serumlaktat 3,0 mg% da indirekt 2,4 mg% Direkter Coombs-Test 1 512 positiv.

Diagnose: Symptomatische autoimmune hämolytische Anämie bei chronischer Lymphadenose. Therapie: SP 54 als Infusion und nachher subkutan.

Patient 1 A weiblich, 48 Jahre, vor 2 Jahren Amputation mehrerer Finger und vor einem Jahr Unterschenkelamputation wegen Gangrän, damals und auch jetzt schwere hämolytische Anämie.

Abb. 2 Patient 1 A

Diagramm: Ein Streudiagramm, das die Häufigkeit von Erythrozyten (x-Achse) über die Zeit (y-Achse) darstellt. Die Kurve zeigt eine deutliche Abnahme der Erythrozytenzahl über die Zeit, was auf eine hämolytische Anämie hindeutet.

Diagnose Idiopathische autoimmune hämolytische Anämie durch Kälteantikörper. Therapie SP 54 als Infusion und nachher subkutan Depot Heparin zu einem anderen Zeitpunkt subkutan

Patient P A, weiblich, 37 Jahre 4 Monate vor Aufnahme zunehmend Blässe und Müdigkeit, fallweise Fieber, Subikterus Multiple Lymphknotenvergrößerungen Histo-

0.65 mg%, indirekt Direkter Coombs Test 1/32 schwach positiv, Kälteagglutinin titrierbar gegen Zellen der Blutgruppe O 1/512 positiv mit hoher Avidität

Diagnose Symptomatische autoimmune hämolytische Anämie durch Kälteantikörper bei Retikulosarkom Therapie SP 54 als Infusion

Patient T M, weiblich 79 Jahre Anämiesymptome erstmals 1 Jahr vor Aufnahme, mehrere Bluttransfusionen Auswärts Diagnosestellung einer autoimmune hämolytischen Anämie Auf Prednisolonbehandlung keine Besserung daher Transfusionsstopp keine Lymphknotenvergrößerungen keine Milzvergrößerung

Befunde Erythrozyten 2.74 Mill, Hb 10.2 g%, Retikulozyten 144‰, Leukozyten 5400 im Diff BB Lymphozyten von 44%. Im Sternmark Verneuerung der Lymphozyten

Infusion und später subkutan

### Ergebnisse

Bei den 6 Patienten, die das SP 54 bzw. das Heparin über einen Zeitraum von 24 Stunden infundiert erhielten, wurden Erythrozytenzahl, Hämoglobin, Serumbilirubin, Retikulozyten und bei einigen Patienten auch die osmotische Erythrozytenresistenz vor, am Ende und 24 Stunden nach Ende der Infusion bestimmt. Mit Ausnahme eines Falles mit Kälteagglutininkrankheit konnte jedes Mal ein Anstieg von Erythrozyten und Hämoglobin festgestellt werden, wobei der durchschnittliche Hämoglobinanstieg am Ende der Infusion 1,22 g% betrug. Wenn man die bei diesen Erkrankungen vorhandene starke regenerative Tätigkeit des Knochenmarks in Betracht zieht und einen weitgehenden Stop der Hämolyse annimmt, dann korrelieren die auf diese Weise errechneten Daten gut mit den erhaltenen Ergebnissen. Der auf das 6-8fache des Normalen gesteigerte Hämoglobinaumsatz von 6-8 g/Tag ergibt einen Anstieg von annähernd 1 g% Hämoglobin pro Tag. Einen Tag nach Absetzen der Medikation war bereits wieder eine deutliche Verminderung der Werte festzustellen. In der Regel kam es unter der Infusion auch zu einem Bilirubinabfall, während die Retikulozytenzahl einen unsicheren Erfolgsparameter

darstellte und keine einheitliche Veränderung erkennen liess (Abb. 2). Eine Veränderung der osmotischen Resistenz konnte nicht mit Sicherheit nachgewiesen werden.

6 Fälle erhielten SP 54 und 3 Fälle Heparin über einen Zeitraum von 3-28 Tagen subkutan bzw. intramuskulär verabreicht. Wurde das SP 54 in einer Dosis von 100 mg% (stündlich 100 mg) gegeben, so war immer eine günstige Beeinflussung der Anämie festzustellen.

So erhielt die Patientin H. E. bei vorher kontinuierlicher Verschlechterung des Blutbildes durch 4 Tage das Präparat in der genannten Dosierung, wobei nun ein Anstieg der Erythrozyten von 2,65 auf 2,85 Mill., des Hämoglobins von 8,5 auf 9,2 g% und des Hämatokrits von 27 auf 30% festzustellen war. Bilirubin und Retikulozyten zeigten einen deutlichen Abfall. Die Verringerung der SP 54-Dosis auf 100 mg täglich hatte sofort eine gegenläufige Bewegung der verschiedenen Parameter zur Folge, und auch eine langdauernde orale Verabreichung von SP 54 in einer Höhe von 150 mg täglich konnte eine laufende Verschlechterung der Befunde nicht verhindern (Abb. 3). Auch die tägliche subkutane Injektion von 200 mg SP 54, welche die Patientin durch 10 Tage zu einem anderen Zeitpunkt erhielt, liess eine eindeutige Beeinflussung der Hämolyse nicht erkennen.

Der Patient S. J. wies eine symptomatische, durch Wärmecantikörper hervorgerufene, autoimmunhämolytische Anämie bei chronischer Lymphadenose auf. Nach 24stündiger Infusion von 600 mg SP 54 erhielt der Patient noch durch weitere 4 Tage täglich 400 mg SP 54 subkutan. In diesem Zeitraum stieg die Erythrozytenzahl von 2,4 auf 2,8 Mill., das Hämoglobin von 7,5 auf 9,2 g% an, während Bilirubin und Retikulozytenzahl absanken. Auch hier kam es nach Absetzen der SP 54-Medikation wieder zu einer Verschlechterung, obwohl die Dosis der gleichzeitig verabfolgten Corticosteroide nicht verändert wurde (Abb. 4).

Bei der Patientin T. M. stieg während der 7tägigen subkutanen Verabreichung von 400 mg SP 54 täglich die Erythrozytenzahl von 2,7 auf 3,1 Mill. und das Hämoglobin von 9,0 auf 9,6 g% an, das Serumbilirubin fiel von 1,25 auf 1,0 mg% ab. Ebenso war bei der Patientin V. A., die an einer schweren progredienten Anämie bei chronischer Kälteagglutininkrankheit litt, unter der gleichen Dosierung von SP 54 durch 8 Tage ein geringer Anstieg von Erythrozytenzahl (2,8 auf 3,0 Mill.), Hämoglobin (8,8 auf 9,5 g%) und Hämatokrit (27 auf 30%) festzustellen. Zwei weitere Patienten, B. F. und F. H.,






Abb 5 Patient E. G

erhielten SP 54 in einer Dosis von 200 mg täglich durch 15 bzw. 7 Tage subkutan. Es konnte in keinem dieser Fälle eine Besserung der Befunde festgestellt werden, obwohl ein bei einem dieser Patienten (F. H.) durchgeführter intravenöser Kurztest mit Heparin von Erfolg begleitet war. Die orale Medikation von SP 54, die bei 3 Fällen vorgenommen wurde, war unwirksam.

An Nebenwirkungen kam es bei der Injektion von 2 mal 200 mg SP 54 intragluteal bei Patientin H. E. zu Hämatomen an der Applikationsstelle, so dass in Zukunft die Einzeldosen auf 100 mg beschränkt wurden und die subkutane Applikation der intramuskularen vorgezogen wurde. Bei Patientin P. A. trat am 4. Tag der Gabe von 1 mal




Abb. 6 Patientin V. A.

100 mg SP 54 subkutan eine oberflächliche Hautnekrose an der Applikationsstelle auf, so dass die Therapie unterbrochen werden musste. In den übrigen Fällen waren Nebenwirkungen der SP 54-Therapie nicht zu beobachten. Regelmässige Kontrollen der Prothrombinzeit, der Thrombinzeit und des Heparintoleranztestes ergaben nur geringfügige Beeinflussungen der Werte, so dass in keinem Fall die Therapie deswegen unterbrochen werden musste.

Heparin wurde in einem Fall (F. H.) im Laufe von 24 Stunden infundiert. Dabei stiegen die Erythrozyten von 3,0 auf 3,4 Mill., und das Hämoglobin von 8,6 auf 10,1 g% an, während das Bilirubin abfiel. Die Dosis von 1000 E/h musste in diesem Fall nach 12 Stunden auf 750 E/h reduziert werden, da die Thrombinzeit bis über 60 sec angestiegen war. Drei weitere Fälle erhielten das Heparin in Depotform subkutan verabreicht.

Bei Patient E. G. mit einer schweren progredienten, im Coombs-Test positiven hämolytischen Anämie war unter einer Gabe von zunächst 220 mg und später 150 mg Heparin täglich keine weitere Verschlechterung, sondern eine mässige Besserung der Befunde festzustellen. Die Erythrozyten stiegen von 2,8 auf 3,2 Mill., das Hämoglobin von 7,8 auf 9,2 g% an, während das Bilirubin von 1,8 auf 1,2 mg% sank.

Heparintherapie wurde bei diesem Patienten ausserdem eine Bestimmung der Erythrozytenlebensdauer mit  $^{51}\text{Cr}$  durchgeführt. Vor der Behandlung zeigte die Eliminationsgerade eine starke Neigung mit einer sich daraus ergebenden scheinbaren halben Erythrozytenlebensdauer von 4 Tagen. Mit Einsetzen der Heparintherapie änderte sich schlagartig die Neigung der Geraden, und die nun festgestellte Erythrozytenlebensdauer war mit 13 Tagen wesentlich länger (Abb. 5).

Die schwere progrediente Anämie bei Patientin V. A. wurde mit hohen Dosen Prednisolon behandelt. Gleichzeitig erhielt sie durch 4 Tage 280 mg Heparin subkutan verabreicht. Die Erythrozytenzahl stieg an, und das Serumbilirubin fiel ab. Durch weitere 4 Tage wurde nun das Heparin auf täglich 200 mg reduziert, worauf sich das Blutbild trotz Fortsetzung der Prednisolontherapie in gleicher Dosierung rasch verschlechterte und bei neuerlicher Steigerung der Heparindosis wieder besserte (Abb. 6). Es kann geschlossen werden, dass die Heparintherapie an der Besserung der Anämie einen wesentlichen Anteil hatte. Bei einer weiteren Patientin (H. L.) konnte eine eindeutige Beeinflussung der Hämolyse unter einer Dosis von 150 mg Heparin subkutan durch 7 Tage nicht festgestellt werden.

### *Diskussion*

Bei Betrachtung der mit der genannten Therapie erzielten Ergebnisse können folgende Schlussfolgerungen gezogen werden:

1. Es lässt sich sowohl mit Heparin wie auch mit SP 54 eine günstige Beeinflussung der Hämolyse bei Fällen mit autoimmunhämolytischer Anämie erzielen, die allerdings nur während der Applikationsdauer anhält.

Es wurde berichtet, dass Heparin und Heparinoide bei Vorliegen eines Aldosteronismus zu einer Diurese führen könnten [2, 9]. Dagegen, dass bei unseren Fällen eine Bluteindickung zu einer scheinbaren Besserung der Blutbefunde geführt hat, spricht, dass in den meisten Fällen gleichzeitig auch eine Reduktion des indirekten Serumbilirubins festzustellen war und dass Fälle von hämolytischer Anämie anderer Genese eine Besserung der Befunde in jedem Fall vermessen liessen. Ein Anhaltspunkt für einen primären oder sekundären Aldosteronismus konnte bei keinem der behandelten Patienten gefunden werden.

2. Die zur Beeinflussung der Hämolyse erforderlichen Dosen sind von Fall zu Fall verschieden. In der Literatur werden Heparinmengen

von 50–800 mg täglich genannt. Wir haben bei einem Patienten sowohl mit 220 wie auch mit 150 mg eine Besserung feststellen können, bei einem anderen Patienten erwies sich eine Dosis von 100 mg als unwirksam, während mit 260 und 320 mg ein deutlicher Erfolg zu erzielen war. Die Verabfolgung von SP 54 zeigte sich im intravenösen Kurztest mit 600 bzw. 700 mg mit Ausnahme eines Falles immer als wirksam, auch war die bei 3 Patienten vorgenommene Verabfolgung von 400 mg subkutan über einen längeren Zeitraum immer von einer Besserung der Befunde begleitet. Eine Dosis von 200 mg subkutan in 2 Fällen und 100 mg subkutan in einem Fall war unwirksam. Wie mit Heparin liess sich auch an einem Fall mit SP 54 eine deutliche Dosisabhängigkeit der Wirkung feststellen (H. L.). Die perorale Verabfolgung war immer unwirksam, selbst bei Dosissteigerung auf 500 mg täglich bei einer Patientin, die auf die intravenöse und subkutane Therapie gut angesprochen hatte. Wir vermuten, dass dies vorwiegend eine Frage der Resorption ist.

3. Das Heparinoid SP 54 bietet gegenüber dem Heparin insofern einen Vorteil, als es wesentlich weniger gerinnungswirksam ist, die zur Beeinflussung der Hämolyse erforderlichen Dosen jedoch nicht nennenswert höher liegen. Während in einem Fall die Infusion von stündlich 1000 E. (= 8,4 mg) Heparin eine so deutliche Beeinflussung der Gerinnungsbefunde zur Folge hatte, dass die Dosis nach 12 Stunden reduziert werden musste, waren mit der 4fachen Menge SP 54 (29 mg/h = 700 mg gesamt) während der 24stündigen Infusion lediglich geringfügige Veränderungen der Gerinnungsbefunde festzustellen, so dass in keinem der hochdosiert behandelten Fälle eine Reduktion der Dosis notwendig wurde. Es ist daher mit diesem Präparat eher die Möglichkeit gegeben, den zur Hemmung der Hämolyse erforderlichen Blutspiegel zu erreichen.

### Zusammenfassung

An 10 Patienten mit autoimmunhämolytischer Anämie wurden Untersuchungen mit dem Heparinoid SP 54 und mit Heparin durchgeführt. Das SP 54 wurde als Infusion subkutan oder peroral verabreicht. Heparin wurde entweder als Infusion oder subkutan in Depotform gegeben. Es zeigte sich, dass in genügend hoher Dosierung sowohl mit Heparin als auch mit SP 54 eine günstige Beeinflussung der Hämolyse erreicht werden kann, wobei die zur Hemmung der Hämolyse erforderlichen Dosen von SP 54 nicht wesentlich höher liegen als die von Heparin. Das SP 54 hat den Vorteil, dass die Beeinflussung des Blutgerinnungssystems wesentlich geringer ist und der erforderliche Wirkspiegel deshalb eher erreicht werden kann.

### Summary

Investigations with heparinoid SP 54 and heparin were conducted in ten patients with auto-immune haemolytic anaemia. SP 54 was given as infusion, by subcutaneous injection or by mouth, and heparin by infusion or subcutaneous injection in depot form. It was shown that with sufficiently high dosage of either heparin or SP 54 a favourable effect on haemolysis could be obtained. The doses of SP 54 required to inhibit haemolysis were not appreciably higher than those of heparin. SP 54 has the advantage of a much less pronounced influence on the blood clotting system than heparin, so that it is easier to reach the effective level required.

### Literatur

- 1 HEINE, K. M., HERRMANN H. und STROBE, H. Die Heparinbehandlung bei erworbener hämolytischer Anämie. *Acta haemat., Basel* 32: 27 (1964).
- 2 MAJOOB, C. L. H., SCHILATMANN, R. J. A., JANSEN, A. P., and PRENEN, H. Excretion pattern and mechanism of diuresis induced by heparin. *Clin. chim. Acta* 5: 591 (1960).
- 3 MCFARLAND, R. G., GALBRAITH, and MIALZ. Heparin therapy in autoimmune hemolytic anemia. *Blood* 15: 741 (1960).
- 4 OWREN, P. A. Acquired hemolytic jaundice. *Scand. J. clin. Lab. Invest.* 1: 41 (1949).
- 5 ROTH, K. L. and FRUMIN, A. M. Effect of intramuscular heparin on antibodies in idiopathic acquired hemolytic anemia. *Amer. J. Med.* 20: 968 (1956).
- 6 SCHIMM, H. J. Paroxysmale nächtliche Hämoglobinurie. Hemmung der *in vivo* Hämolyse durch Germanin, Heparin und Heparinoide. *Schweiz. med. Wschr.* 96: 1297 (1966).
- 7 STORTI, E. and VACCARI, F. Studies on the relationship between anticoagulants and hemolysis. *Acta haemat., Basel* 15: 12 (1956).
- 8 STORTI, E., VACCARI, F., and BALDEN, E. Studies on the relation between anticoagulants and hemolysis. II. The Effect of anticoagulants on the hemolysis caused by antibodies *in vivo*. *Acta haemat., Basel* 15: 106 (1956).
- 9 VALLENT, K. und FACIET, J. Die Wirkung von Heparin in der Regulierung des Wasser- und Elektrolythaushaltes. *Klin. Wschr.* 43: 235 (1965).
- 10 WAGNER, K., SAILER, S., EBNER, O. und PAILER, J. Untersuchungen zur Heparinwirkung bei hämolytischen Anämien. *Wien. Z. inn. Med.* 42: 453 (1961).






Fig 1 Sternal tenderness in patients with leukaemia. ○—○—○ Mean  $\pm$  SD of control patients, ● Acute leukaemia, ● Chronic leukaemia

Table 1 Sternal tenderness in control patients

| Age-group<br>years | Sternal pain threshold (lb) |       |      |     | Females |        |      |     |
|--------------------|-----------------------------|-------|------|-----|---------|--------|------|-----|
|                    | Males                       |       | Mean | SD  | No      | Range  | Mean | SD  |
|                    | No                          | Range |      |     |         |        |      |     |
| 20-29              | 15                          | 5-20  | 10.4 | 4.8 | 15      | 3-10   | 5.6  | 1.7 |
| 30-39              | 15                          | 5-20  | 11.6 | 4.6 | 15      | 3-9    | 5.6  | 2.0 |
| 40-49              | 20                          | 6-20  | 11.4 | 3.7 | 20      | 4-20   | 8.1  | 4.3 |
| 50-59              | 20                          | 6-20  | 11.7 | 3.7 | 20      | 3-9    | 6.3  | 1.4 |
| 60-69              | 20                          | 5-16  | 9.0  | 2.2 | 20      | 3-20   | 7.0  | 3.8 |
| 70-79              | 20                          | 6-20  | 9.5  | 3.1 | 20      | 2.5-20 | 6.9  | 3.6 |
| over 80            | 10                          | 6-15  | 10.0 | 2.9 | 15      | 3.5-8  | 5.9  | 1.4 |
| All ages           | 120                         | 5-20  | 10.5 | 3.8 | 125     | 2.5-20 | 6.6  | 3.0 |

### Results

The pressure required to produce sternal pain (sternal pain threshold) in the control patients, divided according to age and sex, is shown in table 1. There was no trend towards a change in sternal tenderness




Fig 2 Sternal tenderness in patients with myelomatosis, pernicious anaemia and malignant infiltration of the marrow.  $\bigcirc$ — $\bigcirc$  Mean  $\pm$  SD of control patients.  $\square$  Myelomatosis.  $\Delta$  Pernicious anaemia.  $\nabla$  Malignant infiltration of marrow.

with age, but the men had significantly less sternal tenderness at each of the age-groups studied ( $p < 0.05$ ).

The mean sternal tenderness of both male and female patients with leukaemia was less than that of the control patients of the corresponding sex, but this difference reached the 5% significance level only in men. The sternal tenderness of the individual patients with leukaemia, subdivided into acute and chronic forms, is compared with the mean of the control subjects for each sex in figure 1. Only 6 of the 50 patients with leukaemia had a sternal pain threshold below the range found in the control subjects.

The sternal tenderness of patients with myelomatosis, malignant infiltration of the marrow and Addisonian pernicious anaemia is illustrated in figure 2. Only a single patient with myelomatosis and a single patient with pernicious anaemia had unusually low sternal pain threshold, the threshold was low in 4 of the 5 patients with malignant infiltration of the marrow.

#### Comment

In clinical practice sternal tenderness is usually elicited by thumb or finger pressure. In this study, using a more objective assessment of






Fig 1 Sternal tenderness in patients with leukaemia. I—●—I Mean  $\pm$  SD of control patients, ○ Acute leukaemia, ● Chronic leukaemia

Table I Sternal tenderness in control patients

| Age-group<br>years | Sternal pain threshold (lb.) |       |      |     |         |        |      |     |
|--------------------|------------------------------|-------|------|-----|---------|--------|------|-----|
|                    | Males                        |       |      |     | Females |        |      |     |
|                    | No.                          | Range | Mean | SD  | No.     | Range  | Mean | SD  |
| 20-29              | 15                           | 5-20  | 10.4 | 4.8 | 15      | 3-10   | 5.6  | 1.7 |
| 30-39              | 15                           | 5-20  | 11.6 | 4.6 | 15      | 3-9    | 5.6  | 2.0 |
| 40-49              | 20                           | 6-20  | 11.4 | 3.7 | 20      | 4-20   | 8.1  | 4.3 |
| 50-59              | 20                           | 6-20  | 11.7 | 3.7 | 20      | 3-9    | 6.3  | 1.4 |
| 60-69              | 20                           | 5-16  | 9.0  | 2.2 | 20      | 3-20   | 7.0  | 3.8 |
| 70-79              | 20                           | 6-20  | 9.5  | 3.1 | 20      | 2.5-20 | 6.9  | 3.6 |
| over 80            | 10                           | 6-15  | 10.0 | 2.9 | 15      | 3.5-8  | 5.9  | 1.4 |
| All ages           | 120                          | 5-20  | 10.5 | 3.8 | 125     | 2.5-20 | 6.6  | 3.0 |

### Results

The pressure required to produce sternal pain (sternal pain threshold) in the control patients, divided according to age and sex, is shown in table I. There was no trend towards a change in sternal tenderness




Fig. 2 Sternal tenderness in patients with myelomatosis, pernicious anaemia and malignant infiltration of the marrow.  $\bullet$  Mean  $\pm$  SD of control patients.  $\circ$  Myelomatosis,  $\Delta$  Pernicious anaemia,  $\square$  Malignant infiltration of marrow.


with age, but the men had significantly less sternal tenderness at each of the age groups studied ( $p < 0.05$ ).

The mean sternal tenderness of both male and female patients with leukaemia was less than that of the control patients of the corresponding sex, but this difference reached the 5% significance level only in men. The sternal tenderness of the individual patients with leukaemia subdivided into acute and chronic forms is compared with the mean of the control subjects for each sex in figure 1. Only 6 of the 50 patients with leukaemia had a sternal pain threshold below the range found in the control subjects.

The sternal tenderness of patients with myelomatosis, malignant infiltration of the marrow and Addisonian pernicious anaemia is illustrated in figure 2. Only a single patient with myelomatosis and a single patient with pernicious anaemia had unusually low sternal pain threshold, the threshold was low in 1 of the 5 patients with malignant infiltration of the marrow.

#### *Comment*

In clinical practice sternal tenderness is usually elicited by thumb or finger pressure. In this study using a more objective assessment of



ernal tenderness in patients with leukaemia 1-●-1 Mean  $\pm$  SD of control patients,  
: leukaemia ● Chronic leukaemia

Table I Sternal tenderness in control patients

| group    | Sternal pain threshold (lb) |       |      |     | Females |        |      |     |
|----------|-----------------------------|-------|------|-----|---------|--------|------|-----|
|          | Males                       |       | Mean | SD  | No      | Range  | Mean | SD  |
|          | No                          | Range |      |     |         |        |      |     |
| 1-29     | 15                          | 5-20  | 10.4 | 4.8 | 15      | 3-10   | 5.6  | 1.7 |
| 3-39     | 15                          | 5-20  | 11.6 | 4.6 | 15      | 3-9    | 5.6  | 2.0 |
| 0-49     | 20                          | 6-20  | 11.4 | 3.7 | 20      | 4-20   | 8.1  | 4.3 |
| 50-59    | 20                          | 6-20  | 11.7 | 3.7 | 20      | 3-9    | 6.3  | 1.4 |
| 60-69    | 20                          | 5-16  | 9.0  | 2.2 | 20      | 3-20   | 7.0  | 3.8 |
| 70-79    | 20                          | 6-20  | 9.5  | 3.1 | 20      | 2.5-20 | 6.9  | 3.6 |
| over 80  | 10                          | 6-15  | 10.0 | 2.9 | 15      | 3.5-8  | 5.9  | 1.4 |
| All ages | 120                         | 5-20  | 10.5 | 3.8 | 125     | 2.5-20 | 6.6  | 3.0 |

### Results

The pressure required to produce sternal pain (sternal pain threshold) in the control patients, divided according to age and sex, is shown in table I. There was no trend towards a change in sternal tenderness




Fig 2 Sternal tenderness in patients with myelomatosis, pernicious anaemia and malignant infiltration of the marrow.  $\circ$  Mean  $\pm$  SD of control patients.  $\circ$  Myelomatosis,  $\Delta$  Pernicious anaemia,  $\square$  Malignant infiltration of marrow.

with age, but the men had significantly less sternal tenderness at each of the age-groups studied ( $p < 0.05$ ).

The mean sternal tenderness of both male and female patients with leukaemia was less than that of the control patients of the corresponding sex, but this difference reached the 5% significance level only in men. The sternal tenderness of the individual patients with leukaemia, subdivided into acute and chronic forms, is compared with the mean of the control subjects for each sex in figure 1. Only 6 of the 50 patients with leukaemia had a sternal pain threshold below the range found in the control subjects.

The sternal tenderness of patients with myelomatosis, malignant infiltration of the marrow and Addisonian pernicious anaemia is illustrated in figure 2. Only a single patient with myelomatosis and a single patient with pernicious anaemia had unusually low sternal pain threshold, the threshold was low in 1 of the 5 patients with malignant infiltration of the marrow.

#### Comment

In clinical practice sternal tenderness is usually elicited by thumb or finger pressure. In this study, using a more objective assessment of

sternal tenderness, we found that few patients with leukaemia had a degree of sternal tenderness outside the range found in control patients, and it is unlikely that the small increase in sternal tenderness found in a few leukaemic patients could be detected by the usual clinical method. We conclude that the physical sign of sternal tenderness is of very limited value in the clinical diagnosis of leukaemia. Sternal tenderness was also not notably increased in other conditions of increased marrow activity (megaloblastosis and myelomatosis). It may provide helpful evidence of metastatic malignant infiltration of the marrow, but the numbers in the present series are too small to reach a firm conclusion.

### *Summary*

Sternal tenderness was measured in patients with leukaemia, myelomatosis, pernicious anaemia and malignant infiltration of the marrow, and compared with control subjects. Because of the wide scatter of results and the overlap of values with those of control subjects, it is concluded that sternal tenderness is not a useful clinical sign of leukaemia.

### *References*

1. GRULICH, G. C. DE. Clinical haematology in medical practice, 2nd ed (Blackwell, Oxford 1964)
2. WINTROBE, M. M. Clinical Hematology, 6th ed (Kimpton, London 1967)

## A Screening Test for Red Blood Cell Catalase

P. T. ÖZAND and S. ARTVINLI

Department of Biochemistry, Hacettepe University Medical School, Ankara

Acatalasia is a deficiency of catalase in the red blood cells and in various tissues, which was first described by TAKAHARA [1]. The term hypocatalasemia is applied to intermediate values of catalase activity found in family members of patients with acatalasia. Acatalasia and hypocatalasemia are rare inherited conditions, for which a large Turkish population has been surveyed [2]. For this purpose a new, simple screening test suitable for field work was needed. This article describes such a screening test which is inexpensive, simple and which successfully detects acatalasie and hypocatalasemie individuals. It is particularly convenient in remote field survey, where no extensive biochemical facilities are available. Furthermore, it permits a large number of samples to be run within a short time, even by an inexperienced technician.

### Method

*Principle of the test.* Whole blood is finally diluted 50 000 fold to test the catalase while a sample for hemoglobin determination is obtained. The diluted blood sample is allowed to act on  $7.5 \times 10^{-4} M H_2O_2$  buffer for 10 min at room temperature. The reaction is stopped by the addition of acid and after neutralization the residual  $H_2O_2$  is determined colorimetrically by a system of horse radish peroxidase-O-dianisidine. By comparing the color visually to standard colors corresponding to known enzyme units the blood catalase activity is assessed semiquantitatively. In normal individuals there is a linear relation between catalase activity and hemoglobin concentration [3-6]. As the screening test simultaneously allows the determination of hemoglobin on the same blood sample used to test catalase false hypocatalasemie values related to low hemoglobin are avoided and only true cases of hypocatalasemia and acatalasemia can be detected.




Fig 1 Time relation of catalase activity under the conditions of the screening test (1) Whole blood undiluted, (2) the same sample diluted  $\frac{1}{2}$  by saline, and (3)  $\frac{1}{4}$  dilution  $\bar{x}$  denotes the average result of the triplicate determination on the same sample and  $\pm$  SD

**Material** O Dinitrosidine, horse radish peroxidase (type 1), and bovine serum albumin (crystalline) were purchased from the Sigma Chemical Company, St. Louis, USA. All other reagents used were of CP or an equivalent grade, all compounds were dissolved in deionized water.

**Hemoglobin determination** was carried out through the formation of cyanmethemoglobin [5], for which 20  $\mu$ l of blood was withdrawn from the fingertip, and added to 5 ml of water prepipetted into a 130  $\times$  14 mm test tube. After, 50  $\mu$ l of this hemolyzate was taken for catalase assay at the end of the day, 2 drops of a concentrated hemoglobin reagent (10 g  $\text{NaHCO}_3$ , 500 mg  $\text{KCN}$ , 2 g  $\text{K}_3\text{Fe}(\text{CN})_6$  per 100 ml) were added and the tubes were shaken. The results were visually compared to a series of standards ranging from 1.15 g% Hb prepared by the same method in the same size tubes from a sample with a known hemoglobin value, and covered with a cork. Care was taken to select test tubes made of the same type of glass.

The standards and samples prepared this way were stable for at least one week, and if further accuracy was desired they could be brought to the laboratory after a large group of samples had been collected and measured there at 540 nm. In cases where a hypocatalase

Table 1 Absorbance unit relation

| Absorbance | Enzyme units per 100 ml blood <sup>1</sup> |
|------------|--|
| 1.000      | 0  |
| 0.900      | 200  |
| 0.805      | 400  |
| 0.725      | 600  |
| 0.610      | 800  |
| 0.520      | 1,200                                      |
| 0.425      | 1,600                                      |
| 0.335      | 2,000                                      |
| 0.245      | 2,500                                      |
| 0.145      | 3,500                                      |
| 0.000      | 4,500                                      |

<sup>1</sup> The enzyme unit was defined in terms of velocity as follows: 1 unit of enzyme was equivalent to the activity that utilized 1 mM of  $H_2O_2$  per hour. The following formula was used:  $k_{\text{cat}} \ln (a/x) = k t$  where  $k_{\text{cat}}$  was a constant,  $a$  initial  $H_2O_2$  concentration (giving 1.000 absorbation under the conditions listed above),  $x$  the concentration of  $H_2O_2$  at time  $t$ , and  $k$  the velocity.

serum value was detected repeated and conventional hemoglobin determination was carried out on a fresh blood sample taken from the subject.

**Enzyme assay.** The assay system should be freshly prepared on the morning of departure to the field. It consisted of  $10^{-4}M$  potassium phosphate,  $7.5 \times 10^{-4}M$   $H_2O_2$  at pH 7. Five ml of this solution was pipetted into selected 150  $\times$  16 mm pyrex tubes, all of the same colour. This solution is stable for 6 hours, and a stock solution of  $7.5 \times 10^{-4}M$   $H_2O_2$  can be kept cold for a week.

**The screening test.** A fresh blood sample for hemoglobin was obtained as described above. Immediately after the hemolysis had been completed 50  $\mu$ l of this hemolyate was transferred to the tube containing the assay solution at room temperature (23–25°C). Catalase activity changes at temperatures around 23°C and false results are obtained at temperatures lower than 20°C and higher than 28°C. The chronometer was started, the tube was covered with a piece of parafilm and mixed by inverting. The micropipettes should be cleaned with distilled water and acetone between assays, and care should be taken to insure that both pipettes are clean and dry. After exactly 10 min of incubation at room temperature the reaction was stopped by the addition of 1.0 ml  $2 \times 10^{-4}M$   $Na_2SO_3$  and mixing. The tubes may be kept covered and left at room temperature for 6 hours without significant loss of residual  $H_2O_2$ .

*Color determination.* At the end of the

assay the tubes were placed in a colorimeter. The colorimeter should be calibrated with a series of standard solutions of  $Na_2SO_3$  and  $Na_2O_2$  and the colorimeter should be calibrated with a series of standard solutions of  $Na_2SO_3$  and  $Na_2O_2$ .

As the enzyme serum albumin kept at 0°C was diluted O-dianiline may be kept for one week in a dark bottle in the refrigerator, and darkened solutions should be discarded. Peroxidase will last for a fortnight if it is kept cold.






Fig 2 Correlation between units of catalase activity determined spectrophotometrically and by the screening test. Standard correlation coefficients, standard deviation and the  $t$  value of the 20 samples are given

10 ml of the color solution was then pipetted into all the assay tubes and mixed by covering the tube with a piece of parafilm. Color development is very rapid, and should end within 2 min. At the beginning and end of the working day a blank should be prepared and run containing all the components of the assay system except the hemolysate. After the addition of acid and neutralization, color solution should be added to the blank, and color should be developed in the same way, after the full development of the color 0.5 ml  $2 \times \text{HCl}$  was pipetted into all the tubes and mixed.

**Reading the results** Color was visually compared to standard tubes containing a known amount of O-dianthronate. The standard color solutions were transferred to 150  $\times$  16 mm test tubes and covered with a cork. These remain stable for at least a week, however a slight dark precipitate may form after a while in which case the tubes should be shaken and the precipitate dissolved before comparison. The blank assays should give a reading of about 1,000 absorbency, to ensure the validity of the enzyme assay; if this cannot be achieved the assay mixtures may be very stable at this stage, and would satisfactorily detect patients with low blood catalase. When a case of low catalase was detected, the results were reconfirmed in a freshly drawn blood sample and sent to the laboratory

### Results

The assay system, when run spectrophotometrically at 402 nm and plotted logarithmically was found to be linear for 60 min, which is to be expected, as the enzyme has a very large  $E_m$  value, and under the conditions described the disappearance of peroxide should follow first order kinetics. This was confirmed in 20 normal blood samples, undiluted or diluted with fresh isotonic saline. Ten minutes of incubation was found to be satisfactory for samples obtained from normal subjects and it was possible to detect hypocatalisemic subjects using this period of incubation [2]. An example of the spectrophotometric assay is given in figure 1.

The correlation between the units determined spectrophotometrically and the values obtained by the screening test was found to be satisfactory when tested for 20 normal subjects (fig. 2). The accuracy of the screening test was determined in a double blind type of study by 3 different testers using various blood samples. Individual variations in this type of study and also in repeated determinations with the same blood sample, were negligible with a standard deviation of  $100 \pm 4\%$ .

The great dilution of the blood (final 50,000 fold) permits the specific assay of catalase without the interference of other activities due to the presence of undesirable substrates from hemolyzed cells (e.g. glutathione peroxidase). The catalatic activity of catalase has a large  $K_m$  [7] value, and under the conditions described here the disappearance of peroxide follows first order kinetics, velocity can also be calculated (table I). The rates were found to check theoretical calculations for 60 min at room temperature at the dilution selected. The assays were run immediately after the collection of the blood sample, and for only 10 min hence no significant loss of activity could occur. Furthermore, the activity was found to be stoichiometric to the enzyme concentration (fig. 1) upon dilution.

### Comments

The screening test described has certain advantages over the usual assay system [6]. The test is simple, inexpensive, needs no spec for

of 1,200 subjects could be successfully screened by 8 workers within 4 days [2]. It avoids elaborate testing by the conventional technique with a very large number of samples which requires good technicians in the field [6]. As true hypocatalasemic samples detected by this technique constitute only a few percent of the large population surveyed, only a few samples need to be brought to the laboratory to be checked accurately during a large scanning process, which is easy.

The test permits simultaneous hemoglobin determination in the field, and although it is only semiquantitative, a relevant value of catalase units per gram of hemoglobin may successfully be obtained; hence it is possible to avoid false results.

### Summary

A suitable screening test for red blood cell catalase is described. The test was able to detect cases of hypocatalasemia successfully, and was easily applicable to remote field surveys for the presence of this rare inheritable disorder.

### References

- 1 TAKAHARA, S. Progressive oral gangrene, probably due to lack of catalase in the blood (acatalasemia). Report of nine cases. *Lancet* ii 1101 (1952)
- 2 BERTAN, M. Personal communication
- 3 FUNAKI, H. Thermal analysis of blood catalase reaction. *Japan J. Physiol.* 5 183 (1955)
- 4 MILLER, H. The relationship between catalase and hemoglobin in human blood. *Biochem J.* 63 275 (1958)
- 5 MIALLE, J. B. Laboratory medicine. *Hematology*, p. 656 (Mosby, St. Louis 1958)
- 6 TAKAHARA, S., HAMILTON, H. B., NZEL, J. V., KOBARA, T. Y., OGURA, Y., and NISHIMURA, E. T. Hypocatalasemia: a new genetic carrier state. *J. clin. Invest.* 37 610 (1960)
- 7 CHANCE, B. Enzyme substrate compounds. *Adv. Enzymol.* 12 153 (1951)

Authors' address: Dr P. T. ÖZAND and Dr S. ARTYINLI, Department of Biochemistry, Hacettepe University Medical School, Ankara (Turkey)

## Labri

**Progress in Medical Genetics, Vol. VII** Editors: A. G. STEINBERG and A. G. BEARD. Grune & Stratton, New York 1969. 131 p. Price: US\$ 10.75.

The 7th volume of this valuable series upholds the high standards of its predecessors. The list is varied. Four chapters provide critical reviews of the genetics of specific groups of diseases: R. B. MCCOY on the gas nutritional system; G. R. FRANK on thyroid disease; E. FOGARSWORTH on intestinal carbohydrate intolerance; and P. J. FLAXMAN on autoimmunity. F. H. FUCHS deals with histocompatibility in man, genetic and practical considerations. J. C. DAVENPORT contributes a challenging theoretical discussion on the application of bacterial genetics to the study of human genetic phenomena, one which leads him to the conclusion that the existence of regulatory genes has not been demonstrated in higher organisms and that the Jacob-Monod models of genetic control in prokaryotes do not fit the data on human genetic disease. Finally, D. H. CARR presents a survey of chromosomal abnormalities in clinical medicine which brings together in concise manner an immense array of findings in this much cultivated field. All articles are provided with extensive bibliographies and the volume ends with author and subject indexes.

Two criticisms may be directed to the editors. (1) References begin with the first author's name indented and the subsequent lines beginning with first indentation. This is a letter which easy recognition of the specific references. Why return to the method used in earlier volumes and elsewhere—starting with a non-indented first line and indented subsequent ones? (2) It would facilitate use and re-use of each chapter if it were preceded by a table of contents. The extra space needed would seem to be worth the gain.

G. STEINBERG, Editor, Cal

**Blutgerinnungsstörungen in der Geburtshilfe.** Editor: H. STAUDE. Paulistischer Verlag, Nr. 57. Karger, Basel/München/New York 1969. VI + 239 p. 67 Fig., 33 Tab., 2 Cpt. (Fr. 3). US\$ 8.40 DM 33. (70s).

Störungen der Blutgerinnung und Hämostase vor, während und nach der Geburt umfassen thrombotisch-embolische Komplikationen, schwere und dramatische Blutungen als Folge von Verbrauchskoagulopathien sowie eine Reihe von weiteren Syndromen, die in Form von Vorlesungen an der Jahrestagung der Schweizerischen Gesellschaft für Gynäkologie vor 2 Jahren diskutiert wurden. Der Band enthält 33 Abbildungen von charakteristischen, auch zahlreiche Einzelbeobachtungen zu den genannten Themen. Die Beiträge der Vorträge interessieren primär den kliniker. Insgesamt umriss der Band das gesamte komplexe Spektrum der pathogenetisch bedingten Störungen der Hämostase während der Geburtsperiode.

F. A. PATAI, Basel

**Immunology 1968.** Proceedings of the 1st Annual Conference on Immunology, Buffalo, NY, June 1968. N. R. ROSE and F. MACGRAW (ed.) Karger, Basel/München/New York 1969. XXXVIII + 311 pp. 14 fig., 91 tab. (Fr. DSF 1.50). US\$ 21.00 (70s).

In June 1968 an International Conference on Immunology was held in Buffalo to honour Prof. EMBURY WITKOWSKI and to inaugurate a new center for immunology under his direction. With his volume the 42 papers presented have been made generally accessible. As is fitting for the occasion, the papers are concerned almost entirely with immunological problems, the late Prof. Witkowski worked on mainly autoimmune and tumor

The first group of 7 papers concerns 'Chemistry and Biology of Cellular Antigens'. Prof GRABAR gives a stimulating review of methods and new applications of the immunological approach to tissue antigens. Two papers deal with endotoxins, in the first the group of WESTPHAL presents the latest data about the structure of the lipid A component. The paper by PLESZKA *et al*, introducing an experimental model of myasthenia gravis, would be better placed in the later section on autoimmunity. The second section of the book deals with 'Development and Control of the Immune Response'. GOOD and FROSTAN present, as usual, a lucid review about the relation between structure and function of the lymphoid system. The physiological control of the immune response is dealt with in 2 papers by STERZL and THORBECKE. A review by FRANKLYN about proliferative disorders of plasma cells and lymphocytes is among the other papers. In the next section on 'Blood Group and Transplantation Antigens', RACE gives first a review about red cell specificity and human genetics, which is very useful for the immunologist who is not closely concerned with this field. After 3 papers on the human HLA system, CUKROWICZ enlarges the genetic spectrum by introducing the problem of hybrid resistance and parental specific transplantation antigens.

From the section on 'Autoimmunity Models and Mechanisms' stimulating features emerge. Homologous disease becomes fashionable once more and now serves to illustrate the relationship between autoimmune diseases and malignancies of the lymphoreticular system. MELLORS takes the favourite natural model for autoimmune disease of recent years, NZB mice, and goes a step further by proposing viruses as the origin of both the autoimmune phenomena and the subsequent malignancies, with some new data. This view reconciliates many diverging facts in this and similar spontaneous models and has important implications for both genetic and aetiological considerations in human diseases such as SLE. The next section on 'Tumor Specific Antigens' is too short and incomplete around renal diseases, giving in 3 papers a nice cross section, and around autoimmune aspermatogenesis. The last section on 'Tissue Specificity and Autoimmunity' is centered to give even a glance of the variety in this large field.

The proceedings of many meetings lack coherence. This volume, however, is well organized and the main topics, tissue antigens and their implications for medicine and autoimmunity, are well covered without too much dispersion of topics. This book can be recommended to immunologists and clinicians equally.

T. L. VASILEA, Basel

---

## Varia

---

1. Oesterreichische Haematologentagung  
Wien, 23-24 Oktober 1970

Thema: Der Lymphozyt (Morphologie, Biologie, Funktion, Pathologie und Klinik der lymphatischen Reaktion)  
Kongresspräsident: Prof. Dr. R. KLUM, Wien.  
Kongress-Sekretariat: Doz. Dr. H. PIETSCHMANN, II Med. Universitätsklinik, Garnison-  
gasse 13, A 1020 Wien (Oesterreich)

## Effects of Erythropoietin and Testosterone on Erythropoiesis in Bone Marrow of Isolated Perfused Hind Limbs of Dogs<sup>1</sup>

L. A. MALGOR\* and J. W. FISHER

Department of Pharmacology, Tulane University Medical School, New Orleans, La., and  
Department of Pharmacology, University of Tennessee Medical Units, Memphis, Tenn.

Testosterone has been known for several years to stimulate erythropoiesis in experimental animals [1, 2, 3]. However, the mechanism by which this agent stimulates erythropoiesis has been the subject of much recent controversy. Androgens have also been found to be useful in the treatment of clinical anemias which are refractory to other therapeutic agents [4, 5, 6]. It seems clear that at least one action of testosterone is to stimulate erythropoietin production [7, 8, 9]. We have found that testosterone stimulates production of erythropoietin (ESF) in isolated perfused dog kidneys [10]. On the other hand, direct effects of testosterone on bone marrow erythroid cells have also been reported [11, 12]. In addition, a synergistic action of testosterone and erythropoietin has been suggested [13, 14].

In order to clarify a possible direct effect of testosterone on erythropoiesis the effects of this hormone on bone marrow cells in isolated hind limbs of dogs perfused with blood containing testosterone and/or erythropoietin were studied.

### Methods

All perfusions were performed in hind limbs from mongrel dogs weighing between 5.2 to 8.9 kg. The donor dogs used to obtain the blood which was added to the perfusion system ranged between 14 and 25 kg. All dogs used in the perfusion studies were previously heparinized with 1 mg/kg and um heparin i.v. The perfusion system contained 500 ml of blood. All surgical procedures were carried out under pentobarbital anesthesia according to techniques which have been published previously [15-20].

<sup>1</sup> Supported by USPHS grants Am-07073, and USPHS International Post Doctoral Fellowship No. TW 1165 and\* Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina.

Plasma samples were removed from the perfusion system initially and at the end of each experiment for erythropoietin assay. All plasma samples were assayed for ESF in polycythemic mice according to the procedure of Dr Gowaty *et al* [16]. Each mouse was injected subcutaneously with 0.5 ml of plasma on the 4th and 5th day following removal from the low pressure tank, injected i.v. with 0.5  $\mu$ c  $^{59}\text{Fe}$  2 days later and 48 hour  $^{59}\text{Fe}$  incorporation in RBC determined.

All hind limbs were perfused for 5-6 hours. When the perfusions were terminated the femurs were removed and bone marrow smears and cell suspension counts prepared the same as the contralateral limb according to the technique described by REKERS *et al* [17]. Blood with high levels of ESF (0.85 units/ml plasma) was obtained from dogs previously exposed to 18 hours of hypoxia (0.5 atmosphere). The same blood diluted approximately 4 times with blood from a normal donor dog was used in the perfusions with a low concentration (0.165 units/ml plasma) of ESF. A water soluble form of testosterone sodium succinate\* (0.2 and 0.1 mg/ml) was added to normal blood or used in combination with blood containing high or low levels of ESF.

The isolated hind limbs were perfused with (1) normal blood (2) normal blood containing testosterone (0.2 mg/ml) (3) blood containing a high titer of ESF (0.85 unit/ml), (4) blood containing ESF (0.85 unit/ml) and testosterone (0.2 mg/ml), (5) blood containing a low titer of ESF (0.165 unit/ml), or (6) blood containing ESF (0.165 unit/ml) and testosterone (0.1 mg/ml).

### Results

Figure 1 compares the percent change in total nucleated and total erythroid cells in all groups of isolated perfused hind limbs. A slight decrease in total nucleated cell counts was usually seen in all groups of isolated marrow perfusions, except the group containing a low dose of ESF combined with testosterone. However, perfusion of limbs with blood containing the high dose of ESF resulted in a significant ( $P < 0.05$ ) increase in erythroid cell counts. Femoral marrows perfused with blood containing a low dose of ESF showed a moderate increase in total erythroid cells. A significant increase in erythroid cell counts was seen with the combinations of the low dose of erythropoietin and testosterone, when compared with the low dose of ESF alone. Perfusion of marrows with normal blood alone or with blood containing testosterone resulted in a slight to moderate decrease in total erythroid cells.

Figure 2 shows the results of bone marrow differential analyses in each group of isolated perfused femoral marrows. Results are expressed as the percent change in pronormoblasts, basophilic normoblasts, polychromatic normoblasts and orthochromatic normoblasts. As demonstrated in figure 2, femoral marrows perfused with blood

\* Kindly supplied by Dr. JOHN BARCOCK from Upjohn Laboratories, Kalamazoo, Mich.




Fig. 1. Mean total nucleated and total erythroid cell counts in femoral marrow of isolated dog hind limbs perfused with normal blood (A) normal blood + testosterone (0.2 mg/ml) (B) blood containing ESF (0.85 unit/ml) (C) blood containing ESF (0.85 unit/ml) + testosterone (0.2 mg/ml) (D) blood containing ESF (0.165 unit/ml) (E) blood containing ESF (0.165 unit/ml) + testosterone (0.1 mg/ml) (F). The vertical lines at the top of each bar indicate standard error of the mean for each group (5-6 experiments). The broken line represents the 100 percent base line values for the initial contralateral nonperfused limb. \*Significantly different from the initial control.

containing the high dose of ESF (0.85 unit/ml), resulted in a significant ( $P < 0.05$ ) increase in pronormoblasts and basophilic normoblasts and a moderate increase in polychromatic and orthochromatic normoblasts. Perfusion of marrow with blood containing the low dose of ESF (0.165 unit/ml) also resulted in a significant ( $P < 0.05$ ) increase in pronormoblasts, a marked increase in basophilic normoblasts, and a slight increase in polychromatic and orthochromatic normoblasts. When testosterone was combined with the high dosages of ESF no significant increase in any marrow cell type was seen when compared with that of femoral marrow perfused with blood containing ESF alone. However, when testosterone was combined with the low dosage of ESF a significant decrease in pronormoblasts and significant increases in basophilic and polychromatophilic normoblasts were seen when comparisons were made with the respective marrow perfused with the low dosage of ESF alone. No significant difference was noted between erythroid cells in bone marrow from isolated






Fig. 2. Mean percent changes in pronormoblasts, basophilic normoblasts, polychromatic normoblasts and orthochromatic normoblasts in bone marrows from isolated dog hind limbs perfused with blood alone or blood containing erythropoietin and testosterone. Standard errors of the mean are represented by the vertical lines at the top of each bar. \*Significantly different from the initial control.

limbs perfused with blood alone or blood containing testosterone. A slight to moderate decrease in all marrow cell types occurred in both groups.

Figure 3 shows the results of reticulocyte counts in blood perfusates of all isolated hind limb perfusion experiments. A marked increase in reticulocyte counts was observed in the blood perfusates from all groups of hind limb perfusions containing erythropoietin. The increases in reticulocytes were significant ( $P < 0.05$ ) in all groups except the group perfused with the low dose of EPO. No change in reticulocyte counts was seen in the perfusate from isolated hind limbs perfused with normal blood alone or blood containing testosterone. Mean perfusion pressure, femoral artery blood flow, hematocrits, arterial  $O_2$  saturation, leucocyte counts and ESR concentration in plasma perfusates was monitored during all hind limb perfusions. A slight increase in the hematocrit was observed in all groups. Blood arterial oxygen saturation values were maintained near normal level throughout the perfusion. A moderate increase in arterial venous  $O_2$




Fig. 3. Reticulocyte counts in perfusates of isolated hind limbs of dogs perfused with normal blood or blood containing erythropoietin and testosterone. \*S significantly different from the initial control.

saturation difference was observed at the beginning as well as at the end of each experiment. No significant change was observed in WBC counts. A moderate decrease in ESF titers in plasma was usually seen at the end of the perfusion period in all experiments in which the blood perfusates contained an elevated level of ESF initially.

### Discussion

The present findings indicate that testosterone alone does not exert a direct stimulatory effect on bone marrow erythroid cells in the isolated perfused dog hind limb. Isolated femoral marrow perfused with blood containing testosterone did not produce a significant effect on marrow erythroid cells, when compared with that of hind limbs perfused with blood alone. On the other hand, two different dosages of erythropoietin produced an increase in erythroid cells which was proportional to the dose of erythropoietin used in the perfusion system. These findings indicate that our isolated femoral marrow perfusion system is sufficiently sensitive to respond, as early as 5 hours perfusion,

to concentrations of ESF as low as 0.165 unit per ml of blood perfusate. The moderate decrease in pronormoblasts seen during perfusion with the low dosage of ESF and testosterone may be due to an enhancement of maturation of this group of early erythroid cells. The increases seen in the basophilic and polychromatic normoblasts may also be due to the stimulatory action of ESF and testosterone on the already maturing erythroid cells. This suggestion of an effect of the combination of testosterone and ESF on erythroid cells may be support for the reports of other workers [13, 14, 19] that testosterone increases the sensitivity of erythroid cells to ESF.

We also found an increase in the rate of discharge of reticulocytes in perfusates from isolated femurs perfused with blood containing ESF. These data confirm previous observations [20, 21, 22] that ESF, in addition to its action on stem cell differentiation, is capable of stimulating reticulocyte release. Roux and Fisher [23] have also recently shown that rabbits showed an early discharge of reticulocytes after exposure to hypoxia and ESF during continuous perfusion. These findings further support the hypothesis for a secondary action of erythropoietin on the reticulocyte compartment. It has been estimated that the intermitotic generation time for each erythroid cell is about 90 hours [24, 25]. In view of these findings it is probable that the increase in reticulocyte output in our blood perfusates after only 6 hours of perfusion is due to the stem cell pool.

It is also of interest to point out that there was a significant increase in total erythroid cells in isolated femoral marrows perfused with high doses of ESF. The increase was most marked in the pronormoblasts and basophilic normoblasts. Perfusion of femoral marrows with low doses of ESF also resulted in a significant increase in pronormoblasts. These findings certainly support the concept that ESF stimulates stem cell differentiation. However, an increase in the absolute numbers of polychromatic and orthochromatic normoblasts was also observed and is further evidence for a secondary action of erythropoietin on late erythroid cells.

It seems clear from our previous studies that testosterone stimulates erythropoietin production in isolated perfused dog kidneys when the levels of renal erythropoietic factor were elevated by a previous exposure to hypoxia [10]. Accordingly, we have postulated that the erythropoietic effects of testosterone are due, at least in part, to an increase

in kidney ESF elaboration. These results may also suggest that testosterone, in addition to its effect on stimulating kidney ESF production, may exert a synergistic action with ESF on marrow erythroid cells *in vivo*.

*Acknowledgments.* The authors gratefully acknowledge the technical assistance of Mrs. JUDY PARRER YOUNG and Miss JAYNE COX in these studies.

### Summary

Testosterone alone does not exert a direct stimulatory action on bone marrow erythroid cells in the perfused hind limb of the dog. However, a slight to moderate increase in the effect of erythropoietin on erythroid cells was seen when testosterone was combined with erythropoietin in the perfusion system. The results of these studies suggest that the erythropoietic effects of testosterone alone are not due to a direct effect on erythroid cells but may be the result of a synergistic action with erythropoietin. Direct effects of testosterone alone and a more profound effect of the combination of ESF and testosterone on erythroid cells may possibly be demonstrated if the duration of perfusion could be extended over a more prolonged interval or a wider variety of dosages were employed. It is also difficult to extrapolate the present *in vivo* perfusion studies to the *in vivo* effects of testosterone reported in experimental animals and in the treatment of refractory clinical anemias which have responded to testosterone.

### References

- 1 VOLLMER, E. P. and GORDON, A. S. The effect of sex and gonadotropic hormones upon the blood picture of the rat. *Endocrinology*, Springfield 29: 828 (1941).
- 2 VOLLMER, E. P., GORDON, A. S., and CHASIFFER, H. A. Effects of hormones on erythropoiesis in the hypophysectomized rat. *Endocrinology*, Springfield 31: 619 (1942).
- 3 FRIED, W., DEGOWITZ, R., and GURNEY, C. W. Erythropoietic effect of testosterone in the polycythemic mouse. *Proc. Soc. exp. Biol.* N.Y. 117: 839 (1964).
- 4 KENNEDY, B. J. and GILBERTSEN, S. A. Increased erythropoiesis induced by androgenic hormone therapy. *New Engl. J. Med.* 257: 719 (1957).
- 5 BROOKS, J., KAHN, B. S., and MEYER, A. N. Treatment of multiple myeloma. *Cancer* 22: 140 (1967).
- 6 DIAMOND, L. H., and SHAFER, N. T. Treatment of aplastic anemia in children. *Scot. Hemat.* 4: 278 (1967).
- 7 ALEXANDER, R., VAUGHN, W. K., and RUTHELMAN, M. W. Erythropoietin excretion in man following androgens. *J. Lab. clin. Med.* 70: 777 (1967).
- 8 MIRAND, E. A., GORDON, A. S., and WENIG, J. Mechanism of testosterone action in erythropoiesis. *Nature*, Lond. 206: 270 (1965).
- 9 FRIED, W., and GURNEY, C. W. Erythropoietic effect of plasma from mice receiving testosterone. *Nature*, Lond. 207: 1160 (1965).
- 10 MALOOK, L. A., and FRUEN, J. W. Effects of testosterone on erythropoietin production in isolated perfused kidneys from hypoxic dogs. *Fed. Proc.* 27: 402 (1968).
- 11 REINER, E. H. Tissue culture of bone marrow II. Effect of steroid hormones on hematopoiesis *in vitro*. *Blood* 27: 460 (1966).

- 12 ERSLEV, A J Erythropoietin and testosterone in vitro Proc. 9th Congr int Soc Hemat, vol 3, p 143 (1962)
- 13 NAETS, J P and WITTER, M Mechanism of action of androgens on erythropoiesis Amer J Physiol 210 315 (1966)
- 14 JEMOV, J H and LOWENSTEIN, L The effect of testosterone, adrenal steroids and prolactin on erythropoiesis. Acta haemat., Basel 33 292 (1967)
- 15 FISHER, J W, ROSE, B L., COUCH, C., and MORRINGALE, W O Influence of cobalt, sheep erythropoietin and several hormones in bone marrow of isolated perfused hind limbs of dogs Blood 23 87 (1964)
- 16 DEGOWEN, R. L., HOFSTRA, D., and GURNEY, C. W The mouse with hypoxia-induced erythremia an erythropoietin bioassay animal J Lab clin Med 60 816 (1962)
- 17 REKERS, P E. and COULTER, M An haematological study of the bone marrow and peripheral blood of the adult dog Amer J med Sci 216 643 (1948)
- 18 DUNNETT, C. W A multiple comparison procedure for comparing several treatments with a control J Amer statist Ass. 50 1096 (1955)
- 19 McDONALD, T P and LANGE, R. D Effects of testosterone and erythropoietin on bone marrow cells Proc Soc. exp Biol, NY (to be published)
- 20 FISHER, J W, LAJTHA, L. G., BUTTOL, A. S., and PORTER, D. D Direct effects of erythropoietin on bone marrow of the isolated perfused hind limbs of rabbits Brit J Haemat. 11 342 (1965)
- 21 GORDON, A. S., LOBUE, J., DORNETT, B. S., and COOPER, G. W Reticulocyte and leukocyte release from isolated perfused rat legs and femurs, in JACOBSON and DOYLE Erythropoiesis, p 321 (Grune & Stratton New York 1962)
- 22 YOFFEY, J. M., JEFFREYS, R. V., OSWOLD, D. G., TURNER, M. S., TASHIR, S. C., and NIVEN, P. A. R. Studies on hypoxia VI Changes in lymphocytes and transitional cells in the marrow during the intensification of primary hypoxia and rebound Ann NY Acad. Sci 149 179 (1968)
- 23 ROSE, B. L. and FISHER, J. W Influence of nephrectomy and transfusion on the early erythropoietic effects of hypoxia Acta haemat., Basel (submitted for publication, 1969)
- 24 STOHLMAN F. Jr Observations on the kinetics of red cell proliferation in STOHLMAN Kinetics of cellular proliferation, p 318 (Grune & Stratton New York 1959)
- 25 LAJTHA, L. G. Stem cell kinetics and erythropoietin, in JACOBSON and DOYLE Erythropoiesis, p 204 (Grune & Stratton, New York 1962)

Authors addresses: Dr LUIS A. MALGOR, Catedra de Farmacologia Universidad Nacional del Nordeste, Facultad de Medicina, Corrientes (Argentina), Dr JAMES W. FISHER, Department of Pharmacology, Tulane University Medical School New Orleans, La (USA) - Reprint requests from Dr J. W. FISHER

## Effect of Uracil and 2-Thiouracil on Leucocyte Production in the Rat

J. TAYLOR

University Department of Medical Genetics, The Royal Infirmary, Manchester

The effect of 2-thiouracil (2TU) on leucocyte production is known mainly as a side effect of the therapeutic use of this compound and its methyl and propyl derivatives in the treatment of hyperthyroidism. Agranulocytosis is the most common reaction [1, 2]. It has been shown that 2TU can inhibit the mitosis of cultured human lymphocytes [3] and it may be that the fall in the white cell counts of some patients being treated with 2TU is due to its anti-mitotic effect.

The probable mode of action of 2TU is that it competes with uracil in the organism and thus blocks the pyrimidine pathways. It has been shown that in *Bacillus megaterium* the growth inhibition caused by 2TU can be reversed by the addition of equimolar amounts of uracil [4] and that the inhibition caused by 2TU in the fungus *Diplodia natalensis* can be overcome by treatment with uracil, thymine or cytosine [5]. 2TU also inhibits plant growth and this inhibition can be counteracted by uracil [6].

The experiments reported here were designed to investigate the effect of uracil and 2TU on leucocyte production in the rat.

### Materials and Methods

An albino male rat was mated with a black hooded female. When the offspring weighed 50 g they were divided into 3 colonies which were allowed to interbreed. Colony 1 was given water containing 2 mg/ml of uracil, Colony 2, water containing 2 mg/ml of 2TU and colony 3 acted as a control. No restrictions were placed on the volume of liquid drunk by the rats and they were all allowed to eat the same pellet diet. Blood samples were obtained by cardiac puncture from 10 rats from each colony. Only rats which had been exposed to treatment from conception were used.

The blood for the white cell counts was prevented from coagulating by the addition of sequestrene, diluted with 1% acetic acid and the cells were counted in an improved Neubauer counting chamber. The blood films were stained with Jenner and Giemsa stains at pH 6.4 and 200 leucocytes per film were classified into granulocytes (i.e. neutrophils, eosinophils and basophils) and lymphocytes with monocytes.

### Results

Table I shows the mean total white cell counts for each colony. Table II gives the mean differential counts for each colony together with the 95% confidence limits for the granulocytes calculated using the normal approximation to the binomial distribution [7]. Table III shows the absolute numbers of both groups of leucocytes calculated from the data of tables I and II.

### Discussion

From table I it can be seen that while the mean counts for both the uracil and 2TU colonies are lower than the control colony the ranges given by the 95% limits show considerable overlap and there is, therefore, no evidence that either uracil or 2TU had any marked effect

Table I Total white cell counts per mm<sup>3</sup>

| Colony  | Mean  | Standard deviation | 95% confidence limits |
|---------|-------|--------------------|-----------------------|
| Control | 8,875 | 1,761.9            | 5,421.7-12,328.3      |
| Uracil  | 7,719 | 1,818.2            | 4,153.3-11,282.7      |
| 2TU     | 6,281 | 2,400.3            | 1,400.1-11,161.9      |

Table II Differential white cell counts

| Colony  | Differential mean            |                 | 95% confidence limits of % granulocytes |
|---------|------------------------------|-----------------|---|
|         | Lymphocytes and monocytes, % | Granulocytes, % |   |
| Control | 83                           | 12              | 10.6-13.4                               |
| Uracil  | 76                           | 24              | 22.1-25.9                               |
| 2TU     | 90                           | 10              | 8.7-11.3                                |

Table III. White cell counts - absolute numbers per mm<sup>3</sup>

| Colony  | Lymphocytes<br>and monocytes | Granulocytes |
|---------|------------------------------|--------------|
| Control | 7810.0                       | 1055.0       |
| Uracil  | 5966.4                       | 1857.6       |
| 2TU     | 5557.9                       | 628.1        |

on the overall counts. From table II it can be seen that there is a slight reduction in the percentage of granulocytes in the 2TU colony when compared with that of the control. The chi-square calculated from a  $2 \times 2$  table between the controls and the 2TU colony mean differential counts was 0.052 using Yates continuity correction. This is not significant. The difference between both the controls and the 2TU treated rats and the uracil colony tested in this way, however, gave chi-square results of 4.100 between control and uracil ( $p < 0.05$ ) and 5.988 between 2TU and uracil ( $p < 0.025$ ). From this it is possible to conclude that the addition of uracil to the drinking water of these rats caused a significant rise in the numbers of circulating granulocytes with a corresponding decrease in the number of lymphocytes and monocytes.

From table III it can be seen that there has been a fall in the absolute numbers of lymphocytes and monocytes with both uracil and 2TU, and that the absolute numbers of granulocytes has been increased with uracil treatment and decreased with 2TU treatment.

The decrease shown in the numbers of both groups of leucocytes in the rats treated with 2TU is consistent with the agranulocytosis and mitotic inhibition referred to previously. The decrease in the absolute number of lymphocytes and monocytes in the uracil treated rats suggests the possibility that excess uracil may have some inhibitory effect on lymphocyte production. The increase in the number of granulocytes present in the uracil treated rats may have a number of explanations. When uracil is supplied to the body in this manner it may reasonably be assumed that there is unlikely to be a deficiency of the pyrimidines, uracil, thymine or cytosine and that DNA or RNA production will not be a limiting factor in cell growth and replication. It is possible that the diet supplied to the rats was such that they were uracil-deficient although there is no direct evidence that this was so.



and the control rats were certainly healthy. It should be noted, however, that in another experiment in which 5 young male albino rats were given the choice of drinking either water containing uracil or uracil-free water they chose to drink the water containing uracil.

It is possible that the effect observed was due to the oral route being used. This may have stimulated the gut flora and so indirectly induced a rise in the number of circulating granulocytes. Alternatively since it is generally agreed that the granulocytes are relatively short-lived it is possible that in conditions of pyrimidine excess they are more robust and able to survive longer in the body. It will certainly be the case that the precursor cells of the granulocytes will have a greater demand for DNA and RNA than the precursor cells of the much longer-lived lymphocytes and the change in differential count may be a reflection of the increased ability of the body to supply this demand when the animal is being fed excess uracil.

*Acknowledgments* I would like to thank the Smith Kline and French Foundation for financial support, Miss BARBARA WILSON for able technical assistance and Mrs SUSAN BROOKS for typing the manuscript.

### Summary

Inbred colonies of rats were established from sibs in which one colony was treated with uracil in their drinking water and another with 2-thiouracil. A third colony acted as control. Both treated colonies had lower average white cell counts than the control and a significant rise in the number of granulocytes in the uracil treated rats was observed.

### References

1. GOODMAN, L. S. and GILMAN, A. The pharmacological basis of therapeutics, 2nd ed (Macmillan, New York 1955)
2. WILLIAMS, R. H. Textbook of endocrinology, 3rd ed. (Saunders, Philadelphia/London 1962)
3. TINSON, J. The effect of 2 thiouracil on the division of phytohaemagglutinin-stimulated human lymphocytes *in vitro* Biochem. Pharmacol. 17 325-326 (1968)
4. HAMERS, R. Incorporation of S-35-labelled thiouracil in *Banillus rugulatus* Biochem. biophys. Acta 21 170-171 (1956)
5. KLEIN, D. T. and KLEIN, R. M. Effects of antimetabolites of nucleic acid components on the growth of *Diplodia natalensis* Plant Physiol. 30 410-413 (1955)
6. BER, A. Auxin action II The influence of thiouracil on plant growth and a specific antagonism between thiouracil and uracil. Endokrinologie 30 185-194 (1953)
7. BAILEY, N. T. J. Statistical methods in biology (English Universities Press, London 1959)

Author's address: Dr J. TINSON, University Department of Medical Genetics, The Royal Infirmary, Manchester 13 (United Kingdom)

## Heinzkörperbildung in Neugeborenenerythrozyten<sup>1</sup>

*I. In-vitro-Studien über experimentelle Bedingungen und den Einfluss von Austauschtransfusionen*

E. KLEHVALER, A. BERNAL, K. BETKE, M. KELLER, F. KOHNE  
und K. RIEGL

Departement für Kinderheilkunde des Zentrums für Innere Medizin und Kinderheilkunde  
der Universitäten Ulm und Universitätskinderklinik München

Die Denaturierung von Hämoglobin in Erythrozyten durch verschiedene oxydierende Substanzen hat die Bildung von intraerythrozytären Innenkörpern zur Folge, die durch Supravitalfärbung in Form der bekannten Heinzkörper sichtbar gemacht werden können. Ähnliche Präzipitate lassen sich auch in stromafreien Hämolysaten erzeugen [26]. Es wird allgemein anerkannt, dass Heinzkörper aus denaturiertem Globin und Oxydationsprodukten des Hämanteils bestehen [31]. Während über die Denaturierungsvorgänge im Globinmolekül sowie über die Beziehungen zur Membran brauchbare Vorstellungen entwickelt wurden [1, 24, 26, 28, 44], ist der Ablauf in einzelnen Teilschritten mit Einbeziehung des Hämanteils noch weitgehend ungeklärt [2, 5, 17, 21].

Aus frühen klinischen Beobachtungen [16, 45] geht hervor, dass Erythrozyten von Neugeborenen und Frühgeborenen im Vergleich zu Erwachsenenerythrozyten eine ausgeprägte Neigung zur spontanen Heinzkörperbildung besitzen. Dieses Phänomen kommt besonders deutlich zum Ausdruck unter der Einwirkung von bestimmten Medikamenten (Sulfonamide, Vitamin K-Analoga, Naphtalin u. a.), deren Anwendung in der frühen Säuglingszeit das Krankheitsbild der toxischen hämolytischen Innenkörperanämie auslösen kann [4, 14, 16, 42]. Erhöhte Heinzkörperempfindlichkeit von Neugeborenen konnte *in vitro* erstmals von KÜNZER *et al.* [30] nachgewiesen und von anderen Autoren bestätigt werden [1, 7, 11, 20, 39, 40, 41, 43].

<sup>1</sup> Mit Unterstützung der Deutschen Forschungsgemeinschaft (Be 100/23, KL)

Ursache dafür ist nicht befriedigend geklärt. Bislang sind in experimentellen Untersuchungen darüber hauptsächlich die Erythrozytenenzyme [Übersicht bei 10, 19] und die Beziehungen zum fetalen (HbF) bzw. adulten (HbA) Hämoglobin berücksichtigt worden [11].

In der vorliegenden Arbeit wurde die Heinzkörperbildung durch Acetylphenylhydrazin unter verschiedenen *in-vitro*-Bedingungen durchgleichend in Erythrozyten von Neugeborenen und Erwachsenen untersucht. Auf der Grundlage dieser Ergebnisse prüften wir Blutproben von Neugeborenen vor und nach Austauschtransfusion auf ihre Heinzkörperempfindlichkeit. Die zuletzt genannten Experimente sollten zur Klärung der Frage beitragen, ob Spendererythrozyten von Neugeborenenerythrozyten erwerben können. Aus den Ergebnissen lässt sich ableiten, dass die Heinzkörperbildung in Erwachsenen- und Neugeborenenerythrozyten prinzipiell gleich abläuft. Die Unterschiede sind quantitativer Natur. Weiterhin wird gezeigt, dass das Phänomen der verstärkten Innenkörperbildung nicht unbedingt ein Charakteristikum fetaler Erythrozyten<sup>2</sup> ist.

### Material und Methoden

Sämtliche für die Untersuchungen verwendeten Blutproben wurden aus Vergleichsgründen zur gleichen Zeit venös abgenommen und mit  $\frac{1}{10}$  Volumen Natriumzitat (3.8%) versetzt. Die Erythrozytenkonzentrationen zu vergleichender Proben wurden einander über die Hämatokritbestimmung durch Verdünnung mit dem jeweiligen Zitratplasma angeglichen. In den Versuchen im Zusammenhang mit dem jeweiligen Zitratplasma ACD-Stabilisator verwendet.

Das  $\beta$ -Acetylphenylhydrazin (APH) wurde entsprechend dem Vorgehen von BRUTLER *et al* [6] als 1% Lösung in isotonischem Kochsalz Phosphat pH 7.4 verwendet und den Blutproben in einer Endkonzentration von 7,5 mM oder 15,0 mM zugesetzt. Die Inkubation erfolgte bei 37°C im Wasserbad.

Proben zur Herstellung von Heinzkörperpräparaten wurden in halb- bis einständigen Intervallen entnommen und zur Färbung in der feuchten Kammer mit 0,5% Nilblausulfat in 0,9% Kochsalzlösung über 20 Minuten inkubiert. Die Zählung Heinzkörperhaltiger Erythrozyten wurde mit der Zuhilfenahme eines quadratischen Zählfensters vorgenommen. Insgesamt wurden pro Präparat 1000 Zellen ausgezählt.

Bei den Untersuchungen über die Abhängigkeit der Heinzkörperbildung von der Wasserstoffkonzentration wurde die pH-Messung im Gesamtblut und in abzentrifugierten Erythrozyten im Astrup-Radiometer vorgenommen. Die Einstellung von Erythrozytensuspensionen auf verschiedene pH-Stufen (pH 6,3–6,4, 7,4 und 6,4) erfolgte durch wiederholtes Waschen mit entsprechenden isotonischen Phosphat NaCl-Puffern. Die APH-Lösungen wurden für diese Versuche auf das gleiche pH eingestellt.

<sup>2</sup> Nomenklatur: Fetal Erythrozyt = Erythrozyt des Neugeborenen unabhängig vom Gehalt an HbF (= HbF-Zelle) oder HbA (= HbA-Zelle)

Die Abhängigkeit der Heinzkörperbildung von der Gaseinwirkung wurde in Schütteltonometern unter ständigem Durchfluss von definierten Gasgemischen (100% O<sub>2</sub>, 90% O<sub>2</sub> + 10% CO<sub>2</sub>, 70% O<sub>2</sub> + 30% CO<sub>2</sub>, Luft = 20% O<sub>2</sub>, 100% Stickstoff) geprüft. Blutproben von APH-Lösungen wurden 45 Minuten lang vor Versuchbeginn mit dem entsprechenden Gasgemisch in getrennten Tonometern equilibriert. Danach erfolgte die Zugabe der APH-Lösung zu der Blutprobe mittels Spritze durch einen Durchstechkorken.

Bei der überwiegenden Anzahl der Untersuchungen an Blutproben von Kindern mit Morbus haemolyticus neonatorum (MHN) vor und nach Austauschtransfusion (AT) diente neben dem jeweiligen Spenderblut in ACD-Lösung eine weitere Erwachsenenblutprobe als Kontrolle und Bezugswert für spätere Verlaufuntersuchungen. Insgesamt konnten Blutproben von 11 Neugeborenen vor und bis zu 23 Tagen nach der Austauschtransfusion untersucht werden.

Als Masssstab für die Bildungsgeschwindigkeit von Heinzkörpern wurde der Zeitpunkt gewählt, an dem 50% der Erythrozyten Heinzkörper enthalten (50% HK-Wert). Keine Berücksichtigung fand dagegen die Zahl der Heinzkörper pro Einzelerythrozyt. Als Latenzzeit wird jene Zeitspanne bezeichnet, die vergeht, bis in 5% der Erythrozyten Heinzkörper nach Beginn der APH-Inkubation auftreten (vgl. Abb. 1).

## Ergebnisse<sup>a</sup>

**1 Prinzipieller Ablauf der Heinzkörperbildung** Untersucht man die Heinzkörperbildung durch APH in Abhängigkeit von der Zeit unter den Bedingungen einer einfachen *in vitro*-Inkubation bei 37°C unter Luftatmosphäre ohne die Ansätze dauernd zu schütteln, dann ergibt sich folgender Ablauf (Abb. 1). Nach einer Latenzzeit erfolgt eine rasche Zunahme der Zahl der Erythrozyten mit Heinzkörpern. Etwa 30 Minuten nach Ende dieser Latenzzeit lassen sich im Durchschnitt in 50% der Erythrozyten (50% HK-Wert) Heinzkörper nachweisen, der 100% HK-Wert wird etwa innerhalb einer Stunde erreicht. Dieser am Ende der Latenzzeit beginnende Ablauf ist in Erwachsenen- und Nabelschnurerythrozyten prinzipiell gleich. Die Unterschiede in der Geschwindigkeit der Heinzkörperbildung sind allein durch die Dauer der Latenzzeit gegeben. Diese ist für Erwachsenenerythrozyten vierfach länger als für Nabelschnurerythrozyten. Die in Tabelle I dargestellten Daten wurden aus Ergebnissen von je drei Versuchen mit zwei verschiedenen APH-Konzentrationen errechnet. Für die 50% HK-Werte ergibt sich unter Einbeziehung der Latenzzeit eine etwa dreifach raschere Heinzkörperbildung in Nabelschnurerythrozyten, bei den 100% HK-Werten ist die Differenz gegenüber Erwachsenenerythrozyten mehr als doppelt so gross (Tabelle I).

<sup>a</sup> Die Ergebnisse wurden teilweise den Dissertationen von A.B. und M.K. entnommen.




Abb 1 Ablauf der Heinzkörperbildung in Nabelschnur- und Erwachsenenerythrozyten Luftatmosphäre APH 7,5 mm in der Endkonzentration Latenzzeit, 50% und 100% HK-Werte sind eingezeichnet

Tabelle I Vergleich der Latenz- und Bildungszeit von Heinzkörpern in Nabelschnur- und Erwachsenenblut unter zwei verschiedenen APH Konzentrationen Die in Minuten angegebenen Werte stellen Mittelwerte aus je 3 Versuchen dar

|                                 | Nabelschnurblut |      | Erwachsenenblut |      |
|---------------------------------|-----------------|------|-----------------|------|
| APH Konzentration mm            | 7.5             | 15.0 | 7.5             | 15.0 |
| Latenzzeit (min) 5% HK Wert     | 60              | 30   | 240             | 125  |
| Bildungszeit (min) 50% HK Wert  | 90              | 50   | 255             | 150  |
| Bildungszeit (min) 100% HK Wert | 120             | 90   | 300             | 210  |

2 Abhängigkeit der Heinzkörperbildung von der H-Ionenkonzentration Die Ergebnisse der vergleichenden Untersuchungen an Nabelschnur- und Erwachsenenblut während der Dauer der APH-Inkubation sind in Form der Mittelwerte aus je 5 verschiedenen Ansätzen in Abbildung 2 dargestellt Während die Ausgangswerte in beiden Blutproben mit pH 7,22 und 7,23 noch dicht zusammen liegen, erfolgt in den ersten 30 Minuten nach Beginn der APH-Inkubation vor allem in den Ansätzen mit Erwachsenenblut eine deutliche pH-Zunahme Für das Nabelschnurblut liegen die pH-Werte über die ganze Versuchsdauer mit 0,1 pH-Einheiten konstant niedriger. Die Annäherung an die Werte des Erwachsenenblutes erfolgt 3½ Stunden nach Beginn der




Abb. 2 Veränderungen und Differenzen der Wasserlöslichenkonzentration in Ansätzen aus Erwachsenen- und Nabelschnurblut während der Inkubation mit Acetylphenylhydrazin.

**Inkubation** Diese Entwicklung gilt nicht nur für das pH der gesamten Blutprobe, sondern auch für die Erythrozyten und das Plasma, deren pH Werte in diesen Ansätzen getrennt kontrolliert wurden.

Werden Erythrozytensuspensionen durch wiederholtes Waschen mit isotonischem Phosphatpuffer auf differente Ausgangs pH Werte gebracht, dann ist im Prinzip die gleiche Entwicklung zur Annäherung an den physiologischen pH Wert zu erkennen. Nabelschnur- und Erwachsenenerythrozyten zeigen dabei keine prinzipiellen Unterschiede (Abb. 3). Die quantitative Auswertung der Heinzkörperpräparate in diesen Versuchen ergab ausserdem eine grössere Geschwindigkeit der Heinzkörperbildung in höheren pH Bereichen. Nabelschnur- und Erwachsenenerythrozyten zeigten dabei ein gleichsinniges Verhalten in Form einer Verkürzung der Latenzzeit (Abb. 4).

**3 Einfluss der Sauerstoffspannung auf die Heinzkörperbildung** Verglichen wurde in dieser Versuchsserie die Heinzkörperbildung mittels APH in Erwachsenen- und Nabelschnurerythrozyten in Gasmischungen, die Sauerstoff in einer Konzentration von 100 bis 0% enthielten. Die APH Konzentration in den Ansätzen betrug 15 mM. Aus den Kurvenverläufen in Abbildung 5 geht hervor, dass unter Abwesenheit von Sauerstoff (reine Stickstoffatmosphäre) sowohl in Erwachsenen- als auch in Nabelschnurerythrozyten über einen Zeitraum von 4½ Stunden keine Heinzkörperbildung erfolgt. Höhere Sauerstoffkonzentrationen beschleunigen die Bildung von Heinzkörpern ganz erheblich.




Abb 3 Veränderungen der Wasserstoffionenkonzentration in Ansätzen mit verschiedenem Ausgangs-pH während der APH Inkubation A=Erwachsenenblut NS=Nabelschnurblut

In einer Atmosphäre von 92% Sauerstoff mit 8%  $\text{CO}_2$  sind noch Unterschiede in der Heinzkörperbildung zwischen Erwachsenen- und Nabelschnurblut nachzuweisen. Bei 96% und 100% Sauerstoff verläuft der Prozess so rasch, dass Differenzen zwischen beiden Blutproben unter den gegebenen APH-Konzentrationen nicht mehr messbar sind. Die Zunahme der Geschwindigkeit der Heinzkörperbildung erfolgt immer nur über eine Verkürzung der Latenzzeit. Nabelschnur- und Erwachsenenerythrozyten verhalten sich dabei unter den verschiedenen Gasbedingungen prinzipiell gleich.

4 Heinzkörperbildung in Erythrozyten von Neugeborenen vor und nach Austauschtransfusion. Insgesamt wurden in dieser Serie die Blutproben von




Abb 4 Abhängigkeit der Geschwindigkeit der Heinzkörperbildung vom Ausgangs-pH. Gleichzeitig durchgeführte Untersuchungen bei pH 8,2 zeigten eine etwas raschere Heinzkörperbildung als bei pH 7,4. Diese Ergebnisse und der Übersicht halber nicht eingezeichnet. A (gestrichelte Kurve) = Erwachsenenblut, NS (durchgezogene Kurve) = Nabelschnurblut.




Abb 5 Darstellung der Beziehungen zwischen Sauerstoffspannung (20-96%  $O_2$ ) und Geschwindigkeit der Heinzkörperbildung in Erwachsenen (A) und Nabelschnurerthrozyten (NS). Die bei 3 und 4 Stunden Inkubation eingezeichneten Quadrate geben die fehlende Heinzkörperbildung in Sauerstoffarmosphäre an.

11 Kindern mit Morbus haemolyticus neonatorum (MHN) infolge Rh-Inkompatibilität untersucht. APH wurde in einer Endkonzentration von 7,5 mm verwendet. Die Inkubationen erfolgten bei 37°C in






Abb. 6




Abb. 7

Abb. 6 Veränderung der Geschwindigkeit der Heinzkörperbildung im Spenderblut verschiedene Zeiten nach Austauschtransfusion

Abb. 7 Verhalten der Heinzkörperbildung nach zweimaliger Austauschtransfusion (1) Lage der Kurve 12 Stunden nach erstem Austausch, (2) Heinzkörperbildung unmittelbar nach zweitem Austausch Fünf Tage später (3) entspricht die Heinzkörper-Bildungsgeschwindigkeit der in fetalen Erythrozyten (4) vor Austauschtransfusion

normaler Luftatmosphäre. Dabei konnten folgende Veränderungen im Ablauf der Heinzkörperbildung nachgewiesen werden (Abb. 6-8): Erythrozyten von Neugeborenen mit MHN vor Austausch zeigen keine Unterschiede in der Heinzkörperempfindlichkeit gegenüber Erythrozyten von normalen Neugeborenen. Desgleichen stimmen die Werte aus Spenderkonservenblut mit denen anderer Erwachsenenblutkontrollen überein. Nach der Austauschtransfusion ändert sich die Heinzkörperempfindlichkeit der transfundierten Erwachsenenerythrozyten derart, dass sie sich in zunehmendem Maße der von Neugeborenenerythrozyten angleicht (Abb. 6). Die erhöhte Empfindlichkeit zur Heinzkörperbildung ist bereits direkt im Anschluss an die Austauschtransfusion nachzuweisen und nimmt innerhalb der nächsten Stunden bzw. 3-4 Tage zu. Bei drei Kindern wurden Kontrollen bis zu 28 Tagen nach der Austauschtransfusion durchgeführt, wobei in keinem Fall wieder eine rückläufige Entwicklung in Form einer Angleichung an die Erwachsenenwerte nachzuweisen war. Auch nach zweimaliger Austauschtransfusion (Abb. 7) verhalten sich die trans-

e  
h  
m  
mpe  
ant  
sche  
wesen.

ults and  
n is prin-  
d cells are  
ation. The  
s following  
g hypothesis  
ped content

n of hemoglobin  
l  
n the presence of  
ature, Lond 173

Ant Proc Soc exp

enen, in SCHUBOTZ  
Berlin/Göttingen/Hel

vanum and significance  
1093 (1962)  
t of primaquine VI An  
clin Med 45 40 (1955)  
formation Acta haemat,




Abb. 8 Schematische Darstellung der Heinzkörperbildung in Erythrozyten mit unterschiedlichem Hämoglobinemuster bei Neugeborenen vor und nach Austauschtransfusion. Die Zahl der in den Erythrozyten eingezeichneten Heinzkörper soll das Maß für die Geschwindigkeit der Heinzkörperbildung darstellen. Die Bezeichnungen «Adult» und «Fetal» beziehen sich auf die Herkunft bzw. Bildungsorte der Erythrozyten.

ten praktisch ausgeschlossen werden, da ein zweimaliger Blutaustausch den Anteil der fetalen Zellen auf etwa 5% vom Ausgangswert reduziert. Es ist demnach sehr wahrscheinlich, dass der transfundierte Erwachsenenerythrozyt in der neuen Umgebung andere Eigenschaften als vorher erwirbt. Dafür können theoretisch Veränderungen an allen Zellanteilen (Hämoglobin, Enzyme oder Membran) verantwortlich gemacht werden. Ein Wechsel im Hämoglobinemuster der Erythrozyten ist nicht denkbar. Dagegen sind Veränderungen von Enzymaktivitäten ebenso wie Änderungen in der chemischen Zusammensetzung der Zellmembran durchaus diskutierbare Möglichkeiten.

Unsere vorläufige Arbeitshypothese besteht darin, sekundär auftretende Veränderungen des Phospholipidgehaltes in der Membran der transfundierten Erythrozyten anzunehmen. Dies ist vorstellbar, weil einmal die Phospholipide zwischen Plasma und Erythrozytenmembran austauschbar sind [13, 34, 38]. Zum anderen erfolgt in der Membran wahrscheinlich keine *de novo*-Synthese von Phospholipiden [15, 32]. Darüber hinaus sind Unterschiede im Phospholipidgehalt des Serums und der Erythrozytenmembran von Neugeborenen im Vergleich zu Erwachsenen beschrieben worden, wobei die Angaben verschiedener Autoren allerdings erheblich variieren [3, 22, 37]. Inwieweit die nicht veränderte Lipidperoxydation von Neugeborenen-



- BRACCI, R., CORVAGLIA, E., PRINCI, P., BETTINI, F., and PINDINELLI, C. The role of GSH peroxidase deficiency in the increased susceptibility to Heinz body formation in the erythrocytes of newborn infants. *Ital J Biochem* 18 100 (1969)
- BRENNER, S. and ALLISON, A. C. Catalase inhibition: a possible mechanism for the production of Heinz bodies in erythrocytes. *Experientia* 9 381 (1953)
- BROWN, A. K. Erythrocyte metabolism and hemolysis in the newborn. *Pediatr Clin Amer* 13 879 (1966)
- BROWN, A. K. and BEUTER, S. L. Spontaneous Heinz body formation in full term and premature infants. *Amer J Dis Child* 102 589 (1961)
- COHEN, G. and HOCHSTEIN, P. Glutathione peroxidase: The primary agent for the elimination of hydrogen peroxide in erythrocytes. *Biochemistry* 2 1420 (1963)
- COOPER, R. A. and JANDL, J. H. Physiologic and pathologic alterations of red cell lipids, membrane area, and shape, in DEUTSCH, GERLACH and MOSER. *Stoffwechsel und Membranpermeabilität von Erythrocyten und Thrombocyten*, p 376 (Thieme, Stuttgart 1968)
- DAWSON, J. P., THAYER, W. W., and DESFORCES, J. F. Acute hemolytic anemia in the newborn infant due to naphthalene poisoning. Report of two cases, with investigations into the mechanism of the disease. *Blood* 13 1113 (1958)
- VAN DEENEN, L. L. M. and DE GIER, J. Chemical composition and metabolism of lipids in red cells of various animal species, in BISHOP and SURGENOR. *The red blood cell*, p 243 (Academic Press, New York/London 1964)
- GASSER, C. Die hämolytische Frühgeburtenanämie mit spontaner Innenkörperbildung. *Acta* 8 491 (1953)
- GOLDSTEIN, G. W., HAMMAKER, L., and SCHMID, R. The catabolism of Heinz bodies. ein neues Syndrom, beobachtet an 14 Fällen. *Helv paediat* 8 491 (1953)
- GOLDSTEIN, G. W., HAMMAKER, L., and SCHMID, R. The catabolism of Heinz bodies. An experimental model demonstrating conversion to non bilirubin catabolites. *Blood* 31 388 (1968)
- GRÖSCHNER, E. Erythrozytenkatalase bei Frühgeborenen und reifen Säuglingen in der Neugeborenenperiode, med. Diss. Freiburg (1960)
- GROSS, R. T., BRACCI, R., RUDOLPH, N., SCHROEDER, E. A. R., and KOCHEN, J. A. Hydrogen peroxide toxicity and detoxification in the erythrocytes of newborn infants. *Blood* 29 481 (1967)
- GROSS, R. T. and SCHROEDER, E. A. R. The relationship of triphosphopyridine nucleotide content to abnormalities in the erythrocytes of premature infants. *J Pediat* 63 823 (1963)
- HARLEY, J. D. and MAUER, A. M. Studies on the formation of Heinz bodies II The nature and significance of Heinz bodies. *Blood* 17 418 (1961)
- HÜRTER, P. and SCHROEDER, W. Erythrocyte and plasma phospholipids. Studies in adults, neonates and in patients with Rh-erythroblastosis and haemolytic anaemias. *Europ. Soc. paediat. Res.*, Interlaken, Sept 1969
- IRLE, U. Akute hämolytische Anämie durch Naphtalin Inhalation bei zwei Frühgeborenen und einem Neugeborenen. *Dtsch. med. Wschr.* 89 1798 (1964)
- JACOB, H. S., BRAUN, M. C., DAGUE, J. V., CARRELL, R. W., and LEHMANN, H. Abnormal haem binding and globin SH group blockade in unstable haemoglobins. *Nature, Lond* 218 1214 (1968)
- JACOB, H. S., INGBAR, S. H., and JANDL, J. H. Oxidative hemolysis and erythrocyte metabolism in hereditary acatalasia. *J. clin. Invest.* 44 1187 (1965)
- JANDL, J. H., ENGLE, L. K., and ALLEN, D. W. Oxidative hemolysis and precipitation of hemoglobin I. Heinz body anemias as an acceleration of red cell aging. *J. clin. Invest.* 39 1818 (1960)
- JONES, P. E. H. and MCCANCE, R. A. Enzyme activities in the blood of infants and adults. *Biochem. J.* 45 464 (1949)

28. JUNG R. Über toxische Schädigungen an Erythrocyten. *Min. Wochr.* 24: 459 (1917)
29. KÖTZER W. Zur Frage der Heinzkörperbildung in Neugeborenenerythrocyten. *Folia haemat.*, Lpz. 73: 405 (1956)
30. KÖTZER, W. AMER, E. und SCHWITZER D. Untersuchungen zur Heinzkörper-Bildung in Neugeborenenerythrocyten. *Z. Kinderheilk.* 71: 652 (1954)
31. KUYMOTO S. and NAKAJIMA, T. The constitution of Heinz bodies. *Arch. exp. Path. Pharmacol.* 239: 266 (1958)
32. MARAS, P. A., GELLHORN A., and KEMON C. Lipid synthesis in human leucocytes, platelets and erythrocytes. *J. biol. Chem.* 235: 2579 (1960)
33. MARTI H. R. Normale und anormale menschliche Hämoglobine. p. 90 (Springer Berlin-Heidelberg 1963)
34. MULDER E. and VAN DEKENEN L. L. M. Metabolism of red cell lipids. I. Incorporation *in situ* of fatty acids into phospholipids from mature erythrocytes. *Biochim. biophys. Acta* 17: 106 (1955)
35. NICHOLAS, T. F., BOLLES T., and ALLEN D. M. Erythrocyte glutathione peroxidase deficiency and hemolytic disease of the newborn infant. *J. Pediat.* 72: 319 (1965)
36. NICHOLAS, T. F., MALDONADO N., BARGETT-CHENTAR A., and ALLEN D. M. Homozygous erythrocyte glutathione-peroxidase deficiency. Clinical and biochemical studies. *Blood* 31: 164 (1969)
37. NIKKHOFF R. C. Erythrocyte lipids in the neonate. *Pediat. Res.* 2: 172 (1963)
38. REED C. F. Phospholipid exchange between plasma and erythrocytes in man and the dog. *J. clin. Invest.* 47: 749 (1958)
39. SAMONTE G., BORRONE, C., e ROVERI S. Suscettibilità degli eritrociti a formare corpi di Heinz *in vitro* in condizioni normali (neonati e lattanti) e patologiche (favismo e talassemia). *Boll. Soc. ital. Biol. sper.* 31: 1571 (1958)
40. TJOA, G. T. Untersuchungen über Heinzkörperbildung und Glutathionstabilität in Erythrocyten von Neugeborenen. *Z. Kinderheilk.* 81: 434 (1960)
41. ULSTRUP L., KERNHAUT E., and BETKE K. The behaviour of foetal haemoglobin in the enhanced Heinz body formation in red cells of newborn infants. *Acta paediat. scand.* 55: 473 (1966)
42. VALARA, T., DOXIADIS, S. A., and FEMAS P. Acute hemolysis due to naphthalene inhalation. *J. Pediat.* 63: 904 (1963)
43. VERT M. Der Einfluss von Naphthohydroxycondensaten (wasserlöslichen Vitamin A-Ernährungspräparaten Synkavit) auf Erythrocytenabbau und -regeneration bei Frühgeburten und auf das Glukuronidbildungsvermögen der Leber *in vitro*. *Schweiz. med. Wochr.* 67: 969 (1958)
44. WALLER H. D. and LÖHR G. W. Neue Ergebnisse zum Mechanismus der Heinzkörperbildung in Erythrocyten. *Folia haemat.* N. F. 8: 1 (1963)
45. WELLS H. Innenkörperbildung durch Hkoun und spontane Innenkörperbildung. *Schweiz. med. Wochr.* 77: 243 (1947)
46. ZIMMERMAN W. H. An *in vitro* abnormality of glutathione metabolism in erythrocytes from normal newborns. Mechanism and clinical significance. *Pediatrics* 23: 18 (1959)

Adressen der Autoren: Prof. Dr. E. KERNHAUT, Dept. für Innere Medizin und Kinderheilkunde der Universität, Prittwitzstrasse 43, D-79 Ulm; Dr. A. BERNAL, Prof. Dr. K. BETKE, cand. med. M. KELLER, Dr. E. KOHN, und Prof. Dr. K. REIGEL, Univ.-Kinderklinik, Landwurmstrasse 4, D-8 München (Deutschland)

## The Activity of Glutathionperoxydase, Glucose-6-phosphate-dehydrogenase and Glutathionreductase in Sphaerocytes<sup>1</sup>

O. BUTENANDT

Universitätskinderklinik München (Direktor Prof. H. BERTKE), München

The hereditary spherocytosis does not depend – as far as we know – on an intracellular enzyme defect, but on a primary defect of the membranes [4, 10]. Since the reticulocytes in the blood increase during intravital haemolysis in that disease, this gives a variable system which may serve for an investigation of the activity of different enzymes during aging of the erythrocytes. Observations concerning the glucose-6-phosphate dehydrogenase (G-6-PDH), the glutathion reductase (GR) and other enzymes in blood rich in reticulocytes are published, but not concerning the glutathion-peroxydase (GSH-PX). Therefore, it seemed justified to investigate this.

### *Material and Methods*

The activity of the G-6-PDH (1.1.1.49)<sup>2</sup> was measured using the enzyme kit produced by Biochemica Boehringer, Mannheim. The method follows the description by KORNBERG and HORACEK [5]. The activity of the GR (1.6.4.2)<sup>2</sup> was determined according to BEUTLER and LEE [3], and the GSH-PX (1.11.1.2)<sup>2</sup> according to PAGIA and VALENTINE [7]. All biochemical reagents were delivered by Boehringer Mannheim. Perhydrol p.a. ( $H_2O_2$ ) was purchased from E. Merck AG, Darmstadt. The enzyme determinations were performed under constant temperature of 25°C in cuvettes of 1.0 cm lightpath at 340 nm in a photometer 'Eppendorf'. All enzyme activities are given in micromol substrat turnover in 1 min. Each single value is based on a double determination.

The erythrocytes were washed 3 times with saline 0.9% and the leucocytes were removed with the supernatant. Haemolysis was achieved by adding an equal amount of distilled water to the concentrated erythrocytes followed by deep freezing and thawing. The supernatant obtained after centrifugation was used for enzyme determinations after

<sup>1</sup> Supported by the 'Deutsche Forschungsgemeinschaft

<sup>2</sup> Enzyme commission list of enzymes 1965

diluting it to a haemoglobin content of 0.5 g%. The activity, obtained by this way for 1.0 g Hb, was converted to the activity for  $10^{11}$  erythrocytes.

Determinations of enzyme activities were done on several occasions in 6 patients with hereditary sphaerocytosis, 5 patients (2 adults, 3 children) belong to 1 family.

Patient E.T., female, 8 years of age. Enzymes were studied during a haemolytic crisis before extirpation of the spleen as well as during convalescence. At the time of the first examination the reticulocytes were elevated to 45%, increasing further during the next days to 72%. After extirpation of the spleen the reticulocytes decreased to 1.3%.

Family M.Sch. Both adults (=siblings) as well as the 10 year old daughter of one of them had undergone splenectomy before because of haemolytic crisis. No haemolytic process was present when the blood was checked for enzymatic activity, the reticulocytes were not elevated (3-4%) but the blood smear showed typical sphaerocytes. Two other children, aged 7 years (=cousins) were hospitalized for splenectomy because of recurrent haemolytic processes. Enzymes were studied before and after splenectomy. The reticulocytes were 25% and 29% respectively. After the operation they came down to 1-5%.

### Results

An abnormal activity of enzymes was not found in sphaerocytosis as long as no haemolytic process was present. During the time of an increased blood turnover (fall of the haemoglobin content, increased bilirubin and increased reticulocyte count) the activity of the G-6-PDH was increased on an average of 48%, of the GR of 35%, and the activity of the GSH-PX on an average of 58%. Table I shows the results in detail. For comparison, the enzyme activities were measured in erythrocytes of 25 healthy children of the same age as the affected children. The difference between the enzyme activity during active haemolysis and the enzyme activity at other times is highly significant for the GSH-PX ( $P < 0.01$ ) and less significant for G-6-PDH ( $P < 0.05$ ) and the GR ( $P < 0.05$ ). Figure 1 demonstrates the course of the retic-

Table I Mean values and standard deviation of enzyme activities in erythrocytes ( $\mu\text{Mol}$  substrate turnover /  $10^{11}$  erythrocytes per minute)

|         | Healthy persons<br>n=25 | Patients with sphaerocytosis<br>with out      with<br>increased reticulocyte counts<br>n=8            n=6 |      |
|---------|-------------------------|---|------|
| G-6-PDH | 14.0 $\pm$ 2.0          | 13.5  | 18.8 |
| GR      | 10.6 $\pm$ 2.3          | 9.8   | 13.2 |
| GSH-PX  | 200 $\pm$ 30            | 239   | 320  |






Fig. 1 Reticulocytes and erythrocyte enzymes during a haemolytic crisis in a child with hereditary spherocytosis

ulocyte count, and the enzyme activities in one patient. A certain parallelism between enzyme activity and reticulocyte count is present.

Following the procedure described by Wirtz *et al* [11] fractions rich in reticulocytes and others poor in reticulocytes were obtained by centrifugation at  $20,000 \times g$ . At the bottom the fraction poor in reticulocytes, and at the top the fraction rich in reticulocytes can be found. The two fractions were treated like the whole blood. In the top fraction (over 15% reticulocytes) the activities were higher than in the bottom fraction (less than 10% reticulocytes). The results are given in table II.

### Discussion

The basic defect in hereditary spherocytosis concerns the membrane of the cells and manifests itself in an increased permeability for sodium [10]. No abnormal enzyme activities are known. Also the enzyme content of spherocytes does not differ from normal erythrocytes in our investigation. The increase of the G 6-PDH and the GR together with an increased hematopoiesis, documented by an elevation of the reticulocytes, has been described [11]. An increased activity

Table II Enzyme activities in fractions with high and low reticulocyte counts ( $\mu\text{Mol}$  substrate turnover /  $10^3$  erythrocytes per minute)

|         | Fractions with less than 10% reticul. | Fractions with more than 15% reticul. |
|---------|---------------------------------------|---------------------------------------|
| G-6-PDH | $13.9 \pm 2.4$                        | $18.6 \pm 4.3$                        |
| GR      | $10.3 \pm 3.1$                        | $17.9 \pm 3.8$                        |
| GSH PA  | $203 \pm 21$                          | $330 \pm 65$                          |

ty of erythrocytic enzymes points to a decreased mean age of erythrocytes, produced by a premature haemolysis of the old cells or by an augmented haematopoiesis [6]. Since the GSH PA is coupled to the redox system 'Glutathion' as close as the GR and secondarily to the GR also the G-6-PDH - it is not astonishing to find a similar behaviour of all three enzymes. In the investigations with fractions enriched in reticulocytes it was demonstrated, that a different content of enzymes in younger and older reticulocytes can be responsible for the differences found in the specimens of our patients. Preserving erythrocytes, one can find a slow decrease of the activity of different enzymes also *in vitro* [1, 7, 8].

The poor separation of the reticulocytes from the sphaerocytes received by us is remarkable. Usually it is possible to lower the number of reticulocytes to less than 2.5% in the bottom fraction [7]. But it is possible that under the chosen conditions no sufficient separation of reticulocytes and sphaerocytes can be achieved, since both types of cells are more similar to each other in certain qualities, i.e. the shape than reticulocytes and erythrocytes [9].

### Summary

The activities of glutathionperoxydase, glucose-6-phosphatdehydrogenase and glutathionreductase show normal values in sphaerocytes. Elevated activities of all enzymes appeared combined with reticulocytosis during increased haematopoiesis. Reticulocytes contain a greater activity of all three enzymes than older erythrocytes.

### References

- 1 ALLBON A. S. and BURN G. P. Enzyme activity as a function of age in the human erythrocytes. *Brit. J. Haemat.* 1: 297 (1955).
- 2 BETKE K., BALZ A., KLEINHAUER E. and SCHOLZ P. Methämoglobingehalt, Methämoglobinreduktion und Sauerstoffverbrauch in jungen und alten Erythrozyten. *Blut* 6: 203 (1960).

- 3 BEUTLER E. and YEH M K Y Erythrocyte glutathione reductase *Blood* 21 573 (1963)
- 4 JACOB, H S and JANDL, J H Increased cell membrane permeability in the pathogenesis of hereditary spherocytosis *J clin Invest* 43 1704 (1964)
- 5 KORNBERG, A and HORECKER, B L. *Methods in enzymology*, vol 1 (Acad Press, New York 1955)
- 6 MICHOT, F und MARTI H R. Nachweis einer erhöhten Glukose-6-Phosphatdehydrogenase-Aktivität der Erythrozyten mittels Farbreaktion *Klin Wschr* 42 1028 (1964)
- 7 PAGLIAT, D E. and VALENTINE, W V. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase *J Lab. clin. Med* 70 153 (1967)
- 8 SASS, M D, VORLANGER, D, and SPEAR, P B. Enzyme activity as an indicator of red cell age *Clin chim Acta* 10 21 (1964)
- 9 WALLER, H D, SCHLEGEL, B, MÜLLER, A A und LÖHR, G W. Das Reticulozytenvolumen *Klin Wschr* 33 893 (1959)
- 10 WOOD, R. L. and BOWDLER, A J. Metabolic dependence of the critical hemolytic volume of human erythrocytes relationship to osmotic fragility and autohemolysis in hereditary spherocytosis and normal red cells *J clin Invest* 45 1137 (1966)
- 11 WITT, I, HERDAN, M und KÜTZER, W. Vergleichende Untersuchungen von Enzymaktivitäten in reticulozytenreichen und reticulozytenarmen Fraktionen aus Neugeborenen und Erwachsenenblut *Klin Wschr* 46 149 (1968)

## Homozygous Hemoglobin D Punjab

S. ÖRSÖZÜ

Department of Pediatrics Hacettepe University School of Medicine Ankara

Hemoglobin (Hb) D was first described in a patient with atypical hemolytic anemia who was a double heterozygote [1]. Biochemically Hb D is heterogenous and so far it has been found to occur in 4 forms: heterozygous Hb D trait, Hb S D disease, Hb D thalassemia and homozygous Hb D disease. The last form is sufficiently rare to warrant this report.

### Methods

Hemograms were obtained using standard techniques. Hb concentration was determined by the cyanmethemoglobin method. The microhematocrit was used for measuring packed cell volume. The modified methods of SKOVSTAD [2], PETERS *et al.* [3] and HANAYAT *et al.* [4] were used to measure serum iron, total iron binding capacity and the folic acid level respectively. Erythrocyte reduced glutathione (CSH), glutathione stability, glucose-6-phosphate dehydrogenase (G-6-PD) and incubated erythrocyte osmotic resistance and autohemolysis were performed by the methods of BRUTLER *et al.* [5], CUNYER and PITTMAN as modified by BRUTLER [6], ZENKHAM [7] and DACE *et al.* [8] successively. The Heinz body preparations were made as described by DREW *et al.* [9]. The starch gel electrophoresis was performed according to the method of SMITHIES [10] and the agar gel according to ROSENBERG *et al.* [11]. Fetal hemoglobin value was determined by the alkali denaturation method of SICKER *et al.* [12] and quantitative estimation of Hb A<sub>2</sub> was obtained by chromatography on diethyl amino ethyl cellulose (DEAE) [13]. The solubility of the reduced hemoglobin was determined at the 2.24 M phosphate concentration according to JONES and HENNESSY [14].

### Case History

A.R.E., a 32-year-old male, was brought to our attention because his offspring had sickle cell HbD disease [15]. The propositus had no symptoms referable to possible hemolytic disease and the past history was unremarkable, particularly concerning pallor and icterus.

Table I Hematologic data of the patient

|   | Patient | Normal          |
|---|---------|-----------------|
| Hb, g <sup>o</sup>                              | 14.71   | 14-16           |
| Hematocrit, %                                   | 43      | 42-46           |
| Erythrocytes, 10 <sup>6</sup> /mm <sup>3</sup>  | 5.6     | 5-5.5           |
| Mean cell volume, $\mu$ m <sup>3</sup>          | 77      | 81-92           |
| Mean cell hemoglobin, pg                        | 26      | 27-32           |
| Mean cell hemoglobin concentration, %           | 34.2    | 32-36           |
| Reticulocytes, 10 <sup>3</sup> /mm <sup>3</sup> | 63      | 50-100          |
| Serum iron, $\mu$ g <sup>o</sup>                | 122     | 80-120          |
| Serum iron binding capacity, $\mu$ g/100 ml     | 337     | 300-360         |
| Folic acid, ng/ml                               | 7.5     | 7-25            |
| Bilirubin, mg <sup>o</sup>                      | 0.8     | less than 1 mg  |
| Autohemolysis, % at 48 h                        |         |                 |
| without glucose                                 | 0.315   | 4               |
| with glucose                                    | 0.187   | 0.8             |
| G-6 PD, U/100 ml RBC                            | 14      | 110-160         |
| Glutathione, mg/100 ml RBC                      | 23      | 78.8 $\pm$ 15.7 |
| Glutathione stability                           | 19      | more than 40    |

Physical examination revealed a well developed male, weight 73.5 kg, and height 172 cm. There was no jaundice or hepatosplenomegaly. X rays of the long bones and skull were negative and the whole examination was within normal limits. Some of the laboratory findings are given in table I.

The stained blood films revealed normochromic and normocytic erythrocytes with adequate platelets. No target cells or nucleated red blood cells were seen. The sickling test, made with 2% sodium metabisulphate and the direct and indirect antiglobulin (Coombs) tests were negative. Heinz body and inclusion body content was not significantly different from the control cases. Staining of the peripheral blood smear for the differential of hemoglobin S and D did not reveal any hemoglobin S [16]. The bone marrow aspirate was hypercellular, and showed normal erythroid and myeloid maturation with the erythroid/myeloid ratio of 1:3.5. Erythrocyte osmotic fragility was found to be slightly decreased at the beginning (fig. 1). The solubility of the reduced hemoglobin of the patient was compared with those of patients with known sickle cell trait, sickle cell anemia and normal hemoglobin. Although there was some precipitation with sickle cell trait and sickle cell hemoglobin, no precipitation was seen with the patient's hemoglobin as normal control. Hb A<sub>1</sub> and fetal

original observation of electrophoretic mobility was confirmed and the location of the abnormality in the  $\beta$ -chain was identified.

Chemical characterization of the hemoglobin was carried out by Drs. BARNHILL and JONES according to procedures described by SCHWENKER *et al.* [17]. The abnormal peptide obtained from this hemoglobin by chromatography of the  $\beta$ -chain tryptic hydrolysate exhibits the unique behavior characteristic of Hb D-Punjab (Los Angeles).




Fig 1 Incubated erythrocyte osmotic fragility of the patient was found to be slightly decreased in the beginning. Normal range: patient.



Fig 2 Hemoglobin electrophoresis on starch gel at pH 7.6 (tris-citric acid). From top: two sickle cell trait; propoxinus; control.



Fig 3 Agar gel electrophoresis at pH 6.45 (citrate-phosphate). From top: Control, Hb S-D disease with increased Hb F, sickle cell trait, propositus.

a) The abnormal tryptic peptide,  $\beta$  T-13, when chromatographed on a cation-exchange resin, is eluted more rapidly than the corresponding peptide from Hb A.

b) During chromatography in buffers in acid pH range, the abnormal peptide shows almost no color with ninhydrin, and the N-terminal residue is not acted upon by aminopeptidase M.

c) After hydrolysis with 6 N hydrochloric acid, the amino acid analysis of the abnormal peptide shows the same amino acid composition as normal  $\beta$  T-13.

This behavior can be explained by the presence of glutamine instead of glutamic acid at position 121 of the  $\beta$ -chain which forms the N-terminal residue of peptide  $\beta$  T-13 after tryptic hydrolysis of the chain. In acid solution, the glutamyl residue cyclizes and no longer reacts with certain enzymes or ninhydrin. Hydrolysis with hydrochloric acid converts it to glutamic acid.

Since the  $\beta$  T-1 peptide was normal, the presence of Hb S may be eliminated. Chromatography gave only one  $\beta$ -chain peak. The  $\alpha$ -chain was shown to be normal by hybridization of the hemoglobin with canine hemoglobin.

Family study indicated that the patient's wife had sickle cell trait and all four of his live offspring had sickle cell-hemoglobin D disease. Unfortunately, his parents and siblings were not alive and could not be investigated (fig. 4).




Fig. 4. The family pedigree. The arrow indicates the proband.

### Discussion

A hemoglobin which does not cause sickling, but which is indistinguishable from Hb S by conventional methods of electrophoresis and chromatography, is called Hb D. However, this hemoglobin could be separated from Hb S on agar gel at 6.15 [11]. The abnormal hemoglobin found in this patient was, by definition, hemoglobin D, shown to be Hb D Punjab (Los Angeles) ( $\alpha_1\beta_1$ , 121 Glu→Gln).

As has been mentioned, Hb D shown by electrophoresis and chromatography, is heterogeneous. Among others, hemoglobin Da [18] and the two biochemically different hemoglobins D $\beta$ , D Ibadan ( $=\alpha_1\beta_1$ , 87 Lysine) [19] and D Los Angeles ( $\alpha_1\beta_1$ , 121 Glu→Gln [20]), are fairly well documented types.

In general the patients with hemoglobin S-D and thalassemia-hemoglobin D disease, have moderate degree hemolytic anemia. But the cases which are only heterozygote and homozygote for hemoglobin D do not show any specific abnormality related to this abnormal hemoglobin [17]. There have been at least four reported cases of homozygous hemoglobin D disease in the literature [21-23]. The two siblings reported by Stolt *et al* [23] also had Hb D Los Angeles, but both of these patients had moderate degree anemia, high percentages of target cells and no appreciable amounts of  $\Delta_2$  in some members of the family. The possibility of hemoglobin D  $\alpha$  thalassemia



combination which could not be distinguished from homozygous Hb D disease by electrophoresis might be entertained.

It must be emphasized that an electrophoretic pattern of almost 100% Hb D does not alone prove homozygosity for this pigment. For this reason definite diagnosis of homozygous Hb D disease cannot be made without family studies in addition to electrophoretic pattern and Hb A<sub>2</sub> determination. BIRD and LEHMANN's case [21], who also had Hb D Los Angeles, is a good example for the importance of the family study in the diagnosis of homozygous Hb D disease. That sick soldier's family became available to the authors many years later and the erroneous diagnosis of homozygous Hb D disease of this patient was corrected as hemoglobin D $\beta$ -thalassemia [21].

In the case presented here, all the laboratory studies do not contradict homozygosity. In addition, all four living children had D genes which is more evidence that the propositus had pure hemoglobin D disease. However, it would be more convincing if his parents and/or siblings had been available for examination.

Although the association of homozygosity of Hb D with erythrocyte G-6-PD deficiency is unique, it seems to be purely coincidental. In spite of this combination the patient did not present any evidence of hemolytic anemia, but erythrocyte survival could not be performed.

All the previous four cases of homozygous hemoglobin D disease showed appreciable amounts of target cells. However, this more common finding was not detected either in the propositus or in the other family members with this hemoglobinopathy [15]. Erythrocyte osmotic fragility carried out in CHURNOFF's case [22] was significantly decreased, but it was not marked in our patient.

*Acknowledgment* I am indebted to Drs. BRIMHALL and JONES of the University of Oregon Medical School for their kindness in analysing the patient's hemoglobin.

### *Summary*

The case of a Turkish man with very probable homozygous hemoglobin D disease, whose offspring had hemoglobin S-D disease, is reported with laboratory detail. Investigations showed that he was hemoglobin D Punjab (Los Angeles) ( $\alpha_1\beta_1$  121 Glu  $\rightarrow$  Gln). Although he also had erythrocyte glucose-6-phosphate-dehydrogenase deficiency, there was no present evidence and no past history of hemolysis.

### *References*

1. ITANO, H. A. Third abnormal hemoglobin associated with hereditary hemolytic anemia. *Proc. nat. Acad. Sci.* 37: 775 (1951).

2. SCHWARTZ J. S. Determination of serum iron. *Med Publ Health Lab Meths*, 6th ed., p. 415 (Liss & Febiger Philadelphia 1955).
3. PETERS T. GIOVANNELLO, T. J. APT L. and ROSS, J. E. A new method for the determination of serum iron binding capacity. *J lab. clin. Med* 45: 274 (1955).
4. HENRIK V. ENGBER R., and KOONTZ B. J. The assay and nature of lactic acid activity in human serum. *J. clin. Invest* 40: 81 (1961).
5. BEUTLER E. DUKON O. and KELLY B. M. Improved method for the determination of blood glutathione. *J lab. clin. Med* 61: 817 (1963).
6. BEUTLER E. The glutathione instability of drug sensitive red cells. A new method for the *in vitro* detection of drug sensitivity. *J lab. clin. Med* 47: 84 (1957).
7. ZUCKERMAN W. H. An *in vitro* abnormality of glutathione metabolism in erythrocytes from normal newborns. Mechanism and clinical significance. *Pediatrics* 73: 18 (1959).
8. DACEY J. V. and LEWIS, S. M. Practical haematology 3rd ed. pp. 135 and 141 (Churchill London 1963).
9. DICK R. J. WEINSTEIN I. M. LE ROY G. V. TALMACE D. W. and ALVING A. S. The hemolytic effect of primaquine. *J lab. clin. Med* 43: 303 (1954).
10. SWEETMAN, O. Zone electrophoresis in starch gels. Group variations in the serum proteins of normal human adults. *Biochem. J* 61: 679 (1955).
11. ROBINSON A. R. ROBINSON M. A. HARRISON A. P. and ZETZLER W. W. A new technique for the differentiation of hemoglobin. *J lab. clin. Med* 57: 745 (1957).
12. SACHER K. CHERNOFF A. I. and SIEGEL I. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413 (1951).
13. HENMAN T. H. J. and DOZY A. M. Quantitative determination of the minor hemoglobin component Hb A<sub>2</sub> by DEAE cellulose chromatography. *Ann. Biochem.* 2: 400 (1961).
14. JONES H. H. P. and HENMAN T. H. J. A laboratory manual on abnormal haemoglobins. p. 22 (Pitman Oxford 1958).
15. ÖZKURT S. Haemoglobin S-D disease in a Turkish family. *Scand. J. Haemat.* 6: 10 (1969).
16. YAKUBIN A. J. and HELLER P. An elution test for the visualization of haemoglobin S in blood smears. *Blood* 14: 193 (1954).
17. SCHWIDER R. G. UEDA, S. ALPERTIN J. B. LEVIN W. G. JONES R. T. and BRIM HALL B. Hemoglobin D Los Angeles in two Caucasian families, Hemoglobin S-D disease and hemoglobin D (thalassaemia). *Blood* 22: 20 (1963).
18. LEE R. C. and HENMAN T. H. J.  $\beta$  Thalassemia hemoglobin D $\alpha$ . A family report. *Amer. J. hum. Genet.* 17: 148 (1965).
19. WATSON WILLIAMS F. J. BEAZER D. IRVING D. and LEHMANN H. A new haemoglobin D (badan) ( $\beta$ -87 threonine  $\rightarrow$  valine) producing no sickle cell. Haemoglobin D disease with haemoglobin S. *Nature Lond.* 205: 1273 (1965).
20. BARTON C. Chemical studies on haemoglobin D. *Biochem. biophys. Acta* 57: 437 (1967).
21. BRID C. W. C. and LEHMANN H. The finding of haemoglobin D disease in a Sikh man. *SS* 1 (1956).
22. CHERNOFF A. I. The hemoglobin D syndromes. *Blood* 13: 116 (1958).
23. STOUT C. HOLLAND C. K. and BRID R. M. Hemoglobin D in an Oklahoma family. *Arch. intern. Med* 114: 296 (1964).
24. LEHMANN H. and HUNTSMAN R. G. Man's haemoglobins including the haemoglobinopathies and their investigation. p. 124. Lippincott Philadelphia/Montreal 1962.

Author's address: Dr. SENAI ÖZKURT, Department of Pediatrics, Hacettepe University School of Medicine, Ankara (Turkey).

**H. MAST: Morbus haemolyticus neonatorum. Additamentum ad vol. 170 Z. Geburtsh. Gynäk. Fuke, Stuttgart 1969. VIII+96 S., 21 Abb., 22 Tab. DM 27.-**

Die Behandlung der Blutgruppen-Inkompatibilität ist heute nur noch bei schwerer Sensibilisierung problematisch. Vor allem die schon in früher Schwangerschaftszeit einsetzende Hämolyse gefährdet den Fetus, der schon intrauterin lebensbedrohlich erkrankt oder abstirbt. Seit den bahnbrechenden Arbeiten des Neuseeländers LILEY nehmen sich dieser schweren Fälle an den meisten Orten die Geburtshelfer an. Die vorliegende Broschüre berichtet über die Erfahrung der Universitäts-Frauenklinik Münster (Westfalen). Der Autor folgt den Richtlinien von LILEY. Nach gründlicher Schilderung der Methoden und des operativen Vorgehens stellt er die Ergebnisse der Fruchtwasseruntersuchung bei 103 Patientinnen dar. Mit dem Ultraschall-Echogramm gelingt die Lokalisation der Plazenta und der Lage des Kindes auf unschädliche Weise. Bei 11 Schwangeren wurde die Indikation zur intrauterinen Transfusion gestellt, die ein- oder mehrmals durchgeführt wurde. Von den Kindern überlebten lediglich 4.

Ein ausführliches Literaturverzeichnis dokumentiert die Ausführungen. Die Arbeit erweitert die bereits bestehenden Erfahrungen, bringt jedoch keine Neuerungen. Sie kann interessierten Pädiatern und Gynäkologen von einem gewissen Nutzen sein.

W. H. Hirtz, Zürich

**M. K. JENSEN: Chromosome Studies in Acute Leukaemia. Munksgaard, Copenhagen 1969. Preis Dkr. 50.00**

Im grossen und ganzen kann diese Monographie sowohl dem Hämatologen, der sich über den Stand (bis 1966) der chromosomalen Befunde bei akuten Leukämien informieren will, als auch dem Zytogenetiker, der sich in seinem Gebiet hämatologisch informieren will, empfohlen werden. Es werden die gebräuchlichen Techniken der Chromosomenpräparation aus Blut und Knochenmark kurz beschrieben. Zwei Kapitel befassen sich ausführlich mit den Chromosomenbefunden in Blut und Knochenmark bei akuten Leukämien. In weiteren

... 7 ... ..

von Chromosomenanomalien diskutiert. Etwas spekulativ scheinen die Schlüsse, die der Autor aus dem eventuellen Betroffensein nicht nur der weissen, aber auch der erythroiden Vorläufer der leukämischen Zelle zieht. Überzeugender sind seine Hinweise auf die Veränderungen der Chromatinstruktur in den leukämischen Zellen, die dafür sprechen, dass auch in Fällen ohne abnorme Stammzelllinie eine leukämische Zellpopulation vorhanden ist. Erwähnenswert sind die sehr schönen Abbildungen, die auch dem Nicht-Fachmann eindrücklich die diskutierten Phänomene wie «blurring» der Chromosomen in der leukämischen Zellpopulation, «centromere spreading», Chromatinbrücken, Chromosomenbrüche und Austauschfiguren illustrieren. Die Beschreibung der Fälle und die Tabellen am Ende der Arbeit stellen eine anschauliche Illustration der im Text dargestellten Fakten dar. Am Rande sei bemerkt, dass der Ausdruck «medial» oder «submedial» für die Centromerposition falsch ist. Es muss «median» und «submedian» heissen (Denver, London, Chicago Conferences). «Medial» ist ebenso wie «lateral» ein relativer Begriff, der die Angabe eines Bezugsobjektes verlangt.

I. RITA BUNYER, Basel

**H. HAEFLIGER: Zur Geschichte der Hämphilie unter besonderer Berücksichtigung der Schweiz, Vol. 28. Baseler Veröffentlichungen zur Geschichte der Medizin und der Biologie. Schwabe, Basel 1969. 99 p. Preis sfr. 18.-**

Die Geschichte der Hämphilie eignet sich, um die besondere Leistung der Schweizer Forschung zu berücksichtigen. Die sehr grosse und gut bekannte Tenna-Familie hat viel

gen der sich um die Elektronenstruktur des Knochenmarkes und des peripheren Blutes beruht.

1. GRENDMANN, H. *Häpato-Erythroblastose*

OL. SALMON and J. ANDERSEN. *Modern Views on the ABO Blood Groups and Secretor Status*, Series Haematologica, vol. 21. Munksgaard Copenhagen 1969. Price 54 Dkr.

In the first article SALMON presents a tentative approach to variations in ABH and secretor erythrocyte antigens. The paper comprises a review of the recent literature as well as results of his own investigations performed by means of quantitative and thermodynamic methods applied on agglutinations. The study deals first with blood group antigen modifications due to gene interactions whether allelic (weakening of  $A_2$  by the B-gen or not ( $A_m$ ). Then the blood group modifications: deficiency of A, A-B-H, increase of A-antigen as observed in leukaemia and refractory anaemia, the appearance of red cell populations with a weakened A-antigen in elderly and some rare cases of reversible modifications in healthy subjects are treated. The possible mechanisms of the lesion of the genetic function initiating these modifications is discussed extensively.

The second article by ANDERSEN deals with some aspects of the action of secretor genes within the ABO- and the Lewis blood group system. The serological relationship between the ABO- as well as the Lewis-antigen on the red cells and in the secretor are dealt with comprehensively. Quantitative aspects of the distribution of blood group substances in tissues and in secretions and their genetic implication are also considered. Finally aspects of the chemical nature of the blood group specific substances are included in the discussion. It is shown that recent studies fully confirm the predominant role of the *Se*-gene (besides the *Le*-*le*-Hh and ABO-genes) for the genetic control of the biosynthesis of A-B-H-*Le*-a-*Le*-b-substances.

Both articles, written by experts in the field, give an excellent survey of the present knowledge concerning the respective problems.

R. BUTLER, *Ann.*

Second Conference on the Problems of Cooley's Anemia. Consulting editor: H. FINK. Annals of the New York Academy of Sciences, vol. 1651, 1969, 508 p., US\$ 20.

In thalassaemia the underlying disorder is an unbalanced haemoglobin synthesis. By a still unknown genetically determined mechanism the production of one polypeptide chain type is decreased or suppressed. Following the 17th International Congress of Hematology in New York the second conference on the problems of Cooley's anemia was held by the New York Academy of Sciences on September 9th-11th 1968. The whole series of papers is now being published in volume 1651 of the Annals of the New York Academy of Sciences. The conference is divided in 5 parts: thalassaemic syndromes and experimental models, iron metabolism, haemoglobin synthesis, genetics and therapy. In 46 papers all the different aspects of the thalassaemic syndromes are discussed by the world's most competent authors. The book therefore provides an excellent review and contains the present-day knowledge of solved and unsolved problems of this widely distributed hereditary disorder. It can be recommended to the clinical hematologist as well as to the laboratory investigator of haemoglobin synthesis.

H. R. MARTI, *Ann.*

S. WITZ und R. K. ZAHN. *Experimentelle und klinische Erfahrungen mit Cytosin-Arabinosid bei soliden Tumoren und Hämoblastosen*. Arzneimittel-Forschung 19. Beiheft. Edited by Cantor 1969, 19 p., 28 fig., 31 tab., DM 24.

This volume contains 22 papers presented during a recent symposium in Munich, Germany, about clinical and experimental experience with a new anti-tumor agent, the pyrimidine analogue Cytosine Arabinoside (Ara-C). The meeting was organized by the German producer for Ara-C (Mack-Breitwieser) and relates mainly clinical experiences with this particular compound. Six interesting communications present data on DNA and RNA synthesis with Ara-C treatment, studies of cellular pharmacology of the new antineoplastic and on induction of thymidine kinase and other enzyme systems by Ara-C. The clinical part of 16

sehr gut wieder 1 Anti Cancer Agents Their Detection by Screening Tests and their Mechanism of Action (T A CONNORS, London), 2 Extracellular Factors Affecting the Response of Tumours to Chemotherapeutic Agents (J A DOUBILET, London), 3 Intracellular Factors Influencing the Response of Tumours to Chemotherapeutic Agents (C R BALL, London), 4 Chemotherapy and Immune Reactions (J L AMIEL, Paris), 5 Dose Schedules and Modes of Administration of Chemotherapeutic Agents in Man (Y KENN, Brüssel), 6 The Methodology of Controlled Clinical Trials (D SCHWARTZ, Paris), 7 Biological Basis of Hormonal Therapy of Cancer (H J TAYLOR, Brüssel), 8 Operational Research in Cancer Chemotherapy Chemotherapy in the Strategy of Cancer Treatment (G MATHIÉ, Paris) Nur die Magistralvorlesungen des Symposiums welche ausschliesslich Spezialisten ihres Faches übertrugen wurden sind abgedruckt Die Garantie erfahrener Analyse des Standes des gegenwärtigen Wissens und der Vermeidung von thematischen Überschneidungen oder Überbewertung von ins Uferlose führenden subspezialisierten Details ist daher gegeben Auch wird das viel fissettierte Gebiet der onkologischen Chemotherapie niemals in monotoner Schematik behandelt, sondern die individuelle Betrachtungs- und Darstellungsweise jedes einzelnen Autors wird dem komplexen Sachgebiet in jeder Beziehung gerecht Langweilige Passagen fehlen Jede zusammenfassende Darstellungsweise wird erst durch eine gute Dokumentation sinnvoll Dieser Anforderung wird das Buch durch seine reiche graphische Illustration und durch präzise Literaturhinweise vollauf gerecht

Die «Recent Results in Cancer Research»-Serie wird damit um ein weiteres ausgezeichnetes Exemplar erweitert Dem onkologischen Anfänger ist es ein kompetenter Wegweiser, dem Onkologen selbst eine grosse Hilfe rasch das Wesentliche seines Fachgebietes zur Hand zu haben G A NARR, Basel

D HENY and W. STICH: Fine Structure of Blood and Bone Marrow, Lehmanns Verlag 1969 136 p., 130 fig DM 62 -

Blutzellen sind dankbare Objekte für die Elektronenmikroskopie und deshalb früh mit dieser Methode bearbeitet worden Das vorliegende Buch ist daher nicht das erste seiner Art und muss an anderen ähnlichen Ausgaben gemessen werden Es schneidet nicht schlecht dabei ab Dazu hilft zunächst einmal die Beschränkung auf das normale Bild wie sie hier vorgenommen worden ist Weder krankhafte Zellveränderungen wie Alterungsprozesse oder Phänomene der physiologischen Zellmauerung werden berücksichtigt noch sind pathologische Zellen oder pathophysiologische Zustände bei Bluterkrankungen (Leukämien Erythrozytenanomalien primäre Knochenmarkserkrankungen usw.) einbezogen Den Blutkrankheiten soll ein späterer Band gewidmet werden Man muss das wissen, wenn man das Buch kauft Auch findet sich nichts über die lymphatischen Gewebe von den Lymphozyten des peripheren Blutes abgesehen Der Methodikteil stellt nur die hier angewandten Verfahren dar Jeweils von einem kurzen aber prägnanten Text eingeleitet gliedert sich der Band in zwei Teile 1 Knochenmark 2 peripheres Blut In beiden Teilen werden die normalen Zellformen beschrieben und vor allem auch reichhaltig abgebildet wobei verschiedene Nachvergrößerungen auf Details wie etwa der Zytosmalmamellen oder der Zentrionen (z B in Plasmazellen) besonders aufmerksam machen Auf Vollständigkeit musste wohl mit Rücksicht auf den angestrebten Umfang des Bandes verzichtet werden Um so dankbarer findet man Abbildungen der Myeloblastenreihen oder von zwei verschiedenen Lymphozytentypen, «dunklen» und «hellen» Lymphozyten Vielleicht wären um bei den letztgenannten Zellformen zu bleiben die Lymphozyten des Knochenmarkes auch nicht ganz so übersiehende Objekte gewesen Die Bildwiedergabe der «ellenbar guten» primären Klüsches hat durch das Papier gelitten und manche Einzelheiten wie etwa die der Leukozytengranula sind nicht deutlich zu erkennen Das mindert aber den orientierenden Wert des Buches nur wenig Der Band gehört in die Hand jedes Morpholo-

gen der such um die Elektrolytenkonzentration des Knochenmarkes und des peripheren Blutes bemüht.

E. GRUNSMANN, Hupperts, Eberfeld

OL SALMON and J. ANDERSON. *Modern Views on the ABO Blood Groups and Secretor Status*. Series Haematologica, vol. 21. Munksgaard Copenhagen 1979. Price: 54 Dkr.

In the first article SALMON presents a tentative approach to variations in ABH and associated erythrocyte antigens. The paper comprises a review of the recent literature as well as results of his own investigations performed by means of quantitative and thermodynamic methods applied on agglutinations. The study deals first with blood group antigen modifications due to gene interactions whether allelic (weakening of  $A_2$  by the B-gen, or not  $A_0$ ). Then the blood group modifications (deficiency of  $A_1$ , A-B-H, increase of  $A_2$  antigen as observed in leukaemia and refractory anaemia, the appearance of red cell populations with a weakened A antigen in elderly and some rare cases of reversible modifications in healthy subjects are treated. The possible mechanisms of the lesion of the genetic function in causing these modifications is discussed extensively.

The second article by ANDERSON deals with some aspects of the action of secretor genes within the ABO- and the Lewis blood group system. The serological relationship between the ABO- as well as the Lewis-antigens on the red cells and in the secretor are dealt with comprehensively. Quantitative aspects of the distribution of blood group substances in tissues and in secretions and their genetical implication are also considered. Finally, aspects of the chemical nature of the blood group specific substances are included in the discussion. It is shown that recent studies fully confirm the predominant role of the  $S_{\alpha}$ -antigen (besides the Lewis, H<sub>y</sub>- and ABO-genes) for the genetic control of the biosynthesis of  $A_1$ , B-, H-, Le<sup>a</sup>-, Le<sup>b</sup>-substances.

Both articles, written by experts in the field, give an excellent survey of the present knowledge concerning the respective problems.

R. BUTLER, Bonn

Second Conference on the Problems of Cooley's Anemia. Consulting editor: H. FRICK. *Annals of the New York Academy of Sciences*, vol. 165, 1-187, 500 p. U.S. \$ 20.-

In thalassemia the underlying disorder is an unbalanced hemoglobin synthesis. By a still unknown genetically determined mechanism the production of one polypeptide chain type is decreased or suppressed. Following the 12th International Congress of Hematology in New York the second conference on the problems of Cooley's anemia was held by the New York Academy of Sciences on September 9th-11th 1968. The whole series of papers is now being published in volume 165 of the *Annals of the New York Academy of Sciences*. The conference is divided in 5 parts: thalassemic syndromes and experimental models, iron metabolism, hemoglobin synthesis, genetics and therapy. In 40 papers all the different aspects of the thalassemia syndromes are discussed by the world's most competent authors. The book therefore provides an excellent review and contains the present-day knowledge of solved and unsolved problems of this widely distributed hereditary disorder. It can be recommended to the clinical hematologist as well as to the laboratory investigator of hemoglobin synthesis.

H. R. MARTI, Jena

S. WITTE and R. K. ZAHN. *Experimentelle und klinische Erfahrungen mit Cytosin-Arabinosid bei soliden Tumoren und Hämoblastosen*. *Arzneimittelforschung* 19. Beiheft. Editio Cantor 1979. 192 p., 93 fig., 51 tab. DM 24.-

This volume contains 22 papers presented during a recent symposium in Munich, Germany, about clinical and experimental experience with a new antitumor agent, the pyrimidine analogue Cytosine Arabinoside (Ara-C). The meeting was organized by the German producers for Ara-C (Mack, Illertissen) and relates mainly to cytotoxic effects of Ara-C on cellular components of the cell cycle. The papers are arranged in three sections: 1. General aspects of Ara-C, 2. Clinical experience, 3. Experimental experience. The first section contains 10 papers, the second section 7 papers, and the third section 5 papers.

presentations relates recent experience with the drug in the treatment of acute leukemias, polycythemia vera and certain lymphomas as well as some solid tumors. The new agent seems to be of particular interest in the attack and possibly also in the maintenance treatment of acute myeloblastic and lymphoblastic leukemias. Ara C apparently produces promising results in polycythemia vera. The drug seems to be largely effective in lymphomas and solid tumors. The duration of treatment courses of Ara C were usually much shorter and doses given lower than those effected by large American Chemotherapy Groups whose results are mentioned only peripherally during the discussion part. Several well documented papers deal with the hematologic toxicity of the compound especially with the profound megaloblastic bone marrow changes and with thrombocytopenia. Experimental and clinical evidence for the effectiveness of oral Ara C treatment are presented by GOLDFENBERG *et al*. Of the 22 presentations 19 are given in German and 3 in English. A complete literature survey on Ara C up to 1968 (177 references) concludes the volume, which is of interest to medical oncologists and hematologists. H. J. SEHN, Basel

J. CHANARIN. *The Megaloblastic Anaemias*, Blackwell London 1969 1000 p. £ 10.00

Nach einem knapp gefassten historischen Überblick wird in einem ersten, mehr als 300 Seiten umfassenden Abschnitt die Biochemie des Vitamins B<sub>12</sub> des Intrinsic Factors und der Folsäure dargestellt. Die folgenden Kapitel umfassen einerseits eine eingehende Beschreibung der morphologischen Veränderungen andererseits eine eingehende Beschreibung der morphologischen Veränderungen welche im Rahmen der megaloblastären Anämien zu beobachten sind. Die zweite Hälfte des Buches ist der Klinik der megaloblastären Anämien gewidmet. Klinisches Bild Häufigkeit, Januhrität, Kombination mit anderen Krankheiten Befunde am Magen und die Neuropathie werden ausführlich behandelt. Dann wird vor allem auch die Bedeutung der Autoimmunvorgänge diskutiert. Jeder Störung welche einer megaloblastären Anämie zugrunde liegen kann ist ein eigenes Kapitel gewidmet z. B. megaloblastäre Anämie nach Gastrektomie, in der Schwangerschaft, bei Blutkrankheiten mit Steigerung der (effektiven oder ineffektiven) Erythropoese usw. Eingehend werden die megaloblastären Anämien bei Jugendlichen besprochen. Auf den letzten 50 Seiten erörtert der Autor noch die therapeutischen Probleme und gibt gleichzeitig klare Richtlinien über das Vorgehen bei der Abklärung und Behandlung der Patienten mit megaloblastärer Anämie.

Zweifellos handelt es sich um eine der umfassendsten Darstellungen die in letzter Zeit über ein großes und wichtiges Kapitel der Hämatologie erschienen sind. Der Reichtum der Arbeit aber auch der in den letzten Jahren erzielte Fortschritt werden deutlich, wenn man den vorliegenden fast 1000 Seiten umfassenden Band mit der reinen Masse vergleicht. knapp 200 Seiten starken Monographie von HENKERT (1959) vergleicht. Die Literatur sowohl die ältere wie die neueste ist sorgfältig gesichtet und verarbeitet. Die eigenen Arbeiten - sie betreffen vor allem Folsäure und Folsäuremangel - sind organisch in das Ganze eingebaut. Die Ausführungen sind und werden zurückhaltend. Als besonders gelungen dürfen die Abschnitte über die morphologischen Veränderungen in Blut und Knochenmark oder die Bemerkungen zur Nomenklatur bezeichnet werden. Selbst der erschöpfende Darstellung des Buches und der einzelnen Abschnitte zusammengefasst. Die zahl reichen hervorragend ausgewählten und zusammengestellten Abbildungen und Tabellen tragen das Buch zum Verständnis bei. Ein flüssiger klarer Stil macht sehr leicht die Lekture zum Genuss. Jedem Kapitel ist ein reichhaltiges Sachregister angehängt. Ein umfängliches sorgfältig zusammengestelltes Sachregister erleichtert die Benutzung des Buches als Nachschlagewerk. Wer aber etwas nachschlägt wird bald mehr und mehr lesen wollen. U. BUCHNER, Bonn

# Index rerum ad Vol. 43

Bearbeitet von C. B. v. Bawl

(B = Buchrevues, Buchbesprechungen, Literaturauswertungen)

- ABO blood groups and secretor status  
modern views (Series Haematologica  
Vol 21) 3/3 (B)
- Acetylphenylhydrazin v. Hitzig'sper-  
bildung Phenylhydrazinämie Rabl  
Akrocytose congenital deficiency of  
fibrinogen in two sisters (A clinical and  
haematological study) 170
- Alade v. Hypoxia
- Anaemia Cooley's anaemia second con-  
ference 3/3 (B)
- Anaemia haemolytic acquired Swiss type  
hereditary persistence of fetal haemo-  
globin in a case of a quaternary haemolytic  
anaemia 184
- Anaemia iron deficiency gastric mucosa in  
iron deficiency anaemia Results of fol-  
low-up examinations 2/8
- Anaemia megaloblastic 3/3 (B)  
v. Morbus haemolyticus neonatorum (B)
- Anaemia rabl v. Erythrocytes
- Anämie hämolytische tumorartige in ra-  
thorale extramedulläre Hämatopoese  
bei hämolytischer Anämie Bericht über  
einen Fall und Literaturüberblick 111  
v. Phenylhydrazinämie
- Anämie au immunhämolytische Be-  
handlungsergebnisse mit Heparin und  
Heparinod SP 54 = P. Jansson\* 29
- Aras-C v. Cyton-Arabinosid (B)
- Asparaginase (L-Asparaginase) aus *Escheri-*  
*col* Wirkung auf die Selektion von  
Lymphocytenkulturen 210
- Austauschtransfusionen v. Hitzig'sper-  
bildung
- Autontrunkhämolytische Anämien Be-  
handlungsergebnisse mit Heparin und  
Heparinod SP 54 (= P. Jansson\* 29  
Autoradiography v. Microautoradiography  
Beth cyanosis after birth v. Me haemo-  
globinemia
- Blast transformation v. Lymphocytenkul-  
turen Lymphocyte transformation  
Blast and bone marrow fine structure 3/2  
(B)
- Blood coagulation v. Akrocytose  
Bilder und Zeichnungen (B. Hämo-  
lyse (Geschichte) (B. Haemostas (He-  
parin
- Blood coagulation (10th ed.) 64 (B)
- Blood groups human blood and sero-  
groups 3/1 (B)  
modern views on the ABO blood groups  
and secretor status (Series Haematologica  
Vol 21) 3/3 (B)  
immunopathology v. Morbus haemolyticus  
neonatorum (B)
- Blood transfusion proceedings of the 11th  
Congress of the International Society of  
Blood Transfusion (1966) (B. Hämo-  
lyse (Geschichte) (B. Haemostas (He-  
parin
- International Society of Blood Transfu-  
sion Symposium on v. hepatoant-  
gens and antibodies (München August 6  
1970) 192
- Plasma exchange therapy in the treatment  
(B. Hämo-lyse (Geschichte) (B. Haemostas (He-  
parin
- Blutgruppen v. Blood groups
- Bluttransfusion v. Hitzig'sper-  
bildung
- Butterfly fusion research Ergebnisse (Vol.



- foetal haemoglobin, *s. Ghanaian adult*  
 homozygous for hereditary persistence of  
 foetal haemoglobin and heterozygous for  
 elliptocytosis, 100  
 -, *S*us type hereditary persistence of foetal  
 haemoglobin in a case of acquired  
 haemolytic anemia, 181  
 foie, *s. Lebererthropoese*  
 folic acid activity, binding by body fluids  
 272  
 fragility, osmotic, of red cells in newborns  
 and infants, 248  
 fragility, osmotic, and density distribution  
 of erythrocytes in the newborn, 242  
 Frauen, *s. Women*  
 Gammaoglobuline, menschliche immun  
 chemische Untersuchungen an Spalt  
 produkten menschlicher Gammaoglobu  
 line (Untersuchungen an Seren mit H)  
 pergammaglobulinämie und Parapro  
 teinämie, 257  
 Gynghon lymphique, histopathologie,  
 128 (B)  
 Gastric mucosa in iron deficiency anemia  
 (Results of follow up examinations), 228  
 Geburtsperiode, *s. Blutgerinnungsstörungen*  
 (B)  
 Gel filtration (with Sephadex), *s. Folic*  
 acid  
 Genetics, medical, progress (Vol XII)  
 319 (B)  
 Genetics *s. Abbinogamaemii* Diphthorase  
 deficiency Glucose-6-phosphate-dehy  
 drogenase Haemoglobin D Haemo  
 globin foetal Haemoglobin O Indonesia  
 Sphaerocytes  
 Geschichte der Hämophilie unter besonde  
 rer Berücksichtigung der Schweiz (Basler  
 Veröffentl. *s. Geschichte d. Medizin und*  
*d. Biologie* Vol 28), 360 (B)  
 Gesellschaft *s. Bluttransfusionsforschung*  
 (B)  
 Gestation Blutgerinnungsstörungen (Biblio  
 theca gynaecologica Nr 52), 319 B  
 Ghana *s. Ghanaian adult*  
 hereditary persistence of foetal haemo  
 globin and heterozygous for elliptocytosis  
 100  
 Globuline, *s. Gammaoglobuline*  
 Glucose-6-phosphate-dehydrogenase = G-  
 6-PD glutathionperoxidase and glutathionreductase activity in spherocytes
- 318  
 Glucose-6-phosphate-dehydrogenase, the  
 ratio between normal and active eryth  
 rocytes in heterozygous glucose-6-  
 phosphate-dehydrogenase deficient wom  
 en, 291  
 Glutathionperoxidase, Glucose-6-phos  
 phate-dehydrogenase and glutathion  
 reductase, activity in spherocytes 318  
 Glutathionreductase, *s. Glutathionperoxi  
 dase*  
 G-6-PD, *s. Glucose-6-phosphate-dehydro  
 genase*  
 Granulopoese, Zellkennetik der Granulo  
 poese und des Neutrophilenstroms bei  
 einem Fall von zyklischer Neutropenie, 48  
 Gravidität, *s. Blutgerinnungsstörungen* (B)  
 Grossrase, *s. Blutgerinnungsstörungen* (B)  
 Groupes sanguines *s. Blood groups* (B)  
 Guinea pig experimental studies on leukie  
 mia in guinea pigs 193  
 -, *s. Eosinophil leukocytes, Erythroblast*  
*precursors, Reticulocyte*  
*IP, *s. Neutropenie, zyklische, Ribonuclei**  
*acid (synthesis)*  
 Hämatologentagung Österreichische erste  
 (Wien, 23-24 10 1970), 320  
 Hämatopoese, extramedulläre tumorartige  
 intrathorakale extramedulläre Hämatopoese  
 bei hämolytischer Anämie (Bericht  
 über einen Fall und Literaturübersicht),  
 111  
 Haemoglobin, *s. Methaemoglobinaria*  
 Hämoblastosen, experimentelle und klini  
 sche Erfahrungen mit Cytosin Arabino  
 side und bei soliden Tumoren und Hämobla  
 stosen (Arzneimittelforschung 19 Bei  
 heft), 363 (B)  
 Haemoglobin I, *s. Haemoglobin foetal*  
 Haemoglobin foetal *s. Ghanaian adult*  
 homozygous for hereditary persistence of  
 foetal haemoglobin and heterozygous for  
 elliptocytosis 100  
 Sus type hereditary persistence of  
 foetal haemoglobin in a case of acquired  
 hemolytic anemia 181  
 Haemoglobin D Punjab, homozygous 355  
 I (s) in an Italian family, 40  
 Haemoglobinopathy *s. Haemoglobin D*  
 Haemoglobin foetal Haemoglobin O  
 Indonesia Sickle cell disease

- Hämolyse, Phenylhydrazinhämolyse, die makrozytäre Regeneration der Erythropoese (Tierexperimentelle Untersuchungen bei der Phenylhydrazinhämolyse), 144
- Hämolytic anaemia, acquired, Swin type hereditary persistence of foetal haemoglobin in a case of acquired haemolytic anaemia, 184
- Hämolytische Anämie, tumorartige intrathorakale extramedulläre Hämatopoese bei hämolytischer Anämie (Bericht über einen Fall und Literaturbericht), 111
- Hämozytäre, zur Geschichte der Hämozytäre unter besonderer Berücksichtigung der Schweiz (Bäcker Veröffentl. z. Geschichte d. Medizin und d. Biologie, Vol. 23, 3/0 (B))
- , VI Kongress der Weltföderation für Hämozytäre (Baden bei Wien, 25-27. Juli 1970), 192
- , v. Afibrinogenämie
- Haemostasis, disturbances of haemostasis in acute myeloblastic leukaemia, 63
- Hb D, v. Haemoglobin D
- Hb F, v. Haemoglobin, foetal
- Hb O, v. Haemoglobin O Indonesia
- Hämatopoese in Neugeborenenerythrozyten. (I. Jeune-Studien über experimentelle Bedingungen und den Einfluss von Austauschtransfusionen), 333
- Hämoglobin, v. Haemoglobin
- Hämorrhagie, v. Haemorrhagia
- Hepar, v. Lebererythropoese
- Heparin und Heparinoid SP 54. Behandlungsergebnisse mit Heparin und Heparinoid SP 54 (= Polyanion 8) bei autohämolytischen Anämien, 296
- Heparinoid SP 54 (= Polyanion 8), v. Heparin
- Hereditary methaemoglobinemia due to diphosphorase deficiency (Report of a case of heterozygote presenting with cyanosis after birth), 177
- Hereditary persistence of foetal haemoglobin, swin type, in a case of acquired haemolytic anaemia, 184
- Hereditary, v. Afibrinogenämie, Glucose-6-phosphate-dehydrogenase, Haemoglobin D, Haemoglobin, foetal, Haemoglobin O Indonesia, Hereditary sickle cell disease, Sphaerocytes
- Heterozygote, v. Diphosphorase deficiency
- Heterozygous glucose-6-phosphate-dehydrogenase deficient women, ratio between normal and sensitive erythrocytes, 291
- Hg, v. Lymphocyte transformation
- High limits of dye, isolated, perfused, v. Erythropoiesis
- Histology, v. Leukaemia, acute
- Histopathologie du ganglion lymphatique, 128 (B)
- History, v. Haemophili'e (B)
- H<sup>3</sup>leucine and H<sup>3</sup>uridine, incorporation in erythroid cells of normal and anaemic rabbits, 172
- Hämolyse, v. Hypoxia
- Homine, v. Man
- Homozygous haemoglobin D Punjab, 353
- Hormones, v. Testosterone
- H<sup>3</sup> Thymidin, v. Thymidin (H<sup>3</sup>-Thymidin)
- Human blood and serum groups, 361 (B)
- Human erythroblasts, characteristics of the RNA synthesized *in vitro* by human erythroblasts, 1
- Hund, v. Dog
- H<sup>3</sup>uridine and H<sup>3</sup>leucine, incorporation in erythroid cells of normal and anaemic rabbits, 172
- Hypergamma globulinämie, immunchemische Untersuchungen an Spaltprodukten menschlicher Gammaglobuline (Untersuchungen an Seren mit Hypergamma globulinämie und Paraproteinämie), 257
- Hypocalasaemia, v. Catalase
- Hypoxia, eosinophil leukocytes and recovery from severe hypoxia, 31
- Immunchemische Untersuchungen an Spaltprodukten menschlicher Gammaglobuline (Untersuchungen an Seren mit Hypergamma globulinämie und Paraproteinämie), 257
- Immunelektrophorese, v. Immunchemische Untersuchungen
- Immunology, 1968 (Proceedings of the International Convocation on Immunology, June 1968), 319 (B)
- Indonesia, v. Haemoglobin O Indonesia
- Infants, osmotic fragility of red cells in newborns and infants, 248
- International Society of Blood Transfusion, proceedings of the 11th congress (1966) (Bibliotheca haematologica Nr 79), 64 (B)

- 319 (B)  
 Proliferationskinetik der Lebererythropoese  
 heranwachsender Ratten, 232  
 Proteine, v. Gammaglobuline  
 Queckkulturen, v. Lymphocyte transfor-  
 mation  
 Rabbit, incorporation of  $H^3$  uridine and  
 and anaemic rabbits, 172  
 -, v. Erythropoese (Regeneration)  
 Radio-chrome, v. Glucose-6-phosphate-de-  
 hydrogenase  
 Radio-iron, v. Osteomyelofibrose  
 Rat, effect of uracil and 2 thiouracil on  
 leukocyte production in the rat, 329  
 -, zur Proliferationskinetik der Leberery-  
 thropoese heranwachsender Ratten, 232  
 Recent results in cancer research (Scientific  
 basis of cancer chemotherapy, Vol 21),  
 361 (B)  
 Red blood cells, a screening test for red  
 blood cell catalase, 313  
 Red cell metabolism, study of the effects of  
 possible toxic metabolites of uraemia, 129  
 Red cells, osmotic fragility of red cells in  
 newborns and infants, 242  
 Regeneration, makrozytäre, der Erythro-  
 poese (Tierexperimentelle Untersuchun-  
 gen bei der Phenylhydrazin-hämolyse),  
 144  
 Ren, v. Uraemia  
 Reticulocyte generation time and rate of  
 discharge from the marrow, 13  
 Rhesus incompatibility, v. Morbus haemo-  
 lyticus neonatorum (B)  
 Ribonucleic acid (= RNA) synthesis,  
 characteristics of RNA synthesized in  
 RNA, v. Ribonucleic acid  
 RNA, v. Ribonucleic acid  
 Saudi arabs, sickle cell disease, 89  
 Schmerzempfindlichkeit des Sternums, v.  
 Tenderness of sternum  
 Schwangerschaft, v. Blutgerinnungsstö-  
 rungen (B)  
 Schütz, v. Hämphile (Geschichte)  
 Screening test for red blood cell catalase  
 313  
 Secretor status, ABO blood groups and  
 secretor status, modern views (Series  
 haematologica Vol 2/1), 363 (B)  
 Sensitive erythrocytes, v. Glucose-6-phos-  
 phate-dehydrogenase  
 Sensitivité du sternum, v. Tenderness of  
 sternum  
 Sephadex® (filtration gel), v. Folic acid  
 Serum, v. Folic acid  
 Serum groups, human blood and serum  
 groups, 361 (B)  
 Sex hormones, v. Testosterone  
 Sickle cell disease in Saudi arabs, 89  
 Sideropenia, v. Iron deficiency anaemia  
 Society, v. Blood transfusion, Blood trans-  
 fusion (B), Bluttransfusionsforschung (B),  
 Hämphile, Österreichische Hämatolo-  
 gengesellschaft  
 Sphaerocytes, the activity of glutathion-  
 peroxidase, glucose 6-phosphate-de-  
 hydrogenase and glutathionreductase in  
 sphaerocytes, 348  
 -, v. Hämatopoese, extramedulläre  
 Statistische Auswertung v. Erythroblast  
 precursors, Erythropoiesis, Glutathion-  
 peroxidase, Hypoxia, Leukocyte pro-  
 duction, Osteomyelofibrose, Reticulo-  
 cyte, Sternum  
 Sternum (pain), an evaluation of sternal  
 tenderness as a sign of leukaemia, 309  
 Steroide, v. Testosterone  
 Submicroscopical structure, v. Fine struc-  
 ture (B), Leukaemia (virus-like parti-  
 cles), Lymphocyte transformation  
 Sudan black reaction, v. Leukaemias, acute  
 Swiss, v. Hämphile (Histoire)  
 Swiss type hereditary persistence of foetal  
 haemoglobin in a case of acquired  
 haemolytic anaemia, 181  
 Switzerland, v. Hämphile (History)  
 Symposium, v. Blood transfusion, Congress,  
 Cytosin Arabinosid (B), Immunology  
 1968 (B)  
 Synovial fluid, v. Folic acid  
 Technique, v. Catalase  
 Tenderness of sternum, an evaluation of  
 sternal tenderness as a sign of leukaemia,  
 309  
 Test, a screening test for red blood cell  
 catalase, 313  
 Testosterone, effects of erythropoietin and  
 testosterone on erythropoiesis in bone  
 marrow of isolated hind limbs of dogs, 321  
 Thalassaemia, v. Cooley's anaemia (B)  
 Therapy, v. Cancer research (B), Cytosin-  
 Arabinosid (B)

- 2-Thiouracil and uracil, effect on leukocyte production in the rat, 329
- Terrucl<sup>n</sup> (11<sup>n</sup>-Thymidin), v. Lebererythropoese, Neutropenie, zyklische Ribonucleic acid (synthesis)
- Toxic metabolism of uraemia, possible, a study of their effects on red cell metabolism, 129
- Transfusions, v. Blood transfusions, Blood transfusion (B., Bluttransfusion) v. Mischung (B.)
- Transfusion (Austauschtransfusionen), v. Hämokopertation
- Transplantation (von Zellen), v. Leukaemia (virus-like particles)
- Trans, v. Erythroid cells, Lebererythropoese, Neutropenie, zyklische Ribonucleic acid (synthesis)
- Tumors, intrabronchiale extramedulläre Hämatopoese bei hämolytischer Anämie (Bericht über einen Fall und Literaturbericht), 111
- Tumors, experimentelle und klinische Erfahrungen mit Cytosin-Arabinosid bei soliden Tumoren und Hämoblastosen (Arzneimittelforschung, 19 Beiheft), 363 (B.)
- , v. Cancer research (B.), Leukaemia (virus-like particles)
- Ultrastructure, v. Fine structure... (B., Leukaemia (virus-like particles), Lymphocyte transformation)
- Uracil and 2-thiouracil, effect on leukocyte production in the rat, 329
- Uraemia, a study of the effects of possible toxic metabolism of uraemia on red cell metabolism, 129
- Uridine (11<sup>n</sup>-uridine), v. Erythroid cells, Ribonucleic acid (synthesis)
- Vana, 191, 320
- Well federation für Hämatologie, XI Kongress (Baden bei Wien, 25.-27. Juli 1970), 192
- Werner, glucose-6-phosphate dehydrogenase deficient, v. Glucose-6-phosphate dehydrogenase
- Well federation of haematology, v. Well federation
- Zellkinetik der Granulopoese und des Neutrophilensystems bei einem Fall von zyklischer Neutropenie, 48
- Zellkulturen, v. Lymphocytenkulturen, Lymphocyte transformation, Ribonucleic acid (synthesis)
- Zell-, v. Cell
- Zyklische Neutropenie, Zellkinetik der Granulopoese und des Neutrophilensystems bei einem Fall von zyklischer Neutropenie, 49

# Index autorum ad Vol. 43

(B) = Book reviews - Buchbesprechungen - Livres nouveaux

- Addu, S., v Panizon, F  
 Agarwal S P, v Dube, B  
 Andersen, J., v Salmon, Ch  
 Artvinli, S., v Özand, P T  
 Bast, G., v Schulz, K  
 Bauer, S., v Kirchner, H  
 Beam, A G., v Steinberg, A G  
 Beck, E. A., 64 (B), 319 (B)  
 Becker, H., v Knecht, L. H. und Strassl,  
 F., 144  
 Bernau, A., v Kleihauer, E  
 Betke, K., v Kleihauer, E  
 Bhargava, Manorama, v Kumar, S  
 Bremer, G., v Meuret, G  
 Brittinger, G., v Cohnen, G  
 Britton, C. J. C., 64 (B)  
 Bucher, U., 364 (B)  
 Bühler, Erika, 360 (B)  
 Büttler, R., 361, 363 (B)  
 Butenandt O., 348  
 Catta, A., v Sansone, G  
 Chanarin I., 364 (B)  
 Chawla, S. C., v Dube B  
 Cohnen, G., Scholz, N., Messer, B., König,  
 L., Zimmerschitt, E. und Brittinger,  
 G., 111  
 Dtnon, D., v Danon Y  
 Danon, Y., Kleimann, A., and Danon, D.,  
 242  
 Dawson, Audrey A., v McAndrew, G M  
 Dobbs J., v Rosner, F  
 Dreyfus Yolande, v Gross, L.  
 Dube, B., Agarwal, S P Gupta, M M  
 and Chawla, S. C., 120  
 Duckert, F., 360 (B)  
 Duhamel, G., 128 (B)  
 Edwards, A F., v Griffiths D A  
 Edwards, A E., v Rosse, C.  
 Ehrenreich, Th., v Gross, L.  
 Esan, G J F., v Luzzatto, L.  
 Fernbach, Thelma, v Rosner, I.  
 Fink, H. (Editor), 363 (B)  
 Fisher, J W., v Mfalgor, L. A  
 Fliedner, T M., v Haas, R J  
 Fliedner, T M., v Meuret, G  
 Gaches, C. G C., v Griffiths, D A  
 Gaches, C. G C., v Rosse, C  
 Gallo, E., v Sansone, G  
 Gelpi, A P., 89  
 Götz, H., v Scheiffarth, F  
 Griffiths, D A., Rosse, C., Edwards, A E.,  
 Gaches, C. G C., Long, A H L.,  
 Wright, J L W., and Yoffey, J M., 13  
 Griffiths D A., v Rosse, C.  
 Gross, L., Dreyfuss, Yolande, Ehrenreich,  
 Th., and Moore, Lorraine A., 193  
 Grundmann, L., 362 (B)  
 Gupta M M., v Dube, B  
 Haas, R J., Sparrer E. und Fliedner, T  
 M., 232  
 Haefliger H., 360 (B)  
 Hitzig, W H., 128 (B), 360 (B)  
 Hitzig W H., v Lo, S S  
 Holländer L P (Editor), 64 (B)  
 Holländer, L. P und Matthes, M (Edi-  
 tores), 128 (B)  
 Honetz, N. und Neumann, E., 296  
 Hudson, G., v Sibley, Yvonne D L  
 Huhn, D. and Stich, W., 362 (B)  
 Ikkala E., Salma, H J., and Siurala, M., 228

- Jones, M. K., 30 (B)  
 Kötter, M., v. Klebauer, F.  
 Kretsch, H., v. Schulz, K.  
 Kretsch, H. und Bauer, S., 210  
 Klebauer, F., Bercou, A., Beker, K., Bel-  
 ler, M., Köhne, E. und Riegel, K., 333  
 Kleman, A., v. Davon, Y.  
 Kretsch, L. H., v. Becker, H.  
 König, E., v. Cohnen, G.  
 Köhne, E., v. Klebauer, F.  
 Konosty-Alulu, F. I. D., v. Ringelmann, B.  
 Krenzl, H., v. Schulz, K.  
 Kozłowska, F., v. Pawlak, A. L.  
 Kumar, S., and Bhargava, Manorama, 21  
 Lee, S. L., v. Rosner, F.  
 Lehmann, H., v. Ringelmann, B.  
 Lehmann, H., v. Samone, G.  
 Lennora, E. A., 219  
 Le, S. S., H. J. W. H., and Maria, H. R.,  
 177  
 Lo Corno, Margherita, 172  
 Long, A. H. L., v. Griffiths, D. A.  
 Long, A. H. L., v. Rome, C.  
 Lockin, P. A., v. Ringelmann, B.  
 Luzzatto, L., Egan, G. J. F., and Ogemund, S. E., 248  
 Malgre, L. A., and Fisher, J. W., 321  
 Markkanen, T., and Peltola, O., 272  
 Maria, H. R., 303 (B)  
 Maria, H. R., v. Le, S. S.  
 Mast, H., 30 (B)  
 Mads, G. (Editor), 361 (B)  
 Marley, M., v. Hollander, L. P.  
 Mauri, C., v. Torelli, U. L.  
 McAndrew, G. M., Option, D., and Dawson,  
 Audrey A., 309  
 Meier, B., v. Cohnen, G.  
 Meier, G. und Fiedner, T. M. (und  
 Bremer, G.), 43  
 Milgrom, F., v. Rose, N. R.  
 Moore, Lorraine A., v. Gross, L.  
 Nagel, G. A., 31 (B)  
 Nagy, G., v. Schöpf, E.  
 Neumann, E., v. Honetz, N.  
 Nowotny, F., v. Schulz, K.  
 Orand, P. T., and Artvinli, S., 313  
 Ozayta, S., 353  
 Ogemund, S. E., v. Luzzatto, L.  
 Option, D., v. McAndrew, G. M.  
 Pannun, F., Zaccchello, F., Sartori, E., and  
 Alda, S., 291  
 Pawlak, A. L., and Kozłowska, F., 184  
 Peltola, O., v. Markkanen, T.  
 Preumner, S., v. Schulz, K.  
 Prokop, O., and Ullrich, G., 31 (B)  
 Riegel, K., v. Klebauer, F.  
 Ringelmann, B., Konosty-Alulu, F. I. D.  
 Lehmann, H., and Lockin, P. A., 100  
 Ritz, N. D., v. Rosner, F.  
 Rose, N. R., and Milgrom, F. (Editors),  
 319 (B)  
 Rosner, F., Datta, J. V., Ritz, N. D., and  
 Lee, S. L. (and Fernbach, Thelma), 65  
 Rome, C., Griffiths, D. A., Edwards, A. E.,  
 Gaches, C. G. C., Long, A. H. L., Wright,  
 J. L. W., and Yoffey, J. M., 80  
 Rome, C., v. Griffiths, D. A.  
 Roulet, F. G., 129 (B)  
 Salim, H. J., v. Ikala, E.  
 Salmon, Ch., and Andersen, J., 303 (B)  
 Samone, G., Certia, A., Squaratta, V., Gal-  
 la, E., and Lehmann, H., 40  
 Sartori, E., v. Pannun, F.  
 Scherfart, F., Gutz, H. und Schubert, R.,  
 257  
 Schöpf, E., and Nagy, G., 75  
 Scholz, N., v. Cohnen, G.  
 Schubert, R., v. Scherfart, F.  
 Schulz, K., Nowotny, F., Bast, G., Preum-  
 ner, S., Konrad, H. und Kretsch, H.,  
 270  
 Squaratta, V., v. Samone, G.  
 Senn, H. J., 303 (B)  
 Sibley, Yvonne D. L., and Hudson, G., 31  
 Siurala, M., v. Ikala, E.  
 Sparrer, E., v. Haas, R. J.  
 Stamm, H. (Editor), 319 (B)  
 Steinberg, A. G., and Bearn, A. G. (Edi-  
 tors), 319 (P)  
 Stern, C., 319 (B)  
 Stich, W., v. Hahn, D.  
 Strachil, F., v. Becker, H.  
 Timson, J., 329  
 Torelli, U. L., Vaccari, G. L., and Mauri,  
 C., 1  
 Ullrich, G., v. Prokop, O.  
 Vaccari, G. L., v. Torelli, U. L.  
 Vacher, T. L., 319 (B)  
 Wardle, E. N., 129  
 Witter, S., und Zahn, R. K. (Editors), 303  
 (B)  
 Wright, J. L. W., v. Griffiths, D. A.  
 Wright, J. L. W., v. Rome, C.  
 Yoffey, J. M., v. Griffiths, D. A.

Yoffey J M, v Reuse, C,  
Zacchello F v Panizon, F

*Index autorum ad Vol 43*

| Zahn R A v Witte S  
| Zimmerschitt E v Cohnen G

